PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gupta, S; Snow, RW; Donnelly, CA; Marsh, K; Newbold, C				Gupta, S; Snow, RW; Donnelly, CA; Marsh, K; Newbold, C			Immunity to non-cerebral severe malaria is acquired after one or two infections	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM; TRANSMISSION; MORBIDITY	In areas of stable transmission, clinical immunity to mild malaria is acquired slowly, so it is not usually effective until early adolescence. Life-threatening disease is, however, restricted to a much younger age group, indicating that resistance to the severe clinical consequences of infection is acquired more quickly. Understanding how rapidly immunity develops to severe malaria is essential, as severe malaria should be the primary target of intervention strategies, and predicting the result of interventions that reduce host exposure will require consideration of these dynamics(1,2). Severe disease in childhood is less frequent in areas where transmission is the greatest(3). One explanation for this is that infants experience increased exposure to infection(4-6) while they are protected from disease, possibly by maternal antibody. They therefore emerge from this period of clinical protection with considerably more immunity than those who experience lower transmission intensities. Here we use this data(3), assuming a period of clinical protection, to estimate the number of prior infections needed to reduce the risk of severe disease to negligible levels. Contrary to expectations, one or two successful infective bites seem to be all that is necessary across a broad range of transmission intensities.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol & Infect Dis, Oxford OX1 3PS, England; KEMRI Wellcome Trust Collaborat Programme, Nairobi, Kenya; Univ Oxford, Inst Mol Med, Oxford, England; KEMRI, Coastal Unit, Kilifi, Kenya	University of Oxford; University of Oxford	Gupta, S (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol & Infect Dis, S Parks Rd, Oxford OX1 3PS, England.		Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; Donnelly, Christl/0000-0002-0195-2463; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; BAIRD JK, 1995, PARASITOL TODAY, V11, P105, DOI 10.1016/0169-4758(95)80167-7; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Gupta S, 1999, P ROY SOC B-BIOL SCI, V266, P33, DOI 10.1098/rspb.1999.0600; JEFFERY GM, 1966, B WORLD HEALTH ORGAN, V35, P873; Kitua AY, 1996, TROP MED INT HEALTH, V1, P475, DOI 10.1046/j.1365-3156.1996.d01-89.x; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MCGREGOR IA, 1987, ANN TROP MED PARASIT, V81, P647, DOI 10.1080/00034983.1987.11812166; Slutsker L, 1996, AM J TROP MED HYG, V55, P71, DOI 10.4269/ajtmh.1996.55.71; Snow RW, 1996, AM J TROP MED HYG, V55, P144, DOI 10.4269/ajtmh.1996.55.2.TM0550020144; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Snow RW, 1998, J INFECT DIS, V177, P819, DOI 10.1086/517818; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; Wagner G, 1998, AM J TROP MED HYG, V59, P115, DOI 10.4269/ajtmh.1998.59.115	14	317	322	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					340	343		10.1038/6560	http://dx.doi.org/10.1038/6560			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086393				2022-12-25	WOS:000078851600042
J	Kennedy, CRJ; Zhang, YH; Brandon, S; Guan, YF; Coffee, K; Funk, CD; Magnuson, MA; Oates, JA; Breyer, MD; Breyer, RM				Kennedy, CRJ; Zhang, YH; Brandon, S; Guan, YF; Coffee, K; Funk, CD; Magnuson, MA; Oates, JA; Breyer, MD; Breyer, RM			Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor	NATURE MEDICINE			English	Article							INDOMETHACIN; INITIATION; PREGNANCY	Prostaglandins (PGs) are ubiquitous lipid mediators derived from cyclooxygenase metabolism of arachidonic acid that exert a broad range of physiologic activities, including modulation of inflammation, ovulation(1,2) and arterial blood pressure(3,4). PGE(2), a chief cyclooxygenase product, modulates blood pressure and fertility, although the specific G protein-coupled receptors(5,6) mediating these effects remain poorly defined. To evaluate the physiologic role of the PGE(2) EP2 receptor subtype, we created mice with targeted disruption of this gene (EP2-/-). EP2-/- mice develop normally but produce small litters and have slightly elevated baseline systolic blood pressure. In EP2-/- mice, the characteristic hypotensive effect of intravenous PGE(2) infusion was absent; PGE(2) infusion instead produced hypertension. When fed a diet high in salt, the EP2-/- mice developed profound systolic hypertension, whereas wild-type mice showed no change in systolic blood pressure. Analysis of wild-type and EP2-/- mice on day 5 of pregnancy indicated that the reduced litter size of EP2-/- mice is due to a pre-implantation defect. This reduction of implanted embryos could be accounted for by impaired ovulation and dramatic reductions in fertilization observed on day 2 of pregnancy. These data demonstrate that the EP2 receptor mediates arterial dilatation, salt-sensitive hypertension, and also plays an essential part in female fertility.	Dept Med, Div Nephrol, Nashville, TN 37232 USA; Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Dept Pharmacol, Nashville, TN 37232 USA; Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University	Breyer, RM (corresponding author), Dept Med, Div Nephrol, S3223 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	rich.breyer@mcmail.vanderbilt.edu	Funk, Colin D/A-9518-2010	guan, youfei/0000-0002-5231-0209; Magnuson, Mark/0000-0002-8824-6499; Breyer, Matthew/0000-0003-1880-371X; Funk, Colin/0000-0001-7029-4233	NIDDK NIH HHS [DK-46205, DK-37097] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046205, R01DK037097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Challis JRG, 1997, NAT MED, V3, P1326, DOI 10.1038/nm1297-1326; Coleman R A, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P467; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DOWNS SM, 1982, AM J ANAT, V164, P265, DOI 10.1002/aja.1001640307; GARDINER PJ, 1986, BRIT J PHARMACOL, V87, P45, DOI 10.1111/j.1476-5381.1986.tb10155.x; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HOFFMAN LH, 1978, BIOL REPROD, V18, P148, DOI 10.1095/biolreprod18.1.148; Johnson AG, 1997, DRUG SAFETY, V17, P277, DOI 10.2165/00002018-199717050-00001; KENNEDY TG, 1977, BIOL REPROD, V16, P286, DOI 10.1095/biolreprod16.3.286; LAU IF, 1973, PROSTAGLANDINS, V4, P795, DOI 10.1016/0090-6980(73)90115-9; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LLOZUMI N, 1997, NATURE, V390, P618; PRIDDY AR, 1993, PROSTAG LEUKOTR ESS, V49, P827, DOI 10.1016/0952-3278(93)90204-A; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Simpson F. Olaf, 1995, P273; Smith G, 1996, BRIT J RHEUMATOL, V35, P458; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Weitlauf H. M., 1994, P391	20	318	331	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					217	220		10.1038/5583	http://dx.doi.org/10.1038/5583			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930871				2022-12-25	WOS:000078274400032
J	Terauchi, Y; Tsuji, Y; Satoh, S; Minoura, H; Murakami, K; Okuno, A; Inukai, K; Asano, T; Kaburagi, Y; Ueki, K; Nakajima, H; Hanafusa, T; Matsuzawa, Y; Sekihara, H; Yin, YX; Barrett, JC; Oda, H; Ishikawa, T; Akanuma, Y; Komuro, I; Suzuki, M; Yamamura, K; Kodama, T; Suzuki, H; Koyasu, S; Aizawa, S; Tobe, K; Fukui, Y; Yazaki, Y; Kadowaki, T				Terauchi, Y; Tsuji, Y; Satoh, S; Minoura, H; Murakami, K; Okuno, A; Inukai, K; Asano, T; Kaburagi, Y; Ueki, K; Nakajima, H; Hanafusa, T; Matsuzawa, Y; Sekihara, H; Yin, YX; Barrett, JC; Oda, H; Ishikawa, T; Akanuma, Y; Komuro, I; Suzuki, M; Yamamura, K; Kodama, T; Suzuki, H; Koyasu, S; Aizawa, S; Tobe, K; Fukui, Y; Yazaki, Y; Kadowaki, T			Increased insulin sensitivity and hypoglycaemia in mice lacking the P85 alpha subunit of phosphoinositide 3-kinase	NATURE GENETICS			English	Article							RECEPTOR TYROSINE KINASES; RAT ADIPOSE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; PROTEIN; SUBSTRATE-1; TRANSLOCATION	The hallmark of type 2 diabetes, the most common metabolic disorder, is a defect in insulin-stimulated glucose transport in peripheral tissues. Although a role for phosphoinositide-3-kinase (PI3K) activity in insulin-stimulated glucose transport and glucose transporter isoform 4 (Glut4) translocation has been suggested in vitro(1,2), its role in vive and the molecular link between activation of PI3K and translocation has not yet been elucidated. To determine the role of PI3K in glucose homeostasis, we generated mice with a targeted disruption of the gene encoding the p85 alpha regulatory subunit of PI3K (Pik3r1; refs 3-5). Pik3r1(-/-) mice showed increased insulin sensitivity and hypoglycaemia due to increased glucose transport in skeletal muscle and adipocytes. Insulin-stimulated PI3K activity associated with insulin receptor substrates (IRSs) was mediated via full-length p85 alpha in wild-type mice, but via the p50 alpha alternative splicing isoform of the same gene(6,7) in Pik3r1(-/-) mice. This isoform switch was associated with an increase in insulin-induced generation of phosphatidylinositol(3, 4, 5)triphosphate (PtdIns(3, 4, 5)P-3) in Pik3r1(-/-) adipocytes and facilitation of Glut4 translocation from the law-density microsome (LDM) fraction to the plasma membrane (PM). This mechanism seems to be responsible for the phenotype of Pik3r1(-/-) mice, namely increased glucose transport and hypoglycaemia. Our work provides the first direct evidence that PI3K and its regulatory subunit have a role in glucose homeostasis in vive.	Univ Tokyo, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, Dept Pathol, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Tokyo 1138655, Japan; Univ Tokyo, Dept Appl Biol Chem, Biol Chem Lab, Tokyo 1138655, Japan; Osaka Univ, Dept Internal Med 2, Suita, Osaka 565, Japan; Yokohama City Univ, Dept Internal Med, Yokohama, Kanagawa 236, Japan; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo 100, Japan; Kumamoto Univ, Sch Med, Lab Transgen Technol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Dev Genet, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 860, Japan; Keio Univ, Sch Med, Dept Immunol, Tokyo 160, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Osaka University; Yokohama City University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Asahi Life Foundation; Kumamoto University; Kumamoto University; Kumamoto University; Keio University	Kadowaki, T (corresponding author), Univ Tokyo, Dept Internal Med, Tokyo 1138655, Japan.		Koyasu, Shigeo/J-5583-2015; Suzuki, Harumi/L-1271-2013; Terauchi, Yasuo/AAO-4347-2020; Fukui, Yasuhisa/E-8806-2010	Koyasu, Shigeo/0000-0001-9585-3038; Suzuki, Harumi/0000-0003-3616-9361; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; HARANO Y, 1981, J CLIN ENDOCR METAB, V52, P982, DOI 10.1210/jcem-52-5-982; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KADOWAKI T, 1996, ENDOCR J, V43, P533; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	28	326	336	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					230	235		10.1038/6023	http://dx.doi.org/10.1038/6023			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988280				2022-12-25	WOS:000078399500030
J	Fan, JQ; Ishii, S; Asano, N; Suzuki, Y				Fan, JQ; Ishii, S; Asano, N; Suzuki, Y			Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor	NATURE MEDICINE			English	Article							ENDOPLASMIC-RETICULUM; POINT MUTATIONS; A-GENE; DISEASE; FORM	Fabry disease is a disorder of glycosphingolipid metabolism caused by deficiency of lysosomal alpha-galactosidase A (alpha-Gal A), resulting in renal failure along with premature myocardial infarction and strokes(1,2). No effective treatment of this disorder is available at present. Studies of residual activities of mutant enzymes in many Fabry patients showed that some of them had kinetic properties similar to those for normal alpha-Gal A, but were significantly less stable, especially in conditions of neutral pH (refs. 3-5). The biosynthetic processing was delayed in cultured fibroblasts of a Fabry patient(6) and the mutant protein formed an aggregate in endoplasmic reticulum: indicating that the enzyme deficiency in some mutants was mainly caused by abortive exit from the endoplasmic reticulum(7), leading to excessive degradation of the enzyme. We report here that 1-deoxy-galactonojirimycin (DGJ), a potent competitive inhibitor of alpha-Gal A, effectively enhanced alpha-Gal A activity in Fabry lymphoblasts, when administrated at concentrations lower than that usually required for intracellular inhibition of the enzyme. DGJ seemed to accelerate transport and maturation of the mutant enzyme. Oral administration of DGJ to transgenic mice overexpressing a mutant alpha-Gal A substantially elevated the enzyme activity in some organs. We propose a new molecular therapeutic strategy for genetic metabolic diseases of administering competitive inhibitors as 'chemical chaperons' at sub-inhibitory intracellular concentrations.	Hokuriku Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9201181, Japan; Tokyo Metropolitan Inst Med Sci, Dept Membrane Biochem, Tokyo 1138613, Japan; Usuki Bio Res Ctr, Oita 8750061, Japan	Hokuriku University; Tokyo Metropolitan Institute of Medical Science	Fan, JQ (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.							Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; ASANO N, 1994, J MED CHEM, V37, P3701, DOI 10.1021/jm00048a006; Asano N, 1997, J NAT PROD, V60, P98, DOI 10.1021/np960577n; BISHOP DF, 1981, AM J HUM GENET, V33, pA71; Block TM, 1998, NAT MED, V4, P610, DOI 10.1038/nm0598-610; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; DALE MP, 1985, BIOCHEMISTRY-US, V24, P3530, DOI 10.1021/bi00335a022; Desnick RJ., 1995, METABOLIC MOL BASES, P2741; Fleischer S, 1974, Methods Enzymol, V31, P6; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOSS PE, 1994, CANCER RES, V54, P1450; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISHII S, 1992, HUM GENET, V89, P29, DOI 10.1007/BF00207037; ISHII S, 1993, BIOCHEM BIOPH RES CO, V197, P1585, DOI 10.1006/bbrc.1993.2659; Ishii S, 1996, BIOCHEM BIOPH RES CO, V220, P812, DOI 10.1006/bbrc.1996.0486; Ishii S, 1998, GLYCOCONJUGATE J, V15, P591, DOI 10.1023/A:1006915926732; LEMANSKY P, 1987, J BIOL CHEM, V262, P2062; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; NEUENHOFER S, 1985, BIOCHEMISTRY-US, V24, P525, DOI 10.1021/bi00323a042; OSHIMA A, 1994, HUM GENET, V93, P109; ROMEO G, 1975, BIOCHEM GENET, V13, P615, DOI 10.1007/BF00484919; SAKURABA H, 1990, AM J HUM GENET, V47, P784	22	516	558	3	45	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					112	115		10.1038/4801	http://dx.doi.org/10.1038/4801			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883849				2022-12-25	WOS:000077885000039
J	Robinson, C				Robinson, C			Making forest biotechnology a commercial reality - Do we need a tree genome project, or will Arabidopsis point the way?	NATURE BIOTECHNOLOGY			English	Article									John Innes Inst, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Robinson, C (corresponding author), John Innes Inst, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.								0	10	11	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					27	30		10.1038/5199	http://dx.doi.org/10.1038/5199			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920264				2022-12-25	WOS:000077979500020
J	Klein, MA; Frigg, R; Raeber, AJ; Flechsig, E; Hegyi, I; Zinkernagel, RM; Weissmann, C; Aguzzi, A				Klein, MA; Frigg, R; Raeber, AJ; Flechsig, E; Hegyi, I; Zinkernagel, RM; Weissmann, C; Aguzzi, A			PrP expression in B lymphocytes is not required for prion neuroinvasion	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE AGENT; MICE; PROTEIN; MOUSE; CELLS; REPLICATION; ISOFORM; SPLEEN; ONSET	Prion diseases are typically initiated by infection of peripheral sites, as in the case of bovine spongiform encephalopathy, new variant Creutzfeldt-Jakob disease(1), kuru and most cases of iatrogenic Creutzfeldt-Jakob disease. In mouse scrapie, prion infectivity accumulates in lymphoid organs, and the absence of mature B lymphocytes prevents peripherally administered prions from inducing central nervous system disease(2). We have now assessed whether expression of the cellular prion protein, PrPc, is required for B lymphocytes to mediate neuroinvasion. We found that repopulation of SCID and Rag-1(-/-) mice with fetal liver cells from either PrP-expressing or PrP-deficient mice and from T-cell deficient mice, but not from B-cell deficient mice, is equally efficient in restoring neuroinvasion after intraperitoneal inoculation of scrapie prions. These results indicate that cells whose maturation depends on B cells or their products, such as follicular dendritic cells, may enhance neuroinvasion. Alternatively, B cells may transport prions to the nervous system by a PrP-independent mechanism.	Univ Zurich, Inst Neuropathol, Zurich, Switzerland; Univ Zurich, Inst Mol Biol, Zurich, Switzerland; Univ Zurich, Inst Expt Immunol, Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich	Aguzzi, A (corresponding author), Univ Zurich, Inst Neuropathol, Zurich, Switzerland.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; KOSCO MH, 1992, J IMMUNOL, V148, P2331; Lasmezas CI, 1996, J VIROL, V70, P1292; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Weissmann C, 1997, CURR OPIN NEUROBIOL, V7, P695, DOI 10.1016/S0959-4388(97)80091-8	22	227	232	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1429	1433		10.1038/4022	http://dx.doi.org/10.1038/4022			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846583				2022-12-25	WOS:000077336900041
J	Richard, G; Smith, LE; Bailey, RA; Itin, P; Hohl, D; Epstein, EH; DiGiovanna, JJ; Compton, JG; Bale, SJ				Richard, G; Smith, LE; Bailey, RA; Itin, P; Hohl, D; Epstein, EH; DiGiovanna, JJ; Compton, JG; Bale, SJ			Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis	NATURE GENETICS			English	Article							GAP JUNCTION PROTEINS; MOLECULAR-CLONING; EXPRESSION; SKIN; EPIDERMIS; DEAFNESS; FAMILY; MODULATION; LINKAGE	Erythrokeratodermia variabilis (EKV, OMIM 133200) is an autosomal dominant genodermatosis with considerable intra- and interfamilial variability(1). It has a disfiguring phenotype characterized by the independent occurrence of two morphologic features: transient figurate red patches and localized or generalized hyperkeratosis (Fig. 1). Both features can be triggered by external factors such as trauma to the skin. After initial linkage to the RH locus on 1p (refs 2,3). EKV was mapped to an an interval of 2.6 cM on 1p34-p35. and a candidate gene (GJA4) encoding the gap junction protein alpha-4 (connexin 31. Cx31) was excluded by sequence analysis(4). Evidence in mouse suggesting that the EKV region harbours a cluster of epidermally expressed connexin genes(5,6) led us to characterize the human homologues of GJB3 (encoding Cx31) and GJB5 (encoding Cx31.1). GJB3, GJB5 and GJA4 were localized to a 1.1-Mb YAC in the candidate interval. We detected heterozygous missense mutations in GJB3 in four EKV families leading to substitution of a conserved glycine by charged residues (G12R and G12D). or change of a cysteine (C865). These mutations are predicted to interfere with normal Cx31 structure and function, possibly due to a dominant inhibitory effect. Our results implicate Cx31 in the pathogenesis of EKV, and provide evidence that intercellular communication mediated by Cx31 is crucial for epidermal differentiation and response to external factors.	NIAMSD, Genet Studies Sect, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Basel, Dept Dermatol, Basel, Switzerland; Beaumont Hosp, Dept Dermatol, Lausanne, Switzerland; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94143 USA; Brown Univ, Rhode Isl Hosp, Dept Dermatol, Div Dermatopharmacol, Providence, RI 02903 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Basel; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Bale, SJ (corresponding author), NIAMSD, Genet Studies Sect, Skin Biol Lab, NIH, Bethesda, MD 20892 USA.			DiGiovanna, John J./0000-0002-2750-2313				BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUTTERWECK A, 1994, EUR J CELL BIOL, V65, P152; DACOSTA SM, 1925, ACTA DERM-VENEREOL, V6, P255; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Deschenes SM, 1997, J NEUROSCI, V17, P9077; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUO HM, 1992, J INVEST DERMATOL, V99, P460, DOI 10.1111/1523-1747.ep12616154; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; HENNEMANN H, 1992, J BIOL CHEM, V267, P17225; HOH JH, 1991, J BIOL CHEM, V266, P6524; ITIN P, 1992, HAUTARZT, V43, P500; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; Larson DM, 1997, AM J PHYSIOL-CELL PH, V272, pC405, DOI 10.1152/ajpcell.1997.272.2.C405; MasgrauPeya E, 1997, J HISTOCHEM CYTOCHEM, V45, P1207, DOI 10.1177/002215549704500904; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; Richard G, 1997, J INVEST DERMATOL, V109, P666, DOI 10.1111/1523-1747.ep12337713; RICHARDS B, 1993, HUM MOL GENET, V2, P159, DOI 10.1093/hmg/2.2.159; RISEK B, 1992, DEVELOPMENT, V116, P639; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; VANDERSCHROEFF JG, 1988, HUM GENET, V80, P97, DOI 10.1007/BF00451466; VANDERSCHROEFF JG, 1984, HUM GENET, V68, P165, DOI 10.1007/BF00279308; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	30	264	284	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					366	369		10.1038/3840	http://dx.doi.org/10.1038/3840			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843209				2022-12-25	WOS:000077199600024
J	Depre, C; Shipley, GL; Chen, WH; Han, QY; Doenst, T; Moore, ML; Stepkowski, S; Davies, PJA; Taegtmeyer, H				Depre, C; Shipley, GL; Chen, WH; Han, QY; Doenst, T; Moore, ML; Stepkowski, S; Davies, PJA; Taegtmeyer, H			Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy	NATURE MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; LEFT-VENTRICULAR HYPERTROPHY; RAT-HEART; MECHANICAL-STRESS; THYROID-HORMONE; ENHANCER FACTOR-2; SKELETAL-MUSCLE; GROWTH-FACTORS; MESSENGER-RNA; MYOCYTES	The cardiac response to increased work includes a reactivation of fetal genes. The response to a decrease in cardiac work is not known. Such information is of clinical interest, because mechanical unloading can improve the functional capacity of the failing heart. We compared here the patterns of gene expression in unloaded rat heart with those in hypertrophied rat heart. Both conditions induced a re-expression of growth factors and proto-oncogenes, and a downregulation of the 'adult' isoforms, but not of the 'fetal' isoforms, of proteins regulating myocardial energetics. Therefore, opposite changes in cardiac workload in vivo induce similar patterns of gene response. Reactivation of fetal genes may underlie the functional improvement of an unloaded failing heart.	Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Surg, Div Organ Transplantat, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System	Taegtmeyer, H (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, 6431 Fannin, Houston, TX 77030 USA.		Chen, Wenhao/J-6553-2019	Chen, Wenhao/0000-0002-0626-3739	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043133] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL43133] Funding Source: Medline; ORIP NIH HHS [NIH-RI-A139026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ORIP NIH HHS		BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BRAND T, 1995, J MOL CELL CARDIOL, V27, P5, DOI 10.1016/S0022-2828(08)80003-X; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; DEPRE C, IN PRESS CIRCULATION; Dipla K, 1998, CIRCULATION, V97, P2316, DOI 10.1161/01.CIR.97.23.2316; Doevendans PA, 1996, INT J BIOCHEM CELL B, V28, P387, DOI 10.1016/1357-2725(95)00145-X; DORN GW, 1994, AM J PHYSIOL, V267, pH400, DOI 10.1152/ajpheart.1994.267.1.H400; GEENEN DL, 1992, CIRC RES, V70, P554, DOI 10.1161/01.RES.70.3.554; GEENEN DL, 1994, AM J PHYSIOL-HEART C, V267, pH2149, DOI 10.1152/ajpheart.1994.267.6.H2149; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GOULD GW, 1997, FACILITATIVE GLUCOSE, P67; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hasegawa K, 1997, CIRCULATION, V96, P3943; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KLEIN I, 1992, J CLIN INVEST, V89, P68, DOI 10.1172/JCI115587; KLEINMAN LH, 1978, AM J PHYSIOL, V234, pH515, DOI 10.1152/ajpheart.1978.234.5.H515; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1990, J BIOL CHEM, V265, P5391; KORECKY B, 1987, CIRC RES, V60, P824, DOI 10.1161/01.RES.60.6.824; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LIU ML, 1994, J BIOL CHEM, V269, P28514; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Muller J, 1997, CIRCULATION, V96, P542; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Olivieri NF, 1997, LANCET, V350, P491, DOI 10.1016/S0140-6736(05)63080-2; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Robbins J, 1996, CARDIOVASC RES, V31, pE2; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SCHNEIDER MD, 1991, MOL BIOL MED, V8, P167; SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364, DOI 10.1152/ajpregu.1992.262.3.R364; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; TAKAHASHI N, 1994, J CLIN INVEST, V94, P1470, DOI 10.1172/JCI117485; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656	51	337	343	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1269	1275		10.1038/3253	http://dx.doi.org/10.1038/3253			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809550				2022-12-25	WOS:000076731000035
J	Miwa, K; Asano, M; Horai, R; Iwakura, Y; Nagata, S; Suda, T				Miwa, K; Asano, M; Horai, R; Iwakura, Y; Nagata, S; Suda, T			Caspase 1-independent IL-1 beta release and inflammation induced by the apoptosis inducer Fas ligand	NATURE MEDICINE			English	Article							CONFER IMMUNE PRIVILEGE; TUMOR-NECROSIS-FACTOR; CD95 LIGAND; DIFFERENTIAL EXPRESSION; MEDIATED CYTOTOXICITY; MICE DEFICIENT; CELL-DEATH; INTERLEUKIN-1-BETA; NEUTROPHILS; CYTOKINES	Fas ligand is a well-characterized apoptosis inducer. Here we demonstrate that Fas ligand induces the processing and secretion of interleukin-1 beta (IL-1 beta) in peritoneal exudate cells. This IL-1 beta secretion is independent of IL-1 beta converting enzyme (caspase 1), yet it is inhibited by caspase inhibitors, indicating that a caspase(s) in addition to IL-1 beta converting enzyme can process IL-1 beta. Inoculation of tumor cells expressing Fas ligand into wild-type mice induces a massive neutrophil infiltration that is, in contrast, suppressed in IL-1 alpha/beta knockout mice. These results demonstrate a newly discovered role for Fas ligand in inflammation, and challenge the dogma that apoptosis does not induce inflammation.	Osaka Biosci Inst, Dept Biol Mol, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan	University of Tokyo; Osaka University; Kanazawa University	Suda, T (corresponding author), Osaka Biosci Inst, Dept Biol Mol, Osaka 5650874, Japan.		Iwakura, Yoichiro/E-5457-2011; Nagata, Shigekazu/AAG-3203-2019	Iwakura, Yoichiro/0000-0002-9934-5775; Nagata, Shigekazu/0000-0001-9758-8426				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; COLOTTA F, 1992, BLOOD, V80, P2012; DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873; Fantuzzi G, 1996, J IMMUNOL, V157, P291; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; IWAI K, 1994, BLOOD, V84, P1201; JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LINDEMANN A, 1988, J IMMUNOL, V140, P837; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nakamoto Y, 1997, J IMMUNOL, V158, P5692; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Parsey MV, 1998, J IMMUNOL, V160, P1007; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Suda T, 1997, J ALLERGY CLIN IMMUN, V100, pS97, DOI 10.1016/S0091-6749(97)70013-7; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031	43	337	345	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1287	1292		10.1038/3276	http://dx.doi.org/10.1038/3276			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809553				2022-12-25	WOS:000076731000038
J	Bhatia, M; Bonnet, D; Murdoch, B; Gan, OI; Dick, JE				Bhatia, M; Bonnet, D; Murdoch, B; Gan, OI; Dick, JE			A newly discovered class of human hematopoietic cells with SCID-repopulating activity	NATURE MEDICINE			English	Article							HUMAN ENDOTHELIAL-CELLS; ACUTE MYELOID-LEUKEMIA; IMMUNE-DEFICIENT MICE; STEM-CELLS; BONE-MARROW; CORD-BLOOD; IN-VIVO; PROGENITOR CELLS; EXPRESSION; BIOLOGY	The detection of primitive hematopoietic cells based on repopulation of immune-deficient mice is a powerful tool to characterize the human stem-cell compartment. Here, we identify a newly discovered human repopulating cell, distinct from previously identified repopulating cells, that initiates multilineage hematopoiesis in NOD/SCID mice. We call such cells CD34(neg)-SCID repopulating cells, or CD34(neg)-SRC. CD34(neg)-SRC are restricted to a Lin(-)CD34(-)CD38(-) population without detectable surface markers for multiple lineages and CD38 or those previously associated with stem cells (HLA-DR, Thy-1 and CD34). In contrast to CD34(+) subfractions, Lin(-)CD34(-)CD38(-) cells have low clonogenicity in short-and long-term in vitro assays. The number of CD34(neg)-SRC increased in short-term suspension cultures in conditions that did not maintain SRC derived from CD34(+) populations, providing independent biological evidence of their distinctiveness. The identification of this newly discovered cell demonstrates complexity of the organization of the human stem-cell compartment and has important implications for clinical applications involving stem-cell transplantation.	Hosp Sick Children, Res Inst, Programs Caanc Blood & Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Dick, JE (corresponding author), Hosp Sick Children, Res Inst, Programs Caanc Blood & Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	dick@sickkids.on.ca		Dick, John/0000-0002-9527-8317				ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bensinger WI, 1996, BLOOD, V88, P4132; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bodine DM, 1996, BLOOD, V88, P89; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; CROISILLE L, 1994, BLOOD, V84, P4116, DOI 10.1182/blood.V84.12.4116.bloodjournal84124116; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GROSSET C, 1995, BLOOD, V86, P3763, DOI 10.1182/blood.V86.10.3763.bloodjournal86103763; HAO QL, 1995, BLOOD, V86, P3745, DOI 10.1182/blood.V86.10.3745.bloodjournal86103745; Hogan DA, 1997, MICROB ECOL, V34, P90, DOI 10.1007/s002489900038; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KORPELAINEN EI, 1995, BLOOD, V86, P176, DOI 10.1182/blood.V86.1.176.bloodjournal861176; Krause DS, 1996, BLOOD, V87, P1; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LOUACHE F, 1994, BLOOD, V84, P3344; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pflumio F, 1996, BLOOD, V88, P3731, DOI 10.1182/blood.V88.10.3731.bloodjournal88103731; Phillips R A, 1991, Semin Immunol, V3, P337; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Zanjani ED, 1998, EXP HEMATOL, V26, P353	36	476	517	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1038	1045		10.1038/2023	http://dx.doi.org/10.1038/2023			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734397				2022-12-25	WOS:000075804100037
J	Brower, V				Brower, V			Nutraceuticals: Poised for a healthy slice of the healthcare market?	NATURE BIOTECHNOLOGY			English	Article								Designer foods provide benefits for both consumers and the food-processing industry, and represent a significant opportunity for biotechnology companies. But are they also blurring the definition of a drug?											0	197	203	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					728	731		10.1038/nbt0898-728	http://dx.doi.org/10.1038/nbt0898-728			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702769				2022-12-25	WOS:000075183400028
J	Tawfik, DS; Griffiths, AD				Tawfik, DS; Griffiths, AD			Man-made cell-like compartments for molecular evolution	NATURE BIOTECHNOLOGY			English	Article						directed evolution; DNA methylase; cell-free transcription/translation	PEPTIDE LIBRARIES; FILAMENTOUS PHAGE; DISPLAY; SELECTION; RNA; METHYLTRANSFERASE; REPLICATION; ANTIBODIES; CATALYSIS; PROTEINS	Cellular compartmentalization is vital for the evolution of all living organisms. Cells keep together the genes, the RNAs and proteins that they encode, and the products of their activities, thus linking genotype to phenotype. We have reproduced this linkage in the test tube by transcribing and translating single genes in the aqueous compartments of water-in-oil emulsions. These compartments, with volumes close to those of bacteria, can be recruited to select genes encoding catalysts. A protein or RNA with a desired catalytic activity converts a substrate attached to the gene that encodes it to product. In other compartments, substrates attached to genes that do not encode catalysts remain unmodified. Subsequently, genes encoding catalysts are selectively enriched by virtue of their linkage to the product. We demonstrate the linkage of genotype to phenotype in man-made compartments using a model system. A selection for target-specific DNA methylation was based on the resistance of the product (methylated DNA) to restriction digestion. Genes encoding HaeIII methyltransferase were selected from a 10(7)-fold excess of genes encoding another enzyme.	MRC Ctr, Ctr Prot Engn, Cambridge CB2 2QH, England; MRC Ctr, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; University of Cambridge; MRC Laboratory Molecular Biology	Tawfik, DS (corresponding author), MRC Ctr, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.		Griffiths, Andrew D/A-1370-2010	Griffiths, Andrew D/0000-0002-0808-3539				Becher P., 1957, EMULSIONS THEORY PRA; BENNER SA, 1993, SCIENCE, V261, P1402, DOI 10.1126/science.8367723; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; Deamer DW, 1997, MICROBIOL MOL BIOL R, V61, P239, DOI 10.1128/.61.2.239-261.1997; Eigen M., 1992, STEPS LIFE; EISENTHAL R, 1993, ENZYME ASSAYS PRACTI; Fastrez J, 1997, MOL BIOTECHNOL, V7, P37, DOI 10.1007/BF02821543; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Hager AJ, 1996, CHEM BIOL, V3, P717, DOI 10.1016/S1074-5521(96)90246-X; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Jeltsch A, 1996, PROTEIN ENG, V9, P413, DOI 10.1093/protein/9.5.413; JOYCE GF, 1989, NATURE, V338, P214; Lesley S A, 1995, Methods Mol Biol, V37, P265; Leung DW, 1989, TECHNIQUE, V1, P11; Lissant K.J., 1984, EMULSIONS EMULSION T; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Oparin AI., 1957, ORIGIN LIFE EARTH; POHL FM, 1982, EUR J BIOCHEM, V123, P141, DOI 10.1111/j.1432-1033.1982.tb06510.x; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SOUMILLION P, 1994, J MOL BIOL, V237, P415, DOI 10.1006/jmbi.1994.1244; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIDERSTEN M, 1995, J MOL BIOL, V250, P115, DOI 10.1006/jmbi.1995.0362; Williams, 1984, BERGEYS MANUAL SYSTE; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	32	685	931	6	174	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					652	656		10.1038/nbt0798-652	http://dx.doi.org/10.1038/nbt0798-652			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661199				2022-12-25	WOS:000074521800029
J	Baron, H; Fung, S; Aydin, A; Bahring, S; Luft, FC; Schuster, H				Baron, H; Fung, S; Aydin, A; Bahring, S; Luft, FC; Schuster, H			Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia	NATURE BIOTECHNOLOGY			English	Article						familial hypercholesterolemia; mutation detection; oligonucleotide ligation assay; LDL receptor	CORONARY HEART-DISEASE; DEFECTIVE APOLIPOPROTEIN-B-100; SERUM-CHOLESTEROL; GENE; DNA; PCR; AMPLIFICATION; PREVENTION; MUTATION; RISK	More than half of all deaths in Western society are related to arteriosclerotic cardiovascular diseases. Inherited disturbances in the low-density-lipoprotein (LDL) receptor and similar lipid-related defects account for the majority of these deaths. Testing procedures thus far rely on total cholesterol, LDL cholesterol, high-density-lipoprotein cholesterol, and triglyceride determinations. These tests are not able to provide any genetic information. We have developed an oligonucleotide ligation assay (OLA) that enables us to screen for high-risk individuals by testing for 19 common mutations in the LDL receptor and the apolipoprotein B genes using an automated genotyping-based two-step protocol, The novel OLA uses oligomeric pentaethyleneoxide mobility modifiers. The automated test will be useful in screening large populations for genetic data to distinguish relative from absolute risk, as well as for cost-effective familial analysis.	HUMBOLDT UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, MAX DELBRUCK CTR MOL MED, FRANZ VOLHARD CLIN, BERLIN, GERMANY; APPL BIOSYST INC, FOSTER CITY, CA 94404 USA	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Thermo Fisher Scientific; Applied Biosystems				Luft, Friedrich/0000-0002-8635-1199				BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BOLLA MK, 1995, CLIN CHEM, V41, P1599; CLOAD ST, 1991, J AM CHEM SOC, V113, P6324, DOI 10.1021/ja00016a089; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; DELAHUNTY CM, 1995, CLIN CHEM, V41, P59; EGGERDING FA, 1995, HUM MUTAT, V5, P153, DOI 10.1002/humu.1380050209; EGGERDING FA, 1995, PCR METH APPL, V4, P337; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GROSSMAN PD, 1994, NUCLEIC ACIDS RES, V22, P4527, DOI 10.1093/nar/22.21.4527; HANSEN TS, 1995, CLIN CHEM, V41, P413; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; INNERARITY TL, 1990, J LIPID RES, V31, P1337; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; LEVENSON C, 1990, Patent No. 4914210; LIVAK KJ, 1995, PCR METH APPL, V4, P357; NICKERSON DA, 1990, P NATL ACAD SCI USA, V87, P8923, DOI 10.1073/pnas.87.22.8923; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; SACKS FM, 1995, AM J CARDIOL, V75, P621, DOI 10.1016/S0002-9149(99)80631-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUSTER H, 1995, ARTERIOSCL THROM VAS, V15, P2176, DOI 10.1161/01.ATV.15.12.2176; SCHUSTER H, 1990, ARTERIOSCLEROSIS, V10, P577, DOI 10.1161/01.ATV.10.4.577; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018	26	68	71	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1279	1282		10.1038/nbt1096-1279	http://dx.doi.org/10.1038/nbt1096-1279			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631093				2022-12-25	WOS:A1996VK61800027
J	Szkudlinski, MW; Teh, NG; Grossmann, M; Tropea, JE; Weintraub, BD				Szkudlinski, MW; Teh, NG; Grossmann, M; Tropea, JE; Weintraub, BD			Engineering human glycoprotein hormone superactive analogues	NATURE BIOTECHNOLOGY			English	Article						hTSH; hCG; analogue design	HUMAN CHORIONIC-GONADOTROPIN; RECOMBINANT HUMAN THYROTROPIN; FOLLICLE-STIMULATING-HORMONE; ALPHA-SUBUNIT; BETA-SUBUNIT; CHORIOGONADOTROPIN RECEPTOR; METABOLIC-CLEARANCE; TERMINAL RESIDUES; BIOACTIVITY; FOLLITROPIN	We report the generation of superactive analogues of human glycoprotein hormones, with potential applications in thyroid and reproductive disorders. Current biological and structural data were used to rationalize mutagenesis. The 11-20 region in the alpha-subunit with a cluster of lysine residues forms a previously unrecognized domain critical for receptor binding and signal transduction, as well as an important motif in the evolution of glycoprotein hormone activities. The gradual elimination of basic residues in the cu-subunit coincided with the evolutionary divergence of the hominids from the Old World monkeys. By selective reconstitution of certain critical residues present in homologous nonhuman hormones we have developed human thyroid stimulating hormone and chorionic gonadotropin analogues with substantial increases in receptor binding affinity and bioactivity, thus providing a paradigm for the design of novel therapeutic protein analogues.	NIDDKD, MOL & CELLULAR ENDOCRINOL BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Szkudlinski, MW (corresponding author), UNIV MARYLAND, SCH MED,DEPT MED,INST HUMAN VIROL, LAB MOL ENDOCRINOL, 725 W LOMBARD ST, BALTIMORE, MD 21201 USA.							ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BENRAFAEL Z, 1995, FERTIL STERIL, V63, P689; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; Combarnous Yves, 1992, Endocrine Reviews, V13, P670, DOI 10.1210/er.13.4.670; CONDLIFFE PG, 1979, HORM BLOOD, P489; DIAS JA, 1994, J BIOL CHEM, V269, P25289; DIMHOFER S, 1994, J ENDOCRINOL, V140, P145; DZKUDINSKI MW, 1996, TRENDS ENDOCRIN MET, V7, P277; EASTPALMER J, 1995, THYROID, V5, P55, DOI 10.1089/thy.1995.5.55; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; FIDDES JC, 1979, NATURE, V281, P351, DOI 10.1038/281351a0; FONTAINE YA, 1977, GEN COMP ENDOCR, V32, P341, DOI 10.1016/0016-6480(77)90213-1; GAST MJ, 1995, AM J OBSTET GYNECOL, V172, P753, DOI 10.1016/0002-9378(95)90149-3; GOLOS TG, 1991, DNA CELL BIOL, V10, P367, DOI 10.1089/dna.1991.10.367; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; IGARASHI S, 1994, BIOCHEM BIOPH RES CO, V201, P248, DOI 10.1006/bbrc.1994.1696; JI IH, 1993, J BIOL CHEM, V268, P22971; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; LAPOLT PS, 1992, ENDOCRINOLOGY, V131, P2514, DOI 10.1210/en.131.6.2514; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Licht P, 1976, Recent Prog Horm Res, V33, P169; LIU WK, 1974, J BIOL CHEM, V249, P5544; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; MEIER CA, 1994, J CLIN ENDOCR METAB, V78, P188, DOI 10.1210/jc.78.1.188; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STANTON PG, 1987, J BIOL CHEM, V262, P1623; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SZKUDLINSKI MW, 1993, ENDOCRINOLOGY, V133, P1490, DOI 10.1210/en.133.4.1490; SZKUDLINSKI MW, 1995, P NATL ACAD SCI USA, V92, P9062, DOI 10.1073/pnas.92.20.9062; TULLNER WW, 1994, CONTRIB PRIMATOL, V3, P235; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V70, P3, DOI 10.1210/jcem-70-1-3; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YADAV SP, 1994, MOL ENDOCRINOL, V8, P1547, DOI 10.1210/me.8.11.1547; YAMAZAKI K, 1995, J CLIN ENDOCR METAB, V80, P473, DOI 10.1210/jc.80.2.473	44	84	88	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1257	1263		10.1038/nbt1096-1257	http://dx.doi.org/10.1038/nbt1096-1257			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631089				2022-12-25	WOS:A1996VK61800023
J	Yang, F; Moss, LG; Phillips, GN				Yang, F; Moss, LG; Phillips, GN			The molecular structure of green fluorescent protein	NATURE BIOTECHNOLOGY			English	Article						fluorescence; protein structure; beta-can motif; GFP	EXPRESSION; SPECTRA; MODELS	The crystal structure of recombinant wild-type green fluorescent protein (GFP) has been solved to a resolution of 1.9 Angstrom by multiwavelength anomalous dispersion phasing methods. The protein is in the shape of a cylinder, comprising 11 strands of beta-sheet with an alpha-helix inside and short helical segments on the ends of the cylinder This motif, with beta-structure on the outside and alpha-helix on the inside, represents a new protein fold, which we have named the beta-can. Two protomers pack closely together to form a dimer in the crystal. The fluorophores are protected inside the cylinders, and their structures are consistent. with the formation of aromatic systems made up of Tyr(66) with reduction of its C alpha-C beta bond coupled with cyclization of the neighboring glycine and serine residues. The environment inside the cylinder explains the effects of many existing mutants of GFP and suggests specific side chains that could be modified to change the spectral properties of GFP Furthermore, the identification of the dimer contacts may allow mutagenic control of the state of assembly of the protein.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77005; TUFTS UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Rice University; Rice University; Tufts University; Tufts Medical Center			Davies, Anthony/A-4299-2018		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK034447, R55DK034447] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIDDK NIH HHS [DK34928, DK34447] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amsterdam A, 1996, GENE, V173, P99, DOI 10.1016/0378-1119(95)00719-9; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Casper SJ, 1996, GENE, V173, P69, DOI 10.1016/0378-1119(95)00782-2; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DeGiorgi F, 1996, GENE, V173, P113, DOI 10.1016/0378-1119(95)00687-7; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; Epel BL, 1996, GENE, V173, P75, DOI 10.1016/0378-1119(95)00678-8; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KAHANA JA, 1996, CURRENT PROTOCOLS MO; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; Ludin B, 1996, GENE, V173, P107, DOI 10.1016/0378-1119(95)00899-3; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; OLSEN KR, 1995, J CELL BIOL, V130, P639; ORMO M, 1996, IN PRESS SCIENCE; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK WAR; PEROZZO MA, 1988, J BIOL CHEM, V263, P7713; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RAO BDN, 1980, BIOPHYS J, V32, P630, DOI 10.1016/S0006-3495(80)84999-X; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; WARD WW, 1979, PHOTOCH PHOTOBIO SCI, P1; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	46	1233	1314	18	405	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1246	1251		10.1038/nbt1096-1246	http://dx.doi.org/10.1038/nbt1096-1246			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631087	Green Submitted			2022-12-25	WOS:A1996VK61800021
J	Lietman, T; Porco, T; Dawson, C; Blower, S				Lietman, T; Porco, T; Dawson, C; Blower, S			Global elimination of trachoma: How frequently should we administer mass chemotherapy?	NATURE MEDICINE			English	Article							SINGLE-DOSE AZITHROMYCIN; INTRINSIC TRANSMISSION DYNAMICS; CHLAMYDIA-TRACHOMATIS; ENDEMIC TRACHOMA; TUBERCULOSIS EPIDEMICS; GAMBIAN VILLAGE; WOMEN; DOXYCYCLINE; INFECTIONS; BLINDNESS	The World Health Organization has recommended repeat mass drug administration as part of their global initiative to eliminate blinding trachoma by the year 2020. The efficacy of repeat treatment will be tested empirically, but the results will not be available for many years, and recommendations for the necessary frequency of treatment are needed immediately. We have developed a mathematical model that uses available epidemiological data from a variety of countries. We recommend, based on our analysis, that in areas where trachoma is moderately prevalent (<35% in children), it should be treated annually, but hyperendemic areas (>50% in children), it should be treated biannually.	Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lietman, T (corresponding author), Dept Publ Hlth, San Francisco, CA USA.	tml@itsa.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935, K08AI001441] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI 41935, K08 AI 01441-0] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN L, 1998, NY TIMES, pA7; ALTMAN LK, 1998, NY TIMES        0624, pA1; ANDERSON R, 1991, INFECT DIS HUMANS DY, V62, P172; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; ASSAD FA, 1958, B WORLD HEALTH ORGAN, V34, P341; BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944; BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BARAL K, IN PRESS B WHO; Bianchi A, 1998, SEX TRANSM DIS, V25, P366, DOI 10.1097/00007435-199808000-00008; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; Bobo LD, 1997, J INFECT DIS, V176, P1524, DOI 10.1086/514151; COURTRIGHT P, 1989, BRIT J OPHTHALMOL, V73, P536, DOI 10.1136/bjo.73.7.536; DAWSON C, 1966, AM J EPIDEMIOL, V84, P411, DOI 10.1093/oxfordjournals.aje.a120654; DAWSON C, 1998, CHLAMYDIAL INFECT, P352; DAWSON CR, 1976, BRIT J OPHTHALMOL, V60, P245, DOI 10.1136/bjo.60.4.245; DIETZ K, 1985, LECTURE NOTES BIOMAT, V57, P115; DIETZ K, 1975, B I STUT I, V40, P531; GUPTA S, 1989, AIDS, V3, P807, DOI 10.1097/00002030-198912000-00005; HAYES LJ, 1995, J INFECT DIS, V172, P268, DOI 10.1093/infdis/172.1.268; Hethcote H., 1996, MODELS INFECT HUMAN, V215, P238, DOI 10.1017/CBO9780511662935.030; Hillis SD, 1998, SEX TRANSM DIS, V25, P5, DOI 10.1097/00007435-199801000-00002; MABEY D, 1998, CHLAMYDIAL INFECT, P351; Magid D, 1996, ANN INTERN MED, V124, P389, DOI 10.7326/0003-4819-124-4-199602150-00002; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; MUNOZ B, 1995, ANN M SOC MATH BIOL; NGOCHADUONG T, 1995, THESIS LONDON SCH HY, P1; Porco TC, 1998, THEOR POPUL BIOL, V54, P117, DOI 10.1006/tpbi.1998.1366; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; SCHACHTER J, 1998, P 9 INT S HUM CHLAM, P347; SCHACHTER J, 1978, HUMAN CHLAMYDIAL INF, V35; STAMM WE, 1995, JAMA-J AM MED ASSOC, V274, P545, DOI 10.1001/jama.274.7.545; STEINGRIMSSON O, 1994, SEX TRANSM DIS, V21, P43, DOI 10.1097/00007435-199401000-00009; TAYLOR HR, 1989, INVEST OPHTH VIS SCI, V30, P1823; TAYLOR HR, 1991, J CLIN MICROBIOL, V29, P1593, DOI 10.1128/JCM.29.8.1593-1595.1991; Thorpe EM, 1996, GENITOURIN MED, V72, P93; THYGESON P, 1962, AM J OPHTHALMOL, V53, P786, DOI 10.1016/0002-9394(62)93399-8; THYLEFORS B, 1990, INT OPHTHALMOL, V14, P211, DOI 10.1007/BF00158321; TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393, DOI 10.4269/ajtmh.1988.38.393; WARD M, 1990, SCAND J INFECT DIS, P137; WARD M, 1990, P 7 INT S HUM CHL IN, P591; Wehbeh HA, 1998, J REPROD MED, V43, P509; WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088; 1997, 1 M WHO ALL GLOB EL; 1998, 2 M WHO ALL GLOB EL	51	127	127	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					572	576		10.1038/8451	http://dx.doi.org/10.1038/8451			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229236				2022-12-25	WOS:000081497400040
J	Aminoff, M; Carter, JE; Chadwick, RB; Johnson, C; Grasbeck, R; Abdelaal, MA; Broch, H; Jenner, LB; Verroust, PJ; Moestrup, SK; de la Chapelle, A; Krahe, R				Aminoff, M; Carter, JE; Chadwick, RB; Johnson, C; Grasbeck, R; Abdelaal, MA; Broch, H; Jenner, LB; Verroust, PJ; Moestrup, SK; de la Chapelle, A; Krahe, R			Mutations in CUBN, encoding the intrinsic factor-vitamin B-12 receptor, cubilin, cause hereditary megaloblastic anaemia 1	NATURE GENETICS			English	Article							IMERSLUND-GRASBECK SYNDROME; HUMAN GENOME; MALABSORPTION; PROTEIN; MAP; ENDOCYTOSIS; DOMAIN	Megaloblastic anaemia 1 (MGA1, OMIM 261100) is a rare, autosomal recessive disorder characterized by juvenile megaloblastic: anaemia, as well as neurological symptoms that may be the only manifestations(1,2). At the cellular level, MGA1 is characterized by selective intestinal vitamin B-12 (B-12, cobalamin) malabsorption-2. MGA1 occurs worldwide, but its prevalence is higher in several Middle Eastern countries(3-6) and Norway(1,7), and highest in Finlands (0.8/100,000). We previously mapped the MGA1 locus by linkage analysis in Finnish and Norwegian families to a 6-cM region on chromosome 10p12.1 (ref. 8). A functional candidate gene encoding the intrinsic factor (IF)-B-12 receptor, cubilin, was recently cloned(9,10); the human homologue, CUBN, was mapped to the same region(10). We have now refined the MGA1 region by linkage disequilibrium (LD) mapping, fine-mapped CUBN and identified two independent disease-specific CUBN mutations in 17 Finnish MGA1 families. Our genetic and molecular data indicate that mutations in CUBN cause MGA1.	Ohio State Univ, Div Human Canc Genet, Dept Immunol & Med Microbiol, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Helsinki, Dept Med Genet, Folkhalsan Inst Genet, FIN-00280 Helsinki, Finland; Minerva Fdn, Inst Med Res, FIN-00250 Helsinki, Finland; Natl Guard King Khalid Hosp, Dept Pathol, Jeddah 21423, Saudi Arabia; Vestfold Cent Hosp, Dept Pediat, N-3103 Tonesberg, Norway; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark; Hop Tenon, INSERM U 489, F-75020 Paris, France; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Helsinki; King Saud University; King Khalid University Hospital; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Aarhus University	Krahe, R (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Immunol & Med Microbiol, Ctr Comprehens Canc, Columbus, OH 43210 USA.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019; Jenner, Lasse/H-1584-2017	Moestrup, Søren Kragh/0000-0003-3862-2107; Jenner, Lasse/0000-0003-3917-8853	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELAAL MA, 1991, ACTA PAEDIATR SCAND, V80, P1109; ALTAY C, 1995, PEDIATR HEMAT ONCOL, V12, P19, DOI 10.3109/08880019509029524; AMINOFF M, 1995, AM J HUM GENET, V57, P824; BENBASSA.I, 1969, ISRAEL J MED SCI, V5, P62; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BROCH H, 1984, ACTA PAEDIATR SCAND, V73, P248, DOI 10.1111/j.1651-2227.1984.tb09937.x; BURMAN JF, 1985, GUT, V26, P311, DOI 10.1136/gut.26.3.311; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dugue B, 1998, J PEDIATR GASTR NUTR, V26, P21, DOI 10.1097/00005176-199801000-00004; FURUHJELM U, 1973, SCAND J HAEMATOL, V11, P27; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; Grasbeck R, 1997, ACTA BIOCHIM POL, V44, P725; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Imerslund O, 1960, ACTA PAEDIATR, V49, P208; Ismail EAR, 1997, ACTA PAEDIATR, V86, P424, DOI 10.1111/j.1651-2227.1997.tb09035.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kozyraki R, 1998, BLOOD, V91, P3593; KRAULIS P, 1991, J APP CRYST A, V47, P110; MACKENZI.IL, 1972, NEW ENGL J MED, V286, P1021, DOI 10.1056/NEJM197205112861902; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; MOESTRUP SK, IN PRESS CHEM BIOCH; PHELPS RS, 1995, BIOTECHNIQUES, V19, P984; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; SAHALI D, 1992, AM J PATHOL, V140, P33	30	186	189	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					309	313		10.1038/6831	http://dx.doi.org/10.1038/6831			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080186				2022-12-25	WOS:000078977900027
J	Reineke, U; Sabat, R; Misselwitz, R; Welfle, H; Volk, HD; Schneider-Mergener, J				Reineke, U; Sabat, R; Misselwitz, R; Welfle, H; Volk, HD; Schneider-Mergener, J			A synthetic mimic of a discontinuous binding site on interleukin-10	NATURE BIOTECHNOLOGY			English	Article						interleukin-10; protein mimics; antibody epitope; peptide library; mini-protein	BOUND PEPTIDE LIBRARIES; CRYSTAL-STRUCTURE; RECEPTOR; IDENTIFICATION; ERYTHROPOIETIN; ANTIBODY; COMPLEX; HORMONE	We synthetically reconstructed a discontinuous binding site on interleukin-10 (IL-10) that recognizes the neutralizing anti-IL-10 antibody CB/RS/1. To design the 32-mer IL-10 mimic, a discontinuous interaction site on IL-10 was mapped, and binding studies with epitope-derived peptides led to specific replacement of several amino acids. Both parts of the interaction site were combined by addition of a linker molecule. Systematic analoging of the combined molecule then led to introduction of several additional substitutions in both regions and the linker. All possible disulfide bridge-containing variants of the 32-mer were tested by binding studies. Parallel syntheses were performed on continuous cellulose membranes by spot synthesis. As a result, a conformationally stabilized IL-10-derived molecule was obtained that both binds to and neutralizes the biological activity of CB/RS/1 in the low nanomolar range. This synthetic approach is a powerful alternative to phage display methods for the design of protein mimics.	Humboldt Univ, Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Biochem, D-10098 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sabat, R (corresponding author), Humboldt Univ, Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668				ATASSI MZ, 1977, J BIOL CHEM, V252, P8784; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRANK R, 1996, COMBINATORIAL PEPTID, P363; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; Peters KP, 1996, J MOL BIOL, V256, P201, DOI 10.1006/jmbi.1996.0077; Reineke U, 1998, PROTEIN SCI, V7, P951; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; Reineke U, 1998, ANGEW CHEM INT EDIT, V37, P769, DOI 10.1002/(SICI)1521-3773(19980403)37:6<769::AID-ANIE769>3.0.CO;2-B; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Sabat R, 1996, MOL IMMUNOL, V33, P1103, DOI 10.1016/S0161-5890(96)00072-7; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; Zdanov A, 1996, PROTEIN SCI, V5, P1955, DOI 10.1002/pro.5560051001; Zhang HJ, 1997, MULTIMED TOOLS APPL, V4, P5	27	51	65	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					271	275		10.1038/7018	http://dx.doi.org/10.1038/7018			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096295				2022-12-25	WOS:000078977500029
J	VanCott, JL; Chatfield, SN; Roberts, M; Hone, DM; Hohmann, EL; Pascual, DW; Yamamoto, M; Kiyono, H; McGhee, JR				VanCott, JL; Chatfield, SN; Roberts, M; Hone, DM; Hohmann, EL; Pascual, DW; Yamamoto, M; Kiyono, H; McGhee, JR			Regulation of host immune responses by modification of Salmonella virulence genes	NATURE MEDICINE			English	Article							NITRIC-OXIDE PRODUCTION; ALPHA-BETA; PHOP-PHOQ; ATTENUATED SALMONELLA; TYPHIMURIUM INFECTION; T-CELLS; MICE; MACROPHAGES; RESISTANCE; RECEPTOR	Modifying bacterial virulence genes to probe the nature of host immunity is mostly unexplored. Here we investigate whether host immune responses can be regulated by modification of bacterial virulence genes. In mice, attenuated Salmonella mutant strains with clinical relevance elicited differential host immune responses. Oral administration of a mutant strain with a PhoP-null phenotype promoted potent innate immune responses of macrophages that were sufficient for host defense. In contrast, administration of an Aro(-) mutant strain elicited stronger specific antibody and T-helper (Th)-cell responses, wherein Th1-type cells were required for clearance. Thus, genetic manipulation of bacteria may be used to broadly alter immune mechanisms that regulate attenuation within the host and to tailor host immunity to specific bacterial pathogens.	Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, MEDEVA, Vaccine Res Unit, London SW7 2AY, England; Univ Glasgow, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Inst Human Virol, Div Vaccine Res, Baltimore, MD 21201 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Montana State Univ, Bozeman, MT 59717 USA; Osaka Univ, Microbial Dis Res Inst, Dept Mucosal Immun, Suita, Osaka 565, Japan; Univ Alabama Birmingham, Immunobiol Vaccine Ctr, Dept Microbiol, Birmingham, AL 35294 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Imperial College London; University of Glasgow; University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital; Montana State University System; Montana State University Bozeman; Osaka University; University of Alabama System; University of Alabama Birmingham	VanCott, JL (corresponding author), Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA.		Pascual, David/AAC-2248-2022; Kiyono, Hiroshi/AAC-6735-2022		NCRR NIH HHS [RR 13149] Funding Source: Medline; NIAID NIH HHS [AI 18958] Funding Source: Medline; NIDDK NIH HHS [DK 44240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALRAMADI BK, 1991, J IMMUNOL, V146, P2737; ALRAMADI BK, 1992, EUR J IMMUNOL, V22, P2249, DOI 10.1002/eji.1830220911; CHATFIELD SN, 1992, MICROB PATHOGENESIS, V12, P145, DOI 10.1016/0882-4010(92)90117-7; CHATFIELD SN, 1992, BIO-TECHNOL, V10, P888, DOI 10.1038/nbt0892-888; Cowley SC, 1996, MOL MICROBIOL, V20, P867, DOI 10.1111/j.1365-2958.1996.tb02524.x; CURTISS R, 1987, INFECT IMMUN, V55, P3035, DOI 10.1128/IAI.55.12.3035-3043.1987; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; EDWARDS CK, 1992, INFECT IMMUN, V60, P2514, DOI 10.1128/IAI.60.6.2514-2521.1992; Eisenstein TK, 1998, VACCINE, V16, P24, DOI 10.1016/S0264-410X(97)00160-6; Fujihashi K, 1998, METHOD MICROBIOL, V25, P257; GALAN JE, 1989, MICROB PATHOGENESIS, V6, P433, DOI 10.1016/0882-4010(89)90085-5; GANGADHARAM PRJ, 1984, AM REV RESPIR DIS, V130, P834; Gotschlich Emil C., 1993, P1287; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hess J, 1996, J IMMUNOL, V156, P3321; Hohmann EL, 1996, VACCINE, V14, P19, DOI 10.1016/0264-410X(95)00173-X; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Levine MM, 1996, J BIOTECHNOL, V44, P193, DOI 10.1016/0168-1656(95)00094-1; LISSNER CR, 1983, J IMMUNOL, V131, P3006; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1991, MOL MICROBIOL, V5, P2073, DOI 10.1111/j.1365-2958.1991.tb02135.x; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Pawelek JM, 1997, CANCER RES, V57, P4537; Snapper Clifford M., 1993, P837; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SZALAI AJ, 1995, J IMMUNOL, V155, P2557; TACKET CO, 1992, INFECT IMMUN, V60, P536, DOI 10.1128/IAI.60.2.536-541.1992; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; Umezawa K, 1997, INFECT IMMUN, V65, P2932, DOI 10.1128/IAI.65.7.2932-2940.1997; VanCott JL, 1996, J IMMUNOL, V156, P1504; VANCOTT JL, 1995, MUCOSAL IMMUNOL UPDA, V34, P12; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; Weintraub BC, 1997, INFECT IMMUN, V65, P2306, DOI 10.1128/IAI.65.6.2306-2312.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANG JF, 1995, J IMMUNOL, V155, P5728	43	111	119	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1247	1252		10.1038/3227	http://dx.doi.org/10.1038/3227			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809547	Bronze			2022-12-25	WOS:000076731000032
J	During, MJ; Xu, RL; Young, D; Kaplitt, MG; Sherwin, RS; Leone, P				During, MJ; Xu, RL; Young, D; Kaplitt, MG; Sherwin, RS; Leone, P			Peroral gene therapy of lactose intolerance using an adeno-associated virus vector	NATURE MEDICINE			English	Article							LACTASE-PHLORIZIN HYDROLASE; ADULT-TYPE HYPOLACTASIA; IN-VIVO; EXPRESSION; BRAIN; MILK	Gene therapy is usually reserved for severe and medically refractory disorders because of the toxicity, potential long-term risks and invasiveness of most gene transfer protocols. Here we show that an orally administered adeno-associated viral vector leads to persistent expression of a beta-galactosidase transgene in both gut epithelial and lamina propria cells, and that this approach results in long-term phenotypic recovery in an animal model of lactose intolerance. A gene 'pill' associated with highly efficient and stable gene expression might be a practical and cost-effective strategy for even relatively mild disorders, such as lactase deficiency.	Univ Auckland, Sch Med, Dept Mol Med, Auckland, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurosurg, CNS Gene Therapy Ctr, Philadelphia, PA 19107 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; Rockefeller Univ, Dept Neurobiol, New York, NY 10021 USA	University of Auckland; Jefferson University; Yale University; Yale University; Rockefeller University	During, MJ (corresponding author), Univ Auckland, Sch Med, Dept Mol Med, 85 Park Rd, Auckland, New Zealand.	Matthew.During@mail.tju.edu	During, Matthew/AAC-1388-2020	Young, Deborah/0000-0003-1085-2824				Berns K I, 1979, Adv Virus Res, V25, P407, DOI 10.1016/S0065-3527(08)60574-6; BIRGE SJ, 1967, NEW ENGL J MED, V276, P445, DOI 10.1056/NEJM196702232760805; BULLER HA, 1989, AM J PHYSIOL, V257, pG616, DOI 10.1152/ajpgi.1989.257.4.G616; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DURING MJ, 1995, J CLIN INVEST, V95, P2403, DOI 10.1172/JCI117935; FLATZ G, 1987, ADV HUM GENET, V16, P1; Honkanen R, 1997, BONE, V21, P473, DOI 10.1016/S8756-3282(97)00172-5; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; LISKER R, 1975, AM J HUM GENET, V27, P662; MAIURI L, 1994, GASTROENTEROLOGY, V107, P54, DOI 10.1016/0016-5085(94)90060-4; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; SAHI T, 1973, LANCET, V2, P823; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SCRIMSHAW N S, 1988, American Journal of Clinical Nutrition, V48, P1083; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SERVICE RF, 1994, SCIENCE, V265, P1522, DOI 10.1126/science.8079164; STALLINGS VA, 1994, J PEDIATR GASTR NUTR, V18, P440, DOI 10.1097/00005176-199405000-00006; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	23	110	130	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1131	1135		10.1038/2625	http://dx.doi.org/10.1038/2625			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771745				2022-12-25	WOS:000076230100031
J	Hall, AR; Dix, BR; O'Carroll, SJ; Braithwaite, AW				Hall, AR; Dix, BR; O'Carroll, SJ; Braithwaite, AW			p53-dependent cell death apoptosis is required for a productive adenovirus infection	NATURE MEDICINE			English	Article							WILD-TYPE P53; GENE; EXPRESSION; P16(INK4); PROTEIN; MUTANT; TRANSACTIVATION; IMMORTALIZATION; INHIBITION; MUTATIONS	The p53 tumor suppressor protein binds to both cellular and viral proteins, which influence its biological activity. One such protein is the large E1b tumor antigen(1) (E1b58kDa) from adenoviruses (Ads), which abrogates the ability of p53 to transactivate various promoters(2). This inactivation of p53 function is believed to be the mechanism by which E1b58kDa contributes to the cell transformation process(2). Although the p53-E1b58kDa complex occurs during infection(3) and is conserved among different serotypes(4), there are limited data demonstrating that it has a role in virus replication. However, loss of p53 expression occurs after adenovirus infection of human cells(4,5) and an E1b58kDa deletion mutant (Onyx-015, also called dl 1520) selectively replicates in p53-defective cells(6,7). These (and other) data indicate a plausible hypothesis is that loss of p53 function may be conducive to efficient adenovirus replication. However, wild-type (wt) Ad5 grows more efficiently in cells expressing a wt p53 protein(5). These studies indicate that the hypothesis may be an oversimplification. Here, we show that cells expressing wt p53, as well as p53-defective cells, allow adenovirus replication, but only cells expressing wt p53 show evidence of virus-induced cytopathic effect. This correlates with the ability of adenovirus to induce cell death. Our data indicate that p53 plays a necessary part in mediating cellular destruction to allow a productive adenovirus infection. In contrast, p53-deficient cells are less sensitive to the cytolytic effects of adenovirus and as such raise questions about the use of E1b58kDa-deficient adenoviruses in tumor therapy(6,7).	Univ Otago, Dunedin Sch Med, Cell Transformat Grp, Dept Pathol, Dunedin, New Zealand	University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Cell Transformat Grp, Dept Pathol, POB 913, Dunedin, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz						ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; EVDOKIOU A, 1997, THESIS U ADELAIDE; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; LEHMAN TA, 1991, CANCER RES, V51, P4090; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PHILIPSON L, 1973, COMPREHENSIVE VIROLO, V3, P143; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Precious B., 1985, VIROLOGY PRACTICAL A, P193; Ridgway PJ, 1997, VIROLOGY, V237, P404, DOI 10.1006/viro.1997.8782; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROMANO JW, 1989, ONCOGENE, V4, P1483; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHARMA S, 1993, MOL CELL BIOL, V12, P5581; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WHITAKER NJ, 1995, ONCOGENE, V11, P971; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	29	212	221	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1068	1072		10.1038/2057	http://dx.doi.org/10.1038/2057			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734403				2022-12-25	WOS:000075804100043
J	Kelleher, ZT; Fu, HY; Livanos, E; Wendelburg, B; Gulino, S; Vos, JM				Kelleher, ZT; Fu, HY; Livanos, E; Wendelburg, B; Gulino, S; Vos, JM			Epstein-Barr-based episomal chromosomes shuttle 100 kb of self-replicating circular human DNA in mouse cells	NATURE BIOTECHNOLOGY			English	Article						gene transfer; artificial chromosome; functional genomics	MAMMALIAN-CELLS; VIRUS; PLASMID; MAINTENANCE; VECTORS; YEAST; SEQUENCES; FRAGMENTS; CLONING; BINDING	We describe the microcell fusion transfer of 100-200 kb self-replicating circular human minichromosomes from human into mouse cells. This experimental approach is illustrated through the shuttling of the latent 170 kb double-stranded DNA genome from the human herpesvirus, Epstein-Barr virus, into nonpermissive rodent cells. Using this interspecies transfer strategy, circular episomes carrying 95-105 kb of human DNA were successfully established at low copy number in mouse A9 cells. Selected episomes were stably maintained for 6 months, and unselected episomes were characterized by a 95% episomal retention per cell division. The establishment of a mouse artificial episomal chromosome system should facilitate evolutionary and therapeutic studies of large human DNA in rodent genetic backgrounds.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Vos, JM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	vos@mcd.unc.edu						BANERJEE S, 1995, NAT MED, V1, P1303, DOI 10.1038/nm1295-1303; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; FEATHERSTONE T, 1993, GENOMICS, V17, P267, DOI 10.1006/geno.1993.1321; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GLASER R, 1978, J CELL PHYSIOL, V96, P319, DOI 10.1002/jcp.1040960307; JANKELEVICH S, 1992, EMBO J, V11, P1165, DOI 10.1002/j.1460-2075.1992.tb05157.x; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kirby SL, 1996, P NATL ACAD SCI USA, V93, P9402, DOI 10.1073/pnas.93.18.9402; KOSZTOLANYI G, 1991, HUM GENET, V87, P320; KRYSAN PJ, 1993, MOL CELL BIOL, V13, P2688, DOI 10.1128/MCB.13.5.2688; KRYSAN PJ, 1993, GENE, V136, P137, DOI 10.1016/0378-1119(93)90457-E; LAWCE HJ, 1991, ACT CYTOGENETICS LAB, P31; Licht T, 1997, STEM CELLS, V15, P104, DOI 10.1002/stem.150104; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; POTTEN CS, 1988, J CELL SCI, P45; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; SANFORD JA, 1987, SOMAT CELL MOLEC GEN, V13, P279, DOI 10.1007/BF01535210; Shimizu N, 1996, NAT GENET, V12, P65, DOI 10.1038/ng0196-65; Simpson K, 1996, MOL CELL BIOL, V16, P5117; STEPLEWSKI Z, 1978, J CELL PHYSIOL, V97, P1, DOI 10.1002/jcp.1040970102; Sun TQ, 1996, GENE THER, V3, P1081; SUN TQ, 1994, NAT GENET, V8, P33, DOI 10.1038/ng0994-33; SUN TQ, 1996, METHODS MOL GENETICS, P167; Taylor SS, 1996, CHROMOSOMA, V105, P70, DOI 10.1007/BF02509516; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Vos JMH, 1997, NAT BIOTECHNOL, V15, P1257, DOI 10.1038/nbt1197-1257; VOS JMH, 1998, IN PRESS CURR OPIN G, V8; WENDELBURG BJ, 1998, IN PRESS GENE THER; WESTPHAL EM, 1998, IN PRESS HUM GENE TH; Wohlgemuth JG, 1996, GENE THER, V3, P503; YAMAMOTO K, 1978, P NATL ACAD SCI USA, V75, P5155, DOI 10.1073/pnas.75.10.5155; Yates J.L, 1996, DNA REPLICATION EUKA, P751; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	36	36	36	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					762	768		10.1038/nbt0898-762	http://dx.doi.org/10.1038/nbt0898-762			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702776				2022-12-25	WOS:000075183400035
J	Schutze, K; Lahr, G				Schutze, K; Lahr, G			Identification of expressed genes by laser-mediated manipulation of single cells	NATURE BIOTECHNOLOGY			English	Article						gene analysis technology; in situ analysis; RT-PCR	RAS ONCOGENES; N-RAS; MICRODISSECTION; TRANSCRIPTION; MUTATIONS; TUMORS; TISSUE; COLON; PCR	We describe a rapid noncontact method for the capture of single cells or small tissue areas of any size or shape directly within the cap of a common microfuge tube. Prior to the laser-mediated transfer, the specimen is isolated by laser microbeam microdissection, forming a clear-cut gap around the selected area. Laser treatment does not impair subsequent RNA analysis. We have used this method to isolate a single cell from archival colon adenocarcinoma, and were able to detect point mutations within codon 12 of c-Ki-ras2 mRNA after nested RT-PCR analysis.	Acad Hosp Munchen Harlaching, Dept Med 1, Laser Lab & Mol Biol, Munich, Germany		Lahr, G (corresponding author), Acad Hosp Munchen Harlaching, Dept Med 1, Laser Lab & Mol Biol, Munich, Germany.	G.Lahr@extern.lrz-muenchen.de						Antinori S, 1996, HUM REPROD, V11, P2488; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUERLE D, 1996, LASER PROCESSING CHE, P420; Becker I, 1996, LAB INVEST, V75, P801; Bohm M, 1997, INT J ONCOL, V10, P131; Bohm M, 1997, AM J PATHOL, V151, P63; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; Cerroni L, 1997, BRIT J DERMATOL, V136, P743, DOI 10.1111/j.1365-2133.1997.tb03663.x; ClementSengewald A, 1996, J ASSIST REPROD GEN, V13, P259, DOI 10.1007/BF02065947; DEWITH A, 1995, J PHOTOCH PHOTOBIO B, V30, P71, DOI 10.1016/1011-1344(95)07151-Q; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUKUI K, 1992, THEOR APPL GENET, V84, P787, DOI 10.1007/BF00227385; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HEINZMANN U, 1996, MENSCH UMWELT INFORM, V1, P1; JIANG W, 1989, ONCOGENE, V4, P923; KUBO Y, 1995, CANCER RES, V55, P989; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; LAHR G, 1995, MOL BRAIN RES, V33, P179; Liow SL, 1996, HUM REPROD, V11, P1273; MCBRIDE OW, 1983, NUCLEIC ACIDS RES, V11, P8221, DOI 10.1093/nar/11.23.8221; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MEIERRUGE W, 1976, HISTOCHEM J, V8, P387, DOI 10.1007/BF01003828; MIES C, 1994, J HISTOCHEM CYTOCHEM, V42, P811, DOI 10.1177/42.6.7514626; Ponten F, 1997, MUTAT RES-GENOMICS, V382, P45, DOI 10.1016/S1383-5726(97)00008-3; SCHINDLER M, 1989, METHOD CELL BIOL, V32, P423; Schutze K, 1997, GENET ANAL-BIOMOL E, V14, P1, DOI 10.1016/S1050-3862(96)00169-6; SHIBATA D, 1993, AM J PATHOL, V143, P1523; SRINIVASAN R, 1986, SCIENCE, V234, P559, DOI 10.1126/science.3764428; Thalhammer S, 1997, J Biomed Opt, V2, P115, DOI 10.1117/12.259626; Vasmatzis G, 1998, P NATL ACAD SCI USA, V95, P300, DOI 10.1073/pnas.95.1.300; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINER M, 1996, MENSCH UMWELT INFORM, V1, P5; WHETSELL L, 1992, ONCOGENE, V7, P2355; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	37	345	375	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					737	742		10.1038/nbt0898-737	http://dx.doi.org/10.1038/nbt0898-737			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702771				2022-12-25	WOS:000075183400030
J	Sharipo, A; Imreh, M; Leonchiks, A; Imreh, S; Masucci, MG				Sharipo, A; Imreh, M; Leonchiks, A; Imreh, S; Masucci, MG			A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappa B alpha with the proteasome: A new mechanism for selective inhibition of proteolysis	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; SIGNAL-INDUCED PHOSPHORYLATION; DEGRADATION; ACTIVATION; DISSOCIATION; PATHWAY; IDENTIFICATION; SUFFICIENT; ANTIBODIES; PROTEINS	The Epstein-Barr virus nuclear antigen 1 contains a glycine-alanine repeat that inhibits in cis MHC class I-restricted presentation. We report here that insertion of a minimal glycine-alanine repeat motif in different positions of I kappa B alpha protects this NF-kappa B inhibitor from signal-induced degradation dependent on ubiquitin-proteasome, and decreases its basal turnover in vivo resulting in constitutive dominant-negative mutants. The chimeras are phosphorylated and ubiquitinated in response to tumor necrosis factor alpha, but are then released from NF-kappa B and fail to associate with the proteasome. This explains how functionally competent I kappa B alpha is protected from proteasomal disruption and identifies the glycine-alanine repeat as a new regulator of proteolysis.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Kirchenstein Inst Microbiol & Virol, Riga, Latvia	Karolinska Institutet; Riga Stradins University	Masucci, MG (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	maria.masucci@mtc.ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Berg A., 1993, GENE DEV, V7, P2064; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Goldberg AL, 1997, BIOL CHEM, V378, P131; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lin L, 1996, MOL CELL BIOL, V16, P2248; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Oldstone MBA, 1997, VIROLOGY, V234, P179, DOI 10.1006/viro.1997.8674; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; RISE NR, 1993, EMBO J, V12, P4685; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; Thiel BL, 1997, BIOPOLYMERS, V41, P703, DOI 10.1002/(SICI)1097-0282(199706)41:7<703::AID-BIP1>3.0.CO;2-T; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; Yates JL, 1996, VIROLOGY, V222, P1, DOI 10.1006/viro.1996.0392	41	107	111	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					939	944		10.1038/nm0898-939	http://dx.doi.org/10.1038/nm0898-939			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701247				2022-12-25	WOS:000075107400038
J	Figeys, D; Ducret, A; Yates, JR; Aebersold, R				Figeys, D; Ducret, A; Yates, JR; Aebersold, R			Protein identification by solid phase microextraction-capillary zone electrophoresis-microelectrospray-tandem mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						two dimensional gel electrophoresis; yeast genome sequence	AMINO-ACID-SEQUENCES; MICRO-ELECTROSPRAY; PEPTIDES; DATABASE; SENSITIVITY; DBEST; TAGS	We describe an analytical system for the rapid identification of proteins by correlation of tandem mass spectra with protein sequence databases. The system consists of an integrated solid phase microextraction/capillary zone electrophoresis peptide separation device that is connected through a microelectrospray ion source to a tandem mass spectrometer. The limits of detection are 660 amol of sample at a concentration limit of <33 amol/mu l for peptide mass measurement, and <10 fmol of sample, at a concentration limit of <300 amol/mu l for peptide analysis by collision-induced dissociation. Using this system, we have identified low nanogram amounts of yeast proteins separated by high-resolution two-dimensional gel electrophoresis.	UNIV WASHINGTON,DEPT MOL BIOTECHNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Figeys, Daniel/0000-0002-5373-7546				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDREN PE, 1994, J AM SOC MASS SPECTR, V5, P867, DOI 10.1016/1044-0305(94)87010-1; BEATTIE JH, 1995, ELECTROPHORESIS, V16, P322, DOI 10.1002/elps.1150160153; BLEASBY AJ, 1990, PROTEIN ENG, V3, P153, DOI 10.1093/protein/3.3.153; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; Ducret A, 1996, ELECTROPHORESIS, V17, P866, DOI 10.1002/elps.1150170508; EMMETT MR, 1994, J AM SOC MASS SPECTR, V5, P605, DOI 10.1016/1044-0305(94)85001-1; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Figeys D, 1996, ANAL CHEM, V68, P1822, DOI 10.1021/ac960191h; JAZWINSKI M, 1990, METHODS ENZUMOLOGY G, P154; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; *NATL CTR HUM GEN, 1996, INT TEAM COMPL DNA S; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1791, DOI 10.1002/elps.11501601299; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P278, DOI 10.1002/elps.1150150147; STRANG RHC, 1985, PESTIC SCI, V16, P541; Strausbauch MA, 1996, ANAL CHEM, V68, P306, DOI 10.1021/ac9503217; TOMLINSON AJ, 1995, J CHROMATOGR B, V669, P65; WAHL JH, 1994, J CAPILLARY ELECTROP, V1, P62; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	20	161	173	1	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1579	1583		10.1038/nbt1196-1579	http://dx.doi.org/10.1038/nbt1196-1579			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634825				2022-12-25	WOS:A1996VP83300026
J	Eto, T; Takahashi, H				Eto, T; Takahashi, H			Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon	NATURE MEDICINE			English	Article							BETA; EXPRESSION; CELLS; LIPOSOMES; LIVER; ALPHA; LINE; DNA	Most chronic carriers of hepatitis B virus (HBV) do not respond to interferon (IFN) treatment This limitation of IFN therapy may be due in part to scant expression of IFN receptor in the liver(1,2) Because the asialoglycoprotein (ASGP) receptor is specifically expressed in the liver at high denity(3), the ASGP receptor-binding domain was generated within an N-glycosylated human IFN-beta molecule(4,5) by the removal of sialic acid to direct this cytokine to the liver. This modified IFN (asialo-IFN-beta) demonstrated greater inhibition of HBV production in ASGP receptor-positive human liver cells transfected with a replication-competent HBV construct than did conventional IFN-alpha or IFN-beta. Furthermore, the enhanced antiviral effect of asialo-IFN-beta was supported by induction of the 2'-5' oligoadenylate synthetase, an indicator of IFN activity(6), at a level significantly higher than that produced by conventional IFN-beta Moreover, mouse asialo-IFN-beta profoundry reduced viremia in vivo in HBV-transfected athymic nude mice, in contrast to conventional IFN-beta, which had no substantial effect. These experiments demonstrate that directing IFN to ASGP receptor facilitates its signaling in the liver and augments its antiviral effect, and is therefore useful in overcoming the limited antiviral effect of conventional IFNs.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Takahashi, H (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Jackson 7,Fruit St, Boston, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R29CA057584, R01CA057584] Funding Source: NIH RePORTER; NCI NIH HHS [CA57584] Funding Source: Medline; NIDDK NIH HHS [NIDDK4331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BURGESS JB, 1992, HEPATOLOGY, V15, P702, DOI 10.1002/hep.1840150425; CONRADT HS, 1987, J BIOL CHEM, V262, P14600; DERYNCK R, 1980, NATURE, V285, P542, DOI 10.1038/285542a0; EISENBERG C, 1991, J HEPATOL, V13, P305, DOI 10.1016/0168-8278(91)90073-K; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; HUEZ G, 1983, BIOCHEM BIOPH RES CO, V110, P155, DOI 10.1016/0006-291X(83)91273-1; HYODO I, 1993, LIVER, V13, P80; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; KAWADE Y, 1980, J INTERFERON RES, V1, P61, DOI 10.1089/jir.1980.1.61; KILLION JJ, 1989, J NATL CANCER I, V81, P1387, DOI 10.1093/jnci/81.18.1387; LEE YC, 1983, J BIOL CHEM, V258, P199; LIANG TJ, 1993, J CLIN INVEST, V91, P1241, DOI 10.1172/JCI116287; PESKA S, 1997, SEMIN ONCOL, V9; REDLICH PN, 1991, P NATL ACAD SCI USA, V88, P4040, DOI 10.1073/pnas.88.9.4040; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SEIF I, 1991, J VIROL, V65, P664, DOI 10.1128/JVI.65.2.664-671.1991; SHINDO M, 1988, HEPATOLOGY, V8, P366, DOI 10.1002/hep.1840080229; TAKAHASHI H, 1995, P NATL ACAD SCI USA, V92, P1470, DOI 10.1073/pnas.92.5.1470; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TRUBETSKOY VS, 1992, BIOCHIM BIOPHYS ACTA, V1131, P311, DOI 10.1016/0167-4781(92)90030-4; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	25	38	43	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					577	581		10.1038/8462	http://dx.doi.org/10.1038/8462			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229237				2022-12-25	WOS:000081497400041
J	Blezinger, P; Wang, JJ; Gondo, M; Quezada, A; Mehrens, D; French, M; Singhal, A; Sullivan, S; Rolland, A; Ralston, R; Min, W				Blezinger, P; Wang, JJ; Gondo, M; Quezada, A; Mehrens, D; French, M; Singhal, A; Sullivan, S; Rolland, A; Ralston, R; Min, W			Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene	NATURE BIOTECHNOLOGY			English	Article						angiogenesis; endostatin; gene therapy; cancer; intramuscular delivery	IN-VIVO; SKELETAL-MUSCLE; THERAPY; ANGIOGENESIS; ANGIOSTATIN; CANCER; SUPPRESSION; RESISTANCE; PLASMID; PROLIFERATION	Tumors require ongoing angiogenesis to support their growth, Inhibition of angiogenesis by production of angiostatic factors should be a viable approach for cancer gene therapy. Endostatin, a potent angiostatic factor, was expressed in mouse muscle and secreted into the bloodstream for up to 2 weeks after a single intramuscular administration of the endostatin gene. The biological activity of the expressed endostatin was demonstrated by its ability to inhibit systemic angiogenesis. Moreover, the sustained production of endostatin by intramuscular gene therapy inhibited both the growth of primary tumors and the development of metastatic lesions. These results demonstrate the potential utility of intramuscular delivery of an antiangiogenic gene for treatment of disseminated cancers.	GeneMed Inc, The Woodlands, TX 77381 USA		Min, W (corresponding author), GeneMed Inc, 8301 New Trails Dr, The Woodlands, TX 77381 USA.	minw@genemedicine.com	Ralston, Robert O/A-6924-2009	Rolland, Alain/0000-0002-7995-0548				Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Alila H, 1997, HUM GENE THER, V8, P1785, DOI 10.1089/hum.1997.8.15-1785; Anderson WF, 1998, NATURE, V392, P25; Anwer K, 1998, HUM GENE THER, V9, P659, DOI 10.1089/hum.1998.9.5-659; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DAVIS HL, 1993, HUM GENE THER, V4, P733, DOI 10.1089/hum.1993.4.6-733; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1998, NAT MED, V4, P13, DOI 10.1038/nm0198-013; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kong HL, 1998, J NATL CANCER I, V90, P273, DOI 10.1093/jnci/90.4.273; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; Lannutti BJ, 1997, CANCER RES, V57, P5277; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Mumper RJ, 1996, PHARMACEUT RES, V13, P701, DOI 10.1023/A:1016039330870; Mumper RJ, 1998, J CONTROL RELEASE, V52, P191, DOI 10.1016/S0168-3659(97)00215-0; O'Reilly Michael, 1993, Surgical Forum, V44, P474; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OREILLY MS, 1996, NAT MED, V2, P889; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; Rolland AP, 1998, CRIT REV THER DRUG, V15, P143, DOI 10.1615/CritRevTherDrugCarrierSyst.v15.i2.20; SCHOFIELD JP, 1995, BRIT MED BULL, V51, P56, DOI 10.1093/oxfordjournals.bmb.a072953; Sim BKL, 1997, CANCER RES, V57, P1329; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; Tanaka T, 1998, CANCER RES, V58, P3362; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WARREN BA, 1977, PROGR CANC RES THERA, P185; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	37	268	318	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					343	348		10.1038/7895	http://dx.doi.org/10.1038/7895			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207881				2022-12-25	WOS:000079574400021
J	Trivedi, B				Trivedi, B			Encapsulating the right chemistry	NATURE BIOTECHNOLOGY			English	Article								Chemists are turning to biological systems to increase the efficiency and sophistication of molecular syntheses and separations.										Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211	1	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					339	341		10.1038/7892	http://dx.doi.org/10.1038/7892			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207880				2022-12-25	WOS:000079574400020
J	Lanford, PJ; Lan, Y; Jiang, RL; Lindsell, C; Weinmaster, G; Gridley, T; Kelley, MW				Lanford, PJ; Lan, Y; Jiang, RL; Lindsell, C; Weinmaster, G; Gridley, T; Kelley, MW			Notch signalling pathway mediates hair cell development in mammalian cochlea	NATURE GENETICS			English	Article							NEUROGENIC GENE-DELTA; DROSOPHILA; HOMOLOG; EMBRYOGENESIS; JAGGED2; LIGAND; CORTI	The mammalian cochlea contains an invariant mosaic of sensory hair cells and non-sensory supporting cells reminiscent of invertebrate structures such as the compound eye in Drosophila melanogaster(1,2). The sensory epithelium in the mammalian cochlea (the organ of Corti) contains four rows of mechanosensory hair cells: a single row of inner hair cells and three rows of outer hair cells. Each hair cell is separated from the next by an interceding supporting cell, forming an invariant and alternating mosaic that extends the length of the cochlear duct(1). Previous results suggest that determination of cell fates in the cochlear mosaic occurs via inhibitory interactions between adjacent progenitor cells(3-5) (lateral inhibition). Cells populating the cochlear epithelium appear to constitute a developmental equivalence group in which developing hair cells suppress differentiation in their immediate neighbours through lateral inhibition(6). These interactions may be mediated through the Notch signalling pathway, a molecular mechanism that is involved in the determination of a variety of cell fates(7-9) Here we show that genes encoding the receptor protein Notch1 and its ligand, lagged 2, are expressed in alternating cell types in the developing sensory epithelium. In addition, genetic deletion of Jag2 results in a significant increase in sensory hair cells, presumably as a result of a decrease in Notch activation. These results provide direct evidence for Notch-mediated lateral inhibition in a mammalian system and support a role for Notch in the development of the cochlear mosaic.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20007 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90024 USA	Georgetown University; Jackson Laboratory; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kelley, MW (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	kelleym2@gunet.georgetown.edu		Jiang, Rulang/0000-0001-7842-4696	PHS HHS [K02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adam J, 1998, DEVELOPMENT, V125, P4645; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BASLER K, 1991, BIOESSAYS, V13, P621, DOI 10.1002/bies.950131202; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CORWIN JT, 1991, CIBA F SYMP, V160, P103; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; Dornseifer P, 1997, MECH DEVELOP, V63, P159, DOI 10.1016/S0925-4773(97)00037-3; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Haddon C, 1998, DEVELOPMENT, V125, P4637; Haddon C, 1998, DEVELOPMENT, V125, P359; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P123; KELLEY MW, 1995, J NEUROSCI, V15, P3013; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Kopan R, 1997, TRENDS GENET, V13, P465, DOI 10.1016/S0168-9525(97)01318-8; LEWIS J, 1991, CIBA F SYMP, V160, P25, DOI 10.4171/RMI/104; Lewis J, 1996, CURR OPIN NEUROBIOL, V6, P3, DOI 10.1016/S0959-4388(96)80002-X; Lim D., 1992, DEV AUDITORY VESTIBU, P33; LIM DJ, 1985, ACTA OTO-LARYNGOL, P1; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; NADOL JB, 1988, HEARING RES, V34, P253, DOI 10.1016/0378-5955(88)90006-8; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINSTABL C, 1992, J CLIN MONITOR, V8, P116, DOI 10.1007/BF01617429; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	30	369	390	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					289	292		10.1038/6804	http://dx.doi.org/10.1038/6804			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080181				2022-12-25	WOS:000078977900022
J	Battey, J; Jordan, E; Cox, D; Dove, W				Battey, J; Jordan, E; Cox, D; Dove, W			An action plan for mouse genomics	NATURE GENETICS			English	Editorial Material								The mouse has become the leading animal model for studying biological processes in mammals. Creation of additional genomic and genetic resources will make the mouse an even more useful model for the research community. On the basis of recommendations from the scientific community, the National Institutes of Health (NIH) plans to support grants to generate a 'working draft' sequence of the mouse genome by 2003, systematic mutagenesis and phenotyping centres, repositories for mouse strain maintenance, distribution and cryopreservation and training fellowships in mouse pathobiology.	Natl Inst Deafness & Other Commun Disorders, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison	Battey, J (corresponding author), Natl Inst Deafness & Other Commun Disorders, NIH Bldg 31,9000 Rockville Pike, Bethesda, MD 20892 USA.								0	78	80	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					73	75		10.1038/5012	http://dx.doi.org/10.1038/5012			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916794				2022-12-25	WOS:000077960700012
J	Xu, TS; Bianco, P; Fisher, LW; Longenecker, G; Smith, E; Goldstein, S; Bonadio, J; Boskey, A; Heegaard, AM; Sommer, B; Satomura, K; Dominguez, P; Zhao, CY; Kulkarni, AB; Robey, PG; Young, MF				Xu, TS; Bianco, P; Fisher, LW; Longenecker, G; Smith, E; Goldstein, S; Bonadio, J; Boskey, A; Heegaard, AM; Sommer, B; Satomura, K; Dominguez, P; Zhao, CY; Kulkarni, AB; Robey, PG; Young, MF			Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; PROTEOGLYCANS BIGLYCAN; HUMAN SKELETAL; BONE; DECORIN; EXPRESSION; HISTOMORPHOMETRY; FRAGILITY; LETHALITY; COLLAGEN	The resilience and strength of bone is due to the orderly mineralization of a specialized extracellular matrix (ECM) composed of type I collagen (90%) and a host of non-collagenous proteins that are, in general, also found in other tissues. Biglycan (encoded by the gene Bgn) is an ECM proteoglycan that is enriched in bone(1-3) and other non-skeletal connective tissues. in vitro studies indicate that Bgn may function in connective tissue metabolism by binding to collagen fibrils(4) and TGF-beta (refs 5,6), and may promote neuronal survival(7). To study the role of Bgn in vivo, we generated Bgn-deficient mice. Although apparently normal at birth, these mice display a phenotype characterized by a reduced growth rate and decreased bone mass due to the absence of Bgn. To our knowledge, this is the first report in which deficiency of a non-collagenous ECM protein leads to a skeletal phenotype that is marked by low bone mass that becomes more obvious with age. These mice may serve as an animal model to study the role of ECM proteins in osteoporosis.	NIDR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy; Univ Rome, I-00161 Rome, Italy; NIDR, Gene Targeting & Res Core Facil, NIH, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Orthopaed, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Hosp Special Surg, Mineralized Tissue Res Sect, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of L'Aquila; Sapienza University Rome; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Young, MF (corresponding author), Bldg 30,Room 106,30 Convent Dr,MSC 4320, Bethesda, MD 20892 USA.	young@yoda.nidr.nih.gov	Dominguez, Pedro/A-8266-2012; Robey, Pamela Gehron/H-1429-2011	Dominguez, Pedro/0000-0003-4788-1071; Robey, Pamela Gehron/0000-0002-5316-5576; Young, Marian F/0000-0003-0929-8854; Boskey, Adele/0000-0002-6181-2219; Heegaard, Anne-Marie/0000-0003-2754-0800				Andersson G, 1995, ACTA ORTHOP SCAND, V66, P189, DOI 10.3109/17453679509157689; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BONADIO J, 1993, J CLIN INVEST, V92, P1697, DOI 10.1172/JCI116756; BOSKEY AL, 1992, CELL MATER, V2, P209; Boskey AL, 1997, CALCIFIED TISSUE INT, V61, P298, DOI 10.1007/s002239900339; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOVE PE, 1992, P NATL ACAD SCI USA, V89, P9929, DOI 10.1073/pnas.89.20.9929; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Takahashi T, 1996, LAB INVEST, V74, P827; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VETTER U, 1993, INT CONGR SER, V1014, P143; VIGNERY A, 1980, ANAT REC, V196, P191, DOI 10.1002/ar.1091960210; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	33	476	493	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1998	20	1					78	82		10.1038/1746	http://dx.doi.org/10.1038/1746			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731537				2022-12-25	WOS:000075671400025
J	Even-Ram, S; Uziely, B; Cohen, P; Grisaru-Granovsky, S; Maoz, M; Ginzburg, Y; Reich, R; Vlodavsky, I; Bar-Shavit, R				Even-Ram, S; Uziely, B; Cohen, P; Grisaru-Granovsky, S; Maoz, M; Ginzburg, Y; Reich, R; Vlodavsky, I; Bar-Shavit, R			Thrombin receptor overexpression in malignant and physiological invasion processes	NATURE MEDICINE			English	Article							TUMOR-CELLS; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; BASEMENT-MEMBRANE; IV COLLAGENASES; STROMAL CELLS; CANCER-CELLS; BREAST; METASTASIS; EXPRESSION	Although the involvement of soluble and matrix-immobilized proteases in tumor cell invasion and metastasis is well recognized, the role of proteolytically activated cell surface receptors has not been elucidated. We report here that thrombin receptor, a member of the protease-activated receptor family, is preferentially expressed in highly metastatic human breast carcinoma cell lines and breast carcinoma biopsy specimens. Introduction of thrombin receptor antisense cDNA considerably inhibited the invasion of metastatic breast carcinoma cells in culture through a reconstituted basement membrane. During placental implantation of the human embryo, thrombin receptor is transiently expressed in the invading cytotrophoblasts. These results emphasize the involvement of thrombin receptor in cell invasion associated with tumor progression and normal embryonic development.	Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Bar-Shavit, R (corresponding author), Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel.			Even-Ram, Sharona/0000-0002-5540-3822				ALBINI A, 1987, CANCER RES, V47, P3239; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; ESUMI N, 1991, CANCER RES, V51, P4549; FERNANDEZ PL, 1992, LAB INVEST, V66, P572; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.3.CO;2-6; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; KIM SY, 1997, BREAST CANC RES TREA, V43, P175; Lee KS, 1996, CLIN EXP METASTAS, V14, P512; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nehls V, 1996, MICROVASC RES, V51, P347, DOI 10.1006/mvre.1996.0032; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PAGE B, 1995, EURO C COMP, V6, P39; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1991, AM J PATHOL, V138, P1059; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Redman CWG, 1997, NAT MED, V3, P610, DOI 10.1038/nm0697-610; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SAIKI RK, 1988, SCIENCE, V239, P489; SHIMONOVITZ S, 1994, AM J OBSTET GYNECOL, V171, P832, DOI 10.1016/0002-9378(94)90107-4; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P630, DOI 10.1016/S0959-8049(05)80114-5; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOULE HD, 1990, CANCER RES, V50, P6075; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1994, INVAS METAST, V14, P303; WOJTUKIEWICZ MZ, 1993, INT J CANCER, V54, P793, DOI 10.1002/ijc.2910540514; WOJTUKIEWICZ MZ, 1992, THROMB RES, V68, P233, DOI 10.1016/0049-3848(92)90081-K; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; [No title captured]	44	383	403	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					909	914		10.1038/nm0898-909	http://dx.doi.org/10.1038/nm0898-909			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701242				2022-12-25	WOS:000075107400033
J	Miller, HI; Huttner, SL				Miller, HI; Huttner, SL			A baroque solution to a nonproblem	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Calif Syst Wide Biotechnol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley		miller@hoover.stanford.edu						[Anonymous], 1992, Nature, V356, P1; CANTLEY M, 1995, BIOTECHNOLOGY; CHRISPEELS MH, 1994, PLANTS GENES AGR, pCH15; Crompton T, 1998, NAT BIOTECHNOL, V16, P697, DOI 10.1038/nbt0898-697; 1989, FIELD TESTING GENETI	5	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					698	699		10.1038/nbt0898-698	http://dx.doi.org/10.1038/nbt0898-698			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702753				2022-12-25	WOS:000075183400005
J	Fleury, S; de Boer, RJ; Rizzardi, GP; Wolthers, KC; Otto, SA; Welbon, CC; Graziosi, C; Knabenhans, C; Soudeyns, H; Bart, PA; Gallant, S; Corpataux, JM; Gillet, M; Meylan, P; Schnyder, P; Meuwly, JY; Spreen, W; Glauser, MP; Miedema, F; Pantaleo, G				Fleury, S; de Boer, RJ; Rizzardi, GP; Wolthers, KC; Otto, SA; Welbon, CC; Graziosi, C; Knabenhans, C; Soudeyns, H; Bart, PA; Gallant, S; Corpataux, JM; Gillet, M; Meylan, P; Schnyder, P; Meuwly, JY; Spreen, W; Glauser, MP; Miedema, F; Pantaleo, G			Limited CD4(+) T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTES-T; PROGRESSION; PHENOTYPE; ANTIBODY; PLASMA; SYSTEM; KI-67; AIDS	We show that the fraction of proliferating CD4(+) lymphocytes is similar in HIV-infected subjects in the early stage of disease and in HIV-negative subjects, whereas the fraction of proliferating CD8(+) lymphocytes is increased 6.8-fold in HIV-infected subjects. After initiation of antiviral therapy, there is a late increase in proliferating CD4(+) T cells associated with the restoration of CD4(+) T-cell counts. These results provide strong support for the idea of limited CD4(+) T-cell renewal in the early stage of HIV infection and indicate that after effective suppression of virus replication, the mechanisms of CD4(+) T-cell production are still functional in early HIV infection.	Univ Lausanne, Ctr Hosp Vaudois, Dept Med, Lab AIDS Immunopathogenesis,Div Infect Dis, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Div Immunol, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Gen Surg, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Radiol, CH-1015 Lausanne, Switzerland; Univ Utrecht, Utrecht, Netherlands; Univ Amsterdam, Netherlands Red Cross, Blood Transfus Serv, Cent Lab,Dept Clin Viroimmunol, Amsterdam, Netherlands; Univ Amsterdam, Expt & Clin Immunol Lab, Amsterdam, Netherlands; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Univ Lausanne, Inst Microbiol, CH-1015 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Utrecht University; University of Amsterdam; University of Amsterdam; GlaxoSmithKline; University of Lausanne	Pantaleo, G (corresponding author), Univ Lausanne, Ctr Hosp Vaudois, Dept Med, Lab AIDS Immunopathogenesis,Div Infect Dis, CH-1015 Lausanne, Switzerland.		de Boer, Rob/B-6050-2011; Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019; Wolthers, Katja C./E-5140-2018	de Boer, Rob/0000-0002-2130-691X; Wolthers, Katja C./0000-0003-1617-7049				BRUNO S, 1992, CELL PROLIFERAT, V25, P31, DOI 10.1111/j.1365-2184.1992.tb01435.x; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; Clark DR, 1997, J INFECT DIS, V176, P649, DOI 10.1086/514086; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; GERDES J, 1984, J IMMUNOL, V133, P1710; GLICK RM, 1997, N ENGL J MD, V337, P734; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Paganin C, 1997, J CLIN INVEST, V99, P663, DOI 10.1172/JCI119209; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PRESS WH, 1988, CAMBRIDGE UP; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHWARTING R, 1986, J IMMUNOL METHODS, V90, P65, DOI 10.1016/0022-1759(86)90384-4; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	26	133	134	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					794	801		10.1038/nm0798-794	http://dx.doi.org/10.1038/nm0798-794			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662370	Green Published			2022-12-25	WOS:000074543900033
J	Roperch, JP; Alvaro, V; Prieur, S; Tuynder, M; Nemani, M; Lethrosne, F; Piouffre, L; Gendron, MC; Israeli, D; Dausset, J; Oren, M; Amson, R; Telerman, A				Roperch, JP; Alvaro, V; Prieur, S; Tuynder, M; Nemani, M; Lethrosne, F; Piouffre, L; Gendron, MC; Israeli, D; Dausset, J; Oren, M; Amson, R; Telerman, A			Inhibition of presenilin 1 expression is promoted by p53 and p21(WAF-1) and results in apoptosis and tumor suppression	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GENE; ACTIVATION; HOMOLOG	Previously, we cloned a cDNA fragment, TSIP 2 (tumor suppressor inhibited pathway clone 2), that detects by northern blot analysis of M1-LTR6 cells a 3-kb mRNA downregulated during p53-induced apoptosis(1). Cloning the full-length TSIP 2 cDNA showed that it corresponds to the presenilin 1 (PS1) gene, in which mutations have been reported in early-onset familial Alzheimer's disease(2-4). Here we demonstrate that PS1 is downregulated in a series of model systems for p53-dependent and p53-independent apoptosis and tumor suppression. To investigate the biological relevance of this downregulation, we stably transfected U937 cells with antisense PS1 cDNA. The downregulation of PS1 in these U937 transfectants results in reduced growth with an increased fraction of the cells in apoptosis. When injected into mice homozygous for severe combined immunodeficiency disease (scid/scid mice), these cells show a suppression of their malignant phenotype. Our results indicate that PS1, initially identified in a neurodegenerative disease, may also be involved in the regulation of cancer-related pathways.	CEPH, Human Polymorphism Study Ctr, Fondat Jean Dausset, F-75010 Paris, France; Free Univ Brussels, Dept Biol Mol, B-1640 Rhode St Genese, Belgium; Inst Jacques Monod, Flow Cytometry Unit, F-75251 Paris, France; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	UDICE-French Research Universities; Universite Paris Cite; Weizmann Institute of Science	Telerman, A (corresponding author), CEPH, Human Polymorphism Study Ctr, Fondat Jean Dausset, 27 Rue Juliette Dodu, F-75010 Paris, France.			Israeli, David/0000-0003-2762-2195				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JINHE L, 1997, CELL, V90, P917; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; MICHIELI P, 1994, CANCER RES, V54, P3391; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; PARKER SB, 1995, SCIENCE, V267, P1724; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TELERMAN A, 1993, P NATL ACAD SCI USA, V90, P8702, DOI 10.1073/pnas.90.18.8702; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	20	154	159	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					835	838		10.1038/nm0798-835	http://dx.doi.org/10.1038/nm0798-835			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662377				2022-12-25	WOS:000074543900040
J	Wakayama, T; Yanagimachi, R				Wakayama, T; Yanagimachi, R			Development of normal mice from oocytes injected with freeze-dried spermatozoa	NATURE BIOTECHNOLOGY			English	Article						animal husbandry; reproduction; development; fertilization	INTRACYTOPLASMIC SPERM INJECTION; EMBRYOS; MOUSE; FERTILIZATION	Freeze-dried mouse spermatozoa are all motionless and dead in the conventional sense. When injected into oocytes, however, their nuclei can support normal embryonic development even after three month preservation in a dried state. Although the freeze-drying protocol reported here will need further improvement, the results suggest that it may be possible to store the male genomes at room temperature.	Univ Hawaii, Dept Anat & Reprod Biol, Sch Med, Honolulu, HI 96822 USA; Univ Tokyo, Dept Vet Anat, Fac Agr, Bunkyo Ku, Tokyo 113, Japan	University of Hawaii System; University of Tokyo	Yanagimachi, R (corresponding author), Univ Hawaii, Dept Anat & Reprod Biol, Sch Med, Honolulu, HI 96822 USA.	yana@hawaii.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD003402, R01HD034362] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34362, HD-03402] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], LOW TEMP SCI B; BEDFORD JM, 1974, J EXP ZOOL, V188, P137, DOI 10.1002/jez.1401880203; BIALY G, 1957, J DAIRY SCI, V40, P739, DOI 10.3168/jds.S0022-0302(57)94548-4; BUNGE RG, 1954, FERTIL STERIL, V5, P520; CATT J, 1995, FERTIL STERIL, V64, P1210, DOI 10.1016/S0015-0282(16)57988-6; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; Day JG, 1995, METHODS MOL BIOL, V38; Dozortsev D, 1995, HUM REPROD, V10, P2960, DOI 10.1093/oxfordjournals.humrep.a135829; GOTO K, 1990, VET REC, V127, P517; JEYENDRAN RS, 1983, J DAIRY SCI, V66, P887, DOI 10.3168/jds.S0022-0302(83)81872-4; KATAYOSE H, 1992, BIOL REPROD, V47, P277, DOI 10.1095/biolreprod47.2.277; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; KIMURA Y, 1998, IN PRESS BIOL REPROD; Larson E V, 1976, Dev Biol Stand, V36, P343; MERYMAN HT, 1960, ANN NY ACAD SCI, V85, P729, DOI 10.1111/j.1749-6632.1960.tb49993.x; Nakagata N, 1996, LAB ANIM SCI, V46, P236; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; POLGE C, 1952, NATURE, V169, P626, DOI 10.1038/169626b0; POLGE C, 1949, NATURE, V164, P666, DOI 10.1038/164666a0; SAACKE RG, 1961, NATURE, V192, P995, DOI 10.1038/192995a0; SCHULTZ RM, 1995, CURR TOP DEV BIOL, V30, P21, DOI 10.1016/S0070-2153(08)60563-3; SHERMAN JK, 1954, FERTIL STERIL, V5, P357; Sherman JK, 1990, CRC HDB LAB DIAGNOSI, P229; SINGH S G, 1967, Indian Journal of Veterinary Science and Animal Husbandry, V37, P1; SMITH AU, 1950, NATURE, V166, P668, DOI 10.1038/166668a0; Swann K, 1993, ZYGOTE, V1, P273, DOI 10.1017/S0967199400001581; UEHARA T, 1976, BIOL REPROD, V15, P467, DOI 10.1095/biolreprod15.4.467; Wakayama T, 1998, J REPROD FERTIL, V112, P11, DOI 10.1530/jrf.0.1120011; WATSON PF, 1990, MARSHALLS PHYSL REPR, V2, P746; Yanagimachi R, 1997, MICROSCOPY OF REPRODUCTION AND DEVELOPMENT : A DYNAMIC APPROACH, P187; YUSCHENKO NP, 1957, P LENIN ACAD AGR SCI, V22, P37	32	280	301	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					639	641		10.1038/nbt0798-639	http://dx.doi.org/10.1038/nbt0798-639			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661196				2022-12-25	WOS:000074521800026
J	Alexander, TD				Alexander, TD			The patentability of algorithms	NATURE BIOTECHNOLOGY			English	Editorial Material							SEQUENCE		Foley & Lardner, Madison, WI 53706 USA		Alexander, TD (corresponding author), Foley & Lardner, 150 E Gilman St, Madison, WI 53706 USA.	talexander@foleylaw.com						Agris CH, 1998, NAT BIOTECHNOL, V16, P702; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4	4	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					395	395		10.1038/7955	http://dx.doi.org/10.1038/7955			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207891	Bronze			2022-12-25	WOS:000079574400033
J	Greelish, JP; Su, LT; Lankford, EB; Burkman, JM; Chen, HY; Konig, SK; Mercier, IM; Desjardins, PR; Mitchell, MA; Zheng, XG; Leferovich, J; Gao, GP; Balice-Gordon, RJ; Wilson, JM; Stedman, HH				Greelish, JP; Su, LT; Lankford, EB; Burkman, JM; Chen, HY; Konig, SK; Mercier, IM; Desjardins, PR; Mitchell, MA; Zheng, XG; Leferovich, J; Gao, GP; Balice-Gordon, RJ; Wilson, JM; Stedman, HH			Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector	NATURE MEDICINE			English	Article							GLYCOPROTEIN COMPLEX; DELTA-SARCOGLYCAN; MEDIATED TRANSFER; MDX MICE; GENE; HAMSTER; DISRUPTION; VIRUS	Limb-girdle muscular dystrophies 2C-F represent a family of autosomal recessive diseases caused by defects in sarcoglycan genes'. The cardiomyopathic hamster is a naturally occurring model for limb-girdle muscular dystrophy caused by a primary deficiency in delta-sarcoglycan(2-5). We show here that acute sarcolemmal disruption occurs in this animal model during forceful muscle contraction. A recombinant adeno-associated virus vector encoding human delta-sarcoglycan conferred efficient and stable genetic reconstitution in the adult cardiomyopathic hamster when injected directly into muscle. A quantitative assay demonstrated that vector-transduced muscle fibers are stably protected from sarcolemmal disruption; there was no associated inflammation or immunologic response to the vector-encoded protein. Efficient gene transduction with rescue of the sarcoglycan complex in muscle fibers of the distal hindlimb was also obtained after infusion of recombinant adeno-associated virus into the femoral artery in conjunction with histamine-induced endothelial permeabilization. This study provides a strong rationale for the development of gene therapy for limb-girdle muscular dystrophy.	Univ Penn Hlth Syst, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Stedman, HH (corresponding author), Univ Penn Hlth Syst, Dept Surg, Philadelphia, PA 19104 USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Balice-Gordon, Rita/0000-0002-9950-7965; Koenig, Stephane/0000-0002-0801-279X	NHLBI NIH HHS [K08 HL003172-06] Funding Source: Medline; NIAMS NIH HHS [5PO1AR/NS43648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; BRUMBACK RA, 1984, COLOR ATLAS MUSCLE H, V13, P21; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; DeMatteo RP, 1997, J VIROL, V71, P5330, DOI 10.1128/JVI.71.7.5330-5335.1997; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; HOMBURGER F, 1966, ARCH PATHOL, V81, P302; HOMBURGER F, 1962, MED EXP, V6, P339; Nielsen HJ, 1996, ANN MED, V28, P107, DOI 10.3109/07853899609092934; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Stedman H, 1988, GENOMICS, V2, P1, DOI 10.1016/0888-7543(88)90102-4; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	21	175	192	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					439	443		10.1038/7439	http://dx.doi.org/10.1038/7439			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202936				2022-12-25	WOS:000079574300036
J	Fleck, O; Lehmann, E; Schar, P; Kohli, J				Fleck, O; Lehmann, E; Schar, P; Kohli, J			Involvement of nucleotide-excision repair in msh2 pms1-independent mismatch repair	NATURE GENETICS			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; RECOMBINATION; GENE; DNA; PROTEIN; YEAST; MUTATIONS; SPECTRUM; SEQUENCE	Nucleotide-excision repair (NER) and mismatch repair (MMR) are prominent examples of highly conserved DNA repair systems which recognize and replace damaged and/or mispaired nucleotides in DNA. In humans, inheritable defects in components of the NER system are associated with severe diseases such as xeroderma pigmentosum (XP) and Cockayne syndrome(1) (CS), whereas inactivation of MMR is accompanied by predisposition to certain types of cancer(2). In Schizosaccharomyces pombe, the msh2- and pms1-dependent long-patch MMR system efficiently corrects small insertion/deletion leaps and all base-base mismatches, except C/C, Up to 70% of OC mismatches generated in recombination intermediates, and to a lesser extent also other base-base mismatches, are thought to undergo correction by a minor, short-patch excision repair system(3,4). We identify here the NER genes rhp 14, swi10 and rad16 as components of this repair pathway and show that they act independently of msh2 and pms1.	Univ Bern, Inst Gen Microbiol, CH-3012 Bern, Switzerland; Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland	University of Bern; University of Zurich	Fleck, O (corresponding author), Univ Bern, Inst Gen Microbiol, Baltzer Str 4, CH-3012 Bern, Switzerland.	fleck@imb.unibe.ch	Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147; Fleck, Oliver/0000-0003-0550-6513				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; CARPENTER ATC, 1982, P NATL ACAD SCI-BIOL, V79, P5961, DOI 10.1073/pnas.79.19.5961; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; GUTZ H, 1994, HDB GENETICS SCHIZOS, P395; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MONTELONE BA, 1994, YEAST, V10, P13, DOI 10.1002/yea.320100103; MONTELONE BA, 1992, MUTAT RES, V267, P55, DOI 10.1016/0027-5107(92)90110-N; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; Rudolph C, 1999, MOL CELL BIOL, V19, P241; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAR P, 1994, EMBO J, V13, P5212, DOI 10.1002/j.1460-2075.1994.tb06852.x; SCHAR P, 1993, GENETICS, V133, P825; SCHAR P, 1993, GENETICS, V133, P815; Schar P, 1997, GENETICS, V146, P1275; SCHAR P, 1998, NUCL ACID M, V12, P199; SEKELSKY JJ, 1995, GENETICS, V141, P619; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4	20	64	68	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					314	317		10.1038/6838	http://dx.doi.org/10.1038/6838			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080187				2022-12-25	WOS:000078977900028
J	Sakuntabhai, A; Ruiz-Perez, V; Carter, S; Jacobsen, N; Burge, S; Monk, S; Smith, M; Munro, CS; O'Donovan, M; Craddock, N; Kucherlapati, R; Rees, JL; Owen, M; Lathrop, GM; Monaco, AP; Strachan, T; Hovnanian, A				Sakuntabhai, A; Ruiz-Perez, V; Carter, S; Jacobsen, N; Burge, S; Monk, S; Smith, M; Munro, CS; O'Donovan, M; Craddock, N; Kucherlapati, R; Rees, JL; Owen, M; Lathrop, GM; Monaco, AP; Strachan, T; Hovnanian, A			Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease	NATURE GENETICS			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM STORES; PLASMA-MEMBRANE; ATPASE FAMILY; GENE; LOCALIZATION; CELLS; CA-2+-ATPASE; DESMOSOMES; DEPENDENCE	Darier disease (DD) is an autosomal-dominant skin disorder characterized by loss of adhesion between epidermal cells (acantholysis) and abnormal keratinization. Recently we constructed a 2.4-Mb, Pi-derived artificial chromosome contig spanning the DD candidate region on chromosome 12q23-24.1. After screening several genes that mapped to this region, we identified mutations in the ATP2A2 gene, which encodes the sarco/endoplasmic reticulum Ca2+-ATPase type 2 isoform (SERCA2) and is highly expressed in keratinocytes. Thirteen mutations were identified, including frameshift deletions. in-frame deletions or insertions, splice-site mutations and non-conservative missense mutations in functional domains. Our results demonstrate that mutations in ATP2A2 cause DD and disclose a role for this pump in a Ca2+-signalling pathway regulating cell-to-cell adhesion and differentiation of the epidermis.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Newcastle Univ, Dept Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Cardiff Univ, Dept Psychol Med, Cardiff CF4 4XN, S Glam, Wales; Churchill Hosp, Dept Dermatol, Oxford OX3 7LJ, England; So Gen Hosp, Dept Dermatol, Glasgow G51 4TF, Lanark, Scotland; Univ Birmingham, Dept Psychiat, Birmingham B15 2QZ, W Midlands, England; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Newcastle Univ, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Oxford; Wellcome Centre for Human Genetics; Newcastle University - UK; Cardiff University; University of Oxford; University of Glasgow; University of Birmingham; Yeshiva University; Albert Einstein College of Medicine; Newcastle University - UK	Hovnanian, A (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	tom.strachan@ncl.ac.uk; alain.hovanian@well.ox.ac.uk	Hovnanian, Alain/I-4711-2017; Ruiz-Perez, Victor L/K-6066-2014; Kucherlapati, Raju/ABC-8807-2021; Monaco, Anthony P/A-4495-2010; O'Donovan, Michael C/P-7005-2018	Hovnanian, Alain/0000-0003-3412-7512; Ruiz-Perez, Victor L/0000-0003-0635-3619; Monaco, Anthony P/0000-0001-7480-3197; O'Donovan, Michael C/0000-0001-7073-2379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baba-Aissa F, 1998, MOL CHEM NEUROPATHOL, V33, P199, DOI 10.1007/BF02815182; BASHIR R, 1993, HUM MOL GENET, V2, P1937, DOI 10.1093/hmg/2.11.1937; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Burdett IDJ, 1998, MICRON, V29, P309, DOI 10.1016/S0968-4328(98)00015-8; BURGE S, 1994, BRIT J DERMATOL, V131, P153; BURGE SM, 1991, BRIT J DERMATOL, V124, P242, DOI 10.1111/j.1365-2133.1991.tb00568.x; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARTER SA, 1994, GENOMICS, V24, P378, DOI 10.1006/geno.1994.1632; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CRADDOCK N, 1993, HUM MOL GENET, V2, P1941, DOI 10.1093/hmg/2.11.1941; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; GROVER RW, 1970, ARCH DERMATOL, V101, P426, DOI 10.1001/archderm.101.4.426; Hailey H, 1939, ARCH DERMATOL SYPH, V39, P679, DOI 10.1001/archderm.1939.01480220064005; IKEDA S, 1994, J INVEST DERMATOL, V103, P478, DOI 10.1111/1523-1747.ep12395577; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, J BIOL CHEM, V266, P17067; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MacLennan DH, 1998, ACTA PHYSIOL SCAND, V163, P55; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAQUAT LE, 1995, RNA, V1, P453; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; Monk S, 1998, AM J HUM GENET, V62, P890, DOI 10.1086/301794; MUNRO CS, 1992, BRIT J DERMATOL, V127, P126, DOI 10.1111/j.1365-2133.1992.tb08044.x; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; PARFITT E, 1994, HUM MOL GENET, V3, P35, DOI 10.1093/hmg/3.1.35; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; Wakem P, 1996, J INVEST DERMATOL, V106, P365, DOI 10.1111/1523-1747.ep12343145; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211	41	523	552	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					271	277		10.1038/6784	http://dx.doi.org/10.1038/6784			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080178				2022-12-25	WOS:000078977900019
J	Marra, M; Hillier, L; Kucaba, T; Allen, M; Barstead, R; Beck, C; Blistain, A; Bonaldo, M; Bowers, Y; Bowles, L; Cardenas, M; Chamberlain, A; Chappell, J; Clifton, S; Favello, A; Geisel, S; Gibbons, M; Harvey, N; Hill, F; Jackson, Y; Kohn, S; Lennon, G; Mardis, E; Martin, J; Mila, L; McCann, R; Morales, R; Pape, D; Person, B; Prange, C; Ritter, E; Soares, M; Schurk, R; Shin, T; Steptoe, M; Swaller, T; Theising, B; Underwood, K; Wylie, T; Yount, T; Wilson, R; Waterston, R				Marra, M; Hillier, L; Kucaba, T; Allen, M; Barstead, R; Beck, C; Blistain, A; Bonaldo, M; Bowers, Y; Bowles, L; Cardenas, M; Chamberlain, A; Chappell, J; Clifton, S; Favello, A; Geisel, S; Gibbons, M; Harvey, N; Hill, F; Jackson, Y; Kohn, S; Lennon, G; Mardis, E; Martin, J; Mila, L; McCann, R; Morales, R; Pape, D; Person, B; Prange, C; Ritter, E; Soares, M; Schurk, R; Shin, T; Steptoe, M; Swaller, T; Theising, B; Underwood, K; Wylie, T; Yount, T; Wilson, R; Waterston, R			An encyclopedia of mouse genes	NATURE GENETICS			English	Article							EXPRESSED SEQUENCE TAGS; CAENORHABDITIS-ELEGANS; HUMAN GENOME; CDNA LIBRARY; MUTAGENESIS; DISCOVERY; FAMILIES; RICE; MAP	The laboratory mouse is the premier model system for studies of mammalian development due to the powerful classical genetic analysis(1) possible (see also the Jackson Laboratory web site, http://www.jax.org/) and the ever-expanding collection of molecular tools(2,3). To enhance the utility of the mouse system, we initiated a program to generate a large database of expressed sequence tags (ESTs) that can provide rapid access to genes(4-16). Of particular significance was the possibility that cDNA libraries could be prepared from very early stages of development, a situation unrealized in human EST projects(7,12). We report here the development of a comprehensive database of ESTs for the mouse. The project, initiated in March 1996, has focused on 5' end sequences from directionally cloned, oligo-dT primed cDNA libraries. As of 23 October 1998, 352,040 sequences had been generated, annotated and deposited in dbEST, where they comprised 93% of the total ESTs available for mouse. EST data are versatile and have been applied to gene identification(17), comparative sequence analysis(18,19), comparative gene mapping and candidate disease gene identification(20), genome sequence annotation(21,22), microarray development(23) and the development of gene-based map resources(24).	Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Iowa, Iowa City, IA 52242 USA; Univ Calif Lawrence Livermore Natl Lab, IMAGE Consortium, Biol & Biotechnol Res Program, Livermore, CA 94550 USA; Genelogic Inc, Genom, Gaithersburg, MD 20878 USA	Washington University (WUSTL); Oklahoma Medical Research Foundation; University of Iowa; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Marra, M (corresponding author), Washington Univ, Genome Sequencing Ctr, 4444 Forest Pk Blvd, St Louis, MO 63108 USA.		Marra, Marco A/B-5987-2008; Mardis, Elaine/W-2202-2019; Lennon, Greg/T-4717-2019; Wilson, Richard K./AAF-4139-2019	Marra, Marco A/0000-0001-7146-7175; Wilson, Richard K./0000-0002-1992-1358				ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; Bailey LC, 1998, GENOME RES, V8, P362, DOI 10.1101/gr.8.4.362; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Brown SDM, 1996, TRENDS GENET, V12, P433, DOI 10.1016/0168-9525(96)30094-2; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Jiang J, 1998, GENOME RES, V8, P268, DOI 10.1101/gr.8.3.268; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Makalowski W, 1996, GENOME RES, V6, P846, DOI 10.1101/gr.6.9.846; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; Nelson PS, 1998, GENOMICS, V47, P12, DOI 10.1006/geno.1997.5035; PUTNEY SD, 1983, NATURE, V302, P718, DOI 10.1038/302718a0; Sasaki N, 1998, GENOMICS, V49, P167, DOI 10.1006/geno.1998.5209; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; Scharf JM, 1998, NAT GENET, V20, P83, DOI 10.1038/1753; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; Sutherland HF, 1998, GENOMICS, V52, P37, DOI 10.1006/geno.1998.5414; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Yamamoto K, 1997, PLANT MOL BIOL, V35, P135, DOI 10.1023/A:1005735322577; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	30	95	98	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					191	194		10.1038/5976	http://dx.doi.org/10.1038/5976			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988271				2022-12-25	WOS:000078399500021
J	Aitman, TJ; Glazier, AM; Wallace, CA; Cooper, LD; Norsworthy, PJ; Wahid, FN; Al-Majali, KM; Trembling, PM; Mann, CJ; Shoulders, CC; Graf, D; St Lezin, E; Kurtz, TW; Kren, V; Pravenec, M; Ibrahimi, A; Abumrad, NA; Stanton, LW; Scott, J				Aitman, TJ; Glazier, AM; Wallace, CA; Cooper, LD; Norsworthy, PJ; Wahid, FN; Al-Majali, KM; Trembling, PM; Mann, CJ; Shoulders, CC; Graf, D; St Lezin, E; Kurtz, TW; Kren, V; Pravenec, M; Ibrahimi, A; Abumrad, NA; Stanton, LW; Scott, J			Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats	NATURE GENETICS			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; QUANTITATIVE TRAIT LOCI; RECOMBINANT INBRED STRAINS; BLOOD-PRESSURE; LIPOLYSIS; MAP; CHROMOSOMES; LIPOPROTEIN; EXPRESSION; OBESITY	The human insulin-resistance syndromes, type 2 diabetes, obesity, combined hyperlipidaemia and essential hypertension, are complex disorders whose genetic basis is unknown. The spontaneously hypertensive rat (SHR) is insulin resistant and a model of these human syndromes. Quantitative trait loci (QTLs) for SHR defects in glucose and fatty acid metabolism, hypertriglyceridaemia and hypertension map to a single locus on rat chromosome 4. Here we combine use of cDNA microarrays, congenic mapping and radiation hybrid (RH) mapping to identify a defective SHR gene, Cd36 (also known as Fat, as it encodes fatty acid translocase), at the peak of linkage to these QTLs. SHR Cd36 cDNA contains multiple sequence variants, caused by unequal genomic recombination of a duplicated ancestral gene. The encoded protein product is undetectable in SHR adipocyte plasma membrane. Transgenic mice overexpressing Cd36 have reduced blood lipids. We conclude that Cd36 deficiency underlies insulin resistance, defective fatty acid metabolism and hypertriglyceridaemia in SHR and may be important in the pathogenesis of human insulin-resistance syndromes.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Clin Sci Ctr,Mol Med Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Natl Heart & Lung Inst, London W12 0NN, England; Charles Univ Prague, Fac Med 1, Dept Biol, Prague 12800 2, Czech Republic; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague 4, Czech Republic; SUNY Stony Brook, Stony Brook, NY 11733 USA; Scios Inc, Sunnyvale, CA 94086 USA	Imperial College London; Imperial College London; Charles University Prague; University of California System; University of California San Francisco; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Scios	Aitman, TJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Clin Sci Ctr,Mol Med Grp, London W12 0NN, England.	taitman@ic.ac.uk	Pravenec, Michal/B-1666-2012; Graf, Daniel/H-1214-2011	Pravenec, Michal/0000-0001-9197-5871; Graf, Daniel/0000-0003-1163-8117; Aitman, Timothy/0000-0002-7875-4502; Ibrahimi, Azeddine/0000-0003-3226-3836; Norsworthy, Penny/0000-0002-5572-8491; Trembling, Paul/0000-0002-5016-4607	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL56028] Funding Source: Medline; NIDDK NIH HHS [DK33301] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, IN PRESS J LIPID RES; Aitman TJ, 1997, ARTERIOSCL THROM VAS, V17, P748, DOI 10.1161/01.ATV.17.4.748; Aitman TJ, 1997, NAT GENET, V16, P197, DOI 10.1038/ng0697-197; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; Bougneres P, 1997, J CLIN INVEST, V99, P2568, DOI 10.1172/JCI119444; Calvo D, 1998, J LIPID RES, V39, P777; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Curtis BR, 1996, TRANSFUSION, V36, P331, DOI 10.1046/j.1537-2995.1996.36496226147.x; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GOLDMUNTZ EA, 1995, MAMM GENOME, V6, P459, DOI 10.1007/BF00360654; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; Hwang EH, 1998, J NUCL MED, V39, P1681; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; IRITANI N, 1977, ATHEROSCLEROSIS, V28, P217, DOI 10.1016/0021-9150(77)90171-X; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; Kovacs P, 1998, ARCH BIOCHEM BIOPHYS, V354, P139, DOI 10.1006/abbi.1998.0686; KUNZ HW, 1978, J IMMUNOGENET, V5, P365; LANGE K, 1995, GENOME RES, V5, P136, DOI 10.1101/gr.5.2.136; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LIFTON RP, 1995, J CLIN INVEST, V95, P1040; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NATHAN DM, 1997, LANCET S1, V350, P1; Pravenec M, 1996, MAMM GENOME, V7, P117, DOI 10.1007/s003359900031; Pravenec M, 1997, MAMM GENOME, V8, P387, DOI 10.1007/s003359900452; PRAVENEC M, 1995, J CLIN INVEST, V96, P1973, DOI 10.1172/JCI118244; Qu XQ, 1997, AM J HYPERTENS, V10, P1053, DOI 10.1016/S0895-7061(97)00273-2; RANDLE PJ, 1963, LANCET, V1, P785; RAO RH, 1993, DIABETES, V42, P1364, DOI 10.2337/diabetes.42.9.1364; REAVEN GM, 1989, DIABETES, V38, P1155, DOI 10.2337/diabetes.38.9.1155; Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REYNISDOTTIR S, 1995, J CLIN INVEST, V95, P2161, DOI 10.1172/JCI117905; REYNISDOTTIR S, 1994, J CLIN INVEST, V93, P2590, DOI 10.1172/JCI117271; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; SAMANI NJ, 1993, J CLIN INVEST, V92, P1099, DOI 10.1172/JCI116616; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; URWIJITAROON Y, 1995, TRANSFUSION, V35, P868, DOI 10.1046/j.1537-2995.1995.351096026370.x; Watanabe Kenichi, 1997, Kaku Igaku, V34, P1125	49	610	633	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					76	83		10.1038/5013	http://dx.doi.org/10.1038/5013			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916795				2022-12-25	WOS:000077960700013
J	Herzog, RW; Yang, EY; Couto, LB; Hagstrom, JN; Elwell, D; Fields, PA; Burton, M; Bellinger, DA; Read, MS; Brinkhous, KM; Podsakoff, GM; Nichols, TC; Kurtzman, GJ; High, KA				Herzog, RW; Yang, EY; Couto, LB; Hagstrom, JN; Elwell, D; Fields, PA; Burton, M; Bellinger, DA; Read, MS; Brinkhous, KM; Podsakoff, GM; Nichols, TC; Kurtzman, GJ; High, KA			Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; PREVIOUSLY UNTREATED PATIENTS; FACTOR-VIII; INTRAMUSCULAR INJECTION; IMMUNOCOMPETENT MICE; EXPRESSION; THERAPY; PROPHYLAXIS; DOGS; PERSISTENCE	Hemophilia B is a severe X-linked bleeding diathesis caused by the absence of functional blood coagulation factor TX, and is an excellent candidate for treatment of a genetic disease by gene therapy. Using an adeno-associated viral vector, we demonstrate sustained expression (>17 months) of factor IX in a large-animal model at levels that would have a therapeutic effect in humans (up to 70 ng/ml, adequate to achieve phenotypic correction, in an animal injected with 8.5 x 10(12) vector particles/kg). The five hemophilia B dogs treated showed stable, vector dose-dependent partial correction of the whole blood clotting time and, at higher doses, of the activated partial thromboplastin time. In contrast to other viral gene delivery systems, this minimally invasive procedure, consisting of a series of percutaneous intramuscular Injections at a single timepoint, was not associated with local or systemic toxicity. Efficient gene transfer to muscle was shown by immunofluorescence staining and DNA analysis of biopsied tissue, Immune responses against factor IX were either absent or transient. These data provide strong support for the feasibility of the approach for therapy of human subjects.	Univ Penn, Med Ctr, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Avigen Inc, Alameda, CA 94502 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	High, KA (corresponding author), Univ Penn, Med Ctr, Dept Pediat, Philadelphia, PA 19104 USA.	high@email.chop.edu	High, Katherine A./AAB-9322-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009397, P50HL054500, R24HL063098, R01HL053668] Funding Source: NIH RePORTER; NHLBI NIH HHS [R24 HL063098, R01 HL53668, P50 HL54500, F32 HL09397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afione SA, 1996, J VIROL, V70, P3235, DOI 10.1128/JVI.70.5.3235-3241.1996; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; BRAY GL, 1987, AM J DIS CHILD, V141, P1215, DOI 10.1001/archpedi.1987.04460110085030; BRAY GL, 1994, BLOOD, V83, P2428; BRINKHOUS KM, 1993, BLOOD, V82, pA592; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; EVANS JP, 1989, P NATL ACAD SCI USA, V86, P10095, DOI 10.1073/pnas.86.24.10095; EVANS JP, 1989, BLOOD, V74, P207; EYSTER ME, 1978, BLOOD, V51, P1179; Fang B, 1996, GENE THER, V3, P217; Ferrari FK, 1997, NAT MED, V3, P1295, DOI 10.1038/nm1197-1295; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Gilles JG, 1996, J CLIN INVEST, V97, P1382, DOI 10.1172/JCI118558; GILLES JGG, 1993, BLOOD, V82, P2452; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; High KA, 1995, ADV EXP MED BIOL, V386, P79; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Kung SH, 1998, BLOOD, V91, P784, DOI 10.1182/blood.V91.3.784.784_784_790; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; Lusher JM, 1997, THROMB HAEMOSTASIS, V78, P726; Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; MITRUKA BM, 1976, ANIMALS MED RES MODE, P216; Monahan PE, 1998, GENE THER, V5, P40, DOI 10.1038/sj.gt.3300548; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; NIENHUIS AW, 1991, CANCER, V67, P2700, DOI 10.1002/1097-0142(19910515)67:10+<2700::AID-CNCR2820671705>3.0.CO;2-3; Ragni MV, 1997, HAEMOPHILIA, V3, P90, DOI 10.1046/j.1365-2516.1997.00100.x; Sambrook J., 1989, MOL CLONING; Svensson EC, 1997, HUM GENE THER, V8, P1797, DOI 10.1089/hum.1997.8.15-1797; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yang G, 1996, BIOL SIGNAL, V5, P1; YAO SN, 1994, GENE THER, V1, P99	42	445	497	1	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					56	63		10.1038/4743	http://dx.doi.org/10.1038/4743			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883840				2022-12-25	WOS:000077885000030
J	Low, KB; Ittensohn, M; Le, T; Platt, J; Sodi, S; Amoss, M; Ash, O; Carmichael, E; Chakraborty, A; Fischer, J; Lin, SL; Luo, X; Miller, SI; Zheng, LM; King, I; Pawelek, JM; Bermudes, D				Low, KB; Ittensohn, M; Le, T; Platt, J; Sodi, S; Amoss, M; Ash, O; Carmichael, E; Chakraborty, A; Fischer, J; Lin, SL; Luo, X; Miller, SI; Zheng, LM; King, I; Pawelek, JM; Bermudes, D			Lipid A mutant Salmonella with suppressed virulence and TNF alpha induction retain tumor-targeting in vivo	NATURE BIOTECHNOLOGY			English	Article						attenuation; cancer; gene therapy; msbB; Salmonella; septic shock; tumor-specific; TNF alpha	INFLAMMATORY RESPONSE SYNDROME; TYPHI VACCINE STRAIN; COLI MSBB GENE; ESCHERICHIA-COLI; ATTENUATED SALMONELLA; MULTICOPY SUPPRESSOR; ANTITUMOR AGENT; TYPHIMURIUM; LIPOPOLYSACCHARIDE; MICE	Systemically administered tumor-targeted Salmonella has been developed as an anticancer agent, although its use could be limited by the potential induction of tumor necrosis factor alpha (TNF alpha)-mediated septic shock stimulated by lipid A. Genetic modifications of tumor-targeting Salmonella that alter lipid A and increase safety must, however, retain the useful properties of this bacteria. We report here that disruption of the Salmonella msbB gene reduces TNF alpha induction and increases the LD50 of this pathogenic bacteria by 10,000-fold, Notwithstanding this enormous difference, Salmonella retains its tumor-targeting properties, exhibiting tumor accumulation ratios in excess of 1000:1 compared with normal tissues. Administration of this bacteria to mice bearing melanoma results in tumors that are less than 6% the size of tumors in untreated controls at day 18. Thus, the antitumor activity previously demonstrated using tumor-targeting Salmonella with normal lipid A is retained. Lipid modification of tumor-specific bacterial vectors provides a means for reducing septic shock and further suggests that the antitumor activity of these bacteria may be independent of TNF alpha.	Vion Pharmaceut Inc, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Texas A&M Univ, Coll Vet Med, College Stn, TX 77843 USA; Univ Washington, Hlth Sci Ctr, Seattle, WA 98195 USA	Vion Pharmaceuticals, Inc.; Yale University; Yale University; Texas A&M University System; Texas A&M University College Station; University of Washington; University of Washington Seattle	Bermudes, D (corresponding author), Vion Pharmaceut Inc, New Haven, CT 06511 USA.		Bermudes, David/W-1626-2019	Bermudes, David/0000-0003-1910-3192				APICELLA MA, 1994, METHOD ENZYMOL, V235, P243; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; CARRIER MJ, 1992, J IMMUNOL, V148, P1176; Chabalgoity JA, 1996, MOL MICROBIOL, V19, P791, DOI 10.1046/j.1365-2958.1996.426965.x; CLACCIWOOLWINE F, 1998, INFECT IMMUN, V66, P1127; Clementz T, 1997, J BIOL CHEM, V272, P10353; Davis R., 1980, ADV BACTERIAL GENETI; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; EISENSTEIN TK, 1995, MED ONCOL, V12, P103, DOI 10.1007/BF01676710; ELSINGHORST EA, 1994, METHOD ENZYMOL, V236, P405; ENGEL H, 1992, J BACTERIOL, V174, P6394, DOI 10.1128/JB.174.20.6394-6403.1992; FLAD HD, 1993, IMMUNOBIOLOGY, V187, P303, DOI 10.1016/S0171-2985(11)80346-3; GALAN J, 1989, MICROB PATHOG, V6, P422; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GONZALEZ C, 1994, J INFECT DIS, V169, P927, DOI 10.1093/infdis/169.4.927; Hohmann EL, 1996, VACCINE, V14, P19, DOI 10.1016/0264-410X(95)00173-X; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; McSorley SJ, 1997, INFECT IMMUN, V65, P171, DOI 10.1128/IAI.65.1.171-178.1997; OCALLAGHAN D, 1988, INFECT IMMUN, V56, P419, DOI 10.1128/IAI.56.2.419-423.1988; Pawelek JM, 1997, CANCER RES, V57, P4537; RICK PD, 1977, J BIOL CHEM, V252, P4895; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; Saltzman DA, 1997, CANCER BIOTHER RADIO, V12, P37, DOI 10.1089/cbr.1997.12.37; Saltzman DA, 1996, CANCER BIOTHER RADIO, V11, P145, DOI 10.1089/cbr.1996.11.145; SKLAR MD, 1985, J CELL PHYSIOL, V125, P403, DOI 10.1002/jcp.1041250307; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; SU GF, 1992, MICROB PATHOGENESIS, V13, P465, DOI 10.1016/0882-4010(92)90013-E	33	367	406	6	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					37	41		10.1038/5205	http://dx.doi.org/10.1038/5205			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920266				2022-12-25	WOS:000077979500022
J	Ross, P; Hall, L; Smirnov, I; Haff, L				Ross, P; Hall, L; Smirnov, I; Haff, L			High level multiplex genotyping by MALDI-TOF mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						genomics; single nucleotide polymorphisms; multiplex PCR	GENE; POLYMORPHISM; SEQUENCE; IDENTIFICATION; POLYMERASE; PRODUCTS; ARRAYS; SITE	A primer extension assay is used to perform highly multiplexed genotyping of single nucleotide polymorphisms (SNPs) present in genomic DNA amplified by a multiplex PCR. The assay uses matrix-assisted laser desorption ionization time-of-flight mass spectrometry to accurately measure the masses of short oligonucleotide primers extended by a single dideoxynucleotide. The multiplexed genotyping assays rely on the natural molecular weight differences of DNA bases. By careful analysis of primer composition complementary to the target, or by judicious addition of one or more noncomplementary 5' bases to the genotyping primers, mass spectra of interleaved genotyping products can be generated with no ambiguity in allele assignment. Using a model multiplex PCR system, we demonstrate the ability to perform 12-fold multiplex SNP analysis.	PerSept Biosyst, Framingham, MA 01701 USA		Ross, P (corresponding author), PerSept Biosyst, 500 Old Connecticut Path, Framingham, MA 01701 USA.	Philip_Ross@pbio.com						ARMSTRONG M, 1993, HUM GENET, V91, P616; Belgrader P, 1996, GENOME SCI TECHNOLOG, V1, P77, DOI [DOI 10.1089/GST.1996.1.77, 10.1089/gst.1996.1.77]; BOCK SG, 1991, BIOCHEMISTRY-US, V28, P3628; Braun A, 1997, CLIN CHEM, V43, P1151; BROOKS CC, 1993, AM J HUM GENET, V52, P835; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DAI Y, 1996, RAPID COMMUN MASS SP, V9, P1792; DEWALD G, 1993, BIOCHEM BIOPH RES CO, V194, P458, DOI 10.1006/bbrc.1993.1841; DIEPSTRATEN CM, 1991, NUCLEIC ACIDS RES, V19, P5091, DOI 10.1093/nar/19.18.5091; Fu DJ, 1998, NAT BIOTECHNOL, V16, P381, DOI 10.1038/nbt0498-381; GLOUDEMANS T, 1993, CANCER RES, V53, P5754; Griffin TJ, 1997, NAT BIOTECHNOL, V15, P1368, DOI 10.1038/nbt1297-1368; Haff LA, 1997, NUCLEIC ACIDS RES, V25, P3749, DOI 10.1093/nar/25.18.3749; Haff LA, 1997, GENOME RES, V7, P378, DOI 10.1101/gr.7.4.378; Juhasz P, 1996, ANAL CHEM, V68, P941, DOI 10.1021/ac9510503; Little DP, 1997, ANAL CHEM, V69, P4540, DOI 10.1021/ac970758+; MASTUURA S, 1994, HUM GENET, V93, P721; Mouradian S, 1996, RAPID COMMUN MASS SP, V10, P1475; POLLER W, 1991, NUCLEIC ACIDS RES, V19, P198, DOI 10.1093/nar/19.1.198-a; Reina M., 1992, Human Molecular Genetics, V1, P453, DOI 10.1093/hmg/1.6.453-a; Roskey MT, 1996, P NATL ACAD SCI USA, V93, P4724, DOI 10.1073/pnas.93.10.4724; Ross PL, 1997, ANAL CHEM, V69, P4197, DOI 10.1021/ac9703966; Ross PL, 1998, ANAL CHEM, V70, P2067, DOI 10.1021/ac971256z; VELDEN PA, 1993, HUM MOL GENET, V2, P1753; VESTAL ML, 1995, RAPID COMMUN MASS SP, V8, P865; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WARNICH L, 1992, HUM GENET, V89, P362; WU KJ, 1993, RAPID COMMUN MASS SP, V4, P99; Zhao LP, 1998, AM J HUM GENET, V63, P225, DOI 10.1086/301909	30	328	402	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1347	1351		10.1038/4328	http://dx.doi.org/10.1038/4328			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853617				2022-12-25	WOS:000077232600028
J	Cui, HM; Horon, IL; Ohlsson, R; Hamilton, SR; Feinberg, AP				Cui, HM; Horon, IL; Ohlsson, R; Hamilton, SR; Feinberg, AP			Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability	NATURE MEDICINE			English	Article							BECKWITH-WIEDEMANN SYNDROME; FACTOR-II GENE; WILMS-TUMOR; LUNG-CANCER; IGF2; METHYLATION; CARCINOMAS; EXPRESSION; RELAXATION; FREQUENCY	Loss of imprinting (LOI) is an epigenetic alteration of some cancers involving loss of parental origin-specific expression of imprinted genes. We observed LOI of the insulin-like growth factor-ii gene in twelve of twenty-seven informative colorectal cancer patients (44%), as well as in the matched normal colonic mucosa of the patients with LOI in their cancers, and in peripheral blood samples of four patients. Ten of eleven cancers (91%) with microsatellite instability showed LOI, compared with only two of sixteen tumors (12%) without microsatellite instability (P< 0.001). Control patients without cancer showed LOI in colonic mucosa of only two of sixteen cases (12%, P < 0.001) and two of fifteen blood samples (13%, P < 0.001). These data suggest that LOI in tumor and normal tissue identifies most colorectal cancer patients with microsatellite instability in their tumors, and that LOI may identify an important subset of the population with cancer or at risk of developing cancer.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Maryland Div Hlth Stat, Baltimore, MD 21201 USA; Uppsala Univ, Dept Anim Dev, S-75236 Uppsala, Sweden	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Uppsala University	Feinberg, AP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1064 Ross,720 Rutland Ave, Baltimore, MD 21205 USA.	afeinberg@jhu.edu	Cui, Hengmi/A-2598-2008; Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [R01CA065145, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA65145, CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BISGAARD ML, 1994, HUM MUTAT, V3, P121, DOI 10.1002/humu.1380030206; BOLAND CR, UNPUB NAT CANC I WOR; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Brassett C, 1996, J MED GENET, V33, P981, DOI 10.1136/jmg.33.12.981; Bubb VJ, 1996, ONCOGENE, V12, P2641; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; Chetty R, 1998, J CLIN PATHOL-MOL PA, V51, P35, DOI 10.1136/mp.51.1.35; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Dietmaier W, 1997, CANCER RES, V57, P4749; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1994, COLD SPRING HARB SYM, V59, P357, DOI 10.1101/SQB.1994.059.01.040; FEINBERG AP, 1998, GENETIC BASIS HUMAN, P95; FORD D, 1995, AM J HUM GENET, V57, P1457; He LM, 1998, ONCOGENE, V16, P113, DOI 10.1038/sj.onc.1201501; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Kim H, 1998, PATHOL RES PRACT, V194, P3, DOI 10.1016/S0344-0338(98)80006-X; KIM HG, 1994, AM J PATHOL, V145, P148; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Ottini L, 1997, CANCER RES, V57, P4523; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; Sekine I, 1997, JPN J CANCER RES, V88, P559, DOI 10.1111/j.1349-7006.1997.tb00419.x; Senba S, 1998, CANCER, V82, P279, DOI 10.1002/(SICI)1097-0142(19980115)82:2<279::AID-CNCR6>3.3.CO;2-D; Shinmura K, 1997, CANCER EPIDEM BIOMAR, V6, P693; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Thibodeau SN, 1998, CANCER RES, V58, P1713; VOGELSANG HE, 1997, LANGENBECKS ARCH C S, V114, P113; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143	41	244	265	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1276	1280		10.1038/3260	http://dx.doi.org/10.1038/3260			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809551				2022-12-25	WOS:000076731000036
J	Quignon, F; De Bels, F; Koken, M; Feunteun, J; Ameisen, JC; de The, H				Quignon, F; De Bels, F; Koken, M; Feunteun, J; Ameisen, JC; de The, H			PML induces a novel caspase-independent death process	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CELL-DEATH; GROWTH-SUPPRESSOR; RAR-ALPHA; NUCLEAR-BODIES; DNA-DAMAGE; PROTEIN; APOPTOSIS; BAX; EXPRESSION	PML nuclear bodies (NBs) are nuclear matrix-associated structures altered by viruses and oncogenes. We show here that PML overexpression induces rapid cell death, independent of de novo transcription and cell cycling. PML death involves cytoplasmic features of apoptosis in the absence of caspase-3 activation, and caspase inhibitors such as zVAD accelerate PML death, zVAD also accelerates interferon (IFN)-induced death, suggesting that PML contributes to IFN-induced apoptosis. The death effector BAX and the cdk inhibitor p27KIP1 are novel NB-associated proteins recruited by PML to these nuclear domains, whereas the acute promyelocytic leukaemia (APL) PML/RAR alpha oncoprotein delocalizes them. Arsenic enhances targeting of PML BAX and p27KIP1 to NBs and synergizes with PML and IFN to induce cell death. Thus, cell death susceptibility correlates with NE recruitment of NE proteins. These findings reveal a novel cell death pathway that neither requires nor induces caspase-3 activation, and suggest that NBs participate in the control of cell survival.	Univ Paris 07, Hop St Louis, Inst Hematol,CNRS UPR 9051, Lab Associe Comite Paris Ligue Contre Canc, F-75475 Paris 10, France; Hop Bichat, INSERM CJF 9707, F-75877 Paris, France; Inst Gustave Roussy, CNRS URA 1967, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	de The, H (corresponding author), Univ Paris 07, Hop St Louis, Inst Hematol,CNRS UPR 9051, Lab Associe Comite Paris Ligue Contre Canc, 1 Av C Vellefaux, F-75475 Paris 10, France.	ameisen@caramail.com; dethe@chu-stlouis.fr	koken, marcel/J-8154-2012; koken, marcel/N-1349-2019; Feunteun, Jean/AAZ-1267-2020; Quignon, Frédérique/P-4249-2017	koken, marcel/0000-0002-0839-0125; Feunteun, Jean/0000-0003-1212-9189				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; BAZARBACHI A, IN PRESS BLOOD; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; Chan JYH, 1997, BIOCHEM BIOPH RES CO, V240, P640, DOI 10.1006/bbrc.1997.7692; CHELBIALIX M, IN PRESS ONCOGENE; Chen GQ, 1997, BLOOD, V89, P3345; DANIEL MT, 1993, BLOOD, V82, P1858; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Estaquier J, 1997, BLOOD, V90, P1618, DOI 10.1182/blood.V90.4.1618.1618_1618_1625; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; Han J., 1995, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jiang WQ, 1997, CELL GROWTH DIFFER, V8, P513; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MADANI A, 1995, ONCOGENE, V10, P2259; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	54	330	339	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					259	265		10.1038/3068	http://dx.doi.org/10.1038/3068			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806544				2022-12-25	WOS:000076698100019
J	Allay, JA; Persons, DA; Galipeau, J; Riberdy, JM; Ashmun, RA; Blakley, RL; Sorrentino, BP				Allay, JA; Persons, DA; Galipeau, J; Riberdy, JM; Ashmun, RA; Blakley, RL; Sorrentino, BP			In vivo selection of retrovirally transduced hematopoietic stem cells	NATURE MEDICINE			English	Article							LONG-TERM HEMATOPOIESIS; RESISTANT BONE-MARROW; DIHYDROFOLATE-REDUCTASE; GENE-TRANSFER; IN-VIVO; NUCLEOSIDE TRANSPORT; PROGENITOR CELLS; MICE; METHOTREXATE; MOUSE	One of the main impediments to effective gene therapy of blood disorders is the resistance of human hematopoietic stem cells to stable genetic modification. We show here that a small minority of retrovirally transduced stem cells can be selectively enriched in vivo, which might be a way to circumvent this obstacle. We constructed two retroviral vectors containing an antifolate-resistant dihydrofolate reductase cDNA transcriptionally linked to a reporter gene. Mice were transplanted with transduced bone marrow cells and then treated with an antifolate-based regimen that kills unmodified stem cells. Drug treatment significantly increased the percentage of vector-expressing peripheral blood erythrocytes, platelets, granulocytes, and T and B lymphocytes. Secondary transplant experiments demonstrated that selection occurred at the level of hematopoietic stem cells. This system for in vivo stem-cell selection provides a means to increase the number of genetically modified cells after transplant, and may circumvent an substantial obstacle to successful gene therapy for human blood diseases.	St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Mol Pharmacol & Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Sorrentino, BP (corresponding author), St Jude Childrens Res Hosp, Dept Hematol & Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA031922] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 31922, P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allay JA, 1997, EXP HEMATOL, V25, P1069; Allay JA, 1997, BLOOD, V90, P3546, DOI 10.1182/blood.V90.9.3546; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Blau CA, 1996, HUM GENE THER, V7, P2069, DOI 10.1089/hum.1996.7.17-2069; Blau CA, 1997, BLOOD, V89, P146, DOI 10.1182/blood.V89.1.146.146_146_154; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; COREY CA, 1990, BLOOD, V75, P337; Davis BM, 1997, CANCER RES, V57, P5093; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; HARRISON DE, 1980, BLOOD, V55, P77; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARLSSON S, 1991, BLOOD, V78, P2481; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LEWIS WS, 1995, J BIOL CHEM, V270, P5057, DOI 10.1074/jbc.270.10.5057; LI MX, 1994, BLOOD, V83, P3403; LYNCH TP, 1981, CANCER RES, V41, P560; Maze R, 1997, J IMMUNOL, V158, P1006; MOLINEUX G, 1994, BLOOD, V83, P3491; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; PODDA S, 1992, P NATL ACAD SCI USA, V89, P9676, DOI 10.1073/pnas.89.20.9676; RONGEN GA, 1995, J CLIN INVEST, V95, P658, DOI 10.1172/JCI117711; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Spencer HT, 1996, BLOOD, V87, P2579, DOI 10.1182/blood.V87.6.2579.bloodjournal8762579; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLSON JKV, 1989, CANCER RES, V49, P1866; ZHAO SC, 1994, CANCER GENE THER, V1, P27	34	178	182	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1136	1143		10.1038/2632	http://dx.doi.org/10.1038/2632			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771746				2022-12-25	WOS:000076230100032
J	Honeyman, MC; Brusic, V; Stone, NL; Harrison, LC				Honeyman, MC; Brusic, V; Stone, NL; Harrison, LC			Neural network-based prediction of candidate T-cell epitopes	NATURE BIOTECHNOLOGY			English	Article						bioinformatics; MHC; applied immunology	PEPTIDE BINDING-SPECIFICITY; RHEUMATOID-ARTHRITIS; SELECTION; MOLECULES; COMMON	Activation of T cells requires recognition by T-cell receptors of specific peptides bound to major histocompatibility complex (MHC) molecules on the surface of either antigen-presenting or target cells, These peptides, T-cell epitopes, have potential therapeutic applications, such as for use as vaccines. Their identification, however, usually requires that multiple overlapping synthetic peptides encompassing a protein antigen be assayed, which in humans, is limited by volume of donor blood. T-cell epitopes are a subset of peptides that bind to MHC molecules. We use an artificial neural network (ANN) model trained to predict peptides that bind to the MHC class II molecule HLA-DR4(*0401). Binding prediction facilitates identification of T-cell epitopes in tyrosine phosphatase IA-2, an autoantigen in DR4-associated type1 diabetes. Synthetic peptides encompassing IA-2 were tested experimentally for DR4 binding and T-cell proliferation in humans at risk for diabetes. ANN-based binding prediction was sensitive and specific, and reduced the number of peptides required for T-cell assay by more than half, with only a minor loss of epitopes. This strategy could expedite identification of candidate T-cell epitopes in diverse diseases.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Harrison, LC (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	harrison@wehi.edu.au	Brusic, Vladimir/B-1478-2008	Brusic, Vladimir/0000-0003-0523-5266				ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; Beale R., 1990, NEURAL COMPUTING INT; Brusic V, 1998, BIOINFORMATICS, V14, P121, DOI 10.1093/bioinformatics/14.2.121; Brusic V, 1997, NUCLEIC ACIDS RES, V25, P269, DOI 10.1093/nar/25.1.269; BRUSIC V, 1994, COMPLEX SYSTEMS MECH, P253; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; FORREST S, 1993, SCIENCE, V261, P872, DOI 10.1126/science.8346439; Hammer J, 1997, ADV IMMUNOL, V66, P67, DOI 10.1016/S0065-2776(08)60596-9; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Harrison LC, 1997, J EXP MED, V185, P1013, DOI 10.1084/jem.185.6.1013; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; MIYATA Y, 1991, USERS GUIDE PLANET 5; NEPOM GT, 1989, ARTHRITIS RHEUM, V32, P15, DOI 10.1002/anr.1780320104; Nigrin A., 1993, NEURAL NETWORKS PATT; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Raddrizzani L, 1997, J IMMUNOL, V159, P703; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; REECE JC, 1993, J IMMUNOL, V151, P6175; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; SALVETTI M, 1991, ANN NEUROL, V29, P508, DOI 10.1002/ana.410290510; SINIGAGLIA F, 1991, METHOD ENZYMOL, V203, P370; TAIT BD, 1991, BAILLERES CLIN ENDOC, V5, P11; Weiss S. M., 1991, COMPUTER SYSTEMS LEA; Zhang BW, 1997, DIABETES, V46, P40, DOI 10.2337/diabetes.46.1.40; ZURADA JM, 1992, INTRO ARTIFICIAL NEU, P41	27	149	167	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					966	969		10.1038/nbt1098-966	http://dx.doi.org/10.1038/nbt1098-966			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788355				2022-12-25	WOS:000076323300034
J	Koizumi, S; Endo, T; Tabata, K; Ozaki, A				Koizumi, S; Endo, T; Tabata, K; Ozaki, A			Large-scale production of UDP-galactose and globotriose by coupling metabolically engineered bacteria	NATURE BIOTECHNOLOGY			English	Article						metabolic engineering; glycosyltransferase; sugar nucleotide; oligosaccharide	ESCHERICHIA-COLI; HELICOBACTER-PYLORI; GENE; CLONING; BIOSYNTHESIS; REGENERATION; EXPRESSION; SEPARATION; NUCLEOTIDE; ENZYME	A large-scale production system of uridine 5'-diphospho-galactose (UDP-Gal) has been established by the combination of recombinant Escherichia coli and Corynebacterium ammoniagenes. Recombinant E. coli that overexpress the UDP-Gal biosynthetic genes galT, galK, and galU were generated. C. ammoniagenes contribute the production of uridine triphosphate (UTP), a substrate for UDP-Gal biosynthesis, from erotic acid, an inexpensive precursor of UTP. UDP-Gal accumulated to 72 mM (44 g/L) after a 21 h reaction starting with erotic acid and galactose, When E. coli cells that expressed the alpha 1,4-galactosyltransferase gene of Neisseria gonorrhoeae were coupled with this UDP-Gal production system, 372 mM (188 g/L) globotriose (Gal alpha 1-4Gal beta 1-4Glc), a trisaccharide portion of verotoxin receptor, was produced after a 36 h reaction starting with erotic acid, galactose, and lactose. No oligosaccharide by-products were observed in the reaction mixture. The production of globotriose was several times higher than that of UDP-Gal. The strategy of producing sugar nucleotides by combining metabolically engineered recombinant E. coli with a nucleoside 5'-triphosphate producing microorganism, and the concept of producing oligosaccharides by coupling sugar nucleotide production systems with glycosyltransferases, can be applied to the manufacture of other sugar nucleotides and oligosaccharides.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan	Kyowa Kirin Ltd	Koizumi, S (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Tokyo 1948533, Japan.							DEBOUCK C, 1985, NUCLEIC ACIDS RES, V13, P1841, DOI 10.1093/nar/13.6.1841; Fujio T, 1997, BIOSCI BIOTECH BIOCH, V61, P956, DOI 10.1271/bbb.61.956; Fujio T, 1997, BIOSCI BIOTECH BIOCH, V61, P840, DOI 10.1271/bbb.61.840; GABLUS HJ, 1997, GLYCOSCIENCE STATUS; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; GOTSCHLICH EC, 1998, Patent No. 5705367; Khan S. H., 1996, MODERN METHODS CARBO; Kolkman MAB, 1997, MOL MICROBIOL, V26, P197, DOI 10.1046/j.1365-2958.1997.5791940.x; LAGUNAS R, 1994, ANAL BIOCHEM, V216, P188, DOI 10.1006/abio.1994.1024; LAHTI R, 1988, J BACTERIOL, V170, P5901, DOI 10.1128/jb.170.12.5901-5907.1988; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LELOIR LF, 1971, SCIENCE, V172, P1299, DOI 10.1126/science.172.3990.1299; LEMAIRE HG, 1986, NUCLEIC ACIDS RES, V14, P7705, DOI 10.1093/nar/14.19.7705; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; Navarro A, 1997, J CHROMATOGR A, V770, P39, DOI 10.1016/S0021-9673(96)01073-4; Sambrook J., 2002, MOL CLONING LAB MANU; TESHIBA S, 1988, PRODUCTION NUCLEOTID; TOCHIKURA T, 1970, AMINO ACID NUCLEIC A, V22, P144; WEISSBORN AC, 1994, J BACTERIOL, V176, P2611, DOI 10.1128/JB.176.9.2611-2618.1994; WHISTLER RL, 1950, J AM CHEM SOC, V72, P677, DOI 10.1021/ja01158a009; WONG CH, 1992, J ORG CHEM, V57, P4343, DOI 10.1021/jo00042a008; WONG CH, 1982, J ORG CHEM, V47, P5416, DOI 10.1021/jo00148a045; Yamamoto T, 1998, J BIOCHEM-TOKYO, V123, P94	25	132	153	2	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					847	850		10.1038/nbt0998-847	http://dx.doi.org/10.1038/nbt0998-847			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743118				2022-12-25	WOS:000075671700031
J	Litingtung, Y; Lei, L; Westphal, H; Chiang, C				Litingtung, Y; Lei, L; Westphal, H; Chiang, C			Sonic hedgehog is essential to foregut development	NATURE GENETICS			English	Article							MAMMALIAN LUNG DEVELOPMENT; MORPHOGENESIS; MESENCHYME; DIFFERENTIATION; MALFORMATIONS; EPITHELIUM; INDUCTION; GENES	Congenital malformation of the foregut is common in humans, with an estimated incidence of 1 in 3000 live births(1), although its aetiology remains largely unknown. Mice with a targeted deletion of Sonic hedgehog (Shh) have foregut defects that are apparent as early as embryonic day 9.5, when the tracheal diverticulum begins to outgrow. Homozygous Shh-null mutant mice show oesophageal atresia/stenosis, tracheo-oesophageal fistula and tracheal and lung anomalies, features similar to those observed in humans with foregut defects. The lung mesenchyme shows enhanced cell death, decreased cell proliferation and downregulation of Shh target genes. These results indicate that Shh, is required for the growth and differentiation of the oesophagus, trachea and lung, and suggest: that mutations in SHH and its signalling components may be involved in foregut defects in humans.	Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chiang, C (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell Biol, 1161 21st Ave S, Nashville, TN 37232 USA.	chin.chiang@ccmail.vanderbilt.edu						ALESCIO T, 1962, J EXP ZOOL, V150, P83, DOI 10.1002/jez.1401500202; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Bellusci S, 1997, DEVELOPMENT, V124, P53; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Brigid H, 1994, MANIPULATING MOUSE E; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; HAFFEN K, 1987, J PEDIATR GASTR NUTR, V6, P14, DOI 10.1097/00005176-198701000-00005; Hogan BLM, 1997, COLD SPRING HARB SYM, V62, P249; ISHIZUYAOKA A, 1984, J EMBRYOL EXP MORPH, V82, P163; Kos L, 1998, MECH DEVELOP, V70, P25, DOI 10.1016/S0925-4773(97)00168-8; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SCHROEDER HW, 1986, CLIN GENET, V30, P285; SHANNON JM, 1994, DEV BIOL, V166, P600, DOI 10.1006/dbio.1994.1340; Skandalakis JE., 1994, EMBRYOLOGY SURG; SPOONER BS, 1970, J EXP ZOOL, V175, P445, DOI 10.1002/jez.1401750404; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Urase K, 1996, BIOCHEM BIOPH RES CO, V225, P161, DOI 10.1006/bbrc.1996.1147; VERLOES A, 1995, CLIN DYSMORPHOL, V4, P208; WESSELLS NK, 1970, J EXP ZOOL, V175, P455, DOI 10.1002/jez.1401750405	21	526	550	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1998	20	1					58	61		10.1038/1717	http://dx.doi.org/10.1038/1717			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731532				2022-12-25	WOS:000075671400020
J	Saez, E; Tontonoz, P; Nelson, MC; Alvarez, JGA; U, TM; Baird, SM; Thomazy, VA; Evans, RM				Saez, E; Tontonoz, P; Nelson, MC; Alvarez, JGA; U, TM; Baird, SM; Thomazy, VA; Evans, RM			Activators of the nuclear receptor PPAR gamma enhance colon polyp formation	NATURE MEDICINE			English	Article							APC(DELTA-716) KNOCKOUT MICE; OMEGA-6 FATTY-ACIDS; DIETARY-FAT; F344 RATS; COLORECTAL-CANCER; CARCINOGENESIS; EXPRESSION; CYCLOOXYGENASE-2; DIFFERENTIATION; EICOSANOIDS	A high-fat diet increases the risk of colon, breast and prostate cancer. The molecular mechanism by which dietary lipids promote tumorigenesis is unknown. Their effects may be mediated at least in part by the peroxisome proliferator-activated receptors (PPARs). These ligand-activated nuclear receptors modulate gene expression in response to fatty acids, lipid-derived metabolites and antidiabetic drugs. To explore the role of the PPARs in diet-induced carcinogenesis, we treated mice predisposed to intestinal neoplasia with a synthetic PPAR gamma ligand. Reflecting the pattern of expression of PPAR gamma in the gastrointestinal tract, treated mice developed a considerably greater number of polyps in the colon but not in the small intestine, indicating that PPAR gamma activation may provide a molecular link between a high-fat diet and increased risk of colorectal cancer.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92093 USA; VA Med Ctr, San Diego, CA 92161 USA; Univ Texas, Sch Med, Dept Pathol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; University of Texas System; University of Texas System	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; CANTELLO BCC, 1994, J MED CHEM, V37, P3977, DOI 10.1021/jm00049a017; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; Hioki K, 1997, CARCINOGENESIS, V18, P1863, DOI 10.1093/carcin/18.10.1863; HOGAN ML, 1984, J NATL CANCER I, V73, P1293; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Klurfeld DM, 1997, AM J CLIN NUTR, V66, P1530, DOI 10.1093/ajcn/66.6.1530S; LEFEBVRE AM, 1998, NAT MED, V4, pR30; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; OSHIMA M, 1995, CARCINOGENESIS, V16, P2605, DOI 10.1093/carcin/16.11.2605; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; REDDY BS, 1991, CANCER RES, V51, P487; REDDY BS, 1985, JNCI-J NATL CANCER I, V75, P791; REDDY BS, 1984, JNCI-J NATL CANCER I, V72, P745; REDDY BS, 1988, CANCER RES, V48, P6642; SANO H, 1995, CANCER RES, V55, P3785; Singh J, 1997, CANCER RES, V57, P3465; TEMPLE NJ, 1987, CANCER LETT, V37, P109, DOI 10.1016/0304-3835(87)90151-0; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Weisburger JH, 1997, J AM DIET ASSOC, V97, pS16, DOI 10.1016/S0002-8223(97)00725-6; *WHO, 1997, WORLD HLTH REP	35	517	537	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1058	1061		10.1038/2042	http://dx.doi.org/10.1038/2042			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734400				2022-12-25	WOS:000075804100040
J	Letts, VA; Felix, R; Biddlecome, GH; Arikkath, J; Mahaffey, CL; Valenzuela, A; Bartlett, FS; Mori, Y; Campbell, KP; Frankel, WN				Letts, VA; Felix, R; Biddlecome, GH; Arikkath, J; Mahaffey, CL; Valenzuela, A; Bartlett, FS; Mori, Y; Campbell, KP; Frankel, WN			The mouse stargazer gene encodes a neuronal Ca2+-channel gamma subunit	NATURE GENETICS			English	Article							CALCIUM-CHANNEL; SKELETAL-MUSCLE; CA2+ CHANNELS; MUTANT MOUSE; BETA-SUBUNIT; MICE; BRAIN; EXPRESSION; EPILEPSY; SEIZURES	Stargazer mice have spike-wave seizures characteristic of absence epilepsy, with accompanying defects in the cerebellum and inner ear. We describe here a novel gene, Cacng2, whose expression is disrupted in two stargazer alleles. It encodes a 36-kD protein (stargazin) with structural similarity to the gamma-subunit of skeletal muscle voltage-gated calcium (Ca2+) channels. Stargazin is brain-specific and, like other neuronal Ca2+-channel subunits, is enriched in synaptic plasma membranes. In vitro, stargazin increases steady-state inactivation of alpha(1) class A Ca2+ channels. The anticipated effect in stargazer mutants, inappropriate Ca2+ entry, may contribute to their more pronounced seizure phenotype compared with other mouse absence models with Ca2+-channel defects. The discovery that the stargazer gene encodes a gamma-subunit completes the identification of the major subunit types for neuronal Ca2+ channels, namely alpha(1) alpha(2)delta,beta and gamma, providing a new opportunity to understand how these channels function in the mammalian brain and how they may be targeted in the treatment of neuroexcitability disorders.	Jackson Lab, Bar Harbor, ME 04609 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan	Jackson Laboratory; Howard Hughes Medical Institute; University of Iowa; University of Iowa; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Frankel, WN (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	val@jax.org; wnf@jax.org	Felix, Ricardo/A-6989-2008	Felix, Ricardo/0000-0002-5383-7176; Campbell, Kevin/0000-0003-2066-5889	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032801, R01NS032801] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32801] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; COX GA, 1997, CELL, V91, P1; De Waard M, 1996, Ion Channels, V4, P41; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Eberst R, 1997, PFLUG ARCH EUR J PHY, V433, P633, DOI 10.1007/s004240050324; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert RC, 1997, J NEUROSCI, V17, P6621; Lerche H, 1996, PFLUG ARCH EUR J PHY, V431, P461, DOI 10.1007/s004240050021; Letts VA, 1997, GENOMICS, V43, P62, DOI 10.1006/geno.1997.4780; LEVEQUE C, 1994, J BIOL CHEM, V271, P13804; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Lorenzon NM, 1998, J NEUROSCI, V18, P4482; Ludwig A, 1997, J NEUROSCI, V17, P1339; Luthi A, 1998, NEURON, V20, P553, DOI 10.1016/S0896-6273(00)80994-0; Moon BC, 1997, GENOMICS, V42, P152, DOI 10.1006/geno.1997.4701; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; NIIDOME T, 1994, BIOCHEM BIOPH RES CO, V203, P1821, DOI 10.1006/bbrc.1994.2399; Noebels J L, 1986, Adv Neurol, V44, P97; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; Nooney JM, 1997, TRENDS PHARMACOL SCI, V18, P363, DOI 10.1016/S0165-6147(97)01110-3; Ottman R, 1997, AM J HUM GENET, V60, P667; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; QIAO X, 1998, IN PRESS J NEUROSCI; Qiao XO, 1996, J NEUROSCI, V16, P640; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Scott VES, 1998, J NEUROSCI, V18, P641; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; SWEET HO, 1991, MOUSE GENOME, V89, P552; TAYLOR BA, 1993, GENOMICS, V16, P380, DOI 10.1006/geno.1993.1201; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WEI XY, 1991, J BIOL CHEM, V266, P21943; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Wissenbach U, 1998, BIOL CHEM, V379, P45, DOI 10.1515/bchm.1998.379.1.45; WITCHER DR, 1994, METHOD ENZYMOL, V238, P335; [No title captured]	59	448	469	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1998	19	4					340	347		10.1038/1228	http://dx.doi.org/10.1038/1228			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697694				2022-12-25	WOS:000075107600016
J	Bech-Hansen, NT; Naylor, MJ; Maybaum, TA; Pearce, WG; Koop, B; Fishman, GA; Mets, M; Musarella, MA; Boycott, KM				Bech-Hansen, NT; Naylor, MJ; Maybaum, TA; Pearce, WG; Koop, B; Fishman, GA; Mets, M; Musarella, MA; Boycott, KM			Loss-of-function mutations in a calcium-channel alpha(1)-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness	NATURE GENETICS			English	Article							B-WAVE; ELECTRORETINOGRAM; EXPRESSION; SUBTYPE; DNA	X-linked congenital stationary night blindness (CSNB) is a recessive non-progressive retinal disorder characterized by night blindness, decreased visual acuity, myopia, nystagmus and strabismus(1-3). Two distinct clinical entities of X-linked CSNB have been proposed(4). Patients with complete CSNB show moderate to severe myopia, undetectable rod function and a normal cone response, whereas patients with incomplete CSNB show moderate myopia to hyperopia and subnormal but measurable rod and cone function. The electrophysiological and psychophysical features of these clinical entities suggest a defect in retinal neurotransmission. The apparent clinical heterogeneity in X-linked CSNB reflects the recently described genetic heterogeneity in which the locus for complete CSNB (CSNB1) was mapped to Xp11.4, and the locus for incomplete CSNB (CSNB2) was refined within Xp11.23 (ref. 5). A novel retina-specific gene mapping to the CSNB2 minimal region was characterized and found to have similarity to voltage-gated L-type calcium channel alpha(1)-subunit genes. Mutation analysis of this new alpha(1)-subunit gene, CACNA1F, in 20 families with incomplete CSNB revealed six different mutations that are all predicted to cause premature protein truncation. These findings establish that loss-of-function mutations in CACNA1F cause incomplete CSNB, making this disorder an example of a human channelopathy of the retina.	Univ Calgary, Dept Med Genet, Calgary, AB T2N 4N1, Canada; Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2G3, Canada; Univ Victoria, Dept Biol, Victoria, BC V8W 2Y2, Canada; Univ Illinois, Dept Ophthalmol, Chicago, IL 60612 USA; Childrens Mem Hosp, Dept Ophthalmol, Chicago, IL 60614 USA; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Long Isl Coll Hosp, Dept Ophthalmol, Brooklyn, NY 11201 USA	University of Calgary; University of Alberta; University of Victoria; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Toronto; Long Island College Hospital	Bech-Hansen, NT (corresponding author), Univ Calgary, Dept Med Genet, Calgary, AB T2N 4N1, Canada.		Koop, Ben F./A-8151-2008	Koop, Ben F./0000-0003-0045-5200				BECHHANSEN NT, 1993, AM J HUM GENET, V52, P71; BECHHANSEN NT, IN PRESS HUMAN GENET; Boycott KM, 1997, CYTOGENET CELL GENET, V76, P223, DOI 10.1159/000134555; Boycott KM, 1998, AM J HUM GENET, V62, P865, DOI 10.1086/301781; Boycott KM, 1996, GENOMICS, V33, P488, DOI 10.1006/geno.1996.0224; Boycott KM, 1998, GENOMICS, V48, P369, DOI 10.1006/geno.1997.5167; Carr R E, 1974, Trans Am Ophthalmol Soc, V72, P448; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Doyle JL, 1998, TRENDS GENET, V14, P92, DOI 10.1016/S0168-9525(97)01370-X; Epp FH, 1975, MENNONITES CANADA 17; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; FISHMAN GA, 1990, ELECTROPHYSIOLOGIC T; Heon E, 1994, MOL GENETICS INHERIT, P277; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MIYAKE Y, 1986, ARCH OPHTHALMOL-CHIC, V104, P1013, DOI 10.1001/archopht.1986.01050190071042; NATHANS J, 1984, P NATL ACAD SCI USA, V81, P193; PEARCE WG, 1990, CAN J OPHTHALMOL, V25, P3; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SIEVING PA, 1994, VISUAL NEUROSCI, V11, P519, DOI 10.1017/S0952523800002431; Smith LA, 1996, J NEUROSCI, V16, P7868; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; STEA A, 1995, LIGAND VOLTAGE GATED, P113; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; TACHIBANA M, 1993, J NEUROSCI, V13, P2898; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wilkinson MF, 1996, J GEN PHYSIOL, V107, P621, DOI 10.1085/jgp.107.5.621; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; YAGI T, 1994, J NEUROPHYSIOL, V71, P656, DOI 10.1152/jn.1994.71.2.656	34	385	400	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					264	267		10.1038/947	http://dx.doi.org/10.1038/947			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662400				2022-12-25	WOS:000074565900023
J	Woiciechowsky, C; Asadullah, K; Nestler, D; Eberhardt, B; Platzer, C; Schoning, B; Glockner, F; Lanksch, WR; Volk, HD; Docke, WD				Woiciechowsky, C; Asadullah, K; Nestler, D; Eberhardt, B; Platzer, C; Schoning, B; Glockner, F; Lanksch, WR; Volk, HD; Docke, WD			Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury	NATURE MEDICINE			English	Article							PITUITARY-ADRENAL AXIS; NECROSIS-FACTOR-ALPHA; INDUCED SUPPRESSION; HLA-DR; SEPSIS; EXPRESSION; TRAUMA; CATECHOLAMINES; PREDICTION; SURGERY	The mechanism of immunodepression after brain injury is not yet clear. Here we demonstrate rapid systemic release of the immunoinhibitory cytokine interleukin-10, monocytic deactivation and a high incidence of infection in patients with 'sympathetic storm' due to acute accidental or iatrogenic brain trauma. In vitro studies showed that within minutes catecholamines trigger the secretion of interleukin-10 from unstimulated monocytes through a beta-adrenoreceptor-mediated, cAMP/protein kinase A-dependent pathway. We found that in a rat model of acute brain injury, the beta-receptor antagonist propranolol prevented the increase of interleukin-10 plasma levels. Rapid monocytic interleukin-10 release after sympathetic activation may represent a common pathway for immunodepression induced by stress and injury.	Humboldt Univ, Med Sch Charite, Dept Med Immunol, D-10098 Berlin, Germany; Humboldt Univ, Med Sch Charite, Dept Dermatol, D-10098 Berlin, Germany; Humboldt Univ, Med Sch Charite, Dept Neurosurg, D-10098 Berlin, Germany; Univ Jena, Sch Med, Inst Anat 2, D-07740 Jena, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena	Docke, WD (corresponding author), Humboldt Univ, Med Sch Charite, Dept Med Immunol, D-10098 Berlin, Germany.	volkklim@rz.charite.hu-berlin.de	Asadullah, Khusru/AAG-9810-2021; volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668				ADCOCK IM, 1995, AM J PHYSIOL-CELL PH, V268, pC331, DOI 10.1152/ajpcell.1995.268.2.C331; Asadullah K, 1995, Eur J Emerg Med, V2, P184, DOI 10.1097/00063110-199512000-00003; ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Chiolero R, 1994, New Horiz, V2, P432; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOBBIN JP, 1991, BRAIN BEHAV IMMUN, V5, P339, DOI 10.1016/0889-1591(91)90029-A; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; DOCKE WD, 1997, CRIT CARE MED, V25, pA50; DOCKE WD, 1997, 4 INT C IMM CONS TRA, P293; DUNN AJ, 1993, CIBA F SYMP, V172, P226; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; FABIAN TC, 1995, SURGERY, V118, P63, DOI 10.1016/S0039-6060(05)80011-X; GIBBONS RA, 1989, CLIN EXP IMMUNOL, V75, P371; GUILLOU PJ, 1993, LANCET, V342, P217, DOI 10.1016/0140-6736(93)92303-B; HAHN PY, 1995, SHOCK, V4, P269, DOI 10.1097/00024382-199510000-00007; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JAREK MJ, 1993, CRIT CARE MED, V21, P543, DOI 10.1097/00003246-199304000-00015; JIANG CG, 1990, BRAIN BEHAV IMMUN, V4, P278, DOI 10.1016/0889-1591(90)90032-L; Justice Blair, 1994, Comprehensive Therapy, V20, P232; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; KARLSBERG RP, 1981, AM HEART J, V102, P24, DOI 10.1016/0002-8703(81)90408-7; KOFF WC, 1986, LYMPHOKINE RES, V5, P239; LIVINGSTON DH, 1988, ARCH SURG-CHICAGO, V123, P1309; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; NAITO Y, 1992, ANESTHESIOLOGY, V77, P426, DOI 10.1097/00000542-199209000-00004; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; ROTHWELL PM, 1995, CRIT CARE MED, V23, P78, DOI 10.1097/00003246-199501000-00015; Sherry RM, 1996, J TRAUMA, V40, P613, DOI 10.1097/00005373-199604000-00016; STERNBERG EM, 1995, HORM RES, V43, P159, DOI 10.1159/000184268; Suberville S, 1996, EUR J IMMUNOL, V26, P2601, DOI 10.1002/eji.1830261110; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; Uotila P, 1996, CANCER IMMUNOL IMMUN, V43, P1; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Volk HD, 1996, INTENS CARE MED, V22, pS474, DOI 10.1007/BF01743727; VOLK HD, 1989, CLIN TRANSPLANT, V3, P246; WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853; ZORRILLA EP, 1994, BRAIN BEHAV IMMUN, V8, P293, DOI 10.1006/brbi.1994.1028; ZWILLING BS, 1993, BRAIN BEHAV IMMUN, V7, P29, DOI 10.1006/brbi.1993.1003	42	342	376	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					808	813		10.1038/nm0798-808	http://dx.doi.org/10.1038/nm0798-808			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662372				2022-12-25	WOS:000074543900035
J	de Bruin, R; Spelt, K; Mol, J; Koes, R; Quattrocchio, F				de Bruin, R; Spelt, K; Mol, J; Koes, R; Quattrocchio, F			Selection of high-affinity phage antibodies from phage display libraries	NATURE BIOTECHNOLOGY			English	Editorial Material							FLOWERS		Free Univ Amsterdam, BioCentrum Amsterdam, Inst Mol Biol Sci, Dept Dev Genet, NL-1081 HV Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam	Quattrocchio, F (corresponding author), Free Univ Amsterdam, BioCentrum Amsterdam, Inst Mol Biol Sci, Dept Dev Genet, Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.		Quattrocchio, Francesca M./N-6658-2019	Quattrocchio, Francesca M./0000-0001-8040-4061				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; Kay B. K, 1996, PHAGE DISPLAY PEPTID; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4	6	81	97	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					397	399		10.1038/7959	http://dx.doi.org/10.1038/7959			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207892				2022-12-25	WOS:000079574400035
J	Badorff, C; Lee, GH; Lamphear, BJ; Martone, ME; Campbell, KP; Rhoads, RE; Knowlton, KU				Badorff, C; Lee, GH; Lamphear, BJ; Martone, ME; Campbell, KP; Rhoads, RE; Knowlton, KU			Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy	NATURE MEDICINE			English	Article							LINKED DILATED CARDIOMYOPATHY; SEVERE COMBINED IMMUNODEFICIENCY; DUCHENNE MUSCULAR-DYSTROPHY; HEART-FAILURE; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; MICE; COXSACKIEVIRUS; DEFICIENCY; MYOCARDITIS	Enteroviruses such as Coxsackievirus B3 can cause dilated cardiomyopathy, but the mechanism of this pathology is unknown. Mutations in cytoskeletal proteins such as dystrophin cause hereditary dilated cardiomyopathy, but it is unclear if similar mechanisms underlie acquired forms of heart failure. We demonstrate here that purified Coxsackievirus protease 2A cleaves dystrophin in vitro as predicted by computer analysis. Dystrophin is also cleaved during Coxsackievirus infection of cultured myocytes and in infected mouse hearts, leading to impaired dystrophin function. In vivo, dystrophin and the dystrophin-associated glycoproteins alpha-sarcoglycan and beta-dystroglycan are morphologically disrupted in infected myocytes. We suggest a molecular mechanism through which enteroviral infection contributes to the pathogenesis of acquired forms of dilated cardiomyopathy.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, Dept Neurosci, La Jolla, CA 92093 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	University of California System; University of California San Diego; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Knowlton, KU (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Campbell, Kevin/0000-0003-2066-5889	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Beggs AH, 1997, CIRCULATION, V95, P2344, DOI 10.1161/01.CIR.95.10.2344; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CHOW LH, 1992, LAB INVEST, V66, P24; Cohn JN, 1997, CIRCULATION, V95, P766; Dargie HJ, 1996, J INTERN MED, V239, P309, DOI 10.1046/j.1365-2796.1996.461800000.x; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Fadic R, 1996, NEW ENGL J MED, V334, P362, DOI 10.1056/NEJM199602083340604; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; KOENIG M, 1990, J BIOL CHEM, V265, P4560; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; Leiden JM, 1997, NEW ENGL J MED, V337, P1080, DOI 10.1056/NEJM199710093371511; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; MALHOTRA SB, 1988, SCIENCE, V242, P755, DOI 10.1126/science.3055295; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NICHOLSON LVB, 1989, J NEUROL SCI, V94, P125, DOI 10.1016/0022-510X(89)90223-2; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Roberts RG, 1998, HUM MOL GENET, V7, P589, DOI 10.1093/hmg/7.4.589; RUECKERT RR, 1996, FUNDAMENTAL VIROLOGY, V3, P477; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Schwarz EM, 1998, J VIROL, V72, P5654, DOI 10.1128/JVI.72.7.5654-5660.1998; SCHWIMMBECK PL, 1994, CIRC RES, V75, P156, DOI 10.1161/01.RES.75.1.156; SETOGUCHI M, 1993, BIOCHEM BIOPH RES CO, V194, P1012, DOI 10.1006/bbrc.1993.1922; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHOEMAN RL, 1993, AM J PATHOL, V142, P221; Sole MJ, 1993, J AM COLL CARDIOL, V22, P99; Sommergruber W, 1997, VIROLOGY, V234, P203, DOI 10.1006/viro.1997.8595; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Wessely R, 1998, CIRCULATION, V98, P450, DOI 10.1161/01.CIR.98.5.450; Wessely R, 1998, J CLIN INVEST, V102, P1444, DOI 10.1172/JCI1972	45	398	423	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					320	326		10.1038/6543	http://dx.doi.org/10.1038/6543			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086389				2022-12-25	WOS:000078851600038
J	Buetow, KH; Edmonson, MN; Cassidy, AB				Buetow, KH; Edmonson, MN; Cassidy, AB			Reliable identification of large numbers of candidate SNPs from public EST data	NATURE GENETICS			English	Article							EXPRESSED SEQUENCE TAGS	High-resolution genetic analysis of the human genome promises to provide insight into common disease susceptibility. To perform such analysis will require a collection of high-throughput, high-density analysis reagents. We have developed a polymorphism detection system that uses public-domain sequence data. This detection system is called the single nucleotide polyrmorphism pipeline (SNPpipeline). The analytic core of the SNPpipeline is composed of three components: PHRED, PHRAP and DEMIGLACE. PHRED and PHRAP are components of a sequence analysis suite developed to perform the semi-automated analysis required for large-scale genomes(1,2) (provided courtesy of P. Green). Using these informatics tools, which examine redundant raw expressed sequence tag (EST) data, we have identified more than 3,000 candidate single-nucleotide polyrmorphisms (SNPs). Empiric validation studies of a set of 192 candidates indicate that 82% identify variation in a sample of ten Centre d'Etudes Polymorphism Humain (CEPH) individuals. Our results suggest that existing sequence resources may serve as a valuable source for identifying genetic variation.	NCI, Lab Populat Genet, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center	Buetow, KH (corresponding author), NCI, Lab Populat Genet, NIH, Bethesda, MD 20892 USA.							Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; JIN L, 1990, MOL BIOL EVOL, V7, P82; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Sokal RR, 1963, PRINCIPLES NUMERICAL; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	8	207	234	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					323	325		10.1038/6851	http://dx.doi.org/10.1038/6851			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080189				2022-12-25	WOS:000078977900030
J	Dove, AQ				Dove, AQ			Proteomics: translating genomics into products?	NATURE BIOTECHNOLOGY			English	Article							PROTEINS											BARRETT T, 1973, BIOCHIM BIOPHYS ACTA, V294, P165, DOI 10.1016/0005-2787(73)90323-7; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; OFARREL PH, 1975, J BIOL CHEM, V250, P400; Oliver SG, 1998, TRENDS BIOTECHNOL, V16, P373, DOI 10.1016/S0167-7799(98)01214-1; Persidis A, 1998, NAT BIOTECHNOL, V16, P393, DOI 10.1038/nbt0498-393	5	109	126	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					233	236		10.1038/6972	http://dx.doi.org/10.1038/6972			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096288				2022-12-25	WOS:000078977500022
J	Guevara, NV; Kim, HS; Antonova, EI; Chan, L				Guevara, NV; Kim, HS; Antonova, EI; Chan, L			The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo	NATURE MEDICINE			English	Article							APOE-DEFICIENT MICE; APOPTOSIS; RESTENOSIS; MODEL; CYTOMEGALOVIRUS; ATHEROGENESIS; PROGRESSION; LESIONS; GROWTH	The tumor suppressor protein p53 is an essential molecule in cell proliferation and programmed cell death (apoptosis), and has been postulated to play a principal part in the development of atherosclerosis. We have examined the effect of p53 inactivation on atherogenesis in apoE-knockout mice, an animal model for atherosclerosis(1,2). We found that, compared with p53(+/+)/apoE(-/-) mice, p53(-/-)apoE(-/-) mice developed considerably accelerated aortic atherosclerosis in the presence of a similar serum cholesterol in response to a high-fat diet. Furthermore, the atherosclerotic lesions in p53(-/-)apoE(-/-) mice had a significant (similar to 280%) increase in cell proliferation rate and an insignificant (similar to 180%) increase in apoptosis compared with those in p53(+/+)/apoE(-/-) mice. Our observations indicate that the role of p53 in atherosclerotic lesion development might be associated with its function in cell replication control, and that p53-independent mechanisms can mediate the apoptotic response in atherosclerosis.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA.			Guevara, Natalia Valentinova/0000-0002-5244-6691	NHLBI NIH HHS [HL-51586] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; BJARKERUD S, 1996, AM J PATHOL, V149, P367; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P213; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GENG YJ, 1995, AM J PATHOL, V147, P251; HAN DKM, 1995, AM J PATHOL, V147, P267; HARVEY M, 1993, ONCOGENE, V8, P2457; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rembold C, 1996, PERSPECT BIOL MED, V39, P405; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Virchow RLK, 1863, CITED INDIRECTLY, P1; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	23	213	222	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					335	339		10.1038/6585	http://dx.doi.org/10.1038/6585			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086392				2022-12-25	WOS:000078851600041
J	Dittmer, U; Brooks, DM; Hasenkrug, KJ				Dittmer, U; Brooks, DM; Hasenkrug, KJ			Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; MURINE LEUKEMIA VIRUSES; STREET RABIES VIRUS; FRIEND-LEUKEMIA; T-CELLS; IMMUNE-RESPONSE; NEF DELETION; SIV VACCINE; HIV; ERYTHROLEUKEMIA	Infection by live attenuated retroviruses provides excellent protection from challenge with pathogenic viruses in several animal models, but little is known about which immune effecters are necessary for protection. We examined this using adoptive transfer experiments in the Friend virus mouse model. Transfers of immune spleen cells into naive mice conferred complete protection, and transfers of purified lymphocyte subsets demonstrated that this effect required complex immune responses involving CD4(+) and CD8(+) T cells and also B cells. In addition, passive immunization experiments demonstrated that antibodies alone reduced virus loads but did not prevent infection. These findings may have implications for retroviral vaccine design in general.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hasenkrug, KJ (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000753, ZIAAI000753] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BRITT WJ, 1983, J IMMUNOL, V130, P2363; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; CEGLOWSKI WS, 1968, J IMMUNOL, V101, P594; CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X; CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1; Cohen I, 1997, SCIENCE, V278, P24, DOI 10.1126/science.278.5335.24; Cole KS, 1997, J VIROL, V71, P5069, DOI 10.1128/JVI.71.7.5069-5079.1997; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1998, NAT MED, V4, P982, DOI 10.1038/1949; Dittmer U, 1998, J VIROL, V72, P6554, DOI 10.1128/JVI.72.8.6554-6558.1998; DITTMER U, 1995, VIROLOGY, V212, P392, DOI 10.1006/viro.1995.1496; Dittmer U, 1998, J GEN VIROL, V79, P1801, DOI 10.1099/0022-1317-79-7-1801; EARL PL, 1986, SCIENCE, V234, P728, DOI 10.1126/science.3490689; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Hasenkrug KJ, 1998, VIROLOGY, V248, P66, DOI 10.1006/viro.1998.9264; HASENKRUG KJ, 1995, P NATL ACAD SCI USA, V92, P10492, DOI 10.1073/pnas.92.23.10492; Hasenkrug KJ, 1998, J VIROL, V72, P6559, DOI 10.1128/JVI.72.8.6559-6564.1998; Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803; Heilman CA, 1998, NAT MED, V4, P532, DOI 10.1038/nm0598supp-532; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOM RC, 1991, J VIROL, V65, P220, DOI 10.1128/JVI.65.1.220-224.1991; Johnson RP, 1997, J VIROL, V71, P7711, DOI 10.1128/JVI.71.10.7711-7718.1997; Johnson RP, 1998, CURR OPIN IMMUNOL, V10, P436, DOI 10.1016/S0952-7915(98)80118-0; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; JONES SM, 1992, VIRAL IMMUNOL, V5, P201, DOI 10.1089/vim.1992.5.201; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LILLY F, 1967, SCIENCE, V155, P461, DOI 10.1126/science.155.3761.461; LODMELL DL, 1985, J VIROL, V55, P788, DOI 10.1128/JVI.55.3.788-795.1985; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MORRISON RP, 1987, NATURE, V329, P729, DOI 10.1038/329729a0; MORRISON RP, 1986, J EXP MED, V163, P301, DOI 10.1084/jem.163.2.301; Norley S, 1996, VIROLOGY, V219, P195, DOI 10.1006/viro.1996.0237; OLDSTONE MBA, 1993, J VIROL, V67, P4372, DOI 10.1128/JVI.67.7.4372-4378.1993; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; PINCUS T, 1971, J EXP MED, V133, P1234, DOI 10.1084/jem.133.6.1234; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SITBON M, 1985, VIROLOGY, V141, P110, DOI 10.1016/0042-6822(85)90187-4; StahlHennig C, 1996, IMMUNOL LETT, V51, P129, DOI 10.1016/0165-2478(96)02567-9; WALKER CM, 1989, IMMUNOLOGY, V66, P628; WEIDT G, 1995, J VIROL, V69, P2654, DOI 10.1128/JVI.69.4.2654-2658.1995; WENDLING F, 1978, INT J CANCER, V22, P479, DOI 10.1002/ijc.2910220418; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7	50	86	86	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1999	5	2					189	193		10.1038/5550	http://dx.doi.org/10.1038/5550			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930867				2022-12-25	WOS:000078274400028
J	Gupta, A; Matsui, K; Lo, JF; Silver, S				Gupta, A; Matsui, K; Lo, JF; Silver, S			Molecular basis for resistance to silver cations in Salmonella	NATURE MEDICINE			English	Article							P-TYPE ATPASES; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; DETERMINANT PCO; COPPER; EFFLUX; TRANSPORT; CATHETERS	Here we report the genetic and proposed molecular basis for silver resistance in pathogenic microorganisms. The silver resistance determinant from a hospital burn ward Salmonella plasmid contains nine open reading frames, arranged in three measured and divergently transcribed RNAs. The resistance determinant encodes a periplasmic silver-specific binding protein (SilE) plus apparently two parallel efflux pumps: one, a P-type ATPase (SilP); the other, a membrane potential-dependent three-polypeptide cation/proton antiporter (SilCBA). The sil determinant is governed by a two-component membrane sensor and transcriptional responder comprising silS and silR, which are co-transcribed. The availability of the sil silver-resistance determinant will be the basis for mechanistic molecular and biochemical studies as well as molecular epidemiology of silver resistance in clinical settings in which silver is used as a biocide.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gupta, A (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room 703,835 S Wolcott Ave, Chicago, IL 60612 USA.		Matsui, Kazuaki/S-1473-2019; Lo, Jeng-Fan/ABB-2820-2020; Lo, Jeng-Fan/AAE-9626-2020	Matsui, Kazuaki/0000-0002-1563-3308; Lo, Jeng-Fan/0000-0001-7188-9140; Lo, Jeng-Fan/0000-0001-7188-9140; Silver, Simon/0000-0002-5692-3125				ANNEAR DI, 1976, J CLIN PATHOL, V29, P441, DOI 10.1136/jcp.29.5.441; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRIDGES K, 1979, BRIT MED J, V1, P446, DOI 10.1136/bmj.1.6161.446; BROWN NL, 1995, MOL MICROBIOL, V17, P1153, DOI 10.1111/j.1365-2958.1995.mmi_17061153.x; CHU CS, 1995, J TRAUMA, V39, P273, DOI 10.1097/00005373-199508000-00014; Gabriel MM, 1996, CURR MICROBIOL, V33, P1, DOI 10.1007/s002849900064; George N, 1997, BURNS, V23, P493, DOI 10.1016/S0305-4179(97)00047-8; GREENFELD JI, 1995, CRIT CARE MED, V23, P894, DOI 10.1097/00003246-199505000-00018; Gupta A, 1998, APPL ENVIRON MICROB, V64, P5042; Gupta A, 1998, NAT BIOTECHNOL, V16, P888, DOI 10.1038/nbt1098-888; Hobman JL, 1997, MET IONS BIOL SYST, V34, P527; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Li XZ, 1997, J BACTERIOL, V179, P6127, DOI 10.1128/JB.179.19.6127-6132.1997; MCHUGH GL, 1975, LANCET, V1, P235; Modak S M, 1988, J Burn Care Rehabil, V9, P359, DOI 10.1097/00004630-198807000-00009; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Pruitt BA, 1998, WORLD J SURG, V22, P135; Rech S, 1996, J BIOL CHEM, V271, P2557, DOI 10.1074/jbc.271.5.2557; Rouch DA, 1997, MICROBIOL-SGM, V143, P1191, DOI 10.1099/00221287-143-4-1191; Rudd KE, 1998, MICROBIOL MOL BIOL R, V62, P985, DOI 10.1128/MMBR.62.3.985-1019.1998; SAMPATH LA, 1995, J HOSP INFECT, V30, P201, DOI 10.1016/S0195-6701(95)90315-1; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; Silver S, 1998, J IND MICROBIOL BIOT, V20, P1, DOI 10.1038/sj.jim.2900483; SILVER S, IN PRESS METAL BASED; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; TRENOR C, 1994, BIOCHEM BIOPH RES CO, V205, P1644, DOI 10.1006/bbrc.1994.2856; vanderLelie D, 1997, MOL MICROBIOL, V23, P493, DOI 10.1046/j.1365-2958.1997.d01-1866.x	32	359	379	0	60	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					183	188		10.1038/5545	http://dx.doi.org/10.1038/5545			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930866				2022-12-25	WOS:000078274400027
J	Igarashi, T; Brown, C; Azadegan, A; Haigwood, N; Dimitrov, D; Martin, MA; Shibata, R				Igarashi, T; Brown, C; Azadegan, A; Haigwood, N; Dimitrov, D; Martin, MA; Shibata, R			Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma	NATURE MEDICINE			English	Article							INFECTED CHIMPANZEES; HIV-1 INFECTION; IN-VIVO; MONKEYS; REPLICATION; GENERATION; RESISTANCE; STRAIN; LIVE; MAC	The concentration of human immunodeficiency virus type 1 (HIV-1) particles in blood plasma is very predictive of the subsequent disease course in an infected individual; its measurement has become one of the most important parameters for monitoring clinical status'. Steady-state virus levels in plasma reflect a balance between the rates of virions entering and leaving the peripheral blood(2). We analyzed the rate of virus clearance in the general circulation in rhesus macaques receiving a continuous infusion of cell-free particles in the presence and absence of virus-specific antibodies. Here we show, by measuring virion RNA, particle-associated p24 Gag protein and virus infectivity, that the clearance of physical and infectious particles from a primary, dual-tropic virus isolate, HIV-1(DH12), is very rapid in naive animals, with half-lives ranging from 13 to 26 minutes. In the presence of high-titer HIV-1(DH12)-specific neutralizing antibodies, the half-life of virion RNA was considerably reduced (to 3.9-7.2 minutes), and infectious virus in the blood became undetectable. Although physical virus particles were eliminated extravascularly, the loss of virus infectivity in the blood reflected the combined effects of extravascular clearance and intravascular inactivation of HIV-1 infectivity due to antibody binding.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NIH, Vet Resources Program, Bethesda, MD 20892 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; NCI, Lab Expt & Computat Biol, NIH, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; Center for Infectious Disease Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Igarashi, T (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.		Haigwood, Nancy Logan/AAV-7484-2020	Haigwood, Nancy/0000-0002-1477-9575	DIVISION OF BASIC SCIENCES - NCI [Z01BC010042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000415, ZIAAI000415] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; BRUNNER KT, 1960, J IMMUNOL, V85, P99; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; Himathongkham S, 1996, VIROLOGY, V219, P485, DOI 10.1006/viro.1996.0276; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Igarashi T, 1997, J GEN VIROL, V78, P985, DOI 10.1099/0022-1317-78-5-985; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MIMS CA, 1959, BRIT J EXP PATHOL, V40, P533; MIMS CA, 1956, BRIT J EXP PATHOL, V37, P110; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NATHANSON N, 1967, AM J EPIDEMIOL, V85, P494, DOI 10.1093/oxfordjournals.aje.a120712; *NIH, 1985, DHHS PUBL NIH, V8523; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; REED L. J., 1938, AMER JOUR HYG, V27, P493; SCHULTZ I, 1965, J IMMUNOL, V94, P833; Shibata R, 1997, AIDS RES HUM RETROV, V13, P377, DOI 10.1089/aid.1997.13.377; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; SHIBATA R, 1991, J VIROL, V65, P3514, DOI 10.1128/JVI.65.7.3514-3520.1991; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZILVERSMIT DB, 1952, J LAB CLIN MED, V40, P255	28	136	151	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					211	216		10.1038/5576	http://dx.doi.org/10.1038/5576			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930870				2022-12-25	WOS:000078274400031
J	Oberpenning, F; Meng, J; Yoo, JJ; Atala, A				Oberpenning, F; Meng, J; Yoo, JJ; Atala, A			De novo reconstitution of a functional mammalian urinary bladder by tissue engineering	NATURE BIOTECHNOLOGY			English	Article						augmentation; cystoplasty; neo-bladder; cystectomy; cell culture	SMOOTH-MUSCLE; IN-VIVO; UROTHELIUM; URETEROCYSTOPLASTY; AUTOAUGMENTATION; REPLACEMENT; DETRUSOR; MEMBRANE; RABBIT; SYSTEM	Human organ replacement is limited by a donor shortage, problems with tissue compatibility, and rejection. Creation of an organ with autologous tissue would be advantageous. In this study, transplantable urinary bladder neo-organs were reproducibly created in vitro from urothelial and smooth muscle cells grown in culture from canine native bladder biopsies and seeded onto preformed bladder-shaped polymers. The native bladders were subsequently excised from canine donors and replaced with the tissue-engineered neo-organs. In functional evaluations for up to 11 months, the bladder neo-organs demonstrated a normal capacity to retain urine, normal elastic properties, and histologic architecture. This study demonstrates, for the first time, that successful reconstitution of an autonomous hollow organ is possible using tissue-engineering methods.	Childrens Hosp, Dept Urol, Lab Tissue Engn & Cellular Therapeut, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Atala, A (corresponding author), Childrens Hosp, Dept Urol, Lab Tissue Engn & Cellular Therapeut, 300 Longwood Ave, Boston, MA 02115 USA.		Sano, Michael/E-1715-2011	Atala, Anthony/0000-0001-8186-2160	NIDDK NIH HHS [R01 DK 49484] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atala A, 1998, J UROLOGY, V159, P2, DOI 10.1016/S0022-5347(01)63994-6; ATALA A, 1992, J UROLOGY, V148, P658, DOI 10.1016/S0022-5347(17)36685-5; ATALA A, 1993, J UROLOGY, V150, P608, DOI 10.1016/S0022-5347(17)35561-1; ATALA A, 1995, J UROLOGY, V156, P338; ATALA A, 1994, CLIN UROLOGY, P507; Atala Anthony, 1997, P149; BAKER R, 1958, JAMA-J AM MED ASSOC, V168, P1178, DOI 10.1001/jama.1958.03000090008002; BELLINGER MF, 1993, J UROLOGY, V149, P811, DOI 10.1016/S0022-5347(17)36215-8; BONA AV, 1966, UROLOGY, V18, P43; CARTWRIGHT PC, 1989, J UROLOGY, V142, P1050, DOI 10.1016/S0022-5347(17)38985-1; CHENG E, 1994, J UROLOGY, V152, P2252, DOI 10.1016/S0022-5347(17)31652-X; CILENTO BG, 1994, J UROLOGY, V152, P655; DEBOER WI, 1994, AM J PATHOL, V145, P1199; DEWAN PA, 1994, BRIT J UROL, V74, P460, DOI 10.1111/j.1464-410X.1994.tb00423.x; Freeman MR, 1997, J CLIN INVEST, V99, P1028, DOI 10.1172/JCI119230; FUJITA K, 1978, UROLOGY, V15, P355; GLEESON MJ, 1992, J UROLOGY, V148, P1377, DOI 10.1016/S0022-5347(17)36916-1; GONZALEZ R, 1995, UROLOGY, V45, P124, DOI 10.1016/S0090-4295(95)97364-8; GORHAM SD, 1989, EUR UROL, V16, P440; KELAMI A, 1970, EUR SURG RES, V2, P195, DOI 10.1159/000127514; Kropp BP, 1996, J UROLOGY, V156, P599, DOI 10.1016/S0022-5347(01)65761-6; KUDISH HG, 1957, J UROLOGY, V78, P232, DOI 10.1016/S0022-5347(17)66428-0; Lailas NG, 1996, J UROLOGY, V156, P1151, DOI 10.1016/S0022-5347(01)65740-9; MCDOUGAL WS, 1992, J UROLOGY, V147, P1199, DOI 10.1016/S0022-5347(17)37517-1; MONSOUR MJ, 1987, UROL RES, V15, P235; NEUHOF H, 1917, SURG GYNECOL OBSTET, V25, P383; Probst M, 1997, BRIT J UROL, V79, P505, DOI 10.1046/j.1464-410X.1997.00103.x; Rohrmann D, 1996, J UROLOGY, V156, P2094, DOI 10.1016/S0022-5347(01)65442-9; SALLE JLP, 1990, J UROLOGY, V144, P454, DOI 10.1016/S0022-5347(17)39487-9; Tobin Matthew S., 1994, Surgical Forum, V45, P786; TSUJI I, 1967, J UROLOGY, V98, P91, DOI 10.1016/S0022-5347(17)62828-3; TSUJI I, 1961, J UROLOGY, V85, P42, DOI 10.1016/S0022-5347(17)65279-0; WU XR, 1994, J BIOL CHEM, V269, P13716; Yoo JJ, 1997, J UROLOGY, V158, P1066, DOI 10.1016/S0022-5347(01)64390-8; Yoo JJ, 1998, UROLOGY, V51, P221, DOI 10.1016/S0090-4295(97)00644-4	35	588	658	2	68	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					149	155		10.1038/6146	http://dx.doi.org/10.1038/6146			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052350				2022-12-25	WOS:000078508300022
J	Vulpe, CD; Kuo, YM; Murphy, TL; Cowley, L; Askwith, C; Libina, N; Gitschier, J; Anderson, GJ				Vulpe, CD; Kuo, YM; Murphy, TL; Cowley, L; Askwith, C; Libina, N; Gitschier, J; Anderson, GJ			Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; FET3 GENE; FERROXIDASE; EXPRESSION; YEAST	Iron is essential for many cellular functions; consequently, disturbances of iron homeostasis, leading to either iron deficiency or iron overload, can have significant clinical consequences. Despite the clinical prevalence of these disorders, the mechanism by which dietary iron is absorbed into the body is poorly understood. We have identified a key component in intestinal iron transport by study of the sex-linked anaemia (s/a) mouse, which has a block in intestinal iron transport(1). Mice carrying the sla mutation develop moderate to severe microcytic hypochromic anaemia(1). Although these mice take up iron from the intestinal lumen into mature epithelial cells normally(2), the subsequent exit of iron into the circulation is diminished(3). As a result, iron accumulates in enterocytes and is lost during turnover of the intestinal epithelium(4). Biochemical studies have failed to identify the underlying difference between s/a and normal mice, therefore, we used a genetic approach to identify the gene mutant in sla mice. We describe here a novel gene, Heph, encoding a transmembrane-bound ceruloplasmin homologue that is mutant in the sla mouse and highly expressed in intestine. We suggest that the hephaestin protein is a multicopper ferroxidase necessary for iron egress from intestinal enterocytes into the circulation and that it is an important link between copper and iron metabolism in mammals.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Queensland, Joint Clin Sci Program, Brisbane, Qld, Australia; Queensland Inst Med Res, Clin Sci Unit, Brisbane, Qld, Australia; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Queensland; QIMR Berghofer Medical Research Institute; Utah System of Higher Education; University of Utah	Gitschier, J (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.		Vulpe, Chris/AAF-9170-2020; Anderson, Gregory J/G-4148-2013	Vulpe, Chris/0000-0001-5134-8929; Anderson, Gregory J/0000-0002-8814-5866				Anderson GJ, 1998, GENOMICS, V48, P34, DOI 10.1006/geno.1997.5138; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BANNERMAN RM, 1976, FED PROC, V35, P2281; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; Bothwell TH., IRON METABOLISM MAN, P256; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; Danks DM, 1989, METABOLIC BASIS INHE, P1411; Davis LG, 1986, BASIC METHODS MOL BI, P42; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; EDWARDS JA, 1977, J LAB CLIN MED, V90, P68; FALCONER DS, 1962, GENET RES, V3, P248, DOI 10.1017/S0016672300035035; GREWAL MS, 1962, GENET RES, V3, P238, DOI 10.1017/S0016672300035023; HALLIDAY JW, 1992, IRON HUMAN DISEASE, P131; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Kuo YM, 1997, HUM MOL GENET, V6, P1043, DOI 10.1093/hmg/6.7.1043; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Logan JI, 1996, J NEUROL NEUROSUR PS, V61, P431, DOI 10.1136/jnnp.61.5.431; Lombard M, 1997, GUT, V40, P435, DOI 10.1136/gut.40.4.435; MANIS J, 1970, NATURE, V227, P385, DOI 10.1038/227385a0; Skinke B, 1994, IRON METABOLISM HLTH, P151; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552	23	829	857	2	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					195	199		10.1038/5979	http://dx.doi.org/10.1038/5979			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988272				2022-12-25	WOS:000078399500022
J	Yang, YL; Guo, L; Xu, SA; Holland, CA; Kitamura, T; Hunter, K; Cunningham, JM				Yang, YL; Guo, L; Xu, SA; Holland, CA; Kitamura, T; Hunter, K; Cunningham, JM			Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1	NATURE GENETICS			English	Article							MURINE LEUKEMIA-VIRUS; ENVELOPE GLYCOPROTEINS; CELLULAR RECEPTOR; PROTEIN; LEUKEMOGENESIS; CHROMOSOME-1; BINDING; SUSCEPTIBILITY; CONSTRUCTION; RETROVIRUSES	The onset of leukaemia caused by type C retroviruses (MLV) in mice is accelerated by the emergence of recombinant polytropic or mink cell focus-forming (MCF) viruses(1-4). Susceptibility to infection by polytropic/MCF and also by closely related xenotropic MLV has been mapped to Rmc1 on mouse chromosome 1 (refs 5-7). To identify this gene, we introduced an expression cDNA library prepared from mouse NIH3T3 fibroblasts into nonpermissive hamster cells and screened these cells for acquired susceptibility to MCF viruses encoding beta-galactosidase and G418 resistance. From hamster cell clones identified in the screen, we recovered a mouse cDNA that maps to Rmc1 and confers MCF MLV infection when expressed in nonpermissive cell lines. It encodes a membrane protein related to Syg1p (suppressor of yeast G alpha deletion; ref. 8), The receptor-binding domain of the MCF MLV envelope protein binds specifically to Xenopus laevis oocytes that express mouse Syg1, suggesting it functions as a receptor that mediates virus entry. We also obtained the cDNA encoding human SYG1. When expressed in hamster cells, it establishes infectivity by MCF MLV as well as xenotropic MLV, which do not infect laboratory mice.	Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Natl Med Ctr, Ctr Virol Immunol & Infect Dis Res, Washington, DC 20010 USA; Univ Tokyo, Inst Med Sci, Tokyo 108, Japan; Fox Chase Canc Ctr, Dept Mol Biol, Philadelphia, PA 19111 USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Children's National Health System; University of Tokyo; Fox Chase Cancer Center	Cunningham, JM (corresponding author), Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.		Kitamura, Toshio/AAA-2071-2021		NCI NIH HHS [2R01CA/AI61246-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS RM, 1992, P NATL ACAD SCI USA, V89, P8981, DOI 10.1073/pnas.89.19.8981; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CHESEBRO B, 1985, VIROLOGY, V141, P119, DOI 10.1016/0042-6822(85)90188-6; Davey RA, 1997, J VIROL, V71, P8096, DOI 10.1128/JVI.71.11.8096-8102.1997; Fan H, 1997, TRENDS MICROBIOL, V5, P74, DOI 10.1016/S0966-842X(96)10076-7; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; FLUBACHER MM, 1994, J VIROL, V68, P7709, DOI 10.1128/JVI.68.12.7709-7716.1994; HERR W, 1984, J VIROL, V50, P155, DOI 10.1128/JVI.50.1.155-162.1984; HUNTER K, 1991, SOMAT CELL MOLEC GEN, V17, P169, DOI 10.1007/BF01232974; HUNTER KW, 1994, MAMM GENOME, V5, P597, DOI 10.1007/BF00411453; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KOZAK CA, 1983, J VIROL, V48, P300, DOI 10.1128/JVI.48.1.300-303.1983; KOZAK CA, 1985, J VIROL, V55, P690, DOI 10.1128/JVI.55.3.690-695.1985; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; Loiler SA, 1997, J VIROL, V71, P4825, DOI 10.1128/JVI.71.6.4825-4828.1997; Lyu MS, 1996, J VIROL, V70, P830, DOI 10.1128/JVI.70.2.830-833.1996; OTT D, 1992, J VIROL, V66, P4632, DOI 10.1128/JVI.66.8.4632-4638.1992; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RUSCETTI S, 1981, J EXP MED, V154, P907, DOI 10.1084/jem.154.3.907; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; STOYE JP, 1991, J VIROL, V65, P1273, DOI 10.1128/JVI.65.3.1273-1285.1991; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0	26	118	120	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					216	219		10.1038/6005	http://dx.doi.org/10.1038/6005			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988277				2022-12-25	WOS:000078399500027
J	Morales, CP; Holt, SE; Ouellette, M; Kaur, KJ; Yan, Y; Wilson, KS; White, MA; Wright, WE; Shay, JW				Morales, CP; Holt, SE; Ouellette, M; Kaur, KJ; Yan, Y; Wilson, KS; White, MA; Wright, WE; Shay, JW			Absence of cancer-associated changes in human fibroblasts immortalized with telomerase	NATURE GENETICS			English	Article							CELL-CYCLE REGULATION; EPITHELIAL-CELLS; DNA-DAMAGE; GENE; P53; SENESCENCE; DISRUPTION; CULTURE; PROTEIN	The ectopic expression of telomerase(1-2) in normal human cells results in an extended lifespan(3-4), indicating that telomere shortening regulates the timing of cellular senescence, As telomerase expression is a hallmark of cancer, we investigated the long-term effects of forced expression of human telomerase catalytic component (hTERT) in normal human fibroblasts. In vitro growth requirements, cell-cycle checkpoints and karyotypic stability in telomerase-expressing cells are similar to those of untransfected controls. In addition, co-expression of telomerase, the viral oncoproteins HPV16 E6/E7 (which inactivate p53 and pRB) and oncogenic HRAS does not result in growth in soft agar, Thus, although ectopic expression of telomerase in human fibroblasts is sufficient for immortalization, it does not result in changes typically associated with malignant transformation.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, Richmond, VA 23298 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Virginia Commonwealth University	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	shay@utsw.swmed.edu	Gagneja, Kanwalinderjit K/K-3204-2017; Shay, Jerry W/F-7878-2011	Gagneja, Kanwalinderjit K/0000-0001-7844-8583; 	NCI NIH HHS [CA71443] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERCROMBIE M, 1970, IN VITRO CELL DEV B, V6, P128; BENN PA, 1976, AM J HUM GENET, V28, P465; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gustashaw Karen M., 1997, P259; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, INT J ONCOL, V8, P263; Honda T, 1996, MUTAT RES-FUND MOL M, V354, P15, DOI 10.1016/0027-5107(96)00003-6; KASTAN MB, 1991, CANCER RES, V51, P6304; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NOWELL PC, 1987, DEV RECOGNITION TRAN, P1; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SAKSELA E, 1963, P NATL ACAD SCI USA, V50, P390, DOI 10.1073/pnas.50.2.390; SCHER CD, 1971, EXP CELL RES, V68, P479, DOI 10.1016/0014-4827(71)90181-9; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	29	643	679	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					115	118		10.1038/5063	http://dx.doi.org/10.1038/5063			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916803				2022-12-25	WOS:000077960700021
J	Snyder, RO; Miao, C; Meuse, L; Tubb, J; Donahue, BA; Lin, HF; Stafford, DW; Patel, S; Thompson, AR; Nichols, T; Read, MS; Bellinger, DA; Brinkhous, KM; Kay, MA				Snyder, RO; Miao, C; Meuse, L; Tubb, J; Donahue, BA; Lin, HF; Stafford, DW; Patel, S; Thompson, AR; Nichols, T; Read, MS; Bellinger, DA; Brinkhous, KM; Kay, MA			Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors	NATURE MEDICINE			English	Article							HUMAN FACTOR-IX; DEFICIENT MOUSE MODEL; COAGULATION-FACTOR-IX; FACTOR-VIII; GENE-TRANSFER; VONWILLEBRAND-FACTOR; EXPRESSION; MICE; THERAPY; PLASMA	Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.	Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Cell Genesys Inc, Foster City, CA 94404 USA; Univ Washington, Dept Med, Seattle, WA 98104 USA; Univ Washington, Puget Sound Blood Ctr, Seattle, WA 98104 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	Stanford University; Stanford University; Cell Genesys Inc; University of Washington; University of Washington Seattle; Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kay, MA (corresponding author), Stanford Univ, Dept Pediat, Sch Med, 300 Pasteur Dr,Rm G305, Stanford, CA 94305 USA.	markay@stanford.edu		Kay, Mark/0000-0002-2799-2615	NHLBI NIH HHS [HL01648, HL53682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BI L, 1995, NATURE GEN, V10; BRINKHOUS KM, 1993, THROMB HAEMOSTASIS, V69, P852; BRINKHOUS KM, 1993, BLOOD, V82, pA592; DAI Y, 1995, MED SCI, V92, P1401; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Ewenstein BM, 1997, BLOOD, V89, P1115, DOI 10.1182/blood.V89.3.1115; GILES AR, 1982, BLOOD, V60, P727; GRIGGS TR, 1974, P NATL ACAD SCI USA, V71, P2087, DOI 10.1073/pnas.71.5.2087; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P875, DOI 10.1055/s-0038-1651380; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; KINGDON HS, 1981, BLOOD, V58, P868; Kundu RK, 1998, BLOOD, V92, P168, DOI 10.1182/blood.V92.1.168.413k06_168_174; Kung SH, 1998, BLOOD, V91, P784, DOI 10.1182/blood.V91.3.784.784_784_790; LI J, IN PRESS J VIROL; Lin HF, 1997, BLOOD, V90, P3962, DOI 10.1182/blood.V90.10.3962; Mauser AE, 1996, BLOOD, V88, P3451, DOI 10.1182/blood.V88.9.3451.bloodjournal8893451; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; NEUENSCHWANDER S, 1994, HAEMOSTASIS, V24, P27; NICHOLS TC, 1993, BLOOD, V81, P2644; Rosenberg JB, 1998, J CLIN INVEST, V101, P613, DOI 10.1172/JCI1250; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Wang LL, 1997, P NATL ACAD SCI USA, V94, P11563, DOI 10.1073/pnas.94.21.11563; Warrier I, 1997, J PEDIAT HEMATOL ONC, V19, P23, DOI 10.1097/00043426-199701000-00003; YAO SN, 1992, P NATL ACAD SCI USA, V89, P3357, DOI 10.1073/pnas.89.8.3357; YAO SN, 1994, GENE THER, V1, P99; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	31	368	427	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1999	5	1					64	70		10.1038/4751	http://dx.doi.org/10.1038/4751			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883841				2022-12-25	WOS:000077885000031
J	Zhou, T; Song, L; Yang, P; Wang, Z; Lui, D; Jope, RS				Zhou, T; Song, L; Yang, P; Wang, Z; Lui, D; Jope, RS			Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; ANTI-FAS; IN-VIVO; EXPRESSION; LIGAND; ACTIVATION; DEATH; ENCEPHALOMYELITIS; RO-31-8220	Fas-mediated apoptosis is essential for the elimination of cells, and impaired apoptosis can have severe detrimental consequences. Bisindolyimaleimide VIII potentiated Pas-mediated apoptosis in human astrocytoma 1321N1 cells and in Molt-4 T cells, both of which were devoid of apoptosis induced by anti-fas antibody in the absence of bisindolylmaleimide VIII, and in Jurkat and CEM-B T cells, which showed slight and moderate apoptotic responses, respectively, to low levels of Fas stimulation. Potentiation of Fas-mediated apoptosis by bisindolylmaleimide VIII was elective for activated, rather than non-activated, T cells, and was Pas-dependent, as it was not observed in T cells from Fas-deficient lpr/lpr mice. Administration of bisindolylmaleimide VIII to rats during autoantigen stimulation prevented the development of symptoms of T cell-mediated autoimmune diseases in two models, the Lewis rat model of experimental allergic encephalitis and the Lewis adjuvant arthritis model. Thus, the use of agents such as bisindolylmaleimide VIII may be therapeutically useful for supporting more effective elimination of detrimental cells through enhancement of Pas-dependent apoptosis signaling.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhou, T (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R56MH038752, R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44982] Funding Source: Medline; NIA NIH HHS [AG06569] Funding Source: Medline; NIMH NIH HHS [MH38752] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Ehl S, 1996, J IMMUNOL, V156, P2357; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JACOBSON PB, 1995, J PHARMACOL EXP THER, V275, P995; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; McFarland HI, 1995, ADV EXP MED BIOL, V383, P157; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suen WE, 1997, J EXP MED, V186, P1233, DOI 10.1084/jem.186.8.1233; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; TABI Z, 1995, INT IMMUNOL, V7, P967, DOI 10.1093/intimm/7.6.967; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TOULLEC D, 1991, J BIOL CHEM, V266, P1571; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	25	108	113	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					42	48		10.1038/4723	http://dx.doi.org/10.1038/4723			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883838				2022-12-25	WOS:000077885000028
J	Hancock, WW; Buelow, R; Sayegh, MH; Turka, LA				Hancock, WW; Buelow, R; Sayegh, MH; Turka, LA			Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes	NATURE MEDICINE			English	Article							CHRONIC CARDIAC REJECTION; ALLOGRAFT-REJECTION; MACROPHAGE ACTIVATION; ENDOTHELIAL-CELLS; PROTECTIVE GENES; CYTOKINES; BLOCKADE; MODEL; CD40; TH2	We investigated the pathogenesis of chronic allograft rejection in mouse cardiac allografts. Long-term survival occurred after administration of monoclonal antibody to CD4 or CD40-ligand (CD40L) plus donor cells. Both treatments induced permanent graft survival, but, in contrast to transplants in mice treated with CD4 monoclonal antibody, grafts in mice treated with CD40L monoclonal antibody lacked evidence of chronic rejection, including transplant arteriosclerosis, Freedom from chronic rejection in the group treated with CD IOL monoclonal antibody correlated with vascular expression of the 'protective' genes heme oxygenase-1 (HO-1), Bcl-xL and A20. Moreover, arteriosclerosis was induced in allografts in immunoglobulin-deficient mice by antibody transfer only when the transfer was done before expression of protective genes. A direct role for protective gene expression in endothelial cells was demonstrated by in vitro experiments in which induction of HO-1 or Bcl-xL suppressed alloantibody-stimulated endothelial activation. Finally, induction of HO-1 in vivo protected allografts against chronic injury. These data show a role for protective genes in the prevention of chronic rejection, and indicate new approaches to protect grafts against development of transplant arteriosclerosis.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; LeukoSite, Cambridge, MA 02142 USA; SangStat Med Corp, Menlo Pk, CA 94205 USA; Brigham & Womens Hosp, Dept Immunogenet & Transplantat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania	Hancock, WW (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.	Wayne_Hancock@Leukosite.com			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037691, P01AI040152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37691, AI40152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HANCOCK WH, 1993, TRANSPLANTATION, V56, P643, DOI 10.1097/00007890-199309000-00028; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; HANCOCK WW, 1998, GRAFT S2, V1, P21; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; MOTTRAM PL, 1995, TRANSPLANTATION, V59, P559; Murphy B, 1997, TRANSPLANTATION, V64, P14, DOI 10.1097/00007890-199707150-00004; RUSSELL ME, 1995, TRANSPLANTATION, V59, P572; Russell ME, 1996, J CLIN INVEST, V97, P833, DOI 10.1172/JCI118483; Russell PS, 1997, TRANSPLANTATION, V64, P1531, DOI 10.1097/00007890-199712150-00005; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; WELLS AD, 1998, TRANSPLANTATION, V65, P79; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	18	407	433	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1998	4	12					1392	1396		10.1038/3982	http://dx.doi.org/10.1038/3982			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846576				2022-12-25	WOS:000077336900034
J	Vidal, V; Scragg, IG; Cutler, SJ; Rockett, KA; Fekade, D; Warrell, DA; Wright, DJM; Kwiatkowski, D				Vidal, V; Scragg, IG; Cutler, SJ; Rockett, KA; Fekade, D; Warrell, DA; Wright, DJM; Kwiatkowski, D			Variable major lipoprotein is a principal TNF-inducing factor of louse-borne relapsing fever	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; OUTER SURFACE-PROTEIN; JARISCH-HERXHEIMER REACTION; LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; ANTIGENIC VARIATION; FACTOR-ALPHA; EXPRESSION; SEQUENCE; HERMSII	Massive release of tumor necrosis factor is responsible for the potentially fatal jarisch-Herxheimer reaction that follows antibiotic treatment of relapsing fever due to Borrelia recurrentis. We have undertaken the quantitative purification of the components of B. recurrentis that stimulate human monocytes to produce tumor necrosis factor. We show that the predominant factor inducing tumor necrosis factor is a variable lipoprotein homologous to the variable major protein of B. hermsii. We found antibodies to different forms of variable major protein in two patients with louse-borne relapsing fever. The three purified variable major proteins studied here differ in their ability to induce tumor necrosis factor production, which may partly explain the variable clinical severity of borrelial infection. These results may be of considerable relevance for the pathogenesis of Lyme disease and other forms of human borreliosis.	Univ Oxford, Dept Pediat, Oxford OX1 2JD, England; Univ Oxford, Ctr Trop Med, Oxford OX1 2JD, England; Univ London Imperial Coll Sci Technol & Med, Dept Med Microbiol, London, England; Black Lion Hosp, Dept Internal Med, Addis Ababa, Ethiopia	University of Oxford; University of Oxford; Imperial College London	Vidal, V (corresponding author), Univ Oxford, Dept Pediat, Oxford OX1 2JD, England.		Cutler, Sally/AAT-3350-2020	Kwiatkowski, Dominic/0000-0002-5023-0176				ALLAN RJ, 1993, INFECT IMMUN, V61, P4772, DOI 10.1128/IAI.61.11.4772-4776.1993; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; Bouchon B, 1997, ANAL BIOCHEM, V246, P52, DOI 10.1006/abio.1996.9982; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; BRYCESON ADM, 1976, J INFECT DIS, V133, P696, DOI 10.1093/infdis/133.6.696; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Cutler SJ, 1997, INT J SYST BACTERIOL, V47, P958, DOI 10.1099/00207713-47-4-958; CUTLER SJ, 1994, LANCET, V343; deSilva AM, 1997, PARASITOL TODAY, V13, P267, DOI 10.1016/S0169-4758(97)01074-0; deSilva AM, 1997, J CLIN INVEST, V99, P377, DOI 10.1172/JCI119169; Fekade D, 1996, NEW ENGL J MED, V335, P311, DOI 10.1056/NEJM199608013350503; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; JOHNSON WD, 1994, PRINCIPLES PRACTICE, P2141; LUGER SW, 1995, ANTIMICROB AGENTS CH, V39, P661, DOI 10.1128/AAC.39.3.661; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; RADOLF JD, 1991, J IMMUNOL, V147, P1968; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; WRIGHT DJM, 1980, PARASITE IMMUNOL, V2, P201, DOI 10.1111/j.1365-3024.1980.tb00054.x; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8	27	42	42	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1416	1420		10.1038/4007	http://dx.doi.org/10.1038/4007			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846580				2022-12-25	WOS:000077336900038
J	Zeitlin, L; Olmsted, SS; Moench, TR; Co, MS; Martinell, BJ; Paradkar, VM; Russell, DR; Queen, C; Cone, RA; Whaley, KJ				Zeitlin, L; Olmsted, SS; Moench, TR; Co, MS; Martinell, BJ; Paradkar, VM; Russell, DR; Queen, C; Cone, RA; Whaley, KJ			A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes	NATURE BIOTECHNOLOGY			English	Article						applied immunology; agricultural biotechnology; immunization	COMBINATORIAL LIBRARIES; PASSIVE-IMMUNIZATION; VIRUS-INFECTION; PROTECTS MICE; TRANSMISSION; THERAPY; MOUSE	The ability to produce monoclonal antibodies (Mabs) in plants offers the opportunity for the development of an inexpensive method of mucosal immunoprotection against sexually transmitted diseases. To investigate the suitability of plant-expressed Mabs for vaginal preventive applications, we compared a humanized anti-herpes simplex virus 2 (HSV-P) Mab expressed in mammalian cell culture with the same antibody expressed in soybean. We found these Mabs to be similar in their stability in human semen and cervical mucus over 24 h, their ability to diffuse in human cervical mucus, and their efficacy for prevention of vaginal HSV-2 infection in the mouse.	ReProtect LLC, Baltimore, MD USA; Johns Hopkins Univ, Baltimore, MD USA; Monsanto Co, Middleton, WI USA; Prot Design Labs, Mountain View, CA USA	Johns Hopkins University; Monsanto	Whaley, KJ (corresponding author), ReProtect LLC, Baltimore, MD USA.	whale@jhu.edu						BARISAS BG, 1979, BIOPHYS CHEM, V10, P221, DOI 10.1016/0301-4622(79)85044-9; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; CASTLE P, 1995, THESIS J HOPKINS U B; CO MS, 1991, P NATL ACAD SCI USA, V88, P2869, DOI 10.1073/pnas.88.7.2869; CO MS, 1991, NATURE, V351, P501, DOI 10.1038/351501a0; Cone R., 1999, MUCOSAL IMMUNOLOGY, P43; CONE RA, 1994, AM J REPROD IMMUNOL, V32, P114, DOI 10.1111/j.1600-0897.1994.tb01102.x; DAVIDSON GP, 1989, LANCET, V2, P709, DOI 10.1016/S0140-6736(89)90771-X; ELIAS CJ, 1994, AIDS, V8, P1, DOI 10.1097/00002030-199401000-00002; Eng TR, 1997, HIDDEN EPIDEMIC; FIEDLER U, 1995, BIO-TECHNOL, V13, P1090, DOI 10.1038/nbt1095-1090; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Francisco JA, 1997, BIOCONJUGATE CHEM, V8, P708, DOI 10.1021/bc970107k; Friberg J, 1974, Acta Obstet Gynecol Scand Suppl, V36, P59; Gwanzura L, 1998, J INFECT DIS, V177, P481, DOI 10.1086/517381; HIATT A, 1990, NATURE, V344, P469, DOI 10.1038/344469a0; Hiatt A, 1993, Int Rev Immunol, V10, P139, DOI 10.3109/08830189309061691; HIATT A, 1992, FEBS LETT, V307, P71, DOI 10.1016/0014-5793(92)80904-U; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; Ma JKC, 1995, TRENDS BIOTECHNOL, V13, P522, DOI 10.1016/S0167-7799(00)89016-2; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; Matthews D.E., 2016, ACTA HAEMATOL-BASEL, V135, P194; MCCABE DE, 1988, BIO-TECHNOL, V6, P923, DOI 10.1038/nbt0888-923; Miele L, 1997, TRENDS BIOTECHNOL, V15, P45, DOI 10.1016/S0167-7799(97)84202-3; RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133; SALTZMAN WM, 1994, BIOPHYS J, V66, P508, DOI 10.1016/S0006-3495(94)80802-1; SHERMANGOLD R, 1997, GENETIC ENG NEWS AUG, P4; Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468; Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; STONE AB, 1994, AIDS S1, V8, pS285; TAMURA S, 1991, EUR J IMMUNOL, V21, P1337, DOI 10.1002/eji.1830210602; TJOKRONEGORO A, 1974, J REPROD FERTIL, V38, P221; WHALEY KJ, 1994, J INFECT DIS, V169, P647, DOI 10.1093/infdis/169.3.647; WHALEY KJ, 1993, J INFECT DIS, V168, P1009, DOI 10.1093/infdis/168.4.1009; WILLIAMSON RA, 1993, P NATL ACAD SCI USA, V90, P4141, DOI 10.1073/pnas.90.9.4141; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; WOLF DE, 1989, FLUORESCENCE MICRO B, P271; WONG J, 1998, GENETIC ENG NEWS JAN, P21; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; Zeitlin L, 1997, CONTRACEPTION, V56, P329, DOI 10.1016/S0010-7824(97)00154-6; Zeitlin L, 1996, VIROLOGY, V225, P213, DOI 10.1006/viro.1996.0589; ZEITLIN L, IN PRESS EMERG INFEC; ZELTLIN L, 1996, THESIS J HOPKINS U B	47	187	213	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1361	1364		10.1038/4344	http://dx.doi.org/10.1038/4344			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853620				2022-12-25	WOS:000077232600031
J	Albert, ML; Darnell, JC; Bender, A; Francisco, LM; Bhardwaj, N; Darnell, RB				Albert, ML; Darnell, JC; Bender, A; Francisco, LM; Bhardwaj, N; Darnell, RB			Tumor-specific killer cells in paraneoplastic cerebellar degeneration	NATURE MEDICINE			English	Article							DENDRITIC CELLS; T-CELLS; ANTIGENS; ANTIBODY; VIRUS; LYMPHOCYTES; RESPONSES; MECHANISM; CANCER	Models for immune-mediated tumor regression in mice have defined an essential role for cytotoxic T lymphocytes (CTLs); however, naturally occurring tumor immunity in humans is poorly understood(1). Patients with paraneoplastic cerebellar degeneration (PCD) provide an opportunity to explore the mechanisms underlying tumor immunity to breast and ovarian cancer. Although tumor immunity and autoimmune neuronal degeneration in PCD correlates with a specific antibody response to the tumor and brain antigen cdr2(2,3), this humoral response has not been shown to be pathogenic(3,4). Here we present evidence for a specific cellular immune response in PCD patients. We have detected expanded populations of MHC class I-restricted cdr2-specific CTLs in the blood of 3/3 HLA-A2.1(+) PCD patients, providing the first description, to our knowledge, of tumor-specific CTLs using primary human cells in a simple recall assay. Cross-presentation of apoptotic cells by dendritic cells also led to a potent CTL response. These results indicate a model whereby immature dendritic cells that engulf apoptotic tumor cells can mature and migrate to draining lymph organs where they could induce a CTL response to tissue-restricted antigens. In PCD, peripheral activation of cdr2-specific CTLs is likely to contribute to the subsequent development of the autoimmune neuronal degeneration.	Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Darnell, RB (corresponding author), Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA.	darnelr@rockvax.rockefeller.edu	Albert, Matthew L/C-9782-2009; Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039516] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00102] Funding Source: Medline; NIAID NIH HHS [AI-39516] Funding Source: Medline; NIGMS NIH HHS [GM-07739] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BAROUCH D, 1995, J EXP MED, V182, P1847, DOI 10.1084/jem.182.6.1847; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; Corradi JP, 1997, J NEUROSCI, V17, P1406; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; DALMAU J, 1995, CANCER, V75, P99, DOI 10.1002/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DARNELL RB, 1993, LANCET, V341, P21, DOI 10.1016/0140-6736(93)92485-C; DEVITA VT, 1989, CNAC PRINCIPLES PRAC, P1930; DROPCHO EJ, 1987, P NATL ACAD SCI USA, V84, P4552, DOI 10.1073/pnas.84.13.4552; FATHALLAHSHAYKH H, 1991, P NATL ACAD SCI USA, V88, P3451, DOI 10.1073/pnas.88.8.3451; FURNEAUX HF, 1990, NEUROLOGY, V40, P1085, DOI 10.1212/WNL.40.7.1085; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; McMichael A, 1994, Curr Top Microbiol Immunol, V189, P75; PETERSON K, 1992, NEUROLOGY, V42, P1931, DOI 10.1212/wnl.42.10.1931; SAKAI K, 1990, ANN NEUROL, V28, P692, DOI 10.1002/ana.410280515; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	25	342	362	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1321	1324		10.1038/3315	http://dx.doi.org/10.1038/3315			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809559				2022-12-25	WOS:000076731000044
J	Eriksson, PS; Perfilieva, E; Bjork-Eriksson, T; Alborn, AM; Nordborg, C; Peterson, DA; Gage, FH				Eriksson, PS; Perfilieva, E; Bjork-Eriksson, T; Alborn, AM; Nordborg, C; Peterson, DA; Gage, FH			Neurogenesis in the adult human hippocampus	NATURE MEDICINE			English	Article							DENTATE GYRUS; NEURONS; CELLS; DIFFERENTIATION; RAT; PROTEIN; BRAIN; MICE; NEUN	The genesis of new cells, including neurons, in the adult human brain has not yet been demonstrated. This study was undertaken to investigate whether neurogenesis occurs in the adult human brain, in regions previously identified as neurogenic in adult rodents and monkeys. Human brain tissue was obtained postmortem from patients who had been treated with the thymidine analog, bromodeoxyuridine (BrdU), that labels DNA during the S phase. Using immunofluorescent labeling for BrdU and for one of the neuronal markers, NeuN, calbindin or neuron specific enolase (NSE), we demonstrate that new neurons, as defined by these markers, are generated from dividing progenitor cells in the dentate gyrus of adult humans. Our results further indicate that the human hippocampus retains its ability to generate neurons throughout life.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Sahlgrens Univ Hosp, Inst Neurol, Dept Clin Neurosci, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden	Salk Institute; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Bjork-Eriksson, Thomas/0000-0003-3680-5196				ALTMAN J, 1967, NATURE, V214, P1098, DOI 10.1038/2141098a0; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DELRIO JA, 1989, DEV BRAIN RES, V49, P311, DOI 10.1016/0165-3806(89)90033-3; DOLBEARE F, 1995, HISTOCHEM J, V27, P339; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GUENEAU G, 1982, DEV NEUROSCI-BASEL, V5, P345, DOI 10.1159/000112694; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kuhn HG, 1996, J NEUROSCI, V16, P2027; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	27	4555	4811	10	461	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1313	1317		10.1038/3305	http://dx.doi.org/10.1038/3305			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809557	Bronze			2022-12-25	WOS:000076731000042
J	Persidis, A				Persidis, A			Signal transduction as a drug-discovery platform	NATURE BIOTECHNOLOGY			English	Editorial Material							INHIBITION; TYROSINE; PRODUCT; KINASE		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd,Suite 202, Charlottesville, VA 22901 USA.							COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; ECKHART W, 1979, CELL, V18, P925, DOI 10.1016/0092-8674(79)90205-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOMAN A, 1979, J BACTERIOL, V138, P739, DOI 10.1128/JB.138.3.739-747.1979; Persidis A, 1998, NAT BIOTECHNOL, V16, P393, DOI 10.1038/nbt0498-393; Persidis A, 1998, NAT BIOTECHNOL, V16, P100, DOI 10.1038/nbt0198-100; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	10	43	43	2	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1082	1083		10.1038/3553	http://dx.doi.org/10.1038/3553			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831041				2022-12-25	WOS:000076870100034
J	Coin, F; Marinoni, JC; Rodolfo, C; Fribourg, S; Pedrini, AM; Egly, JM				Coin, F; Marinoni, JC; Rodolfo, C; Fribourg, S; Pedrini, AM; Egly, JM			Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH	NATURE GENETICS			English	Article							NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR TFIIH; RNA-POLYMERASE-II; DNA HELICASE; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; RAD3 PROTEIN; KINASE; ASSOCIATION; BTF2/TFIIH	In most cases, xeroderma pigmentosum group D (XP-D) and trichothiodystrophy (TTD) patients carry mutations in the carboxy-terminal domain of the evolutionarily conserved helicase XPD, which is one of the subunits of the transcription/repair factor TFIIH (ref 1, 2). In this study, we demonstrate that XPD interacts specifically with p44, another subunit of TFIIH, and that this interaction results in the stimulation of 5' --> 3' helicase activity. Mutations in the XPD C-terminal domain, as found in most patients, prevent the interaction with p44, thus explaining the decrease in XPD helicase activity and the nucleotide excision repair (NER) defect.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Consiglio Nazionale delle Ricerche (CNR)	Egly, JM (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.		Fribourg, Sebastien/M-7418-2014; Coin, Frédéric/F-5925-2013; Rodolfo, Carlo/H-8953-2019	Fribourg, Sebastien/0000-0003-4112-7510; Coin, Frédéric/0000-0002-5620-8519; Rodolfo, Carlo/0000-0001-7087-545X	Telethon [E.0550] Funding Source: Medline	Telethon(Fondazione Telethon)		BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Burglen L, 1997, AM J HUM GENET, V60, P72; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Evans J, 1997, INTERNET WORLD, V8, P16; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JOHNSON RT, 1985, J CELL SCI, V76, P115; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; MA LB, 1994, NUCLEIC ACIDS RES, V22, P4095, DOI 10.1093/nar/22.20.4095; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	27	290	302	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					184	188		10.1038/2491	http://dx.doi.org/10.1038/2491			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771713				2022-12-25	WOS:000076231300022
J	Lange, CC; Wackett, LP; Minton, KW; Daly, MJ				Lange, CC; Wackett, LP; Minton, KW; Daly, MJ			Engineering a recombinant Deinococcus radiodurans for organopollutant degradation in radioactive mixed waste environments	NATURE BIOTECHNOLOGY			English	Article						toluene dioxygenase; bioremediation	PSEUDOMONAS-PUTIDA F1; ESCHERICHIA-COLI; TOLUENE DIOXYGENASE; BACTERIUM; RECA; DNA; EXPRESSION; REPAIR; OXIDATION; TOXICITY	Thousands of waste sites around the world contain mixtures of toxic chlorinated solvents, hydrocarbon solvents, and radionuclides. Because of the inherent danger and expense of cleaning up such wastes by physicochemical methods, other methods are being pursued for cleanup of those sites. One alternative is to engineer radiation-resistant microbes that degrade or transform such wastes to less hazardous mixtures. We describe the construction and characterization of recombinant Deinococcus radiodurans, the most radiation-resistant organism known, expressing toluene dioxygenase (TDO). Cloning of the tod genes (which encode the multicomponent TDO) into the chromosome of this bacterium imparted to the strain the ability to oxidize toluene, chlorobenzene, 3,4-dichloro-1-butene, and indole. The recombinant strain was capable of growth and functional synthesis of TDO in the highly irradiating environment (60 Gy/h) of a Cs-137 irradiator, where 5x10(8) cells/ml degraded 125 nmol/ml of chlorobenzene in 150 min. D. radiodurans strains were also tolerant to the solvent effects of toluene and trichloroethylene at levels exceeding those of many radioactive waste sites. These data support the prospective use of engineered D. radiodurans for bioremediation of mixed wastes containing both radionuclides and organic solvents.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Biol Proc Technol Inst, St Paul, MN 55108 USA; Univ Minnesota, Ctr Biodegradat Res & Informat, Gortner Lab, St Paul, MN 55108 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Uniformed Services University of the Health Sciences - USA	Daly, MJ (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Biol Proc Technol Inst, St Paul, MN 55108 USA.	mdaly@usuhs.mil		Lange, Cleston/0000-0002-9203-5918				*BAS ENV MAN, 1996, BAS ENV MAN REP; BROOKS BW, 1980, INT J SYST BACTERIOL, V30, P627, DOI 10.1099/00207713-30-4-627; Carroll JD, 1996, J BACTERIOL, V178, P130, DOI 10.1128/jb.178.1.130-135.1996; Daly MJ, 1997, GENE, V187, P225, DOI 10.1016/S0378-1119(96)00755-X; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; DALY MJ, 1994, J BACTERIOL, V176, P7506, DOI 10.1128/JB.176.24.7506-7515.1994; Daly MJ, 1996, J BACTERIOL, V178, P4461, DOI 10.1128/jb.178.15.4461-4471.1996; DESMET MJ, 1978, BIOCHIM BIOPHYS ACTA, V506, P64, DOI 10.1016/0005-2736(78)90435-2; DIELS L, 1995, J IND MICROBIOL, V14, P142, DOI 10.1007/BF01569896; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; Lange CC, 1997, J BACTERIOL, V179, P3858, DOI 10.1128/jb.179.12.3858-3865.1997; Leisinger T, 1981, MICROBIAL DEGRADATIO; LI S, 1992, BIOCHEM BIOPH RES CO, V58, P2820; LOVLEY DR, 1995, J IND MICROBIOL, V14, P85, DOI 10.1007/BF01569889; Macilwain C, 1996, NATURE, V383, P375; MATTIMORE V, 1995, J BACTERIOL, V177, P5232, DOI 10.1128/jb.177.18.5232-5237.1995; McKlveen J W, 1990, Australas Phys Eng Sci Med, V13, P101; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Minton KW, 1996, MUTAT RES-DNA REPAIR, V363, P1, DOI 10.1016/0921-8777(95)00014-3; MOSELEY BEB, 1983, J GEN MICROBIOL, V129, P2437; MURRAY RGE, 1992, PROKARYOTES, V4, P3732; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; Riley, 1992, CHEM CONTAMINANTS DO; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SMITH MD, 1988, J BACTERIOL, V170, P2126, DOI 10.1128/jb.170.5.2126-2135.1988; THOMAS A, 1982, MERRILL PALMER QUART, V28, P1; THOMPSON BG, 1982, CAN J MICROBIOL, V28, P522, DOI 10.1139/m82-078; THORNLEY MJ, 1963, J APPL BACTERIOL, V26, P334, DOI 10.1111/j.1365-2672.1963.tb04784.x; *US GEN ACC OFF, 1988, GAORCED88229FS; WACKETT LP, 1994, NATURE, V368, P627, DOI 10.1038/368627a0; WACKETT LP, 1990, METHOD ENZYMOL, V188, P39; WACKETT LP, 1989, APPL ENVIRON MICROB, V55, P2723, DOI 10.1128/AEM.55.10.2723-2725.1989; ZIFFER H, 1977, TETRAHEDRON, V33, P2491, DOI 10.1016/0040-4020(77)80070-7; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	36	116	150	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					929	933		10.1038/nbt1098-929	http://dx.doi.org/10.1038/nbt1098-929			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788348				2022-12-25	WOS:000076323300027
J	Pandolfe, WD; Butrym, JA				Pandolfe, WD; Butrym, JA			In the laboratory - When is homogenization the best processing choice?	NATURE BIOTECHNOLOGY			English	Editorial Material									APV Homogenizer Grp, Wilmington, MA USA		Pandolfe, WD (corresponding author), APV Homogenizer Grp, Wilmington, MA USA.								0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					974	975		10.1038/nbt1098-974	http://dx.doi.org/10.1038/nbt1098-974			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788357				2022-12-25	WOS:000076323300036
J	Persons, DA; Allay, JA; Riberdy, JM; Wersto, RP; Donahue, RE; Sorrentino, BP; Nienhuis, AW				Persons, DA; Allay, JA; Riberdy, JM; Wersto, RP; Donahue, RE; Sorrentino, BP; Nienhuis, AW			Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells	NATURE MEDICINE			English	Article							MEDIATED GENE-TRANSFER; BONE-MARROW CELLS; PERIPHERAL-BLOOD LYMPHOCYTES; TITER RETROVIRAL VECTORS; SELECTABLE MARKER; PROGENITOR CELLS; MAMMALIAN-CELLS; T-LYMPHOCYTES; IN-VIVO; EXPRESSION		St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Nienhuis, AW (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, 332 N Lauderdale Dr, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bierhuizen MFA, 1997, BLOOD, V90, P3304, DOI 10.1182/blood.V90.9.3304; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Brenner MK, 1996, NEW ENGL J MED, V335, P337, DOI 10.1056/NEJM199608013350508; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Comoli P, 1996, NAT MED, V2, P1280, DOI 10.1038/nm1296-1280b; Conneally E, 1996, BLOOD, V87, P456, DOI 10.1182/blood.V87.2.456.bloodjournal872456; Donahue RE, 1996, BLOOD, V88, P4166; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Limon A, 1997, BLOOD, V90, P3316, DOI 10.1182/blood.V90.9.3316; MAVILIO F, 1994, BLOOD, V83, P1988; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Phillips K, 1996, NAT MED, V2, P1154, DOI 10.1038/nm1096-1154; Ren SC, 1996, BLOOD, V87, P2518, DOI 10.1182/blood.V87.6.2518.bloodjournal8762518; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Rudoll T, 1996, GENE THER, V3, P695; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SORRENTINO BP, IN PRESS DEV GENE TH; STRAIR RK, 1990, NUCLEIC ACIDS RES, V18, P4759, DOI 10.1093/nar/18.16.4759; vanBeusechem VW, 1996, HUM GENE THER, V7, P1649, DOI 10.1089/hum.1996.7.14-1649; WARD M, 1994, BLOOD, V84, P1408; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; YANG Z, 1987, MOL CELL BIOL, V7, P3923, DOI 10.1128/MCB.7.11.3923; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	35	91	96	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1201	1205		10.1038/2704	http://dx.doi.org/10.1038/2704			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771757				2022-12-25	WOS:000076230100044
J	Rugh, CL; Senecoff, JF; Meagher, RB; Merkle, SA				Rugh, CL; Senecoff, JF; Meagher, RB; Merkle, SA			Development of transgenic yellow poplar for mercury phytoremediation	NATURE BIOTECHNOLOGY			English	Article						mercuric reductase; mercury; Liriodendron tulipifera	PLANTS; ACCUMULATION; REDUCTION; BOMBARDMENT; RESISTANCE; CATALASE; EMBRYOS; CYCLE; VAPOR; GENES	We examined the ability of yellow poplar (Liriodendron tulipifera) tissue cultures and plantlets to express modified mercuric reductase (merA) gene constructs. Mercury-resistant bacteria express merA to convert highly toxic, ionic mercury, Hg(II), to much less toxic, elemental mercury, Hg(0). Expression of merA in transgenic plants might provide an ecologically compatible approach for the remediation of mercury pollution. Because the alteration of the bacterial merA gene sequence is necessary for high-level expression in Arabidopsis thaliana, yellow poplar proembryogenic masses (PEMs) were transformed with three modified merA constructs via microprojectile bombardment. Each construct was synthesized to have altered flanking regions with increasing amounts of modified coding sequence. All merA constructs conferred resistance to toxic, ionic mercury in independently transformed PEM colonies. Stability of merA transgene expression increased in parallel with the extent of gene coding sequence modification. Regenerated plantlets containing the most modified merA gene (merA18) germinated and grew vigorously in media containing normally toxic levels of ionic mercury. The merA18 plantlets released elemental mercury at approximately 10 times the rate of untransformed plantlets. These results indicate that plants expressing modified merA constructs may provide a means for the phytoremediation of mercury pollution.	Univ Georgia, Daniel B Warnell Sch Forest Resources, Athens, GA 30602 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Merkle, SA (corresponding author), Univ Georgia, Daniel B Warnell Sch Forest Resources, Athens, GA 30602 USA.	smerkle@arches.uga.edu						ALLARD B, 1991, WATER AIR SOIL POLL, V56, P457, DOI 10.1007/BF00342291; BAKER A J M, 1989, Biorecovery, V1, P81; BAKER AJM, 1994, RESOUR CONSERV RECY, V11, P41, DOI 10.1016/0921-3449(94)90077-9; BARRINEAU P, 1984, Journal of Molecular and Applied Genetics, V2, P601; Dittmer HJ, 1937, AM J BOT, V24, P417, DOI 10.2307/2436424; DU SH, 1983, ENVIRON EXP BOT, V23, P347, DOI 10.1016/0098-8472(83)90009-6; FOX B, 1982, J BIOL CHEM, V257, P2498; Gray DH, 1996, BIOTECHNICAL SOIL BI; HANSEN CL, 1984, BIOTECHNOL BIOENG, V26, P1330, DOI 10.1002/bit.260261110; HANSON PJ, 1995, WATER AIR SOIL POLL, V80, P373, DOI 10.1007/BF01189687; HUDSON RJM, 1995, WATER AIR SOIL POLL, V80, P265, DOI 10.1007/BF01189676; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; JERNELOV A, 1971, OIKOS, V22, P403, DOI 10.2307/3543865; KLEIN TM, 1989, PLANT PHYSIOL, V91, P440, DOI 10.1104/pp.91.1.440; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MALIK VS, 1993, J PLANT BIOCHEM BIOT, V2, P60; Mason RP, 1996, ENVIRON SCI TECHNOL, V30, P1835, DOI 10.1021/es950373d; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MCLEAN BG, 1990, CELL MOTIL CYTOSKEL, V17, P276; MERKLE SA, 1990, IN VITRO CELL DEV B, V26, P1086; MURRAY EE, 1989, NUCLEIC ACIDS RES, V17, P477, DOI 10.1093/nar/17.2.477; Nriagu J.O., 1979, BIOGEOCHEMISTRY MERC, P23; OGATA M, 1984, BIOCHEM PHARMACOL, V33, P490, DOI 10.1016/0006-2952(84)90246-6; Pawlowski WP, 1996, MOL BIOTECHNOL, V6, P17, DOI 10.1007/BF02762320; Rugh CL, 1996, P NATL ACAD SCI USA, V93, P3182, DOI 10.1073/pnas.93.8.3182; SALT DE, 1995, PLANT PHYSIOL, V109, P1427, DOI 10.1104/pp.109.4.1427; Schmitt F, 1997, J BIOL CHEM, V272, P1534, DOI 10.1074/jbc.272.3.1534; SCHNOOR J, 1995, ENVIRON SCI TECHNOL, V7, P318; SOTAK RJ, 1991, PLANT CELL REP, V10, P175, DOI 10.1007/BF00234289; SUMMERS AO, 1973, J BACTERIOL, V113, P1070, DOI 10.1128/JB.113.2.1070-1072.1973; SUSZCYNSKY EM, 1995, ENVIRON TOXICOL CHEM, V14, P61, DOI 10.1002/etc.5620140108; SUZUKI T, 1968, J FERMENT TECHNOL, V12, P1048; WILDE HD, 1992, PLANT PHYSIOL, V98, P114, DOI 10.1104/pp.98.1.114; Window H. L., 1979, BIOGEOCHEMISTRY MERC, P303	35	255	295	5	88	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					925	928		10.1038/nbt1098-925	http://dx.doi.org/10.1038/nbt1098-925			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788347				2022-12-25	WOS:000076323300026
J	Blouin, JL; Dombroski, BA; Nath, SK; Lasseter, VK; Wolyniec, PS; Nestadt, G; Thornquist, M; Ullrich, G; McGrath, J; Kasch, L; Lamacz, M; Thomas, MG; Gehrig, C; Radhakrishna, U; Snyder, SE; Balk, KG; Neufeld, K; Swartz, KL; DeMarchi, N; Papadimitriou, GN; Dikeos, DG; Stefanis, CN; Chakravarti, A; Childs, B; Housman, DE; Kazazian, HH; Antonarakis, SE; Pulver, AE				Blouin, JL; Dombroski, BA; Nath, SK; Lasseter, VK; Wolyniec, PS; Nestadt, G; Thornquist, M; Ullrich, G; McGrath, J; Kasch, L; Lamacz, M; Thomas, MG; Gehrig, C; Radhakrishna, U; Snyder, SE; Balk, KG; Neufeld, K; Swartz, KL; DeMarchi, N; Papadimitriou, GN; Dikeos, DG; Stefanis, CN; Chakravarti, A; Childs, B; Housman, DE; Kazazian, HH; Antonarakis, SE; Pulver, AE			Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; VULNERABILITY LOCUS; GENETIC-LINKAGE; SUGGESTIVE EVIDENCE; POTENTIAL LINKAGE; FAMILIAL RISK; HUMAN GENOME; HETEROGENEITY; IDENTIFY; SUPPORT	Schizophrenia is a common disorder characterized by psychotic symptoms; diagnostic criteria have been established(1). Family, twin and adoption studies suggest that both genetic and environmental factors influence susceptibility (heritability is approximately 71%; ref. 2), however, little is known about the aetiology of schizophrenia. Clinical and family studies suggest aetiological heterogeneity(3-6). Previously, we reported that regions on chromosomes 22, 3 and 8 may be associated with susceptibility to schizophrenia(7-8), and collaborations provided some support for regions on chromosomes 8 and 22 (refs 9-13). We present here a genome-wide scan for schizophrenia susceptibility loci (SSL) using 452 microsatellite markers on 54 multiplex pedigrees. Non-parametric linkage (NPL) analysis provided significant evidence for an SSL on chromosome 13q32 (NPL score=4.18; P=0.00002), and suggestive evidence for another SSL on chromosome 8p21-22 (NPL=3.64; P=0.0001). Parametric linkage analysis provided additional support for these SSL. Linkage evidence at chromosome 8 is weaker than that at chromosome 13, so it is more probable that chromosome 8 may be a false positive linkage. Additional putative SSL were noted on chromosomes 14q13 (NPL=2.57: P=0.005), 7q11 (NPL=2.50, P=0.007) and 22q11 (NPL=2.42, P=0.009). Verification of suggestive SSL on chromosomes 13q and 8p was attempted in a follow-up sample of 54 multiplex pedigrees. This analysis confirmed the SSL in 13q14-q33 (NPL=2.36, P=0.007) and supported the SSL in 8p22-p21 (NPL=1.95, P=0.023).	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21231 USA; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland; Univ Geneva, Hop Cantonal, CH-1211 Geneva, Switzerland; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Naples 2, Inst Psichiatria, I-80138 Naples, Italy; Univ Athens, Eginit Hosp, Mental Hlth Res Inst, GR-11528 Athens, Greece; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Johns Hopkins University; University of Geneva; University of Geneva; University of Pennsylvania; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Universita della Campania Vanvitelli; National & Kapodistrian University of Athens; Massachusetts Institute of Technology (MIT)	Pulver, AE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21231 USA.	aepulver@welchlink.welch.jhu.edu	Antonarakis, Stylianos E/N-8866-2014	Antonarakis, Stylianos E/0000-0001-8907-5823; Neufeld, Karin/0000-0002-2395-1883; Swartz, Karen/0000-0003-0420-5823	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045588] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00722] Funding Source: Medline; NIMH NIH HHS [R01 MH-45588] Funding Source: Medline; PHS HHS [1 R01 35712] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th ed.; ANTONARAKIS SE, 1995, NAT GENET, V11, P235, DOI 10.1038/ng1195-235; ANTONARAKIS SE, IN PRESS AM J MED GE; BUETOW KH, 1991, AM J HUM GENET, V49, P985; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Freedman R, 1997, P NATL ACAD SCI USA, V94, P587, DOI 10.1073/pnas.94.2.587; Gill M, 1996, AM J MED GENET, V67, P40, DOI 10.1002/(SICI)1096-8628(19960216)67:1<40::AID-AJMG6>3.0.CO;2-W; Kendler KS, 1996, AM J PSYCHIAT, V153, P1534; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LASHER L, 1991, AM J HUM GENET, V49, P369; LASSETER VK, 1995, AM J MED GENET, V60, P172, DOI 10.1002/ajmg.1320600217; Levinson DF, 1996, AM J MED GENET, V67, P580; Lin MW, 1995, PSYCHIATR GENET, V5, P117, DOI 10.1097/00041444-199505030-00004; Lin MW, 1997, HUM GENET, V99, P417, DOI 10.1007/s004390050382; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MELTON B, 1994, GENET EPIDEMIOL, V11, P311, DOI 10.1002/gepi.1370110402; PULVER AE, 1989, GENET EPIDEMIOL, V6, P671, DOI 10.1002/gepi.1370060604; PULVER AE, 1991, GENET EPIDEMIOL, V8, P339, DOI 10.1002/gepi.1370080506; PULVER AE, 1995, AM J MED GENET, V60, P252, DOI 10.1002/ajmg.1320600316; Pulver AE, 1996, COLD SPRING HARB SYM, V61, P797; PULVER AE, 1992, BRIT J PSYCHIAT, V160, P65, DOI 10.1192/bjp.160.1.65; PULVER AE, 1994, AM J MED GENET, V54, P36, DOI 10.1002/ajmg.1320540108; PULVER AE, 1994, J NERV MENT DIS, V182, P476, DOI 10.1097/00005053-199408000-00010; RAO DC, 1981, HUM HERED, V31, P325, DOI 10.1159/000153233; Straub RE, 1997, MOL PSYCHIATR, V2, P148, DOI 10.1038/sj.mp.4000258; STRAUB RE, 1995, NAT GENET, V11, P287, DOI 10.1038/ng1195-287; TSUANG MT, 1995, SCHIZOPHR RES, V17, P161, DOI 10.1016/0920-9964(95)00057-S; Wildenauer DB, 1996, COLD SPRING HARB SYM, V61, P845	30	426	452	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					70	73		10.1038/1734	http://dx.doi.org/10.1038/1734			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731535				2022-12-25	WOS:000075671400023
J	Liu, J; Aoki, M; Illa, I; Wu, CY; Fardeau, M; Angelini, C; Serrano, C; Urtizberea, JA; Hentati, F; Ben Hamida, M; Bohlega, S; Culper, EJ; Amato, AA; Bossie, K; Oeltjen, T; Bejaoui, K; McKenna-Yasek, D; Hosler, BA; Schurr, E; Arahata, K; de Jong, PJ; Brown, RH				Liu, J; Aoki, M; Illa, I; Wu, CY; Fardeau, M; Angelini, C; Serrano, C; Urtizberea, JA; Hentati, F; Ben Hamida, M; Bohlega, S; Culper, EJ; Amato, AA; Bossie, K; Oeltjen, T; Bejaoui, K; McKenna-Yasek, D; Hosler, BA; Schurr, E; Arahata, K; de Jong, PJ; Brown, RH			Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy	NATURE GENETICS			English	Article							FERTILIZATION-DEFECTIVE MUTANTS; HUMAN GENOME; CAENORHABDITIS-ELEGANS; CHROMOSOME 2P; SPERM; LOCUS; CYTOSKELETON; PROTEINS; DOMAINS; DOC2	Miyoshi myopathy (MM) is an adult onset, recessive inherited distal muscular dystrophy that we have mapped to human chromosome 2p13. We recently constructed a 3-Mb P1-derived artificial chromosome (PAC) contig spanning the MM candidate region. This clarified the order of genetic markers across the MM locus, provided five new polymorphic markers within it and narrowed the locus to approximately 2 Mb. Five skeletal muscle expressed sequence tags (ESTs) map in this region. We report that one of these is located in a novel, full-length 6.9-kb muscle cDNA, and we designate the corresponding protein 'dysferlin'. We describe nine mutations in the dysferlin gene in nine families; five are predicted to prevent dysferlin expression. Identical mutations in the dysferlin gene can produce more than one myopathy phenotype (MM, limb girdle dystrophy, distal myopathy with anterior tibial onset).	Day Neuromuscular Res Lab, Charlestown, MA 02129 USA; UAB, Hosp St Pau, Dept Neurol, Neuromuscular Dis Sect, Barcelona, Spain; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Hop La Pitie Salpetriere, Assoc Francaise Myopathies, Inst Myol, F-75651 Paris 13, France; Univ Padua, Dept Neurol, Neuromuscular Ctr, I-35128 Padua, Italy; Serv Neurol, Tunis, Tunisia; King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Riyadh 11211, Saudi Arabia; Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX 78284 USA; Montreal Gen Hosp, Res Inst, McGill Ctr Study Host Resistance, Montreal, PQ H3G 1A4, Canada; NCNP, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan	Autonomous University of Barcelona; Roswell Park Cancer Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Padua; King Faisal Specialist Hospital & Research Center; University of Texas System; University of Texas Health San Antonio; McGill University; National Center for Neurology & Psychiatry - Japan	Brown, RH (corresponding author), Day Neuromuscular Res Lab, Room 6627,Bldg 149,13th St,Navy Yard, Charlestown, MA 02129 USA.	brown@helix.mgh.harvard.edu	Angelini, Corrado I/J-3655-2019; ILLA, Isabel/AAD-1816-2019	Angelini, Corrado I/0000-0002-9554-8794; Serrano Munuera, Carmen/0000-0003-3551-8240	NIA NIH HHS [5PO1AG12992] Funding Source: Medline; NINDS NIH HHS [5PO1NS31248] Funding Source: Medline; PHS HHS [5RO1N834913A] Funding Source: Medline; Telethon [552] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Aoki M, 1998, ANN NEUROL, V43, P645, DOI 10.1002/ana.410430514; ARGON Y, 1980, GENETICS, V96, P413; Bashir R, 1996, GENOMICS, V33, P46, DOI 10.1006/geno.1996.0157; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BEJAOUI K, 1995, NEUROLOGY, V45, P768, DOI 10.1212/WNL.45.4.768; Bejaoui K, 1998, NEUROGENETICS, V1, P189, DOI 10.1007/s100480050028; Benes V, 1997, BIOTECHNIQUES, V23, P98, DOI 10.2144/97231bm21; Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; Brown RH, 1997, ANNU REV MED, V48, P457, DOI 10.1146/annurev.med.48.1.457; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; Haravuori H, 1998, AM J HUM GENET, V62, P620, DOI 10.1086/301752; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; Hoffman EP, 1996, BRAIN PATHOL, V6, P49, DOI 10.1111/j.1750-3639.1996.tb00782.x; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Illarioshkin SN, 1997, GENOMICS, V42, P345, DOI 10.1006/geno.1997.4725; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Liu J, 1998, GENOMICS, V49, P23, DOI 10.1006/geno.1998.5204; MIYOSHI K, 1986, BRAIN, V109, P31, DOI 10.1093/brain/109.1.31; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; PASSOSBUENO MR, 1995, GENOMICS, V27, P192, DOI 10.1006/geno.1995.1024; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; SAMBROOK J, 1989, MOL CLONING LIB MANU; SCHON EA, J BIOENEG BIOMEMBR, V29, P131; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; Weiler T, 1996, AM J HUM GENET, V59, P872	35	626	650	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1998	20	1					31	36		10.1038/1682	http://dx.doi.org/10.1038/1682			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731526				2022-12-25	WOS:000075671400014
J	Bajou, K; Noel, A; Gerard, RD; Masson, V; Brunner, N; Holst-Hansen, C; Skobe, M; Fusenig, NE; Carmeliet, P; Collen, D; Foidart, JM				Bajou, K; Noel, A; Gerard, RD; Masson, V; Brunner, N; Holst-Hansen, C; Skobe, M; Fusenig, NE; Carmeliet, P; Collen, D; Foidart, JM			Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization	NATURE MEDICINE			English	Article							GENE DEFICIENT MICE; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; BREAST-CANCER; PAI-1; EXPRESSION; TUMOR; PROGNOSIS; INVIVO; SYSTEM	Acquisition of invasive/metastatic potential through protease expression is an essential event in tumor progression. High levels of components of the plasminogen activation system, including urokinase, but paradoxically also its inhibitor, plasminogen activator inhibitor 1 (PAI1), have been correlated with a poor prognosis for some cancers. We report here that deficient PAI1 expression in host mice prevented local invasion and tumor vascularization of transplanted malignant keratinocytes. When this PAI1 deficiency was circumvented by intravenous injection of a replication-defective adenoviral vector expressing human PAI1, invasion and associated angiogenesis were restored. This experimental evidence demonstrates that host-produced PAI is essential for cancer cell invasion and angiogenesis.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark; German Canc Res Ctr, Div Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany	University of Liege; Rigshospitalet; University of Copenhagen; Helmholtz Association; German Cancer Research Center (DKFZ)	Foidart, JM (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Pathol Tower B23, B-4000 Liege, Belgium.		Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BIANCHI E, 1995, INT J CANCER, V60, P597, DOI 10.1002/ijc.2910600505; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOUKAMP P, 1990, CANCER RES, V50, P2840; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DENG G, 1996, J CELL BIOL, V134, P1; DEVRIES TJ, 1995, CANCER RES, V55, P4681; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; FUSENIG NE, 1978, B CANCER, V65, P271; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; HEISS MM, 1995, J CLIN ONCOL, V13, P2084, DOI 10.1200/JCO.1995.13.8.2084; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KRISTENSEN P, 1990, HISTOCHEMISTRY, V93, P559, DOI 10.1007/BF00272198; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; KRUITHOF EKO, 1988, THROMB HAEMOSTASIS, V59, P7; KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P1126; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NAKAMURA M, 1992, THROMB RES, V65, P709, DOI 10.1016/0049-3848(92)90110-V; NAKARDA H, 1994, CANCER RES, V54, P2900; OSSOWSKI L, 1991, CANCER RES, V51, P274; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; SAPPINO AP, 1991, J CLIN INVEST, V88, P1073, DOI 10.1172/JCI115406; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; SIER CFM, 1994, GASTROENTEROLOGY, V107, P1449, DOI 10.1016/0016-5085(94)90549-5; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; YU H, 1990, CANCER RES, V50, P7623	42	578	606	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					923	928		10.1038/nm0898-923	http://dx.doi.org/10.1038/nm0898-923			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701244	Green Submitted			2022-12-25	WOS:000075107400035
J	Di Cristofano, A; Pesce, B; Cordon-Cardo, C; Pandolfi, PP				Di Cristofano, A; Pesce, B; Cordon-Cardo, C; Pandolfi, PP			Pten is essential for embryonic development and tumour suppression	NATURE GENETICS			English	Article							STEM-CELL DIFFERENTIATION; LHERMITTE-DUCLOS DISEASE; YOLK-SAC; MOUSE; GENE; MXI1; DISRUPTION; 10Q24-Q25; DEATH; LINES	The PTEN gene encodes a dual-specificity phosphatase mutated in a variety of human cancers. PTEN germline mutations are found in three related human autosomal dominant disorders, Cowden disease (CD), Lhermitte-Duclos disease (LDD) and Bannayan-Zonana syndrome (BZS), characterized by tumour susceptibility and developmental defects. To examine the role of PTEN in ontogenesis and tumour suppression, we disrupted mouse PTEN by homologous recombination. Pten inactivation resulted in early embryonic lethality. Pten(-/-) ES cells formed aberrant embryoid bodies and displayed an altered ability to differentiate into endodermal, ectodermal and mesodermal derivatives. Pten(+/-) mice and chimaeric mice derived from Pten(+/-) ES cells showed hyperplastic-dysplastic changes in the prostate, skin and colon, which are characteristic of to, LDD and BZS. They also spontaneously developed germ cell, gonadostromal, thyroid and colon tumours. In addition, Pten inactivation enhanced the ability of ES cells to generate tumours in nude and syngeneic mice, due to increased anchorage-independent growth and aberrant differentiation. These results support the notion that PTEN haploinsufficiency plays a causal role in Co, LDD and BZS pathogenesis, and demonstrate that Pten is a tumour suppressor essential for embryonic development.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		di cristofano, antonio/AAJ-3796-2020; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; 	NCI NIH HHS [CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BANNAYAN GA, 1971, ARCH PATHOL, V92, P1; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Collignon J, 1996, DEVELOPMENT, V122, P509; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gerlach C, 1997, LAB INVEST, V77, P697; GORLIN RJ, 1992, AM J MED GENET, V44, P307, DOI 10.1002/ajmg.1320440309; Guldberg P, 1997, CANCER RES, V57, P3660; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; PADBERG GW, 1991, ANN NEUROL, V29, P517, DOI 10.1002/ana.410290511; Risinger JI, 1997, CANCER RES, V57, P4736; ROACH S, 1994, EXP CELL RES, V215, P189, DOI 10.1006/excr.1994.1331; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Rosti V, 1997, J CLIN INVEST, V100, P1028, DOI 10.1172/JCI119613; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WILES MV, 1993, METHOD ENZYMOL, V225, P900; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; ZONANA J, 1976, J PEDIATR-US, V89, P600, DOI 10.1016/S0022-3476(76)80397-6	44	1210	1235	2	58	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					348	355		10.1038/1235	http://dx.doi.org/10.1038/1235			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697695				2022-12-25	WOS:000075107600017
J	Gilbert, M; Bayer, R; Cunningham, AM; Defrees, S; Gao, YH; Watson, DC; Young, NM; Wakarchuk, WW				Gilbert, M; Bayer, R; Cunningham, AM; Defrees, S; Gao, YH; Watson, DC; Young, NM; Wakarchuk, WW			The synthesis of sialylated oligosaccharides using a CMP-Neu5Ac synthetase/sialyltransferase fusion	NATURE BIOTECHNOLOGY			English	Article						glycobiology; carbohydrates; protein engineering	NEISSERIA-MENINGITIDIS; SIALIC-ACID; SIALYLTRANSFERASES	Large-scale enzymatic synthesis of oligosaccharides, which contain terminal N-acetyl-neuraminic acid residues requires large amounts of the sialyltransferase and the corresponding sugar-nucleotide synthetase, which is required for the synthesis of the sugar-nucleotide donor, CMP-Neu5Ac. Using genes cloned from Neisseria meningitidis, we constructed a fusion protein that has both CMP-Neu5Ac synthetase and alpha-2,3-sialyltransferase activities. The fusion protein was produced in high yields (over 1200 U/L, measured using an alpha-2,3-sialyltransferase assay) in Escherichia coli and functionally pure enzyme could be obtained using a simple protocol. In small-scale enzymatic syntheses, the fusion protein could sialylate various oligosaccharide accepters (branched and linear) with N-acetyl-neuraminic acid as well as N-glycolyl- and N-propionyl-neuraminic acid in high conversion yield. The fusion protein was also used to produce alpha-2,3-sialyllactose at the 100 g scale using a sugar nucleotide cycle reaction, starting from lactose, sialic acid, phosphoenolpyruvate, and catalytic amounts of ATP and CMP.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Cytel Corp, San Diego, CA 92121 USA	National Research Council Canada	Wakarchuk, WW (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.		Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408				FROSCH M, 1991, MOL MICROBIOL, V5, P1251, DOI 10.1111/j.1365-2958.1991.tb01899.x; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 1997, BIOTECHNOL LETT, V19, P417, DOI 10.1023/A:1018379607492; Hannig G, 1998, TRENDS BIOTECHNOL, V16, P54, DOI 10.1016/S0167-7799(97)01155-4; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; ICHIKAWA Y, 1991, J AM CHEM SOC, V113, P4698, DOI 10.1021/ja00012a058; Kajihara Y, 1996, J ORG CHEM, V61, P8632, DOI 10.1021/jo961214v; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; SCHURIG H, 1995, EMBO J, V14, P442, DOI 10.1002/j.1460-2075.1995.tb07020.x; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wakarchuk W, 1996, J BIOL CHEM, V271, P19166, DOI 10.1074/jbc.271.32.19166; WARREN L, 1962, J BIOL CHEM, V237, P3527; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357	16	115	140	2	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					769	772		10.1038/nbt0898-769	http://dx.doi.org/10.1038/nbt0898-769			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702777				2022-12-25	WOS:000075183400036
J	Goldfarb, LG; Park, KY; Cervenakova, L; Gorokhova, S; Lee, HS; Vasconcelos, O; Nagle, JW; Semino-Mora, C; Sivakumar, K; Dalakas, MC				Goldfarb, LG; Park, KY; Cervenakova, L; Gorokhova, S; Lee, HS; Vasconcelos, O; Nagle, JW; Semino-Mora, C; Sivakumar, K; Dalakas, MC			Missense mutations in desmin associated with familial cardiac and skeletal myopathy	NATURE GENETICS			English	Article							ELECTRON-MICROSCOPY; CELLS	Desmin-related myopathy (OMIM 601419) is a familial disorder characterized by skeletal muscle weakness associated with cardiac conduction blocks, arrhythmias and restrictive heart failure, and by intracytoplasmic accumulation of desmin-reactive deposits in cardiac and skeletal muscle cells(1-4). The underlying molecular mechanisms are unknown. Involvement of the desmin gene (DES) has been excluded in three families diagnosed with desmin-related myopathy(5), We report two new families with desmin-related cardioskeletal myopathy associated with mutations in the highly conserved carboxy-terminal end of the desmin rod domain. A heterozygous A337P mutation was identified in a family with an adult-onset skeletal myopathy and mild cardiac involvement. Compound heterozygosity for two other mutations, A360P and N393I, was detected in a second family characterized by childhood-onset aggressive course of cardiac and skeletal myopathy.	NINDS, Med Neurol Branch, NIH, Bethesda, MD 20892 USA; NINDS, Cent Nervous Syst Studies Lab, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA; Barrow Neurol Inst, Phoenix, AZ 85013 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); American Red Cross; Barrow Neurological Institute	Goldfarb, LG (corresponding author), NINDS, Med Neurol Branch, NIH, Bethesda, MD 20892 USA.		Gorokhova, Svetlana/L-9380-2019	Gorokhova, Svetlana/0000-0001-6870-4061				FARDEAU M, 1978, REV NEUROL, V134, P411; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GOEBEL HH, 1978, MUSCLE NERVE, V1, P14, DOI 10.1002/mus.880010104; GOEBEL HH, 1995, MUSCLE NERVE, V18, P1306, DOI 10.1002/mus.880181114; HOROWITZ SH, 1994, MUSCLE NERVE, V17, P151, DOI 10.1002/mus.880170204; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; Nakano S, 1996, J NEUROPATH EXP NEUR, V55, P549, DOI 10.1097/00005072-199605000-00008; RAATS JMH, 1991, EUR J CELL BIOL, V56, P84; Raats JMH, 1996, EUR J CELL BIOL, V71, P221; Vicart P, 1996, HUM GENET, V98, P422, DOI 10.1007/s004390050233; YU KR, 1994, P NATL ACAD SCI USA, V91, P2497, DOI 10.1073/pnas.91.7.2497	11	375	390	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					402	403		10.1038/1300	http://dx.doi.org/10.1038/1300			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697706				2022-12-25	WOS:000075107600028
J	Goldstein, DJ				Goldstein, DJ			An unacknowledged problem for structural genomics?	NATURE BIOTECHNOLOGY			English	Editorial Material							PROTEIN; SEQUENCE; CELL		Univ Buenos Aires, Fac Exact & Nat Sci, Dept Biol Sci, RA-1053 Buenos Aires, DF, Argentina	University of Buenos Aires	Goldstein, DJ (corresponding author), Univ Buenos Aires, Fac Exact & Nat Sci, Dept Biol Sci, RA-1053 Buenos Aires, DF, Argentina.							Ellis RJ, 1996, SCIENCE, V272, P1448; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MURRAY AJ, 1995, P NATL ACAD SCI USA, V92, P7337, DOI 10.1073/pnas.92.16.7337; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775	9	3	3	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					696	696		10.1038/nbt0898-696	http://dx.doi.org/10.1038/nbt0898-696			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702751	Bronze			2022-12-25	WOS:000075183400003
J	Lodmell, DL; Ray, NB; Parnell, MJ; Ewalt, LC; Hanlon, CA; Shaddock, JH; Sanderlin, DS; Rupprecht, CE				Lodmell, DL; Ray, NB; Parnell, MJ; Ewalt, LC; Hanlon, CA; Shaddock, JH; Sanderlin, DS; Rupprecht, CE			DNA immunization protects nonhuman primates against rabies virus	NATURE MEDICINE			English	Article							VACCINE; DISEASE; CELLS	More than 40,000 people die annually from rabies worldwide(1). Most of these fatalities occur in developing countries, where rabies is endemic, public health resources are inadequate and there is limited access to preventive treatment(2). Because of the high cost of vaccines derived from cell culture, many countries still use vaccines produced in sheep, goat or suckling mouse brain(3). The stability and low cost for mass production of DNA vaccines would make them ideal for use in developing countries(4). To investigate the potential of DNA vaccines for rabies immunization in humans, we vaccinated Macaca fascicularis (Cynomolgus) monkeys with DNA encoding the glycoprotein of the challenge virus standard rabies virus, or with a human diploid cell vaccine (HDCV). The monkeys then were challenged with a non-passaged rabies virus. DNA or HDCV vaccination elicited comparable primary and anamnestic neutralizing antibody responses. All ten vaccinated monkeys (DNA or HDCV) survived a rabies virus challenge, whereas monkeys vaccinated with only the DNA vector developed rabies. Furthermore, serum samples from DNA- or HDCV-vaccinated monkeys neutralized a global spectrum of rabies virus variants in vitro. This study shows that DNA immunization elicits protective immunity in nonhuman primates against lethal challenge with a human viral pathogen of the central nervous system. Our findings indicate that DNA vaccines may have a promising future in human rabies immunization.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, Hamilton, MT 59840 USA; Ctr Dis Control & Prevent, Rabies Sect, Viral & Rickettsial Zooneses Branch, Div Viral & Rickettsial Dis,Natl Ctr Infect Dis, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA	Lodmell, DL (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, Hamilton, MT 59840 USA.		Rupprecht, Charles/AAI-1544-2020					Arai YT, 1997, ARCH VIROL, V142, P1787, DOI 10.1007/s007050050197; CHARLTON KM, 1982, COMP IMMUNOL MICROB, V5, P113; Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213; DRESSEN DW, 1997, VACCINE S, V15; GLUCK R, 1991, VACCINES IMMUNOTHERA, P246; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; Krebs JW, 1997, J AM VET MED ASSOC, V211, P1525; Liu MA, 1997, VACCINE, V15, P909, DOI 10.1016/S0264-410X(96)00280-0; Lodmell DL, 1998, VACCINE, V16, P115, DOI 10.1016/S0264-410X(97)88325-9; Lu S, 1996, J VIROL, V70, P3978, DOI 10.1128/JVI.70.6.3978-3991.1996; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; Ray NB, 1997, VACCINE, V15, P892, DOI 10.1016/S0264-410X(96)00281-2; Robinson H L, 1997, Semin Immunol, V9, P271, DOI 10.1006/smim.1997.0083; SMITH AL, 1977, INTERVIROLOGY, V8, P92, DOI 10.1159/000148883; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535; SMITH JS, 1993, PROG MED VIROL, V40, P82; Smith JS, 1996, CLIN MICROBIOL REV, V9, P166, DOI 10.1128/CMR.9.2.166; SMITH JS, 1986, J CLIN MICROBIOL, V24, P573, DOI 10.1128/JCM.24.4.573-580.1986; Ugen KE, 1997, VACCINE, V15, P927, DOI 10.1016/S0264-410X(96)00254-X; VODOPIJA I, 1991, NATURAL HIST RABIES, V2, P571; *WHO, 1985, WHO TECHN REP SER, V725; World Health Organization (WHO), 1992, WHO TECHN REP SER, V824	23	106	115	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					949	952		10.1038/nm0898-949	http://dx.doi.org/10.1038/nm0898-949			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701249				2022-12-25	WOS:000075107400040
J	Powell-Braxton, L; Veniant, M; Latvala, RD; Hirano, KI; Won, WB; Ross, J; Dybdal, N; Zlot, CH; Young, SG; Davidson, NO				Powell-Braxton, L; Veniant, M; Latvala, RD; Hirano, KI; Won, WB; Ross, J; Dybdal, N; Zlot, CH; Young, SG; Davidson, NO			A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet	NATURE MEDICINE			English	Article							E-DEFICIENT MICE; APOLIPOPROTEIN-E; KNOCKOUT MICE; RECEPTOR; LESIONS; LACKING; EXPRESSION; CLEARANCE; APOBEC-1; CELLS	Mutations in the low density lipoprotein (LDL) receptor gene cause familial hypercholesterolemia, a human disease characterized by premature atherosclerosis and markedly elevated plasma levels of LDL cholesterol and apolipoprotein (apo) B100. In contrast, mice deficient for the LDL receptor (Ldlr(-/-)) have only mildly elevated LDL cholesterol levels and little atherosclerosis. This difference results from extensive editing of the hepatic apoB mRNA in the mouse, which limits apoB100 synthesis in favor of apoB48 synthesis. We have generated Ldlr(-/-) mice that cannot edit the apoB mRNA and therefore synthesize exclusively apoB100. These mice had markedly elevated LDL cholesterol and apoB100 levels and developed extensive atherosclerosis on a chow diet. This authentic model of human familiar hypercholesterolemia will provide a new tool for studying atherosclerosis.	Genentech Inc, Cardiovasc Res, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Roche Holding; Genentech; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Chicago	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.			Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL 18577, HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180, P01HL018577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DAVIDSON NO, 1995, RNA, V1, P3; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Kim E, 1998, J CLIN INVEST, V101, P1468; Kim E, 1998, J LIPID RES, V39, P703; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1996, CIRCULATION, V94; NAKAMURA Y, 1994, RHODIUM EX, V6, P14; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sanan DA, 1998, P NATL ACAD SCI USA, V95, P4544, DOI 10.1073/pnas.95.8.4544; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	33	162	170	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					934	938		10.1038/nm0898-934	http://dx.doi.org/10.1038/nm0898-934			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701246				2022-12-25	WOS:000075107400037
J	Cibelli, JB; Stice, SL; Golueke, PJ; Kane, JJ; Jerry, J; Blackwell, C; de Leon, FAP; Robl, JM				Cibelli, JB; Stice, SL; Golueke, PJ; Kane, JJ; Jerry, J; Blackwell, C; de Leon, FAP; Robl, JM			Transgenic bovine chimeric offspring produced from somatic cell-derived stem-like cells	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; nuclear transplantation	ES CELLS	We have developed a method, using nuclear transplantation, to produce transgenic embryonic stem (ES)-like cells from fetal bovine fibroblasts. These cells, when reintroduced into preimplantation embryos, differentiated into derivatives from the three embryonic germ layers, ectoderm, mesoderm, and endoderm, in 5-month-old animals. Six out of seven (86%) carves born were found to be chimeric for at least one tissue. These experiments demonstrate that somatic cells can be genetically modified and then dedifferentiated by nuclear transfer into ES-like cells, opening the possibility of using them in differentiation studies and human cell therapy.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Adv Cell Technol Inc, Worcester, MA 01605 USA; Univ Minnesota, Coll Agr Food & Environm Sci, St Paul, MN 55108 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Minnesota System; University of Minnesota Twin Cities	Robl, JM (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.			Cibelli, Jose/0000-0002-2176-3854; Ponce de Leon, Federico/0000-0001-8645-553X				Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cibelli J. B., 1997, Theriogenology, V47, P241, DOI 10.1016/S0093-691X(97)82368-0; DOETSCHMAN T, 1988, DEV BIOL, V127, P224, DOI 10.1016/0012-1606(88)90204-7; FORRESTER LM, 1991, P NATL ACAD SCI USA, V88, P7514, DOI 10.1073/pnas.88.17.7514; HILL DP, 1993, METHOD ENZYMOL, V225, P664; PALACIOS R, 1995, P NATL ACAD SCI USA, V92, P7530, DOI 10.1073/pnas.92.16.7530; PIEDRAHITA JA, 1990, THERIOGENOLOGY, V34, P879, DOI 10.1016/0093-691X(90)90559-C; SAITO S, 1992, ROUX ARCH DEV BIOL, V201, P134, DOI 10.1007/BF00188711; Schoonjans L, 1996, MOL REPROD DEV, V45, P439, DOI 10.1002/(SICI)1098-2795(199612)45:4&lt;439::AID-MRD5&gt;3.0.CO;2-S; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; SUSKOPARRISH JL, 1994, DEV BIOL, V166, P729, DOI 10.1006/dbio.1994.1351; ELECTROPORATOR MANUA	12	238	304	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					642	646		10.1038/nbt0798-642	http://dx.doi.org/10.1038/nbt0798-642			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661197				2022-12-25	WOS:000074521800027
J	Cucca, F; Goy, JV; Kawaguchi, Y; Esposito, L; Merriman, ME; Wilson, AT; Cordell, HJ; Bain, SC; Todd, JA				Cucca, F; Goy, JV; Kawaguchi, Y; Esposito, L; Merriman, ME; Wilson, AT; Cordell, HJ; Bain, SC; Todd, JA			A male-female bias in type 1 diabetes and linkage to chromosome Xp in MHC HLA-DR3-positive patients	NATURE GENETICS			English	Article							GLUTAMIC-ACID DECARBOXYLASE; ISLET-CELL ANTIBODIES; INSULIN AUTOANTIBODIES; HLA; MELLITUS; ASSOCIATION; RISK; SUSCEPTIBILITY; ONSET; IDDM	It is generally assumed that the male:female (M:F) ratio in patients with type 1 (insulin-dependent) diabetes mellitus (IDDM) is 1. A recent survey, however, revealed that high incidence countries (mainly European) have a high M:F ratio and low incidence ones (Asian and African) have a low M:F ratio(1) We have now analysed the M:F ratio according to genotype at the major locus, the major histocompatibility complex (MHC; IDDM1). There are two main IDDM1 susceptibility haplotypes, HLA-DR3 and -DR4, which are present in 95% of Caucasian cases(2-4). We report here that in medium/high incidence Caucasian populations from the United States of America, United Kingdom and Sardinia (1307 cases), the bias in male incidence is largely restricted to the DR3/X category of patients (X not equal DR4) with a M:F ratio of 1.7 (P = 9.3 x 10(-7)), compared with a ratio of 1.0 in the DR4/Y category (Y not equal DR3). This is additional evidence for significant heterogeneity between the aetiology of 'DR4-associated' and 'DR3-associated' diabetes(5-13). We analysed linkage of type 1 diabetes to chromosome X, and as expected, most of the linkage to Xp13-p11 was in the DR3/X affected sib-pair families (n=97; peak multipoint Mts at DXS1068 = 3.5, P = 2.7 x 10(-4); single point MLS = 4.5, P = 2.7 x 10(-5)). This is evidence for aetiological heterogeneity at the IDDM1/MHC locus and, therefore, in the search for non-MHC loci in type 1 diabetes, conditioning of linkage data by HLA type is advised.	Univ Oxford, Nuffield Dept Surg, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Cagliari, Ist Clin & Biol Eta Evolut, I-09100 Cagliari, Italy; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44109 USA; Univ Birmingham, Birmingham Heartlands Hosp, Dept Med, Birmingham B9 5SS, W Midlands, England	University of Oxford; Wellcome Centre for Human Genetics; University of Cagliari; Case Western Reserve University; Heart of England NHS Foundation Trust; University of Birmingham	Todd, JA (corresponding author), Univ Oxford, Nuffield Dept Surg, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; CUCCA, Francesco/0000-0002-7414-1995; Cordell, Heather/0000-0002-1879-5572; Wilson, Amanda/0000-0001-5681-9611	Telethon [E.0604] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission)		BAIN SC, 1990, AUTOIMMUNITY, V7, P83, DOI 10.3109/08916939008993380; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; CORDELL HJ, 1995, ANN HUM GENET, V59, P435, DOI 10.1111/j.1469-1809.1995.tb00761.x; CUCCA F, 1993, HUM IMMUNOL, V37, P85, DOI 10.1016/0198-8859(93)90146-R; CUCCA F, 1996, HLA MHC GENES MOL FU, P383; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Genovese S, 1996, DIABETOLOGIA, V39, P1223, DOI 10.1007/BF02658510; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; Ilonen J, 1996, DIABETES CARE, V19, P795, DOI 10.2337/diacare.19.8.795; Jackerott M, 1997, J AUTOIMMUN, V10, P35, DOI 10.1006/jaut.1996.0105; Karvonen M, 1997, DIABETES METAB REV, V13, P275, DOI 10.1002/(SICI)1099-0895(199712)13:4<275::AID-DMR197>3.0.CO;2-V; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LERNMARK A, 1990, AM J HUM GENET, V47, P1028; Roep BO, 1996, EUR J IMMUNOL, V26, P1285, DOI 10.1002/eji.1830260616; Sanjeevi CB, 1996, DIABETIC MED, V13, P209, DOI 10.1002/(SICI)1096-9136(199603)13:3<209::AID-DIA39>3.0.CO;2-2; SERJEANTSON SW, 1992, DIABETOLOGIA, V35, P996, DOI 10.1007/BF00401432; She JX, 1996, IMMUNOL TODAY, V17, P323, DOI 10.1016/0167-5699(96)10014-1; THOMSON G, 1988, AM J HUM GENET, V43, P799; Thorsby E, 1996, J PEDIATR ENDOCR MET, V9, P75; VANDEWALLE CL, 1993, DIABETOLOGIA, V36, P1155, DOI 10.1007/BF00401060; WORDSWORTH BP, 1990, IMMUNOGENETICS, V32, P413; ZIEGLER R, 1991, DIABETES, V40, P709, DOI 10.2337/diabetes.40.6.709	23	112	112	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					301	302		10.1038/995	http://dx.doi.org/10.1038/995			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662410				2022-12-25	WOS:000074565900033
J	Lockhart, DJ; Dong, HL; Byrne, MC; Follettie, MT; Gallo, MV; Chee, MS; Mittmann, M; Wang, CW; Kobayashi, M; Horton, H; Brown, EL				Lockhart, DJ; Dong, HL; Byrne, MC; Follettie, MT; Gallo, MV; Chee, MS; Mittmann, M; Wang, CW; Kobayashi, M; Horton, H; Brown, EL			Expression monitoring by hybridization to high-density oligonucleotide arrays	NATURE BIOTECHNOLOGY			English	Article						gene expression; mRNA abundance; parallel; quantitative; hybridization; combinatorial synthesis; oligonucleotide arrays; DNA chips	GENE-EXPRESSION; CDNA; RNA	The human genome encodes approximately 100,000 different genes, and at least partial sequence information for nearly all will be available soon. Sequence information alone, however, is insufficient for a full understanding of gene function, expression, regulation, and splice-site variation. Because cellular processes are governed by the repertoire of expressed genes, and the levels and timing of expression, it is important to have experimental tools for the direct monitoring of large numbers of mRNAs in parallel. We have developed an approach that is based on hybridization to small, high-density arrays containing tens of thousands of synthetic oligonucleotides. The arrays are designed based on sequence information alone and are synthesized in situ using a combination of photolithography and oligonucleotide chemistry. RNAs present at a frequency of 1:300,000 are unambiguously detected, and detection is quantitative over more than three orders of magnitude. This approach provides a way to use directly the growing body of sequence information for highly parallel experimental investigations. Because of the combinatorial nature of the chemistry and the ability to synthesize small arrays containing hundreds of thousands of specifically chosen oligonucleotides, the method is readily scalable to the simultaneous monitoring of tens of thousands of genes.	GENET INST INC,CAMBRIDGE,MA 02140		Lockhart, DJ (corresponding author), AFFYMETRIX,3380 CENT EXPRESSWAY,SANTA CLARA,CA 95051, USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Favaloro J, 1980, Methods Enzymol, V65, P718; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; FODOR SPA, 1991, SCIENCE, V251, P757; GRESS TM, 1992, MAMM GENOME, V3, P60; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; LEWIN B, 1980, GENE EXPRESSION, V2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; Maruo S, 1996, J IMMUNOL, V156, P1748; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; Milosavljevic A, 1996, GENOME RES, V6, P132, DOI 10.1101/gr.6.2.132; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PLETU G, 1996, GENOME RES, V6, P492; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; TAKAHASHI N, 1995, GENE, V164, P219, DOI 10.1016/0378-1119(95)00396-N; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; ZHAO ND, 1995, GENE, V156, P207, DOI 10.1016/0378-1119(95)00023-Y	28	2607	3222	4	167	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1996	14	13					1675	1680		10.1038/nbt1296-1675	http://dx.doi.org/10.1038/nbt1296-1675			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VX107	9634850				2022-12-25	WOS:A1996VX10700028
J	Ogawa, T; Hori, T; Ishida, I				Ogawa, T; Hori, T; Ishida, I			Virus-induced cell death in plants expressing the mammalian 2',5' oligoadenylate system	NATURE BIOTECHNOLOGY			English	Article						2-5A system; transgenic plant virus resistance; cell death	MOSAIC-VIRUS; 2-5A-DEPENDENT RNASE; RESISTANCE; INFECTION; GENE; SYNTHETASE; PROTEIN	The major components of the 2-5A system, responsible for the mammalian inferferon-induced antiviral response, are the 2',5' oligoadenylate Synthetase (2-5Aase) and 2',5' oIigoadenylate (2-5A) dependent ribonuclease (RNase L). Transgenic tobacco plants expressing these two enzyme activities were produced by crossing the transgenic plants expressing RNase L with those expressing 2-5Aase. The double transgenic plants showed complete resistance against cucumber mosaic virus (CMV), infection with necrotic spots only forming on the virus-inoculated leaf. On the other hand, although plants inoculated with potato virus Y (PVY) formed necrotic spots on the inoculated leaf and virus amplification could not be detected, all plants died within 20 days of inoculation, The transgenic tobacco plants expressing either 2-5Aase or RNase L activity showed typical disease symptoms with CMV- or PVY-inoculation. These results suggest that the introduced 2-5A system is activated in tobacco cells by dsRNA, the replicating intermediates of RNA viruses, leading to death of the host cells, which has not been observed in mammalian cells.	CENT LABS KEY TECHNOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN									BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; DEVASH Y, 1985, BIOCHEMISTRY-US, V24, P593, DOI 10.1021/bi00324a008; FITCHEN JH, 1993, ANNU REV MICROBIOL, V47, P739, DOI 10.1146/annurev.mi.47.100193.003515; LAWSON C, 1990, BIO-TECHNOL, V8, P127, DOI 10.1038/nbt0290-127; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MESHI T, 1982, J BIOCHEM-TOKYO, V91, P1441, DOI 10.1093/oxfordjournals.jbchem.a133833; Mitra A, 1996, P NATL ACAD SCI USA, V93, P6780, DOI 10.1073/pnas.93.13.6780; OHSHIMA K, 1991, Annals of the Phytopathological Society of Japan, V57, P615, DOI 10.3186/jjphytopath.57.615; OKUNO T, 1993, PHYTOPATHOLOGY, V83, P542, DOI 10.1094/Phyto-83-542; PUSKA R, 1994, 4 INT C PLANT MOL BI; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; TRUVE E, 1993, BIO-TECHNOL, V11, P1048, DOI 10.1038/nbt0993-1048; TRUVE E, 1994, ARCH VIROL, P41; VALVERDE RA, 1986, PHYTOPATHOLOGY, V76, P459, DOI 10.1094/Phyto-76-459; WATANABE Y, 1995, FEBS LETT, V372, P165, DOI 10.1016/0014-5793(95)00901-K; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	21	47	48	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1566	1569		10.1038/nbt1196-1566	http://dx.doi.org/10.1038/nbt1196-1566			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634822				2022-12-25	WOS:A1996VP83300023
J	Speed, MA; Wang, DIC; King, J				Speed, MA; Wang, DIC; King, J			Specific aggregation of partially folded polypeptide chains: The molecular basis of inclusion body composition	NATURE BIOTECHNOLOGY			English	Article						aggregation; folding intermediates; in vitro refolding; inclusion body; P22 coat protein; P22 tailspike protein	PHAGE-P22 TAILSPIKE PROTEIN; BOVINE GROWTH-HORMONE; FOLDING INTERMEDIATE; IN-VITRO; ESCHERICHIA-COLI; COAT PROTEIN; P22; MUTATIONS; PATHWAY; ENDORHAMNOSIDASE	During expression of many recombinant proteins, off-pathway association of partially folded intermediates into inclusion bodies competes with productive folding. A common assumption is that such aggregation reactions are nonspecific processes. The multimeric intermediates along the aggregation pathway have been identified for both the P22 tailspike and P22 coat protein. We show that for a mixture of proteins refolding in vitro, folding intermediates do not coaggregate with each other but only with themselves. This indicates that aggregation occurs by specific interaction of certain conformations of folding intermediates rather than by nonspecific coaggregation, providing a rationale for recovering relatively pure protein from the inclusion body state.	MIT, CTR BIOTECHNOL PROC ENGN, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM17980, 2-T32-GM08334] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, T32GM008334, R37GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; BREMS DN, 1988, P NATL ACAD SCI USA, V85, P3367, DOI 10.1073/pnas.85.10.3367; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHARGE SBP, 1995, BIOCHEMISTRY-US, V34, P14588, DOI 10.1021/bi00044a038; CHEN CC, 1995, AICHE J, V41, P1015, DOI 10.1002/aic.690410433; CLELAND JL, 1993, ACS SYM SER, V526, P1; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DEBERNARDEZCLARK E, 1991, ACS SYM SER, V470, P1; DEYOUNG LR, 1993, BIOCHEMISTRY-US, V32, P3877, DOI 10.1021/bi00066a006; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GORDON CL, 1994, J BIOL CHEM, V269, P27941; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; Jaenicke R, 1986, Methods Enzymol, V131, P218; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; King J, 1986, Methods Enzymol, V131, P250; KING J, 1980, Q REV BIOL, V55, P369, DOI 10.1086/411981; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; LEHMAN SR, 1991, BIOCHEM, V30, P5777; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; SATHER SK, 1994, J BIOL CHEM, V269, P25268; SHEA RG, 1971, THESIS MIT CAMBRIDGE; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; TESCHKE CM, 1995, BIOCHEMISTRY-US, V34, P6815, DOI 10.1021/bi00020a028; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; WETZEL R, 1994, FEBS LETT, V350, P245, DOI 10.1016/0014-5793(94)00775-6; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	41	272	281	2	22	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1283	1287		10.1038/nbt1096-1283	http://dx.doi.org/10.1038/nbt1096-1283			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631094				2022-12-25	WOS:A1996VK61800028
J	Gilles, PN; Wu, DJ; Foster, CB; Dillon, PJ; Chanock, SJ				Gilles, PN; Wu, DJ; Foster, CB; Dillon, PJ; Chanock, SJ			Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips	NATURE BIOTECHNOLOGY			English	Article						single nucleotide polymorphism; mannose binding protein; microarray; chip	MANNOSE-BINDING PROTEIN; HUMAN GENOME; DNA; HYBRIDIZATION; INFECTION; GENE; MUTATIONS; ALLELE; CHIPS	We have developed a rapid assay for single nucleotide polymorphism (SNP) detection that utilizes electronic circuitry on silicon microchips. The method was validated by the accurate discrimination of blinded DNA samples for the complex quadra-allelic SNP of mannose binding protein. The microchip directed the transport, concentration, and attachment of amplified patient DNA to selected electrodes (test sites) creating an array of DNA samples. Through control of the electric field, the microchip enabled accurate genetic identification of these samples using fluorescently labeled DNA reporter probes. The accuracy of this approach was established by internal controls of dual labeled reporters and by using mismatched sequences in addition to the wild-type and variant reporter sequences to validate the SNP-genotype. The ability to customize this assay for multiple genes has advantages over other existing approaches.	Nanogen Inc, San Diego, CA 92121 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, DJ (corresponding author), Nanogen Inc, 10398 Pacific Ctr Ct, San Diego, CA 92121 USA.	dwu@nanogen.com						Cheng J, 1998, NAT BIOTECHNOL, V16, P541, DOI 10.1038/nbt0698-541; Cheng J, 1998, ANAL CHEM, V70, P2321, DOI 10.1021/ac971274g; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; Edman CF, 1997, NUCLEIC ACIDS RES, V25, P4907, DOI 10.1093/nar/25.24.4907; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Ezekowitz A, 1996, LANCET, V348, P1396, DOI 10.1016/S0140-6736(05)67498-3; Foster CB, 1998, J CLIN INVEST, V102, P2146, DOI 10.1172/JCI5084; Fu DJ, 1998, NAT BIOTECHNOL, V16, P381, DOI 10.1038/nbt0498-381; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Hilsum, 1993, HDB SEMICONDUCTORS; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; Malmgren H, 1996, CLIN GENET, V50, P202; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; Marshall E, 1998, SCIENCE, V279, P317, DOI 10.1126/science.279.5349.317; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Pennisi E, 1998, SCIENCE, V280, P814, DOI 10.1126/science.280.5365.814; Piatek AS, 1998, NAT BIOTECHNOL, V16, P359, DOI 10.1038/nbt0498-359; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Sullivan KE, 1996, ARTHRITIS RHEUM, V39, P2046, DOI 10.1002/art.1780391214; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; Thomas HC, 1996, LANCET, V348, P1417, DOI 10.1016/S0140-6736(96)05409-8; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; VANZANT P, 1997, MICROCHIP FABRICATIO; Vesell ES, 1997, ANN INTERN MED, V126, P653, DOI 10.7326/0003-4819-126-8-199704150-00012; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Weiler J, 1997, NUCLEIC ACIDS RES, V25, P2792, DOI 10.1093/nar/25.14.2792; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P3929, DOI 10.1093/nar/19.14.3929	37	194	233	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					365	370		10.1038/7921	http://dx.doi.org/10.1038/7921			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207885				2022-12-25	WOS:000079574400025
J	Sawa, T; Yahr, TL; Ohara, M; Kurahashi, K; Gropper, MA; Wiener-Kronish, JP; Frank, DW				Sawa, T; Yahr, TL; Ohara, M; Kurahashi, K; Gropper, MA; Wiener-Kronish, JP; Frank, DW			Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury	NATURE MEDICINE			English	Article							AERUGINOSA EXOENZYME-S; YERSINIA YOP VIRULON; FUSION PEPTIDE; SECRETION SYSTEMS; EUKARYOTIC CELLS; ADP-RIBOSYLATES; STRUCTURAL GENE; PESTIS; CYTOTOXICITY; VIRULENCE	Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause fatal acute lung infections in critically ill individuals. Damage to the lung epithelium is associated with the expression of toxins that are directly injected into eukaryotic cells through a type Ill-mediated secretion and translocation mechanism. Here we show that the P. aeruginosa homolog of the Yersinia V antigen, PcrV, is involved in the translocation of type III toxins. Vaccination against PcrV ensured the survival of challenged mice and decreased lung inflammation and injury. Antibodies to PcrV inhibited the translocation of type III toxins.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Medical College of Wisconsin; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Frank, DW (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Planck Rd, Milwaukee, WI 53226 USA.	frankd@mcw.edu	Kurahashi, Kiyoyasu/AAE-9806-2021	Yahr, Timothy/0000-0001-9054-8704				AIDI Y, 1990, J IMMUNOL METHODS, V132, P191; Anderson GW, 1996, INFECT IMMUN, V64, P4580, DOI 10.1128/IAI.64.11.4580-4585.1996; APODACA G, 1995, INFECT IMMUN, V63, P1541, DOI 10.1128/IAI.63.4.1541-1551.1995; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; FALLMAN M, 1995, INFECT IMMUN, V63, P3117; FinckBarbancon V, 1997, MOL MICROBIOL, V25, P547, DOI 10.1046/j.1365-2958.1997.4891851.x; Fleiszig SMJ, 1997, INFECT IMMUN, V65, P579, DOI 10.1128/IAI.65.2.579-586.1997; FRANK DW, 1994, INFECT IMMUN, V62, P554, DOI 10.1128/IAI.62.2.554-563.1994; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Frithz-Lindsten E, 1998, MOL MICROBIOL, V29, P1155, DOI 10.1046/j.1365-2958.1998.00994.x; FrithzLindsten E, 1997, MOL MICROBIOL, V25, P1125, DOI 10.1046/j.1365-2958.1997.5411905.x; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Hauser AR, 1998, MOL MICROBIOL, V27, P807, DOI 10.1046/j.1365-2958.1998.00727.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; KUDOH I, 1994, AM J PHYSIOL-LUNG C, V267, P551; KULICH SM, 1994, J BIOL CHEM, V269, P10431; LEARY SEC, 1995, INFECT IMMUN, V63, P2854, DOI 10.1128/IAI.63.8.2854-2858.1995; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; MOTIN VL, 1994, INFECT IMMUN, V62, P4192, DOI 10.1128/IAI.62.10.4192-4201.1994; NAKAJIMA R, 1995, INFECT IMMUN, V63, P3021, DOI 10.1128/IAI.63.8.3021-3029.1995; Nedialkov YA, 1997, INFECT IMMUN, V65, P1196, DOI 10.1128/IAI.65.4.1196-1203.1997; Nilles ML, 1998, J BACTERIOL, V180, P3410, DOI 10.1128/JB.180.13.3410-3420.1998; Sarker MR, 1998, J BACTERIOL, V180, P1207, DOI 10.1128/JB.180.5.1207-1214.1998; Sawa T, 1998, INFECT IMMUN, V66, P3242, DOI 10.1128/IAI.66.7.3242-3249.1998; Sawa T, 1997, J IMMUNOL, V159, P2858; SCHWEIZER HP, 1992, MOL MICROBIOL, V6, P1195, DOI 10.1111/j.1365-2958.1992.tb01558.x; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; SKRZYPEK E, 1995, J BACTERIOL, V177, P2530, DOI 10.1128/jb.177.9.2530-2542.1995; Vallis AJ, 1999, INFECT IMMUN, V67, P914, DOI 10.1128/IAI.67.2.914-920.1999; VALLIS AJ, IN PRESS INFECT IMMU; Welkos S, 1998, MICROB PATHOGENESIS, V24, P185, DOI 10.1006/mpat.1997.0188; YAHR TL, 1995, J BACTERIOL, V177, P1169, DOI 10.1128/jb.177.5.1169-1178.1995; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; Yahr TL, 1996, J BACTERIOL, V178, P1412, DOI 10.1128/jb.178.5.1412-1419.1996; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yahr TL, 1997, J BACTERIOL, V179, P7165, DOI 10.1128/jb.179.22.7165-7168.1997	40	283	301	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					392	398		10.1038/7391	http://dx.doi.org/10.1038/7391			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202927				2022-12-25	WOS:000079574300027
J	Horwitz, EM; Prockop, DJ; Fitzpatrick, LA; Koo, WWK; Gordon, PL; Neel, M; Sussman, M; Orchard, P; Marx, JC; Pyeritz, RE; Brenner, MK				Horwitz, EM; Prockop, DJ; Fitzpatrick, LA; Koo, WWK; Gordon, PL; Neel, M; Sussman, M; Orchard, P; Marx, JC; Pyeritz, RE; Brenner, MK			Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta	NATURE MEDICINE			English	Article							MALIGNANT OSTEOPETROSIS; GENE-THERAPY; EXPRESSION; GROWTH; REPAIR; MICE	In principle, transplantation of mesenchymal progenitor cells would attenuate or possibly correct genetic disorders of bone, cartilage and muscle, but clinical support for this concept is lacking. Here we describe the initial results of allogeneic bone marrow transplantation in three children with osteogenesis imperfecta, a genetic disorder in which osteoblasts produce defective type I collagen, leading to osteopenia, multiple fractures, severe bony deformities and considerably shortened stature. Three months after osteoblast engraftment (1.5-2.0% donor cells), representative specimens of trabecular bone showed histologic changes indicative of new dense bone formation. All patients had increases in total body bone mineral content ranging from 21 to 29 grams (median, 28), compared with predicted values of 0 to 4 grams (median, 0) for healthy children with similar changes in weight. These improvements were associated with increases in growth velocity and reduced frequencies of bone fracture. Thus, allogeneic bone marrow transplantation can lead to engraftment of functional mesenchymal progenitor cells, indicating the feasibility of this strategy in the treatment of osteogenesis imperfecta and perhaps other mesenchymal stem cell disorders as well.	St Jude Childrens Res Hosp, Cell & Gene Therapy Program, Memphis, TN 38105 USA; Allegheny Univ Hlth Sci, Philadelphia, PA 19102 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Wayne State Univ, Detroit, MI 48201 USA; Shriners Hosp Children, Portland, OR 97201 USA; Univ Minnesota, Minneapolis, MN 55455 USA	St Jude Children's Research Hospital; Drexel University; Mayo Clinic; Wayne State University; University of Minnesota System; University of Minnesota Twin Cities	Horwitz, EM (corresponding author), St Jude Childrens Res Hosp, Cell & Gene Therapy Program, 332 N Lauderdale St, Memphis, TN 38105 USA.		Lima, Thaísa/AAG-6483-2021; Koo, Winston/Q-5251-2017; Pyeritz, Reed/A-1364-2010; Brenner, Malcolm/Y-2509-2019	Koo, Winston/0000-0002-0428-6603; 	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003266] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [K08 HL 03266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aubin Jane E., 1996, P51; BLAZAR BR, 1985, TRANSPLANTATION, V39, P597, DOI 10.1097/00007890-198506000-00004; BYERS PH, 1995, METABOLIC MOL BASES, P4029; COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301; CONSTANTINOU CD, 1990, AM J HUM GENET, V47, P670; Fedde K. N., 1996, American Journal of Human Genetics, V59, pA15; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FROST HM, 1973, ORTHOPEDIC LECT, V3, P59; Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402; GOSHIMA J, 1991, CLIN ORTHOP RELAT R, P298; GROWCHOW LB, 1993, SEMIN ONCOL S4, V20, P18; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARTMANN O, 1986, J CLIN ONCOL, V4, P1804, DOI 10.1200/JCO.1986.4.12.1804; HOU Z, 1997, J BONE MINER RES, pS428; JETT S, 1966, ARCH PATHOL, V81, P112; KOO WWK, 1995, J BONE MINER RES, V10, P1111; Koo WWK, 1998, J AM COLL NUTR, V17, P65, DOI 10.1080/07315724.1998.10720457; Koo WWK, 1996, J BONE MINER RES, V11, P997; Lajeunesse D, 1996, J CLIN INVEST, V98, P1835, DOI 10.1172/JCI118984; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MARINI JC, 1993, AM J MED GENET, V45, P261, DOI 10.1002/ajmg.1320450223; Marini JC, 1997, JAMA-J AM MED ASSOC, V277, P746, DOI 10.1001/jama.277.9.746; NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402; OHGUSHI H, 1989, ACTA ORTHOP SCAND, V60, P334, DOI 10.3109/17453678909149289; Onyia JE, 1998, J BONE MINER RES, V13, P20, DOI 10.1359/jbmr.1998.13.1.20; PARSONS V, 1980, COLOR ATLAS BONE DIS, P85; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; SANDVOSS G, 1986, NEUROCHIRURGIA, V29, P1; SILLENCE DO, 1997, PRINCIPLES PRACTICE, P2779; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033; Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381; Triffitt James T., 1996, P39	36	1399	1530	6	127	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					309	313		10.1038/6529	http://dx.doi.org/10.1038/6529			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086387				2022-12-25	WOS:000078851600036
J	Corda, Y; Schramke, V; Longhese, MP; Smokvina, T; Paciotti, V; Brevet, V; Gilson, E; Geli, V				Corda, Y; Schramke, V; Longhese, MP; Smokvina, T; Paciotti, V; Brevet, V; Gilson, E; Geli, V			Interaction between Set1p and checkpoint protein Mec3p in DNA repair and telomere functions	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; GROUP GENE ENHANCER; BUDDING YEAST; TRITHORAX; LENGTH; DAMAGE; REPLICATION; SIR4	The yeast protein Set1p, inactivation of which alleviates telomeric position effect (TPE), contains a conserved SET domain present in chromosomal proteins involved in epigenetic control of transcription(1-2). Mec3p is required for efficient DNA-damage-dependent checkpoints at G1/S, intra-S and G2/M (refs 3-7). We show here that the SET domain of Set1p interacts with Mec3p. Deletion of SET1 increases the viability of mec3 Delta mutants after DNA damage (in a process that is mostly independent of Rad53p kinase, which has a central role in checkpoint control(8-9)) but does not significantly affect cell-cycle progression. Deletion of MEC3 enhances TPE and attenuates the set1 Delta-induced silencing defect. Furthermore, restoration of TPE in a set1 Delta mutant by overexpression of the isolated SET domain requires Mec3p. Finally, deletion of MEC3 results in telomere elongation, whereas cells with deletions of both SET1 and MEC3 do not have elongated telomeres. Our findings indicate that interactions between SET1 and MEC3 have a role in DNA repair and telomere function.	CNRS, Lab Ingn & Dynam Syst Macromol, F-13402 Marseille 20, France; Univ Milan, Dipartimento Genet & Biol Micorganismi, I-20133 Milan, Italy; Ecole Normale Super Lyon, CNRS, UMR 8510, Biol Cellulaire & Mol Lab, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); University of Milan; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Geli, V (corresponding author), CNRS, Lab Ingn & Dynam Syst Macromol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Pia, Maria/AAK-2693-2020	Longhese, Maria Pia/0000-0003-1726-2034				Adams AK, 1996, MOL CELL BIOL, V16, P4614; Allen JB, 1994, GENE DEV, V8, P2416; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Fairhead C, 1996, YEAST, V12, P1439; GOLEMIS EA, 1990, CURRENT PROTOCOLS MO, V27, P1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; LONGHESE MP, 1996, MOL CELL BIOL, V16, P3225; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748	30	87	93	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					204	208		10.1038/5991	http://dx.doi.org/10.1038/5991			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988274				2022-12-25	WOS:000078399500024
J	Bossi, G; Griffiths, GM				Bossi, G; Griffiths, GM			Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells	NATURE MEDICINE			English	Article							SECRETORY LYSOSOMES; LYMPHOCYTES-T; GRANULES; RECEPTOR; ANTIGEN; CYTOTOXICITY; ACTIVATION; MECHANISM; PERFORIN; RELEASE	Fas ligand (FasL) triggers apoptosis during cytotoxicity mediated by cytotoxic T lymphocytes and during immune downregulation(1). The ability of T cells and natural killer cells to trigger apoptosis through this mechanism is controlled by the cell surface expression of Fast (ref. 2). Because Fast expression is upregulated on activation(2,3), Fast was thought to be delivered directly to the cell surface. Here we show that newly synthesized Fast is stored in specialized secretory lysosomes in both CD4(+) and CD8(+) T cells and natural killer cells, and that polarized degranulation controls the delivery of Fast to the cell surface. In this way, Fast-mediated apoptosis is finely controlled by receptor-mediated target-cell recognition. The cytoplasmic tail of Fast contains signals that sort Fast to secretory lysosomes in hemopoietic cells. This pathway may provide a general mechanism for controlling the cell surface appearance of proteins involved in immune regulation.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Griffiths, GM (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.			Griffiths, Gillian/0000-0003-0434-5842	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffiths G M, 1997, Semin Immunol, V9, P109, DOI 10.1006/smim.1997.0059; Griffiths GM, 1996, TRENDS CELL BIOL, V6, P329, DOI 10.1016/0962-8924(96)20031-5; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kiener PA, 1997, J IMMUNOL, V159, P1594; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; STOKES TA, 1998, SCIENCE, V279, P2015; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; YODOI J, 1985, J IMMUNOL, V134, P1623; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	26	311	317	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					90	96		10.1038/4779	http://dx.doi.org/10.1038/4779			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883845				2022-12-25	WOS:000077885000035
J	Gurunathan, S; Prussin, C; Sacks, DL; Seder, RA				Gurunathan, S; Prussin, C; Sacks, DL; Seder, RA			Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection	NATURE MEDICINE			English	Article							LEISHMANIA-MAJOR INFECTION; INTERFERON-GAMMA PRODUCTION; CD4(+) T-CELLS; BALB/C MICE; INTERLEUKIN-12; IL-12; DNA; RESPONSES; ANTIGEN; RESISTANCE	The humoral immunity induced by many viral and bacterial vaccines mediates protection that is maintained over a long period of time. In contrast, for other intracellular infections (such as with Leishmania major or Mycobacterium tuberculosis) for which cell-mediated immunity is required for protection, the mechanisms for developing durable responses after vaccination have not been well defined. Here we demonstrate that vaccination with plasmid DNA encoding a specific leishmanial antigen is more effective than leishmanial protein plus recombinant IL-12 in eliciting long-term immunity capable of controlling L. major infection. We also show that leishmanial protein plus IL-12 DNA produces an immunity that lasts much longer than does immunity elicited by leishmanial protein plus IL-12 protein, indicating that the persistence of IL-12 may be the essential determinant in maintaining durable cell-mediated immune responses for an intracellular parasitic infection.	NIH, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.	rseder@nih.gov		Prussin, Calman/0000-0002-3917-3326				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; CLERICI M, 1994, P NATL ACAD SCI USA, V91, P11811, DOI 10.1073/pnas.91.25.11811; Conceicao-Silva F, 1998, EUR J IMMUNOL, V28, P237, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;237::AID-IMMU237&gt;3.0.CO;2-O; DACONCEICAOSILVA F, 1994, EUR J IMMUNOL, V24, P2813, DOI 10.1002/eji.1830241135; Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HuLi J, 1997, P NATL ACAD SCI USA, V94, P3189, DOI 10.1073/pnas.94.7.3189; Jankovic D, 1997, J IMMUNOL, V159, P2409; Julia V, 1996, SCIENCE, V274, P421, DOI 10.1126/science.274.5286.421; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Launois P, 1997, J IMMUNOL, V158, P3317; Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MA X, 1996, J EXP MED, V183; Marth T, 1996, J IMMUNOL, V157, P2348; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; MULLER I, 1993, INFECT IMMUN, V61, P3730; MURPHY EE, 1994, J EXP MED, V180, P223, DOI 10.1084/jem.180.1.223; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHARTONKERSTEN T, 1995, J IMMUNOL, V154, P5320; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Seder RA, 1996, J IMMUNOL, V157, P2745; STEFANI MMA, 1994, EUR J IMMUNOL, V24, P746, DOI 10.1002/eji.1830240338; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zimmermann S, 1998, J IMMUNOL, V160, P3627	32	190	201	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1409	1415		10.1038/4000	http://dx.doi.org/10.1038/4000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846579				2022-12-25	WOS:000077336900037
J	Hulander, M; Wurst, W; Carlsson, P; Enerback, S				Hulander, M; Wurst, W; Carlsson, P; Enerback, S			The winged helix transcription factor Fkh10 is required for normal development of the inner ear	NATURE GENETICS			English	Article							SEGMENTATION MUTANT; GENE-EXPRESSION; 2 RHOMBOMERES; MOUSE EMBRYO; DNA-BINDING; HNF-3-BETA; PAX-3; MICE; KR	Fkh10 is a member of the forkhead family of winged helix transcriptional regulators. Genes encoding forkhead proteins are instrumental during embryogenesis in mammals, in particular during development of the nervous system(1-5). Here we report that mice with a targeted disruption of the Fkh10 locus exhibit circling behaviour, poor swimming ability and abnormal reaching response-all common findings in mice with vestibular dysfunction(6). These animals also fail to elicit a Preyer reflex in response to a suprathreshold auditory stimulation, as seen in mice with profound hearing impairment(7,8). Histological examination of the inner ear reveals a gross structural malformation of the vestibulum as well as the cochlea. These structures have been replaced by a single irregular cavity in which neither proper semicircular ducts nor cochlea can be identified. We also show that at 9.5 days post coitum (dpc), Fkh10 is exclusively expressed in the otic vesicle. These findings implicate Fkh10 as an early regulator necessary for development of both cochlea and vestibulum and identify its human homologue FKHL10 as a previously unknown candidate deafness gene at 5q34.	Univ Gothenburg, Lundberg Lab, Dept Biol Mol, SE-40530 Gothenburg, Sweden; Max Planck Inst Psychiat, D-80804 Munich, Germany; Chalmers Univ Technol, Dept Chem Phys, Unit Biotechnol, SE-41296 Gothenburg, Sweden	University of Gothenburg; Max Planck Society; Chalmers University of Technology	Enerback, S (corresponding author), Univ Gothenburg, Lundberg Lab, Dept Biol Mol, Box 462, SE-40530 Gothenburg, Sweden.	sven.enerback@molbio.gu.se	Carlsson, Peter/B-5551-2008	Carlsson, Peter/0000-0001-6535-5927; Wurst, Wolfgang/0000-0003-4422-7410				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DEOL MS, 1964, J EMBRYOL EXP MORPH, V12, P475; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hadrys T, 1998, DEVELOPMENT, V125, P33; Labosky PA, 1997, DEVELOPMENT, V124, P1263; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LYON MF, 1996, GENETIC VARIANTS STR; MARK M, 1993, DEVELOPMENT, V119, P319; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; Overdier DG, 1997, J BIOL CHEM, V272, P13725, DOI 10.1074/jbc.272.21.13725; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; STEEL KP, 1983, BEHAV NEUROSCI, V97, P381, DOI 10.1037/0735-7044.97.3.381; STEEL KP, 1992, DEV AUDITORY VESTIBU, V2, P221; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wang WD, 1998, DEVELOPMENT, V125, P621; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	30	70	70	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					374	376		10.1038/3850	http://dx.doi.org/10.1038/3850			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843211				2022-12-25	WOS:000077199600026
J	Szallasi, Z				Szallasi, Z			Gene expression patterns and cancer	NATURE BIOTECHNOLOGY			English	Editorial Material							DNA; MICROARRAY		Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Szallasi, Z (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA.	zszallas@mxc.usuhs.mil		Szallasi, Zoltan/0000-0001-5395-7509				Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DeRisi J, 1996, NAT GENET, V14, P457; Hua VY, 1997, P NATL ACAD SCI USA, V94, P9614, DOI 10.1073/pnas.94.18.9614; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Li RH, 1997, P NATL ACAD SCI USA, V94, P14506, DOI 10.1073/pnas.94.26.14506; MIKI T, 1995, METHOD ENZYMOL, V254, P196; RONINSON IB, 1995, CANCER RES, V55, P4023; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	11	19	22	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1292	1293		10.1038/4381	http://dx.doi.org/10.1038/4381			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853591				2022-12-25	WOS:000077232600002
J	Kovalchuk, I; Kovalchuk, O; Arkhipov, A; Hohn, B				Kovalchuk, I; Kovalchuk, O; Arkhipov, A; Hohn, B			Transgenic plants are sensitive bioindicators of nuclear pollution caused by the Chernobyl accident	NATURE BIOTECHNOLOGY			English	Article						recombination; Arabidopsis thaliana; radiation	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; WHOLE PLANTS; REPAIR; ARABIDOPSIS; INDUCTION; SYSTEM; CELLS	To evaluate the genetic consequences of radioactive contamination originating from the nuclear reactor accident of Chernobyl on indigenous populations of plants and animals, it is essential to determine the rates of accumulating genetic changes in chronically irradiated populations. An increase in germline mutation rates in humans living close to the Chernobyl Nuclear Power Plant site, and a two- to tenfold increase in germline mutations in barn swallows breeding in Chernobyl have been reported. Little is known, however, about the effects of chronic irradiation on plant genomes. Ionizing radiation causes double-strand breaks in DNA, which are repaired via illegitimate or homologous recombination. We make use of Arabidopsis thaliana plants carrying a beta-glucuronidase marker gene as a recombination substrate to monitor genetic alterations in plant populations, which are caused by nuclear pollution of the environment around Chernobyl. A significant (p < 0.05) increase in somatic intrachromosomal recombination frequencies was observed at nuclear pollution levels from 0.1-900 Ci/km(2), consistent with an increase in chromosomal aberrations. This bioindicator may serve as a convenient and ethically acceptable alternative to animal systems.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Ivano Frankivsk State Med Acad, UA-284000 Ivano Frankovsk, Ukraine; Chernobyl Sci & Tech Ctr Int Res, UA-255620 Chernobyl, Ukraine	Friedrich Miescher Institute for Biomedical Research; Ivano-Frankivsk National Medical University	Hohn, B (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	Barbara.Hohn@fmi.ch						ABRAMOV VI, 1992, SCI TOTAL ENVIRON, V112, P19, DOI 10.1016/0048-9697(92)90234-J; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; ARKHIPOV NP, 1994, SCI TOTAL ENVIRON, V157, P383, DOI 10.1016/0048-9697(94)90601-7; ARKHIPOV NP, 1995, ECOLOGICAL STATUS CH, P20; ARKHIPOV NP, 1990, P SEM COMP ASS ENV I, V2, P977; ATHMA P, 1991, GENETICS, V128, P163; Britt AB, 1996, ANNU REV PLANT PHYS, V47, P75, DOI 10.1146/annurev.arplant.47.1.75; Chiurazzi M, 1996, PLANT CELL, V8, P2057, DOI 10.1105/tpc.8.11.2057; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Ellegren H, 1997, NATURE, V389, P593, DOI 10.1038/39303; Fiskesjo G, 1995, Methods Mol Biol, V43, P119; Fiskesjo G., 1997, PLANTS ENV STUDIES, P307, DOI DOI 10.1201/9781420048711.CH11; GAL S, 1991, EMBO J, V10, P1571, DOI 10.1002/j.1460-2075.1991.tb07677.x; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; GREEN MM, 1986, P NATL ACAD SCI USA, V83, P6667, DOI 10.1073/pnas.83.18.6667; Kovalchuk O, 1998, MUTAT RES-GEN TOX EN, V415, P47, DOI 10.1016/S1383-5718(98)00053-9; LEBEL EG, 1993, P NATL ACAD SCI USA, V90, P422, DOI 10.1073/pnas.90.2.422; LIN F, 1984, MOL CELL BIOL, V11, P3268; MOISEEV A, 1991, DIRECTORY DOSIMETRY, P220; MURTI JR, 1994, MUTAT RES, V307, P583, DOI 10.1016/0027-5107(94)90268-2; PAUSHEVA Z, 1980, PLANT CYTOGENETICS; PETERHANS A, 1990, EMBO J, V9, P3437, DOI 10.1002/j.1460-2075.1990.tb07551.x; PUCHTA H, 1995, PLANT J, V7, P203, DOI 10.1046/j.1365-313X.1995.7020203.x; Puchta H, 1996, TRENDS PLANT SCI, V1, P340; Puchta H, 1996, P NATL ACAD SCI USA, V93, P5055, DOI 10.1073/pnas.93.10.5055; SALOMON S, 1998, IN PRESS EMBO J; Satoh C, 1996, NATURE, V383, P226, DOI 10.1038/383226a0; Shalev G, 1997, GENETICS, V146, P1143; SHEVCHENKO V V, 1990, Radiobiologiya, V30, P728; SHKVARNIKOV P K, 1990, Tsitologiya i Genetika, V24, P33; Sokal R. R., 2012, BIOMETRY; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x; SYOMOV AB, 1992, SCI TOTAL ENVIRON, V112, P1, DOI 10.1016/0048-9697(92)90232-H; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; Wang Shaoke, 1994, Journal of Genetics and Breeding, V48, P113; Ziablitskaia E Ia, 1996, Radiats Biol Radioecol, V36, P498	37	69	72	0	41	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1054	1059		10.1038/3505	http://dx.doi.org/10.1038/3505			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831035				2022-12-25	WOS:000076870100028
J	Chen, ZF; Paquette, AJ; Anderson, DJ				Chen, ZF; Paquette, AJ; Anderson, DJ			NRSF/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis	NATURE GENETICS			English	Article							RESTRICTIVE SILENCER ELEMENT; CELL-ADHESION MOLECULE; SODIUM-CHANNEL GENE; CHICK-EMBRYO; SYNAPSIN-I; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; PROTEIN; VECTORS	The neuron-restrictive silencer factor NRSF (also known as REST and XBR) can silence transcription from neuronal promoters in non-neuronal cell lines, but its function during normal development is unknown. In mice, a targeted mutation of Rest, the gene encoding NRSF, caused derepression of neuron-specific tubulin in a subset of non-neural tissues and embryonic lethality. Mosaic inhibition of NRSF in chicken embryos, using a dominant-negative form of NRSF, also caused derepression of neuronal tubulin, as well as of several other neuronal target genes, in both non-neural tissues and central nervous system neuronal progenitors. These results indicate that NRSF is required to repress neuronal gene expression in vivo, in both extra-neural and undifferentiated neural tissue.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Anderson, DJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							Arnone MI, 1997, DEVELOPMENT, V124, P1851; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; Homburger SA, 1996, DEV DYNAM, V206, P112, DOI 10.1002/(SICI)1097-0177(199605)206:1<112::AID-AJA10>3.0.CO;2-7; Hunter E, 1979, Methods Enzymol, V58, P379; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; KALLUNKI P, IN PRESS P NATL ACAD; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; Kohler J, 1996, NUCLEIC ACIDS RES, V24, P2543, DOI 10.1093/nar/24.13.2543; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOODY SA, 1989, J COMP NEUROL, V279, P567, DOI 10.1002/cne.902790406; MORGAN BA, 1996, METHODS AVIAN EMBRYO, P185; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; Palm K, 1998, J NEUROSCI, V18, P1280; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; Scholl T, 1996, J IMMUNOL, V156, P1448; STRAHLE U, 1994, TRENDS GENET, V10, P75, DOI 10.1016/0168-9525(94)90221-6; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; VANDENBERGH DJ, 1989, NEURON, V3, P507, DOI 10.1016/0896-6273(89)90209-2; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	36	381	387	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					136	142		10.1038/2431	http://dx.doi.org/10.1038/2431			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771705				2022-12-25	WOS:000076231300014
J	Nurse, P; Masui, Y; Hartwell, L				Nurse, P; Masui, Y; Hartwell, L			Understanding the cell cycle	NATURE MEDICINE			English	Editorial Material							DIVISION CYCLE; GENETIC-CONTROL; M-PHASE; OOCYTES; YEAST; MATURATION; EVENTS; EGGS; MPF		Imperial Canc Res Fund, London WC2A 3PX, England; Univ Toronto, Ramsay Wright Zool Labs, Toronto, ON M5S 1A1, Canada; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Cancer Research UK; University of Toronto; Fred Hutchinson Cancer Center	Nurse, P (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.							EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GURDON JB, 1968, BIOL REV, V43, P233, DOI 10.1111/j.1469-185X.1968.tb00960.x; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; KISHIMOTO T, 1976, NATURE, V221, P273; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MURRAY A, 1993, CELL CYCLE; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; WASSERMAN WJ, 1976, SCIENCE, V199, P1266; WASSERMAN WJ, 1978, J CELL BIOL, V78, pR12; WEINTRAUB H, 1982, CR ACAD SCI III-VIE, V295, P787; WOOD WB, 1967, SCI AM, V217, P61	21	116	123	1	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1103	1106		10.1038/2594	http://dx.doi.org/10.1038/2594			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771732				2022-12-25	WOS:000076230100018
J	Roth, FP; Hughes, JD; Estep, PW; Church, GM				Roth, FP; Hughes, JD; Estep, PW; Church, GM			Finding DNA regulatory motifs within unaligned noncoding sequences clustered by whole-genome mRNA quantitation	NATURE BIOTECHNOLOGY			English	Article						functional genomics; gene expression	GENE-EXPRESSION PATTERNS; RESPONSE ELEMENT STRE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CELL-CYCLE; TRANSCRIPTIONAL REGULATION; ACTIVATION SITES; YEAST; PROMOTERS; PROTEINS	Whole-genome mRNA quantitation can be used to identify the genes that are most responsive to environmental or genotypic change. By searching for mutually similar DNA elements among the upstream noncoding DNA sequences of these genes, we can identify candidate regulatory motifs and corresponding candidate sets of coregulated genes. We have tested this strategy by applying it to three extensively studied regulatory systems in the yeast Saccharomyces cerevisiae: galactose response, heat shock, and mating type. Galactose-response data yielded the known binding site of Gal4, and six of nine genes known to be induced by galactose. Heat shock data yielded the cell-cycle activation motif, which is known to mediate cell-cycle dependent activation, and a set of genes coding for all four nucleosomal proteins. Mating type alpha and a data yielded all of the four relevant DNA motifs and most of the known a- and alpha-specific genes.	Harvard Univ, Grad Biophys Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Church, GM (corresponding author), Harvard Univ, Grad Biophys Program, Boston, MA 02115 USA.		Roth, Frederick P/H-6308-2011	Roth, Frederick/0000-0002-6628-649X; church, george/0000-0001-6232-9969				BAILEY TL, 1995, MACH LEARN, V21, P51, DOI 10.1007/BF00993379; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; CHEN P, 1995, J BACTERIOL, V177, P5401, DOI 10.1128/jb.177.19.5401-5410.1995; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; CRAIG EA, 1992, MOL CELLULAR BIOL YE, V2, P501; DeRisi J, 1996, NAT GENET, V14, P457; Frech K, 1997, COMPUT APPL BIOSCI, V13, P89; FREEMAN KB, 1992, MOL CELL BIOL, V12, P5455, DOI 10.1128/MCB.12.12.5455; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lipman DJ, 1997, NUCLEIC ACIDS RES, V25, P3580, DOI 10.1093/nar/25.18.3580; Liu JS, 1995, J AM STAT ASSOC, V90, P1156, DOI 10.2307/2291508; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MILLER MJ, 1982, J BACTERIOL, V151, P311, DOI 10.1128/JB.151.1.311-327.1982; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; NI HT, 1995, MOL MICROBIOL, V16, P1197, DOI 10.1111/j.1365-2958.1995.tb02342.x; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Pennisi E, 1997, SCIENCE, V277, P1432, DOI 10.1126/science.277.5331.1432; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; VASHEE S, 1993, J BIOL CHEM, V268, P24699; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; WENZEL TJ, 1995, NUCLEIC ACIDS RES, V23, P883, DOI 10.1093/nar/23.5.883; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	42	683	724	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					939	945		10.1038/nbt1098-939	http://dx.doi.org/10.1038/nbt1098-939			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788350				2022-12-25	WOS:000076323300029
J	Van Laer, L; Huizing, EH; Verstreken, M; van Zuijlen, D; Wauters, JG; Bossuyt, PJ; Van de Heyning, P; McGuirt, WT; Smith, RJH; Willems, PJ; Legan, PK; Richardson, GP; Van Camp, G				Van Laer, L; Huizing, EH; Verstreken, M; van Zuijlen, D; Wauters, JG; Bossuyt, PJ; Van de Heyning, P; McGuirt, WT; Smith, RJH; Willems, PJ; Legan, PK; Richardson, GP; Van Camp, G			Nonsyndromic hearing impairment is associated with a mutation in DFNA5	NATURE GENETICS			English	Article							PRE-MESSENGER-RNA; FAMILY; GENE; INTRON	Nonsyndromic hearing impairment is one of the most heterogeneous hereditary conditions, with more than 40 loci mapped on the human genome(1), however, only a limited number of genes implicated in hearing loss have been identified. We previously reported linkage to chromosome 7p15 for autosomal dominant hearing impairment segregating in an extended Dutch family(2,3) (DFNA5). Here. we report a further refinement of the DFNA5 candidate region and the isolation of a gene from this region that is expressed in the cochlea. In intron 7 of this gene. we identified an insertion/deletion mutation that does not affect intron-exon boundaries, but deletes five G-triplets at the 3' end of the intron. The mutation co-segregated with deafness in the family and causes skipping of exon 8. resulting in premature termination of the open reading frame. As no physiological function could be assigned, the gene was designated DFNA5.	Univ Instelling Antwerp, Dept Med Genet, B-2610 Antwerp, Belgium; Univ Utrecht Hosp, Dept Otorhinolaryngol, NL-3584 CX Utrecht, Netherlands; Univ Instelling Antwerp, Dept Otorhinolaryngol, B-2610 Antwerp, Belgium; Univ Iowa Hosp & Clin, Dept Otolaryngol, Iowa City, IA 52242 USA; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Antwerp; Utrecht University; Utrecht University Medical Center; University of Antwerp; University of Iowa; University of Sussex	Van Camp, G (corresponding author), Univ Instelling Antwerp, Dept Med Genet, Univ Plein 1, B-2610 Antwerp, Belgium.	gvcamp@uia.ua.ac.be	Heyning, Paul H Vande/I-8278-2017; Van Camp, Guy/F-3386-2013	Heyning, Paul H Vande/0000-0002-8424-3717; Van Camp, Guy/0000-0001-5105-9000; Legan, P. Kevin/0000-0002-7403-6415; Smith, Richard/0000-0003-1201-6731	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003544] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC 03544] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cogan JD, 1997, HUM MOL GENET, V6, P909, DOI 10.1093/hmg/6.6.909; Huizing E H, 1966, Acta Otolaryngol, V61, P161, DOI 10.3109/00016486609127053; Huizing E H, 1966, Acta Otolaryngol, V61, P35, DOI 10.3109/00016486609127040; HUIZING EH, 1983, ACTA OTO-LARYNGOL, V95, P620, DOI 10.3109/00016488309139453; HUIZING EH, 1972, AUDIOLOGY, V11, P261; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x; Van Laer L, 1997, EUR J HUM GENET, V5, P397, DOI 10.1159/000484798; VanCamp G, 1997, AM J HUM GENET, V60, P758; VANCAMP G, 1995, HUM MOL GENET, V4, P2159; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P336; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P233; WAUTERS JG, 1992, CYTOGENET CELL GENET, V60, P194, DOI 10.1159/000133334; Xu Y, 1994, Genet Eng (N Y), V16, P241; Zhang MQ, 1997, P NATL ACAD SCI USA, V94, P565, DOI 10.1073/pnas.94.2.565	21	234	243	2	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1998	20	2					194	197						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771715				2022-12-25	WOS:000076231300024
J	Magnaghi, P; Roberts, C; Lorain, S; Lipinski, M; Scambler, PJ				Magnaghi, P; Roberts, C; Lorain, S; Lipinski, M; Scambler, PJ			HIRA, a mammalian homologue of Saccharomyces cerevisiae transcriptional co-repressors, interacts with Pax3	NATURE GENETICS			English	Article							CONGENITAL HEART-DISEASE; DIGEORGE-SYNDROME; NEURAL CREST; WAARDENBURG-SYNDROME; VELOCARDIOFACIAL SYNDROMES; CRITICAL REGION; CANDIDATE GENE; MOUSE; 22Q11; MUTANT	HIRA maps to the DiGeorge/velocardiofacial syndrome critical region (DGCR) at 22q11 (refs 1,2) and encodes a WD40 repeat protein similar to yeast Hir1p and Hir2p. These transcriptional co-repressors regulate cell cycle-dependent histone gene transcription(3), possibly by remodelling local chromatin structure. We report an interaction between HIRA and the transcription factor Pax3. Pax3 haploinsufficiency results in the mouse splotch and human Waardenburg syndrome (WSI and WSIII) phenotypes. Mice homozygous for Pax3 mutations die in utero with a phenocopy of DCS, or neonatally with neural tube defects. HIRA was also found to interact with core histones. Thus, altered stoichiometry of complexes containing HIRA may be important for the development of structures affected in WS and DCS.	Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Inst Gustave Roussy, CNRS UMR1598, Lab Biol Tumeurs Humaines, F-94805 Villejuif, France	University of London; University College London; UNICANCER; Gustave Roussy	Scambler, PJ (corresponding author), Inst Child Hlth, Mol Med Unit, 30 Guilford St, London WC1N 1EH, England.		Scambler, Peter/AAZ-6026-2020; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628; Lorain, Stephanie/0000-0001-5266-9994				BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Budarf ML, 1997, HUM MOL GENET, V6, P1657, DOI 10.1093/hmg/6.10.1657; Carlson C, 1997, AM J HUM GENET, V61, P620, DOI 10.1086/515508; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Conway SJ, 1997, DEVELOPMENT, V124, P505; Dallapiccola B, 1996, AM J HUM GENET, V59, P7; Daw SCM, 1996, NAT GENET, V13, P458, DOI 10.1038/ng0896-458; EDMUNDSON DG, 1996, GENE DEV, V10, P1247; FRANZ T, 1989, ANAT EMBRYOL, V180, P457, DOI 10.1007/BF00305120; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HALFORD S, 1993, HUM MOL GENET, V2, P2099, DOI 10.1093/hmg/2.12.2099; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JOSTES B, 1991, MECH DEVELOP, V33, P27; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; Kurahashi H, 1996, AM J HUM GENET, V58, P1377; LAMOUR V, 1995, HUM MOL GENET, V4, P791, DOI 10.1093/hmg/4.5.791; LORAIN S, 1998, IN PRESS MOL CELL BI; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Mansouri A, 1996, DEVELOPMENT, V122, P831; MOASE CE, 1990, TERATOLOGY, V42, P171, DOI 10.1002/tera.1420420208; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Rizzu P, 1996, MAMM GENOME, V7, P639, DOI 10.1007/s003359900197; Roberts C, 1997, HUM MOL GENET, V6, P237, DOI 10.1093/hmg/6.2.237; Spector MS, 1997, MOL CELL BIOL, V17, P545, DOI 10.1128/MCB.17.2.545; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; Wilming LG, 1997, HUM MOL GENET, V6, P247, DOI 10.1093/hmg/6.2.247; ZAPPAVIGNA V, 1996, EMBO J, V15, P5981; ZLOTOGORA J, 1995, AM J HUM GENET, V56, P1173	30	104	108	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					74	77		10.1038/1739	http://dx.doi.org/10.1038/1739			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731536				2022-12-25	WOS:000075671400024
J	Motoyama, J; Liu, J; Mo, R; Ding, Q; Post, M; Hui, CC				Motoyama, J; Liu, J; Mo, R; Ding, Q; Post, M; Hui, CC			Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus	NATURE GENETICS			English	Article							PALLISTER-HALL SYNDROME; SONIC-HEDGEHOG; PATCHED GENE; MOUSE; MORPHOGENESIS; INVOLVEMENT; EXPRESSION; INDUCTION; POLARITY; MESODERM	Foregut malformations (oesophageal atresia. tracheo-oesophageal fistula, lung anomalies and congenital stenosis of the oesophagus and trachea) are relatively common anomalies occurring in 1 in 2,000-5,000 live births, although their aetiology is poorly understood(1). The secreted glycoprotein Sonic hedgehog (Shh) has been suggested to act as an endodermal signal that controls hindgut patterning(2) and lung growth(3). In mice, three zinc-finger transcription factors, Gli1, Gli2 and Gli3, have been implicated in the transduction of Shh signal(4-10). We report here that mutant mice lacking Gli2 function exhibit Foregut defects, including stenosis of the oesophagus and trachea, as well as hypoplasia and lobulation defects of the lung. A reduction of 50% in the gene dosage of Gli3 in a Gli2(-/-) background resulted in oesophageal atresia with tracheo-oesophageal fistula and a severe lung phenotype. Mutant mice lacking both Gli2 and Gli3 function did not form oesophagus, trachea and lung. These results indicate that Gli2 and Gli3 possess specific and overlapping functions in Shh signalling during foregut development, and suggest that mutations in GLI genes may be involved in human foregut malformations.	Hosp Sick Children, Res Inst, Programs Dev Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Program Lung Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Program Canc & Blood, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Hui, CC (corresponding author), Hosp Sick Children, Res Inst, Programs Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cchui@sickkids.on.ca						Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; Biesecker LG, 1997, NAT GENET, V17, P259, DOI 10.1038/ng1197-259; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ding Q, 1998, DEVELOPMENT, V125, P2533; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; GASCA S, 1995, DEV GENET, V17, P141, DOI 10.1002/dvg.1020170206; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Masuya H, 1997, DEV BIOL, V182, P42, DOI 10.1006/dbio.1996.8457; Mo R, 1997, DEVELOPMENT, V124, P113; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Skandalakis JE., 1994, EMBRYOLOGY SURG; SPOONER BS, 1970, J EXP ZOOL, V175, P445, DOI 10.1002/jez.1401750404; Takabatake T, 1997, FEBS LETT, V410, P485, DOI 10.1016/S0014-5793(97)00645-5; VERLOES A, 1995, J MED GENET, V32, P605, DOI 10.1136/jmg.32.8.605; WESSELLS NK, 1970, J EXP ZOOL, V175, P455, DOI 10.1002/jez.1401750405	27	412	431	2	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					54	57		10.1038/1711	http://dx.doi.org/10.1038/1711			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731531				2022-12-25	WOS:000075671400019
J	Grassy, G; Calas, B; Yasri, A; Lahana, R; Woo, JK; Iyer, S; Kaczorek, M; Floc'h, R; Buelow, R				Grassy, G; Calas, B; Yasri, A; Lahana, R; Woo, JK; Iyer, S; Kaczorek, M; Floc'h, R; Buelow, R			Computer-assisted rational design of immunosuppressive compounds	NATURE BIOTECHNOLOGY			English	Article						virtual screening; virtual chemistry; applied immunology	HLA CLASS-I; 3-DIMENSIONAL STRUCTURE; ALLOGRAFT SURVIVAL; PROLONGATION; PARAMETERS; PEPTIDE; MICE; RATS	We describe the rational design of immunosuppressive peptides without relying on information regarding their receptors or mechanisms of action. The design strategy uses a variety of topological and shape descriptors in combination with an analysis of molecular dynamics trajectories for the identification of potential drug candidates. This strategy was applied to the development of immunosuppressive peptides with enhanced potency. The lead compounds were peptides, derived from the heavy chain of HLA class I, that modulate immune responses in vitro and in vivo. In particular, a peptide derived from HLA-B2702, amino acids 75-84 (2702.75-84) prolonged skin and heart allograft survival in mice. The biological activity of the rationally designed peptides was tested in a heterotopic mouse heart allograft model. The molecule predicted to be most potent displayed an immunosuppressive activity approximately 100 times higher than the lead compound.	Syntem, F-30000 Nimes, France; Fac Pharm Montpellier, Ctr Biochim Struct, CNRS, UMR 9955,INSERM,U414, F-34060 Montpellier, France; CNRS, UPR 9008, CRBM, F-34000 Montpellier, France; SangStat Med Corp, Menlo Pk, CA USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lahana, R (corresponding author), Syntem, Parc Sci Georges Besse, F-30000 Nimes, France.	rlahana@synte.ecrie.fr	GRASSY, Gerard/E-4865-2013	Yasri, Abdelaziz/0000-0002-7513-9037				BALABAN AT, 1982, CHEM PHYS LETT, V89, P399, DOI 10.1016/0009-2614(82)80009-2; BROTO P, 1984, EUR J MED CHEM, V19, P61; BUELOW R, 1995, TRANSPLANTATION, V59, P455; BUELOW R, 1995, TRANSPLANTATION, V59, P649, DOI 10.1097/00007890-199503150-00001; CLAYBERGER C, 1993, TRANSPLANT P, V25, P477; CUTURI MC, 1995, TRANSPLANTATION, V59, P661, DOI 10.1097/00007890-199503150-00003; DEVILLERS J, 1994, QSAR MOL MODELLING C, P57; Gao L, 1996, J HEART LUNG TRANSPL, V15, P78; GHOSE AK, 1986, J COMPUT CHEM, V7, P565, DOI 10.1002/jcc.540070419; Giral M, 1997, TRANSPLANTATION, V63, P1004, DOI 10.1097/00007890-199704150-00017; GOOD AC, 1993, J MED CHEM, V36, P433, DOI 10.1021/jm00056a002; Grassy G, 1995, J MOL GRAPHICS, V13, P356, DOI 10.1016/0263-7855(95)00079-8; GRASSY G, 1993, TRENDS QSAR MOL MODE, P216; HALL LH, 1992, REV COMPUTATIONAL CH; Hatch KL, 1998, QUANT STRUCT-ACT REL, V17, P20, DOI 10.1002/(SICI)1521-3838(199801)17:01<20::AID-QSAR20>3.3.CO;2-6; HYDE RM, 1988, J COMPUT AID MOL DES, V2, P145, DOI 10.1007/BF01532089; Iyer S, 1998, J BIOL CHEM, V273, P2692, DOI 10.1074/jbc.273.5.2692; LaniadoSchwartzman M, 1997, BIOCHEM PHARMACOL, V53, P1069, DOI 10.1016/S0006-2952(97)00080-4; MIHALIC Z, 1992, J CHEM EDUC, V69, P701, DOI 10.1021/ed069p701; Nikolovska-Coleska Z, 1998, QUANT STRUCT-ACT REL, V17, P7, DOI 10.1002/(SICI)1521-3838(199801)17:01<07::AID-QSAR7>3.3.CO;2-E; NISCO S, 1994, J IMMUNOL, V152, P3786; Nossner E, 1996, J EXP MED, V183, P339, DOI 10.1084/jem.183.2.339; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; SEYDEL JK, 1993, TRENDS QSAR MOL MODE, P120; WIENER H, 1947, J AM CHEM SOC, V69, P2636, DOI 10.1021/ja01203a022; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 1997, TRANSPLANTATION, V64, P1460, DOI 10.1097/00007890-199711270-00015; WOO J, 1998, IN PRESS TRANSPLANTA; Yasri A, 1996, PROTEIN ENG, V9, P959, DOI 10.1093/protein/9.11.959	29	109	128	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					748	752		10.1038/nbt0898-748	http://dx.doi.org/10.1038/nbt0898-748			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702773				2022-12-25	WOS:000075183400032
J	Rendahl, KG; Leff, SE; Otten, GR; Spratt, SK; Bohl, D; Van Roey, M; Donahue, BA; Cohen, LK; Mandel, RJ; Danos, O; Snyder, RO				Rendahl, KG; Leff, SE; Otten, GR; Spratt, SK; Bohl, D; Van Roey, M; Donahue, BA; Cohen, LK; Mandel, RJ; Danos, O; Snyder, RO			Regulation of gene expression in vivo following transduction by two separate rAAV vectors	NATURE BIOTECHNOLOGY			English	Article						gene therapy; erythropoietin; tetracycline	TRANSGENIC MICE; SKELETAL-MUSCLE; MAMMALIAN-CELLS; PROTEIN; TISSUE	Control of gene expression is important to gene therapy for purposes of both dosing and safety. In vivo regulation of gene expression was demonstrated following co-injection of two separate recombinant adeno-associated virus vectors, one encoding an inducible murine erythropoietin transgene and the other a transcriptional activator, directly into the skeletal muscle of adult immunocompetent mice. Transcription was controlled by systemic administration or withdrawal of tetracycline over an 18 week period, demonstrating that the two vectors were capable of transducing the same cell. Cellular or humoral immune responses against the transactivator protein were not detected.	Cell Genesys Inc, Foster City, CA 94404 USA; Inst Pasteur, Lab RTG, Dept SIDA Retrovirus, F-75015 Paris, France	Cell Genesys Inc; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Snyder, RO (corresponding author), Cell Genesys Inc, Foster City, CA 94404 USA.		Bohl, Delphine/L-8709-2016; Wilson, Matthew H/K-3193-2013					Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; Clark KR, 1997, HUM GENE THER, V8, P659, DOI 10.1089/hum.1997.8.6-659; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOODMAN S, 1994, BLOOD, V84, P1492; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL ZW, 1989, CELL, V59, P771, DOI 10.1016/0092-8674(89)90597-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Mandel RJ, 1998, J NEUROSCI, V18, P4271; Manning WC, 1997, J VIROL, V71, P7960, DOI 10.1128/JVI.71.10.7960-7962.1997; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; Naffakh N, 1996, MOL MED TODAY, V2, P343, DOI 10.1016/1357-4310(96)81800-4; Neering SJ, 1996, BLOOD, V88, P1147, DOI 10.1182/blood.V88.4.1147.bloodjournal8841147; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Rinsch C, 1997, HUM GENE THER, V8, P1881, DOI 10.1089/hum.1997.8.16-1881; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	31	97	144	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					757	761		10.1038/nbt0898-757	http://dx.doi.org/10.1038/nbt0898-757			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702775				2022-12-25	WOS:000075183400034
J	Geller, DS; Rodriguez-Soriano, J; Boado, AV; Schifter, S; Bayer, M; Chang, SS; Lifton, RP				Geller, DS; Rodriguez-Soriano, J; Boado, AV; Schifter, S; Bayer, M; Chang, SS; Lifton, RP			Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I	NATURE GENETICS			English	Article							EPITHELIAL SODIUM-CHANNEL; RNA SPLICE JUNCTIONS; BETA-SUBUNIT; ALDOSTERONE; SALT; CORTICOSTERONE; HYPERTENSION	Pseudohypoaldosteronism type I (PHA1) is characterized by neonatal renal salt wasting with dehydration, hypotension, hyperkalaemia and metabolic acidosis, despite elevated aldosterone levels. Two forms of PHA1 exist. An autosomal recessive form features severe disease with manifestations persisting into adulthood(1). This form is caused by toss-of-function mutations in genes encoding subunits of the amiloride-sensitive epithelial sodium channel (ENaC; refs 2,3). Autosomal dominant or sporadic PHA1 is a milder disease that remits with age. Among six dominant and seven sporadic PHA1 kindreds, we have found no ENaC gene mutations, implicating mutations in other genes. As ENaC activity in the kidney is regulated by the steroid hormone aldosterone acting through the mineralocorticoid receptor(4), we have screened the mineralocorticoid receptor gene (MLR) for variants and have identified heterozygous mutations in one sporadic and four dominant kindreds. These include two frameshift mutations tone a de novo mutation), two premature termination codons and one splice donor mutation. These mutations segregate with PHA1 and are not found in unaffected subjects. These findings demonstrate that heterozygous MLR mutations cause PHA1, underscore the important role of mineralocorticoid receptor function in regulation of salt and blood pressure homeostasis in humans and motivate further study of this gene for a potential role in blood pressure variation.	Yale Univ, Sch Med, Dept Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Hosp Cruces, Dept Pediat, E-48903 Barakaldo, Spain; Glostrup Cty Hosp, Dept Clin Physiol & Nucl Med, DK-2600 Glostrup, Denmark; Charles Univ, Fac Med 1, Dept Pediat, Prague, Czech Republic	Howard Hughes Medical Institute; Yale University; Yale University; Hospital Universitario Cruces; University of Copenhagen; Charles University Prague	Lifton, RP (corresponding author), Yale Univ, Sch Med, Dept Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.							ARAI K, 1995, J CLIN ENDOCR METAB, V80, P814, DOI 10.1210/jc.80.3.814; BAYER M, 1993, ACTA PAEDIATR, V82, P504, DOI 10.1111/j.1651-2227.1993.tb12736.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Berger S, 1996, ENDOCR RES, V22, P641, DOI 10.1080/07435809609043758; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; EPPLE HJ, 1995, AM J PHYSIOL-GASTR L, V269, pG42, DOI 10.1152/ajpgi.1995.269.1.G42; GomezSanchez EP, 1996, STEROIDS, V61, P184, DOI 10.1016/0039-128X(96)00010-4; Grunder S, 1997, CURR OPIN NEPHROL HY, V6, P35; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; KOMESAROFF PA, 1994, J CLIN ENDOCR METAB, V79, P27, DOI 10.1210/jc.79.1.27; KOO WWK, 1982, ARCH DIS CHILD, V57, P500, DOI 10.1136/adc.57.7.500; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kuhnle U, 1997, MOL CELL ENDOCRINOL, V133, P77, DOI 10.1016/S0303-7207(97)00149-4; LimTio SS, 1997, ENDOCRINOLOGY, V138, P2537, DOI 10.1210/en.138.6.2537; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P4996, DOI 10.1073/pnas.89.11.4996; PETERSEN S, 1978, ACTA PAEDIATR SCAND, V67, P255, DOI 10.1111/j.1651-2227.1978.tb16314.x; RODRIGUEZSORIANO J, 1990, PEDIATR NEPHROL, V4, P105, DOI 10.1007/BF00858819; ROSLER A, 1984, J CLIN ENDOCR METAB, V59, P689; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SIPPELL WG, 1980, PEDIATR RES, V14, P39, DOI 10.1203/00006450-198014010-00010; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016; ZENNARO MC, 1994, J CLIN ENDOCR METAB, V79, P32, DOI 10.1210/jc.79.1.32	24	253	259	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					279	281		10.1038/966	http://dx.doi.org/10.1038/966			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662404				2022-12-25	WOS:000074565900027
J	McKee, C; Gibson, A; Dalrymple, M; Emslie, L; Garner, I; Cottingham, I				McKee, C; Gibson, A; Dalrymple, M; Emslie, L; Garner, I; Cottingham, I			Production of biologically active salmon calcitonin in the milk of transgenic rabbits	NATURE BIOTECHNOLOGY			English	Article						protein processing; posttranslational modification; bioreactor; mammary gland	BOVINE ENTEROKINASE; PEPTIDE; PROTEINS; BIOSYNTHESIS; SPECIFICITY; EXPRESSION; AMIDATION; MICE	Salmon calcitonin (sCT) is an example of one of the many bioactive peptides that require amidation of the carboxy terminus for full potency. We describe a method for the production of amidated sCT in the mammary gland of transgenic rabbits. Expression of a fusion protein comprising human alpha lactalbumin joined by an enterokinase cleavable linker to sCT was directed to the mammary gland under the control of the ovine beta lactoglobulin promoter. C-terminal amidation in vivo was achieved by extending the sCT by a single glycine residue that provides a substrate for endogenous amidating activity in the mammary gland. Full characterization of the released sCT demonstrated it to be equivalent to synthetic standard in terms of structure, purity, and potency.	PPL Therapeut Ltd, Edinburgh EH25 9PP, Midlothian, Scotland		McKee, C (corresponding author), PPL Therapeut Ltd, Edinburgh EH25 9PP, Midlothian, Scotland.	McKee@pplros.demon.co.uk						AVRAMIDES A, 1977, CLIN ORTHOP RELAT R, P78; BREW K, 1975, REV PHYSIOL BIOCH P, V72, P105, DOI 10.1007/BFb0031548; CONNOLLY JM, 1988, LIFE SCI, V42, P1751, DOI 10.1016/0024-3205(88)90041-0; CUDD A, 1995, J PHARM SCI, V84, P717, DOI 10.1002/jps.2600840610; DEVINOY E, 1994, TRANSGENIC RES, V3, P79, DOI 10.1007/BF01974085; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EPAND RM, 1988, J MED CHEM, V31, P1595, DOI 10.1021/jm00403a019; HAN KK, 1992, INT J BIOCHEM, V24, P1349, DOI 10.1016/0020-711X(92)90060-E; Kelley WS, 1996, BIO-TECHNOL, V14, P28, DOI 10.1038/nbt0196-28; KUMAR MA, 1965, J ENDOCRINOL, V33, P469, DOI 10.1677/joe.0.0330469; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LIGHT A, 1980, ANAL BIOCHEM, V106, P199, DOI 10.1016/0003-2697(80)90138-4; LINDAHL L, 1984, ANAL BIOCHEM, V140, P394, DOI 10.1016/0003-2697(84)90184-2; Lubon H, 1996, TRANSFUS MED REV, V10, P131, DOI 10.1016/S0887-7963(96)80089-7; MUNDY GR, 1994, OSTEOPOROSIS, V20, P557; RAY MVL, 1993, BIO-TECHNOL, V11, P64, DOI 10.1038/nbt0193-64; SHAH GV, 1989, ENDOCRINOLOGY, V125, P61, DOI 10.1210/endo-125-1-61; SILVA OL, 1973, ARCH INTERN MED, V132, P337, DOI 10.1001/archinte.132.3.337; STACEY A, 1995, P NATL ACAD SCI USA, V92, P2835, DOI 10.1073/pnas.92.7.2835; STREWLER GJ, 1989, ENDOCRINOLOGY, V124, P152; TAMBURINI PP, 1990, INT J PEPT PROT RES, V35, P153; WALLIS M, 1995, BIOCH POLYPEPTIDE HO, P336; WRIGHT G, 1991, BIO-TECHNOL, V9, P77	23	41	48	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					647	651		10.1038/nbt0798-647	http://dx.doi.org/10.1038/nbt0798-647			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661198				2022-12-25	WOS:000074521800028
J	Pearce, DA; Ferea, T; Nosel, SA; Das, B; Sherman, F				Pearce, DA; Ferea, T; Nosel, SA; Das, B; Sherman, F			Action of BTN1, the yeast orthologue of the gene mutated in Batten disease	NATURE GENETICS			English	Article							MITOCHONDRIAL ATP SYNTHASE; NEURONAL CEROID-LIPOFUSCINOSIS; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; SUBUNIT-C; MEMBRANE; PROTEIN; EXPRESSION; STORAGE; MUTANTS	Neuronal ceroid-lipofuscinoses (NCL) are autosomal recessive disorders that form the most common group of progressive neurodegenerative diseases in children, with an incidence as high as 1 in 12,500 live births, and with approximately 440,000 carriers in the United States(1,2). Disease progression is characterized by a decline in mental abilities, increased severity of untreatable seizures, blindness, loss of motor skills and premature death. The CLN3 gene, which is responsible for Batten disease, has been positionally cloned(3). The yeast gene, denoted BTN1, encodes a non-essential protein that is 39% identical and 59% similar to human CLN3 (ref. 4). Strains lacking Btn1p, btn1-Delta, are resistant to D-(-)-threo-2-amino-1-[p-nitrophenyl]-1,3-propanediol (ANP) in a pH-dependent manner(5). This phenotype was complemented by expression of human CLN3, demonstrating that yeast Btn1p and human CLN3 share the same function(5). Here, we report that btn1-Delta yeast strains have an abnormally acidic vacuolar pH in the early phases of growth. Furthermore, DNA microarray analysis of BTN1 and btn1-Delta strains revealed differential expression of two genes, with at least one, HSP30, involved in pH control. Because Btn1p is located in the vacuole, we suggest that Batten disease is caused by a defect in vacuolar (lysosomal) pH control. Our findings draw parallels between fundamental biological processes in yeast and previously observed characteristics of neurodegeneration in humans.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	University of Rochester; Stanford University	Pearce, DA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.		Das, Biswadip/AAN-6505-2021	Das, Biswadip/0000-0002-2839-2048	NCI NIH HHS [CA 36856] Funding Source: Medline; NINDS NIH HHS [R01 NS36610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE P, 1992, AM J MED GENET, V42, P549, DOI 10.1002/ajmg.1320420426; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; Croopnick JB, 1998, BIOCHEM BIOPH RES CO, V250, P335, DOI 10.1006/bbrc.1998.9272; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; GOEBEL HH, 1995, J CHILD NEUROL, V10, P424, DOI 10.1177/088307389501000602; HALL NA, 1991, BIOCHEM J, V275, P269, DOI 10.1042/bj2750269; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; HEMENWAY CS, 1995, GENETICS, V141, P833; Jarvela I, 1998, HUM MOL GENET, V7, P85, DOI 10.1093/hmg/7.1.85; KOENIG H, 1964, J NEUROPATH EXP NEUR, V23, P191; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MORANO KA, 1994, J CELL SCI, V107, P2813; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pearce DA, 1998, P NATL ACAD SCI USA, V95, P6915, DOI 10.1073/pnas.95.12.6915; Pearce DA, 1997, YEAST, V13, P691, DOI 10.1002/(SICI)1097-0061(19970630)13:8<691::AID-YEA123>3.0.CO;2-D; Pearce DA, 1999, MOL GENET METAB, V66, P320, DOI 10.1006/mgme.1999.2819; Pearce DA, 1999, MOL GENET METAB, V66, P314, DOI 10.1006/mgme.1999.2820; Piper PW, 1997, CELL STRESS CHAPERON, V2, P12, DOI 10.1379/1466-1268(1997)002<0012:HTIPMH>2.3.CO;2; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	26	147	152	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					55	58		10.1038/8861	http://dx.doi.org/10.1038/8861			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319861				2022-12-25	WOS:000080096300022
J	Roy, K; Mao, HQ; Huang, SK; Leong, KW				Roy, K; Mao, HQ; Huang, SK; Leong, KW			Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy	NATURE MEDICINE			English	Article							CHOLERA-TOXIN; IN-VIVO; DRUG-DELIVERY; IGE ANTIBODY; IMMUNIZATION; INDUCTION; ANAPHYLAXIS; ABSORPTION; INHIBITION; IMMUNITY	Food allergy is a common and often fatal disease with no effective treatment. We describe here a new immunoprophylactic strategy using oral allergen-gene immunization to modulate peanut antigen-induced murine anaphylactic responses. Oral administration of DNA nanoparticles synthesized by complexing plasmid DNA with chitosan, a natural biocompatible polysaccharide, resulted in transduced gene expression in the intestinal epithelium. Mice receiving nanoparticles containing a dominant peanut allergen gene (pCMVArah2) produced secretory IgA and serum lgG2a. Compared with non-immunized mice or mice treated with 'naked' DNA, mice immunized with nanoparticles showed a substantial reduction in allergen-induced anaphylaxis associated with reduced levels of IgE, plasma histamine and vascular leakage. These results demonstrate that oral allergen-gene immunization with chitosan-DNA nanoparticles is effective in modulating murine anaphylactic responses, and indicate its prophylactic utility in treating food allergy.	Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Leong, KW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.		Leong, Kam W/A-7270-2009; Huang, Shau-Ku/F-5509-2010	Leong, Kam W/0000-0002-8133-4955; Mao, Hai-Quan/0000-0002-4262-9988	NATIONAL CANCER INSTITUTE [R01CA068011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040274, R29AI034002] Funding Source: NIH RePORTER; NCI NIH HHS [CA68011] Funding Source: Medline; NIAID NIH HHS [AI40274, AI34002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai K., 1968, B TOKAI REG FISH LAB, V56, P889; ARTURSSON P, 1994, PHARMACEUT RES, V11, P1358, DOI 10.1023/A:1018967116988; Aspden TJ, 1997, J PHARM SCI, V86, P509, DOI 10.1021/js960182o; Bernkop-Schnurch A, 1998, J CONTROL RELEASE, V50, P215, DOI 10.1016/S0168-3659(97)00136-3; BODMEIER R, 1989, PHARMACEUT RES, V6, P413, DOI 10.1023/A:1015987516796; Chen SC, 1998, J VIROL, V72, P5757, DOI 10.1128/JVI.72.7.5757-5761.1998; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Etchart N, 1997, J GEN VIROL, V78, P1577, DOI 10.1099/0022-1317-78-7-1577; Ferrari F, 1997, FARMACO, V52, P493; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450; KANAUCHI O, 1994, BIOSCI BIOTECH BIOCH, V58, P1617, DOI 10.1271/bbb.58.1617; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Lee WY, 1998, ARZNEIMITTELFORSCH, V48, P300; Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6; LYCKE N, 1990, J IMMUNOL, V145, P3316; MAEZAKI Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1439, DOI 10.1271/bbb.57.1439; MIYAZAKI S, 1994, BIOL PHARM BULL, V17, P745; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; ROY K, 1997, 24 INT S CONTR REL B, V24, P673; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SNIDER DP, 1994, J IMMUNOL, V153, P647; STROBER W, 1994, IMMUNOLOGY, P541; TAKEUCHI H, 1994, CHEM PHARM BULL, V42, P1954; Tozaki H, 1997, J PHARM SCI, V86, P1016, DOI 10.1021/js970018g; Ulmer J B, 1997, Behring Inst Mitt, P79; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG QF, 1997, J ALLERGY CLIN IMMUN, V99, P480; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	35	929	1012	5	206	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					387	391		10.1038/7385	http://dx.doi.org/10.1038/7385			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202926				2022-12-25	WOS:000079574300026
J	Irby, RB; Mao, WG; Coppola, D; Kang, J; Loubeau, JM; Trudeau, W; Karl, R; Fujita, DJ; Jove, R; Yeatman, TJ				Irby, RB; Mao, WG; Coppola, D; Kang, J; Loubeau, JM; Trudeau, W; Karl, R; Fujita, DJ; Jove, R; Yeatman, TJ			Activating SRC mutation in a subset of advanced human colon cancers	NATURE GENETICS			English	Article							PROTEIN-KINASE ACTIVITY; C-SRC; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; SARCOMA VIRUS; PP60C-SRC; CARCINOMA; ONCOGENES; MUTANTS; REGION	The discovery of Rous sarcoma virus (RSV) led to the identification of cellular Src (c-Src), a non-receptor tyrosine kinase, which has since been implicated in the development of numerous human cancers(1-4). c-Src has been found to be highly activated in colon cancers, particularly in those metastatic to the liver(5-11) Studies of the mechanism of c-Src regulation have suggested that c-Src kinase activity is downregulated by phosphorylation of a critical carboxy-terminal tyrosine (Tyr 530 in human c-Src, equivalent to Tyr 527 in chicken Src) and have implied the existence of activating mutations in this C-terminal regulatory region(12-18). We report here the identification of a truncating mutation in SRC at codon 531 in 12% of cases of advanced human colon cancer tested and demonstrate that the mutation is activating, transforming, tumorigenic and promotes metastasis. These results provide, for the first time, genetic evidence that activating SRC mutations may have a role in the malignant progression of human colon cancer.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ Calgary, Med Ctr, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Calgary	Yeatman, TJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Surg, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA055652, K11CA065512] Funding Source: NIH RePORTER; NCI NIH HHS [CA65512, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; Guo Z, 1997, NAT BIOTECHNOL, V15, P331, DOI 10.1038/nbt0497-331; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TALAMONTI MA, 1991, J CLIN INVEST, V91, P53; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	28	414	431	3	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					187	190		10.1038/5971	http://dx.doi.org/10.1038/5971			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988270				2022-12-25	WOS:000078399500020
J	Liu, D; Matzuk, MM; Sung, WK; Guo, QX; Wang, P; Wolgemuth, DJ				Liu, D; Matzuk, MM; Sung, WK; Guo, QX; Wang, P; Wolgemuth, DJ			Cyclin A1 is required for meiosis in the male mouse	NATURE GENETICS			English	Article							MALE GERM-CELL; DIFFERENTIAL EXPRESSION; PROMOTING FACTOR; MESSENGER-RNA; GENE; SPECIFICITY; ONCOGENESIS; COMPLEXES; DISTINCT; TESTIS	The mammalian A-type cyclin family consists of two members. cyclin Al (encoded by Ccna1) and cyclin AZ (encoded by Ccna2). Cyclin AZ promotes both G1/S and G2/M transitions(1,2), and targeted deletion of Ccna2 in mouse is embryonic lethal(3). Cyclin Al is expressed in mice exclusively in the germ cell lineage(4) and is expressed in humans at highest levels in the testis and certain myeloid leukaemia cells(5,6). To investigate the role of cyclin Al and possible redundancy among the cyclins in vivo, we generated mice bearing a null mutation of Ccna1. Ccna1(-/-) males were sterile due to a block of spermatogenesis before the first meiotic division, whereas females were normal. Meiosis arrest in Ccna1(-/-) males was associated with increased germ cell apoptosis, desynapsis abnormalities and reduction of Cdc2 kinase activation at the end of meiotic prophase. Cyclin Al is therefore essential for spermatocyte passage into the first meiotic division in mate mice, a function that cannot be complemented by the concurrently expressed B-type cyclins.	Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Irving Comprehens Canc Ctr, New York, NY 10032 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Wolgemuth, DJ (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, 630 W 168th St, New York, NY 10032 USA.	djw3@columbia.edu		Wang, Pei/0000-0003-2373-7315				ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; CHAPMAN DL, 1994, DEV BIOL, V165, P500, DOI 10.1006/dbio.1994.1270; Dix DJ, 1997, DEVELOPMENT, V124, P4595; DRESSER ME, 1979, EXP CELL RES, V121, P416, DOI 10.1016/0014-4827(79)90023-5; DUGGAL RN, 1987, ANN NY ACAD SCI, V513, P112, DOI 10.1111/j.1749-6632.1987.tb25002.x; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOETZ P, 1984, J CELL SCI, V65, P249; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; KREMER EJ, 1991, EXP CELL RES, V197, P330, DOI 10.1016/0014-4827(91)90442-W; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sweeney C, 1996, DEVELOPMENT, V122, P53; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207; Yang R, 1997, CANCER RES, V57, P913	25	287	300	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					377	380		10.1038/3855	http://dx.doi.org/10.1038/3855			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843212				2022-12-25	WOS:000077199600027
J	Rossi, FMV; Guicherit, OM; Spicher, A; Kringstein, AM; Fatyol, K; Blakely, BT; Blau, HM				Rossi, FMV; Guicherit, OM; Spicher, A; Kringstein, AM; Fatyol, K; Blakely, BT; Blau, HM			Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16	NATURE GENETICS			English	Article							MAMMALIAN-CELLS; GENE-EXPRESSION; ANTIBIOTIC-RESISTANCE; RETROVIRAL VECTORS; PRIMARY MYOBLASTS; TET REPRESSOR; COMPLEX; SYSTEM; PROMOTERS; DESIGN	Continuous regulation is required to maintain a given cell state(1,2) or to allow it to change in response to the environment(3,4). Studies of the mechanisms underlying such regulation have often been hindered by the inability to control gene expression at will. Among the inducible systems available for regulating gene expression in eukaryotes(5-8), the tetracycline (tet) regulatable system has distinct advantages(9-11). It is highly specific, non-toxic and non-eukaryotic, and consequently does not have pleiotropic effects on host cell genes. Previously this system also had drawbacks, as it did not extinguish gene expression completely, precluding the study of toxic or growth-inhibitory gene products. We report here the development of a facile reversible tetracycline-inducible retroviral system (designated RetroTet-ART) in which activators and repressors together are expressed in cells. Gene expression can now be actively repressed in the absence of tet and induced in the presence of tet, as we have engineered distinct dimerization domains that allow co-expression of homodimeric tet-regulated transactivators and transrepressors in the same cells, without the formation of non-functional heterodimers. Using this system, we show that growth arrest by the cell cycle inhibitor p16 is reversible and dependent on its continuous expression.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Rossi, Fabio MV/B-5587-2013	Rossi, Fabio MV/0000-0002-0368-2620	NCI NIH HHS [CA59717] Funding Source: Medline; NIA NIH HHS [AG09521] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA059717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Dupin E, 1998, CURR TOP DEV BIOL, V36, P1; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GALBRAITH DW, IN PRESS METH CELL B; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kringstein AM, 1998, P NATL ACAD SCI USA, V95, P13670, DOI 10.1073/pnas.95.23.13670; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Poulos NE, 1996, CANCER RES, V56, P1719; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPICHER A, 1994, DEV BIOL, V164, P72, DOI 10.1006/dbio.1994.1181; Springer ML, 1997, SOMAT CELL MOLEC GEN, V23, P203, DOI 10.1007/BF02721371; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; ZHAO J, 1992, MICROBIOL IMMUNOL, V36, P1051, DOI 10.1111/j.1348-0421.1992.tb02109.x	31	91	97	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					389	393		10.1038/3871	http://dx.doi.org/10.1038/3871			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843215				2022-12-25	WOS:000077199600030
J	Coffey, AJ; Brooksbank, RA; Brandau, O; Oohashi, T; Howell, GR; Bye, JM; Cahn, AP; Durham, J; Heath, P; Wray, P; Pavitt, R; Wilkinson, J; Leversha, M; Huckle, E; Shaw-Smith, CJ; Dunham, A; Rhodes, S; Schuster, V; Porta, G; Yin, L; Serafini, P; Sylla, B; Zollo, M; Franco, B; Bolino, A; Seri, M; Lanyi, A; Davis, JR; Webster, D; Harris, A; Lenoir, G; St Basile, GD; Jones, A; Behloradsky, BH; Achatz, H; Murken, J; Fassler, R; Sumegi, J; Romeo, G; Vaudin, M; Ross, MT; Meindl, A; Bentley, DR				Coffey, AJ; Brooksbank, RA; Brandau, O; Oohashi, T; Howell, GR; Bye, JM; Cahn, AP; Durham, J; Heath, P; Wray, P; Pavitt, R; Wilkinson, J; Leversha, M; Huckle, E; Shaw-Smith, CJ; Dunham, A; Rhodes, S; Schuster, V; Porta, G; Yin, L; Serafini, P; Sylla, B; Zollo, M; Franco, B; Bolino, A; Seri, M; Lanyi, A; Davis, JR; Webster, D; Harris, A; Lenoir, G; St Basile, GD; Jones, A; Behloradsky, BH; Achatz, H; Murken, J; Fassler, R; Sumegi, J; Romeo, G; Vaudin, M; Ross, MT; Meindl, A; Bentley, DR			Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene	NATURE GENETICS			English	Article							EPSTEIN-BARR-VIRUS; ARTIFICIAL CHROMOSOME LIBRARIES; BONE-MARROW TRANSPLANTATION; HUMAN DYSTROPHIN GENE; XLP LOCUS; LARGE INSERTS; SH3 DOMAINS; HUMAN DNA; PROTEIN; DELETION	X-linked lymphoproliferative syndrome (XLP or Duncan disease) is characterized by extreme sensitivity to Epstein-Barr virus (EBV), resulting in a complex phenotype manifested by severe or fatal infectious mononucleosis, acquired hypogammaglobulinemia and malignant lymphoma. We have identified a gene, SH2D1A, that is mutated in XLP patients and encodes a novel protein composed of a single SH2 domain. SH2D1A is expressed in many tissues involved in the immune system. The identification of SH2D1A will allow the determination of its mechanism of action as a possible regulator of the EBV-induced immune response.	Sanger Ctr, Hinxton CB10 1SA, Cambs, England; LMU, Abt Med Genet, D-80336 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Addenbrookes Hosp, Dept Resp Med, Cambridge CB2 2QQ, England; Univ Wurzburg, Kinderklin, D-97080 Wurzburg, Germany; Osped San Paolo, Ist Sci Biomed, Cattedra Gen Umana, Milan, Italy; Univ Pavia, Fac Med 2, Dip Patol Umana & Ereditaria, I-27100 Pavia, Italy; Int Agcy Res Canc, Genet Canc Susceptibil Unit, F-69372 Lyon, France; TIGEM, I-20132 Milan, Italy; Inst Gaslini, Mol Genet Lab, Genoa, Italy; Univ Nebraska, Dept Microbiol & Pathol, Omaha, NE 68182 USA; Royal Free Hosp, Sch Med, Dept Clin Immunol, London, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Int Agcy Res Canc, Programme Viral & Hereditary Factors Carcinogenes, F-69372 Lyon, France; Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; LMU, Haunersche Immundefektambulanz, D-80336 Munich, Germany	Wellcome Trust Sanger Institute; University of Munich; Max Planck Society; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Wurzburg; San Paolo-Polo Universitaria Hospital; University of Pavia; World Health Organization; International Agency for Research on Cancer (IARC); Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Nebraska System; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford; World Health Organization; International Agency for Research on Cancer (IARC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Munich	Coffey, AJ (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	ajc@sanger.ac.uk	Bolino, Alessandra/O-2933-2013; Oohashi, Toshitaka/B-1599-2011; Bolino, Alessandra/AAN-5442-2020; FRANCO, Brunella/S-2882-2018; Seri, Marco/A-4339-2014	Bolino, Alessandra/0000-0002-8980-4878; FRANCO, Brunella/0000-0001-5588-4569; porta, giovanni/0000-0001-5260-2415; Oohashi, Toshitaka/0000-0002-9302-1913; Seri, Marco/0000-0003-2425-2176	NIAID NIH HHS [1 R01 AI33532-OIA3] Funding Source: Medline; Telethon [TGM06S01, E.0440] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033532] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; ARKWRIGHT PD, IN PRESS ARCH DIS CH; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOLINO A, IN PRESS EUR J HUM G; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COFFEY AJ, 1992, GENOMICS, V12, P474, DOI 10.1016/0888-7543(92)90437-W; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FILIPOVICH AH, 1986, TRANSPLANTATION, V42, P222; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; HARRINGTON DS, 1987, CANCER-AM CANCER SOC, V59, P1419, DOI 10.1002/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P; HUANG SH, 1993, METHODS MOL BIOL PCR, P357; IMAI S, 1994, P NATL ACAD SCI USA, V91, P9131, DOI 10.1073/pnas.91.19.9131; KLEIN G, 1975, NEW ENGL J MED, V293, P1353, DOI 10.1056/NEJM197512252932607; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; Lamartine J, 1996, EUR J HUM GENET, V4, P342; Lanyi A, 1997, GENOMICS, V39, P55, DOI 10.1006/geno.1996.4466; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; PURTILO D T, 1991, Pediatric Pathology, V11, P685; PURTILO DT, 1975, LANCET, V1, P936; Rickinson AB, 1996, CURR OPIN IMMUNOL, V8, P492, DOI 10.1016/S0952-7915(96)80036-7; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROBERTS RG, 1993, GENOMICS, V16, P536, DOI 10.1006/geno.1993.1225; SANGER WG, 1990, CANCER GENET CYTOGEN, V47, P163, DOI 10.1016/0165-4608(90)90026-7; SCHUSTER V, 1994, EUR J PEDIATR, V153, P432; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SKARE J, 1993, GENOMICS, V16, P254, DOI 10.1006/geno.1993.1169; SKARE JC, 1989, HUM GENET, V82, P354; Soderlund C, 1995, COMPUT APPL BIOSCI, V11, P645; SOLOVYEV VV, 1995, INTELLIGENT SYSTEMS, V3, P367; Thompson AD, 1996, ONCOGENE, V13, P2649; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VOWELS MR, 1993, NEW ENGL J MED, V329, P1623, DOI 10.1056/NEJM199311253292205; Ware JE, 1996, BEHAV HEALTHC TOM, V5, P88; WEISENBURGER DD, 1986, EPSTEINBARR VIRUS RE, P129; WILLIAMS LL, 1993, LANCET, V342, P587, DOI 10.1016/0140-6736(93)91413-G; WU BL, 1993, GENOMICS, V17, P163, DOI 10.1006/geno.1993.1298; WYANDT HE, 1989, AM J MED GENET, V33, P426, DOI 10.1002/ajmg.1320330331; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	53	589	610	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1998	20	2					129	135		10.1038/2424	http://dx.doi.org/10.1038/2424			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771704				2022-12-25	WOS:000076231300013
J	Wallace, RH; Wang, DW; Singh, R; Scheffer, IE; George, AL; Phillips, HA; Saar, K; Reis, A; Johnson, EW; Sutherland, GR; Berkovic, SF; Mulley, JC				Wallace, RH; Wang, DW; Singh, R; Scheffer, IE; George, AL; Phillips, HA; Saar, K; Reis, A; Johnson, EW; Sutherland, GR; Berkovic, SF; Mulley, JC			Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta 1 subunit gene SCN1B	NATURE GENETICS			English	Article							SKELETAL-MUSCLE; SODIUM-CHANNEL; BRAIN; CONVULSIONS	Febrile seizures affect approximately 3% of all children under six years of age and are by far the most common seizure disorder(1). A small proportion of children with febrile seizures later develop ongoing epilepsy with afebrile seizures(2). Segregation analysis suggests the majority of cases have complex inheritance(3) but rare families show apparent autosomal dominant: inheritance. Two putative loci have been mapped (FEB1 and FEB2), but specific genes have not yet been identified(4,5). We recently described a clinical subset, termed generalized epilepsy with febrile seizures plus (GEFS(+)), in which many family members have seizures with fever that may persist beyond six years of age or be associated with afebrile generalized seizures(6). We now report linkage, in another large GEFS(+) family, to chromosome region 19q13.1 and identification of a mutation in the voltage-gated sodium (Na+)-channel beta 1 subunit gene (SCN1B). The mutation changes a conserved cysteine residue disrupting a putative disulfide bridge which normally maintains an extracellular immunoglobulin-like fold. Go-expression of the mutant pr subunit with a brain Na+-channel alpha subunit in Xenopus laevis oocytes demonstrates that the mutation interferes with the ability of the subunit to modulate channel-gating kinetics consistent with a loss-of-function allele. This observation develops the theme that idiopathic epilepsies are a family of channelopathies and raises the possibility of involvement of other Na+-channel subunit genes in febrile seizures and generalized epilepsies with complex inheritance patterns.	Womens & Childrens Hosp, Ctr Genet Med, Dept Cytogenet & Mol Genet, N Adelaide, SA 5006, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA, Australia; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Dept Pharmacol, Nashville, TN 37232 USA; Univ Melbourne, Dept Med Neurol, Austin & Repatriat Med Ctr, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Neurol, Melbourne, Vic, Australia; Monash Med Ctr, Melbourne, Vic, Australia; Max Delbruck Zentrum, Mikrosatellitenzentrum, D-14059 Berlin, Germany; Humboldt Univ, Inst Human Genet, Berlin, Germany; Marshfield Med Res Fdn, Ctr Med Genet, Marshfield, WI 54449 USA; Univ Adelaide, Dept Genet, Adelaide, SA, Australia	University of Adelaide; Vanderbilt University; Vanderbilt University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Children's Hospital Melbourne; Monash University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; University of Adelaide	Mulley, JC (corresponding author), Womens & Childrens Hosp, Ctr Genet Med, Dept Cytogenet & Mol Genet, N Adelaide, SA 5006, Australia.		Sutherland, Grant Robert/D-2606-2012; Reis, André/D-2309-2009; Scheffer, Ingrid E/G-1668-2013; jiang, yu/HGU-0029-2022	Reis, André/0000-0002-6301-6363; Scheffer, Ingrid E/0000-0002-2311-2174; Wallace, Robyn/0000-0001-6141-3317; Berkovic, Samuel/0000-0003-4580-841X; Saar, Kathrin/0000-0002-4483-1557	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032387, R37NS032387] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32387] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERKOVIC SF, 1997, EPILEPSY COMPREHENSI, P217; BLERVERT C, 1998, SCIENCE, V279, P403; Bulman DE, 1997, HUM MOL GENET, V6, P1679, DOI 10.1093/hmg/6.10.1679; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DONOHUE NV, 1992, EPILEPTIC SYNDROMES, P45; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Guipponi M, 1997, HUM MOL GENET, V6, P473, DOI 10.1093/hmg/6.3.473; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Johnson EW, 1998, HUM MOL GENET, V7, P63, DOI 10.1093/hmg/7.1.63; Johnson WG, 1996, AM J MED GENET, V61, P345; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MACDONALD RL, 1994, EPILEPSIA, V35, P541; MAKITA N, 1994, GENOMICS, V23, P628, DOI 10.1006/geno.1994.1551; Makita N, 1996, J NEUROSCI, V16, P7117; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; Mohrenweiser HW, 1998, GENOMICS, V47, P153, DOI 10.1006/geno.1997.5097; NELSON KB, 1981, FEBRILE SEIZURES, P360; RICH SS, 1987, AM J HUM GENET, V41, P249; RYAN SG, 1995, NAT GENET, V10, P4, DOI 10.1038/ng0595-4; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; Wallace RH, 1996, J MED GENET, V33, P308, DOI 10.1136/jmg.33.4.308	30	821	874	0	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					366	370		10.1038/1252	http://dx.doi.org/10.1038/1252			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697698				2022-12-25	WOS:000075107600020
J	Wang, ZQ; Boudjelal, M; Kang, S; Voorhees, JJ; Fisher, GJ				Wang, ZQ; Boudjelal, M; Kang, S; Voorhees, JJ; Fisher, GJ			Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment	NATURE MEDICINE			English	Article							IN-VIVO; NUCLEAR RECEPTORS; RXR HETERODIMERS; UV-RADIATION; MOUSE SKIN; EXPRESSION; ACTIVATION; BINDING; PROTEIN; PROGRESSION	We report here that ultraviolet irradiation substantially reduced the mRNA and protein of the two major nuclear retinoid receptors, RAR-gamma and RXR-alpha, in human skin in vivo. Pre-treatment with retinoic acid mitigated this loss of nuclear retinoid receptors. Ultraviolet irradiation caused a near-total loss of retinoic acid induction of two RAR/RXR target genes, cellular retinoic acid binding protein-II and RA 4-hydroxylase, but did not affect 1,25-dihydroxyvitamin D-3 induction of the vitamin D receptor/RXR-regulated gene vitamin D 24-hydroxylase. In effect, ultraviolet irradiation causes a functional vitamin A deficiency that may have deleterious effects on skin function, contributing to skin photo-aging and carcinogenesis.	Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Dept Dermatol, 1150 W Med Ctr Dr,Med Sci 1 R6447, Ann Arbor, MI 48109 USA.	dianemch@umich.edu						ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; ASTROM A, 1991, J BIOL CHEM, V266, P17662; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL C, 1993, CANCER RES, V53, P2697; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; Darwiche N, 1996, CANCER RES, V56, P4942; DARWICHE N, 1995, CANCER RES, V55, P2774; DE LUCA LM, 1991, FASEB J, V5, P2924; DE LUCA LM, 1994, NUTR REV, V52, P45; Duell EA, 1996, J INVEST DERMATOL, V106, P316, DOI 10.1111/1523-1747.ep12342972; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Fitzgerald P, 1997, CANCER RES, V57, P2642; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUTORYAN T, 1994, NUTR REV, V52, P299, DOI 10.1111/j.1753-4887.1994.tb01461.x; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HOLICK MF, 1995, AM J CLIN NUTR, V61, p638S, DOI 10.1093/ajcn/61.3.638S; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; Kang SW, 1997, J INVEST DERMATOL, V108, P513, DOI 10.1111/1523-1747.ep12289736; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; Li XY, 1997, J INVEST DERMATOL, V108, P506, DOI 10.1111/1523-1747.ep12289733; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, V1, P910; vanderLeun JC, 1996, J PHOTOCH PHOTOBIO B, V35, P237, DOI 10.1016/S1011-1344(95)07188-1; White SD, 1997, J COMPUT INFORM SYST, V38, P1; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001	44	92	94	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					418	422		10.1038/7417	http://dx.doi.org/10.1038/7417			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202931				2022-12-25	WOS:000079574300031
J	Grivel, JC; Margolis, LB				Grivel, JC; Margolis, LB			CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue	NATURE MEDICINE			English	Article							CORECEPTOR USAGE; INFECTION; HISTOCULTURES; PHENOTYPE; TYPE-1	A rapid decline in T-cell counts and the progression to AIDS is often associated with a switch from CCR5-tropic (R5) HIV-1 to CXCR4-tropic (X4) HIV-1 or R5/X4 HIV-1 variants(1,2) Experimental infection with R5 HIV-1 causes less T-cell depletion than infection with X4 or R5/X4 variants in T-cell cultures(3), in ex vivo infected human lymphoid tissue(4,5) and in SCID/hu mice(6), despite similar replication levels. Experimental genetic changes in those sequences in gp120 that transform R5 HIV-1 variants into otherwise isogenic X4 viruses make them highly cytopathic(6,7). Thus, it is now believed that R5 variants are less cytopathic for T cells than are X4 variants. However, it is not known why CCR5-mediated HIV-1 infection does not lead to a massive CD4(+) T-cell depletion, as occurs in CXCR4-mediated HIV-1 infection. Here we demonstrate that R5 HIV-1 isolates are indeed highly cytopathic, but only for CCR5(+)/CD4(+) T cells. Because these cells constitute only a small fraction of CD4(+) T cells, their depletion does not substantially change the total CD4(+) T-cell count. These results may explain why the clinical stage of HIV disease correlates with viral tropism.	NICHHD, Lab Mol & Cellular Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Margolis, LB (corresponding author), NICHHD, Lab Mol & Cellular Biophys, NIH, Bethesda, MD 20892 USA.			Grivel, Jean-Charles/0000-0003-0365-3181				Berger EA, 1997, AIDS, V11, pS3; Bjorndal A, 1997, J VIROL, V71, P7478; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Casella C R, 1997, Curr Opin Hematol, V4, P24; Glushakova S, 1997, AIDS RES HUM RETROV, V13, P461, DOI 10.1089/aid.1997.13.461; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; Glushakova S, 1998, NAT MED, V4, P346, DOI 10.1038/nm0398-346; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Penn ML, 1999, P NATL ACAD SCI USA, V96, P663, DOI 10.1073/pnas.96.2.663; Picchio GR, 1998, J VIROL, V72, P2002, DOI 10.1128/JVI.72.3.2002-2009.1998; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; TERSMETTE M, 1989, LANCET, V1, P983; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369	15	143	145	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					344	346		10.1038/6565	http://dx.doi.org/10.1038/6565			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086394				2022-12-25	WOS:000078851600043
J	Lapham, CK; Zaitseva, MB; Lee, S; Romanstseva, T; Golding, H				Lapham, CK; Zaitseva, MB; Lee, S; Romanstseva, T; Golding, H			Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR; CELL-LINES; T-CELL; INFECTION; TROPISM; ENTRY; 7-TRANSMEMBRANE; GLYCOPROTEINS; CORECEPTOR	Human macrophages can be infected more efficiently by M-tropic than by T-tropic HIV-1 strains, despite surface expression of both CXCR4 and CCR5 co-receptors. Western blot analyses of total cell extracts and surface proteins from multiple sets of monocytes and macrophages demonstrated substantial differences between CXCR4 molecules. CXCR4 was mainly a monomer in monocytes, but was mainly a species of higher molecular weight (90 kDa) on the surface of macrophages. CCR5 was monomeric in both cell types. A constitutive association between CD4 and the co-receptors was seen in monocytes and macrophages. However, CD4 co-precipitated with CCR5 and CXCR4 monomers, but not with the high-molecular-weight forms of CXCR4, indicating that the high-molecular-weight CXCR4 species in macrophages are not available for association with CD4, which may contribute to the inefficient entry of T-tropic strains into mature macrophages.	US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Lapham, CK (corresponding author), US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, HFM-454,8800 Rockville Pike, Bethesda, MD 20892 USA.	Lapham@CBER.FDA.GOV						Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAYT KJ, 1997, JAMA-J AM MED ASSOC, V256, P2356; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; ChengMayer C, 1997, J VIROL, V71, P1657, DOI 10.1128/JVI.71.2.1657-1661.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Di Marzio P, 1998, AIDS RES HUM RETROV, V14, P129, DOI 10.1089/aid.1998.14.129; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ghorpade A, 1998, J VIROL, V72, P3340, DOI 10.1128/JVI.72.4.3340-3350.1998; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; NUOVO GJ, 1993, AM J PATHOL, V143, P40; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OVARECZ T, 1997, J EXP MED, V184, P1865; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; Schmidtmayerova H, 1998, J VIROL, V72, P4633, DOI 10.1128/JVI.72.6.4633-4642.1998; Simmons G, 1998, J VIROL, V72, P8453, DOI 10.1128/JVI.72.10.8453-8457.1998; SPENCER LT, 1994, J INFECT DIS, V169, P491, DOI 10.1093/infdis/169.3.491; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Verani A, 1998, J IMMUNOL, V161, P2084; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yi YJ, 1998, J VIROL, V72, P772, DOI 10.1128/JVI.72.1.772-777.1998; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; Zaitseva MB, 1998, J IMMUNOL, V161, P3103; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	33	102	104	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					303	308		10.1038/6523	http://dx.doi.org/10.1038/6523			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086386				2022-12-25	WOS:000078851600035
J	Bartlett, JS; Kleinschmidt, J; Boucher, RC; Samulski, RJ				Bartlett, JS; Kleinschmidt, J; Boucher, RC; Samulski, RJ			Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab 'gamma)(2) antibody	NATURE BIOTECHNOLOGY			English	Article						gene therapy vector; targeted transduction; parvovirus; adeno-associated virus (AAV); bispecific antibody	HUMAN HEMATOPOIETIC-CELLS; GLYCOPROTEIN-IIB-IIIA; GAMMA-GLOBIN GENE; ADENOASSOCIATED VIRUS; RETROVIRAL VECTORS; PHENOTYPIC CORRECTION; NONDIVIDING CELLS; ERYTHROID-CELLS; HIGH-LEVEL; EXPRESSION	We have developed a system for the targeted delivery of adeno-associated virus (AAV) vectors. Targeting is achieved via a bispecific F(ab')(2) antibody that mediates a novel interaction between the AAV vector and a specific cell surface receptor expressed on human megakaryocytes. Targeted AAV vectors were able to transduce megakaryocyte cell lines, DAMI and MO7e, which were nonpermissive for normal AAV infection, 70-fold above background and at levels equivalent to permissive K562 cells. Transduction was shown to occur through the specific interaction of the AAV vector-bispecific F(ab')(2) complex and cell-associated targeting receptor. Importantly, targeting appeared both selective and restrictive as the endogenous tropism of the AAV vector was significantly reduced. Binding and internalization through the alternative receptor did not alter subsequent steps (escape from endosomes, migration to nucleus, or uncoating) required to successfully transduce target cells. These results demonstrate that AAV vectors can be targeted to a specific cell population and that transduction can be achieved by circumventing the normal virus receptor.	Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Pulm & Cyst Fibrosis Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Helmholtz Association; German Cancer Research Center (DKFZ)	Bartlett, JS (corresponding author), Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA.	jbart@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 533016, HL 42384, HL 51818] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER IE, 1994, J VIROL, V68, P8282, DOI 10.1128/JVI.68.12.8282-8287.1994; Bartlett JS, 1998, HUM GENE THER, V9, P1181, DOI 10.1089/hum.1998.9.8-1181; BARTLETT JS, 1996, PROTOCOLS GENE TRANS, P115; Bodey B, 1996, ANTICANCER RES, V16, P661; CHU THT, 1994, GENE THER, V1, P292; Conrad CK, 1996, GENE THER, V3, P658; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1994, AM J RESP CELL MOL, V11, P517, DOI 10.1165/ajrcmb.11.5.7946381; Goldman CK, 1997, CANCER RES, V57, P1447; GOODMAN S, 1994, BLOOD, V84, P1492; HALBERT CL, 1995, J VIROL, V69, P1473, DOI 10.1128/JVI.69.3.1473-1479.1995; HANDAGAMA P, 1993, BLOOD, V82, P135, DOI 10.1182/blood.V82.1.135.bloodjournal821135; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Imai K, 1997, Int Rev Immunol, V14, P213, DOI 10.3109/08830189709116853; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; Malik P, 1997, J VIROL, V71, P1776, DOI 10.1128/JVI.71.3.1776-1783.1997; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; Mizukami H, 1996, VIROLOGY, V217, P124, DOI 10.1006/viro.1996.0099; MONTGOMERY RR, 1983, J CLIN INVEST, V71, P385, DOI 10.1172/JCI110780; PIDARD D, 1983, J BIOL CHEM, V258, P2582; Ponnazhagan S, 1996, J GEN VIROL, V77, P1111, DOI 10.1099/0022-1317-77-6-1111; PONNAZHAGAN S, 1994, BLOOD, V84, pA742; RUSSELL DW, 1994, P NATL ACAD SCI USA, V91, P8915, DOI 10.1073/pnas.91.19.8915; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SAMULSKI RJ, 1993, CURR OPIN GENET DEV, V3, P74, DOI 10.1016/S0959-437X(05)80344-2; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SAMULSKI RJ, 1983, CELL, V33, P135, DOI 10.1016/0092-8674(83)90342-2; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; WALSH CE, 1992, P NATL ACAD SCI USA, V89, P7257, DOI 10.1073/pnas.89.15.7257; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wickham TJ, 1995, GENE THER, V2, P750; WISTUBA A, 1995, J VIROL, V69, P5311, DOI 10.1128/JVI.69.9.5311-5319.1995; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	45	170	197	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					181	186		10.1038/6185	http://dx.doi.org/10.1038/6185			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052356				2022-12-25	WOS:000078508300028
J	Lander, ES				Lander, ES			Array of hope	NATURE GENETICS			English	Article									MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.							Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194	18	420	472	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			3	4		10.1038/4427	http://dx.doi.org/10.1038/4427			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915492				2022-12-25	WOS:000078008200003
J	Ross, AJ; Ruiz-Perez, V; Wang, YM; Hagan, DM; Scherer, S; Lynch, SA; Lindsay, S; Custard, E; Belloni, E; Wilson, DI; Wadey, R; Goodman, F; Orstavik, KH; Monclair, T; Robson, S; Reardon, W; Burn, J; Scambler, P; Strachan, T				Ross, AJ; Ruiz-Perez, V; Wang, YM; Hagan, DM; Scherer, S; Lynch, SA; Lindsay, S; Custard, E; Belloni, E; Wilson, DI; Wadey, R; Goodman, F; Orstavik, KH; Monclair, T; Robson, S; Reardon, W; Burn, J; Scambler, P; Strachan, T			A homeobox gene, HLXB9, is the major locus for dominantly inherited sacral agenesis	NATURE GENETICS			English	Article							SONIC HEDGEHOG; CURRARINO TRIAD; MALFORMATIONS; EMBRYOGENESIS; MUTATIONS; DISEASE; REGION; MOUSE; MAPS; 7Q36	Partial absence of the sacrum is a rare congenital defect which also occurs as an autosomal dominant trait; association with anterior meningocoele. presacral teratoma and anorectal abnormalities constitutes the Currarino triad(1) (MIM 176450). Malformation at the caudal end of the developing notochord at approximately Carnegie stage 7 (16 post-ovulatory days). which results in aberrant secondary neurulation. can explain the observed pattern of anomalies(2,4). We previously reported linkage to 7q36 markers in two dominantly inherited sacral agenesis families(2). We now present data refining the initial subchromosomal localization in several additional hereditary sacral agenesis (HSA) families. We excluded several candidate genes before identifying patient-specific mutations in a homeobox gene, HLXB9 which was previously reported to map to 1q41-q42.1 and to be expressed in lymphoid and pancreatic tissues(5,6).	Univ Newcastle Upon Tyne, Sch Biochem & Genet, Human Genet Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ London, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Univ Oslo, Ulleval Hosp, Dept Med Genet, N-0315 Oslo, Norway; Natl Hosp Norway, Dept Pediat Surg, N-0027 Oslo, Norway; Univ Newcastle Upon Tyne, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ London, Inst Child Hlth, Clin Genet Unit, London WC1N 1EH, England	Newcastle University - UK; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of London; University College London; University of Oslo; University of Oslo; National Hospital Norway; Newcastle University - UK; University of London; University College London	Strachan, T (corresponding author), Univ Newcastle Upon Tyne, Sch Biochem & Genet, Human Genet Unit, Ridley Bldg,Claremont Pl, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	tom.strachan@ncl.ac.uk	Scherer, Stephen W./B-3785-2013; belloni, elena/H-9909-2013; Scambler, Peter J/C-4998-2008; Scambler, Peter/AAZ-6026-2020; Ruiz-Perez, Victor L/K-6066-2014; Wilson, David/A-6264-2010	Scherer, Stephen W./0000-0002-8326-1999; Scambler, Peter J/0000-0002-1487-4628; Scambler, Peter/0000-0002-1487-4628; Ruiz-Perez, Victor L/0000-0003-0635-3619; Wilson, David/0000-0001-8779-2060; Lindsay, Susan/0000-0003-2980-4582; Belloni, Elena/0000-0003-3214-0780; Reardon, Willie/0000-0001-7329-9179; Lynch, Sally Ann/0000-0003-3540-1333; Burn, John/0000-0002-9823-2322				Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Bullen P, 1997, MOL GENETICS EARLY H; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COPP AJ, 1989, J MED GENET, V26, P160, DOI 10.1136/jmg.26.3.160; CURRARINO G, 1981, AM J ROENTGENOL, V137, P395, DOI 10.2214/ajr.137.2.395; HARDWICK RJ, 1992, J PAEDIATR CHILD H, V28, P328, DOI 10.1111/j.1440-1754.1992.tb02680.x; HARLOW CL, 1995, PEDIATR NEUROSURG, V23, P140, DOI 10.1159/000120951; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KALTER H, 1993, CLIN GENET, V43, P174, DOI 10.1111/j.1399-0004.1993.tb04443.x; Lako M, 1998, HUM MOL GENET, V7, P813, DOI 10.1093/hmg/7.5.813; Lanoue L, 1997, AM J MED GENET, V73, P24; LYNCH SA, 1995, NAT GENET, V11, P93, DOI 10.1038/ng0995-93; Mackay M, 1996, GENOMICS, V37, P345, DOI 10.1006/geno.1996.0569; Masuno M, 1996, J MED GENET, V33, P877, DOI 10.1136/jmg.33.10.877; MORICHONDELVALLEZ N, 1993, J MED GENET, V30, P521, DOI 10.1136/jmg.30.6.521; NAJFELD V, 1992, GENE CHROMOSOME CANC, V5, P343, DOI 10.1002/gcc.2870050410; ORIORDAIN DS, 1991, BRIT J SURG, V78, P536, DOI 10.1002/bjs.1800780507; PANG D, 1993, NEUROSURGERY, V32, P755, DOI 10.1227/00006123-199305000-00009; PLACZEK M, 1995, CURR OPIN GENET DEV, V5, P499, DOI 10.1016/0959-437X(95)90055-L; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Roessler E, 1997, HUM MOL GENET, V6, P1847, DOI 10.1093/hmg/6.11.1847; Saha MS, 1997, DEV BIOL, V187, P209, DOI 10.1006/dbio.1997.8625; Savage NM, 1997, J MED GENET, V34, P866, DOI 10.1136/jmg.34.10.866; TSUKUROV O, 1994, NAT GENET, V6, P282, DOI 10.1038/ng0394-282; VARGAS EC, 1992, PEDIATRIE, V47, P273; Vargas FR, 1998, HUM GENET, V102, P387, DOI 10.1007/s004390050709; 1998, CLIN GENET, V53, P333	28	209	221	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					358	361		10.1038/3828	http://dx.doi.org/10.1038/3828			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843207				2022-12-25	WOS:000077199600022
J	Vingsbo-Lundberg, C; Nordquist, N; Olofsson, P; Sundvall, M; Saxne, T; Pettersson, U; Holmdahl, R				Vingsbo-Lundberg, C; Nordquist, N; Olofsson, P; Sundvall, M; Saxne, T; Pettersson, U; Holmdahl, R			Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats	NATURE GENETICS			English	Article							BB RAT; SUSCEPTIBILITY	Rheumatoid arthritis (RA) is a chronic and genetically complex inflammatory disorder that leads to erosive destruction of peripheral joints(1-5). The use of animal models mimicking RA, such as pristane-induced arthritis (PIA) in rats, should facilitate its genetic analysis. Pristane is a non-immunogenic synthetic oil that, after a single subcutaneous injection into DA rats, induces arthritis restricted to peripheral joints with a chronic relapsing disease course(6). To identify genes involved in the control of chronic arthritis, we made crosses between susceptible DA rats and resistant E3 rats and analysed the progeny with microsatellite markers covering the entire rat genome. Our results show that different arthritis phenotypes are associated with different chromosomal loci. Loci on chromosomes 4 and 6 (Pia2 and Pia3) influence arthritis onset, whereas a locus on chromosome 12 (Pia4) is associated with severity and joint erosion. We found that chronicity is associated with a different set of loci, one on chromosome 4 and the other on chromosome 14 (Pia5, Pia6). These findings demonstrate for the first time that different phases of a chronic self-perpetuative disease which mimics RA are associated with distinct sets of genes.	Univ Lund, Dept Cell & Mol Biol, Sect Med Inflammat Res, Lund, Sweden; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden; Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Res, Lund, Sweden; Univ Lund, Dept Rheumatol, Lund, Sweden	Lund University; Uppsala University; Lund University; Lund University	Holmdahl, R (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Med Inflammat Res, Lund, Sweden.	rikard.holmdahl@inflam.lu.se	Holmdahl, Rikard/AAI-7682-2020; Nordquist, Niklas/B-9334-2011	Nordquist, Niklas/0000-0002-3864-937X; Olofsson, Peter/0000-0003-4849-8541				GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; Holmdahl R, 1998, HUMAN GENOME METHODS, P215; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINCOLN S, 1992, MAPPING GENES CONTRO; Lincoln S, 1992, CONSTRUCING GENETIC, V3rd; Lorentzen JC, 1998, P NATL ACAD SCI USA, V95, P6383, DOI 10.1073/pnas.95.11.6383; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PETTERSSON A, 1995, J AUTOIMMUN, V8, P493, DOI 10.1016/0896-8411(95)90004-7; Remmers EF, 1996, NAT GENET, V14, P82, DOI 10.1038/ng0996-82; SILMAN AJ, 1993, BRIT J RHEUMATOL, V32, P903; Vingsbo C, 1996, AM J PATHOL, V149, P1675; Vingsbo-Lundberg C, 1998, ARTHRITIS RHEUM, V41, P544, DOI 10.1002/1529-0131(199803)41:3<544::AID-ART21>3.0.CO;2-#; WORDSWORTH P, 1992, AM J HUM GENET, V51, P585; WORDSWORTH P, 1991, ANN RHEUM DIS, V50, P343, DOI 10.1136/ard.50.6.343	17	141	147	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					401	404		10.1038/3887	http://dx.doi.org/10.1038/3887			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843218	Green Published			2022-12-25	WOS:000077199600033
J	de Winter, JP; Waisfisz, Q; Rooimans, MA; van Berkel, CGM; Bosnoyan-Collins, L; Alon, N; Carreau, M; Bender, O; Demuth, I; Schindler, D; Pronk, JC; Arwert, F; Hoehn, H; Digweed, M; Buchwald, M; Joenje, H				de Winter, JP; Waisfisz, Q; Rooimans, MA; van Berkel, CGM; Bosnoyan-Collins, L; Alon, N; Carreau, M; Bender, O; Demuth, I; Schindler, D; Pronk, JC; Arwert, F; Hoehn, H; Digweed, M; Buchwald, M; Joenje, H			The Fanconi anaemia group G gene FANCG is identical with XRCC9	NATURE GENETICS			English	Article							CHROMOSOMAL INSTABILITY; ANEMIA GENES; COMPLEMENTATION; SUSCEPTIBILITY; SENSITIVITY; UV40; MICE; FAA	Fanconi anemia (FA) is an autosomal recessive disease with diverse clinical symptoms including developmental anomalies, bone marrow failure and early occurrence of malignancies'. In addition to spontaneous chromosome instability, FA cells exhibit cell cycle disturbances and hypersensitivity to crosslinking agents(1). Eight complementation groups (A-H) have been distinguished(2), each group possibly representing a distinct FA gene(3). The genes mutated in patients of complementation groups A (FANCA; refs 4,5) and C (FANCC; ref. 6) have been identified, and FANCD has been mapped to chromosome band 3p22-26 (ref. 7). An additional FA gene has recently been mapped to chromosome 9p (ref. 8). Here we report the identification of the gene mutated in group G, FANCG, on the basis of complementation of an FA-G cell line and the presence of pathogenic mutations in four FA-C patients. We identified the gene as human XRCC9, a gene which has been shown to complement the MMC-sensitive Chinese hamster mutant UV40, and is suspected to be involved in DNA post-replication repair or cell cycle checkpoint control(9,10). The gene is localized to chromosome band 9p13 (ref. 9), corresponding with a known localization of an FA gene.	Free Univ Amsterdam, Dept Human Genet, NL-1081 BT Amsterdam, Netherlands; Hosp Sick Children, Program Genet & Genomic Biol, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Humboldt Univ, Inst Human Genet, D-13353 Berlin, Germany; Univ Wurzburg, Inst Human Genet, D-8700 Wurzburg, Germany	Vrije Universiteit Amsterdam; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Humboldt University of Berlin; University of Wurzburg	Joenje, H (corresponding author), Free Univ Amsterdam, Dept Human Genet, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	h.joenje.humgen@med.vu.nl	Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523; Carreau, Madeleine/0000-0002-0582-6114; Waisfisz, Quinten/0000-0002-7384-9182	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050131] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50131] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; Auerbach Arleen D., 1997, Current Opinion in Pediatrics, V9, P600, DOI 10.1097/00008480-199712000-00010; BUCHWALD M, 1995, NAT GENET, V11, P228, DOI 10.1038/ng1195-228; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Carreau M, 1998, MOL MED TODAY, V4, P201, DOI 10.1016/S1357-4310(98)01243-X; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Hoatlin ME, 1998, BLOOD, V91, P1418, DOI 10.1182/blood.V91.4.1418; ISHIDA R, 1982, CANCER RES, V42, P4000; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Levran O, 1997, P NATL ACAD SCI USA, V94, P13051, DOI 10.1073/pnas.94.24.13051; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; MOSHELL AN, 1981, IN VITRO CELL DEV B, V17, P299; Saar K, 1998, EUR J HUM GENET, V6, P501, DOI 10.1038/sj.ejhg.5200241; SAVOV A, 1992, NUCLEIC ACIDS RES, V20, P6741, DOI 10.1093/nar/20.24.6741; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; SEYSCHAB H, 1995, BLOOD, V85, P2233, DOI 10.1182/blood.V85.8.2233.bloodjournal8582233; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Whitney MA, 1996, BLOOD, V88, P49	25	260	265	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					281	283		10.1038/3093	http://dx.doi.org/10.1038/3093			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806548				2022-12-25	WOS:000076698100023
J	Flax, JD; Aurora, S; Yang, CH; Simonin, C; Wills, AM; Billinghurst, LL; Jendoubi, M; Sidman, RL; Wolfe, JH; Kim, SU; Snyder, EY				Flax, JD; Aurora, S; Yang, CH; Simonin, C; Wills, AM; Billinghurst, LL; Jendoubi, M; Sidman, RL; Wolfe, JH; Kim, SU; Snyder, EY			Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes	NATURE BIOTECHNOLOGY			English	Article						cell therapy; progenitor cell; gene therapy; Tay-Sachs disease; transplantation; differentiation	CENTRAL-NERVOUS-SYSTEM; REGION-SPECIFIC DIFFERENTIATION; FIBROBLAST GROWTH-FACTOR; PROGENITOR CELLS; MOUSE-BRAIN; PRECURSORS; LINES; CNS; TRANSPLANTATION; FOREBRAIN	Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. These self-renewing clones give rise to all fundamental neural lineages in vitro, Following transplantation into germinal zones of the newborn mouse brain they participate in aspects of normal development, including migration along established migratory pathways to disseminated central nervous system regions, differentiation into multiple developmentally and regionally appropriate cell types, and nondisruptive interspersion with host progenitors and their progeny. These human NSCs can be genetically engineered and are capable of expressing foreign transgenes in vivo. Supporting their gene therapy potential, secretory products from NSCs can correct a prototypical genetic metabolic defect in neurons and glia in vitro, The human NSCs can also replace specific deficient neuronal populations, Cryopreservable human NSCs may be propagated by both epigenetic and genetic means that are comparably safe and effective, By analogy to rodent NSCs, these observations may allow the development of NSC transplantation for a range of disorders.	Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; NEI, NIH, Bethesda, MD 20892 USA; Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Ctr Comparat Med Genet, Philadelphia, PA 19104 USA; Univ British Columbia, Univ Hosp, Dept Med, Div Neurol, Vancouver, BC V5Z 1M9, Canada	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Harvard University; University of Pennsylvania; University of Pennsylvania; University of British Columbia	Snyder, EY (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.	Snyder@A1.TCH.Harvard.edu		Simonin, Clemence/0000-0002-2282-4372	NIDDK NIH HHS [DK46637, DK42707] Funding Source: Medline; NINDS NIH HHS [NS33852] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046637, R01DK042707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033852] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BORTONGAN CV, 1998, EXP NEUROL, V149, P310; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; FISHELL G, 1995, DEVELOPMENT, V121, P803; Fisher LJ, 1997, NEUROBIOL DIS, V4, P1, DOI 10.1006/nbdi.1997.0137; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 1998, NATURE, V392, P18; Gage FH, 1997, ISOLATION CHARACTERI; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Gritti A, 1996, J NEUROSCI, V16, P1091; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; KORNBLUM HI, 1990, BRAIN RES, V535, P255, DOI 10.1016/0006-8993(90)91608-J; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MORETTO G, 1994, J NEUROPATH EXP NEUR, V53, P78, DOI 10.1097/00005072-199401000-00010; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Rosario CM, 1997, DEVELOPMENT, V124, P4213; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; Snyder EY, 1996, CURR OPIN NEUROL, V9, P126, DOI 10.1097/00019052-199604000-00013; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; SNYDER EY, 1992, CELL, V68, P1; SNYDER EY, 1997, P NATL ACAD SCI USA, V94, P11645; SNYDER EY, 1998, IN PRESS NEUROSCIENT; Stemple DL, 1997, NEURON, V18, P1, DOI 10.1016/S0896-6273(01)80018-0; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	41	607	702	1	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1033	1039		10.1038/3473	http://dx.doi.org/10.1038/3473			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831031				2022-12-25	WOS:000076870100024
J	Gupta, A; Silver, S				Gupta, A; Silver, S			Molecular genetics - Silver as a biocide: Will resistance become a problem?	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gupta, A (corresponding author), Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA.	agupta@uic.edu; simon@uic.edu		Silver, Simon/0000-0002-5692-3125				*FDA, 1994, FDA HLTH FRAUD B, V19; Fung MC, 1996, J TOXICOL-CLIN TOXIC, V34, P119, DOI 10.3109/15563659609020246; LEVY SB, 1998, SCI AM, V278, P32, DOI DOI 10.1038/SCIENTIFICAMERICAN0398-46; MCHUGH GL, 1975, LANCET, V1, P235; Pruitt BA, 1998, WORLD J SURG, V22, P135; SILVER S, 1998, IN PRESS METAL BASED, V6; SLAWSON RM, 1992, PLASMID, V27, P72, DOI 10.1016/0147-619X(92)90008-X; 1996, FED REG         1015, V16, P53685	8	212	219	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					888	888		10.1038/nbt1098-888	http://dx.doi.org/10.1038/nbt1098-888			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788326	Bronze			2022-12-25	WOS:000076323300005
J	Inoue, H; Tanizawa, Y; Wasson, J; Behn, P; Kalidas, K; Bernal-Mizrachi, E; Mueckler, M; Marshall, H; Donis-Keller, H; Crock, P; Rogers, D; Mikuni, M; Kumashiro, H; Higashi, K; Sobue, G; Oka, Y; Permutt, MA				Inoue, H; Tanizawa, Y; Wasson, J; Behn, P; Kalidas, K; Bernal-Mizrachi, E; Mueckler, M; Marshall, H; Donis-Keller, H; Crock, P; Rogers, D; Mikuni, M; Kumashiro, H; Higashi, K; Sobue, G; Oka, Y; Permutt, MA			A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome)	NATURE GENETICS			English	Article							BETA-CELL; DIDMOAD SYNDROME; LINKAGE	Wolfram syndrome (WFS; OMIM 222300) is an autosomal recessive neurodegenerative disorder defined by young-onset non-immune insulin-dependent diabetes mellitus and progressive optic atrophy. Linkage to markers on chromosome 4p was confirmed in five families. On the basis of meiotic recombinants and disease-associated haplotypes, the WFS gene was localized to a BAC/P1 contig of less than 250 kb. Mutations in a novel gene (WFS1) encoding a putative transmembrane protein were found in all affected individuals in six WFS families, and these mutations were associated with the disease phenotype. WFS1 appears to function in survival of islet beta-cells and neurons.	Washington Univ, Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, Div Human Mol Genet, St Louis, MO 63110 USA; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Ube, Yamaguchi 755, Japan; John Hunter Hosp, Newcastle, NSW, Australia; Cleveland Clin Fdn, Div Pediat, Cleveland, OH 44195 USA; Gunma Univ, Sch Med, Dept Neuropsychiat, Gunma, Japan; Fukushima Med Coll, Dept Neuropsychiat, Fukushima, Japan; Fujiwara Mem Hosp, Akita, Japan; Nagoya Univ, Sch Med, Dept Neurol, Nagoya, Aichi 466, Japan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Yamaguchi University; John Hunter Hospital; Cleveland Clinic Foundation; Gunma University; Fukushima Medical University; Nagoya University	Permutt, MA (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016746, T32DK007120, P60DK020579, R37DK016746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20579, DK07120, DK16746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett TG, 1997, J MED GENET, V34, P838, DOI 10.1136/jmg.34.10.838; Barrientos A, 1996, AM J HUM GENET, V58, P963; Blackwood DHR, 1996, NAT GENET, V12, P427, DOI 10.1038/ng0496-427; Chadwick RB, 1996, BIOTECHNIQUES, V20, P676; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collier DA, 1996, AM J HUM GENET, V59, P855; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; Ferrer J, 1997, DIABETES, V46, P386, DOI 10.2337/diabetes.46.3.386; FRASER FC, 1977, J MED GENET, V14, P190, DOI 10.1136/jmg.14.3.190; Groop LC, 1997, ANN MED, V29, P37, DOI 10.3109/07853899708998742; Hanis CL, 1998, SCIENTIST, V12, P11; HIGASHI K, 1991, AM J OTOL, V12, P57; HOFFMANN S, 1997, GENOMICS, V39, P8; Inoue H, 1996, DIABETES, V45, P789, DOI 10.2337/diabetes.45.6.789; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; KARASIK A, 1989, DIABETES CARE, V12, P135, DOI 10.2337/diacare.12.2.135; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARUYAMA A, 1987, MAKROMOL CHEM-RAPID, V8, P27; Mein CA, 1998, NAT GENET, V19, P297, DOI 10.1038/991; NANKO S, 1992, BRIT J PSYCHIAT, V161, P282, DOI 10.1192/bjp.161.2.282; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; POLYMEROPOULOS MH, 1994, NAT GENET, V8, P95, DOI 10.1038/ng0994-95; Pratley RE, 1998, J CLIN INVEST, V101, P1757, DOI 10.1172/JCI1850; RAITI S, 1963, Br Med J, V2, P1625; RANDO TA, 1992, NEUROLOGY, V42, P1220, DOI 10.1212/WNL.42.6.1220; Ries S, 1998, HUM MUTAT, V12, P44, DOI 10.1002/(SICI)1098-1004(1998)12:1<44::AID-HUMU7>3.0.CO;2-O; ROTTER JI, 1990, DIABETES MELLITUS TH, P378; Swift RG, 1998, MOL PSYCHIATR, V3, P86, DOI 10.1038/sj.mp.4000344; WILSON RK, GENOME ANAL LAB MANU; Wolfram DJ, 1938, P MAYO CLIN, V13, P715	33	514	540	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					143	148		10.1038/2441	http://dx.doi.org/10.1038/2441			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771706				2022-12-25	WOS:000076231300015
J	Sevenier, R; Hall, RD; van der Meer, IM; Hakkert, HJC; van Tunen, AJ; Koops, AJ				Sevenier, R; Hall, RD; van der Meer, IM; Hakkert, HJC; van Tunen, AJ; Koops, AJ			High level fructan accumulation in a transgenic sugar beet	NATURE BIOTECHNOLOGY			English	Article						agricultural biology; metabolic engineering; carbohydrate	POTATO PLANTS; PHOTOSYNTHESIS; CARBOHYDRATE; ENZYMES; TOBACCO; TUBERS	have transformed sugar beet into a crop that produces fructans. The gene encoding 1-sucrose:sucrose fructosyl transferase (1-SST), which was isolated from Helianthus tuberosus, was introduced into sugar beet. In H. tuberosus, 1-SST mediates the first steps in fructan synthesis through the conversion of sucrose (GF) into low molecular weight fructans GF(2), GF(3), and GF(4). In the taproot of sugar beet transformed with the 1-sst gene, the stored sucrose is almost totally converted into low molecular weight fructans. In contrast, 1-sst expression in the leaves resulted in only low levels of fructans. Despite the storage carbohydrate having been altered, the expression of the 1-sst gene did not have any visible effect on phenotype and did not affect the growth rate of the taproot as observed under greenhouse conditions.	DLO, CPRO, Dept Cell Biol, Ctr Plant Breeding & Reprod Res,Agr Res Dept, NL-6700 AA Wageningen, Netherlands		Koops, AJ (corresponding author), DLO, CPRO, Dept Cell Biol, Ctr Plant Breeding & Reprod Res,Agr Res Dept, POB 16, NL-6700 AA Wageningen, Netherlands.		HALL, ROBERT D/B-8707-2015	HALL, ROBERT D/0000-0002-5786-768X				CAIRNS AJ, 1993, NEW PHYTOL, V123, P15, DOI 10.1111/j.1469-8137.1993.tb04526.x; DELZENNE NM, 1994, FOOD SCI TECHNOL-LEB, V27, P1, DOI 10.1006/fstl.1994.1001; HALL RD, 1993, PLANT CELL REP, V12, P339, DOI 10.1007/BF00237431; Hall RD, 1996, NAT BIOTECHNOL, V14, P1133, DOI 10.1038/nbt0996-1133; Hellwege EM, 1997, PLANT J, V12, P1057, DOI 10.1046/j.1365-313X.1997.12051057.x; Hirayama M., 1993, Inulin and inulin-containing crops. Proceedings of the international congress on food and non-food applications of inulin and inulin-containing crops, Wageningen, Netherlands, 17-21 February 1991., P347; HUBER SC, 1989, PLANT PHYSIOL, V91, P656, DOI 10.1104/pp.91.2.656; Koops AJ, 1996, PLANT PHYSIOL, V110, P1167, DOI 10.1104/pp.110.4.1167; PEN J, 1992, BIO-TECHNOL, V10, P292, DOI 10.1038/nbt0392-292; PILLONSMITS EAH, 1996, IND CROPS PRODUCTS, V5, P35; POLLOCK CJ, 1991, ANNU REV PLANT PHYS, V42, P77, DOI 10.1146/annurev.pp.42.060191.000453; Rober M, 1996, PLANTA, V199, P528, DOI 10.1007/BF00195183; SAFTNER RA, 1983, PLANT PHYSIOL, V72, P1, DOI 10.1104/pp.72.1.1; VANDERMEER IM, 1994, PLANT CELL, V6, P561, DOI 10.1105/tpc.6.4.561; VANDERMEER IM, 1998, IN PRESS PLANT J; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; WISE CS, 1955, ANAL CHEM, V27, P33, DOI 10.1021/ac60097a011	17	86	104	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					843	846		10.1038/nbt0998-843	http://dx.doi.org/10.1038/nbt0998-843			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743117				2022-12-25	WOS:000075671700030
J	Zhuang, ZP; Park, WS; Pack, S; Schmidt, L; Vortmeyer, AO; Pak, E; Pham, T; Weil, RJ; Candidus, S; Lubensky, IA; Linehan, WM; Zbar, B; Weirich, G				Zhuang, ZP; Park, WS; Pack, S; Schmidt, L; Vortmeyer, AO; Pak, E; Pham, T; Weil, RJ; Candidus, S; Lubensky, IA; Linehan, WM; Zbar, B; Weirich, G			Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas	NATURE GENETICS			English	Article							HUMAN CANCER; MUTATIONS; LYMPHOMA; TUMORS	The gene defect for hereditary papillary renal carcinoma(1) (HPRC) has recently been mapped to chromosome 7q, and germline mutations of MET (also known as c-met) at 7q31 have been detected in patients with HPRC (ref, 2). Tumours from these patients commonly show trisomy of chromosome 7 when analysed by cytogenetic studies and comparative genomic hybridization(3) (CGH), However, the relationship between trisomy 7 and MET germline mutations is not clear. We studied 16 renal tumours from two patients with documented germline mutations in exon 16 of MET. Flourescent in situ hybridization (FISH) analysis showed trisomy 7 in all tumours, To determine whether the chromosome bearing the mutant or wild-type MET gene was duplicated, we performed duplex PCR and phosphoimage densitometry using polymorphic microsatellite markers D7S1801 and D7S1822, which were linked to the disease gene locus, and D1S1646 as an internal control. We determined the parental origin of chromosome alleles by genotyping parental DNA, In ail 16 tumours there was an increased signal intensity (2:1 ratio) of the microsatellite allele from the chromosome bearing the mutant MET compared with the allele from the chromosome bearing the wild-type MET. Our study demonstrates a non-random duplication of the chromosome bearing the mutated MET in HPRC and implicates this event in tumorigenesis.	NCI, Pathol Lab, Bethesda, MD 20892 USA; Sci Applicat Int Corp, Intramural Res Support Program, Frederick, MD USA; Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany; NCI, Urol Oncol Branch, Bethesda, MD 20892 USA; NCI, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Technical University of Munich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Zhuang, ZP (corresponding author), NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA.		Pack, Svetlana D./C-2020-2014	Pack, Svetlana D./0000-0003-3256-6626				BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; ROWLEY JD, 1984, CANCER RES, V44, P3159; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	11	224	234	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					66	69		10.1038/1727	http://dx.doi.org/10.1038/1727			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731534				2022-12-25	WOS:000075671400022
J	Street, VA; McKee-Johnson, JW; Fonseca, RC; Tempel, BL; Noben-Trauth, K				Street, VA; McKee-Johnson, JW; Fonseca, RC; Tempel, BL; Noben-Trauth, K			Mutations in a plasma membrane Ca2+-ATPase gene cause deafness in deafwaddler mice	NATURE GENETICS			English	Article							HAIR-CELLS; GERBIL COCHLEA; CA-ATPASE; TRANSDUCTION; EXPRESSION	Hearing loss is the most common sensory deficit in humans. Because the auditory systems of mice and humans are conserved, studies on mouse models have predicted several human deafness genes and identified new genes involved in hearing(1,2). The deafwaddler (dfw) mouse mutant is deaf and displays vestibular/motor imbalance. Here we report that the gene encoding a plasma membrane Ca2+-ATPase type 2 pump (Atp2b2, also known as Pmca2) is mutated in dfw. An A-->G nucleotide transition in dfw DNA causes a glycine-to-serine substitution at a highly conserved amino-acid position, whereas in a second allele, dfw(2J), a 2-base-pair deletion causes a frameshift that predicts a truncated protein. In the cochlea, the protein Atp2b2 is localized to stereocilia and the basolateral wall of hair cells in wild-type mice, but is not detected in dfw(2J) mice. This indicates that mutation of Atp2b2 may cause deafness and imbalance by affecting sensory transduction in stereocilia(3) as well as neurotransmitter release from the basolateral membrane(4). These mutations affecting Atp2b2 in dfw and dfw(2J) are the first to be found in a mammalian plasma membrane calcium pump and define a new class of deafness genes that directly affect hair-cell physiology.	Univ Washington, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA; Natl Inst Deafness & Commun Disorders, Sect Murine Genet, NIH, Rockville, MD 20850 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Tempel, BL (corresponding author), Univ Washington, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Box 357923, Seattle, WA 98195 USA.							ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Apicella S, 1997, NEUROSCIENCE, V79, P1145, DOI 10.1016/S0306-4522(97)00035-3; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; Crouch JJ, 1996, HEARING RES, V101, P55, DOI 10.1016/S0378-5955(96)00132-3; Crouch JJ, 1995, HEARING RES, V92, P112, DOI 10.1016/0378-5955(95)00201-4; Denk W, 1995, NEURON, V15, P1311, DOI 10.1016/0896-6273(95)90010-1; EATOCK RA, 1987, J NEUROSCI, V7, P2821; GAO JZ, 1995, CANCER RES, V55, P743; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; KUZMIN I, 1994, CANCER RES, V54, P2486; Lane PW, 1987, MOUSE NEWS LETT, V77, P129; Lumpkin EA, 1997, P NATL ACAD SCI USA, V94, P10997, DOI 10.1073/pnas.94.20.10997; McKee-Johnson JW, 1998, GENOMICS, V49, P371, DOI 10.1006/geno.1998.5274; MCKEEJOHNSON J, 1996, PROTOCOLS YEAST ARTI, P167; NobenTrauth K, 1997, GENOMICS, V44, P266, DOI 10.1006/geno.1997.4869; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; NORTON SJ, 1996, ASS RES OT ABSTR, V19, P82; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; STAHL WL, 1992, MOL BRIN RES, V16, P222; Steel KP, 1996, CURR OPIN NEUROBIOL, V6, P520, DOI 10.1016/S0959-4388(96)80059-6; STREET VA, 1995, GENOMICS, V29, P123, DOI 10.1006/geno.1995.1222; Tucker T, 1995, NEURON, V15, P1323, DOI 10.1016/0896-6273(95)90011-X; Yamoah EN, 1998, J NEUROSCI, V18, P610	23	222	233	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					390	394		10.1038/1284	http://dx.doi.org/10.1038/1284			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697703				2022-12-25	WOS:000075107600025
J	Klivenyi, P; Ferrante, RJ; Matthews, RT; Bogdanov, MB; Klein, AM; Andreassen, OA; Mueller, G; Wermer, M; Kaddurah-Daouk, R; Beal, MF				Klivenyi, P; Ferrante, RJ; Matthews, RT; Bogdanov, MB; Klein, AM; Andreassen, OA; Mueller, G; Wermer, M; Kaddurah-Daouk, R; Beal, MF			Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis	NATURE MEDICINE			English	Article							SUPEROXIDE-DISMUTASE MUTATION; NMR MAGNETIZATION-TRANSFER; MOTOR-NEURON DISEASE; MOUSE MODEL; KINASE; DEGENERATION; BRAIN; EXPRESSION; MICE	Mitochondria are particularly vulnerable to oxidative stress, and mitochondrial swelling and vacuolization are among the earliest pathologic features found in two strains of transgenic amyotrophic lateral sclerosis (ALS) mice with SOD1 mutations(1,2). Mice with the G93A human SOD1 mutation have altered electron transport enzymes, and expression of the mutant enzyme in vitro results in a loss of mitochondrial membrane potential and elevated cytosolic calcium concentration(3). Mitochondrial dysfunction may lead to ATP depletion, which may contribute to cell death. If this is true, then buffering intracellular energy levels could exert neuroprotective effects. Creatine kinase and its substrates creatine and phosphocreatine constitute an intricate cellular energy buffering and transport system connecting sites of energy production (mitochondria) with sites of energy consumption(4) and creatine administration stabilizes the mitochondrial creatine kinase and inhibits opening of the mitochondrial transition pore(5). We found that oral administration of creatine produced a dose-dependent improvement in motor performance and extended survival in G93A transgenic mice, and it protected mice from loss of both motor neurons and substantia nigra neurons at 120 days of age. Creatine administration protected G93A transgenic mice from increases in biochemical indices of oxidative damage. Therefore, creatine administration may be a new therapeutic strategy for ALS.	Massachusetts Gen Hosp, Neurol Serv, Neurochem Lab, Boston, MA 02118 USA; Harvard Univ, Sch Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Dept Vet Affairs, Bedford, MA 01730 USA; Avicena Grp Inc, Cambridge, MA 02142 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Boston University; Boston University; Cornell University	Beal, MF (corresponding author), Massachusetts Gen Hosp, Neurol Serv, Neurochem Lab, 32 Fruit St, Boston, MA 02118 USA.		Andreassen, Ole A./AAY-7531-2020	Klivenyi, Peter/0000-0002-5389-3266; Kaddurah-Daouk, Rima/0000-0003-1858-5732; Andreassen, Ole A./0000-0002-4461-3568	NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH011692] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG12292] Funding Source: Medline; NIMH NIH HHS [MH11692] Funding Source: Medline; NINDS NIH HHS [NS37102] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLANCHARD V, 1994, MOL BRAIN RES, V22, P29, DOI 10.1016/0169-328X(94)90029-9; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; CORBETT RJT, 1994, J CEREBR BLOOD F MET, V14, P1070, DOI 10.1038/jcbfm.1994.140; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; Matthews RT, 1998, J NEUROSCI, V18, P156; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SASAKI S, 1990, J NEUROL SCI, V97, P233, DOI 10.1016/0022-510X(90)90221-8; SAUTER A, 1993, J BIOL CHEM, V268, P13166; Siklos L, 1996, ANN NEUROL, V39, P203, DOI 10.1002/ana.410390210; SIPILA I, 1981, NEW ENGL J MED, V304, P867, DOI 10.1056/NEJM198104093041503; White RJ, 1996, J NEUROSCI, V16, P5688; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xu CJ, 1996, J BIOL CHEM, V271, P13435, DOI 10.1074/jbc.271.23.13435	22	551	583	1	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					347	350		10.1038/6568	http://dx.doi.org/10.1038/6568			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086395				2022-12-25	WOS:000078851600044
J	Shibata, R; Igarashi, T; Haigwood, N; Buckler-White, A; Ogert, R; Ross, W; Willey, R; Cho, MW; Martin, MA				Shibata, R; Igarashi, T; Haigwood, N; Buckler-White, A; Ogert, R; Ross, W; Willey, R; Cho, MW; Martin, MA			Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE GLOBULIN; MONOCLONAL-ANTIBODY; VACCINE DEVELOPMENT; CHIMPANZEES; TYPE-1; CHALLENGE; PROTECTION; GP120; PREVENTION	Virus-specific antibodies protect individuals against a wide variety of viral infections(1-7). To assess whether human immunodeficiency virus type 1 (HIV-1) envelope-specific antibodies confer resistance against primate lentivirus infections, we purified immunoglobulin (IgG) from chimpanzees infected with several different HIV-1 isolates, and used this for passive immunization of pig-tailed macaques. These monkeys were subsequently challenged intravenously with a chimeric simian-human immunodeficiency virus (SHIV) bearing an envelope glycoprotein derived form HIV-1(DH12), a dual-tropic primary virus isolate. Here we show that anti-SHIV neutralizing activity, determined in vitro using an assay measuring loss of infectivity, is the absolute requirement for antibody-mediated protection in vivo. Using an assay that measures 100% neutralization, the titer in plasma for complete protection of the SHIV-challenged macaques was in the range of 1:5-1:8. The HIV-1-specific neutralizing antibodies studied are able to bind to native gp120 present on infectious virus particles. Administration of non-neutralizing anti-HIV IgG neither inhibited nor enhanced a subsequent SHIV infection.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; Georgetown Med Ctr, Div Mol Virol & Immunol, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Center for Infectious Disease Research; Georgetown University	Shibata, R (corresponding author), VaxGen, 1000 Marina Blvd, Brisbane, CA 94005 USA.		Haigwood, Nancy Logan/AAV-7484-2020	Cho, Michael/0000-0003-0522-345X; Haigwood, Nancy/0000-0002-1477-9575	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000415, Z01AI000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BOGERS WMJM, 1995, AIDS, V9, pF13; BRUCK C, 1994, VACCINE, V12, P1141, DOI 10.1016/0264-410X(94)90185-6; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; HAMMON WM, 1953, JAMA-J AM MED ASSOC, V151, P1272; JANEWAY CA, 1945, B NEW YORK ACAD MED, V21, P202; Johnson RP, 1996, CURR OPIN IMMUNOL, V8, P554, DOI 10.1016/S0952-7915(96)80046-X; KRUGMAN S, 1960, JAMA-J AM MED ASSOC, V174, P83; Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733; *NIH, 1985, DHHS PUBL NIH, V8523; PRINCE PN, 1991, OMEGA-J DEATH DYING, V23, P1; REED L. J., 1938, AMER JOUR HYG, V27, P493; Shibata R, 1997, AIDS RES HUM RETROV, V13, P377, DOI 10.1089/aid.1997.13.377; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; Stott E J, 1994, Curr Top Microbiol Immunol, V188, P221; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; WILLEY RL, 1991, VIROLOGY, V184, P319, DOI 10.1016/0042-6822(91)90848-6; Willey RL, 1996, J VIROL, V70, P6431, DOI 10.1128/JVI.70.9.6431-6436.1996	31	480	516	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					204	210		10.1038/5568	http://dx.doi.org/10.1038/5568			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930869				2022-12-25	WOS:000078274400030
J	Walczak, H; Miller, RE; Ariail, K; Gliniak, B; Griffith, TS; Kubin, M; Chin, W; Jones, J; Woodward, A; Le, T; Smith, C; Smolak, P; Goodwin, RG; Rauch, CT; Schuh, JCL; Lynch, DH				Walczak, H; Miller, RE; Ariail, K; Gliniak, B; Griffith, TS; Kubin, M; Chin, W; Jones, J; Woodward, A; Le, T; Smith, C; Smolak, P; Goodwin, RG; Rauch, CT; Schuh, JCL; Lynch, DH			Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo	NATURE MEDICINE			English	Article							TNF RECEPTOR SUPERFAMILY; TRAIL-INDUCED APOPTOSIS; FAS-LIGAND; RECOMBINANT HUMAN; RHEUMATOID-ARTHRITIS; DEATH DOMAIN; CELL-DEATH; T-CELLS; FAMILY; ACTIVATION	To evaluate the utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ-huCD95L in vivo, administration of either LZ-huTRAIL or LZ-muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ-huTRAIL actively suppressed growth of the TRAIL-sensitive human mammary adenocarcinoma cell line MDA-231 in CB. 17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection.	Immunex Res & Dev Corp, Seattle, WA 98101 USA		Lynch, DH (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.	Lynch@Immunex.com	Griffith, Thomas/ABF-8225-2020	Walczak, Henning/0000-0002-6312-4591; Schuh, JoAnn C. L./0000-0002-2399-8518				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BROUCKAERT PGG, 1986, INT J CANCER, V38, P763, DOI 10.1002/ijc.2910380521; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CERAMI A, 1988, IMMUNOL TODAY, V9, P28, DOI 10.1016/0167-5699(88)91353-9; COHEN J, 1988, BONE MARROW TRANSPL, V3, P193; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Griffith TS, 1998, J IMMUNOL, V161, P2833; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1997, BRIT MED BULL, V53, P604; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; REVEL M, 1987, CIBA F SYMP, V129, P223; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tanaka M, 1997, J IMMUNOL, V158, P2303; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	46	2163	2318	1	86	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					157	163		10.1038/5517	http://dx.doi.org/10.1038/5517			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930862				2022-12-25	WOS:000078274400023
J	Ambs, S; Merriam, WG; Ogunfusika, MO; Bennett, WP; Ishibe, N; Hussain, SP; Tzeng, EE; Geller, DA; Billiar, TR; Harris, CC				Ambs, S; Merriam, WG; Ogunfusika, MO; Bennett, WP; Ishibe, N; Hussain, SP; Tzeng, EE; Geller, DA; Billiar, TR; Harris, CC			P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; INDUCED APOPTOSIS; SUPPRESSOR GENE; MESSENGER-RNA; IN-VITRO; EXPRESSION; ANGIOGENESIS; HEPATOCYTES; INHIBITION	The finding of frequent nitric oxide synthase expression in human cancers indicates that nitric oxide has a pathophysiological role in carcinogenesis. To determine the role of nitric oxide in tumor progression, we generated human carcinoma cell lines that produced nitric oxide constitutively. Cancer cells expressing inducible nitric oxide synthase that had wild-type p53 had reduced tumor growth in athymic nude mice, whereas those with mutated p53 had accelerated tumor growth associated with increased vascular endothelial growth factor expression and neovascularization. Our data indicate that tumor-associated nitric oxide production may promote cancer progression by providing a selective growth advantage to tumor cells with mutant p53, and that inhibitors of inducible nitric oxide synthase may have therapeutic activity in these tumors.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Genet Epidemiol Branch, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Hussain, S. Perwez/0000-0002-2294-522X; Ambs, Stefan/0000-0001-7651-9309				Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Ambs S, 1998, CANCER RES, V58, P334; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONG ZY, 1994, CANCER RES, V54, P789; Edwards P, 1996, J SURG RES, V63, P49, DOI 10.1006/jsre.1996.0221; Ellie E, 1995, NEUROREPORT, V7, P294, DOI 10.1097/00001756-199512290-00070; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Garcia-Cardena G, 1998, J NATL CANCER I, V90, P560, DOI 10.1093/jnci/90.8.560; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Geng YJ, 1996, CANCER RES, V56, P866; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRIFFITHS MJD, 1993, BRIT J PHARMACOL, V110, P963, DOI 10.1111/j.1476-5381.1993.tb13907.x; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nicotera P, 1995, ADV NEUROIMMUNOL, V5, P411, DOI 10.1016/0960-5428(95)00025-9; PIAZZA GA, 1995, CANCER RES, V55, P3110; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAK J, 1995, CANCER RES, V55, P4575; Thomsen LL, 1997, CANCER RES, V57, P3300; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Vermeulen PB, 1996, MICROVASC RES, V51, P164, DOI 10.1006/mvre.1996.0018; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	33	254	277	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1371	1376		10.1038/3957	http://dx.doi.org/10.1038/3957			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846573				2022-12-25	WOS:000077336900031
J	Khanna, KK; Keating, KE; Kozlov, S; Scott, S; Gatei, M; Hobson, K; Taya, Y; Gabrielli, B; Chan, D; Lees-Miller, SP; Lavin, MF				Khanna, KK; Keating, KE; Kozlov, S; Scott, S; Gatei, M; Hobson, K; Taya, Y; Gabrielli, B; Chan, D; Lees-Miller, SP; Lavin, MF			ATM associates with and phosphorylates p53: mapping the region of interaction	NATURE GENETICS			English	Article							ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; PROTEIN; KINASE; PRODUCT; DOMAIN; GENE	The human genetic disorder ataxia-telangiectasia (AT) is characterized by immunodeficiency. progressive cerebellar ataxia. radiosensitivity, cell cycle checkpoint defects and cancer predisposition(1). The gene mutated in this syndrome, ATM (for AT mutated), encodes a protein containing a phosphatidyl-inositol 3-kinase (PI-3 kinase)-like domain(2,3). ATM also contains a proline-rich region(4) and a leucine zipper(2,5), both of which implicate this protein in signal transduction. The proline-rich region has been shown to bind to the SH3 domain of c-Abl, which facilitates its phosphorylation and activation by ATM (refs 4,6). Previous results have demonstrated that AT cells are defective in the G1/S checkpoint activated after radiation damage and that this defect is attributable to a defective p53 signal transduction pathway(7,8). We report here direct interaction between ATM and p53 involving two regions in ATM. one at the amino terminus and the other at the carboxy terminus, corresponding to the PI-3 kinase domain. Recombinant ATM protein phosphorylates p53 on serine 15 near the N terminus. Furthermore, ectopic expression of ATM in AT cells restores normal ionizing radiation (IR)-induced phosphorylation of p53, whereas expression of ATM antisense RNA in control cells abrogates the rapid IR-induced phosphorylation of p53 on serine 15. These results demonstrate that ATM can bind p53 directly and is responsible for its serine 15 phosphorylation. thereby contributing to the activation and stabilization of p53 during the IR-induced DNA damage response.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Dept Pathol, Brisbane, Qld 4029, Australia; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Univ Calgary, Calgary, AB T2N 1N4, Canada; PO Royal Brisbane Hosp, Queensland Inst Med Res, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; National Cancer Center - Japan; University of Calgary; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Dept Pathol, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Lavin, Martin F/F-5961-2014; Chan, Doris/O-1227-2014; Khanna, Kum Kum/I-1747-2013; Gabrielli, Brian G/B-3655-2011; Kozlov, Sergei/M-2067-2014; Kozlov, Sergei/T-9779-2019; Hobson, Keith/Q-9306-2019	Lavin, Martin F/0000-0002-5940-4769; Chan, Doris/0000-0002-4990-986X; Gabrielli, Brian G/0000-0003-3933-1651; Kozlov, Sergei/0000-0001-6183-7339; Khanna, Kum Kum/0000-0001-8650-5381				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	20	382	401	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					398	400		10.1038/3882	http://dx.doi.org/10.1038/3882			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843217				2022-12-25	WOS:000077199600032
J	Krantz, A				Krantz, A			Diversification of the drug discovery process	NATURE BIOTECHNOLOGY			English	Editorial Material									Bullet Therapeut, San Mateo, CA USA		Krantz, A (corresponding author), Bullet Therapeut, San Mateo, CA USA.								0	25	26	3	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1294	1294		10.1038/4243	http://dx.doi.org/10.1038/4243			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853592	Bronze			2022-12-25	WOS:000077232600003
J	Machelska, H; Cabot, PJ; Mousa, SA; Zhang, Q; Stein, C				Machelska, H; Cabot, PJ; Mousa, SA; Zhang, Q; Stein, C			Pain control in inflammation governed by selectins	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING FACTOR; PERIPHERAL OPIOID ANALGESIA; INFLAMED TISSUE; POLYSACCHARIDE FUCOIDIN; GENE-EXPRESSION; BETA-ENDORPHIN; IMMUNE CELLS; P-SELECTIN; RECEPTORS; RATS	Opioid-containing immune cells migrate preferentially to inflamed sites, where they release beta-endorphin which activates peripheral opioid receptors to inhibit pain(1,2). Immunocyte recruitment is a multistep, sequential engagement of various adhesion molecules located on immune cells and vascular endothelium. Selectins mediate the initial phase of immunoctye extravasation into inflamed sites(3,4). Here we show that anti-selectin treatment abolishes peripheral opioid analgesia elicited either endogenously (by stress) or by corticotropin-releasing factor. This results from a blockade of the infiltration of immunocytes containing beta-endorphin and the consequent decrease of the beta-endorphin content in the inflamed tissue. These findings indicate that the immune system uses mechanisms of cell migration not only to fight pathogens but also to control pain in injured tissue. Thus, pain is exacerbated by measures inhibiting the immigration of opioid-producing cells or, conversely, analgesia might be conveyed by adhesive interactions that recruit those cells to injured tissue.	Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; NIDA, Preclin Pharmacol Lab, IRP, NIH, Baltimore, MD 21224 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Machelska, H (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St, Baltimore, MD 21287 USA.		Mousa, Shaker A/A-7151-2017; Cabot, Peter John/B-2424-2013	Mousa, Shaker A/0000-0002-9294-015X; Cabot, Peter John/0000-0003-1778-3753; Machelska, Halina/0000-0001-6315-2958; Stein, Christoph/0000-0001-5240-6836				ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Bochner BS, 1995, INFLAMMATION MEDIATO, P29; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Davenpeck KL, 1997, J IMMUNOL, V159, P1977; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Ji RR, 1995, J NEUROSCI, V15, P8156; Kanwar S, 1997, J EXP MED, V185, P1077, DOI 10.1084/jem.185.6.1077; KUBES P, 1995, J CLIN INVEST, V95, P2510, DOI 10.1172/JCI117952; LEY K, 1993, BLOOD, V81, P177; LIM HC, 1988, EXP NEUROL, V99, P133, DOI 10.1016/0014-4886(88)90133-1; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; MEBIUS RE, 1993, J IMMUNOL, V151, P3252; Mousa SA, 1996, EUR J PHARMACOL, V311, P221, DOI 10.1016/0014-2999(96)00440-2; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Schafer M, 1996, P NATL ACAD SCI USA, V93, P6096, DOI 10.1073/pnas.93.12.6096; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Sharp B, 1997, NAT MED, V3, P831, DOI 10.1038/nm0897-831; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; Stein C, 1996, J CLIN INVEST, V98, P793, DOI 10.1172/JCI118852; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Teixeira MM, 1997, BRIT J PHARMACOL, V120, P1059, DOI 10.1038/sj.bjp.0701024	27	140	144	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1425	1428		10.1038/4017	http://dx.doi.org/10.1038/4017			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846582				2022-12-25	WOS:000077336900040
J	Robertson, NG; Lu, L; Heller, S; Merchant, SN; Eavey, RD; McKenna, M; Nadol, JB; Miyamoto, RT; Linthicum, FH; Neto, JFL; Hudspeth, AJ; Seidman, CE; Morton, CC; Seidman, JG				Robertson, NG; Lu, L; Heller, S; Merchant, SN; Eavey, RD; McKenna, M; Nadol, JB; Miyamoto, RT; Linthicum, FH; Neto, JFL; Hudspeth, AJ; Seidman, CE; Morton, CC; Seidman, JG			Mutations in a novel cochlear gene cause DFNA9, a human nonsyndromic deafness with vestibular dysfunction	NATURE GENETICS			English	Article							SENSORINEURAL HEARING-LOSS; MYOSIN-VIIA GENE; SERINE-PROTEASE ZYMOGEN; TEMPORAL BONE FINDINGS; EXTRACELLULAR-MATRIX; FACTOR-C; DOMAINS; HYBRIDIZATION; PROTEINS; LIMULUS	DFNA9 is an autosomal dominant, nonsyndromic, progressive sensorineural hearing loss with vestibular pathology. Here we report three missense mutations in human COCH (previously described as Coch5b2), a novel cochlear gene, in three unrelated kindreds with DFNA9. All three residues mutated in DFNA9 are conserved in mouse and chicken Coch, and are found in a region containing four conserved cysteines with homology to a domain in factor C, a lipopolysaccharide-binding coagulation factor in Limulus polyphemus. COCH message, found at high levels in human cochlear and vestibular organs, occurs in the chicken inner ear in the regions of the auditory and vestibular nerve fibres, the neural and abneural limbs adjacent to the cochlear sensory epithelium and the stroma of the crista ampullaris of the vestibular labyrinth. These areas correspond to human inner ear structures which show histopathological findings of acidophilic ground substance in DFNA9 patients.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dept Genet, Sch Med, Boston, MA 02115 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Rockefeller Univ, Lab Sensory Neurosci, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA; Indiana Univ, Sch Med, Dept Otolaryngol, Indianapolis, IN 46202 USA; House Ear Inst, Dept Histopathol, Los Angeles, CA 90057 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Rockefeller University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Indiana University System; Indiana University-Purdue University Indianapolis; House Research Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Morton, CC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003402] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00317, DC03402] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Benson DW, 1996, CIRCULATION, V93, P1791, DOI 10.1161/01.CIR.93.10.1791; Cohen M. M., 1995, HEREDITARY HEARING L, P9; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; COLOMBATTI A, 1991, BLOOD, V77, P2305; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; HALPIN C, 1996, AM J AUDIOL, V5, P105; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KHETARPAL U, 1991, ARCH OTOLARYNGOL, V117, P1032; KHETARPAL U, 1993, ARCH OTOLARYNGOL, V119, P106; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Manolis EN, 1996, HUM MOL GENET, V5, P1047, DOI 10.1093/hmg/5.7.1047; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAKAMURA T, 1988, EUR J BIOCHEM, V176, P89, DOI 10.1111/j.1432-1033.1988.tb14254.x; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Robertson NG, 1997, GENOMICS, V46, P345, DOI 10.1006/geno.1997.5067; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; VanCamp G, 1997, AM J HUM GENET, V60, P758; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191	29	251	280	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					299	303		10.1038/3118	http://dx.doi.org/10.1038/3118			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806553				2022-12-25	WOS:000076698100028
J	Pratico, D; Tangirala, RK; Rader, DJ; Rokach, J; FitzGerald, GA				Pratico, D; Tangirala, RK; Rader, DJ; Rokach, J; FitzGerald, GA			Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice	NATURE MEDICINE			English	Article							APOLIPOPROTEIN-E; OXIDATIVE MODIFICATION; MEMORIAL-LECTURE; HYPERCHOLESTEROLEMIA; LESIONS; ATHEROGENESIS; LDL	Oxidative modification of low density lipoprotein (LDL) has been implicated in atherogenesis'. Evidence consistent with this hypothesis includes the presence of oxidized lipids in atherosclerotic lesions(2,3), the newly discovered biological properties conferred on LDL by oxidation(1,4) and the acceleration of atherogenesis by in vivo delivery of the gene for 15-lipoxygenase(5), an oxidizing enzyme present in atherosclerotic lesions(6). However, it is still unknown whether oxidative stress actually coincides with the evolution of the disease or whether it is of functional relevance to atherogenesis in vivo. Isoprostanes are products of arachidonic acid catalyzed by free radicals, which reflect oxidative stress and lipid peroxidation in vivo(7). Elevation of tissue and urinary isoprostanes is characteristic of human atherosclerosis(8,9). Here, deficiency in apolipoprotein E in the mouse (apoE(-/-)) resulted in atherogenesis and an increase in iPF2(alpha)-VI, an F-2-isoprostane(10), in urine, plasma and vascular tissue. Supplementation with vitamin E significantly reduced isoprostane generation, but had no effect on plasma cholesterol levels in apoE(-/-) mice. Aortic lesion areas and IPF2(alpha)-VI levels in the arterial wall were also reduced significantly by vitamin E. Our results indicate that oxidative stress is increased in the apoE(-/-) mouse, is of functional importance in the evolution of atherosclerosis and can be suppressed by oral administration of vitamin E.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NHLBI NIH HHS [HL5400, HL,AG55323] Funding Source: Medline; NIDDK NIH HHS [DK-44730] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bird DA, 1998, J LIPID RES, V39, P1079; Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; FREUBIS J, 1995, ATHEROSCLEROSIS, V117, P617; Fruebis J, 1997, J LIPID RES, V38, P2455; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAYEK T, 1991, ARTERIOSCLER THROMB, V11, P1295, DOI 10.1161/01.ATV.11.5.1295; KUHN H, 1994, J EXP MED, V179, P1911; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1998, J INVEST MED, V46, P51; PRATICO D, 1997, AGENTS ACTIONS, V48, P26; PRATICO D, 1997, J CLIN INVEST, V100, P2027; REILLY MP, IN PRESS CIRCULATION; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; SANTARELLI E, 1994, SMALL BUS ECON, V6, P95, DOI 10.1007/BF01065182; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; Steinberg D, 1997, CIRCULATION, V95, P1062; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	27	443	453	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1189	1192		10.1038/2685	http://dx.doi.org/10.1038/2685			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771755				2022-12-25	WOS:000076230100041
J	Xu, JF; Meyers, D; Freije, D; Isaacs, S; Wiley, K; Nusskern, D; Ewing, C; Wilkens, E; Bujnovszky, P; Bova, GS; Walsh, P; Isaacs, W; Schleutker, J; Matikainen, M; Tammela, T; Visakorpi, T; Kallioniemi, OP; Berry, R; Schaid, D; French, A; McDonnell, S; Schroeder, J; Blute, M; Thibodeau, S; Gronberg, H; Emanuelsson, M; Damber, JE; Bergh, A; Jonsson, BA; Smith, J; Bailey-Wilson, J; Carpten, J; Stephan, D; Gillanders, E; Amundson, I; Kainu, T; Freas-Lutz, D; Baffoe-Bonnie, A; Van Aucken, A; Sood, R; Collins, F; Brownstein, M; Trent, J				Xu, JF; Meyers, D; Freije, D; Isaacs, S; Wiley, K; Nusskern, D; Ewing, C; Wilkens, E; Bujnovszky, P; Bova, GS; Walsh, P; Isaacs, W; Schleutker, J; Matikainen, M; Tammela, T; Visakorpi, T; Kallioniemi, OP; Berry, R; Schaid, D; French, A; McDonnell, S; Schroeder, J; Blute, M; Thibodeau, S; Gronberg, H; Emanuelsson, M; Damber, JE; Bergh, A; Jonsson, BA; Smith, J; Bailey-Wilson, J; Carpten, J; Stephan, D; Gillanders, E; Amundson, I; Kainu, T; Freas-Lutz, D; Baffoe-Bonnie, A; Van Aucken, A; Sood, R; Collins, F; Brownstein, M; Trent, J			Evidence for a prostate cancer susceptibility locus on the X chromosome	NATURE GENETICS			English	Article							ANDROGEN-RECEPTOR GENE; LINKAGE ANALYSIS; FAMILY HISTORY; RISK; INHERITANCE; SUPPORT; HUMANS; CAG	Over 200.000 new prostate cancer cases are diagnosed in the United States each year, accounting for more than 35% of all cancer cases affecting men, and resulting in 40,000 deaths annually(1). Attempts to characterize genes predisposing to prostate cancer have been hampered by a high phenocopy rate, the late age of onset of the disease and, in the absence of distinguishing clinical features, the inability to stratify patients into subgroups relative to suspected genetic locus heterogeneity. We previously performed a genome-wide search for hereditary prostate cancer (HPC) genes, finding evidence of a prostate cancer susceptibility locus on chromosome 1 (termed HPC1; ref. 2). Here we present evidence for the location of a second prostate cancer susceptibility gene, which by heterogeneity estimates accounts for approximately 16% of HPC cases. This HPC locus resides on the X chromosome (Xq27-28), a finding consistent with results of previous population-based studies suggesting an X-linked mode of HPC inheritance. Linkage to Xq27-28 was observed in a combined study population of 360 prostate cancer families collected at four independent sites in North America, Finland and Sweden. A maximum two-point lod score of 4.60 was observed at DXS1113, theta=0.26, in the combined data set. Parametric multipoint and non-parametric analyses provided results consistent with the two-point analysis. Significant evidence for genetic locus heterogeneity was observed, with similar estimates of the proportion of linked families in each separate family collection. Genetic mapping of the locus represents an important initial step in the identification of an X-linked gene implicated in the aetiology of HPC.	Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21287 USA; Univ Maryland, Ctr Genet Asthma & Complex Dis, Baltimore, MD 21201 USA; Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55902 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55902 USA; Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55902 USA; Umea Univ, Dept Oncol, Umea, Sweden; Umea Univ, Dept Urol & Androl, Umea, Sweden; Umea Univ, Dept Pathol, Umea, Sweden; Natl Human Genome Res Inst, Canc Invest Grp, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19012 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; Tampere University; Tampere University; Tampere University Hospital; Mayo Clinic; Mayo Clinic; Mayo Clinic; Umea University; Umea University; Umea University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Fox Chase Cancer Center	Isaacs, W (corresponding author), Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21287 USA.	wisaacs@jhmi.edu	Kallioniemi, Olli P/H-5111-2011; Brownstein, Michael/B-8609-2009; Smith, Jeff/C-3484-2012	Kallioniemi, Olli P/0000-0002-3231-0332; Bailey-Wilson, Joan/0000-0002-9153-2920; Schleutker, Johanna/0000-0002-1863-0305; McDonnell, Shannon/0000-0001-6201-369X; Bova, George/0000-0003-1639-3104; Smith, Jeffrey/0000-0001-8424-910X; Visakorpi, Tapio/0000-0002-5004-0364	NATIONAL CANCER INSTITUTE [P50CA058236, R01CA072818] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [N01HG055389] Funding Source: NIH RePORTER; NCI NIH HHS [CA72818, CA58236] Funding Source: Medline; NHGRI NIH HHS [N01-HG-55389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; Collins A, 1996, GENOMICS, V36, P157, DOI 10.1006/geno.1996.0436; Cooney KA, 1997, J NATL CANCER I, V89, P955, DOI 10.1093/jnci/89.13.955; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Eeles RA, 1998, AM J HUM GENET, V62, P653, DOI 10.1086/301745; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Gronberg H, 1997, CANCER RES, V57, P4707; Gronberg H, 1997, AM J EPIDEMIOL, V146, P552, DOI 10.1093/oxfordjournals.aje.a009313; Hakimi JM, 1996, WORLD J UROL, V14, P329; HAYES RB, 1995, INT J CANCER, V60, P361, DOI 10.1002/ijc.2910600315; Hsieh CL, 1997, J NATL CANCER I, V89, P1893, DOI 10.1093/jnci/89.24.1893; IRVINE RA, 1995, CANCER RES, V55, P1937; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; McIndoe RA, 1997, AM J HUM GENET, V61, P347, DOI 10.1086/514853; MONROE KR, 1995, NAT MED, V1, P827, DOI 10.1038/nm0895-827; NAROD SA, 1995, NAT MED, V1, P99, DOI 10.1038/nm0295-99; Ott J., 1991, ANAL HUMAN GENETIC L; Schaid DJ, 1998, AM J HUM GENET, V62, P1425, DOI 10.1086/301862; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stanford JL, 1997, CANCER RES, V57, P1194; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; WHITTEMORE AS, 1995, AM J EPIDEMIOL, V141, P732, DOI 10.1093/oxfordjournals.aje.a117495; WOOLF CM, 1960, CANCER, V13, P361	28	357	362	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					175	179		10.1038/2477	http://dx.doi.org/10.1038/2477			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771711				2022-12-25	WOS:000076231300020
J	Mummidi, S; Ahuja, SS; Gonzalez, E; Anderson, SA; Santiago, EN; Stephan, KT; Craig, FE; O'Connell, P; Tryon, V; Clark, RA; Dolan, MJ; Ahuja, SK				Mummidi, S; Ahuja, SS; Gonzalez, E; Anderson, SA; Santiago, EN; Stephan, KT; Craig, FE; O'Connell, P; Tryon, V; Clark, RA; Dolan, MJ; Ahuja, SK			Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression	NATURE MEDICINE			English	Article							INFECTION; RECEPTOR; ENTRY; LESTR/FUSIN; INDIVIDUALS; RESISTANCE; COFACTOR; LIGAND; ALLELE; SDF-1	Allelic variants for the HIV-1 co-receptors chemokine receptor 5 (CCR5) and CCR2, as well as the ligand for the co-receptor CXCR4 stromal-derived factor (SDF-1), have been associated with a delay in disease progression. We began this study to test whether polymorphisms in the CCR5 regulatory regions influence the course of HIV-1 disease, as well as to examine the role of the previously identified allelic variants in 1,090 HIV-1 infected individuals. Here we describe the evolutionary relationships between the phenotypically important CCR5 alleles, define precisely the CCR5 regulatory sequences that are linked to the CCR5-Delta 32 and CCR2-64i polymorphisms, and identify genotypes associated with altered rates of HIV-1 disease progression. The disease-retarding effects of the CCR2-641 allele were found in African Americans but not in Caucasians, and the SDF1-3'A/3'A genotype was associated with an accelerated progression to death. In contrast, the CCR5-Delta 32 allele and a CCR5 promoter mutation with which it is tightly linked were associated with limited disease-retarding effects. Collectively, these findings draw attention to a complex array of genetic determinants in the HIV-host interplay.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA; Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA; Wilford Hall USAF Med Ctr, Dept Med, Infect Dis Serv, Lackland AFB, TX 78236 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA.		Clark, Robert/Q-6764-2019; Mummidi, Srinivas/C-1004-2008; Mummidi, Srinivas/H-3335-2017	Clark, Robert/0000-0002-4892-3619; Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berger EA, 1997, AIDS, V11, pS3; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Garred P, 1998, LANCET, V351, P2, DOI 10.1016/S0140-6736(98)22001-0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004; Katzenstein TL, 1997, J ACQ IMMUN DEF SYND, V16, P10, DOI 10.1097/00042560-199709010-00002; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Meyer L, 1997, AIDS, V11, pF73, DOI 10.1097/00002030-199711000-00001; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Morawetz RA, 1997, EUR J IMMUNOL, V27, P3223, DOI 10.1002/eji.1830271220; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Rizzardi GP, 1998, NAT MED, V4, P252, DOI 10.1038/nm0398-252; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; Weatherall D, 1997, GENOME RES, V7, P967, DOI 10.1101/gr.7.10.967; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	34	285	300	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					786	793		10.1038/nm0798-786	http://dx.doi.org/10.1038/nm0798-786			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662369				2022-12-25	WOS:000074543900032
J	Hansen, J; KiellandBrandt, MC				Hansen, J; KiellandBrandt, MC			Inactivation of MET10 in brewer's yeast specifically increases SO2 formation during beer production	NATURE BIOTECHNOLOGY			English	Article						sulfite; brewing yeast; MET10	SACCHAROMYCES-CEREVISIAE; SULFATE ASSIMILATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ENERGY-METABOLISM; MET25 GENE; CARLSBERGENSIS; SULFITE; TRANSFORMATION; EXPRESSION	Sulfite is widely used as an antioxidant in food production. In beer brewing, sulfite has the additional role of stabilizing the flavor by forming adducts with aldehydes. Inadequate amounts of sulfite are sometimes produced by brewer's yeasts, so means of controlling the sulfite production are desired. In Saccharomyces yeasts, MET10 encodes a subunit of sulfite reductase. Partial or full elimination of MET10 gene activity in a brewer's yeast resulted in increased sulfite accumulation. Beer produced with such yeasts was quite satisfactory and showed increased flavor stability.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK		Hansen, J (corresponding author), CARLSBERG RES LAB, GAMLE CARLSBERG VEJ 10, DK-2500 COPENHAGEN, DENMARK.		Kielland-Brandt, Morten C./D-2563-2015	Hansen, Jorgen/0000-0003-4806-4014; Kielland-Brandt, Morten/0000-0002-1272-3877				ANNESS BJ, 1982, J I BREWING, V88, P244, DOI 10.1002/j.2050-0416.1982.tb04101.x; BARNFORTH CW, 1981, J I BREWING, V87, P30; BARONI M, 1986, GENE, V46, P71, DOI 10.1016/0378-1119(86)90168-X; Brewer J. D, 1980, P CONV I BREW AUSTR, V16, P155; CHEREST H, 1985, GENE, V34, P269; CHEREST H, 1992, GENETICS, V130, P51; Dufour, 1991, P EUR BREW CONV C, P209; Dufour J-P., 1989, P EUR BREW CONV C ZU, P331; GJERMANSEN C, 1981, CARLSBERG RES COMMUN, V46, P1, DOI 10.1007/BF02906193; GJERMANSEN C, 1991, THESIS U COPENHAGEN; GRANT WM, 1947, ANAL CHEM, V19, P345, DOI 10.1021/ac60005a023; Gyllang H, 1989, P EUR BREW CONV C ZU, P347; HADFIELD C, 1994, MOL GENETICS YEAST P, P17; HANSEN J, 1994, GENE, V140, P33, DOI 10.1016/0378-1119(94)90727-7; HANSEN J, 1994, J BACTERIOL, V176, P6050, DOI 10.1128/jb.176.19.6050-6058.1994; HAUKELI AD, 1971, J I BREWING, V77, P538, DOI 10.1002/j.2050-0416.1971.tb03418.x; HINZE H, 1986, ARCH MICROBIOL, V145, P27, DOI 10.1007/BF00413023; HOUGH JS, 1982, MALTING BREWING SCI, V2, P881; KOCH C, 1991, P EUR BREW CONV C LI, P201; KORCH C, 1991, MOL GEN GENET, V229, P96, DOI 10.1007/BF00264218; LANGIN T, 1986, GENE, V49, P283, DOI 10.1016/0378-1119(86)90364-1; MAIER K, 1986, BIOCHIM BIOPHYS ACTA, V848, P120, DOI 10.1016/0005-2728(86)90167-2; Meilgaard M. C., 1975, Technical Quarterly, Master Brewers Association of America, V12, P151; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; NILSSONTILLGREN T, 1986, CARLSBERG RES COMMUN, V51, P309, DOI 10.1007/BF02907164; Nordloev H., 1985, P EUR BREW CONV C HE, P291; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PETERSEN JGL, 1987, CURR GENET, V12, P167, DOI 10.1007/BF00436875; PICKERELL A T W, 1991, Journal of the American Society of Brewing Chemists, V49, P87; PILKINGTON BJ, 1988, J GEN MICROBIOL, V134, P2823; RIKKERINK EHA, 1988, J BACTERIOL, V170, P895, DOI 10.1128/jb.170.2.895-899.1988; SANGSODA S, 1985, MOL GEN GENET, V200, P407, DOI 10.1007/BF00425724; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIGSGAARD P, 1985, ASBC J, V43, P104; STRATFORD M, 1987, J GEN MICROBIOL, V133, P2173; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; THOMAS D, 1990, J BIOL CHEM, V265, P15518; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; 1977, J I BREWING, V83, P109	40	54	62	2	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1587	1591		10.1038/nbt1196-1587	http://dx.doi.org/10.1038/nbt1196-1587			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634827				2022-12-25	WOS:A1996VP83300028
J	Yokoe, E; Meyer, T				Yokoe, E; Meyer, T			Spatial dynamics of GFP-tagged proteins investigated by local fluorescence enhancement	NATURE BIOTECHNOLOGY			English	Article						mRNA transfection; green fluorescent protein; protein diffusion; K-ras	EXPRESSION; MUTATIONS; KINASE; RAS	We describe a method of monitoring the spatial dynamics of proteins in intact cells by locally enhancing the blue excited fluorescence of green fluorescent protein (GFP) using a spatially focused ultraviolet-laser pulse. GFP fusion proteins were efficiently expressed by micro-electroporation of in vitro synthesized mRNA into adherent mammalian cells. We found that the diffusion coefficient of cycle 3 mutant GFP was 43 mu m(2)/sec, compared to 4 mu m(2)/sec for wild-type GFP, suggesting that cycle 3 GFP diffuses freely in mammalian cells and is ideally suited as a fusion tag. The local fluorescence enhancement method was used to study the membrane dissociation rate of GFP-tagged K-ras, a small GTP binding protein that localizes to plasma membranes by a farnesyl lipid group and a polybasic region. Our data suggest that K-ras exists in a dynamic equilibrium and rapidly switches between a plasma membrane bound form and a cytosolic form with a plasma membrane dissociation time constant of 1.5 sec.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM-51457, GM-48113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113, R55GM048113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLAUDIO T, 1992, METHOD ENZYMOL, V207, P391; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LUBYPHELPS K, 1993, BIOPHYS J, V65, P236, DOI 10.1016/S0006-3495(93)81075-0; MASTRO AM, 1984, J CELL BIOL, V99, pS180, DOI 10.1083/jcb.99.1.180s; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; STEAMS T, 1995, CURR BIOL, V5, P3; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	25	163	240	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1252	1256		10.1038/nbt1096-1252	http://dx.doi.org/10.1038/nbt1096-1252			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631088				2022-12-25	WOS:A1996VK61800022
J	Sewell, AK; Gerth, UC; Price, DA; Purbhoo, MA; Boulter, JM; Gag, GF; Bell, JI; Phillips, RE; Jakobsen, BK				Sewell, AK; Gerth, UC; Price, DA; Purbhoo, MA; Boulter, JM; Gag, GF; Bell, JI; Phillips, RE; Jakobsen, BK			Antagonism of cytotoxic T-lymphocyte activation by soluble CD8	NATURE MEDICINE			English	Article							CELL RECEPTOR ANTAGONISTS; CLASS-I MOLECULE; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; ANTIGEN RECOGNITION; TYROSINE KINASE; ALPHA-3 DOMAIN; LIGANDS; COMPLEX; SELECTION	The CD8 co-receptor is important in the differentiation and selection of class 1 MHC-restricted 7 cells during thymic development, and in the activation of mature T lymphocytes in response to antigen. Here we show that soluble CD8 alpha alpha receptor, despite an extremely low affinity for MHC, inhibits activation of cytotoxic lymphocytes by obstructing CD3 zeta-chain phosphorylation. We propose a model for this effect that involves interference of productive receptor multimerization at the T-cell surface. These results provide new insights into the mechanism of T-cell activation and evidence that CD8 function is exquisitely sensitive to disruption, an effect that might be exploited by molecular therapeutics.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Clin Med,Mol Immunol Grp, Oxford OX3 9DS, England	University of Oxford	Jakobsen, BK (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Clin Med,Mol Immunol Grp, Oxford OX3 9DS, England.		Price, David A/C-7876-2013; Sewell, Andrew/GPT-4220-2022	Price, David A/0000-0001-9416-2737; Sewell, Andrew/0000-0003-3194-3135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGOSTINI C, 1989, CLIN IMMUNOL IMMUNOP, V50, P146, DOI 10.1016/0090-1229(89)90229-8; ALLEN PM, 1994, NATURE, V369, P355, DOI 10.1038/369355a0; Anel A, 1996, EUR J IMMUNOL, V26, P2310, DOI 10.1002/eji.1830261007; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; Choksi S, 1998, NAT MED, V4, P309, DOI 10.1038/nm0398-309; COBBOLD SP, 1992, IMMUNOL REV, V129, P165, DOI 10.1111/j.1600-065X.1992.tb01423.x; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DOHERTY PC, 1985, BRIT MED BULL, V41, P7, DOI 10.1093/oxfordjournals.bmb.a072028; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GIBLIN P, 1989, P NATL ACAD SCI USA, V86, P998, DOI 10.1073/pnas.86.3.998; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3; HO AD, 1989, LEUKEMIA, V3, P718; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KWANLIM GE, 1993, INT IMMUNOL, V5, P1219, DOI 10.1093/intimm/5.10.1219; LEUNG WPF, 1991, CELL, V65, P443; LEUNG WPF, 1993, EUR J IMMUNOL, V23, P212; LINKERISRAELI M, 1994, J IMMUNOL, V152, P3158; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MAIMONE D, 1991, NEUROLOGY, V41, P851, DOI 10.1212/WNL.41.6.851; MASON DW, 1986, ANNU REV IMMUNOL, V4, P119, DOI 10.1146/annurev.immunol.4.1.119; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Price DA, 1998, J MOL MED-JMM, V76, P699, DOI 10.1007/s001090050270; Purbhoo MA, 1998, P NATL ACAD SCI USA, V95, P4527, DOI 10.1073/pnas.95.8.4527; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WILLIAMS O, 1991, INT IMMUNOL, V3, P785, DOI 10.1093/intimm/3.8.785; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; YOON ST, 1994, IMMUNITY, V1, P563; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; ZIELINSKI CC, 1990, CLIN IMMUNOL IMMUNOP, V57, P74, DOI 10.1016/0090-1229(90)90023-J	54	32	36	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					399	404		10.1038/7398	http://dx.doi.org/10.1038/7398			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202928				2022-12-25	WOS:000079574300028
J	Takahashi, T; Kalka, C; Masuda, H; Chen, D; Silver, M; Kearney, M; Magner, M; Isner, JM; Asahara, T				Takahashi, T; Kalka, C; Masuda, H; Chen, D; Silver, M; Kearney, M; Magner, M; Isner, JM; Asahara, T			Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; GRANULOCYTE-COLONY; ANGIOGENESIS; ACTIVATION; MODEL; MICE	Endothelial progenitor cells (EPCs) have been isolated from circulating mononuclear cells in human peripheral blood and shown to be incorporated into foci of neovascularization, consistent with postnatal vasculogenesis'. We determined whether endogenous stimuli (tissue ischemia) and exogenous cytokine therapy (granulocyte macrophage-colony stimulating factor, GM-CSF) mobilize EPCs and thereby contribute to neovascularization of ischemic tissues. The development of regional ischemia in both mice and rabbits increased the frequency of circulating EPCs. In mice, the effect of ischemia-induced EPC mobilization was demonstrated by enhanced ocular neovascularization after cornea micropocket surgery in mice with hindlimb ischemia compared with that in non-ischemic control mice. In rabbits with hindlimb ischemia, circulating EPCs were further augmented after pretreatment with CM-CSF, with a corresponding improvement in hindlimb neovascularization. There was direct evidence that EPCs that contributed to enhanced corneal neovascularization were specifically mobilized from the bone marrow in response to ischemia and GM-CSF in mice transplanted with bone marrow from transgenic donors expressing P-galactosidase transcriptionally regulated by the endothelial cell-specific Tie-2 promoter. These findings indicate that circulating EPCs are mobilized endogenously in response to tissue ischemia or exogenously by cytokine therapy and thereby augment neovascularization of ischemic tissues.	Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med Cardiol, Boston, MA 02135 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Biomed Res, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Isner, JM (corresponding author), Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med Cardiol, 736 Cambridge St, Boston, MA 02135 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002824, R01HL040518, R01HL057516] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57516, HL02824, HL 40518] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGLIETTA M, 1989, J CLIN INVEST, V83, P551, DOI 10.1172/JCI113917; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; ASAHARA T, 1997, SCIENCE, V275, P965; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; BUSSOLINO F, 1989, J BIOL CHEM, V264, P18284; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Couffinhal T, 1998, AM J PATHOL, V152, P1667; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; FLEISCHMAN RA, 1995, EXP HEMATOL, V23, P1407; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1652; LEDNEY GD, 1985, J SURG RES, V38, P55, DOI 10.1016/0022-4804(85)90010-1; PERKINS S, 1990, BLOOD, V75, P620; PROKOP DJ, 1997, SCIENCE, V276, P71; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SOCINSKI MA, 1988, LANCET, V1, P1194; Soldi R, 1997, BLOOD, V89, P863, DOI 10.1182/blood.V89.3.863; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018	18	2000	2190	0	90	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					434	438		10.1038/7434	http://dx.doi.org/10.1038/7434			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202935				2022-12-25	WOS:000079574300035
J	Wallace, MJ; Batt, J; Fladd, CA; Henderson, JT; Skarnes, W; Rotin, D				Wallace, MJ; Batt, J; Fladd, CA; Henderson, JT; Skarnes, W; Rotin, D			Neuronal defects and posterior pituitary hypoplasia in mice lacking the receptor tyrosine phosphatase PTP sigma	NATURE GENETICS			English	Article							MOTOR AXON GUIDANCE; NERVOUS-SYSTEM; EXPRESSION; RAT; DROSOPHILA	The LAR-family protein tyrosine phosphatase sigma (PTP sigma, encoded by the gene Ptprs) consists of a cell adhesion-like extracellular domain composed of immunoglobulin and fibronectin type-ill repeats, a single transmembrane domain and two intracellular catalytic domains(1,2). It was previously shown to be expressed in neuronal and lung epithelial tissues in a developmentally regulated manner(2-8). To study the role of PTP sigma in mouse development, we inactivated Ptprs by gene targeting, All Ptprs(+/-) mice developed normally, whereas 60% of Ptprs(-/-) mice died within 48 hours after birth. The surviving Ptprs(-/-) mice demonstrated stunted growth, developmental delays and severe neurological defects including spastic movements, tremor, ataxic gait abnormal limb flexion and defective proprioception. Histopathology of brain sections revealed reduction and hypocellularity of the posterior pituitary of Ptptrs(-/-) mice, as well as a reduction of approximately 50-75%, in the number of choline acetyl transferase-positive cells in the forebrain. Moreover peripheral nerve electrophysiological analysis revealed slower conduction velocity in Ptprs(-/-) mice relative to wild-type or heterozygous animals, associated with an increased proportion of slowly conducting, small-diameter myelinated fibres and relative hypomyelination. By approximately three weeks of age, most remaining Ptprs(-/-) mice died from a wasting syndrome with atrophic intestinal villi, These results suggest that PTP sigma has a role in neuronal and epithelial development in mice.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Programme Lung Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Berkeley	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.on.ca	Fladd, Christopher/G-2422-2013	Fladd, Christopher/0000-0002-3521-1479; Wallace, Megan/0000-0001-5785-5120				BOURBON JR, 1996, PULMONARY SURFACTANT, P257; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; FERRIERE G, 1985, MUSCLE NERVE, V8, P697, DOI 10.1002/mus.880080812; Haworth K, 1998, MOL CELL NEUROSCI, V12, P93, DOI 10.1006/mcne.1998.0707; Henderson JT, 1996, J NEUROSCI, V16, P7574; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; JACOBOWITZ DM, 1997, CHEMOARCHITECTONIC A; Kim H, 1996, AM J PHYSIOL-LUNG C, V270, pL566, DOI 10.1152/ajplung.1996.270.4.L566; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Oliver J., 1983, HDB VET NEUROLOGIC D, P19; OUVRIER RA, 1987, MUSCLE NERVE, V10, P47, DOI 10.1002/mus.880100110; PITKANEN O, 1997, ANN MED, V30, P134; ROBERTSON A, 1993, ACTA NEUROPATHOL, V86, P163, DOI 10.1007/BF00334883; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; SAHIN M, 1993, J NEUROSCI, V13, P4968; SCHAAPVEID RQJ, 1995, DEV BIOL, V188, P134; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SMORTO MP, 1979, CLIN ELECTRONEUROGRA, P19; Sommer L, 1997, DEV DYNAM, V208, P48, DOI 10.1002/(SICI)1097-0177(199701)208:1<48::AID-AJA5>3.0.CO;2-1; STOKER AW, 1995, DEVELOPMENT, V121, P1833; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WANG H, 1995, J NEUROSCI RES, V41, P297, DOI 10.1002/jnr.490410303; YAN H, 1993, J BIOL CHEM, V268, P24880; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	28	111	113	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					334	338		10.1038/6866	http://dx.doi.org/10.1038/6866			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080192				2022-12-25	WOS:000078977900033
J	Genain, CP; Cannella, B; Hauser, SL; Raine, CS				Genain, CP; Cannella, B; Hauser, SL; Raine, CS			Identification of autoantibodies associated with myelin damage in multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; OLIGODENDROCYTE GLYCOPROTEIN; BASIC-PROTEIN; NONHUMAN PRIMATE; CELL; DEMYELINATION; RATS; LOCALIZATION; SPECIFICITY; ANTIBODIES	The molecular mechanisms underlying myelin sheath destruction in multiple sclerosis lesions remain unresolved. With immunogold-labeled peptides of myelin antigens and high-resolution microscopy, techniques that can detect antigen-specific antibodies in situ, we have identified autoantibodies specific for the central nervous system myelin antigen myelin/oligodendrocyte glycoprotein. These autoantibodies were specifically bound to disintegrating myelin around axons in lesions of acute multiple sclerosis and the marmoset model of allergic encephalomyelitis. These findings represent direct evidence that autoantibodies against a specific myelin protein mediate target membrane damage in central nervous system demyelinating disease.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol Neuropathol, Bronx, NY 10461 USA	University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine	Genain, CP (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Hauser, Stephen L/J-2978-2016		NIAID NIH HHS [AI 43073] Funding Source: Medline; NINDS NIH HHS [NS 11920, NS 08952] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011920, R01NS008952, P50NS011920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEU FP, 1963, J NEUROPATH EXP NEUR, V22, P403, DOI 10.1097/00005072-196307000-00003; AMOR S, 1994, J IMMUNOL, V153, P4349; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Brosnan C F, 1983, Acta Neuropathol Suppl, V9, P59; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; BRUNNER C, 1989, J NEUROCHEM, V52, P296, DOI 10.1111/j.1471-4159.1989.tb10930.x; COMPSTON A, 1991, TRENDS NEUROSCI, V14, P175, DOI 10.1016/0166-2236(91)90099-G; DALCANTO MC, 1975, J NEUROL SCI, V24, P313, DOI 10.1016/0022-510X(75)90251-8; EPSTEIN LG, 1983, J NEUROL SCI, V61, P341, DOI 10.1016/0022-510X(83)90167-3; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; GERRITSE K, 1994, J NEUROIMMUNOL, V49, P153, DOI 10.1016/0165-5728(94)90191-0; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Ichikawa M, 1996, J IMMUNOL, V157, P919; Kirschner Daniel A., 1992, P3; LASSMANN H, 1988, ACTA NEUROPATHOL, V75, P566, DOI 10.1007/BF00686201; Lassmann H, 1998, J NEUROIMMUNOL, V86, P213, DOI 10.1016/S0165-5728(98)00031-9; LININGTON C, 1987, J NEUROIMMUNOL, V17, P61, DOI 10.1016/0165-5728(87)90031-2; MOORE GRW, 1988, LAB INVEST, V59, P641; MORRIS G, 1996, EPITOPE MAPPING PROT, P1; PHAMDINH D, 1994, J NEUROCHEM, V63, P2353; PIDDLESDEN SJ, 1993, AM J PATHOL, V143, P555; PRINEAS JW, 1978, NEUROLOGY, V28, P68, DOI 10.1212/WNL.28.9_Part_2.68; RAINE CS, 1981, J NEUROL SCI, V52, P117, DOI 10.1016/0022-510X(81)90140-4; RAINE CS, 1974, LAB INVEST, V31, P369; RAINE CS, 1973, J NEUROL SCI, V20, P127, DOI 10.1016/0022-510X(73)90026-9; RAINE CS, 1970, J NEUROPATH EXP NEUR, V29, P177, DOI 10.1097/00005072-197004000-00002; SEIL FJ, 1968, EXP NEUROL, V22, P545, DOI 10.1016/0014-4886(68)90148-9; SUN JB, 1991, J IMMUNOL, V146, P1490; Tabira Takeshi, 1992, P783; TAKIZAWA T, 1994, J HISTOCHEM CYTOCHEM, V43, P1615; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WILLENBORG DO, 1983, J NEUROIMMUNOL, V5, P99, DOI 10.1016/0165-5728(83)90001-2; Wolf SD, 1996, J EXP MED, V184, P2271, DOI 10.1084/jem.184.6.2271	35	677	706	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					170	175		10.1038/5532	http://dx.doi.org/10.1038/5532			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930864				2022-12-25	WOS:000078274400025
J	Brodie, SJ; Lewinsohn, DA; Patterson, BK; Jiyamapa, D; Krieger, J; Corey, L; Greenberg, PD; Riddell, SR				Brodie, SJ; Lewinsohn, DA; Patterson, BK; Jiyamapa, D; Krieger, J; Corey, L; Greenberg, PD; Riddell, SR			In vivo migration and function of transferred HIV-1-specific cytotoxic T cells	NATURE MEDICINE			English	Article							ALLOGENEIC BONE-MARROW; VIRUS TYPE-1 INFECTION; EPSTEIN-BARR-VIRUS; HIV-1 INFECTION; IN-VIVO; LYMPHOCYTE RESPONSES; ADOPTIVE TRANSFER; IMMUNE-RESPONSES; FLOW-CYTOMETRY; VIRAL LOAD	The persistence of HIV replication in infected individuals may reflect an inadequate host HIV-specific CD8(+) cytotoxic T lymphocyte (CTL) response. The functional activity of HIV-specific CTLs and the ability of these effector cells to migrate in vivo to sites of infection was directly assessed by expanding autologous HIV-1 Gag-specific CD8(+) CTL clones in vitro and adoptively transferring these CTLs to HIV-infected individuals, The transferred CTLs retained lytic function in vivo, accumulated adjacent to HIV-infected cells in lymph nodes and transiently reduced the levels of circulating productively infected CD4(+) T cells. These results provide direct evidence that HIV-specific CTLs target sites of HIV replication and mediate antiviral activity, and indicate that the development of immunotherapeutic approaches to sustain a strong CTL response to HIV may be a useful adjunct to treatment of HIV infection.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Lab Med, Seattle, WA 98101 USA; Univ Washington, Dept Pediat, Seattle, WA 98101 USA; Univ Washington, Dept Urol, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA 98101 USA; Univ Washington, Dept Immunol, Seattle, WA 98101 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Foster City, CA 94404 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University	Riddell, SR (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI036613, U01AI041535] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41535, AI36613] Funding Source: Medline; NICHD NIH HHS [HD28834] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADA GL, 1986, CURR TOP MICROBIOL, V128, P1; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brodie SJ, 1998, J VIROL, V72, P5599, DOI 10.1128/JVI.72.7.5599-5609.1998; BRODIE SJ, 1995, AM J PATHOL, V146, P250; BRODIE SJ, 1994, J IMMUNOL, V153, P5790; Brodie SJ, 1998, J VIROL, V72, P3863, DOI 10.1128/JVI.72.5.3863-3871.1998; BYRNE JA, 1986, J IMMUNOL, V136, P698; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Diamond C, 1998, J VIROL, V72, P6223, DOI 10.1128/JVI.72.7.6223-6227.1998; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX WS, 1994, REV HIGH EDUC, V18, P1; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Harrer T, 1996, J IMMUNOL, V156, P2616; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; JASSOY C, 1992, J IMMUNOL, V149, P3113; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Pantaleo G, 1997, EUR J IMMUNOL, V27, P3166, DOI 10.1002/eji.1830271213; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PATTERSON BK, 1995, J VIROL, V69, P4316, DOI 10.1128/JVI.69.7.4316-4322.1995; Patterson BK, 1998, CYTOMETRY, V31, P265, DOI 10.1002/(SICI)1097-0320(19980401)31:4&lt;265::AID-CYTO6&gt;3.0.CO;2-I; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; Posavad CM, 1997, P NATL ACAD SCI USA, V94, P10289, DOI 10.1073/pnas.94.19.10289; REDDEHASE MJ, 1987, J EXP MED, V165, P650, DOI 10.1084/jem.165.3.650; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL SR, 1993, CURR OPIN IMMUNOL, V5, P484, DOI 10.1016/0952-7915(93)90027-P; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RIDDELL SR, 1992, SCIENCE, V257, P238; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SAFRIT JT, 1995, CURR OPIN IMMUNOL, V7, P456, DOI 10.1016/0952-7915(95)80088-3; Walker RE, 1998, NAT MED, V4, P852, DOI 10.1038/nm0798-852; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; Yang LP, 1998, J EXP MED, V187, P1139, DOI 10.1084/jem.187.7.1139; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	49	275	295	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1999	5	1					34	41		10.1038/4716	http://dx.doi.org/10.1038/4716			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883837				2022-12-25	WOS:000077885000027
J	Brustle, O; Choudhary, K; Karram, K; Huttner, A; Murray, K; Dubois-Dalcq, M; McKay, RDG				Brustle, O; Choudhary, K; Karram, K; Huttner, A; Murray, K; Dubois-Dalcq, M; McKay, RDG			Chimeric brains generated by intraventricular transplantation of fetal human brain cells into embryonic rats	NATURE BIOTECHNOLOGY			English	Article						stem cell; neural progenitor cell; cell therapy	CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS; STEM-CELLS; NEURAL PROGENITORS; GROWTH-FACTOR; PRECURSORS; OLIGODENDROCYTES; MYELINATION; FOREBRAIN; PROTEIN	Limited experimental access to the central nervous system (CNS) is a key problem in the study of human neural development, disease, and regeneration. We have addressed this problem by generating neural chimeras composed of human and rodent cells. Fetal human brain cells implanted into the cerebral ventricles of embryonic rats incorporate individually into all major compartments of the brain, generating widespread CNS chimerism. The human cells differentiate into neurons, astrocytes, and oligodendrocytes, which populate the host fore-, mid-, and hindbrain. These chimeras provide a unique model to study human neural cell migration and differentiation in a functional nervous system.	NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Inst Pasteur, Unite Neurovirol & Regenerat Syst Nerveux, F-75724 Paris, France	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Bonn; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brustle, O (corresponding author), NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.							ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307; BLAKEMORE WF, 1995, BRAIN PATHOL, V5, P443, DOI 10.1111/j.1750-3639.1995.tb00623.x; BROPHY PJ, 1993, TRENDS NEUROSCI, V16, P515, DOI 10.1016/0166-2236(93)90196-S; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; BRUSTLE O, 1997, CURRENT PROTOCOLS NE; BUCCARON MH, 1995, NEUROBIOL DIS, V2, P37, DOI 10.1006/nbdi.1995.0004; CAMMER W, 1992, J COMP NEUROL, V321, P40, DOI 10.1002/cne.903210105; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; Craig CG, 1996, J NEUROSCI, V16, P2649; DUNCAN ID, 1995, BRAIN PATHOL, V5, P301, DOI 10.1111/j.1750-3639.1995.tb00607.x; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Dunnett S.B., 1992, NEURAL TRANSPLANTATI; FISHELL G, 1995, DEVELOPMENT, V121, P803; Fouquet F, 1997, NEUROBIOL DIS, V3, P271, DOI 10.1006/nbdi.1997.0127; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; GUMPEL M, 1987, ANN NY ACAD SCI, V495, P71, DOI 10.1111/j.1749-6632.1987.tb23666.x; Kuhn HG, 1997, J NEUROSCI, V17, P5820; LACHAPELLE F, 1995, BRAIN PATHOL, V5, P289, DOI 10.1111/j.1750-3639.1995.tb00606.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVISON SW, 1993, DEVELOPMENT, V119, P611; Lim DA, 1997, P NATL ACAD SCI USA, V94, P14832, DOI 10.1073/pnas.94.26.14832; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Murray K, 1997, J NEUROSCI RES, V50, P146; Nave KA, 1996, NEUROSCIENTIST, V2, P33, DOI 10.1177/107385849600200111; Olsson M, 1998, EUR J NEUROSCI, V10, P71, DOI 10.1046/j.1460-9568.1998.00015.x; Ono K, 1997, NEURON, V19, P283, DOI 10.1016/S0896-6273(00)80939-3; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Seilhean D, 1996, ACTA NEUROPATHOL, V91, P82; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403	37	231	256	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1040	1044		10.1038/3481	http://dx.doi.org/10.1038/3481			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831032				2022-12-25	WOS:000076870100025
J	Henzler, HJ; Kaiser, K				Henzler, HJ; Kaiser, K			Avoiding viral contamination in biotechnological and pharmaceutical processes	NATURE BIOTECHNOLOGY			English	Editorial Material							INACTIVATION; RADIATION; VIRUS		Bayer AG, Biotechnol Proc Grp, D-51368 Leverkusen, Germany	Bayer AG								ANDERSSON I, 1996, 24 C INT SOC BLOOD T; Chin S, 1997, PHOTOCHEM PHOTOBIOL, V65, P432, DOI 10.1111/j.1751-1097.1997.tb08584.x; Goelker C. F., 1996, Biologicals, V24, P103; HIEMSTRA H, 1991, TRANSFUSION, V31, P32, DOI 10.1046/j.1537-2995.1991.31191096182.x; Huebner Guenter E., 1996, Arzneimittel-Forschung, V46, P657; Maerz H, 1996, NAT BIOTECHNOL, V14, P651, DOI 10.1038/nbt0596-651; Marx G, 1996, PHOTOCHEM PHOTOBIOL, V63, P541, DOI 10.1111/j.1751-1097.1996.tb03081.x; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; [No title captured], DOI DOI 10.1007/BF01863914	9	12	16	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1077	1079		10.1038/3538	http://dx.doi.org/10.1038/3538			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831040	Bronze			2022-12-25	WOS:000076870100033
J	Wang, H; Long, QM; Marty, SD; Sassa, S; Lin, S				Wang, H; Long, QM; Marty, SD; Sassa, S; Lin, S			A zebrafish model for hepatoerythropoietic porphyria	NATURE GENETICS			English	Article							HUMAN UROPORPHYRINOGEN DECARBOXYLASE; NUCLEOTIDE-SEQUENCE; POINT MUTATION; GENE SEQUENCE; CUTANEA-TARDA; IDENTIFICATION; DEFECTS; CLONING; CDNA; DNA	Defects in the enzymes involved in the haem biosynthetic pathway can lead to a group of human diseases known as the porphyrias. yquem (yqe(tp61)) is a zebrafish mutant with a photosensitive porphyria syndrome. Here we show that the porphyric phenotype is due to an inherited homozygous mutation in the gene encoding uroporphyrinogen decarboxylase (UROD); a homozygous deficiency of this enzyme causes hepatoerythropoietic porphyria (HEP) in humans. The zebrafish mutant represents the first genetically 'accurate' animal model of HEP, and should be useful for studying the pathogenesis of UROD deficiency and evaluating gene therapy vectors.. We rescued the mutant phenotype by transient and germline expression of the wild-type allele.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Rockefeller Univ, New York, NY 10021 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Rockefeller University	Lin, S (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.		Long, Qiaoming/L-5074-2017; Wang, Han/A-9774-2008	Long, Qiaoming/0000-0001-8243-589X; Wang, Han/0000-0003-2420-3147	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054508, R01DK032890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32890, R01 DK54508-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; CHELSTOWSKA A, 1992, BIOCHEM J, V288, P753, DOI 10.1042/bj2880753; CULP P, 1991, P NATL ACAD SCI USA, V88, P7953, DOI 10.1073/pnas.88.18.7953; de Verneuil H, 1978, Hum Genet, V44, P145; DEVERNEUIL H, 1983, BIOCHEM J, V214, P145, DOI 10.1042/bj2140145; DEVERNEUIL H, 1992, HUM GENET, V89, P548; DEVERNEUIL H, 1986, SCIENCE, V234, P732, DOI 10.1126/science.3775362; ELDER GH, 1989, CLIN BIOCHEM, V22, P163, DOI 10.1016/S0009-9120(89)80072-4; Elder GH, 1998, SEMIN LIVER DIS, V18, P67, DOI 10.1055/s-2007-1007142; GAREY JR, 1992, EUR J BIOCHEM, V205, P1011, DOI 10.1111/j.1432-1033.1992.tb16868.x; GAREY JR, 1989, BLOOD, V73, P892; Haffter P, 1996, DEVELOPMENT, V123, P1; Kappas A, 1995, METABOLIC MOL BASES, P2103; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; Long QM, 1997, DEVELOPMENT, V124, P4105; McManus JF, 1996, BLOOD, V88, P3589, DOI 10.1182/blood.V88.9.3589.bloodjournal8893589; MEGURO K, 1994, J INVEST DERMATOL, V102, P681, DOI 10.1111/1523-1747.ep12374134; MoranJimenez MJ, 1996, AM J HUM GENET, V58, P712; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; NISHIMURA K, 1993, GENE, V133, P109; NUSSLEINVOLHARD C, 1994, SCIENCE, V266, P572, DOI 10.1126/science.7939708; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; Ransom DG, 1996, DEVELOPMENT, V123, P311; ROBERTS AG, 1995, J INVEST DERMATOL, V104, P500, DOI 10.1111/1523-1747.ep12605953; ROMANA M, 1991, EUR J CLIN INVEST, V21, P225, DOI 10.1111/j.1365-2362.1991.tb01814.x; ROMANA M, 1987, NUCLEIC ACIDS RES, V15, P7343, DOI 10.1093/nar/15.18.7343; ROMANA M, 1987, NUCLEIC ACIDS RES, V15, P7211, DOI 10.1093/nar/15.17.7211; ROMEO PH, 1986, J BIOL CHEM, V261, P9825; Weinstein BM, 1996, DEVELOPMENT, V123, P303; Westerfield M, 1995, ZEBRAFISH BOOK; Wu C, 1996, MAMM GENOME, V7, P349, DOI 10.1007/s003359900101; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	33	121	131	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					239	243		10.1038/3041	http://dx.doi.org/10.1038/3041			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806541				2022-12-25	WOS:000076698100016
J	Arakawa, T; Yu, J; Chong, DKX; Hough, J; Engen, PC; Langridge, WHR				Arakawa, T; Yu, J; Chong, DKX; Hough, J; Engen, PC; Langridge, WHR			A plant-based cholera toxin B subunit - insulin fusion protein protects against the development of autoimmune diabetes	NATURE BIOTECHNOLOGY			English	Article							ORAL TOLERANCE; TRANSGENIC PLANTS; BACTERIAL LUCIFERASE; T-CELLS; EXPRESSION; ANTIGEN; MICE; IMMUNIZATION; AUTOANTIGENS; SUPPRESSION	Oral administration of disease-specific autoantigens can prevent or delay the onset of autoimmune disease symptoms. We have generated transgenic potato plants that synthesize human insulin, a major insulin-dependent diabetes mellitus autoantigen, at levels up to 0.05% of total soluble protein. To direct delivery of plant-synthesized insulin to the gut-associated lymphoid tissues, insulin was linked to the C-terminus of the cholera toxin B subunit (CTB). Transgenic potato tubers produced 0.1% of total soluble protein as the pentameric CTB-insulin fusion, which retained GM(1)-ganglioside binding affinity and native antigenicity of both CTB and insulin. Nonobese diabetic mice fed transformed potato tuber tissues containing microgram amounts of the CTB-insulin fusion protein showed a substantial reduction in pancreatic islet inflammation (insulitis), and a delay in the progression of clinical diabetes. Feeding transgenic potato tissues producing insulin or CTB protein alone did not provide a significant reduction in insulitis or diabetic symptoms. The experimental results indicate that food plants are feasible production and delivery systems for immunotolerization against this T cell-mediated autoimmune disease.	Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Microbiol & Mol Genet, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Anat, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University	Langridge, WHR (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA.							Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381; Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810; Bergerot I, 1997, P NATL ACAD SCI USA, V94, P4610, DOI 10.1073/pnas.94.9.4610; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; DOYLE JJ, 1992, FOCUS, V12, P135; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Elson CO, 1996, ESSENTIALS OF MUCOSAL IMMUNOLOGY, P543, DOI 10.1016/B978-012394330-9/50040-5; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; Fujihashi K, 1996, ANN NY ACAD SCI, V778, P55, DOI 10.1111/j.1749-6632.1996.tb21114.x; HANCOCK WW, 1995, AM J PATHOL, V147, P1193; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HUSBY S, 1994, J IMMUNOL, V152, P4663; Kim PH, 1998, J IMMUNOL, V160, P1198; KONCZ C, 1987, P NATL ACAD SCI USA, V84, P131, DOI 10.1073/pnas.84.1.131; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LANGRIDGE WHR, 1989, P NATL ACAD SCI USA, V86, P3219, DOI 10.1073/pnas.86.9.3219; LIPSCOMBE M, 1991, MOL MICROBIOL, V5, P1385; Ma SW, 1997, NAT MED, V3, P793, DOI 10.1038/nm0797-793; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PURVIS IJ, 1987, J MOL BIOL, V193, P413, DOI 10.1016/0022-2836(87)90230-0; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANDELT CI, 1992, PLANT J, V2, P181; WEINER HL, 1994, P NATL ACAD SCI USA, V91, P10762, DOI 10.1073/pnas.91.23.10762; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	32	216	262	2	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					934	938		10.1038/nbt1098-934	http://dx.doi.org/10.1038/nbt1098-934			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788349	Bronze			2022-12-25	WOS:000076323300028
J	Brooks-Kayal, AR; Shumate, MD; Jin, H; Rikhter, TY; Coulter, DA				Brooks-Kayal, AR; Shumate, MD; Jin, H; Rikhter, TY; Coulter, DA			Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy	NATURE MEDICINE			English	Article							MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; GENE-EXPRESSION; RAT HIPPOCAMPUS; GRANULE CELLS; STATUS-EPILEPTICUS; DELTA-SUBUNIT; DENTATE GYRUS; A RECEPTORS; NEURONS	Temporal robe epilepsy is the most prevalent seizure disorder in adults. Compromised inhibitory neurotransmitter function in the hippocampus contributes to the hyperexcitability generating this condition, but the underlying molecular mechanisms are unknown. Combining patch-clamp recording and single-cell mRNA amplification (aRNA) techniques in single dentate granule cells, we demonstrate that expression of GABA(A) receptor subunit mRNAs is substantially altered in neurons from epileptic rats. These changes in gene expression precede epilepsy onset by weeks and correlate with profound alterations in receptor function, indicating that aberrant GABA(A) receptor expression and function has an essential role in the process of epileptogenesis.	Childrens Hosp Philadelphia, Pediat Reg Epilepsy Progam, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol & Anat, Richmond, VA 23298 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Virginia Commonwealth University; Virginia Commonwealth University	Brooks-Kayal, AR (corresponding author), Childrens Hosp Philadelphia, Pediat Reg Epilepsy Progam, 34th & Civ Btr Blvd, Philadelphia, PA 19104 USA.			Rikhter, Tatiana/0000-0003-4049-0238; Coulter, Douglas/0000-0002-1486-119X	NICHD NIH HHS [HD28815] Funding Source: Medline; NINDS NIH HHS [K08 NS01936, R01 NS32403] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001936, R01NS032403] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Brooks-Kayal AR, 1998, J NEUROCHEM, V70, P1017; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; BUREAU M, 1990, MOL PHARMACOL, V37, P497; Burgard EC, 1996, MOL PHARMACOL, V50, P119; Cao YX, 1996, P NATL ACAD SCI USA, V93, P9844, DOI 10.1073/pnas.93.18.9844; DEDEYN P, 1990, ACTA NEUROL BELG, P90; Donnelly JL, 1996, NEUROPHARMACOLOGY, V35, P1233, DOI 10.1016/S0028-3908(96)00053-6; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Fisher JL, 1998, J NEUROSCI, V18, P2944; FRASER DD, 1995, J NEUROSCI, V15, P2720; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924, DOI 10.1152/jn.1997.77.4.1924; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Jones A, 1997, J NEUROSCI, V17, P1350; KAMPHUIS W, 1995, MOL BRAIN RES, V31, P33, DOI 10.1016/0169-328X(95)00022-K; KILLISCH I, 1991, NEURON, V7, P927, DOI 10.1016/0896-6273(91)90338-Z; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mellor JR, 1998, J NEUROSCI, V18, P2822; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; PERLIN JB, 1993, P NATL ACAD SCI USA, V90, P1741, DOI 10.1073/pnas.90.5.1741; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rice A, 1996, P NATL ACAD SCI USA, V93, P9665, DOI 10.1073/pnas.93.18.9665; SAXENA NC, 1994, J NEUROSCI, V14, P7077; SAXENA NC, 1996, MOL PHARMACOL, V49, P458; SCHWARZER C, 1995, NEUROSCIENCE, V69, P705, DOI 10.1016/0306-4522(95)00348-M; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; Sloviter RS, 1996, J COMP NEUROL, V373, P593; TASKER JG, 1991, NEUROCHEM RES, V16, P251, DOI 10.1007/BF00966088; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VICINI S, 1991, NEUROPSYCHOPHARMACOL, V4, P9; WALKER MC, 1995, J NEUROCHEM, V65, P725; White H S, 1998, Adv Neurol, V76, P29; WHITEHOUSE K, 1995, IEEE MULTIMEDIA, V2, P6; Whiting PJ, 1997, J NEUROSCI, V17, P5027; WISDEN W, 1992, J NEUROSCI, V12, P1040	45	585	592	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1166	1172		10.1038/2661	http://dx.doi.org/10.1038/2661			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771750				2022-12-25	WOS:000076230100036
J	Kohn, DB; Hershfield, MS; Carbonaro, D; Shigeoka, A; Brooks, J; Smogorzewska, EM; Barsky, LW; Chan, R; Burotto, F; Annett, G; Nolta, JA; Crooks, G; Kapoor, N; Elder, M; Wara, D; Bowen, T; Madsen, E; Snyder, FF; Bastian, J; Muul, L; Blaese, RM; Weinberg, K; Parkman, R				Kohn, DB; Hershfield, MS; Carbonaro, D; Shigeoka, A; Brooks, J; Smogorzewska, EM; Barsky, LW; Chan, R; Burotto, F; Annett, G; Nolta, JA; Crooks, G; Kapoor, N; Elder, M; Wara, D; Bowen, T; Madsen, E; Snyder, FF; Bastian, J; Muul, L; Blaese, RM; Weinberg, K; Parkman, R			T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34(+) cells in ADA-deficient SCID neonates	NATURE MEDICINE			English	Article							ADENOSINE-DEAMINASE DEFICIENCY; SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; PEG-ADA; THERAPY; ENGRAFTMENT; REVERSION; PATIENT; MOLONEY; VIRUS	Adenosine deaminase-deficient severe combined immunodeficiency was the first disease investigated for gene therapy because of a postulated production or survival advantage for gene-corrected T lymphocytes, which may overcome inefficient gene transfer. Four years after three newborns with this disease were given infusions of transduced autologous umbilical cord blood CD34(+) cells, the frequency of gene-containing T lymphocytes has risen to 1-10%, whereas the frequencies of other hematopoietic and lymphoid cells containing the gene remain at 0.01-0.1%. Cessation of polyethylene glycol-conjugated adenosine deaminase enzyme replacement in one subject led to a decline in immune function, despite the persistence of gene-containing T lymphocytes. Thus, despite the long-term engraftment of transduced stem cells and selective accumulation of gene-containing T lymphocytes, improved gene transfer and expression will be needed to attain a therapeutic effect.	Childrens Hosp Los Angeles, Div Immunol Res Bone Marrow Transplantat, Los Angeles, CA 90027 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84132 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5CT, Canada; Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Natl Ctr Human Genome Res, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA	Children's Hospital Los Angeles; Duke University; Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco; Alberta Childrens Hospital; University of Calgary; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kohn, DB (corresponding author), Childrens Hosp Los Angeles, Div Immunol Res Bone Marrow Transplantat, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kohn, Donald/N-5085-2016	Kohn, Donald/0000-0003-1840-6087; Nolta, Jan/0000-0003-4576-8542	NCRR NIH HHS [M01 RR000043, 3 MO1 RR0043-35S1] Funding Source: Medline; NHLBI NIH HHS [P50 HL054850, 1P50 HL54850] Funding Source: Medline; NIDDK NIH HHS [R01 DK053041-06, R01 DK053041, DK20902, R01 DK020902] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020902, R01DK053041] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; DESGROSEILLERS L, 1984, J VIROL, V52, P448, DOI 10.1128/JVI.52.2.448-456.1984; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; GATTI RA, 1968, LANCET, V2, P1366; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1995, HUM MUTAT, V5, P107, DOI 10.1002/humu.1380050202; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOCK RA, 1989, BLOOD, V74, P876; Hoogerbrugge PM, 1996, GENE THER, V3, P179; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; PARKMAN R, 1975, NEW ENGL J MED, V292, P714, DOI 10.1056/NEJM197504032921402; RUHL E, 1997, BLOOD S1 2, V90, pB417; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; TJONNFJORD GE, 1994, BLOOD, V84, P3584; TSICHLIS PN, 1987, ANTICANCER RES, V7, P171; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626	22	252	264	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					775	780		10.1038/nm0798-775	http://dx.doi.org/10.1038/nm0798-775			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662367	Green Accepted			2022-12-25	WOS:000074543900030
J	Rapalino, O; Lazarov-Spiegler, O; Agranov, E; Velan, GJ; Yoles, E; Fraidakis, M; Solomon, A; Gepstein, R; Katz, A; Belkin, M; Hadani, M; Schwartz, M				Rapalino, O; Lazarov-Spiegler, O; Agranov, E; Velan, GJ; Yoles, E; Fraidakis, M; Solomon, A; Gepstein, R; Katz, A; Belkin, M; Hadani, M; Schwartz, M			Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; MOTOR EVOKED-POTENTIALS; APOLIPOPROTEIN-A-I; WALLERIAN DEGENERATION; NEUROTROPHIC FACTORS; CORTICOSPINAL AXONS; NEURONS REGENERATE; IMMUNE-SYSTEM; OPTIC NERVES	Postinjury recovery in most tissues requires an effective dialog with macrophages; however, in the mammalian central nervous system, this dialog may be restricted (possibly due to its immune-privileged status), which probably contributes to its regeneration failure. We circumvented this by implanting macrophages, pre-exposed ex vivo to peripheral nerve segments, into transected rat spinal cord. This stimulated tissue repair and partial recovery of motor function, manifested behaviorally by movement of hind limbs, plantar placement of the paws and weight support, and electrophysiologically by cortically evoked hind-limb muscle response. We substantiated these findings immunohistochemically by demonstrating continuity of labeled nerve fibers across the transected site, and by tracing descending fibers distally to it by anterograde labeling. In recovered rats, re-transection of the cord above the primary transection site led to loss of recovery, indicating the involvement of long descending spinal tracts. Injection of macrophages into the site of injury is relatively non-invasive and, as the cells are autologous, it may be developed into a clinical therapy.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Beit Levinstein Hosp, Raanana, Israel; Meir Hosp, Dept Orthoped, Kefar Sava, Israel; Karolinska Inst, Dept Neurosci, Stockholm, Sweden; Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Karolinska Institutet; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnschwar@weizmann.weizmann.ac.il	Belkin, Michael/AAK-4728-2020; Lazarov, Orly/F-9406-2015; Solomon, Arieh/AAF-4361-2021	Rapalino, Otto/0000-0002-5038-4183; Lazarov, Orly/0000-0002-5887-948X				AGUAYO AJ, 1981, J EXP BIOL, V95, P231; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BENZEEVBRANN A, INPRESS GLIA; BISBY MA, 1990, BRAIN RES, V530, P117, DOI 10.1016/0006-8993(90)90666-Y; BLAUGRUND E, 1993, J COMP NEUROL, V330, P105, DOI 10.1002/cne.903300109; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brooks CM, 1940, J NEUROPHYSIOL, V3, P66, DOI 10.1152/jn.1940.3.1.66; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FaberElman A, 1995, FASEB J, V9, P1605, DOI 10.1096/fasebj.9.15.8529840; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GOLDBERGER ME, 1990, EXP NEUROL, V107, P113, DOI 10.1016/0014-4886(90)90149-M; Grill R, 1997, J NEUROSCI, V17, P5560; GRUNER JA, 1993, J NEUROTRAUM, V10, P327, DOI 10.1089/neu.1993.10.327; HAREL A, 1989, J NEUROCHEM, V52, P1218, DOI 10.1111/j.1471-4159.1989.tb01869.x; HAREL A, 1990, J NEUROCHEM, V55, P1237, DOI 10.1111/j.1471-4159.1990.tb03130.x; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hikawa N, 1996, CELL MOL NEUROBIOL, V16, P517, DOI 10.1007/BF02150231; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11185, DOI 10.1073/pnas.93.20.11185; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; KONRAD PE, 1990, BRAIN RES, V522, P14, DOI 10.1016/0006-8993(90)91572-X; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LAZAROVSPIEGLER O, IN PRESS GLIA; LAZAROVSPIEGLER O, IN PRESS MOL MED TOD; LAZAROVSPIEGLER O, IN PRESS VISION RES; LEVY WJ, 1984, NEUROSURGERY, V15, P214, DOI 10.1227/00006123-198408000-00011; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MEDIRATTA NK, 1983, J PHYSIOL-LONDON, V336, P545, DOI 10.1113/jphysiol.1983.sp014597; NANCE DM, 1990, BRAIN RES BULL, V25, P139, DOI 10.1016/0361-9230(90)90264-Z; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWARTZ M, 1995, MOL MED TODAY, V1, P60, DOI 10.1016/S1357-4310(95)92274-1; SCHWARTZ M, 1989, FASEB J, V3, P2371, DOI 10.1096/fasebj.3.12.2676680; SIMPSON RK, 1987, NEUROSURGERY, V20, P131; STOLL G, 1989, J NEUROCYTOL, V18, P671, DOI 10.1007/BF01187086; Streilein J. Wayne, 1993, Regional Immunology, V5, P253; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451	54	636	663	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					814	821		10.1038/nm0798-814	http://dx.doi.org/10.1038/nm0798-814			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662373				2022-12-25	WOS:000074543900036
J	Chang, B; Smith, RS; Hawes, NL; Anderson, MG; Zabaleta, A; Savinova, O; Roderick, TH; Heckenlively, JR; Davisson, MT; John, SWM				Chang, B; Smith, RS; Hawes, NL; Anderson, MG; Zabaleta, A; Savinova, O; Roderick, TH; Heckenlively, JR; Davisson, MT; John, SWM			Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice	NATURE GENETICS			English	Article							PIGMENT DISPERSION SYNDROME; TYROSINASE-RELATED PROTEIN; MOUSE MUTATION; WILD-TYPE; GENE; BROWN; MAPS	Glaucomas are a major cause of blindness'. Visual loss typically involves retinal ganglion cell death and optic nerve atrophy subsequent to a pathologic elevation of intraocular pressure (IOP). Some human glaucomas are associated with anterior segment abnormalities such as pigment dispersion syndrome (PDS) and iris atrophy with associated synechiae(2). The primary causes of these abnormalities are unknown, and their aetiology is poorly understood. We recently characterized a mouse strain (DBA/2J) that develops glaucoma subsequent to anterior segment changes including pigment dispersion and iris atrophy(3). Using crosses between mouse strains DBA/2J (D2) and C57BL/6J (B6), we now show there are two chromosomal regions that contribute to the anterior segment changes and glaucoma. Progeny homozygous for the D2 allele of one locus on chromosome 6 (called ipd) develop an iris pigment dispersion phenotype similar to human PDS, ipd resides on a region of mouse chromosome 6 with conserved synteny to a region of human chromosome 7q that is associated with human PDS (ref. 4), Progeny homozygous for the D2 allele of a different locus on chromosome 4 (called isa) develop an iris stromal atrophy phenotype (ISA). The Tyrp1 gene is a candidate for isa and likely causes ISA via a mechanism involving pigment production. Progeny homozygous for the D2 alleles of both ipd and isa develop an earlier onset and more severe disease involving pigment dispersion and iris stromal atrophy.	Jackson Lab, Bar Harbor, ME 04609 USA; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jules Stein Eye Inst, Torrance, CA USA; Tufts Univ, Sch Med, Boston, MA USA	Jackson Laboratory; Howard Hughes Medical Institute; Tufts University	John, SWM (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Anderson, Michael/B-4580-2009	Anderson, Michael/0000-0001-5730-6105; Chang, Bo/0000-0001-8259-7290	NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007758] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196] Funding Source: Medline; NEI NIH HHS [EY07758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andersen JS, 1997, ARCH OPHTHALMOL-CHIC, V115, P384, DOI 10.1001/archopht.1997.01100150386012; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BLUM J V, 1962, Trans Am Acad Ophthalmol Otolaryngol, V66, P493; FARRAR SM, 1989, AM J OPHTHALMOL, V108, P223, DOI 10.1016/0002-9394(89)90110-4; FRANKKAMENETZKI SG, 1925, KLIN MONATSBL AUGENH, V74, P133; HEON E, 1995, HUM MOL GENET, V4, P485, DOI 10.1093/hmg/4.3.485; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JAMPOL LM, 1974, AM J OPHTHALMOL, V77, P353, DOI 10.1016/0002-9394(74)90741-7; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; Manga P, 1997, AM J HUM GENET, V61, P1095, DOI 10.1086/301603; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; MIGLIAZZO CV, 1986, OPHTHALMOLOGY, V93, P1528; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; RICHTER CU, 1986, ARCH OPHTHALMOL-CHIC, V104, P211, DOI 10.1001/archopht.1986.01050140065021; RITCH R, 1993, AM J OPHTHALMOL, V115, P707, DOI 10.1016/S0002-9394(14)73635-9; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SHIBAHARA S, 1992, PIGM CELL RES, V2, P93; Shields M B, 1983, Trans Am Ophthalmol Soc, V81, P736; Shields M. B., 1996, GLAUCOMAS, P957; SHIELDS MB, 1979, OPHTHALMOLOGY, V86, P1533; SHIELDS MB, 1979, SURV OPHTHALMOL, V24, P3, DOI 10.1016/0039-6257(79)90143-7; SHIELDS MB, 1997, CHANDLER GRANTS GLAU, P319; Spencer W.H., 1996, OPHTHALMIC PATHOLOGY; SPENCER WH, 1996, OPHTHALMIC PATHOLOGY, P438; ZDARSKY E, 1990, GENETICS, V126, P443	28	215	221	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					405	409		10.1038/7741	http://dx.doi.org/10.1038/7741			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192392				2022-12-25	WOS:000079439700023
J	Nutt, SL; Vambrie, S; Steinlein, P; Kozmik, Z; Rolink, A; Weith, A; Busslinger, M				Nutt, SL; Vambrie, S; Steinlein, P; Kozmik, Z; Rolink, A; Weith, A; Busslinger, M			Independent regulation of the two Pax5 alleles during B-cell development	NATURE GENETICS			English	Article							MATERNAL-SPECIFIC METHYLATION; LYMPHOCYTES-B; BONE-MARROW; IGF2R LOCUS; IGH LOCUS; GENE; MOUSE; INACTIVATION; CONSERVATION; EXPRESSION	The developmental control genes of the Pax family are frequently associated with mouse mutants and human disease syndromes(1-3). The function of these transcription factors is sensitive to gene dosage, as mutation of one allele(1-3) or a modest increase in gene number(4) results in phenotypic abnormalities. Pax5 has an important role in B-cell and midbrain development(5-7). By following the expression of individual Pax5 alleles at the single-cell level, we demonstrate here that Pax5 is subject to allele-specific regulation during B-lymphopoiesis. Pax5 is predominantly transcribed from only one allele in early progenitors and mature B cells, whereas it switches to a biallelic transcription mode in immature B cells. The allele-specific regulation of Pax5 is stochastic, reversible, independent of parental origin and correlates with synchronous replication, in contrast with imprinted(8,9) and other monoallelically expressed genes(10,11). As a consequence, B-lymphoid tissues are mosaics with respect to the transcribed Pax5 allele, and thus mutation of one allele in heterozygous mice results in deletion of the cell population expressing the mutant allele due to loss of Pax5 function at the single-cell level. Similar allele-specific regulation may be a common mechanism causing the haploinsufficiency and frequent association of other Pax genes with human disease.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Basel Inst Immunol, CH-4005 Basel, Switzerland; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Busslinger, M (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	Busslinger@nt.imp.univie.ac.at	Kozmik, Zbynek/G-3581-2014; Nutt, Stephen L/C-9256-2013; Busslinger, Meinrad J./J-1249-2016; Kozmik, Zbynek/I-8807-2014	Nutt, Stephen L/0000-0002-0020-6637; Busslinger, Meinrad J./0000-0002-9111-9351; Kozmik, Zbynek/0000-0002-5850-2105				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Ghia P, 1996, J EXP MED, V184, P2217, DOI 10.1084/jem.184.6.2217; Held W, 1998, EUR J IMMUNOL, V28, P2407, DOI 10.1002/(SICI)1521-4141(199808)28:08&lt;2407::AID-IMMU2407&gt;3.0.CO;2-D; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	30	118	118	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1999	21	4					390	395		10.1038/7720	http://dx.doi.org/10.1038/7720			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192389				2022-12-25	WOS:000079439700020
J	Gong, YQ; Krakow, D; Marcelino, J; Wilkin, D; Chitayat, D; Babul-Hirji, R; Hudgins, L; Cremers, CW; Cremers, FPM; Brunner, HG; Reinker, K; Rimoin, DL; Cohn, DH; Goodman, FR; Reardon, W; Patton, M; Francomano, CA; Warman, ML				Gong, YQ; Krakow, D; Marcelino, J; Wilkin, D; Chitayat, D; Babul-Hirji, R; Hudgins, L; Cremers, CW; Cremers, FPM; Brunner, HG; Reinker, K; Rimoin, DL; Cohn, DH; Goodman, FR; Reardon, W; Patton, M; Francomano, CA; Warman, ML			Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis	NATURE GENETICS			English	Article							DELETION DEL(17) Q21.3Q23; SPEMANN ORGANIZER; XENOPUS; FOLLISTATIN; BINDING; PROTEIN; BMP-4; CDMP1	The secreted polypeptide noggin (encoded by the Nog gene) binds and inactivates members of the transforming growth factor beta superfamily of signalling proteins (TGF beta-FMs), such as BMP4 (ref. 1). By diffusing through extracellular matrices more efficiently than TGF beta-FMs, noggin may have a principal role in creating morphogenic gradients2. During mouse embryogenesis, Nog is expressed at multiple sites(3), including developing bones(4,5). Nog(-/-) mice die at birth from multiple defects that include bony fusion of the appendicular skeleton(3,4). We have identified five dominant human NOG mutations in unrelated families segregating proximal symphalangism (SYM1; OMIM 185800) and a de novo mutation in a patient with unaffected parents. We also found a dominant NOG mutation in a family segregating multiple synostoses syndrome (SYNS1; OMIM 186500); both SYM1 and SYNS1 have multiple joint fusion as their principal feature(6,7). All seven NOG mutations alter evolutionarily conserved amino CI acid residues. The findings reported here confirm that NOG is essential for joint formation and suggest that NOG requirements during skeletogenesis differ between species and between specific skeletal elements within species.	Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Shandong Med Univ, Dept Genet, Jinan, Peoples R China; Cedars Sinai Med Ctr, Ahmanson Dept Pediat, Steven Spielberg Pediat Res Ctr, Burns & Allen Cedars Sinai Res Inst, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Obstet, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Gynecol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD USA; Hosp Sick Children, Div Genet, Toronto, ON M5G 1X8, Canada; Childrens Hosp & Med Ctr, Div Med Genet, Washington, DC USA; Univ Nijmegen, Dept Otorhinolaryngol, Nijmegen, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands; Shriners Hosp Crippled Children, Dept Orthoped, Honolulu, HI USA; Inst Child Hlth, Mothercare Unit Clin Genet & Fetal Med, London, England; St George Hosp, Sch Med, London, England	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Shandong University; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's National Health System; Radboud University Nijmegen; Radboud University Nijmegen; University of London; University College London; St Georges University London	Warman, ML (corresponding author), Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA.		Reinker, Kent/R-5231-2019; Cremers, Frans/A-5625-2014; Brunner, Han/C-9928-2013; Cremers, C.W.R.J./L-4254-2015	Cremers, Frans/0000-0002-4954-5592; Reardon, Willie/0000-0001-7329-9179	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001205, P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043827] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-43827] Funding Source: Medline; NICHD NIH HHS [HD-22657, HD-01205] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; CREMERS C, 1985, ARCH OTOLARYNGOL, V111, P765; DALLAPICCOLA B, 1993, CLIN GENET, V43, P54, DOI 10.1111/j.1399-0004.1993.tb04452.x; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; ENSINK RJH, IN PRESS AM J OTOL; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; KHALIFA MM, 1993, CLIN GENET, V44, P258; Krakow D, 1998, AM J HUM GENET, V63, P120, DOI 10.1086/301921; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PARK JP, 1992, CLIN GENET, V41, P54; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; POLYMEROPOULOS MH, 1995, GENOMICS, V27, P225, DOI 10.1006/geno.1995.1035; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STORM EE, 1994, NATURE, V368, P693; STRASBURGER AK, 1965, B JOHNS HOPKINS HOSP, V117, P108; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; VALENZUELA DM, 1995, J NEUROSCI, V15, P6077; WITTA SE, 1995, DEVELOPMENT, V121, P721; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	24	240	260	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					302	304		10.1038/6821	http://dx.doi.org/10.1038/6821			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080184				2022-12-25	WOS:000078977900025
J	Liu, L; Dilworth, D; Gao, LZ; Monzon, J; Summers, A; Lassam, N; Hogg, D				Liu, L; Dilworth, D; Gao, LZ; Monzon, J; Summers, A; Lassam, N; Hogg, D			Mutation of the CDKN2A 5 ' UTR creates an aberrant initiation codon and predisposes to melanoma	NATURE GENETICS			English	Article							CUTANEOUS MALIGNANT-MELANOMA; FAMILIAL MELANOMA; DYSPLASTIC NEVI; GENETIC-HETEROGENEITY; P16; EXPRESSION; LOCUS; MLM	Approximately 8-12% Of melanoma is inherited in an autosomal dominant fashion with variable penetrance(1-8). A chromosome 9p21 locus has been linked to this disease in 50-80% of affected families(5-7,9). CDKN2A (also known as P16, INK4, p16(INK4A) and MTS1) is allelic to this locus and encodes a cdk4/cdk6 kinase inhibitor that constrains cells from progressing through the G1 restriction point(10-12). Although germline CDKN2A coding mutations cosegregate with melanoma in 25-60% of families predisposed to the disease(8,9,13-19), there remains a number of mutation-negative families that demonstrate linkage of inherited melanoma to 9p21 markers(9). We show here that a subset of these kindreds possess a G-->T transversion at base -34 of CDKN2A, designated G-34T. This mutation gives rise to a novel AUG translation initiation codon that decreases translation from the wild-type AUG. The G-34T mutation is not seen in controls, segregates with melanoma in families and, on the basis of haplotyping studies, probably arose from a common founder in the United Kingdom. Characterization of this and other CDKN2A non-coding mutations should have an impact on current efforts to identify susceptible melanoma-prone families and individuals.	Univ Toronto, Dept Clin Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto	Hogg, D (corresponding author), Univ Toronto, Dept Clin Sci, 100 Coll St, Toronto, ON, Canada.							BALE SJ, 1986, AM J HUM GENET, V38, P188; BERGENHEM NCH, 1992, P NATL ACAD SCI USA, V89, P8798, DOI 10.1073/pnas.89.18.8798; BERGER EG, 1994, TRANSFUS CLIN BIOL, V1, P103, DOI 10.1016/S1246-7820(94)80004-9; Borg A, 1996, CANCER RES, V56, P2497; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1994, J NATL CANCER I, V86, P1385, DOI 10.1093/jnci/86.18.1385; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; Hogg D, 1998, J Cutan Med Surg, V2, P172; Hollmann P, 1989, Tierarztl Prax, V17, P1; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LIU L, 1995, ONCOGENE, V11, P405; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845	25	199	206	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					128	132		10.1038/5082	http://dx.doi.org/10.1038/5082			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916806				2022-12-25	WOS:000077960700024
J	Moley, KH; Chi, MMY; Knudson, CM; Korsmeyer, SJ; Mueckler, MM				Moley, KH; Chi, MMY; Knudson, CM; Korsmeyer, SJ; Mueckler, MM			Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways	NATURE MEDICINE			English	Article							PREIMPLANTATION EMBRYO; PROTEASES; MALFORMATIONS; MECHANISM; ANOMALIES; MICE	Although perinatal mortality rates have improved for pregnant diabetic women because of insulin therapy and tight metabolic control, infants of diabetics still experience significantly higher rates of congenital malformations and spontaneous miscarriages compared with those of non-diabetic women(1). Our results here indicate that hyperglycemic conditions, either in vivo or in vitro, modulate the expression of an apoptosis regulatory gene as early as the pre-implantation blastocyst stage in the mouse. Apoptosis in the mammalian pre-implantation blastocyst is a normal process, thought to protect the early embryo by eliminating abnormal cells'. Here we demonstrate that expression of Bar, a Bcl-2-like protein, is increased at the blastocyst stage in the presence of high concentrations of glucose, and that these changes correlate morphologically with increased DNA fragmentation. Expression of Bar and caspase are necessary for this in vitro glucose-induced apoptotic event, and ceramide is involved in mediating this embryotoxic effect of glucose. We also show that these apoptotic cellular changes can be prevented in vivo by treating hyperglycemic mice with insulin before and immediately after conception. These findings emphasize the importance of tight glycemic control in diabetic women at the earliest stages after conception.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Mueckler, MM (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012	Knudson, Charles Michael/0000-0003-3964-5466				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRINSON DR, 1996, MOL REPROD DEV, V44, P171; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; FREINKEL N, 1988, HORM METAB RES, V20, P463, DOI 10.1055/s-2007-1010861; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jurisicova A, 1996, MOL HUM REPROD, V2, P93, DOI 10.1093/molehr/2.2.93; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lea RG, 1996, DIABETES, V45, P1463, DOI 10.2337/diabetes.45.11.1463; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; Moley KH, 1998, AM J PHYSIOL-ENDOC M, V275, pE38, DOI 10.1152/ajpendo.1998.275.1.E38; MOLEY KH, 1991, J REPROD FERTIL, V93, P325; Ortiz A, 1997, J INVEST MED, V45, P50; Pampfer S, 1997, DEVELOPMENT, V124, P4827; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; Polifka JE, 1996, TERATOLOGY, V53, P1, DOI 10.1002/(SICI)1096-9926(199601)53:1<1::AID-TERA1>3.0.CO;2-A; Reece EA, 1996, OBSTET GYN CLIN N AM, V23, P29, DOI 10.1016/S0889-8545(05)70243-6; Siman CM, 1997, DIABETES, V46, P1054, DOI 10.2337/diabetes.46.6.1054; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TAM PPL, 1988, TERATOLOGY, V37, P205, DOI 10.1002/tera.1420370305; WANG E, 1991, J BIOL CHEM, V266, P14486; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	23	268	283	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1421	1424		10.1038/4013	http://dx.doi.org/10.1038/4013			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846581				2022-12-25	WOS:000077336900039
J	Simon, JHM; Gaddis, NC; Fouchier, RAM; Malim, MH				Simon, JHM; Gaddis, NC; Fouchier, RAM; Malim, MH			Evidence for a newly discovered cellular anti-HIV-1 phenotype	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 INFECTION; DNA-SYNTHESIS; VIF MUTANTS; SOR GENE; PROTEINS; CELLS; TRANSMISSION; REPLICATION; REQUIREMENT	Animal cells have developed many ways to suppress viral replication, and viruses have evolved diverse strategies to resist these. Here we provide evidence that the virion infectivity factor protein of human immunodeficiency virus type 1 (HIV-1) functions to counteract a newly discovered activity in human cells that otherwise inhibits virus replication. This anti-viral phenotype is shown by human T cells, the principal in vivo targets for HIV-1, and, based on our present understanding of virion infectivity factor action, is presumed to act by interfering with a late step(s) in the virus life cycle. These observations indicate that the inhibition of virion infectivity factor function in vivo may prevent HIV-1 replication by 'unmasking' an innate anti-viral phenotype.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Malim, MH (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.		Gaddis, Nathan/GXG-6447-2022; Fouchier, Ron A/A-1911-2014; Gaddis, Nathan/GXG-6395-2022	Fouchier, Ron A/0000-0001-8095-2869; Gaddis, Nathan/0000-0001-5205-7138; Malim, Michael/0000-0002-7699-2064	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038715] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38715] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEGGS AH, 1988, P NATL ACAD SCI USA, V85, P7632, DOI 10.1073/pnas.85.20.7632; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Bouyac M, 1997, J VIROL, V71, P2473, DOI 10.1128/JVI.71.3.2473-2477.1997; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; DUBAY JW, 1992, J VIROL, V66, P6616, DOI 10.1128/JVI.66.11.6616-6625.1992; FAN LJ, 1992, VIROLOGY, V190, P19, DOI 10.1016/0042-6822(92)91188-Z; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harmache A, 1996, VIROLOGY, V224, P246, DOI 10.1006/viro.1996.0526; Hu SM, 1997, J BIOL CHEM, V272, P9621; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; Mathews M B, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P173; MEVELNINIO M, 1981, J CELL BIOL, V90, P339, DOI 10.1083/jcb.90.2.339; Moss B., 1996, FIELDS VIROLOGY, P2637; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; REDDY TR, 1995, J VIROL, V69, P3549, DOI 10.1128/JVI.69.6.3549-3553.1995; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Smith GL, 1996, CURR OPIN IMMUNOL, V8, P467, DOI 10.1016/S0952-7915(96)80032-X; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STEEVES R, 1977, ANNU REV GENET, V11, P277, DOI 10.1146/annurev.ge.11.120177.001425; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TOMONAGA K, 1992, J VIROL, V66, P6181, DOI 10.1128/JVI.66.10.6181-6185.1992; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389	38	228	231	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1397	1400		10.1038/3987	http://dx.doi.org/10.1038/3987			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846577				2022-12-25	WOS:000077336900035
J	Tinsley, J; Deconinck, N; Fisher, R; Kahn, D; Phelps, S; Gillis, JM; Davies, K				Tinsley, J; Deconinck, N; Fisher, R; Kahn, D; Phelps, S; Gillis, JM; Davies, K			Expression of full-length utrophin prevents muscular dystrophy in mdx mice	NATURE MEDICINE			English	Article							MOUSE; CONTRACTIONS; MUSCLES; GENE	Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fiber leading to the gradual depletion of skeletal muscle(1). The molecular structure of dystrophin is very similar to that of the related protein utrophin(2). Utrophin is found in all tissues(3) and is confined to the neuromuscular and myotendinous junctions in mature muscle(4). Sarcolemmal localization of a truncated utrophin transgene in the dystrophin-deficient mdx mouse significantly improves the dystrophic muscle phenotype(5,6). Therefore, upregulation of utrophin by drug therapy is a plausible therapeutic approach in the treatment of DMD. Here we demonstrate that expression of full-length utrophin in mdx mice prevents the development of muscular dystrophy. We assessed muscle morphology, fiber regeneration and mechanical properties (force development and resistance to stretch) of mdx and transgenic mdx skeletal and diaphragm muscle. The utrophin levels required in muscle are significantly less than the normal endogenous utrophin levels seen in lung and kidney, and we provide evidence that the pathology depends on the amount of utrophin expression. These results also have important implications for DMD therapies in which utrophin replacement is achieved by delivery using exogenous vectors.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Univ Catholique Louvain, Dept Physiol, UCL 5540, B-1200 Brussels, Belgium	University of Oxford; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Tinsley, J (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.							Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CARLSON CG, 1990, MUSCLE NERVE, V13, P480, DOI 10.1002/mus.880130603; DECONINCK AE, 1997, J CELL BIOL, V136, P88; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8	20	455	488	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1441	1444		10.1038/4033	http://dx.doi.org/10.1038/4033			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846586				2022-12-25	WOS:000077336900044
J	Brownell, AL; Jenkins, BG; Elmaleh, DR; Deacon, TW; Spealman, RD; Isacson, O				Brownell, AL; Jenkins, BG; Elmaleh, DR; Deacon, TW; Spealman, RD; Isacson, O			Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; N-ACETYLASPARTATE; HUMAN GLIOMAS; D2 RECEPTORS; C-11 CFT; DOPAMINE; PET; STRIATUM; LACTATE	We used brain imaging to study long-term neurodegenerative and bioadaptive neurochemical changes in a primate model of Parkinson disease. We gradually induced a selective loss of nigrostriatal dopamine neurons, similar to that of Parkinson disease, by creating oxidative stress through infusion of the mitochondrial complex 1 inhibitor MPTP for 14 +/- 5 months. Repeated evaluations over 3 years by positron emission tomography (PET) demonstrated progressive and persistent loss of neuronal dopamine pre-synaptic re-uptake sites; repeated magnetic resonance spectroscopy (MRS) studies indicated a 23-fold increase in lactate and macromolecules in the striatum region of the brain for up to 10 months after the last administration of MPTP. By 2 years after the MPTP infusions, these MRS striatal lactate and macromolecule values had returned to normal levels. In contrast, there were persistent increases in striatal choline and decreases in N-acetylaspartate. Thus, these combined PET/MRS studies demonstrate patterns of neurochemical changes that are both dynamic and persistent long after selective dopaminergic degeneration.	Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; McLean Hosp, Neuroregenerat Labs, Belmont, MA 02178 USA; New England Reg Primate Res Ctr, Southborough, MA 01772 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital	Isacson, O (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.			Isacson, Ole/0000-0001-8091-8302	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NCRR NIH HHS [P51RR00168-36] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALGER JR, 1990, RADIOLOGY, V177, P633, DOI 10.1148/radiology.177.3.2243962; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Brooks D. J., 1993, Neurology, V43, pS6; Brownell AL, 1996, J NUCL MED, V37, P1186; Brownell G. L., 1989, International Journal of Imaging Systems and Technology, V1, P207, DOI 10.1002/ima.1850010210; BROWNELL GL, 1985, METABOLISM HUMAN BRA, P13; BUGIANI O, 1980, EUR NEUROL, V19, P339, DOI 10.1159/000115172; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DDB, 1985, NATURE, V317, P244; CARVEY PM, 1993, PHARMACOL BIOCHEM BE, V46, P195, DOI 10.1016/0091-3057(93)90340-Y; CHESLER DA, 1973, TOMOGRAPHIC IMAGING, P176; Clarke CE, 1997, MOVEMENT DISORD, V12, P297, DOI 10.1002/mds.870120306; Cruz CJ, 1997, MAGN RESON IMAGING, V15, P619, DOI 10.1016/S0730-725X(97)00079-9; DAVIES CA, 1994, BRAIN, V11, P49; DELFORGE J, 1991, J CEREBR BLOOD F MET, V11, P914, DOI 10.1038/jcbfm.1991.156; DERENZO SE, 1988, IEEE T NUCL SCI, V35, P659, DOI 10.1109/23.12807; DUNNETT SB, 1986, NEUROSCI LETT, V68, P127, DOI 10.1016/0304-3940(86)90242-9; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; Federico F, 1997, MOVEMENT DISORD, V12, P903, DOI 10.1002/mds.870120611; FOSTER DM, 1994, BMES BULL, V18, P19; FROHNA PA, 1995, SYNAPSE, V19, P46, DOI 10.1002/syn.890190107; FROST JJ, 1993, ANN NEUROL, V34, P423, DOI 10.1002/ana.410340331; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; GJAEDDE A, 1990, QUANT IMAGING, P51; GUIMAREAEAS AR, 1995, NEUROSCIENCE, V69, P1093; HANTRAYE P, 1986, LIFE SCI, V39, P1375, DOI 10.1016/0024-3205(86)90336-X; HANTRAYE P, 1992, NEUROREPORT, V3, P265, DOI 10.1097/00001756-199203000-00013; HERHOLZ K, 1992, ANN NEUROL, V31, P319, DOI 10.1002/ana.410310315; Higuchi T, 1997, MAGNET RESON MED, V37, P851, DOI 10.1002/mrm.1910370608; HOLSHOUSER BA, 1995, MAGNET RESON MED, V33, P589, DOI 10.1002/mrm.1910330502; HUGG JW, 1992, J CEREBR BLOOD F MET, V12, P734, DOI 10.1038/jcbfm.1992.104; Hwang JH, 1996, MAGNET RESON MED, V35, P633, DOI 10.1002/mrm.1910350502; IMAI H, 1988, BRAIN RES, V474, P327, DOI 10.1016/0006-8993(88)90446-5; Jenkins BG, 1996, J CEREBR BLOOD F MET, V16, P450, DOI 10.1097/00004647-199605000-00011; KAUFMAN MJ, 1991, SYNPASE, V9; LANGE CS, 1984, RADIAT RES, V100, P1, DOI 10.2307/3576516; Leenders KL, 1997, J NEURAL TRANSM-SUPP, P39; MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006-8993(88)90124-2; Petrukhin Konstantin E., 1992, Human Molecular Genetics, V1, P349, DOI 10.1093/hmg/1.5.349; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Schapira AHV, 1997, BAILLIERE CLIN NEUR, V6, P15; Strauss I, 1997, MAGNET RESON MED, V37, P24, DOI 10.1002/mrm.1910370106; Temlett JA, 1996, CURR OPIN NEUROL, V9, P303, DOI 10.1097/00019052-199608000-00011; UNGERSTEDT U, 1968, EUR J PHARMACOL, V5, P107, DOI 10.1016/0014-2999(68)90164-7; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; WULLNER U, 1994, EXP NEUROL, V126, P305, DOI 10.1006/exnr.1994.1069	47	75	82	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1308	1312		10.1038/3300	http://dx.doi.org/10.1038/3300			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809556				2022-12-25	WOS:000076731000041
J	Fletcher, MC; Kuderova, A; Cygler, M; Lee, JS				Fletcher, MC; Kuderova, A; Cygler, M; Lee, JS			Creation of a ribonuclease abzyme through site-directed mutagenesis	NATURE BIOTECHNOLOGY			English	Article						protein engineering; catalytic antibody; rational design	SINGLE-CHAIN FV; CATALYTIC ANTIBODIES; ESCHERICHIA-COLI; FAB FRAGMENT; DNA-BINDING; PROTEIN; AUTOANTIBODY; ASSAYS; SYSTEM	The development of abzymes (antibody/enzymes) is one method of creating reagents with novel catalytic activity. To date, most abzymes have been obtained by immunization with transition state analogs. We have chosen to start with an existing antibody and convert it into an enzyme by the addition of catalytic residues to the binding site. We have introduced a histidine residue into antibody Jel 103 and converted it into an abzyme that cleaves poly(rl) with a kinetic efficiency of about 100 M(-1)sec(-1).	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Masaryk Univ, Lab Plant Mol Physiol, CS-61137 Brno, Czech Republic; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	University of Saskatchewan; Masaryk University Brno; National Research Council Canada	Lee, JS (corresponding author), Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada.		Kuderova, Alena/E-3627-2012					BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRAUN RP, 1986, MOL IMMUNOL, V23, P685, DOI 10.1016/0161-5890(86)90107-0; BRESLOW R, 1989, P NATL ACAD SCI USA, V86, P1746, DOI 10.1073/pnas.86.6.1746; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOHDA K, 1994, J BIOL CHEM, V269, P17531; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; JIA Z, 1987, J BIOL CHEM, V268, P22490; Kirby AJ, 1996, ACTA CHEM SCAND, V50, P203, DOI 10.3891/acta.chem.scand.50-0203; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; KUDEROVA A, 1994, J BIOL CHEM, V269, P32957; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; POKKULURI PR, 1994, J MOL BIOL, V243, P283, DOI 10.1006/jmbi.1994.1654; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; PRASAD L, 1988, J BIOL CHEM, V263, P2571; QUERMENEUR E, 1998, NATURE, V391, P301; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; Tanha J, 1997, NUCLEIC ACIDS RES, V25, P1442, DOI 10.1093/nar/25.7.1442; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; WAIZ FG, 1979, ARCH BIOCHEM BIOPHYS, V195, P95	28	18	18	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1065	1067		10.1038/3519	http://dx.doi.org/10.1038/3519			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831037				2022-12-25	WOS:000076870100030
J	Nurse, P				Nurse, P			The Imperial Cancer Research Fund - Cancer research for the future	NATURE MEDICINE			English	Editorial Material									Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Nurse, P (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1224	1227		10.1038/3202	http://dx.doi.org/10.1038/3202			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809534				2022-12-25	WOS:000076731000019
J	Corder, EH; Robertson, K; Lannfelt, L; Bogdanovic, N; Eggertsen, G; Wilkins, J; Hall, C				Corder, EH; Robertson, K; Lannfelt, L; Bogdanovic, N; Eggertsen, G; Wilkins, J; Hall, C			HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; AIDS DEMENTIA; BETA; MICROGLIA; PROTEIN; ACCUMULATION; CYTOKINES; EPSILON-4	HIV produces a chronic viral infection of the central nervous system that elicits chronic glial activation and overexpression of glial cytokines(1-5) that are also implicated in Alzheimer disease (AD) pathogenesis(6-11). A genetic risk factor for AD is the E4 isoform for apolipoprotein E (APOE)(12,13). Here we compare the frequency of neurologic symptoms for subjects with and without the E4 isoform (E4(+)and E4(-), respectively) in an HIV cohort(14-17). Compared with E4(-) subjects, twice as many E4(+) subjects were demented (30% compared with 15%) or had peripheral neuropathy (70% compared with 39%) at least once, and they had threefold more symptomatic examinations (13% compared with 3% and 42% compared with 14%, respectively)(P < 0.0001). Thus, neurologic symptoms for HIV-infection and AD are linked through an etiologic risk factor. Long-term survivors of HIV infection with E4 may be at high risk for AD; conversely, gene-viral interactions may speed AD pathogenesis.	Odense Univ, Odense, Denmark; Duke Univ, Durham, NC USA; Univ N Carolina, Dept Neurol, Chapel Hill, NC USA; Huddinge Univ Hosp, Karolinska Inst, Dept Clin Neurosci, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Clin Chem, S-14186 Huddinge, Sweden	University of Southern Denmark; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Karolinska Institutet; Karolinska Institutet	Corder, EH (corresponding author), Odense Univ, Odense, Denmark.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036518, P01NS026680] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS36518, R01-NS34234, P01-NS26680] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SF, 1997, J NEUROPATH EXP NEUR, V56, P1262, DOI 10.1097/00005072-199711000-00011; Buttini M, 1998, NAT MED, V4, P441, DOI 10.1038/nm0498-441; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Dunlop O, 1997, ACTA NEUROL SCAND, V95, P315, DOI 10.1111/j.1600-0404.1997.tb00217.x; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; HALL CD, 1992, ANN CLIN LAB SCI, V22, P139; HALL M, 1996, NEUROLOGY, V46, P697; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; MCGEER PL, 1994, NEUROPATH APPL NEURO, V20, P191; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mrak RE, 1997, J NEUROVIROL, V3, P241, DOI 10.3109/13550289709029465; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nuovo GJ, 1996, MOL MED, V2, P358, DOI 10.1007/BF03401633; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; ROBERTSON KR, 1992, SEMIN NEUROL, V12, P18, DOI 10.1055/s-2008-1041153; ROBERTSON KR, 1993, ARCH NEUROL-CHICAGO, V50, P807, DOI 10.1001/archneur.1993.00540080018007; SAS Institute, 1996, SAS STAT SOFTW CHANG; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408	25	197	205	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1182	1184		10.1038/2677	http://dx.doi.org/10.1038/2677			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771753				2022-12-25	WOS:000076230100039
J	Reddy, PH; Williams, M; Charles, V; Garrett, L; Pike-Buchanan, L; Whetsell, WO; Miller, G; Tagle, DA				Reddy, PH; Williams, M; Charles, V; Garrett, L; Pike-Buchanan, L; Whetsell, WO; Miller, G; Tagle, DA			Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA	NATURE GENETICS			English	Article							HUNTINGTONS-DISEASE GENE; INTRANUCLEAR INCLUSIONS; CAG REPEAT; NEUROLOGICAL PHENOTYPE; WIDESPREAD EXPRESSION; TRINUCLEOTIDE REPEAT; PROTEIN; BRAIN; ONSET; AGE	Huntington disease (HD) is an adult-onset, autosomal dominant inherited human neurodegenerative disorder characterized by hyperkinetic involuntary movements, including motor restlessness and chorea, slowing of voluntary movements and cognitive impairment. Selective regional neuron loss and gliosis in striatum. cerebral cortex, thalamus, subthalamus and hippocampus(1-4) are well recognized as neuropathological correlates for the clinical manifestations of HD. The underlying genetic mutation is the expansion of CAG trinucleotide repeats (coding for polyglutamines) to 36-121 copies in exon 1 of the HD gene(5-8). The HD mRNA and protein product (huntingtin) show widespread distribution(9-11), and thus much remains to be understood about the selective and progressive neurodegeneration in HD. To create an experimental animal model for HD, transgenic mice were generated showing widespread expression of full-length human HD cDNA with either 16, 48 or 89 CAG repeats. Only mice with 48 or 89 CAG repeats manifested progressive behavioural and motor dysfunction with neuron loss and gliosis in striatum, cerebral cortex, thalamus and hippocampus. These animals represent clinically relevant models for HD pathogenesis, and may provide insights into the underlying pathophysiological mechanisms of other triplet repeat disorders.	Natl Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Lab Genet Dis Res, Bethesda, MD 20892 USA; NIH, Off Res Serv, Vet Resources Program, Bethesda, MD 20892 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Vanderbilt University	Tagle, DA (corresponding author), Natl Human Genome Res Inst, Genet & Mol Biol Branch, Bldg 49,Room 3A26,49 Convent Dr MSC 4442, Bethesda, MD 20892 USA.	datagle@helix.nih.gov			NINDS NIH HHS [NS-28236] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028236] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Brinkman RR, 1997, AM J HUM GENET, V60, P1202; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Folstein S.E., 1990, HUNTINGTONS DIS; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Kosinski CM, 1997, EXP NEUROL, V144, P239, DOI 10.1006/exnr.1997.6441; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SPARGO E, 1993, J NEUROL NEUROSUR PS, V56, P487, DOI 10.1136/jnnp.56.5.487; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; Wood JD, 1996, HUM MOL GENET, V5, P481, DOI 10.1093/hmg/5.4.481	30	322	328	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					198	202		10.1038/2510	http://dx.doi.org/10.1038/2510			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771716				2022-12-25	WOS:000076231300025
J	Ul Haque, MF; King, LM; Krakow, D; Cantor, RM; Rusiniak, ME; Swank, RT; Superti-Furga, A; Haque, S; Abbas, H; Ahmad, W; Ahmad, M; Cohn, DH				Ul Haque, MF; King, LM; Krakow, D; Cantor, RM; Rusiniak, ME; Swank, RT; Superti-Furga, A; Haque, S; Abbas, H; Ahmad, W; Ahmad, M; Cohn, DH			Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse	NATURE GENETICS			English	Article							SULFATE-TRANSPORTER GENE; ADENOSINE 5'-PHOSPHOSULFATE KINASE; ATP-SULFURYLASE; EXPRESSION CLONING; RAT CHONDROSARCOMA; FIBROBLAST GROWTH; BLEEDING-TIME; MICE; PROTEOGLYCANS; CARTILAGE	The osteochondrodysplasias are a genetically heterogeneous group of disorders affecting skeletal development, linear growth and the maintenance of cartilage and bone. We have studied a large inbred Pakistani family with a distinct form of recessively inherited spondyloepimetaphyseal dysplasia (SEMD) and mapped a gene associated with this dwarfing condition to chromosome 10q23-24, a region syntenic with the locus for the brachymorphic mutation on mouse chromosome 19. We identified two orthologous genes, ATPSK2 and Atpsk2, encoding novel ATP sulfurylase/APS kinase orthologues in the respective regions of the human and mouse genomes, We characterized a nonsense mutation in ATPSK2 in the SEMD family and a missense mutation in the region of Atpsk2 encoding the APS kinase activity in the brachymorphic mouse. ATP sulfurylase/APS kinase catalyses the metabolic activation of inorganic sulfate to PAPS, the universal donor for post-translational protein sulfation in all cell types. The cartilage-specificity of the human and mouse phenotypes provides further evidence of the critical role of sulfate activation in the maturation of cartilage extracellular matrix molecules and the effect of defects in this process on the architecture of cartilage and skeletogenesis.	Cedars Sinai Res Inst, Stephen Spielberg Pediat Res Ctr, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Cedars Sinai Res Inst, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Zurich, Childrens Hosp, Dept Pediat, Div Metab & Mol Dis, CH-8032 Zurich, Switzerland; Quaid I Azam Univ, Dept Biol Sci, Islamabad, Pakistan; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Roswell Park Cancer Institute; University Children's Hospital Zurich; University of Zurich; Quaid I Azam University; Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cohn, DH (corresponding author), Cedars Sinai Res Inst, Stephen Spielberg Pediat Res Ctr, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA.		Ahmad, Wasim/GSD-8904-2022; superti-furga, andrea/E-9162-2015; Ahmad, Wasim/E-9713-2015	superti-furga, andrea/0000-0002-3543-7531; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051480] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51480] Funding Source: Medline; NIAMS NIH HHS [AR02038] Funding Source: Medline; NICHD NIH HHS [HD22657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmad M, 1998, AM J MED GENET, V78, P468; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BISSIG M, 1994, J BIOL CHEM, V269, P3017; Blache D, 1995, BBA-LIPID LIPID MET, V1259, P291, DOI 10.1016/0005-2760(95)00177-8; BOBERG EW, 1983, CANCER RES, V43, P5163; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; ELGAVISH A, 1985, J CELL PHYSIOL, V125, P243, DOI 10.1002/jcp.1041250211; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; GELLER DH, 1987, J BIOL CHEM, V262, P7374; Gray IC, 1997, GENOMICS, V43, P85, DOI 10.1006/geno.1997.4809; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI CC, 1987, CARCINOGENESIS, V8, P471, DOI 10.1093/carcin/8.3.471; LANE PW, 1968, J HERED, V59, P300, DOI 10.1093/oxfordjournals.jhered.a107725; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1995, BIOCHEMISTRY-US, V34, P940, DOI 10.1021/bi00003a028; LYMAN SD, 1983, BIOCHEM PHARMACOL, V32, P3345, DOI 10.1016/0006-2952(83)90360-X; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MILLER WA, 1976, J COMP PATHOL, V86, P349, DOI 10.1016/0021-9975(76)90002-5; OBRIEN EP, 1994, MAMM GENOME, V5, P356, DOI 10.1007/BF00356554; ORKIN RW, 1977, J CELL BIOL, V73, P287, DOI 10.1083/jcb.73.2.287; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rossi A, 1997, EUR J BIOCHEM, V248, P741, DOI 10.1111/j.1432-1033.1997.t01-1-00741.x; Rossi A, 1996, J BIOL CHEM, V271, P18456, DOI 10.1074/jbc.271.31.18456; ROSSI A, IN PRESS MATRIX BIOL; Rusiniak ME, 1996, MAMM GENOME, V7, P98, DOI 10.1007/s003359900027; Schlicht W, 1995, ANXIETY STRESS COPIN, V8, P357, DOI 10.1080/10615809508249385; SCHWARTZ NB, 1978, BIOCHEM BIOPH RES CO, V82, P173, DOI 10.1016/0006-291X(78)90592-2; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P602, DOI 10.1016/0003-9861(82)90065-0; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; SupertiFurga A, 1996, ANN NY ACAD SCI, V785, P195, DOI 10.1111/j.1749-6632.1996.tb56259.x; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Willing MC, 1996, AM J HUM GENET, V59, P799; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	42	156	160	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					157	162		10.1038/2458	http://dx.doi.org/10.1038/2458			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771708				2022-12-25	WOS:000076231300017
J	Scharf, JM; Endrizzi, MG; Wetter, A; Huang, S; Thompson, TG; Zerres, K; Dietrich, WF; Wirth, B; Kunkel, LM				Scharf, JM; Endrizzi, MG; Wetter, A; Huang, S; Thompson, TG; Zerres, K; Dietrich, WF; Wirth, B; Kunkel, LM			Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics	NATURE GENETICS			English	Article							WERDNIG-HOFFMANN DISEASE; LARGE-SCALE DELETIONS; MOTOR-NEURON GENE; 5Q13 REGION; PROTEIN; SEVERITY; SMN; COPIES; ASSOCIATION; (C)BCD541	Spinal muscular atrophy (SMA) is a common recessive disorder characterized by the loss of lower motor neurons in the spinal cord. The disease has been classified into three types based on age of onset and severity(1). SMA I-III all map to chromosome 5q13 (refs 2,3), and nearly all patients display deletions or gene conversions of the survival motor neuron (SMN1) gene(4-7). Some correlation has been established between SMN protein levels and disease course(8-10): nevertheless, the genetic basis for SMA phenotypic variability remains unclear, and it has been postulated that the loss of an additional modifying factor contributes to the severity of type I SMA. Using comparative genomics to screen for such a factor among evolutionarily conserved sequences between mouse and human, we have identified a novel transcript, H4F5, which lies closer to SMN? than any previously identified gene in the region. A multi-copy microsatellite marker that is deleted in more than 90% of type I SMA chromosomes is embedded in an intron of this gene, indicating that H4F5 is also highly deleted in type I SMA chromosomes, and thus is a candidate phenotypic modifier for SMA.	Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Univ Bonn, Inst Human Genet, D-53111 Bonn, Germany; Childrens Hosp, Howard Hughes Med Inst, Div Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Bonn; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Kunkel, LM (corresponding author), Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.		Wirth, Brunhilde/H-3192-2019	Huang, Sidong/0000-0002-2838-4726; Wirth, Brunhilde/0000-0003-4051-5191	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23740] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Burglen L, 1997, AM J HUM GENET, V60, P72; Burlet P, 1996, J MED GENET, V33, P281, DOI 10.1136/jmg.33.4.281; Carter TA, 1997, HUM MOL GENET, V6, P229, DOI 10.1093/hmg/6.2.229; Chen QF, 1998, GENOMICS, V48, P121, DOI 10.1006/geno.1997.5141; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Hahnen E, 1996, AM J HUM GENET, V59, P1057; Harris NL, 1997, GENOME RES, V7, P754, DOI 10.1101/gr.7.7.754; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; Mortillaro MJ, 1998, J BIOL CHEM, V273, P8183, DOI 10.1074/jbc.273.14.8183; MUNSAT TL, 1992, NEUROMUSCULAR DISORD, V2, P423, DOI 10.1016/S0960-8966(06)80015-5; Nishio H, 1997, NEUROLOGY, V48, P1266, DOI 10.1212/WNL.48.5.1266; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Scharf JM, 1996, GENOMICS, V38, P405, DOI 10.1006/geno.1996.0644; Schwartz M, 1997, HUM MOL GENET, V6, P99, DOI 10.1093/hmg/6.1.99; SELIG S, 1995, P NATL ACAD SCI USA, V92, P3702, DOI 10.1073/pnas.92.9.3702; THOMPSON TG, 1996, THESIS U CALIFORNIA; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; WIRTH B, 1995, HUM MOL GENET, V4, P1273, DOI 10.1093/hmg/4.8.1273	30	92	102	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					83	86		10.1038/1753	http://dx.doi.org/10.1038/1753			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731538				2022-12-25	WOS:000075671400026
J	Korinek, V; Barker, N; Moerer, P; van Donselaar, E; Huls, G; Peters, PJ; Clevers, H				Korinek, V; Barker, N; Moerer, P; van Donselaar, E; Huls, G; Peters, PJ; Clevers, H			Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR LEF-1; MOUSE SMALL-INTESTINE; BETA-CATENIN; APC GENE; DIFFERENTIATION; MUTATION; NEOPLASIA; RENEWAL	Mutations of the genes encoding APC or beta-catenin in colon carcinoma induce the constitutive formation of nuclear beta-catenin/Tcf-4 complexes, resulting in activated transcription of Tcf target genes(1,2). To study the physiological role of Tcf-4 (which is encoded by the Tcf712 gene), we disrupted Tcf712 by homologous recombination. Tcf712(-/-) mice die shortly after birth. A single histopathological abnormality was observed. An apparently normal transition of intestinal endoderm into epithelium occurred at approximately embryonic day (E) 14.5. However, no proliferative compartments were maintained in the prospective crypt regions between the villi. As a consequence, the neonatal epithelium was composed entirely of differentiated, non-dividing villus cells. We conclude that the genetic program controlled by Tcf-4 maintains the crypt stem cells of the small intestine. The constitutive activity of Tcf-4 in APC-deficient human epithelial cells may contribute to their malignant transformation by maintaining stem-cell characteristics.	Univ Utrecht Hosp, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht Hosp, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Clevers, H (corresponding author), Univ Utrecht Hosp, Dept Immunol, POB 85500, NL-3508 GA Utrecht, Netherlands.		Barker, Nick/AAS-2774-2020; Korinek, Vladimir/G-6348-2014; Barker, Nick/AAE-9833-2021; Barker, Nick/A-5535-2011	Korinek, Vladimir/0000-0002-9777-4664; Barker, Nick/0000-0003-3566-4475; 				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CALVERT R, 1990, ANAT REC, V227, P199, DOI 10.1002/ar.1092270208; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Hermiston Michelle L., 1994, P521; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0	30	1252	1331	1	60	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					379	383		10.1038/1270	http://dx.doi.org/10.1038/1270			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697701				2022-12-25	WOS:000075107600023
J	Clerc, P; Avner, P				Clerc, P; Avner, P			Role of the region 3 ' to Xist exon 6 in the counting process of X-chromosome inactivation	NATURE GENETICS			English	Article							GENE; EXPRESSION; INTERPHASE; NUCLEUS; MICE; RNA	During early embryogenesis of female mammals, one of the two X chromosomes is randomly chosen to be inactivated in each cell(1), leading to the transcriptional silencing of thousands of genes on this chromosome. This random X-inactivation process also occurs during in vitro differentiation of female embryonic stem (ES) cells(2-4). A locus on the X chromosome, the X inactivation centre (Xic) is initially 'counted', given that at least two copies of Xic must be present per diploid genome in order for inactivation to occur(2). The counting process ensures that one X chromosome remains active in diploid cells, In the mouse, the essential functions of Xic can be assured by a 450-kb region(5,6) containing the Xist gene. Xist maps within Xic (refs 7-10) and is necessary in cis for inactivation(11,12), The Xist transcript is a 15-kb RNA which is confined within the nucleus and coats the inactive X chromosome(13). In order to characterize functional elements within Xic and the Xist gene, we created a 65-kb cre/loxP deletion extending 3' to Xist exon 6, In undifferentiated ES cells, Xist expression from the deleted X chromosome was markedly reduced. in differentiated XX ES cells containing one deleted X chromosome, the X inactivation process still occurred but was never initiated from the unmutated X chromosome, In differentiated ES cells that were essentially XO, the mutated Xic was capable of initiating X inactivation, even in the absence of another Xic, These results demonstrate a role for the region 3' to Xist exon 6 in the counting process and suggest that counting is mediated by a repressive mechanism which prevents inactivation of a single X chromosome in diploid cells.	Inst Pasteur, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Clerc, P (corresponding author), Inst Pasteur, 25 Rue Dr Roux, F-75015 Paris, France.							BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CATTANACH BM, 1970, GENET RES, V15, P189; CATTANACH BM, 1975, ANNU REV GENET, V75, P1; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; HEARD E, 1993, GENOMICS, V15, P559, DOI 10.1006/geno.1993.1108; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PLENGE MR, 1997, NAT GENET, V17, P353; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROUGEULLE C, 1994, MAMM GENOME, V5, P416, DOI 10.1007/BF00357001; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; Simmler MC, 1997, MAMM GENOME, V8, P760, DOI 10.1007/s003359900561	30	149	153	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					249	253		10.1038/924	http://dx.doi.org/10.1038/924			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662396				2022-12-25	WOS:000074565900019
J	Soto, C; Sigurdsson, EM; Morelli, L; Kumar, RA; Castano, EM; Frangione, B				Soto, C; Sigurdsson, EM; Morelli, L; Kumar, RA; Castano, EM; Frangione, B			beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy	NATURE MEDICINE			English	Article							A-BETA; TRANSGENIC MICE; DISEASE; PROTEIN; NEUROTOXICITY; CONFORMATION; FRAGMENT; PLAQUES	Inhibition of cerebral amyloid beta-protein deposition seems to be an important target for Alzheimer's disease therapy. Amyloidogenesis could be inhibited by short synthetic peptides designed as beta-sheet breakers. Here we demonstrate a 5-residue peptide that inhibits amyloid beta-protein fibrillogenesis, disassembles preformed fibrils in vitro and prevents neuronal death induced by fibrils in cell culture. In addition, the beta-sheet breaker peptide significantly reduces amyloid beta-protein deposition in vivo and completely blocks the formation of amyloid fibrils in a rat brain model of amyloidosis. These findings may provide the basis for a new therapeutic approach to prevent amyloidosis in Alzheimer's disease.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Univ Buenos Aires, IDEHU, RA-1053 Buenos Aires, DF, Argentina	New York University; New York University; University of Buenos Aires	Soto, C (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	Claudio.Soto@mcfpo.med.nyu.edu		Sigurdsson, Einar/0000-0003-1451-0952	NIAMS NIH HHS [AR02594] Funding Source: Medline; NIA NIH HHS [AG10953, AG05891] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R37AG005891, R35AG010953] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DUKE CR, 1995, CRRENT PROTOCOLS IMM; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; HILSICH C, 1992, J MOL BIOL, V228, P460; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JANOSSY G, 1973, CLIN EXP IMMUNOL, V14, P581; Jimenez-Huete A, 1998, ALZHEIMERS REP, V1, P41; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Sigurdsson EM, 1996, NEUROBIOL AGING, V17, P893, DOI 10.1016/S0197-4580(96)00169-8; Sigurdsson EM, 1997, NEUROBIOL AGING, V18, P591, DOI 10.1016/S0197-4580(97)00154-1; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SOTO C, 1994, J NEUROCHEM, V63, P1191; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; SOTO C, UNPUB; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	30	763	833	3	109	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					822	826		10.1038/nm0798-822	http://dx.doi.org/10.1038/nm0798-822			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662374				2022-12-25	WOS:000074543900037
J	Watts, AM; Stanley, JR; Shearer, MH; Hefty, PS; Kennedy, RC				Watts, AM; Stanley, JR; Shearer, MH; Hefty, PS; Kennedy, RC			Fetal immunization of baboons induces a fetal-specific antibody response	NATURE MEDICINE			English	Article							INFECTION	Neonates face a high risk of infection because of the immaturity of their immune systems. Although the transplacental transfer of maternal antibodies to the fetus may convey improved postnatal immunity, this transfer occurs late in gestation and may fail to prevent in utero infection. Both fetal immunization and in utero exposure to antigen can result in a state of immunologic tolerance in the neonate. Tolerance induction of fetal and premature infant lymphocytes has become a paradigm for neonatal responsiveness(1,2). However, fetal IgM responses have been demonstrated to maternal immunization with tetanus toroid and to congenital infections such as rubella, toxoplasma, cytomegalovirus and human immunodeficiency virus(3-6). Moreover, 1-week-old infants can respond to standard pediatric vaccination, and neonates immunized with polysaccharide antigens do not develop immunologic tolerance(7). Here, direct immunization of the baboon fetus with recombinant hepatitis B surface antigen produced a specific fetal IgG antibody response. No specific maternal antibody response was detected, eliminating the possibility of vertical antibody transmission to the fetus. Some infants also responded to later vaccinations with hepatitis B surface antigen, indicating that no immunological tolerance was induced by prior fetal immunization. These results characterize the ability of the fetal immune system to respond to in utero vaccination. We demonstrate that active fetal immunization can serve as a safe and efficient vaccination strategy for the fetus and neonate.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Kennedy, RC (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA.				NCRR NIH HHS [P40 RR-12317] Funding Source: Medline; PHS HHS [T32 A1-07634] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012317] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ATTANASIO R, 1991, J IMMUNOL, V146, P507; BONA C, 1997, IMMUNOLOGIST, V5, P5; DELPORTILLO HA, 1987, VET IMMUNOL IMMUNOP, V16, P201, DOI 10.1016/0165-2427(87)90018-3; ENDERS G, 1985, REV INFECT DIS, V7, pS113; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; GRIFFITHS PD, 1982, PEDIATRICS, V69, P544; HOWARD JG, 1976, EUR J IMMUNOL, V6, P486, DOI 10.1002/eji.1830060708; KENNEDY RC, 1983, J IMMUNOL, V130, P385; KENNEDY RC, 1997, IMMUNOLOGIST, V5, P150; NAOT Y, 1981, J PEDIATR-US, V98, P32, DOI 10.1016/S0022-3476(81)80528-8; OWEN RD, 1957, PROC R SOC SER B-BIO, V146, P8; Shearer MH, 1997, INFECT IMMUN, V65, P3267, DOI 10.1128/IAI.65.8.3267-3270.1997; SHEARER MH, 1995, DEV COMP IMMUNOL, V6, P547	13	47	48	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					427	430		10.1038/7426	http://dx.doi.org/10.1038/7426			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202933				2022-12-25	WOS:000079574300033
J	Giaever, G; Shoemaker, DD; Jones, TW; Liang, H; Winzeler, EA; Astromoff, A; Davis, RW				Giaever, G; Shoemaker, DD; Jones, TW; Liang, H; Winzeler, EA; Astromoff, A; Davis, RW			Genomic profiling of drug sensitivities via induced haploinsufficiency	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; GENES; EXPRESSION	Lowering the dosage of a single gene from two copies to one copy in diploid yeast results in a heterozygote that is sensitized to any drug that acts on the product of this gene. This haploinsufficient phenotype thereby identifies the gene product of the heterozygous locus as the likely drug target. We exploited this finding in a genomic approach to drug-target identification. Genome sequence information was used to generate molecularly tagged heterozygous yeast strains that were pooled, grown competitively in drug and analysed for drug sensitivity using high-density oligonucleotide arrays. Individual heterozygous strain analysis verified six known drug targets. Parallel analysis identified the known target and two hypersensitive loci in a mixed culture of 233 strains in the presence of the drug tunicamycin, Our discovery that both drug target and hypersensitive loci exhibit drug-induced haploinsufficiency may have important consequences in pharmacogenomics and variable drug toxicity observed in human populations.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Rosetta Inpharmat, Kirkland, WA 98034 USA; Stanford DNA Sequencing & Technol Ctr, Palo Alto, CA 94394 USA	Stanford University; Merck & Company; Stanford University	Giaever, G (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	ggiaever@cmgm.stanford.edu	Winzeler, Elizabeth/AAP-6752-2020	Winzeler, Elizabeth/0000-0002-4049-2113	PHS HHS [H600198] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baganz F, 1997, YEAST, V13, P1563, DOI 10.1002/(SICI)1097-0061(199712)13:16<1563::AID-YEA240>3.3.CO;2-Y; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; Karim FD, 1996, GENETICS, V143, P315; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; Launhardt H, 1998, YEAST, V14, P935, DOI 10.1002/(SICI)1097-0061(199807)14:10<935::AID-YEA289>3.0.CO;2-9; LINDSLEY DL, 1972, GENETICS, V71, P157; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; RINE J, 1991, METHOD ENZYMOL, V194, P239; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; RITTBERG DAH, 1989, BIOCHEM CELL BIOL, V67, P352, DOI 10.1139/o89-055; Rose MD., 1990, METHODS YEAST GENETI; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STEARNS T, 1990, GENETICS, V124, P251; TURI TG, 1992, J BIOL CHEM, V267, P2046; VOGEL F, 1997, HUM GENET, P267; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Zinn AR, 1998, CURR OPIN GENET DEV, V8, P322, DOI 10.1016/S0959-437X(98)80089-0	24	418	450	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					278	283		10.1038/6791	http://dx.doi.org/10.1038/6791			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080179				2022-12-25	WOS:000078977900020
J	Itoh, K; Yoshioka, K; Akedo, H; Uehata, M; Ishizaki, T; Narumiya, S				Itoh, K; Yoshioka, K; Akedo, H; Uehata, M; Ishizaki, T; Narumiya, S			An essential part for Rho-associated kinase in the transcellular invasion of tumor cells	NATURE MEDICINE			English	Article							BINDING PROTEIN-RHO; CANCER METASTASIS; FOCAL ADHESIONS; GTPASE	Adhesion of tumor cells to host cell layers and subsequent transcellular migration are pivotal steps in cancer invasion and metastasis(1-3). The small GTPase Rho controls cell adhesion and motility through reorganization of the actin cytoskeleton and regulation of actomyosin contractility(4). Cultured rat MM1 hepatoma cells migrate through a mesothelial cell monolayer in vitro in a serum-dependent, Rho-mediated manner(5). Among several proteins isolated as putative target molecules of Rho, the ROCK (ROK) family of Rho-associated serine-threonine protein kinases(6-8) are thought to participate in the induction of focal adhesions and stress fibers in cultured cells(9), and to mediate calcium sensitization of smooth muscle contraction by enhancing phosphorylation of the regulatory light chain of myosin(10) Transfection of MM1 cells with cDNA encoding a dominant active mutant of ROCK conferred invasive activity independently of serum and Rho. In contrast, expression of a dominant negative, kinase-defective ROCK mutant substantially attenuated the invasive phenotype. A specific ROCK inhibitor (Y-27632; ref. 11) blocked both Rho-mediated activation of actomyosin and invasive activity of these cells. Furthermore, continuous delivery of this inhibitor using osmotic pumps considerably reduced the dissemination of MM1 cells implanted into the peritoneal cavity of syngeneic rats. These results indicate that ROCK plays an essential part in tumor cell invasion, and demonstrate its potential as a therapeutic target for the prevention of cancer invasion and metastasis.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biol, Higashinari Ku, Osaka 5378511, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto University	Itoh, K (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biol, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.			Itoh, Kazuyuki/0000-0002-0761-0499				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NICOLSON GL, 1989, INVAS METAST, V9, P102; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VIEMINCKX K, 1991, CELL, V66, P107; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	20	551	596	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					221	225		10.1038/5587	http://dx.doi.org/10.1038/5587			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930872				2022-12-25	WOS:000078274400033
J	Wilson, CA; Ramos, L; Villasenor, MR; Anders, KH; Press, MF; Clarke, K; Karlan, B; Chen, JJ; Scully, R; Livingston, D; Zuch, RH; Kanter, MH; Cohen, S; Calzone, FJ; Slamon, DJ				Wilson, CA; Ramos, L; Villasenor, MR; Anders, KH; Press, MF; Clarke, K; Karlan, B; Chen, JJ; Scully, R; Livingston, D; Zuch, RH; Kanter, MH; Cohen, S; Calzone, FJ; Slamon, DJ			Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas	NATURE GENETICS			English	Article							CANCER SUSCEPTIBILITY GENE; EARLY-ONSET BREAST; OVARIAN-CANCER; SUBCELLULAR-LOCALIZATION; NUCLEAR PHOSPHOPROTEIN; MUTATIONS; EXPRESSION; POLYMORPHISMS; FAMILIES; LOCATION	Although the link between the BRCA1 tumour-suppressor gene and hereditary breast and ovarian cancer is established(1-5), the role, if any, of BRCA1 in non-familial cancers is unclear. BRCA1 mutations are rare in sporadic cancers(6-8), but loss of BRCA1 resulting from reduced expression or incorrect subcellular localization(9,10) is postulated to be important in non-familial breast and ovarian cancers. Epigenetic loss, however, has not received general acceptance due to controversy regarding the subcellular localization of BRCA1 proteins, reports of which have ranged from exclusively nuclear(11-15), to conditionally nuclear(10), to the ER/golgi(16), to cytoplasmic invaginations into the nucleus(17). In an attempt to resolve this issue, we have comprehensively characterized 19 anti-BRCA1. antibodies. These reagents detect a 220-kD protein localized in discrete nuclear foci in all epithelial cell lines, including those derived from breast malignancies. Immunohistochemical staining of human breast specimens also revealed BRCA1 nuclear foci in benign breast, invasive lobular cancers and low-grade ductal carcinomas. Conversely, BRCA1 expression was reduced or undetectable in the majority of high-grade, ductal carcinomas, suggesting that absence of BRCA1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA 91365 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of Southern California; Harvard University; Dana-Farber Cancer Institute; Amgen	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.	dslamon@med1.medsch.ucla.edu	Scully, Ralph/F-5008-2013		NCI NIH HHS [R01 CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Coene E, 1997, NAT GENET, V16, P122, DOI 10.1038/ng0697-122; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Dobrovic A, 1997, CANCER RES, V57, P3347; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Schmutzler RK, 1997, INT J CANCER, V74, P322, DOI 10.1002/(SICI)1097-0215(19970620)74:3<322::AID-IJC15>3.3.CO;2-J; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924	27	353	364	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					236	240		10.1038/6029	http://dx.doi.org/10.1038/6029			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988281				2022-12-25	WOS:000078399500031
J	Karet, FE; Finberg, KE; Nelson, RD; Nayir, A; Mocan, H; Sanjad, SA; Rodriguez-Soriano, J; Santos, F; Cremers, CWRJ; Di Pietro, A; Hoffbrand, BI; Winiarski, J; Bakkaloglu, A; Ozen, S; Dusunsel, R; Goodyer, P; Hulton, SA; Wu, DK; Skvorak, AB; Morton, CC; Cunningham, MJ; Jha, V; Lifton, RP				Karet, FE; Finberg, KE; Nelson, RD; Nayir, A; Mocan, H; Sanjad, SA; Rodriguez-Soriano, J; Santos, F; Cremers, CWRJ; Di Pietro, A; Hoffbrand, BI; Winiarski, J; Bakkaloglu, A; Ozen, S; Dusunsel, R; Goodyer, P; Hulton, SA; Wu, DK; Skvorak, AB; Morton, CC; Cunningham, MJ; Jha, V; Lifton, RP			Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness	NATURE GENETICS			English	Article							DIFFERENTIAL EXPRESSION; INNER-EAR; HETEROGENEITY; ASSOCIATION; EXCHANGER; CHILDREN; ISOFORM; CELLS; DNA	H+-ATPases are ubiquitous in nature; V-ATPases pump protons against an electrochemical gradient, whereas F-ATPases reverse the process, synthesizing ATP. We demonstrate here that mutations in ATP6B1, encoding the B-subunit of the apical proton pump mediating distal nephron acid secretion, cause distal renal tubular acidosis, a condition characterized by impaired renal acid secretion resulting in metabolic acidosis. Patients with ATP6B1 mutations also have sensorineural hearing loss; consistent with this finding, we demonstrate expression of ATP6B1 in cochlea and endolymphatic sac. Our data, together with the known requirement for active proton secretion to maintain proper endolymph pH, implicate ATP6B1 in endolymph pH homeostasis and in normal auditory function. ATP6B1 is the first member of the H+-ATPase gene family in which mutations are shown to cause human disease.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Med, New Haven, CT 06510 USA; Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA; Univ Istanbul, Dept Pediat Nephrol, Istanbul, Turkey; Karadeniz Tekn Univ, Dept Pediat Nephrol, Trabzon, Turkey; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Hosp Cruces, Dept Pediat, Bilbao, Spain; Univ Oviedo, Div Pediat Nephrol, Oviedo, Spain; Acad Ziekenhuis, Dept Otorhinolaryngol, Nijmegen, Netherlands; Serv Osped Rilievo Nazl, Serv Nefrol Pediat, Naples, Italy; Whittington Hosp, Dept Nephrol, London N19 5NF, England; Karolinska Inst, Dept Pediat, Huddinge, Sweden; Hacettepe Univ, Dept Pediat Nephrol, Ankara, Turkey; Erciyes Univ, Dept Pediat Nephrol, Kayseri, Turkey; Montreal Childrens Hosp, Div Pediat Nephrol, Montreal, PQ H3H 1P3, Canada; Childrens Hosp, Dept Nephrol, Birmingham B16 8ET, W Midlands, England; Natl Inst Deafness & Other Commun Disorders, Rockville, MD USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA; Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh 160012, India	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Utah System of Higher Education; University of Utah; Istanbul University; Karadeniz Technical University; King Faisal Specialist Hospital & Research Center; Hospital Universitario Cruces; University of Oviedo; University of London; University College London; Karolinska Institutet; Hacettepe University; Erciyes University; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Lifton, RP (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06510 USA.	richard.lifton@yale.edu	NAYIR, AHMET NEVZAT/A-9276-2019; OZEN, SEZA/I-9096-2013; Cremers, C.W.R.J./L-4254-2015	Karet, Fiona/0000-0002-2457-2869; Jha, Vivekanand/0000-0002-8015-9470	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003402] Funding Source: NIH RePORTER; NIDCD NIH HHS [DCO3402] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bastani B, 1996, MINER ELECTROL METAB, V22, P396; BATLLE DC, 1981, KIDNEY INT, V20, P389, DOI 10.1038/ki.1981.151; BATTLE D, 1996, AM J KIDNEY DIS, V6, P896; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BROWN MT, 1993, ARCH OTOLARYNGOL, V119, P458; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Butler AM, 1936, J PEDIATR-US, V8, P489, DOI 10.1016/S0022-3476(36)80111-5; CANLON B, 1991, HEARING RES, V53, P7, DOI 10.1016/0378-5955(91)90209-R; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig HD, 1998, HUM MOL GENET, V7, P1851, DOI 10.1093/hmg/7.12.1851; CREMERS CWRJ, 1980, ARCH OTOLARYNGOL, V106, P287; DONCKERWOLCKE RA, 1976, ACTA PAEDIATR SCAND, V65, P100, DOI 10.1111/j.1651-2227.1976.tb04414.x; GYORY AZ, 1968, AM J MED, V45, P43, DOI 10.1016/0002-9343(68)90006-5; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Lightwood R., 1935, ARCH DIS CHILD, V10, P205, DOI [10.1136/adc.10.57.205, DOI 10.1136/ADC.10.57.205]; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; MISRAHY GA, 1958, AM J PHYSIOL, V194, P393, DOI 10.1152/ajplegacy.1958.194.2.393; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NANCE W E, 1971, Birth Defects Original Article Series, V7, P70; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROYER P, 1967, P ACTUALITES NEPHROL; SELLICK P M, 1975, Progress in Neurobiology (Oxford), V5, P337, DOI 10.1016/0301-0082(75)90015-5; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Stankovic KM, 1997, HEARING RES, V114, P21, DOI 10.1016/S0378-5955(97)00072-5; STERKERS O, 1984, AM J PHYSIOL, V246, pF47, DOI 10.1152/ajprenal.1984.246.1.F47; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TASAKI I, 1959, J NEUROPHYSIOL, V22, P149, DOI 10.1152/jn.1959.22.2.149; VANHILLE B, 1994, BIOCHEM J, V303, P191, DOI 10.1042/bj3030191; Walker W G, 1971, Birth Defects Orig Artic Ser, V07, P126; ZAKZOUK SM, 1995, J LARYNGOL OTOL, V109, P930, DOI 10.1017/S0022215100131706	41	532	558	0	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					84	90		10.1038/5022	http://dx.doi.org/10.1038/5022			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916796				2022-12-25	WOS:000077960700014
J	Ueki, N; Oda, T; Kondo, M; Yano, K; Noguchi, T; Muramatsu, MA				Ueki, N; Oda, T; Kondo, M; Yano, K; Noguchi, T; Muramatsu, MA			Selection system for genes encoding nuclear-targeted proteins	NATURE BIOTECHNOLOGY			English	Article						screen; nuclear transport; nuclear localization signals	NUCLEOCYTOPLASMIC TRANSPORT; MOLECULAR-CLONING; DNA-BINDING; DOMAIN; EXPORT; IDENTIFICATION; SEQUENCE; SIGNAL; YEAST; IMPORTIN	Nuclear proteins have essential roles in cell proliferation and differentiation. We have developed a yeast selection system-the nuclear transportation trap (NTT)-to identify genes encoding nuclear transport signals. Both unknown and previously identified nuclear localization signals were identified from a human fetal brain cDNA library. The majority (75%) of the unknown proteins examined were exclusively localized to the nucleus in COS-7 cells. We propose that NTT is an efficient method for isolating cDNAs that encode nuclear targeted proteins that can be applied to the retrieval of novel nuclear proteins and to annotate gene function.	Helix Res Inst, Biol Technol Lab, Chiba 2920812, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Biol Cybernet, Tokyo 1130034, Japan	Tokyo Medical & Dental University (TMDU)	Ueki, N (corresponding author), Mitsubishi Chem Corp, Pharmaceut Discovery Lab, Aoba Ku, Yokohama, Kanagawa 2278502, Japan.	goose@rc.m-kagaku.co.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; HOSHINO T, 1989, J BACTERIOL, V171, P6300, DOI 10.1128/jb.171.11.6300-6306.1989; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACLEOD AR, 1986, NUCLEIC ACIDS RES, V14, P8413, DOI 10.1093/nar/14.21.8413; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; PELFER M, 1994, CELL, V76, P789; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Tanaka T, 1996, GENOMICS, V32, P128, DOI 10.1006/geno.1996.0087; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TRATNER I, 1991, ONCOGENE, V6, P2049; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3	37	37	62	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1338	1342		10.1038/4315	http://dx.doi.org/10.1038/4315			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853615				2022-12-25	WOS:000077232600026
J	Minassian, BA; Lee, JR; Herbrick, JA; Huizenga, J; Soder, S; Mungall, AJ; Dunham, I; Gardner, R; Fong, CG; Carpenter, S; Jardim, L; Satishchandra, P; Andermann, E; Snead, OC; Lopes-Cendes, I; Tsui, LC; Delgado-Escueta, AV; Rouleau, GA; Scherer, SW				Minassian, BA; Lee, JR; Herbrick, JA; Huizenga, J; Soder, S; Mungall, AJ; Dunham, I; Gardner, R; Fong, CG; Carpenter, S; Jardim, L; Satishchandra, P; Andermann, E; Snead, OC; Lopes-Cendes, I; Tsui, LC; Delgado-Escueta, AV; Rouleau, GA; Scherer, SW			Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy	NATURE GENETICS			English	Article							LAFORAS-DISEASE; FORM; DIAGNOSIS	Lafora's disease (LD; OMIM 254780) is an autosomal recessive form of progressive myoclonus epilepsy characterized by seizures and cumulative neurological deterioration. Onset occurs during late childhood and usually results in death within ten years of the first symptoms(1,2). With few exceptions, patients follow a homogeneous clinical course despite the existence of genetic heterogeneity(3). Biopsy of various tissues, including brain, revealed characteristic polyglucosan inclusions called Lafora bodies(4-8), which suggested LD might be a generalized storage disease(6,9). Using a positional cloning approach, we have identified at chromosome 6q24 a novel gene, EPM2A. that encodes a protein with consensus amino acid sequence indicative of a protein tyrosine phosphatase (PTP). mRNA transcripts representing alternatively spliced forms of EPM2A were found in every tissue examined, including brain. Six distinct DNA sequence variations in EPM2A in nine families, and one homozygous microdeletion in another family have been found to cosegregate with LD. These mutations are predicted to cause deleterious effects in the putative protein product, named laforin, resulting in LD.	Univ Toronto, Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada; Sanger Ctr, Hinxton CB10 1SA, Cambs, England; Salisbury Dist Hosp, Salisbury Hlth Care NHS Trust, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England; Univ Calif Los Angeles, Sch Med, Calif Comprehens Epilepsy Program, Los Angeles, CA USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Univ Toronto, Toronto Hosp, Dept Pathol, Toronto, ON M5T 2S8, Canada; Hosp Clin Porto Alegre, Med Genet Serv, BR-90035003 Porto Alegre, RS, Brazil; Deemed Univ, Natl Inst Mental Hlth & Neurosci, Bangalore 560029, Karnataka, India; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Wellcome Trust Sanger Institute; Salisbury District Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institute of Mental Health & Neurosciences - India; McGill University; McGill University; University of Toronto	Scherer, SW (corresponding author), Univ Toronto, Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada.		Mungall, Andrew J./U-7067-2018; Scherer, Stephen W./B-3785-2013; Jardim, Laura B/B-6149-2013; Tsui, Lap-chee/A-1081-2010; Lopes-Cendes, Iscia/B-9416-2013	Mungall, Andrew J./0000-0002-0905-2742; Scherer, Stephen W./0000-0002-8326-1999; Lopes-Cendes, Iscia/0000-0002-6221-6822; Dunham, Ian/0000-0003-2525-5598; Delgado-Escueta, Antonio V./0000-0002-1581-6999	NINDS NIH HHS [5P01-NS21908] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS021908] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHARYA JN, 1993, EPILEPSIA, V34, P476, DOI 10.1111/j.1528-1157.1993.tb02588.x; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; CARPENTER S, 1981, NEUROLOGY, V31, P1564, DOI 10.1212/WNL.31.12.1564; CARPENTER S, 1974, NEUROLOGY, V24, P531, DOI 10.1212/WNL.24.6.531; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; FONG CG, 1998, EPILEPSIA, V39, P4; Gurd JW, 1997, J NEUROCHEM, V69, P623; HARRIMAN DGF, 1955, BRAIN, V78, P325, DOI 10.1093/brain/78.3.325; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lafora GR, 1911, VIRCHOWS ARCH A, V205, P295, DOI 10.1007/BF01989438; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Llinas R, 1997, P NATL ACAD SCI USA, V94, P1990, DOI 10.1073/pnas.94.5.1990; LOPESCENDES I, 1995, EPILEPSIA, V36, P6; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; Minassian Berge A., 1996, Epilepsia, V37, P126; Sainz J, 1997, AM J HUM GENET, V61, P1205, DOI 10.1086/301596; SAKAI M, 1970, NEUROLOGY, V20, P160, DOI 10.1212/WNL.20.2.160; SCHWARZ GA, 1965, ARCH NEUROL-CHICAGO, V12, P172, DOI 10.1001/archneur.1965.00460260062008; SERRATOSA JM, 1995, HUM MOL GENET, V9, P1657; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Van Heycop Ten Ham MW., 1974, HDB CLIN NEUROLOGY, V15, P382; WANG QM, 1994, J BIOL CHEM, V269, P14566; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	24	356	369	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					171	174		10.1038/2470	http://dx.doi.org/10.1038/2470			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771710				2022-12-25	WOS:000076231300019
J	Dove, A				Dove, A			From bits to bases: Computing with DNA	NATURE BIOTECHNOLOGY			English	Article								Biocomputers could one day rival the efficiency of silicon computers for solving complex mathematical problems.										ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473	3	9	10	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					830	832		10.1038/nbt0998-830	http://dx.doi.org/10.1038/nbt0998-830			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743114				2022-12-25	WOS:000075671700027
J	Kimura, Y; Koga, H; Araki, N; Mugita, N; Fujita, N; Takeshima, H; Nishi, T; Yamashima, T; Saido, TC; Yamasaki, T; Moritake, K; Saya, H; Nakao, M				Kimura, Y; Koga, H; Araki, N; Mugita, N; Fujita, N; Takeshima, H; Nishi, T; Yamashima, T; Saido, TC; Yamasaki, T; Moritake, K; Saya, H; Nakao, M			The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas	NATURE MEDICINE			English	Article							NEUROFIBROMATOSIS TYPE-2 GENE; CALCIUM-CHANNEL ANTAGONISTS; SEQUENCE-ANALYSIS; MU-CALPAIN; PHOSPHORYLATION; INHIBITION; PROTEINS; CELLS; ACTIVATION; MUTATIONS	Neurofibromatosis type 2 (NF2) protein, also known as merlin or schwannomin, is a tumor suppressor, and NF2 is mutated in most schwannomas and meningiomas. Although these tumors are dependent on NF2, some lack detectable NF2 mutations, which indicates that alternative mechanisms exist for inactivating merlin. Here, we demonstrate cleavage of merlin by the ubiquitous protease calpain and considerable activation of the calpain system resulting in the loss of merlin expression in these tumors. Increased proteolysis of merlin by calpain in some schwannomas and meningiomas exemplifies tumorigenesis linked to the calpain-mediated proteolytic pathway.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Shimane Med Univ, Dept Neurosurg, Izumo, Shimane 6930021, Japan; Kanazawa Univ, Sch Med, Dept Neurosurg, Kanazawa, Ishikawa 9200934, Japan; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510106, Japan	Kumamoto University; Kumamoto University; Shimane University; Kanazawa University; RIKEN	Nakao, M (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Sado, Takaomi/AAN-2759-2021; Saya, Hideyuki/J-4325-2013; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Burkhart WA, 1996, ANAL BIOCHEM, V236, P364, DOI 10.1006/abio.1996.0184; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; Eldridge R, 1981, Adv Neurol, V29, P57; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Harada T, 1996, J NEUROSURG, V84, P847, DOI 10.3171/jns.1996.84.5.0847; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Jay D, 1997, BIOCHEM BIOPH RES CO, V232, P555, DOI 10.1006/bbrc.1997.6238; JENSEN RL, 1995, NEUROSURGERY, V36, P365, DOI 10.1227/00006123-199502000-00017; JENSEN RL, 1995, NEUROSURGERY, V37, P937, DOI 10.1227/00006123-199511000-00013; KOGA H, IN PRESS ONCOGENE; Lee JH, 1997, NEUROSURGERY, V40, P578, DOI 10.1097/00006123-199703000-00031; LEKANNE DRH, 1994, AM J HUM GENET, V54, P1022; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; MILLER CG, 1995, TECH PROT CHEM, V6, P219, DOI 10.1016/S1080-8914(06)80029-3; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEKIDO Y, 1995, CANCER RES, V55, P1227; Selliah N, 1996, J IMMUNOL, V156, P3215; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; STEMMERRACHAMIM.OA, 1997, AM J PATHOL, V151, P1649; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Welling DB, 1996, HUM GENET, V98, P189, DOI 10.1007/s004390050188; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x	50	95	96	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					915	922		10.1038/nm0898-915	http://dx.doi.org/10.1038/nm0898-915			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701243				2022-12-25	WOS:000075107400034
J	Hofstetter, O; Hofstetter, H; Wilchek, M; Schurig, V; Green, BS				Hofstetter, O; Hofstetter, H; Wilchek, M; Schurig, V; Green, BS			Chiral discrimination using an immunosensor	NATURE BIOTECHNOLOGY			English	Article						applied immunology; chiral sensor; amino acid	SURFACE-PLASMON RESONANCE; D-AMINO ACIDS; MURCHISON METEORITE; D-SERINE; SENSORS; DISEASE; PROTEIN	Based on the stereoselectivity of immunoglobulins, we have developed a new chiral sensor for the detection of low-molecular-weight analytes. Using surface plasmon resonance detection, enantiomers of free, underivatized alpha-amino acids can be monitored in a competitive assay by their interaction with antibodies specific for the chiral center of this class of substances. The sensitivity to the minor enantiomer in nonracemic mixtures exceeds currently available methods; therefore, such immunosensors can readily detect traces of enantiomeric impurities and are attractive for a range of applications in science and industry.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Hebrew Univ Jerusalem, Dept Pharmaceut Chem, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; Eberhard Karls University of Tubingen; Hebrew University of Jerusalem	Green, BS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	csgreen@md2.huji.ac.il	Hofstetter, Heike/GXH-9439-2022	Hofstetter, Heike/0000-0003-4501-4206				Ansell RJ, 1996, CURR OPIN BIOTECH, V7, P89, DOI 10.1016/S0958-1669(96)80101-7; Bodenhofer K, 1997, NATURE, V387, P577, DOI 10.1038/42426; CALDWELL J, 1995, J CHROMATOGR A, V694, P39, DOI 10.1016/0021-9673(94)00812-N; Coppola GM., 1987, ASYMMETRIC SYNTHESIS; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; EICHELBAUM M, 1996, ADV DRUG RES, V28, P1; Engel MH, 1997, NATURE, V389, P265, DOI 10.1038/38460; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FISHER GH, 1994, MOL CHEM NEUROPATHOL, V23, P115, DOI 10.1007/BF02815405; HASHIMOTO A, 1993, J NEUROCHEM, V61, P348, DOI 10.1111/j.1471-4159.1993.tb03575.x; Hofstetter O, 1998, J AM CHEM SOC, V120, P3251, DOI 10.1021/ja973680n; Imai K, 1996, BIOMED CHROMATOGR, V10, P303, DOI 10.1002/(SICI)1099-0801(199611)10:6<303::AID-BMC624>3.0.CO;2-B; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KRETSCHM.E, 1968, Z NATURFORSCH PT A, VA 23, P2135, DOI 10.1515/zna-1968-1247; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LUTHRA M, 1994, J BIOL CHEM, V269, P22678; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Moore DE, 1996, J AM CHEM SOC, V118, P12997, DOI 10.1021/ja9630405; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Parker D, 1997, CHEM COMMUN, P141, DOI 10.1039/a603564g; Pizzarello S, 1998, NATURE, V394, P236, DOI 10.1038/28306; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; SCHURIG V, 1995, METHODS ORGANIC CH A, V21, P147; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Stinson SC, 1997, CHEM ENG NEWS, V75, P38; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0	27	96	100	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					371	374		10.1038/7927	http://dx.doi.org/10.1038/7927			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207886				2022-12-25	WOS:000079574400026
J	Koob, MD; Moseley, ML; Schut, LJ; Benzow, KA; Bird, TD; Day, JW; Ranum, LPW				Koob, MD; Moseley, ML; Schut, LJ; Benzow, KA; Bird, TD; Day, JW; Ranum, LPW			An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8)	NATURE GENETICS			English	Article							MACHADO-JOSEPH DISEASE; RNA-BINDING-PROTEIN; MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEAT; CLINICAL-FEATURES; MICE; TRANSCRIPTS; FAMILIES; MYOPATHY; LENGTH	Myotonic dystrophy (DM) is the only disease reported to be caused by a CTG expansion. We now report that a non-coding CTC expansion causes a novel form of spinocerebellar ataxia (SCA8). This expansion, located on chromosome 13q21, was isolated directly from the genomic DNA of an ataxia patient by RAPID cloning. SCA8 patients have expansions similar in size (107-127 CTG repeats) to those found among adult-onset DM patients. SCA8 is the first example of a dominant SCA not caused by a CAG expansion translated as a polyglutamine tract.	Univ Minnesota, Dept Neurol & Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Cell Biol & Dev, Minneapolis, MN 55455 USA; Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Koob, MD (corresponding author), Univ Minnesota, Dept Neurol & Genet, Box 295 UMHC,420 Delaware St SE, Minneapolis, MN 55455 USA.				NINDS NIH HHS [P01 NS33718, R01 NS36282] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033718, R01NS036282] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brice A, 1998, J NEUROL, V245, P505, DOI 10.1007/s004150050234; Cancel G, 1997, HUM MOL GENET, V6, P709, DOI 10.1093/hmg/6.5.709; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Groenen P, 1998, BIOESSAYS, V20, P901, DOI 10.1002/(SICI)1521-1878(199811)20:11<901::AID-BIES5>3.0.CO;2-0; HARDING AE, 1982, BRAIN, V105, P1, DOI 10.1093/brain/105.1.1; HOFFMANRADVANYI H, 1993, HUM MOL GENET, V2, P1263; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Jodice C, 1997, HUM MOL GENET, V6, P1973, DOI 10.1093/hmg/6.11.1973; Klockgether T, 1998, TRENDS NEUROSCI, V21, P413, DOI 10.1016/S0166-2236(98)01315-0; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MACIEL P, 1995, AM J HUM GENET, V57, P54; MARUYAMA H, 1995, HUM MOL GENET, V4, P807, DOI 10.1093/hmg/4.5.807; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SCHANK SC, 1993, BIOMASS BIOENERG, V4, P1, DOI 10.1016/0961-9534(93)90021-U; SUBRAMONY SH, 1991, HDB CLIN NEUROLOGY, P271; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; Zoghbi HY, 1991, CURR NEUROL, V11, P121	29	458	483	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					379	384		10.1038/7710	http://dx.doi.org/10.1038/7710			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192387				2022-12-25	WOS:000079439700018
J	Brower, V				Brower, V			Human ES cells: Can you build a business around them?	NATURE BIOTECHNOLOGY			English	Article																			0	16	17	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					139	142		10.1038/6140	http://dx.doi.org/10.1038/6140			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052348				2022-12-25	WOS:000078508300020
J	Munroe, PB; Olgunturk, RO; Fryns, JP; Van Maldergem, L; Ziereisen, F; Yuksel, B; Gardiner, RM; Chung, E				Munroe, PB; Olgunturk, RO; Fryns, JP; Van Maldergem, L; Ziereisen, F; Yuksel, B; Gardiner, RM; Chung, E			Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome	NATURE GENETICS			English	Article							VITAMIN-K; ASSIGNMENT; MOUSE; MAP	Keutel syndrome (KS, MIM 245150) is an autosomal recessive disorder characterized by abnormal cartilage calcification, peripheral pulmonary stenosis and midfacial hypoplasia(1). A genome search using homozygosity mapping provided evidence of linkage to chromosome 12p12.3-13.1 (maximum multipoint lod score, 4.06). MGP was a candidate on the basis of its localization to this chromosomal region and the known function of its protein(2-4). MGP maps to chromosome 12p near D12S363 (refs 2,3). Human MCP is a 10-kD skeletal extracellular matrix (ECM) protein that consists of an 84-aa mature protein and a 19-aa transmembrane signal peptide(5). It is a member of the Gla protein family, which includes osteocalcin(6), another skeletal ECM protein, and a number of coagulation factors(7) (factors II, VII, IX, X and proteins S and C). All members of this family have glutamic acid residues modified to gamma-carboxyglutamic acids (Gla) by a specific gamma-carboxylase using Vitamin K as a cofactors(8,9). The modified glutamic acid residues of Gla proteins confer a high affinity for mineral ions such as calcium, phosphate and hydroxyapatite crystals, the mineral components of the skeletal ECM. The pattern and tissue distribution of Mgp expression in mice suggest a role for Mgp in regulating ECM calcification(10). Mglap-deficient mice (Mglap(-/-)) have been reported to have inappropriate calcification of cartilage(4). Mutational analysis of MGP in three unrelated probands identified three different mutations: c.69delG, IVS1-2A-->G and c.113T-->A. All three mutations predict a non-functional MGP. Our data indicate that mutations in MGP are responsible for KS and confirm its role in the regulation of extracellular matrix calcification.	UCL Royal Free & Univ Coll Med Sch, Dept Paediat, Rayne Inst, London, England; Gazi Univ Hosp, Dept Paediat Cardiol, Ankara, Turkey; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Inst Pathol & Genet, Ctr Human Genet, Loverval, Belgium; Hop Univ Enfants Reine Fabiola, Dept Radiol, Brussels, Belgium; Chase Farm Hosp NHS Trust, Dept Paediat, London, England	University of London; King's College London; University College London; UCL Medical School; Gazi University; KU Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Munroe, PB (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Paediat, Rayne Inst, Univ St, London, England.	p.munroe@ucl.ac.uk	Van Maldergem, Lionel/G-9849-2017; Van Maldergem, Lionel/O-3242-2019	Van Maldergem, Lionel/0000-0001-8880-5214; Van Maldergem, Lionel/0000-0001-8880-5214; Munroe, Patricia/0000-0002-4176-2947				CANCELA L, 1990, J BIOL CHEM, V265, P15040; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; CORMODE EJ, 1986, AM J MED GENET, V24, P289, DOI 10.1002/ajmg.1320240209; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FRANKE TF, 1995, CELL, V81, P1; FRASER JD, 1988, J BIOL CHEM, V263, P11033; FRYNS JP, 1984, EUR J PEDIATR, V142, P201, DOI 10.1007/BF00442449; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALLOP PM, 1980, NEW ENGL J MED, V302, P1460, DOI 10.1056/NEJM198006263022608; HALE JE, 1988, J BIOL CHEM, V263, P5820; HOWE AM, 1995, AM J MED GENET, V58, P238, DOI 10.1002/ajmg.1320580309; JOHNSON TL, 1991, GENOMICS, V11, P770, DOI 10.1016/0888-7543(91)90089-W; KEUTEL J, 1972, Birth Defects Original Article Series, V8, P60; KHOSROSHAHI HE, 1989, EUR J PEDIATR, V149, P188, DOI 10.1007/BF01958278; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LUO GB, 1995, J BONE MINER RES, V10, P325; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Munroe PB, 1997, AM J HUM GENET, V61, P310, DOI 10.1086/514846; PAULI RM, 1987, AM J HUM GENET, V41, P566; PETTIFOR JM, 1975, J PEDIATR-US, V86, P459; Say B, 1973, Pediatr Radiol, V1, P127, DOI 10.1007/BF00973228; SHEFFIELD LJ, 1976, J PEDIATR-US, V89, P916, DOI 10.1016/S0022-3476(76)80596-3; SPRANGER JW, 1970, HUM GENET, V11, P190; Watanabe I, 1998, J HUM GENET, V43, P75, DOI 10.1007/s100380050044	27	314	323	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					142	144		10.1038/5102	http://dx.doi.org/10.1038/5102			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916809				2022-12-25	WOS:000077960700027
J	Chen, LL; Marmey, P; Taylor, NJ; Brizard, JP; Espinoza, C; D'Cruz, P; Huet, H; Zhang, SP; de Kochko, A; Beachy, RN; Fauquet, CM				Chen, LL; Marmey, P; Taylor, NJ; Brizard, JP; Espinoza, C; D'Cruz, P; Huet, H; Zhang, SP; de Kochko, A; Beachy, RN; Fauquet, CM			Expression and inheritance of multiple transgenes in rice plants	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; metabolic engineering; particle bombardment	BIOLISTIC METHOD; TRANSFORMATION; INDICA; REGENERATION; RESISTANCE; VARIETIES; CELLS; GENE; DNA	The ability to control integration, inheritance, and expression of multiple transgenes is a prerequisite for manipulating biosynthetic pathways and complex agronomic characteristics in plants. One hundred and twenty-five independent transgenic rice plants were regenerated after cobombarding embryogenic tissues with a mixture of 14 different pUC-based plasmids. Eighty-five percent of the R0 plants contained more than two, and 17% more than nine, of the target genes. Plants containing multiple transgenes displayed normal morphologies and 63% set viable seed. Multigene cotransformation efficiency was correlated with the ratio in which the plasmids were mixed with respect to the selectable marker. All target genes had an equal chance of integration, indicating that the nature of the coding region had no effect on the efficiency of integration. Three plant lines containing 11, 10, and 9 transgenes, respectively, were analyzed for patterns of integration and inheritance until the R3 generation. Integration of multiple transgenes occurred at either one or two genetic loci, with inheritance conforming to a 3:1 Mendelian ratio. Coexpression of four marker genes was investigated until the R2 generation.	Scripps Res Inst, Div Plant Biol, ORSTOM TSRI, Int Lab Trop Agr Biotechnol, La Jolla, CA 92037 USA; Volcani Res Inst, Tel Aviv, Israel	Scripps Research Institute; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Fauquet, CM (corresponding author), Scripps Res Inst, Div Plant Biol, ORSTOM TSRI, Int Lab Trop Agr Biotechnol, BCC 206, La Jolla, CA 92037 USA.		Taylor, Nigel/M-2851-2013; de Kochko, Alexandre/C-7512-2009	de Kochko, Alexandre/0000-0001-9212-3195; MARMEY, Philippe/0000-0003-3973-9868				CHEN L, 1998, IN PRESS PLANT CELL; CHRISTOU P, 1991, BIO-TECHNOL, V9, P957, DOI 10.1038/nbt1091-957; Christou P, 1996, TRENDS PLANT SCI, V1, P423, DOI 10.1016/S1360-1385(96)10047-9; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; FUGIMOTO H, 1993, BIOTECHNOLOGY, V11, P1151; Hadi MZ, 1996, PLANT CELL REP, V15, P500, DOI 10.1007/BF00232982; Hamilton CM, 1996, P NATL ACAD SCI USA, V93, P9975, DOI 10.1073/pnas.93.18.9975; HAYAKAWA T, 1992, P NATL ACAD SCI USA, V89, P9865, DOI 10.1073/pnas.89.20.9865; HERRERAESTRELLA L, 1996, PLANT MICROBE INTERA, V1, P33; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; LI LC, 1993, PLANT CELL REP, V12, P250, DOI 10.1007/BF00237129; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; Qu RD, 1996, IN VITRO CELL DEV-PL, V32, P233, DOI 10.1007/BF02822693; REDENBAUGH K, 1993, IN VITRO CELL DEV-PL, V29P, P17; Ronald PC, 1997, PLANT MOL BIOL, V35, P179, DOI 10.1023/A:1005750811983; Sambrook J., 2002, MOL CLONING LAB MANU; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; TIRCOLI DM, 1995, BIOTECHNOLOGY, V13, P1458; Vickers JE, 1996, PLANT MOL BIOL REP, V14, P363, DOI 10.1007/BF02673368; WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134; ZHANG S, 1998, IN PRESS MOL BREEDIN; Zhang SP, 1996, PLANT CELL REP, V15, P465, DOI 10.1007/BF00232975; ZHANG SP, 1995, PLANT CELL REP, V15, P68, DOI 10.1007/BF01690256	24	188	230	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1060	1064		10.1038/3511	http://dx.doi.org/10.1038/3511			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831036				2022-12-25	WOS:000076870100029
J	Pooga, M; Soomets, U; Hallbrink, M; Valkna, A; Saar, K; Rezaei, K; Kahl, U; Hao, JX; Xu, XJ; Wiesenfeld-Hallin, Z; Hokfelt, T; Bartfai, T; Langel, U				Pooga, M; Soomets, U; Hallbrink, M; Valkna, A; Saar, K; Rezaei, K; Kahl, U; Hao, JX; Xu, XJ; Wiesenfeld-Hallin, Z; Hokfelt, T; Bartfai, T; Langel, U			Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo	NATURE BIOTECHNOLOGY			English	Article						drug delivery; antisense; neuropeptides	PEPTIDE NUCLEIC-ACIDS; ANTENNAPEDIA HOMEODOMAIN; ANTISENSE PROPERTIES; 3RD HELIX; RAT; OLIGOMERS; DNA	Peptide nucleic acids (PNAs) form stable and tight complexes with complementary DNA and/or RNA and would be promising antisense reagents if their cellular delivery could be improved, We show that a 21-mer PNA, complementary to the human galanin receptor type 1 mRNA, coupled to the cellular transporter peptides, transportan or pAntennapedia(43-58), is efficiently taken up into Bowes cells where they block the expression of galanin receptors, In rat, the intrathecal administration of the peptide-PNA construct results in a decrease in galanin binding in the dorsal horn, The decrease in binding results in the inability of galanin to inhibit the C fibers stimulation-induced facilitation of the rat flexor reflex, demonstrating that peptide-PNA constructs act in vivo to suppress expression of functional galanin receptors.	Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Neurophysiol, S-14186 Huddinge, Sweden; Estonian Bioctr, EE-2400 Tartu, Estonia; Tartu State Univ, Dept Biochem, EE-2400 Tartu, Estonia; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; F Hoffmann La Roche & Co Ltd, Dpt PRPN, CH-4070 Basel, Switzerland	Stockholm University; Karolinska Institutet; Estonian Biocentre; University of Tartu; Karolinska Institutet; Roche Holding	Langel, U (corresponding author), Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden.	ulo@neurochem.su.se	Pooga, Margus/A-8575-2011; Soomets, Ursel/H-5919-2015	Pooga, Margus/0000-0003-4532-4087; Soomets, Ursel/0000-0002-3681-188X; Langel, Ulo/0000-0001-6107-0844				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; BARTFAI T, 1993, P NATL ACAD SCI USA, V90, P11287, DOI 10.1073/pnas.90.23.11287; Bartfai Tamas, 1995, P563; Bennett CF, 1998, BIOCHEM PHARMACOL, V55, P9, DOI 10.1016/S0006-2952(97)00214-1; BONHAM MA, 1995, NUCLEIC ACIDS RES, V23, P1197, DOI 10.1093/nar/23.7.1197; BURGEVIN MC, 1995, J MOL NEUROSCI, V6, P1; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; Harlow E., 1988, ANTIBODIES LAB MANUA; HOWARD A, FEBS LETT, V405, P285; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Melander T, 1988, J Chem Neuroanat, V1, P213; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Roush W, 1997, SCIENCE, V276, P1192, DOI 10.1126/science.276.5316.1192; Storkson RV, 1996, J NEUROSCI METH, V65, P167, DOI 10.1016/0165-0270(95)00164-6; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Troy CM, 1996, J NEUROSCI, V16, P253; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; WIESENFELDHALLIN Z, 1989, BRAIN RES, V486, P205, DOI 10.1016/0006-8993(89)90506-4; WIESENFELDHALLIN Z, 1992, P NATL ACAD SCI USA, V89, P3334, DOI 10.1073/pnas.89.8.3334; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231; YOUNG WS, 1979, BRAIN RES, V179, P255	31	504	547	1	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					857	861		10.1038/nbt0998-857	http://dx.doi.org/10.1038/nbt0998-857			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743120				2022-12-25	WOS:000075671700033
J	De Felice, M; Ovitt, C; Biffali, E; Rodriguez-Mallon, A; Arra, C; Anastassiadis, K; Macchia, PE; Mattei, MG; Mariano, A; Scholer, H; Macchia, V; Di Lauro, R				De Felice, M; Ovitt, C; Biffali, E; Rodriguez-Mallon, A; Arra, C; Anastassiadis, K; Macchia, PE; Mattei, MG; Mariano, A; Scholer, H; Macchia, V; Di Lauro, R			A mouse model for hereditary thyroid dysgenesis and cleft palate	NATURE GENETICS			English	Article							CONGENITAL HYPOTHYROIDISM; LUNG; FUSION; HAIR	Alteration of thyroid gland morphogenesis (thyroid dysgenesis) is a frequent human malformation. Among the one in three to four thousand newborns in which congenital hypothyroidism is detected, 80% have either an ectopic, small and sublingual thyroid, or have no thyroid tissue(1). Most of these cases appear sporadically, although a few cases of recurring familial thyroid dysgenesis have been described(2). The lack of evidence for hereditary thyroid dysgenesis may be due to the severity of the hypothyroid phenotype. Neonatal screening and early thyroid hormone therapy have eliminated most of the clinical consequences of hypothyroidism such that the heritability of this condition may become apparent in the near future. We have recently cloned cDNA encoding a forkhead domain-containing transcription factor, TTF-2, and have located the position of the gene, designated Titf2, to mouse chromosome 4 (ref. 3). Titf2 is expressed in the developing thyroid, in most of the foregut endoderm and in craniopharyngeal ectoderm, including Rathke's pouch(3). Expression of Titf2 in thyroid cell precursors is down-regulated as they cease migration, suggesting that this factor is involved in the process of thyroid gland morphogenesis. Here we show that Titf2-null mutant mice exhibit cleft palate and either a sublingual or completely absent thyroid gland. Thus, mutation of Titf2(-/-) results in neonatal hypothyroidism that shows similarity to thyroid dysgenesis in humans.	Stn Zool A Dohrn, I-80121 Napoli, Italy; European Mol Biol Lab, Heidelberg, Germany; Ist Nazl Tumori Fdn Senatore Pascale, Naples, Italy; Fac Med Timone, Marseille, France; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Napoli, Italy	European Molecular Biology Laboratory (EMBL); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Naples Federico II	Di Lauro, R (corresponding author), Stn Zool A Dohrn, I-80121 Napoli, Italy.	rdilauro@unina.it	Rodriguez Mallon, Alina/GVU-0924-2022; Macchia, Paolo Emidio/B-7391-2012; Macchia, Paolo Emidio/AGZ-2839-2022; Anastassiadis, Konstantinos/A-8944-2010; Di Lauro, Roberto/A-2746-2012	Macchia, Paolo Emidio/0000-0001-6503-6942; Macchia, Paolo Emidio/0000-0001-6503-6942; Anastassiadis, Konstantinos/0000-0002-9814-0559; Di Lauro, Roberto/0000-0001-9493-3036; Scholer, Hans/0000-0003-2643-5136; Arra, Claudio/0000-0003-3162-2091	Telethon [D.067] Funding Source: Medline	Telethon(Fondazione Telethon)		Abramowicz MJ, 1997, J CLIN INVEST, V99, P3018, DOI 10.1172/JCI119497; Acampora D, 1998, DEVELOPMENT, V125, P1229; BAMFORTH JS, 1989, J MED GENET, V26, P49, DOI 10.1136/jmg.26.1.49; BUNTINCX IM, 1993, J MED GENET, V30, P427, DOI 10.1136/jmg.30.5.427; CARETTE MJM, 1992, DEVELOPMENT, V114, P379; Clifton-Bligh RJ, 1998, NAT GENET, V19, P399, DOI 10.1038/1294; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; Gentile F., 1995, ENDOCRINOLOGY, P517; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MCKUSICK VA, 1994, MENDELIAN INHERTANCE; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; TOUBLANC JE, 1992, HORM RES, V38, P230, DOI 10.1159/000182549; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185	21	230	235	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					395	398		10.1038/1289	http://dx.doi.org/10.1038/1289			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697704				2022-12-25	WOS:000075107600026
J	Rufer, N; Dragowska, W; Thornbury, G; Roosnek, E; Lansdorp, PM				Rufer, N; Dragowska, W; Thornbury, G; Roosnek, E; Lansdorp, PM			Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry	NATURE BIOTECHNOLOGY			English	Article						cell analysis; peptide nucleic acid; fluorescence in situ hybridization	INSITU HYBRIDIZATION; HUMAN FIBROBLASTS; DNA-SEQUENCES; BONE-MARROW; T-CELLS; SUSPENSION; NUCLEI; IDENTIFICATION; TETRAHYMENA; CHROMOSOMES	To measure the average length of telomere repeats at chromosome ends in individual cells we developed a flow cytometry method using fluorescence in situ hybridization (flow FISH) with labeled peptide nucleic acid (PNA) probes. Results of flow FISH measurements correlated with results of conventional telomere length measurements by Southern blot analysis (R = 0.9). Consistent differences in telomere length in CD8(+) T-cell subsets were identified. Naive and memory CD4(+) T lymphocytes in normal adults differed by around 2.5 kb in telomere length, in agreement with known replicative shortening of telomeres in lymphocytes in vivo. T-cell clones grown in vitro showed stabilization of telomere length after an initial decline and rare clones capable of growing beyond 100 population doublings showed variable telomere length. These results show that flow FISH can be used to measure specific nucleotide repeat sequences in single cells and indicate that the very large replicative potential of lymphocytes is only indirectly related to telomere length.	British Columbia Canc Res Ctr, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Hop Cantonal Univ Geneva, CH-1211 Geneva, Switzerland; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; University of Geneva; University of British Columbia	Lansdorp, PM (corresponding author), British Columbia Canc Res Ctr, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada.			Lansdorp, Peter/0000-0001-7435-1071	NIAID NIH HHS [AI29524] Funding Source: Medline; NIGMS NIH HHS [GM56162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI029524, R01AI029524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ARKESTEIJN GJA, 1995, CYTOMETRY, V19, P353, DOI 10.1002/cyto.990190410; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Blackburn EH, 1995, TELOMERES; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CAO J, 1995, J CLIN INVEST, V95, P964, DOI 10.1172/JCI117805; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; ROOSNEK E, 1989, J EXP MED, V170, P297, DOI 10.1084/jem.170.1.297; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; SMITH TW, 1986, ADV COGNITIVE BEHAVI, V1, P63; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; TRASK B, 1988, HUM GENET, V78, P251, DOI 10.1007/BF00291672; TRASK B, 1985, SCIENCE, V230, P1401, DOI 10.1126/science.2416058; VANDEKKEN H, 1990, CYTOMETRY, V11, P153, DOI 10.1002/cyto.990110118; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Wynn RF, 1998, LANCET, V351, P178, DOI 10.1016/S0140-6736(97)08256-1; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	38	424	491	3	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					743	747		10.1038/nbt0898-743	http://dx.doi.org/10.1038/nbt0898-743			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702772				2022-12-25	WOS:000075183400031
J	Doherty, DH; Doyle, MP; Curry, SR; Vali, RJ; Fattor, TJ; Olson, JS; Lemon, DD				Doherty, DH; Doyle, MP; Curry, SR; Vali, RJ; Fattor, TJ; Olson, JS; Lemon, DD			Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin	NATURE BIOTECHNOLOGY			English	Article						protein engineering; blood substitute	RECOMBINANT HUMAN HEMOGLOBIN; BLOOD SUBSTITUTE; OPOSSUM; OXYHEMOGLOBIN	Administration of extracellular hemoglobin-based oxygen carriers often induces mild increases in blood pressure, In order to test whether nitric oxide (NO) scavenging is responsible for the hypertensive effect, we constructed and tested a set of recombinant hemoglobins that vary in rates of reaction with NO. The results suggest that the rapid reactions of oxy-and deoxyhemoglobin with nitric oxide are the fundamental cause of the hypertension. The magnitude of the blood-pressure effect correlates directly with the in vitro rate of NO oxidation. Hemoglobins with decreased NO-scavenging activity may be more suitable for certain therapeutic applications than those that cause depletion of nitric oxide.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77251 USA	Rice University; Rice University	Lemon, DD (corresponding author), Baxter Hemoglobin Therapeut Inc, Boulder, CO 80301 USA.	lemondo@baxter.com		Olson, John/0000-0002-0760-5403				ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; ALAYASH AI, 1995, MOL MED TODAY, V1, P122, DOI 10.1016/S1357-4310(95)80089-1; ALAYASH AI, 1993, ARCH BIOCHEM BIOPHYS, V303, P332, DOI 10.1006/abbi.1993.1292; Apostol I, 1997, J BIOL CHEM, V272, P28980, DOI 10.1074/jbc.272.46.28980; Chang TMS, 1997, ARTIF CELL BLOOD SUB, V25, P1, DOI 10.3109/10731199709118893; CONKLIN JL, 1995, J PHARMACOL EXP THER, V273, P762; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; ELCH RF, 1996, BIOCHEMISTRY-US, V35, P6976; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; Gould SA, 1996, WORLD J SURG, V20, P1200; GUYTON AC, 1964, CIRC RES, V15, P60; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Innis MA, 1990, PCR PROTOCOLS GUIDE; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; LEE R, 1995, J APPL PHYSIOL, V79, P236, DOI 10.1152/jappl.1995.79.1.236; LOOKER D, 1994, METHOD ENZYMOL, V231, P364; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; Migita R, 1997, J APPL PHYSIOL, V82, P1995, DOI 10.1152/jappl.1997.82.6.1995; MOORE EG, 1976, J BIOL CHEM, V251, P2788; MURRAY J, 1991, AM J PHYSIOL, V261, pG401, DOI 10.1152/ajpgi.1991.261.3.G401; PLOMER JJ, 1996, Patent No. 9615151; Rohlfs RJ, 1998, J BIOL CHEM, V273, P12128, DOI 10.1074/jbc.273.20.12128; ROONEY MW, 1993, ANESTHESIOLOGY, V79, P60, DOI 10.1097/00000542-199307000-00011; SCHULTZ SC, 1993, J LAB CLIN MED, V122, P301; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; THOMPSON A, 1994, J APPL PHYSIOL, V77, P2348, DOI 10.1152/jappl.1994.77.5.2348; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; TSAI AG, 1995, BLOOD SUBSTITUTES, P155; TSUCHIDA E, 1995, ARTIFICIAL RED CELLS, P1; VANDEGRIFF KD, 1995, BLOOD SUBSTITUTES, P143; Weickert MJ, 1997, ARCH BIOCHEM BIOPHYS, V348, P337, DOI 10.1006/abbi.1997.0410; Weickert MJ, 1997, APPL ENVIRON MICROB, V63, P4313, DOI 10.1128/AEM.63.11.4313-4320.1997; YAMATO S, 1992, GASTROENTEROLOGY, V103, P197, DOI 10.1016/0016-5085(92)91113-I; [No title captured]	37	339	358	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					672	676		10.1038/nbt0798-672	http://dx.doi.org/10.1038/nbt0798-672			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661203				2022-12-25	WOS:000074521800033
J	Hattersley, AT; Beards, F; Ballantyne, E; Appleton, M; Harvey, R; Ellard, S				Hattersley, AT; Beards, F; Ballantyne, E; Appleton, M; Harvey, R; Ellard, S			Mutations in the glucokinase gene of the fetus result in reduced birth weight	NATURE GENETICS			English	Article							DEPENDENT DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; FETAL GROWTH; INSULIN; HYPERGLYCEMIA; CHILDREN; LINKAGE; DEFECT; YOUNG; SIZE	Low birth weight and fetal thinness have been associated with non-insulin dependent diabetes mellitus (NIDDM) and insulin resistance in childhood and adulthood(1-6). It has been proposed that this association results from fetal programming in response to the intrauterine environment(7,8). An alternative explanation is that the same genetic influences alter both intrauterine growth and adult glucose tolerance. Fetal insulin secretion in response to maternal glycaemia plays a key role in fetal growth, and adult insulin secretion is a primary determinant of glucose tolerance. We hypothesized that a defect in the sensing of glucose by the pancreas, caused by a heterozygous mutation in the glucokinase gene(9), could reduce fetal growth and birth weight in addition to causing hyperglycaemia after birth. In 58 offspring, where one parent has a glucokinase mutation, the inheritance of a glucokinase mutation by the fetus resulted in a mean reduction of birth weight of 533 g (P=0.002). In 19 of 21 sibpairs discordant for the presence of a glucokinase mutation, the child with the mutation had a lower birth weight, with a mean difference of 521 g (P=0.0002). Maternal hyperglycaemia due to a glucokinase mutation resulted in a mean increase in birth weight of 601 g (P=0.001). The effects of maternal and fetal glucokinase mutations on birth weight were additive. We propose that these changes in birth weight reflect changes in fetal insulin secretion which are influenced directly by the fetal genotype and indirectly, through maternal hyperglycaemia, by the maternal genotype. This observation suggests that variation in fetal growth could be used in the assessment of the role of genes which modify either insulin secretion or insulin action.	Univ Exeter, Postgrad Med Sch, Dept Vasc Med & Diabet Res, Exeter EX2 5AX, Devon, England; Dr Grays Hosp, Elgin IV30 1SN, Moray, Scotland	University of Exeter	Hattersley, AT (corresponding author), Univ Exeter, Postgrad Med Sch, Dept Vasc Med & Diabet Res, Barrack Rd, Exeter EX2 5AX, Devon, England.			Hattersley, Andrew/0000-0001-5620-473X; Ellard, Sian/0000-0002-7620-5526				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEARDS FE, 1998, DIABETIC MED; BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; Clausen JO, 1997, AM J EPIDEMIOL, V146, P23, DOI 10.1093/oxfordjournals.aje.a009188; DONOHUE WL, 1954, J PEDIATR-US, V45, P505, DOI 10.1016/S0022-3476(54)80113-2; ELSAS LJ, 1985, AM J HUM GENET, V37, P73; Frayling TM, 1997, DIABETES, V46, P720, DOI 10.2337/diabetes.46.4.720; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; PEDERSON J, 1977, PREGNANT DIABETIC HE; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; TANNER JM, 1970, ARCH DIS CHILD, V45, P566, DOI 10.1136/adc.45.242.566; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; WRIGHT NM, 1993, AM J DIS CHILD, V147, P607; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	27	421	429	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					268	270		10.1038/953	http://dx.doi.org/10.1038/953			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662401				2022-12-25	WOS:000074565900024
J	Osada, M; Ohba, M; Kawahara, C; Ishioka, C; Kanamaru, R; Katoh, I; Ikawa, Y; Nimura, Y; Nakagawara, A; Obinata, M; Ikawa, S				Osada, M; Ohba, M; Kawahara, C; Ishioka, C; Kanamaru, R; Katoh, I; Ikawa, Y; Nimura, Y; Nakagawara, A; Obinata, M; Ikawa, S			Cloning and functional analysis of human p51, which structurally and functionally resembles p53	NATURE MEDICINE			English	Article							TRANSCRIPTIONAL ACTIVATION; SUPPRESSION; CELLS; GENE	The p53 tumor suppressor gene, which is induced by DNA damage and/or stress stimuli, causes cells to undergo G1-arrest or apoptotic death; thus it plays an essential role in human carcino-genesis(1,2). We have searched for p53-related genes by using degenerate PCR, and have identified two cDNA fragments similar to but distinct from p53: one previously reported, p73 (refs. 3,4), and the other new. We cloned two major splicing variants of the latter gene and named these p51A and p51B(a human homologue of rat Ket). The p51A gene encodes a 448-amino-acid protein with a molecular weight of 50.9 kDa; and p51B, a 641-amino-acid protein with a molecular weight of 71.9 kDa. In contrast with the ubiquitous expression of p53, expression of p51 mRNA was found in a limited number of tissues, including skeletal muscle, placenta, mammary gland, prostate, trachea, thymus, salivary gland, uterus, heart and lung. In p53-deficient cells, p51A induced growth-suppression and apoptosis, and upregulated p21(waf-1) through p53 regulatory elements. Mutations in p51 were found in some human epidermal tumors.	Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9800872, Japan; Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1130034, Japan; Chiba Canc Ctr Res Inst, Biochem Lab, Chiba 2600801, Japan	Tohoku University; Tohoku University; Tokyo Medical & Dental University (TMDU); Chiba Cancer Center	Ikawa, S (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan.	sikawa@idac.tohoku.ac.jp	井川, 俊太郎/L-5911-2015	Ishioka, Chikashi/0000-0002-3023-1227				ANSEN R, 1997, CURR OPIN GENE DEV, V7, P46; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DCKMAN S, 1997, SCIENCE, V277, P1605; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; TAHASHI H, IN PRESS CANC RES; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x	20	466	489	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					839	843		10.1038/nm0798-839	http://dx.doi.org/10.1038/nm0798-839			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662378				2022-12-25	WOS:000074543900041
J	Thomson, J				Thomson, J			Funding of human embryo research in the US	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Wisconsin, Madison, WI 53715 USA	University of Wisconsin System; University of Wisconsin Madison	Thomson, J (corresponding author), Univ Wisconsin, 1223 Capitol Court, Madison, WI 53715 USA.	thomson@primate.wisc.edu						*ADV COMM DIR AD H, 1994, REP HUM EMBR RES PAN; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	3	0	1	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					312	312		10.1038/7826	http://dx.doi.org/10.1038/7826			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207858				2022-12-25	WOS:000079574400002
J	Stein, CA				Stein, CA			Keeping the biotechnology of antisense in context	NATURE BIOTECHNOLOGY			English	Editorial Material							MESSENGER-RNA; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GROWTH-FACTOR; OLIGONUCLEOTIDES; INHIBITION; EXPRESSION; RECEPTORS; CELLS		Columbia Univ, New York, NY 10027 USA	Columbia University	Stein, CA (corresponding author), Columbia Univ, New York, NY 10027 USA.							Benimetskaya L, 1998, NUCLEIC ACIDS RES, V26, P5310, DOI 10.1093/nar/26.23.5310; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; DEAN NM, 1994, J BIOL CHEM, V269, P16416; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; GILES RV, 1995, BLOOD, V86, P744, DOI 10.1182/blood.V86.2.744.bloodjournal862744; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Monia BP, 1999, NAT MED, V5, P127, DOI 10.1038/5476; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Neckers LM, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P147; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; Smetsers TFCM, 1996, ANTISENSE NUCLEIC A, V6, P63, DOI 10.1089/oli.1.1996.6.63; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125	12	60	80	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					209	209		10.1038/6909	http://dx.doi.org/10.1038/6909			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096271	Bronze			2022-12-25	WOS:000078977500004
J	Hanzel, DK; Trojanowski, JQ; Johnston, RF; Loring, JF				Hanzel, DK; Trojanowski, JQ; Johnston, RF; Loring, JF			High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner	NATURE BIOTECHNOLOGY			English	Article						Alzheimer's disease; confocal scanner; fluorescent; quantitative morphology; amyloid	AMYLOID PRECURSOR PROTEIN; NEUROPATHOLOGY; DEPOSITION; PLAQUES	To develop a rapid method of quantifying immunohistochemical information in tissue sections, we tested a confocal laser fluorescence microscanner initially designed for DNA microarray analysis. This instrument collects digital images at multiple wavelengths, scans entire sections at a resolution of 5 or 10 mu m in less than 10 min, and quantifies structures labeled with fluorescent or nonfluorescent probes. We assessed the microscanner by studying immunostained amyloid plaques in the Alzheimer's disease (AD) brain and in the brain of a transgenic mouse model of AD amyloidosis, as efforts to correlate measures of amyloid plaques in brain sections with behavioral impairments are impeded by limitations in current morphometric methods. Microscanner analysis was used to determine amyloid burden in the occipital and entorhinal cortices of the mouse (3.7%) and human AD brain (1.6%). We also quantified the colocalization of plaque beta-amyloid (A beta) with glial fibrillary acidic protein, a marker of gliosis (mouse 0.9%, human AD 3.7%), The microscanner may be generally applicable to a wide variety of human histopathologies and their animal models, wherever rapid unbiased quantitative analysis is needed.	Mol Dynam Inc, Sunnyvale, CA 94086 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; ARC Genom Res, Foster City, CA 94404 USA	University of Pennsylvania	Hanzel, DK (corresponding author), Mol Dynam Inc, Sunnyvale, CA 94086 USA.	dhanzel@mdyn.com	Loring, Jeanne F/A-1620-2011	Loring, Jeanne F/0000-0001-6226-9767				Alexay C, 1996, P SOC PHOTO-OPT INS, V2705, P63, DOI 10.1117/12.236191; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Belichenko PV, 1996, J NEUROSCI METH, V69, P155, DOI 10.1016/S0165-0270(96)00035-0; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Goedert M., 1997, MOL GENETIC BASIS NE, P613; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Masliah E, 1996, J NEUROSCI, V16, P5795; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; Russ J. C., 2016, IMAGE PROCESSING HDB, V7th; Schmidt ML, 1998, ACTA NEUROPATHOL, V95, P117, DOI 10.1007/s004010050774; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X	18	33	34	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					53	57		10.1038/5225	http://dx.doi.org/10.1038/5225			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920269				2022-12-25	WOS:000077979500025
J	Shayesteh, L; Lu, YL; Kuo, WL; Baldocchi, R; Godfrey, T; Collins, C; Pinkel, D; Powell, B; Mills, GB; Gray, JW				Shayesteh, L; Lu, YL; Kuo, WL; Baldocchi, R; Godfrey, T; Collins, C; Pinkel, D; Powell, B; Mills, GB; Gray, JW			PIK3CA is implicated as an oncogene in ovarian cancer	NATURE GENETICS			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CELLS; OVERREPRESENTATION; TRANSFORMATION; HYBRIDIZATION; CARCINOMAS; APOPTOSIS; ADHESION; SURVIVAL; PATHWAY	Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women(1), yet little is known about its molecular aetiology. Studies using comparative genomic: hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number(2-4) that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian(2) and other(5) cancers contains PIK3CA, which encodes the p110 alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). The association between PIK3CA copy number and PI3-kinase activity makes PIK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with PI3-kinase mediated signalling(6). These include proliferation(7), glucose transport and catabotism(8), cell adhesion(9), apoptosis(10), RAS signalling6 and oncogenic transformation(11-14). In addition, downstream effecters of Pl3-kinase, AKT1 and AKR, have been found to be amplified(15,16) or activated(17) in human tumours, including ovarian cancer. We show here that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PIK3CA transcription, p110 alpha protein expression and PO-kinase activity and that treatment with the PI3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer.	Univ Calif San Francisco, Ctr Canc, San Francisco, CA USA; Univ Texas, Md Anderson Canc Ctr, Houston, TX 77030 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94702 USA	University of California System; University of California San Francisco; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Gray, JW (corresponding author), Univ Calif San Francisco, Ctr Canc, San Francisco, CA USA.	gray@cc.ucsf.edu	Godfrey, Tony/A-5572-2013	Godfrey, Tony/0000-0002-3283-6983	NCI NIH HHS [P01-CA64602, CA09215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064602, T32CA009215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gibson S, 1998, BIOCHEM J, V330, P1123, DOI 10.1042/bj3301123; Gorczyca W, 1998, METH MOL B, V91, P217; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HINSON D, 1998, BIOTECHNIQUES, V6, P14; HURTEAU J, 1994, CANCER, V74, P93, DOI 10.1002/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu AX, 1998, CANCER RES, V58, P2973; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nigro JM, 1997, CANCER RES, V57, P3635; PHYLLIS A, 1995, CA-CANCER J CLIN, V45, P8; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Schildkraut JM, 1997, JNCI-J NATL CANCER I, V89, P932, DOI 10.1093/jnci/89.13.932; SHI YF, 1995, CANCER RES, V55, P1982; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; STERNBERG N, 1990, New Biologist, V2, P151; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071	34	953	1041	3	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					99	102		10.1038/5042	http://dx.doi.org/10.1038/5042			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916799				2022-12-25	WOS:000077960700017
J	Crooke, ST; Eckstein, F; Christoffersen, RE; Mehta, V; Cotter, FE; Bennett, CF; Agrawal, S; Haller, H; Dorr, FA; Grinstead, EA				Crooke, ST; Eckstein, F; Christoffersen, RE; Mehta, V; Cotter, FE; Bennett, CF; Agrawal, S; Haller, H; Dorr, FA; Grinstead, EA			Antisense 98: Work in progress	NATURE BIOTECHNOLOGY			English	Editorial Material									ISIS Pharmaceut, Carlsbad, CA 92008 USA; Max Planck Inst, Gottingen, Germany; Ribozyme Pharmaceut, Boulder, CO USA; Mehta Partners, New York, NY USA; Inst Child Hlth, London, England; Hybridon Inc, Milford, MA USA; Max Delbruck Ctr Mol Med, Berlin, Germany; ISIS Pharmaceut, Drug Dev, Carisbad, CA USA	Isis Pharmaceuticals Inc; Max Planck Society; University of London; University College London; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut, Carlsbad, CA 92008 USA.								0	6	6	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1319	1321						3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853610				2022-12-25	WOS:000077232600021
J	Hirsch, VM; Sharkey, ME; Brown, CR; Brichacek, B; Goldstein, S; Wakefield, J; Byrum, R; Elkins, WR; Hahn, BH; Lifson, JD; Stevenson, M				Hirsch, VM; Sharkey, ME; Brown, CR; Brichacek, B; Goldstein, S; Wakefield, J; Byrum, R; Elkins, WR; Hahn, BH; Lifson, JD; Stevenson, M			Vpx is required for dissemination and pathogenesis of SIVSM PBj: Evidence of macrophage-dependent viral amplification	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CYCLE ARREST; INFECTION; HIV-1; MACAQUES; REPLICATION; GENE; TRANSMISSION; PROTEIN; AIDS	The viral accessory protein Vpx is required for productive in vitro infection of macrophages by simian immunodeficiency virus from sooty mangabey monkeys (SIVSM). To evaluate the roles of Vpx and macrophage infection in vivo, we inoculated pigtailed macaques intravenously or intrarectally with the molecularly cloned, macrophage tropic, acutely pathogenic virus SIVSM PBj 6.6, or accessory gene deletion mutants (Delta Vpr or Delta Vpx) of this virus. Both wild-type and SIVSM PBj Delta Vpx viruses were readily transmitted across the rectal mucosa. A subsequent 'stepwise' process of local amplification of infection and dissemination was observed for wild-type virus, but not for SIVSM PBj Delta Vpx, which also showed considerable impairment of the overall kinetics and extent of its replication. In animals co-inoculated with equivalent amounts of wild-type and SIVSM Pbj Delta Vpx intravenously ol intrarectally, the Delta Vpx mutant was at a strong competitive disadvantage. Vpx-dependent viral amplification at local sites of initial infection, perhaps through a macrophage-dependent mechanism, may be a prerequisite for efficient dissemination of infection and pathogenic consequences after exposure through either mucosal or intravenous routes.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; NIAID, Mol Microbiol Lab, Twin Facil, Rockville, MD 20852 USA; Univ Alabama, Birmingham, AL 35294 USA; Bioqual Inc, Rockville, MD 20850 USA; NIAID, Infect Dis Lab, Rockville, MD 20852 USA; NCI, Lab Retroviral Pathogenesis, AIDS Vaccine Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham; BIOQUAL Inc.; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Stevenson, M (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.			Hahn, Beatrice/0000-0002-9400-9887	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR011589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037475, R37AI037475] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11589] Funding Source: Medline; NHLBI NIH HHS [HL57880] Funding Source: Medline; NIAID NIH HHS [R37 AI037475, R21 AI127091, AI37475, R01 AI037475, R01 AI032890] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLIET JW, 1994, VIROLOGY, V200, P623; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Campbell BJ, 1997, J VIROL, V71, P5593, DOI 10.1128/JVI.71.7.5593-5602.1997; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DESROSIERS RC, 1991, AM J PATHOL, V139, P29; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DU Z, 1995, CELL, V82, P655; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FULTZ PN, 1994, VIRUS RES, V32, P205, DOI 10.1016/0168-1702(94)90042-6; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; ISRAEL ZR, 1993, AIDS RES HUM RETROV, V9, P277, DOI 10.1089/aid.1993.9.277; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; Lifson JD, 1997, J VIROL, V71, P9508, DOI 10.1128/JVI.71.12.9508-9514.1997; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LU L, 1996, J VIROL, V70, P3045; MANN DL, 1990, J IMMUNOL, V144, P2152; Marx PA, 1998, SEMIN IMMUNOL, V10, P215, DOI 10.1006/smim.1998.0135; Miller C J, 1994, Curr Top Microbiol Immunol, V188, P107; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Reece JC, 1998, J EXP MED, V187, P1623, DOI 10.1084/jem.187.10.1623; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SCHRIER RD, 1993, J VIROL, V67, P5713, DOI 10.1128/JVI.67.10.5713-5720.1993; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sharp PM, 1996, NATURE, V383, P586, DOI 10.1038/383586a0; SLEIGH R, 1998, VIROLOGY, V245; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; ZHANG L, 1998, 5 C RETR OPP INF CHI; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	45	146	150	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1401	1408		10.1038/3992	http://dx.doi.org/10.1038/3992			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846578	Green Accepted			2022-12-25	WOS:000077336900036
J	Mandl, CW; Aberle, JH; Aberle, SW; Holzmann, H; Allison, SL; Heinz, FX				Mandl, CW; Aberle, JH; Aberle, SW; Holzmann, H; Allison, SL; Heinz, FX			In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model	NATURE MEDICINE			English	Article							BORNE ENCEPHALITIS-VIRUS; GENETIC IMMUNIZATION; DNA VACCINES	Live virus vaccines have in many cases proven to be an extremely effective tool for the prevention of viral diseases(1,2). However, the production of conventional live vaccines in eu; karyotic cell cultures has many disadvantages, including the potential for contamination with adventitious agents(3) and genetic alterations during propagation, making it necessary to do extensive testing before distribution(4,5). Based on results obtained with a flavivirus(6) (tick-borne encephalitis virus) in an experimental animal system, we propose a novel live attenuated virus vaccination strategy consisting of the application of in vitro-synthesized infectious RNA instead of the live virus itself. When administered using the GeneGun, less than 1 ng of RNA was required to initiate replication of virus that was attenuated by a specifically engineered deletion(7) and this induced a protective immunity in laboratory mice. Because this approach uses RNA, it does not have the potential drawbacks of DNA vaccines(8-10) and thus combines the advantages of conventional live virus vaccines(1,2) (for example, mimicking natural infection and inducing long-lasting immunity) with those of nucleic acid-based vaccines(2,8,11,12) (for example, ease of production without a requirement for eukaryotic cell culture, stability and purity).	Univ Vienna, Inst Virol, A-1095 Vienna, Austria	University of Vienna	Mandl, CW (corresponding author), Univ Vienna, Inst Virol, Kinderspitalgasse 15, A-1095 Vienna, Austria.							Ada G, 1997, MOL BIOTECHNOL, V8, P123, DOI 10.1007/BF02752256; Chattergoon M, 1997, FASEB J, V11, P753, DOI 10.1096/fasebj.11.10.9271360; Conry RM, 1996, SEMIN ONCOL, V23, P135; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Gregoriadis G, 1998, PHARM RES-DORDR, V15, P661, DOI 10.1023/A:1011950415325; HEINZ FX, 1986, J BIOL STAND, V14, P133, DOI 10.1016/0092-1157(86)90032-6; Liu MA, 1998, NAT MED, V4, P515, DOI 10.1038/nm0598supp-515; Mandl CW, 1998, J VIROL, V72, P2132, DOI 10.1128/JVI.72.3.2132-2140.1998; Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; PARKMAN PD, 1994, VACCINES, P889; PETRICCIANI JC, 1991, DEV BIOLOGICALS, V75, P9; Qiu P, 1996, GENE THER, V3, P262; REED L. J., 1938, AMER JOUR HYG, V27, P493; RICE CM, 1996, FIELDS VIROLOGY, P931; VOGEL FR, 1995, CLIN MICROBIOL REV, V8, P406, DOI 10.1128/CMR.8.3.406; WENGLER G, 1995, VIRUS TAXONOMY, P415; Wood DJ, 1997, BIOLOGICALS, V25, P3, DOI 10.1006/biol.1997.0055; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4	20	84	93	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1438	1440		10.1038/4031	http://dx.doi.org/10.1038/4031			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846585				2022-12-25	WOS:000077336900043
J	Vrana, PB; Guan, XJ; Ingram, RS; Tilghman, SM				Vrana, PB; Guan, XJ; Ingram, RS; Tilghman, SM			Genomic imprinting is disrupted in interspecific Peromyscus hybrids	NATURE GENETICS			English	Article							GENE; LOCUS; REGION	Genomic imprinting, the unequal expression of gene alleles on the basis of parent of origin, is a major exception to mendelian laws of inheritance(1). By maintaining one allele of a gene in a silent state, imprinted genes discard the advantages of diploidy. and for this reason the rationale for the evolution of imprinting has been debated(2). One explanation is the parent-offspring conflict model, which proposes that imprinting arose in polyandrous mammals as the result of a parental conflict over the allocation of maternal resources to embryos(3). This theory predicts that there should be no selection for imprinting in a monogamous species. Crosses between the monogamous rodent species Peromyscus polionotus and the polyandrous Peromyscus maniculatus yield progeny with parent-of-origin growth defects that could be explained if imprinting was absent in the monogamous species(4). We find. however, that imprinting is maintained in P. polionotus, but there is widespread disruption of imprinting in the hybrids. We suggest that the signals governing genomic imprinting are rapidly evolving and that disruptions in the process may contribute to mammalian speciation.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.				NIGMS NIH HHS [GM51460] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051460] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRDSALL DA, 1973, EVOLUTION, V27, P106, DOI 10.1111/j.1558-5646.1973.tb05922.x; BLAIR WF, 1950, EVOLUTION, V4, P253, DOI 10.2307/2405335; DAWSON WD, 1965, EVOLUTION, V19, P44, DOI 10.2307/2406294; DAWSON WD, 1993, GROWTH DEVELOP AGING, V57, P121; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FOLTZ DW, 1981, AM NAT, V117, P665, DOI 10.1086/283751; Gray A. P., 1972, MAMMALIAN HYBRIDS; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; HAIG D, 1992, SEMIN DEV BIOL, V3, P153; Hu JF, 1998, MOL ENDOCRINOL, V12, P220, DOI 10.1210/me.12.2.220; Hurst L. D., 1997, GENOMIC IMPRINTING, P211; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; Mochizuki A, 1996, GENETICS, V144, P1283; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; THORVALDSON JL, IN PRESS GENES DEV; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zechner U, 1996, NAT GENET, V12, P398, DOI 10.1038/ng0496-398	28	154	155	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					362	365		10.1038/3833	http://dx.doi.org/10.1038/3833			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843208				2022-12-25	WOS:000077199600023
J	Shields, AF; Grierson, JR; Dohmen, BM; Machulla, HJ; Stayanoff, JC; Lawhorn-Crews, JM; Obradovich, JE; Muzik, O; Mangner, TJ				Shields, AF; Grierson, JR; Dohmen, BM; Machulla, HJ; Stayanoff, JC; Lawhorn-Crews, JM; Obradovich, JE; Muzik, O; Mangner, TJ			Imaging proliferation in vivo with [F-18]FLT and positron emission tomography	NATURE MEDICINE			English	Article							CELLULAR PROLIFERATION; PET; 3'-AZIDO-3'-DEOXYTHYMIDINE; METABOLISM; TRANSPORT; PLASMA	Positron emission tomography (PET) is now regularly used in the diagnosis and staging of cancer. These uses and its ability to monitor treatment response would be aided by the development of imaging agents that can be used to measure tissue and tumor proliferation. We have developed and tested [F-18]FLT (3'-deoxy-3'-fluorothymidine); it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects.	Wayne State Univ, Detroit Med Ctr, Dept Med, Karmanos Canc Inst, Detroit, MI 48301 USA; Wayne State Univ, Detroit Med Ctr, Dept Radiol, Karmanos Canc Inst, Detroit, MI 48301 USA; Univ Washington, Dept Radiol, Imaging Res Lab, Seattle, WA 98195 USA; Univ Tubingen, Dept Nucl Med, Tuebingen, Germany; Oakland Vet Referral Serv, Bloomfield Hills, MI USA	Barbara Ann Karmanos Cancer Institute; Detroit Medical Center; Wayne State University; Barbara Ann Karmanos Cancer Institute; Detroit Medical Center; Wayne State University; University of Washington; University of Washington Seattle; Eberhard Karls University of Tubingen	Shields, AF (corresponding author), Wayne State Univ, Detroit Med Ctr, Dept Med, Karmanos Canc Inst, 5 Hudson,3990 John R St, Detroit, MI 48301 USA.				NCI NIH HHS [CA 39566] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039566] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CONTI PS, 1995, NUCL MED BIOL, V22, P783, DOI 10.1016/0969-8051(95)00017-R; CRAWFORD EJ, 1982, ADV ENZYME REGUL, V20, P3, DOI 10.1016/0065-2571(82)90005-X; Findlay M, 1996, J CLIN ONCOL, V14, P700, DOI 10.1200/JCO.1996.14.3.700; FLEXNER C, 1994, J INFECT DIS, V170, P1394, DOI 10.1093/infdis/170.6.1394; Grierson J. R., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P290; Grierson John R., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P60; HERHOLZ K, 1992, J NEURO-ONCOL, V12, P159; KONG XB, 1992, ANTIMICROB AGENTS CH, V36, P808, DOI 10.1128/AAC.36.4.808; KUBOTA R, 1992, J NUCL MED, V33, P1972; NICOLAS F, 1995, DRUG METAB DISPOS, V23, P308; Romer W, 1998, BLOOD, V91, P4464; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHIELDS A, IN PRESS J NUCL MED; Shields AF, 1996, NUCL MED BIOL, V23, P17, DOI 10.1016/0969-8051(95)02005-5; Shields Anthony F., 1995, V1995, P129; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TJUVAJEV JG, 1994, J NUCL MED, V35, P1407; VANDERBORGHT T, 1991, APPL RADIAT ISOTOPES, V42, P103; vanEijkeren ME, 1996, ACTA ONCOL, V35, P737, DOI 10.3109/02841869609084008; Yamada Y, 1998, J NUCL MED, V39, P1160	20	983	1021	2	57	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1334	1336		10.1038/3337	http://dx.doi.org/10.1038/3337			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809561				2022-12-25	WOS:000076731000046
J	Kuwabara, T; Warashina, M; Orita, M; Koseki, S; Ohkawa, J; Taira, K				Kuwabara, T; Warashina, M; Orita, M; Koseki, S; Ohkawa, J; Taira, K			Formation of a catalytically active dimer by tRNA(Val)-driven short ribozymes	NATURE BIOTECHNOLOGY			English	Article						antisense; minizymes; gene-inactivation	HUMAN-IMMUNODEFICIENCY-VIRUS; HAMMERHEAD RIBOZYME; METAL-ION; INTRACELLULAR IMMUNIZATION; MEDIATED CLEAVAGE; CRYSTAL-STRUCTURE; MESSENGER-RNA; GENE-THERAPY; MECHANISM; EXPRESSION	A minizyme is a hammerhead ribozyme with a short oligonucleotide linker instead of stem/loop II. Minizymes with low activity as monomers form active dimeric structures with a common stem. We explored the use of dimeric minizymes as gene-inactivating agents by placing minizymes under the control of a tRNA(Val) promoter. The tRNA(Val) portion of the transcript did not hinder dimerization as the tRNA-embedded minizyme formed an active dimeric structure. The cleavage activity of this minizyme that had been expressed either in vitro or in HeLa cells was almost one order of magnitude higher than that of the tRNA(Val)-embedded conventional hammerhead ribozyme. The tRNA(Val)-driven minizyme inhibited reporter gene activity (95%) whereas the tRNA(Val)-driven hammerhead ribozyme resulted in approximately 55% inhibition.	Natl Inst Adv Interdisciplinary Res, Tsukuba Sci City 3058562, Japan; MITI, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba Sci City 3058566, Japan; Yamanouchi Pharmaceut Co Ltd, Tsukuba Sci City 3050841, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City 3058572, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Astellas Pharmaceuticals; University of Tsukuba	Taira, K (corresponding author), Natl Inst Adv Interdisciplinary Res, Tsukuba Sci City 3058562, Japan.	taira@nibh.go.jp						ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; Amontov SV, 1996, J AM CHEM SOC, V118, P1624, DOI 10.1021/ja9517734; BAIER G, 1994, MOL IMMUNOL, V31, P923, DOI 10.1016/0161-5890(94)90012-4; Bertrand E, 1997, RNA, V3, P75; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; ECKSTEIN F, 1996, CATALYTIC RNA NUCL A, V10; FU DJ, 1994, J AM CHEM SOC, V116, P4591, DOI 10.1021/ja00090a007; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HENDRY P, 1995, NUCLEIC ACIDS RES, V23, P3922, DOI 10.1093/nar/23.19.3922; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KAZAKOV S, 1992, P NATL ACAD SCI USA, V89, P7939, DOI 10.1073/pnas.89.17.7939; Koseki S, 1998, J CONTROL RELEASE, V53, P159, DOI 10.1016/S0168-3659(97)00250-2; Kuwabara T, 1996, NUCLEIC ACIDS RES, V24, P2302, DOI 10.1093/nar/24.12.2302; Leavitt MC, 1996, GENE THER, V3, P599; Leontis NB, 1995, METHOD ENZYMOL, V261, P183; LONG DM, 1994, P NATL ACAD SCI USA, V91, P6977, DOI 10.1073/pnas.91.15.6977; Lott WB, 1998, P NATL ACAD SCI USA, V95, P542, DOI 10.1073/pnas.95.2.542; MARSCHALL P, 1994, CELL MOL NEUROBIOL, V14, P523, DOI 10.1007/BF02088835; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; Orita M, 1996, J BIOL CHEM, V271, P9447, DOI 10.1074/jbc.271.16.9447; Perriman Rhonda, 1997, V74, P393; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAWATA S, 1995, J AM CHEM SOC, V117, P2357, DOI 10.1021/ja00113a028; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Sun CK, 1996, PORTL PR P, V10, P329; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; YAMADA O, 1994, GENE THER, V1, P38; YU M, 1995, P NATL ACAD SCI USA, V92, P699, DOI 10.1073/pnas.92.3.699; Zhou DM, 1998, CHEM REV, V98, P991, DOI 10.1021/cr9604292; Zhou DM, 1997, P NATL ACAD SCI USA, V94, P14343, DOI 10.1073/pnas.94.26.14343	42	60	67	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					961	965		10.1038/nbt1098-961	http://dx.doi.org/10.1038/nbt1098-961			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788354				2022-12-25	WOS:000076323300033
J	Zhang, YM; Buchholz, F; Muyrers, JPP; Stewart, AF				Zhang, YM; Buchholz, F; Muyrers, JPP; Stewart, AF			A new logic for DNA engineering using recombination in Escherichia coli	NATURE GENETICS			English	Article							SITE-SPECIFIC RECOMBINATION; STRAND-BREAK REPAIR; HOMOLOGOUS RECOMBINATION; IN-VIVO; BACTERIOPHAGE-LAMBDA; RECT PROTEIN; GENE; CONSTRUCTION; FRAGMENTS; CLONING	A straightforward way to engineer DNA in E. coli using homologous recombination is described. The homologous recombination reaction uses RecE and RecT and is transferable between E. coli strains. Several target molecules were manipulated, including high copy plasmids, a large episome and the E. coli chromosome. Sequential steps of homologous or site-specific recombination were used to demonstrate a new logic for engineering DNA, unlimited by the disposition of restriction endonuclease cleavage sites or the size of the target DNA.	European Mol Biol Lab, Gene Express Program, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Stewart, AF (corresponding author), European Mol Biol Lab, Gene Express Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Stewart, A. Francis/E-7789-2010; Buchholz, Frank/B-4700-2017	Buchholz, Frank/0000-0002-4577-3344				BARBOUR SD, 1970, P NATL ACAD SCI USA, V67, P128, DOI 10.1073/pnas.67.1.128; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1447, DOI 10.1111/j.1365-2958.1991.tb00791.x; BUBECK P, 1993, NUCLEIC ACIDS RES, V21, P3601, DOI 10.1093/nar/21.15.3601; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P3118, DOI 10.1093/nar/24.15.3118; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CLARK AJ, 1984, COLD SPRING HARB SYM, V49, P453, DOI 10.1101/SQB.1984.049.01.051; CLARK AJ, 1994, J BACTERIOL, V176, P7024, DOI 10.1128/JB.176.22.7024-7031.1994; CLARK AJ, 1974, GENETICS, V78, P259; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; COLLINS J, 1978, P NATL ACAD SCI USA, V75, P4242, DOI 10.1073/pnas.75.9.4242; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; Dabert P, 1997, GENETICS, V145, P877; Degryse E, 1996, GENE, V170, P45, DOI 10.1016/0378-1119(95)00858-6; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; Jessen JR, 1998, P NATL ACAD SCI USA, V95, P5121, DOI 10.1073/pnas.95.9.5121; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KUSANO K, 1994, GENE, V138, P17; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; LUISIDELUCA C, 1992, J MOL BIOL, V227, P72, DOI 10.1016/0022-2836(92)90682-A; Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; MURPHY KC, 1991, J BACTERIOL, V173, P5808, DOI 10.1128/jb.173.18.5808-5821.1991; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Newton C.R., 1997, PCR; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; OLINER JD, 1993, NUCLEIC ACIDS RES, V21, P5192, DOI 10.1093/nar/21.22.5192; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sauer Brian, 1994, Current Opinion in Biotechnology, V5, P521, DOI 10.1016/0958-1669(94)90068-X; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; Storck T, 1996, NUCLEIC ACIDS RES, V24, P4594, DOI 10.1093/nar/24.22.4594; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859	49	884	1090	19	215	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					123	128		10.1038/2417	http://dx.doi.org/10.1038/2417			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771703				2022-12-25	WOS:000076231300012
J	Reiss, J; Cohen, N; Dorche, C; Mandel, H; Mendel, RR; Stallmeyer, B; Zabot, MT; Dierks, T				Reiss, J; Cohen, N; Dorche, C; Mandel, H; Mendel, RR; Stallmeyer, B; Zabot, MT; Dierks, T			Mutations in a polycistronic nuclear gene associated with molybdenum cofactor deficiency	NATURE GENETICS			English	Article							ESCHERICHIA-COLI; DROSOPHILA-MELANOGASTER; MESSENGER-RNA; EARLY STEPS; BIOSYNTHESIS; MOLYBDOPTERIN; COMPLEMENTATION; REINITIATION; PROTEIN; LENGTH	All molybdoenzymes other than nitrogenase require molyb-dopterin as a metal-binding cofactor(1). Several genes necessary for the synthesis of the molybdenum cofactor (MoCo) have been characterized in bacteria(2,3) and plants(4). The proteins encoded by the Escherichia coli genes moaA and moaC catalyse the first steps in MoCo synthesis. The human homologues of these genes are therefore candidate genes for molybdenum cofactor deficiency, a rare and fatal disease(5). Using oligonucleotides complementary to a conserved region in the moaA gene, we have isolated a human cDNA derived from liver mRNA. This transcript contains an open reading frame (ORF) encoding the human moaA homologue and a second ORF encoding a human moaC homologue. Mutations can be found in the majority of MoCo-deficient patients that confirm the functional role of both ORFs in the corresponding gene MOCS1 (for 'molybdenum cofactor synthesis-step 1'). Northern-blot analysis detected only full-length transcripts containing both consecutive ORFs in various human tissues. The mRNA structure suggests a translation reinitiation mechanism for the second ORF, These data indicate the existence of a eukaryotic mRNA, which as a single and uniform transcript guides the synthesis of two different enzymatic polypeptides with disease-causing potential.	Univ Gottingen, Inst Humangenet, D-37073 Gottingen, Germany; Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany; Technion Israel Inst Technol, Dept Genet, Tamkin Human Mol Genet Res Facil, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Dept Pediat, IL-31096 Haifa, Israel; Hop Debrousse, Serv Biochim, F-69322 Lyon 05, France; Tech Univ Braunschweig, Inst Bot, D-38106 Braunschweig, Germany	University of Gottingen; University of Gottingen; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; CHU Lyon; Braunschweig University of Technology	Reiss, J (corresponding author), Univ Gottingen, Inst Humangenet, Gosslerstr 12D, D-37073 Gottingen, Germany.		Dierks, Thomas/A-3596-2012; Stallmeyer, Birgit/AAE-3020-2020	Dierks, Thomas/0000-0001-6426-1339; 				BOUHIDEL K, 1994, NUCLEIC ACIDS RES, V22, P2370, DOI 10.1093/nar/22.12.2370; Brogna S, 1997, EMBO J, V16, P2023, DOI 10.1093/emboj/16.8.2023; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; HOFF T, 1995, J BIOL CHEM, V270, P6100, DOI 10.1074/jbc.270.11.6100; IRBY RB, 1994, J BIOL CHEM, V269, P23981; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Shalata A, 1998, AM J HUM GENET, V63, P148, DOI 10.1086/301916; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	17	94	95	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					51	53		10.1038/1706	http://dx.doi.org/10.1038/1706			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731530				2022-12-25	WOS:000075671400018
J	Honda, H; Oda, H; Nakamoto, T; Honda, Z; Sakai, R; Suzuki, T; Saito, T; Nakamura, K; Nakao, K; Ishikawa, T; Katsuki, M; Yazaki, Y; Hirai, H				Honda, H; Oda, H; Nakamoto, T; Honda, Z; Sakai, R; Suzuki, T; Saito, T; Nakamura, K; Nakao, K; Ishikawa, T; Katsuki, M; Yazaki, Y; Hirai, H			Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130(Cas)	NATURE GENETICS			English	Article							CRK-ASSOCIATED SUBSTRATE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; STABLE ASSOCIATION; PROTEINS; GROWTH; MOLECULE; P130; DISRUPTION	p130(Cas) (Cas), the protein encoded by the Crkas gene (also known as Gas), is an adaptor molecule with a unique structure that contains a Src homology (SH)-3 domain followed by multiple YXXP motifs and a proline-rich region(1). Cas was originally cloned as a highly tyrosine-phosphorylated protein in cells transformed by v-Src (refs 2,3) or v-Crk (ref, 4) and has subsequently been implicated in a variety of biological processes including cell adhesion(5), cell migration(6), growth factor stimulation(7-9), cytokine receptor engagement(10,11) and bacterial infection(12,13). To determine its role in vivo, we generated mice lacking Gas. Cas-deficient embryos died in utero showing marked systemic congestion and growth retardation. Histologically, the heart was poorly developed and blood vessels were prominently dilated. Electron microscopic analysis of the heart revealed disorganization of myofibrils and disruption of Z-disks. In addition, actin stress fiber formation was severely impaired in Cas-deficient primary fibroblasts. Moreover, expression of activated Src in Cas-deficient primary fibroblasts did not induce a fully transformed phenotype, possibly owing to insufficient accumulation of actin cytoskeleton in podosomes. These findings have defined Cas function in cardiovascular development, actin filament assembly and Src-induced transformation.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Pathol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Internal Med & Phys Therapy, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Inst Med Sci, Dept DNA Embryol, Minato Ku, Tokyo 108, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.			Sakai, Ryuichi/0000-0001-6833-1103; zhong wei, he gui/0000-0002-3066-3564				Alexandropoulos K, 1996, SIN GENES DEV, V10, P1341; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishino M, 1995, ONCOGENE, V11, P2331; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; KWEE L, 1995, DEVELOPMENT, V121, P489; Law SF, 1996, MOL CELL BIOL, V16, P3327; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANGER JW, 1984, J CELL BIOL, V98, P825, DOI 10.1083/jcb.98.3.825; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	30	303	304	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					361	365		10.1038/1246	http://dx.doi.org/10.1038/1246			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697697				2022-12-25	WOS:000075107600019
J	Chahine, KG				Chahine, KG			Building the proper foundation for genomics-based patents	NATURE BIOTECHNOLOGY			English	Editorial Material									Avigen, Alameda, CA 94502 USA		Chahine, KG (corresponding author), Avigen, 1201 Harbor Bay Pkwy,Suite 1000, Alameda, CA 94502 USA.								0	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					683	685		10.1038/nbt0798-683	http://dx.doi.org/10.1038/nbt0798-683			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661205				2022-12-25	WOS:000074521800035
J	Gaasterland, T				Gaasterland, T			Structural genomics: Bioinformatics in the driver's seat	NATURE BIOTECHNOLOGY			English	Article									Argonne Natl Lab, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory	Gaasterland, T (corresponding author), Argonne Natl Lab, 9700 S Cass Ave, Argonne, IL 60439 USA.	gaasterland@mcs.anl.gov						FerreDAmare AR, 1997, METHOD ENZYMOL, V276, P157, DOI 10.1016/S0076-6879(97)76056-7; Gaasterland T, 1996, BIOCHIMIE, V78, P302, DOI 10.1016/0300-9084(96)84761-4; HENDRICKSON W, 1991, SCIENCE, V25, P51; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Rost B, 1997, COMPUT APPL BIOSCI, V13, P345; ROST B, 1998, IN PRESS CURR OPIN S; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9	9	41	46	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					625	627		10.1038/nbt0798-625	http://dx.doi.org/10.1038/nbt0798-625			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661193				2022-12-25	WOS:000074521800022
J	Petrukhin, K; Koisti, MJ; Bakall, B; Li, W; Xie, GC; Marknell, T; Sandgren, O; Forsman, K; Holmgren, G; Andreasson, S; Vujic, M; Bergen, AAB; McGarty-Dugan, V; Figueroa, D; Austin, CP; Metzker, ML; Caskey, CT; Wadelius, C				Petrukhin, K; Koisti, MJ; Bakall, B; Li, W; Xie, GC; Marknell, T; Sandgren, O; Forsman, K; Holmgren, G; Andreasson, S; Vujic, M; Bergen, AAB; McGarty-Dugan, V; Figueroa, D; Austin, CP; Metzker, ML; Caskey, CT; Wadelius, C			Identification of the gene responsible for Best macular dystrophy	NATURE GENETICS			English	Article							RETINAL-PIGMENT EPITHELIUM; FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA; ANTISENSE; LIPOFUSCIN; DEGENERATION; LINKAGE; OOCYTES; CELLS	Best macular dystrophy (BMD). also known as vitelliform macular dystrophy (VMD2; OMIM 153700), is an autosomal dominant form of macular degeneration characterized by an abnormal accumulation of lipofuscin within and beneath the retinal pigment epithelium cells. In pursuit of the disease gene, we limited the minimum genetic region by recombination breakpoint analysis and mapped to this region a novel retina-specific gene (VMD2). Genetic mapping data, identification of five independent disease-specific mutations and expression studies provide evidence that mutations within the candidate gene are a cause of BMD. The 3' UTR of the candidate gene contains a region of antisense complementarity to the 3' UTR of the ferritin heavy-chain gene (FTH1), indicating the possibility of antisense interaction between VMD2 and FTH1 transcripts.	Merck Res Labs, Dept Human Genet, West Point, PA 19486 USA; Merck Res Labs, Dept Bioinformat, West Point, PA 19486 USA; Univ Uppsala Hosp, Dept Genet & Pathol, Clin Genet Unit, S-75185 Uppsala, Sweden; Umea Univ Hosp, Dept Clin Genet, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Ophthalmol, S-90185 Umea, Sweden; Univ Lund Hosp, Dept Ophthalmol, S-22185 Lund, Sweden; East Hosp, Dept Clin Genet, S-41685 Gothenburg, Sweden; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands	Merck & Company; Merck & Company; Uppsala University; Uppsala University Hospital; Umea University; Umea University; Lund University; Skane University Hospital; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Petrukhin, K (corresponding author), Merck Res Labs, Dept Human Genet, West Point, PA 19486 USA.	konstantin_petrukhin@merck.com; Claes.Wadelius@klingen.uu.se	Bergen, Arthur/J-3637-2013	Petrukhin, Konstantin/0000-0002-5545-6924; Bergen, Arthur/0000-0002-6333-9576				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; Batshake B, 1996, BIOCHEM BIOPH RES CO, V227, P70, DOI 10.1006/bbrc.1996.1469; BAZAN NG, 1994, WORLD REV NUTR DIET, V75, P120; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Cooper PR, 1997, GENOMICS, V41, P185, DOI 10.1006/geno.1997.4660; CROSS HE, 1974, AM J OPHTHALMOL, V77, P46, DOI 10.1016/0002-9394(74)90603-5; DHAR M, 1993, GENE, V126, P275, DOI 10.1016/0378-1119(93)90380-L; Dryja T. P., 1998, SCIENCE, V279; Eldred GE, 1995, GERONTOLOGY, V41, P15; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; FORSMAN K, 1992, CLIN GENET, V42, P156; GODEL V, 1986, Acta Ophthalmologica Supplementum, V175, P1; GRAFF C, 1994, GENOMICS, V24, P425, DOI 10.1006/geno.1994.1648; Graff C, 1997, HUM GENET, V101, P263, DOI 10.1007/s004390050627; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; Hunt RC, 1996, J CELL PHYSIOL, V168, P71, DOI 10.1002/(SICI)1097-4652(199607)168:1<71::AID-JCP9>3.0.CO;2-5; KATZ ML, 1993, INVEST OPHTH VIS SCI, V34, P3161; KATZ ML, 1994, INVEST OPHTH VIS SCI, V35, P3613; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNEE RS, 1994, BIOCHEM BIOPH RES CO, V205, P577, DOI 10.1006/bbrc.1994.2704; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEIBOWITZ HM, 1980, SURV OPHTHALMOL S, V24, P428; NORDSTROM S, 1976, HEREDITAS, V84, P163; PETRUKHIN KE, 1993, GENOMICS, V15, P76, DOI 10.1006/geno.1993.1012; Salem N. Jr., 1986, Health effects of polyunsaturated fatty acids in seafoods, P263; Shah AB, 1997, AM J HUM GENET, V61, P317, DOI 10.1086/514864; STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246; Swalla BJ, 1996, DEV BIOL, V178, P23, DOI 10.1006/dbio.1996.0195	32	518	543	3	30	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1998	19	3					241	247		10.1038/915	http://dx.doi.org/10.1038/915			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662395				2022-12-25	WOS:000074565900018
J	Douglas, JT; Rogers, BE; Rosenfeld, ME; Michael, SI; Feng, MZ; Curiel, DT				Douglas, JT; Rogers, BE; Rosenfeld, ME; Michael, SI; Feng, MZ; Curiel, DT			Targeted gene delivery by tropism-modified adenoviral vectors	NATURE BIOTECHNOLOGY			English	Article						targeted adenovirus; gene therapy	RECEPTOR-MEDIATED ENDOCYTOSIS; FOLATE-BINDING PROTEIN; RETROVIRAL VECTORS; TUMOR-CELLS; KB-CELLS; TISSUES; DOMAIN; THERAPY; CLONING; PATHWAY	The utility of adenoviral vectors for gene therapy is currently limited due, in part, to the widespread distribution of the cellular receptor for the adenovirus fiber that precludes the targeting of specific cell types. In order to develop a targeted adenovirus, it is therefore necessary both to ablate endogenous viral tropism and to introduce navel tropism. We hypothesized that these two goals could be achieved by employing a neutralizing anti-fiber antibody, or antibody fragment, chemically conjugated to a cell-specific ligand. To test this concept, we chose to target the folate receptor, which is overexpressed on the surface of a variety of malignant cells, Therefore, we conjugated folate to the neutralizing Fab fragment of an anti-fiber monoclonal antibody. This Fab-folate conjugate was complexed with an adenoviral vector carrying the luciferase reporter gene and was shown to redirect adenoviral infection ob target cells via the folate receptor at a high efficiency Furthermore, when complexed with an adenoviral vector carrying the gene for herpes simplex virus thymidine kinase, the Fab-folate conjugate mediated the specific killing of cells that overexpress the folate receptor. This work thus represents the first demonstration of the retargeting of a recombinant adenoviral vector vie a non-adenoviral cellular receptor.	UNIV ALABAMA, GENE THERAPY PROGRAM, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham					PHS HHS [R01 5025505] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; CONEY LR, 1991, CANCER RES, V51, P6125; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; DOUGLAS JT, 1995, TUMOR TARGET, V1, P67; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; GOTTSCHALK S, 1994, GENE THER, V1, P185; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUARD J, 1995, GENE THER, V2, P107; JOLLY D, 1994, CANCER GENE THER, V1, P51; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KIM M, 1996, IN RPESS TUMOR TARGE; KRANZ DM, 1995, P NATL ACAD SCI USA, V92, P9057, DOI 10.1073/pnas.92.20.9057; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; MICHAEL SI, 1993, J BIOL CHEM, V268, P6866; MOOLTEN FL, 1986, CANCER RES, V46, P5276; Rosenfeld ME, 1995, CLIN CANCER RES, V1, P1571; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Trapnell Bruce C., 1994, Current Opinion in Biotechnology, V5, P617, DOI 10.1016/0958-1669(94)90084-1; VARGA MJ, 1991, J VIROL, V65, P6061, DOI 10.1128/JVI.65.11.6061-6070.1991; WEITMAN SD, 1994, J NEURO-ONCOL, V21, P107, DOI 10.1007/BF01052894; WEITMAN SD, 1992, CANCER RES, V52, P3396; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E	36	371	413	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1574	1578		10.1038/nbt1196-1574	http://dx.doi.org/10.1038/nbt1196-1574			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634824				2022-12-25	WOS:A1996VP83300025
J	Hewitson, L; Dominko, T; Takahashi, D; Martinovich, C; Ramalho-Santos, J; Sutovsky, P; Fanton, J; Jacob, D; Monteith, D; Neuringer, M; Battaglia, D; Simerly, C; Schatten, G				Hewitson, L; Dominko, T; Takahashi, D; Martinovich, C; Ramalho-Santos, J; Sutovsky, P; Fanton, J; Jacob, D; Monteith, D; Neuringer, M; Battaglia, D; Simerly, C; Schatten, G			Unique checkpoints during the first cell cycle of fertilization after intracytoplasmic sperm injection in rhesus monkeys	NATURE MEDICINE			English	Article							HUMAN OOCYTES; CHILDREN; MOUSE; MITOSIS; EMBRYOS; ICSI	Intracytoplasmic sperm injection has begun an era of considerable improvements in treating male infertility. Despite its success, questions remain about the dangers of transmitting traits responsible for male infertility, sex and autosomal chromosome aberrations' and possible mental, physical and reproductive abnormalities(2,3). We report here the first births of rhesus monkeys produced by intracytoplasmic sperm injection at rates greater or equal to those reported by clinics. Essential assumptions about this process are flawed, as shown by results with the preclinical, nonhuman primate model and with clinically discarded specimens. Dynamic imaging demonstrated the variable position of the second meiotic spindle in relation to the first polar body; consequently, microinjection targeting is imprecise and potentially lethal. Intracytoplasmic sperm injection resulted in abnormal sperm decondensation, with the unusual retention of vesicle-associated membrane protein and the perinuclear theca, and the exclusion of the nuclear mitotic apparatus from the decondensing sperm nuclear apex. Male pronuclear remodeling in the injected oocytes was required before replication of either parental genome, indicating a unique G(1)-to-S transition checkpoint during zygotic interphase (the first cell cycle). These irregularities indicate that the intracytoplasmic sperm injection itself might lead to the observed increased chromosome anomalies(4-5).	Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Dev & Cell Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Oregon Reg Primate Res Ctr, Portland, OR 97201 USA; Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Univ Coimbra, Dept Zool, Ctr Neurosci Coimbra, P-3000 Coimbra, Portugal	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; University of Washington; University of Washington Seattle; Universidade de Coimbra	Schatten, G (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	schatten@ohsu.edu	Schatten, Gerald/B-3253-2009; simerly, Calvin/AAC-9564-2021; Ramalho-Santos, João/F-8641-2012; Santos, João/HHZ-5595-2022	Schatten, Gerald/0000-0001-5206-7782; Ramalho-Santos, João/0000-0002-1172-4018; Sutovsky, Peter/0000-0002-9231-2823				Antczak M, 1997, MOL HUM REPROD, V3, P1067, DOI 10.1093/molehr/3.12.1067; Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; Bonduelle M, 1998, HUM REPROD, V13, P781, DOI 10.1093/humrep/13.4.781; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; Conner S, 1997, MOL REPROD DEV, V48, P106; DALE B, 1995, ZYGOTE, V3, P31, DOI 10.1017/S0967199400002355; Edwards RG, 1997, MOL HUM REPROD, V3, P863, DOI 10.1093/molehr/3.10.863; FISHEL S, 1995, LANCET, V345, P1641, DOI 10.1016/S0140-6736(95)90149-3; GORBSKY GJ, 1990, P NATL ACAD SCI USA, V87, P6049, DOI 10.1073/pnas.87.16.6049; Hewitson L, 1998, HUM REPROD, V13, P3449, DOI 10.1093/humrep/13.12.3449; INTVELD P, 1995, LANCET, V773, P346; Kent-First MG, 1996, MOL HUM REPROD, V2, P943, DOI 10.1093/molehr/2.12.943; LUETJENS M, 1998, J REPROD FERT, V22; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Schatten G, 1998, J LAW MED ETHICS, V26, P29, DOI 10.1111/j.1748-720X.1998.tb01903.x; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; Silber SJ, 1998, HUM REPROD, V13, P509, DOI 10.1093/humrep/13.3.509; SILVA CP, 1998, 54 ANN M AM SOC REPR, pP742; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; Sofikitis N, 1998, LANCET, V351, P1177, DOI 10.1016/S0140-6736(05)79121-2; Sutovsky P, 1997, DEV BIOL, V188, P75, DOI 10.1006/dbio.1997.8618; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192	24	178	189	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					431	433		10.1038/7430	http://dx.doi.org/10.1038/7430			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202934				2022-12-25	WOS:000079574300034
J	Altamirano, MM; Garcia, C; Possani, LD; Fersht, AR				Altamirano, MM; Garcia, C; Possani, LD; Fersht, AR			Oxidative refolding chromatography: folding of the scorpion toxin Cn5	NATURE BIOTECHNOLOGY			English	Article						minichaperone; DsbA; GroEL; peptidyl-prolyl isomerase; disulfide; renaturation	PROTEIN DISULFIDE-ISOMERASE; FORMATION IN-VIVO; ANDROCTONUS-AUSTRALIS HECTOR; SITE CYSTEINE RESIDUES; BOND FORMATION INVIVO; ESCHERICHIA-COLI; GLUCOSAMINE-6-PHOSPHATE DEAMINASE; MOLECULAR CHAPERONES; FUNCTIONAL-ROLE; VICINAL THIOLS	We have made an immobilized and reusable molecular chaperone system for oxidative refolding chromatography. Its three components-GroEL minichaperone (191-345), which can prevent protein aggregation; DsbA, which catalyzes the shuffling and oxidative formation of disulfide bonds; and peptidyl-prolyl isomerase-were immobilized on an agarose gel. The gel was applied to the refolding of denatured and reduced scorpion toxin Cn5. The 66-residue toxin, which has four disulfide bridges and a cis peptidyl-proline bond, had not previously been refolded in reasonable yield. We recovered an 87% yield of protein with 100% biological activity.	Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, Chem Lab, MRC Ctr, Cambridge CB2 2QH, England; Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Mol Recognit & Struct Biol, Cuernavaca 62210, Morelos, Mexico	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Fersht, AR (corresponding author), Cambridge Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf10@cam.ac.uk	Possani, Lourival D/J-2397-2013; Fersht, Alan R/B-2189-2008					AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ALTAMIRANO MM, 1989, ARCH BIOCHEM BIOPHYS, V269, P555, DOI 10.1016/0003-9861(89)90140-9; Altamirano MM, 1997, P NATL ACAD SCI USA, V94, P3576, DOI 10.1073/pnas.94.8.3576; ALTAMIRANO MM, 1992, BIOCHEMISTRY-US, V31, P1153, DOI 10.1021/bi00119a026; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BUCHNER J, 1992, BIO-TECHNOL, V10, P682, DOI 10.1038/nbt0692-682; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; BULEID NJ, 1993, ACCESSORY PROTEINS, P125; Chatellier J, 1998, P NATL ACAD SCI USA, V95, P9861, DOI 10.1073/pnas.95.17.9861; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; CREIGHTON T. E., 1985, UCLA S MOL CELLULAR, V39, P249; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; ELLIS JR, 1996, CHAPERONINS, P1; FLORENCE TM, 1980, BIOCHEM J, V189, P507, DOI 10.1042/bj1890507; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; Freedman Robert B., 1992, P455; Garcia C, 1997, COMP BIOCHEM PHYS B, V116, P315, DOI 10.1016/S0305-0491(96)00246-5; Golbik R, 1998, J MOL BIOL, V276, P505, DOI 10.1006/jmbi.1997.1538; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P6350, DOI 10.1021/bi00186a039; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; LORET EP, 1991, BIOCHEMISTRY-US, V30, P633, DOI 10.1021/bi00217a007; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MORJANA NA, 1994, PROTEIN EXPRES PURIF, V5, P144, DOI 10.1006/prep.1994.1022; Muronetz VI, 1998, FEBS LETT, V426, P107, DOI 10.1016/S0014-5793(98)00319-6; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SABATIER JM, 1987, INT J PEPT PROT RES, V30, P125; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Stempfer G, 1996, NAT BIOTECHNOL, V14, P329, DOI 10.1038/nbt0396-329; Thomas JG, 1997, APPL BIOCHEM BIOTECH, V66, P197, DOI 10.1007/BF02785589; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	48	110	134	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					187	191		10.1038/6192	http://dx.doi.org/10.1038/6192			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052357				2022-12-25	WOS:000078508300029
J	Hartley, CJ; Lacy, JL; Dai, DY; Nayak, N; Taffet, GE; Entman, ML; Michael, LH				Hartley, CJ; Lacy, JL; Dai, DY; Nayak, N; Taffet, GE; Entman, ML; Michael, LH			Functional cardiac imaging in mice using Ta-178	NATURE MEDICINE			English	Article							MULTIWIRE GAMMA-CAMERA; TANTALUM-178; DISEASE; MODEL; MOUSE		Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Proport Technol, Houston, TX 77054 USA	Baylor College of Medicine	Hartley, CJ (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022512, P01HL042550, R44HL057086] Funding Source: NIH RePORTER; NHLBI NIH HHS [R44-HL57086, P01-HL42550, R37-HL22512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHIEN KR, 1995, AM J PHYSIOL-HEART C, V269, pH755, DOI 10.1152/ajpheart.1995.269.3.H755; Franco F, 1998, AM J PHYSIOL-HEART C, V274, pH679, DOI 10.1152/ajpheart.1998.274.2.H679; HARTLEY CJ, 1995, AM J PHYSIOL-HEART C, V268, pH499, DOI 10.1152/ajpheart.1995.268.1.H499; ISKANDRIAN AS, 1996, NUCL CARDIAC IMAGING; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; James JF, 1998, CIRC RES, V82, P407, DOI 10.1161/01.RES.82.4.407; KISHIMOTO C, 1991, J AM COLL CARDIOL, V17, P821, DOI 10.1016/S0735-1097(10)80203-7; LACY JL, 1988, J NUCL MED, V29, P1526; LACY JL, 1988, J NUCL MED, V29, P293; Li BS, 1997, AM J PHYSIOL-HEART C, V273, pH2508, DOI 10.1152/ajpheart.1997.273.5.H2508; MANNING WJ, 1993, LAB ANIM SCI, V43, P583; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Patten RD, 1998, AM J PHYSIOL-HEART C, V274, pH1812, DOI 10.1152/ajpheart.1998.274.5.H1812; ROCKMAN HA, 1993, CIRCULATION, V87, P14; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; SLUTSKY RA, 1983, AM HEART J, V105, P802, DOI 10.1016/0002-8703(83)90244-2; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; VERANI MS, 1992, J AM COLL CARDIOL, V19, P297, DOI 10.1016/0735-1097(92)90482-3; Williams RV, 1998, AM J PHYSIOL-HEART C, V274, pH1828, DOI 10.1152/ajpheart.1998.274.5.H1828	20	12	12	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					237	239		10.1038/5602	http://dx.doi.org/10.1038/5602			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930875				2022-12-25	WOS:000078274400036
J	Mason, CAE; Bigras, JL; O'Blenes, SB; Zhou, B; McIntyre, B; Nakamura, N; Kaneda, Y; Rabinovitch, M				Mason, CAE; Bigras, JL; O'Blenes, SB; Zhou, B; McIntyre, B; Nakamura, N; Kaneda, Y; Rabinovitch, M			Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation	NATURE MEDICINE			English	Article							INTIMAL PROLIFERATION; EXTRACELLULAR-MATRIX; CARDIAC MALFORMATION; C-MYC; BINDING; PROSTAGLANDIN-E1; EXPRESSION; THERAPY	Closure of the ductus arteriosus requires prenatal formation of intimal cushions, which occlude the vessel lumen at birth. Survival of newborns with severe congenital heart defects, however, depends on ductal patency. We used a gene transfer approach to create a patent ductus arteriosus by targeting the fibronectin-dependent smooth muscle cell migration required for intimal cushion formation. Fetal lamb ductus arteriosus was transfected in utero with hemagglutinating virus of Japan liposomes containing plasmid encoding 'decoy' RNA to sequester the fibronectin mRNA binding protein. Fibronectin translation was inhibited and intimal cushion formation was prevented. We thus established the essential role of fibronectin-dependent smooth muscle cell migration in intimal cushion formation in the intact animal and the feasibility of incorporating biological engineering in the management of congenital heart disease.	Univ Toronto, Hosp Sick Children, Dept Pediat, Inst Res,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Inst Res,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Med, Inst Res,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 565, Japan	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Osaka University	Rabinovitch, M (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Inst Res,Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BOTNEY MD, 1992, AM J PATHOL, V140, P357; BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; BOUDREAU N, 1992, LAB INVEST, V67, P350; BOUDREAU N, 1991, LAB INVEST, V64, P187; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CLAUSELL N, 1995, BRIT HEART J, V73, P534; Forsyth EA, 1997, J VASC SURG, V26, P1002, DOI 10.1016/S0741-5214(97)70013-2; GITTENBERGERDEGROOT AC, 1980, J PEDIATR-US, V96, P88, DOI 10.1016/S0022-3476(80)80337-4; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; GITTENBERGERDEGROOT AC, 1980, CIRCULATION, V62, P183, DOI 10.1161/01.CIR.62.1.183; HALLIDIESMITH KA, 1984, ARCH DIS CHILD, V59, P1020, DOI 10.1136/adc.59.11.1020; HORNBLAD PY, 1967, CARDIOLOGIA, V51, P262, DOI 10.1159/000165823; HOST A, 1988, DAN MED BULL, V35, P81; Jones PL, 1997, AM J PATHOL, V150, P1349; Kaneda Y, 1997, ANN NY ACAD SCI, V811, P299, DOI 10.1111/j.1749-6632.1997.tb52010.x; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; Liebermann DA, 1998, INT J ONCOL, V12, P685; Mann MJ, 1997, MOL CELL BIOCHEM, V172, P3, DOI 10.1023/A:1006801807206; MOLOSSI S, 1995, J CLIN INVEST, V95, P2601, DOI 10.1172/JCI117962; MOLOSSI S, 1993, CIRCULATION, V88, P248; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; OILEY PM, 1976, CIRCULATION, V53, P728; ROME JJ, 1994, HUM GENE THER, V5, P1249, DOI 10.1089/hum.1994.5.10-1249; SANDERS M, 1994, PHARMACOL THERAPEUT, V61, P109, DOI 10.1016/0163-7258(94)90060-4; SILVER MM, 1981, HUM PATHOL, V12, P1123, DOI 10.1016/S0046-8177(81)80333-4; Veyrune J L, 1997, Prog Mol Subcell Biol, V18, P35; YODER MJ, 1978, ANAT REC, V192, P19, DOI 10.1002/ar.1091920103; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhou B, 1998, CIRC RES, V83, P481, DOI 10.1161/01.RES.83.5.481	31	69	71	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					176	182		10.1038/5538	http://dx.doi.org/10.1038/5538			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930865				2022-12-25	WOS:000078274400026
J	Wu, KJ; Grandori, C; Amacker, M; Simon-Vermot, N; Polack, A; Lingner, J; Dalla-Favera, R				Wu, KJ; Grandori, C; Amacker, M; Simon-Vermot, N; Polack, A; Lingner, J; Dalla-Favera, R			Direct activation of TERT transcription by c-MYC	NATURE GENETICS			English	Article							TELOMERASE ACTIVITY; CATALYTIC SUBUNIT; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; GENE; PROTEINS; DIFFERENTIATION; SENESCENCE; MAX	The MYC proto-oncogene encodes a ubiquitous transcription factor (c-MYC) involved in the control of cell proliferation and differentiation(1). Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis(2). The function of c-MYC and its role in tumorigenesis are poorly understood because few c-MYC targets have been identified(3). Here we show that c-MYC has a direct role in induction of the activity of telomerase, the ribonucleoprotein complex expressed in proliferating and transformed cells, in which it preserves chromosome integrity by maintaining telomere length(4-6). c-MYC activates telomerase by inducing expression of its catalytic subunit, telomerase reverse transcriptase(7-9) (TERT). Telomerase complex activity is dependent on TERT, a specialized type of reverse transcriptase(10,11). TERT and c-MYC are expressed in normal and transformed proliferating cells, downregulated in quiescent and terminally differentiated cells(1,9,12,13), and can both induce immortalization when constitutively expressed in transfected cells(2,10,11). Consistent with the recently reported association between MYC overexpression and induction of telomerase activity(14), we find here that the TERT promoter contains numerous c-MYC-binding sites that mediate TERT transcriptional activation. c-MYC-induced TERT expression is rapid and independent of cell proliferation and additional protein synthesis, consistent with direct transcriptional activation of TERT. Our results indicate that TERT is a target of c-MYC activity and identify a pathway linking cell proliferation and chromosome integrity in normal and neoplastic cells.	Columbia Univ, Dept Pathol, New York, NY 10027 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10027 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; GSF Munich, Natl Res Inst Environm & Hlth, Inst Clin Mol Biol & Tumor Gent, D-81377 Munich, Germany	Columbia University; Columbia University; Fred Hutchinson Cancer Center; Swiss Institute Experimental Cancer Research; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dalla-Favera, R (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10027 USA.	rd10@columbia.edu	Wu, Kou-Juey/P-4654-2015	Lingner, Joachim/0000-0002-2853-5803	NCI NIH HHS [CA37165, CA20525, CA75125-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037165, R29CA075125, R01CA020525, R37CA020525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; Ramakrishnan S, 1998, CANCER RES, V58, P622; SASSON S, 1991, PATHOL BIOL, V39, P59; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; WU KJ, IN PRESS SCIENCE	30	729	787	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					220	224		10.1038/6010	http://dx.doi.org/10.1038/6010			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988278				2022-12-25	WOS:000078399500028
J	Ku, MSB; Agarie, S; Nomura, M; Fukayama, H; Tsuchida, H; Ono, K; Hirose, S; Toki, S; Miyao, M; Matsuoka, M				Ku, MSB; Agarie, S; Nomura, M; Fukayama, H; Tsuchida, H; Ono, K; Hirose, S; Toki, S; Miyao, M; Matsuoka, M			High-level expression of maize phosphoenolpyruvate carboxylase in transgenic rice plants	NATURE BIOTECHNOLOGY			English	Article						transformation; rice; maize; C-4 photosynthesis pathway; phosphoenolpyruvate carboxylase	LIGHT-REGULATED EXPRESSION; MALIC-ENZYME GENE; C-4 PHOTOSYNTHESIS; CO2-CONCENTRATING MECHANISM; TOBACCO PLANTS; MESSENGER-RNA; C3 PLANT; AGROBACTERIUM; PROMOTER; PHOTORESPIRATION	Using an Agrobacterium-mediated transformation system, we have introduced the intact gene of maize phosphoenolpyruvate carboxylase (PEPC), which catalyzes the initial fixation of atmospheric CO2 in C-4 plants into the C-3 crop rice. Most transgenic rice plants showed high-level expression of the maize gene; the activities of PEPC in leaves of some transgenic plants were two- to threefold higher than those in maize, and the enzyme accounted for up to 12% of the total leaf soluble protein. RNA gel blot and Southern blot analyses showed that the level of expression of the maize PEPC in transgenic rice plants correlated with the amount of transcript and the copy number of the inserted maize gene, Physiologically, the transgenic plants exhibited reduced O-2 inhibition of photosynthesis and photosynthetic rates comparable to those of untransformed plants. The results demonstrate a successful strategy for installing the key biochemical component of the C-4 pathway of photosynthesis in C-3 plants.	Washington State Univ, Dept Bot, Pullman, WA 99164 USA; Natl Inst Agrobiol Resources, Tsukuba, Ibaraki 3058602, Japan; Nagoya Univ, BioSci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Washington State University; National Institute of Agrobiological Sciences - Japan; Nagoya University	Ku, MSB (corresponding author), Washington State Univ, Dept Bot, Pullman, WA 99164 USA.	mku@wsunix.wsu.edu		Agarie, Sakae/0000-0003-0594-2104				Birch RG, 1997, ANNU REV PLANT PHYS, V48, P297, DOI 10.1146/annurev.arplant.48.1.297; Bowes G, 1996, ADV PHOTOSYNTHESIS, V5, P387, DOI DOI 10.1007/0-306-48135-9_16; BROWN RH, 1993, ANNU REV PLANT PHYS, V44, P435, DOI 10.1146/annurev.pp.44.060193.002251; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; CHAN MT, 1993, PLANT MOL BIOL, V22, P491, DOI 10.1007/BF00015978; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; DAI Z, 1994, PLANTA, V192, P287, DOI 10.1007/BF00198562; DAI ZY, 1993, PLANT PHYSIOL, V103, P83, DOI 10.1104/pp.103.1.83; DAI ZY, 1995, PLANT PHYSIOL, V107, P815, DOI 10.1104/pp.107.3.815; DRICOVICH MF, 1988, PLANT CELL ENVIRON, V21, P63; ECKES P, 1989, MOL GEN GENET, V217, P263, DOI 10.1007/BF02464891; Edwards G., 1983, C3 C4 MECH CELLULAR; FURBANK RT, 1995, PLANT CELL, V7, P797, DOI 10.2307/3870037; FUSHIMI T, 1994, PLANT MOL BIOL, V24, P965, DOI 10.1007/BF00014450; GALLARDO F, 1995, PLANTA, V197, P324, DOI 10.1007/BF00202654; Gehlen J, 1996, PLANT MOL BIOL, V32, P831, DOI 10.1007/BF00020481; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; HARLEY PC, 1991, PHOTOSYNTH RES, V27, P169, DOI 10.1007/BF00035838; HARRIS GC, 1983, PLANT PHYSIOL, V71, P108, DOI 10.1104/pp.71.1.108; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HUDSPETH RL, 1992, PLANT PHYSIOL, V98, P458, DOI 10.1104/pp.98.2.458; KANAI R, 1973, PLANT PHYSIOL, V51, P1133, DOI 10.1104/pp.51.6.1133; KEITH B, 1986, EMBO J, V5, P2419, DOI 10.1002/j.1460-2075.1986.tb04516.x; KOGAMI H, 1994, TRANSGENIC RES, V3, P287, DOI 10.1007/BF01973588; Koziel MG, 1996, PLANT MOL BIOL, V32, P393, DOI 10.1007/BF00039392; Ku MSB, 1996, PLANT PHYSIOL, V111, P949, DOI 10.1104/pp.111.4.949; KU MSB, 1977, PLANT PHYSIOL, V59, P986; MATSUOKA M, 1993, P NATL ACAD SCI USA, V90, P9586, DOI 10.1073/pnas.90.20.9586; MATSUOKA M, 1994, PLANT J, V6, P311, DOI 10.1046/j.1365-313X.1994.06030311.x; MATSUOKA M, 1989, EUR J BIOCHEM, V181, P593, DOI 10.1111/j.1432-1033.1989.tb14765.x; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MCGOOKIN R, 1984, METHOD MOL BIOL, V2, P113; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; OGREN WL, 1984, ANNU REV PLANT PHYS, V35, P415, DOI 10.1146/annurev.pp.35.060184.002215; Rashid H, 1996, PLANT CELL REP, V15, P727, DOI 10.1007/BF00232216; SCHAAF J, 1995, PLANT PHYSIOL, V108, P949, DOI 10.1104/pp.108.3.949; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SOMERVILLE CR, 1990, PLANT PHYSL PLANT MO, P490; Toki S, 1997, PLANT MOL BIOL REP, V15, P16, DOI 10.1007/BF02772109; WALTER MH, 1994, EUR J BIOCHEM, V224, P999, DOI 10.1111/j.1432-1033.1994.t01-1-00999.x	41	264	440	2	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					76	80		10.1038/5256	http://dx.doi.org/10.1038/5256			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920274				2022-12-25	WOS:000077979500030
J	Luo, L; Salunga, RC; Guo, HQ; Bittner, A; Joy, KC; Galindo, JE; Xiao, HN; Rogers, KE; Wan, JS; Jackson, MR; Erlander, MG				Luo, L; Salunga, RC; Guo, HQ; Bittner, A; Joy, KC; Galindo, JE; Xiao, HN; Rogers, KE; Wan, JS; Jackson, MR; Erlander, MG			Gene expression profiles of laser-captured adjacent neuronal subtypes	NATURE MEDICINE			English	Article							DIFFERENTIAL EXPRESSION; MESSENGER-RNA; RAT; MICROARRAY; GANGLIA; CDNA		RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Erlander, MG (corresponding author), RW Johnson Pharmaceut Res Inst, 3535 Gen Atom Court,Suite 100, San Diego, CA 92121 USA.							Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; COGGESHALL RE, 1991, SENSORY MECH SPINAL; Costigan M, 1998, J NEUROSCI, V18, P5891; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Goldstein ME, 1996, NEUROSCIENCE, V71, P243, DOI 10.1016/0306-4522(95)00404-1; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; LOCKHART DJ, 1998, NUCL ACIDS S SER, V38, P11; Naciff JM, 1996, J COMP NEUROL, V368, P356; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; OH YS, 1995, MOL BRAIN RES, V30, P357, DOI 10.1016/0169-328X(95)00052-T; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1998, PATHOL BIOL, V46, P107; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059	23	593	631	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					117	122		10.1038/4806	http://dx.doi.org/10.1038/4806			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883850				2022-12-25	WOS:000077885000040
J	Puel, A; Ziegler, SF; Buckley, RH; Leonard, WJ				Puel, A; Ziegler, SF; Buckley, RH; Leonard, WJ			Defective IL7R expression in T-B+NK+ severe combined immunodeficiency	NATURE GENETICS			English	Article							RECEPTOR-GAMMA-CHAIN; NATURAL-KILLER-CELLS; IL-2 RECEPTOR; INTERLEUKIN-7 RECEPTOR; FUNCTIONAL COMPONENT; PROGENITOR CELLS; LIGAND-BINDING; DIFFERENTIATION; MUTATION; JAK3	Severe combined immunodeficiency (SCID) is caused by multiple genetic defects(1-3). The most common form of SCID, X-linked SCID (XSCID), results from mutations in IL2RG (ref. 4), which encodes the common cytokine receptor gamma chain (gamma(c)) that is shared by the IL-2, IL-4, IL-7, IL-9 and IL-15 receptors(1,5-10). In XSCID and SCID resulting from mutations in JAK3, which encodes a Janus family tyrosine kinase that couples to gamma(c) (refs 9,11,12) and is required for gamma(c)-dependent signalling, T- and natural killer (NK)-cells are decreased but B-cell numbers are normal(1-3,13,14) (T-B+NK- SCID). Some SCID patients lack T cells but retain NK cells. Given diminished T-cell development in IL7- or IL7r-deficient mice(15,16) and that Il7r-deficient mice have NK cells(17), we hypothesized that T-B+NK+ SCID might result from defective IL-7 signalling, although apparent differences in the role of the IL-7/IL-7R pathway in humans and mice in T-cell and B-cell development have been suggested(1,18). We now demonstrate medium control that defective IL7R expression causes T-B+NK+ SCID, indicating that the T-cell, but not the NK-cell, defect in XSCID results from inactivation of IL-7 alpha signalling.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Virginia Mason Med Ctr, Seattle, WA 98101 USA; Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Sch Med, Dept Pediat, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Virginia Mason Medical Center; Duke University; Duke University	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022; Puel, Anne/H-7305-2017; Buckley, Rebecca/AAB-1578-2019	Puel, Anne/0000-0003-2603-0323; 				BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; CavazzanaCalvo M, 1996, BLOOD, V88, P3901, DOI 10.1182/blood.V88.10.3901.bloodjournal88103901; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; He YW, 1996, J EXP MED, V184, P289, DOI 10.1084/jem.184.1.289; ISHII N, 1994, J IMMUNOL, V153, P1310; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Leclercq G, 1996, J EXP MED, V184, P325, DOI 10.1084/jem.184.2.325; Leonard WJ, 1996, ANNU REV MED, V47, P229; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; Puck JM, 1997, BLOOD, V89, P1968; Puzanov IJ, 1996, J IMMUNOL, V157, P4282; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	29	607	621	1	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					394	397		10.1038/3877	http://dx.doi.org/10.1038/3877			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843216				2022-12-25	WOS:000077199600031
J	Xia, JH; Liu, CY; Tang, BS; Pan, Q; Huang, L; Dai, HP; Zhang, BR; Xie, W; Hu, DX; Zheng, D; Shi, XL; Wang, DA; Xia, K; Yu, KP; Liao, XD; Feng, Y; Yang, YF; Xiao, JY; Xie, DH; Huang, JZ				Xia, JH; Liu, CY; Tang, BS; Pan, Q; Huang, L; Dai, HP; Zhang, BR; Xie, W; Hu, DX; Zheng, D; Shi, XL; Wang, DA; Xia, K; Yu, KP; Liao, XD; Feng, Y; Yang, YF; Xiao, JY; Xie, DH; Huang, JZ			Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant healing impairment	NATURE GENETICS			English	Article							MARIE-TOOTH DISEASE; HEARING IMPAIRMENT; DEAFNESS; HETEROGENEITY; FAMILIES; LINKAGE; REGION; MAPS	Hearing impairment is the most commonly occurring condition that affects the ability of humans to communicate(1). More than 50% of the cases of profound early-onset deafness are caused by genetic factors(2,3). Over 40 loci for non-syndromic deafness have been genetically mapped, and mutations in several genes have been shown to cause hearing loss(4). Mutations in the gene encoding connexin 26 (GJB2) cause both autosomal recessive and dominant forms of hearing impairment(5,6). To study the possible involvement of other members of the connexin family in hereditary hearing impairment, we cloned the gene (GJB3) encoding human gap junction protein beta-3 using homologous EST searching and nested PCR. GJB3 was mapped to human chromosome 1p33-p35. Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were associated with high-frequency hearing loss in two families. Moreover. expression of Gjb3 was identified in rat inner ear tissue by RT-PCR. These findings suggest that mutations in GJB3 may be responsible for bilateral high-frequency hearing impairment.	Affiliated Xiangya Hosp, Natl Lab Med Genet China, Changsha 410078, Hunan, Peoples R China; Affiliated Xiangya Hosp, Dept Neurol, Changsha 410078, Hunan, Peoples R China; Affiliated Xiangya Hosp, Dept Otorhinol, Changsha 410078, Hunan, Peoples R China; Hunan Med Univ, Affiliated Hosp 2, Dept Otorhinol, Changsha 410078, Hunan, Peoples R China; Hunan Med Univ, Affiliated Hosp 2, Dept Cardiothorac Surg, Changsha 410078, Hunan, Peoples R China; Zhejiang Med Univ, Affiliated Hosp 2, Dept Neurol, Hangzhou 310009, Zhejiang, Peoples R China	Central South University; Central South University; Zhejiang University	Xia, JH (corresponding author), Affiliated Xiangya Hosp, Natl Lab Med Genet China, Changsha 410078, Hunan, Peoples R China.	nlmglcy@public.cs.hn.cn	Liu, Chunyu/G-7561-2012; XIA, KUN/AAO-3525-2020; Liu, chunyu/Q-3901-2017	Liu, Chunyu/0000-0002-5986-4415; Shi, Xiaoliu/0000-0002-9759-2254				AYIMU D, 1997, J AUDIOL SPEECH PATH, V5, P144; BENOTHMANE K, 1993, GENOMICS, V17, P370; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Engle EC, 1997, AM J HUM GENET, V60, P1150; FAIN PR, 1994, AM J HUM GENET, V54, P229; HULL R, 1978, HDB CLIN AUDIOLOGY, P426; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; REARDON W, 1992, J MED GENET, V29, P521, DOI 10.1136/jmg.29.8.521; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; VanCamp G, 1997, AM J HUM GENET, V60, P758; VanCamp G, 1997, GENOMICS, V41, P70, DOI 10.1006/geno.1997.4624; VANDERSCHROEFF JG, 1988, HUM GENET, V80, P97, DOI 10.1007/BF00451466; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202	19	345	428	0	27	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					370	373		10.1038/3845	http://dx.doi.org/10.1038/3845			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843210				2022-12-25	WOS:000077199600025
J	Brown, SA; Warburton, D; Brown, LY; Yu, CY; Roeder, ER; Stengel-Rutkowski, S; Hennekam, RCM; Muenke, M				Brown, SA; Warburton, D; Brown, LY; Yu, CY; Roeder, ER; Stengel-Rutkowski, S; Hennekam, RCM; Muenke, M			Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired	NATURE GENETICS			English	Article							SONIC-HEDGEHOG GENE; PROTEIN; DEFINITION; EXPRESSION; REGION; DOMAIN	Holoprosencephaly (HPE) is the most common structural anomaly of the human brain and is one of the anomalies seen in patients with deletions and duplications of chromosome 13. On the basis of molecular analysis of a series of patients with hemizygous deletions of the long arm of chromosome 13. we have defined a discrete region in band 13q32 where deletion leads to major developmental anomalies (the 13q32 deletion syndrome). This approximately 1-Mb region(1) lies between markers D13S136 and D13S147. Patients in which this region is deleted usually have major congenital malformations, including brain anomalies such as HPE or exencephaly, and digital anomalies such as absent thumbs(2). We now report that human ZIC2 maps to this critical deletion region and that heterozygous mutations in ZIC2 are associated with HPE. Haploinsufficiency for ZIC2 is likely to cause the brain malformations seen in 13q deletion patients.	Columbia Univ, Dept Obstet & Gynecol, New York, NY 10027 USA; Columbia Univ, Dept Pediat, New York, NY 10027 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10027 USA; Presbyterian Hosp, New York, NY 10032 USA; Valley Childrens Hosp, Fresno, CA 93703 USA; Kinderzentrum Munchen, Munich, Germany; Univ Amsterdam, Inst Human Genet, NL-1012 WX Amsterdam, Netherlands; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD USA	Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; University of Amsterdam; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Brown, SA (corresponding author), Columbia Univ, Dept Obstet & Gynecol, New York, NY 10027 USA.	brown@cuccfa.ccc.columbia.edu		Muenke, Maximilian/0000-0002-7719-6545	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029862, R29HD028732, R29HD032467] Funding Source: NIH RePORTER; NICHD NIH HHS [HD28732, HD32467, HD29862] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akarsu AN, 1996, HUM MOL GENET, V5, P945, DOI 10.1093/hmg/5.7.945; Aruga J, 1996, GENE, V172, P291, DOI 10.1016/0378-1119(96)00111-4; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; BONALDO MD, 1994, HUM MOL GENET, V3, P1663; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; BROWN S, 1993, AM J MED GENET, V45, P52, DOI 10.1002/ajmg.1320450115; BROWN S, 1995, AM J HUM GENET, V57, P859; CIMBORA DM, 1995, DEV BIOL, V169, P580, DOI 10.1006/dbio.1995.1171; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Goodman FR, 1997, P NATL ACAD SCI USA, V94, P7458, DOI 10.1073/pnas.94.14.7458; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; Johnson KR, 1998, HUM MOL GENET, V7, P1033, DOI 10.1093/hmg/7.6.1033; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; Ming JE, 1998, MOL MED TODAY, V4, P343, DOI 10.1016/S1357-4310(98)01299-4; Muenke Maximilian, 1994, Seminars in Developmental Biology, V5, P293, DOI 10.1006/sedb.1994.1038; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Roessler E, 1998, J INHERIT METAB DIS, V21, P481, DOI 10.1023/A:1005406719292; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Roessler E, 1997, HUM GENET, V100, P172, DOI 10.1007/s004390050486; Roessler E, 1997, HUM MOL GENET, V6, P1847, DOI 10.1093/hmg/6.11.1847; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280	28	365	372	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					180	183		10.1038/2484	http://dx.doi.org/10.1038/2484			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771712				2022-12-25	WOS:000076231300021
J	Morgan, D; Turnpenny, L; Goodship, J; Dai, WL; Majumder, K; Matthews, L; Gardner, A; Schuster, G; Vien, L; Harrison, W; Elder, FEB; Penman-Splitt, M; Overbeek, P; Strachan, T				Morgan, D; Turnpenny, L; Goodship, J; Dai, WL; Majumder, K; Matthews, L; Gardner, A; Schuster, G; Vien, L; Harrison, W; Elder, FEB; Penman-Splitt, M; Overbeek, P; Strachan, T			Inversin, a novel gene in the vertebrate left-right axis pathway, is partially deleted in the inv mouse	NATURE GENETICS			English	Article							LEFT-RIGHT ASYMMETRY; NODAL EXPRESSION; SITUS-INVERSUS; EMBRYOGENESIS; LIBRARIES; SEQUENCES; MUTATION; EMBRYOS; LINKAGE; XENOPUS	Visceral left-right asymmetry occurs in all vertebrates, but the inversion of embryo turning (inv) mouse, which resulted following a random transgene insertion, is the only model in which these asymmetries are consistently reversed(1). We report positional cloning of the gene underlying this recessive phenotype. Although transgene insertion was accompanied by neighbouring deletion and duplication events(1,2), our YAC phenotype rescue studies indicate that the mutant phenotype results from the deletion. After extensively characterizing the 47-kb deleted region and flanking sequences from the wild-type mouse genome, we found evidence for only one gene sequence in the deleted region. We determined the full-length 5.5-kb cDNA sequence and identified 16 exons, of which exons 3-11 were eliminated by the deletion, causing a frameshift. The novel gene specifies a 1062-aa product with tandem ankyrin-like repeat sequences. Characterization of complementing and non-complementing YAC transgenic families revealed that correction of the inv mutant phenotype was concordant with integration and intact expression of this novel gene, which we have named inversin (Invs).	Newcastle Univ, Dept Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Sanger Ctr, Cambridge CB10 1RQ, England; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA	Newcastle University - UK; Baylor College of Medicine; Baylor College of Medicine; Wellcome Trust Sanger Institute; University of Texas System; University of Texas Health Science Center Houston	Goodship, J (corresponding author), Newcastle Univ, Dept Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	j.a.goodship@ncl.ac.uk; tom.strachan@ncl.ac.uk		Overbeek, Paul/0000-0001-9784-2084	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; EWING B, IN PRESS GENOME RES; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; GNIRKE A, 1993, GENOMICS, V15, P659, DOI 10.1006/geno.1993.1121; HARRISON SM, 1995, DEVELOPMENT, V121, P2479; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hogan B, 1994, MANIPULATING MOUSE E; Huxley C, 1994, Genet Eng (N Y), V16, P65; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Innis MA, 1990, PCR PROTOCOLS GUIDE; Kaufman MH, 1995, ATLAS MOUSE DEV; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; Levin M, 1998, SEMIN CELL DEV BIOL, V9, P67, DOI 10.1006/scdb.1997.0192; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; PENMANSPLITT M, 1996, J MED GENET, V33, P498; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; ROBINSON TJ, 1987, CHROMOSOMA, V96, P45, DOI 10.1007/BF00285882; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; SMITH DJ, 1995, GENOMICS, V27, P425, DOI 10.1006/geno.1995.1073; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; VALDES JM, 1994, P NATL ACAD SCI USA, V91, P5377, DOI 10.1073/pnas.91.12.5377; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; Wood WB, 1997, ANNU REV CELL DEV BI, V13, P53; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOKOYAMA T, 1995, DEV MECH HEART DIS; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	42	192	194	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1998	20	2					149	156		10.1038/2450	http://dx.doi.org/10.1038/2450			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771707				2022-12-25	WOS:000076231300016
J	Lefebvre, AM; Chen, IH; Desreumaux, P; Najib, J; Fruchart, JC; Geboes, K; Briggs, M; Heyman, R; Auwerx, J				Lefebvre, AM; Chen, IH; Desreumaux, P; Najib, J; Fruchart, JC; Geboes, K; Briggs, M; Heyman, R; Auwerx, J			Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APC(Min)/+ mice	NATURE MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; INTESTINAL NEOPLASIA; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; COLORECTAL-CANCER; SULINDAC SULFONE; MAJOR MODIFIER; APC GENE; INHIBITION; EXPRESSION	The development of colorectal cancer, one of the most frequent cancers, is influenced by prostaglandins and fatty acids' Decreased prostaglandin production, seen in mice with mutations in the cyclooxygenase 2 gene or in animals and humans treated with cyclooxygenase inhibitors, prevents or attenuates colon cancer development(2-4). There is also a strong correlation between the intake of fatty acids from animal origin and colon cancer(5,6). Therefore, the peroxisome proliferator-activated receptor gamma (PPAR gamma; ref. 7), a downstream transcriptional mediator for prostaglandins and fatty acids which is highly expressed in the colon(8,9), may be involved in this process. Activation of PPAR gamma by two different synthetic agonists increased the frequency and size of colon tumors in C57BL/6J-APC(Min)/+ mice, an animal model susceptible to intestinal neoplasia. Tumor frequency was only increased in the colon, and did not change in the small intestine, coinciding with the colon-restricted expression of PPAR gamma. Treatment with PPAR gamma agonists increased beta-catenin levels both in the colon of C57BL/6J-APC(Min)/+ mice and in HT-29 colon carcinoma cells. Genetic abnormalities in the Wnt/wingless/APC pathway, which enhance the transcriptional activity of the beta-catenin-T-cell factor/lymphoid enhancer factor 1 transcription complex, often underly the development of colon tumors. Our data indicate that PPAR gamma activation modifies the development of colon tumors in C57BL/6J-APC(Min)/+ mice.	Inst Pasteur, Dept Atherosclerose, U325 INSERM, LBRE, F-59019 Lille, France; Catholic Univ Louvain, Dept Pathol, B-3000 Louvain, Belgium; CHU Lille, Hop Claude Huriez, Clin Malad Appareil Digestif, F-59037 Lille, France; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Catholique Louvain; Universite de Lille - ISITE; CHU Lille; Ligand Pharmaceuticals	Auwerx, J (corresponding author), Inst Pasteur, Dept Atherosclerose, U325 INSERM, LBRE, F-59019 Lille, France.		Desreumaux, Pierre F/R-6877-2018	Desreumaux, Pierre F/0000-0002-6127-5281; Auwerx, Johan/0000-0002-5065-5393; Lefebvre, Anne-Marie/0000-0001-5644-0441				Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chiu CH, 1997, CANCER RES, V57, P4267; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOLM E, 1995, CANCER RES, V55, P1373; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jacoby RF, 1996, CANCER RES, V56, P710; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piazza GA, 1997, CANCER RES, V57, P2909; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SAEZ E, 1998, NAT MED, V4, pR30; SCHEPPACH W, 1994, GUT, V35, pS35, DOI 10.1136/gut.35.1_Suppl.S35; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3	38	542	570	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1053	1057		10.1038/2036	http://dx.doi.org/10.1038/2036			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734399				2022-12-25	WOS:000075804100039
J	Abdel-Majid, RM; Leong, WL; Schalkwyk, LC; Smallman, DS; Wong, ST; Storm, DR; Fine, A; Dobson, MJ; Guernsey, DL; Neumann, PE				Abdel-Majid, RM; Leong, WL; Schalkwyk, LC; Smallman, DS; Wong, ST; Storm, DR; Fine, A; Dobson, MJ; Guernsey, DL; Neumann, PE			Loss of adenylyl cyclase I activity disrupts patterning of mouse somatosensory cortex	NATURE GENETICS			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; DEVELOPING RAT; MUTANT MICE; SEROTONIN; GENOME; RECEPTORS; CONSTRUCTION; ACTIVATION; INSERTION; BEHAVIOR	The somatosensory (SI) cortex of mice displays a patterned, nonuniform distribution of neurons in layer IV called the "barrelfield' (ref. 1). Thalamocortical afferents (TCAs) that terminate in layer IV are segregated such that each barrel, a readily visible cylindrical array of neurons surrounding a cell-sparse center, represents a distinct receptive field. TCA arbors are confined to the barrel hollow and synapse on barrel-wail neurons whose dendrites are oriented toward the center of the barrel(2). Mice homozygous for the barrelless (brl) mutation, which occurred spontaneously in ICR stock at Universitd de Lausanne (Switzerland), fail to develop this patterned distribution of neurons, but still display normal topological organization of the SI cortex(3). Despite the absence of barrels and the overlapping zones of TCA arborization, the size of individual whisker representations, as judged by 2-deoxyglucose uptake, is similar to that of wild-type mice. We identified adenylyl cyclase type I(Adcy1) as the gene disrupted in brl mutant mice by fine mapping of proximal chromosome 11, enzyme assay, mutation analysis and examination of mice homozygous for a targeted disruption of Adcy1. These results provide the first evidence for involvement of cAMP signalling pathways in pattern formation of the brain.	Dalhousie Univ, Fac Med, Dept Anat & Neurobiol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Fac Med, Dept Surg, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Fac Med, Dept Pathol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Fac Med, Dept Phys & Biophys, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Fac Med, Dept Biochem, Halifax, NS B3H 4H7, Canada; Max Planck Inst Mol Genet, Abt Lehrach, Berlin, Germany; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University; Max Planck Society; University of Washington; University of Washington Seattle	Neumann, PE (corresponding author), Dalhousie Univ, Fac Med, Dept Anat & Neurobiol, Halifax, NS B3H 4H7, Canada.	neumannp@tupdean1.med.dal.ca	Schalkwyk, Leonard C/A-2150-2010	Schalkwyk, Leonard C/0000-0001-7030-5756; Neumann, Paul/0000-0002-8480-4799; Dobson, Melanie/0000-0001-9291-7200				BENNETTCLARKE CA, 1993, P NATL ACAD SCI USA, V90, P153, DOI 10.1073/pnas.90.1.153; BENNETTCLARKE CA, 1994, J NEUROSCI, V14, P7594; BOUHELAL R, 1988, EUR J PHARMACOL, V151, P189, DOI 10.1016/0014-2999(88)90799-6; BYRNE JH, 1991, ANN NY ACAD SCI, V627, P124, DOI DOI 10.1111/J.1749-6632.1991.TB25918.X; Cases O, 1996, NEURON, V16, P297, DOI 10.1016/S0896-6273(00)80048-3; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CLAUDIO JO, 1994, GENOMICS, V21, P437, DOI 10.1006/geno.1994.1291; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; EDELHOFF S, 1995, MAMM GENOME, V6, P111, DOI 10.1007/BF00303253; Haldi ML, 1996, MAMM GENOME, V7, P767, DOI 10.1007/s003359900228; JOHNSON RA, 1973, J BIOL CHEM, V248, P5114; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1993, METHOD ENZYMOL, V225, P623; Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9; MITREITER K, 1994, VIROLOGY, V200, P837, DOI 10.1006/viro.1994.1253; Mitrovic N, 1996, EUR J NEUROSCI, V8, P1793, DOI 10.1111/j.1460-9568.1996.tb01323.x; RHOADES RW, 1994, J NEUROPHYSIOL, V72, P2438, DOI 10.1152/jn.1994.72.5.2438; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; VILLACRES EC, 1995, J BIOL CHEM, V270, P14352, DOI 10.1074/jbc.270.24.14352; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; Welker E, 1996, SCIENCE, V271, P1864, DOI 10.1126/science.271.5257.1864; WOOLSEY TA, 1975, P NATL ACAD SCI USA, V72, P2165, DOI 10.1073/pnas.72.6.2165; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOVELL Y, 1992, P NATL ACAD SCI USA, V89, P6526, DOI 10.1073/pnas.89.14.6526	30	128	132	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1998	19	3					289	291		10.1038/980	http://dx.doi.org/10.1038/980			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662407				2022-12-25	WOS:000074565900030
J	Anderson, SE; Schlegel, BP; Nakajima, T; Wolpin, ES; Parvin, JD				Anderson, SE; Schlegel, BP; Nakajima, T; Wolpin, ES; Parvin, JD			BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase a	NATURE GENETICS			English	Article							TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; BREAST; DROSOPHILA	The breast cancer specific tumour suppressor protein, BRCA1 (refs 1,2), activates transcription when linked with a DNA-binding domain(3,4) and is a component of the RNA polymerase II (Pol II) holoenzyme(5,6). We show here that RNA helicase A (RHA) protein(7,8) links BRCA1 to the holoenzyme complex. The region of BRCA1 which interacts with RHA and, thus, the holoenzyme complex, corresponds to subregions of the BRCT domain of BRCA1 (ref. 9). This interaction was shown to occur in yeast nuclei, and expression in human cells of a truncated RHA molecule which retains binding to BRCA1 inhibited transcriptional activation mediated by the BRCA1 carboxy terminus. These data are the first to identify a specific protein interaction with the BRCA1 C-terminal domain and are consistent with the model that BRCA1 functions as a transcriptional coactivator.	Brigham & Womens Hosp, Dept Pathol, Div Mol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Tsukuba, Inst Appl Biochem, Ibaraki, Osaka 3058572, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Tsukuba	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Mol Oncol, 75 Francis St, Boston, MA 02115 USA.		Parvin, Jeffrey D/C-8955-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053504] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18829, GM53504] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LEE CG, 1993, J BIOL CHEM, V268, P16822; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Zhang SS, 1997, J BIOL CHEM, V272, P11487	17	324	342	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					254	256		10.1038/930	http://dx.doi.org/10.1038/930			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662397				2022-12-25	WOS:000074565900020
J	Sanberg, PR; Borlongan, CV; Saporta, S; Cameron, DF				Sanberg, PR; Borlongan, CV; Saporta, S; Cameron, DF			Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain	NATURE BIOTECHNOLOGY			English	Article						Sertoli cells; neural transplantation; Parkinson's disease; xenotransplantation; striatum	CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; TRANSPLANTATION; GRAFTS; THERAPY; TISSUE	Transplantation of neural tissue into the mammalian central nervous system has become an alternative treatment for neurodegenerative disorders such as Parkinson's disease. Logistical and ethical problems in the clinical use of human fetal neural grafts as a source of dopamine for Parkinson's disease patients has hastened a search for successful ways to use animal dopaminergic cells for human transplantation. The present study demonstrates that transplanted testis-derived Sertoli cells into adult rat brains survive. Furthermore, when cotransplanted with bovine adrenal chromaffin cells (xenograft), Sertoli cells produce localized immunoprotection, suppress microglial response and allow the bovine cells to survive in the rat brain without continuous systemic immunosuppressive drugs. These novel features support Sertoli cells as a viable graft source for facilitating the use of xenotransplantation for Parkinson's disease and suggest their use as facilitators (i.e., localized immunosuppression) for cell transplantation in general.	UNIV S FLORIDA,COLL MED,DEPT NEUROL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT PSYCHIAT,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT PHARMACOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT ANAT,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sanberg, PR (corresponding author), UNIV S FLORIDA,COLL MED,DEPT SURG,DIV NEUROL SURG,MDC BOX 16,12901 B DOWNS BLVD,TAMPA,FL 33612, USA.		Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782				BARKER CF, 1977, ADV IMMUNOL, V25, P1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BERDEN JHM, 1985, LANCET, V1, P219; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; Bjorklund A, 1985, NEURAL GRAFTING MAMM, P3; BRUNDIN P, 1989, EXP BRAIN RES, V75, P195; DEGROEN C, 1984, NEW ENGL J MED, V317, P861; EMERICH DF, 1992, NEUROSCI BIOBEHAV R, V16, P437, DOI 10.1016/S0149-7634(05)80185-X; FINSEN B, 1988, EXP BRAIN RES, V70, P117; FINSEN BR, 1991, RESTOR NEUROL NEUROS, V2, P271, DOI 10.3233/RNN-1991-245616; FREEMAN TB, 1995, CELL TRANSPLANT, V4, P141, DOI 10.1016/0963-6897(94)00048-O; HEDGER MP, 1989, REPROD FERT DEVELOP, V1, P75, DOI 10.1071/RD9890075; LINDVALL O, 1987, ANN NEUROL, V22, P457, DOI 10.1002/ana.410220403; LYSAGHT MJ, 1994, J CELL BIOCHEM, V56, P196, DOI 10.1002/jcb.240560214; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; ORTEGAS JD, 1992, J COMP NEUROL, V323, P1; Paxinos G., 2004, J CHEM INF MODEL, V5th; SAGEN J, 1993, J NEUROSCI, V13, P2415, DOI 10.1523/JNEUROSCI.13-06-02415.1993; SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206; SKINNER MK, 1993, SERTOLI CELL, P237; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0	22	121	132	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1996	14	13					1692	1695		10.1038/nbt1296-1692	http://dx.doi.org/10.1038/nbt1296-1692			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VX107	9634853				2022-12-25	WOS:A1996VX10700031
J	Altpeter, F; Vasil, V; Srivastava, V; Vasil, IK				Altpeter, F; Vasil, V; Srivastava, V; Vasil, IK			Integration and expression of the high-molecular-weight glutenin subunit 1Ax1 gene into wheat	NATURE BIOTECHNOLOGY			English	Article						Triticum aestivum L; 1Ax1; bread-making quality; transformation; high-molecular-weight glutenin; wheat	BREAD-MAKING QUALITY; STORAGE PROTEINS; IMMATURE EMBRYOS; MAIZE; INHERITANCE; PLANTS	The unique bread-making characteristic of wheat flour is closely related to the elasticity and extensibility of the gluten proteins stored in the starchy endosperm, particularly the high-molecular-weight glutenin subunits (HMW-GS), which are important in determining gluten and dough elasticity. The quality of wheat cultivars depends on the number and composition of the HMW-GS present. We have introduced the HMW-GS 1Ax1 gene, known to be associated with good bread-making quality, into the Bob White cultivar of wheat (Triticum aestivum L.), in which it is not present in nature, by the biolistic bombardment of cultured immature embryos. Of the 21 independent transformed lines selected, 20 expressed the selectable bar gene, and nine the 1Ax1 gene. The amount of HMW-GS 1Ax1 protein produced in the different transgenic lines varied from 0.6% to 2.3% of the total protein, resulting in an increase of up to 71% in total HMW-GS proteins. The transgenic plants were normal, fertile, and showed Mendelian segregation of the transgenes. The accumulation of HMW-GS 1Ax1 was consistent and stable up to the R3 seed generation. These results demonstrate that it is possible to manipulate both the quantity and quality of HMW-GS, which influence the bread-making quality of wheat.	UNIV FLORIDA,LAB PLANT CELL & MOL BIOL,GAINESVILLE,FL 32611	State University System of Florida; University of Florida			Vasil, Indra K/F-6192-2011	Vasil, Indra K/0000-0002-8900-4897; Srivastava, Vibha/0000-0002-3031-6984				ALTPETER F, 1996, IN PRESS PLANT CELL; Blechl AE, 1996, NAT BIOTECHNOL, V14, P875, DOI 10.1038/nbt0796-875; BRANLARD G, 1987, P 3 INT WORKSH GLUT, P604; CHRISTOU P, 1989, P NATL ACAD SCI USA, V86, P7500, DOI 10.1073/pnas.86.19.7500; CRHISTENSEN AH, 1996, TRANGEN RES, V5, P213; FLAVELL RB, 1989, BIO-TECHNOL, V7, P1281; HALFORD NG, 1992, THEOR APPL GENET, V83, P373, DOI 10.1007/BF00224285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lassner MW., 1989, PLANT MOL BIOL REP, V7, P116, DOI DOI 10.1007/BF02669627; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; PAYNE PI, 1979, THEOR APPL GENET, V55, P153, DOI 10.1007/BF00295442; PAYNE PI, 1981, J SCI FOOD AGR, V32, P51, DOI 10.1002/jsfa.2740320109; SEILMEIER W, 1991, Z LEBENSM UNTERS FOR, V192, P124, DOI 10.1007/BF01202625; SHEWRY PR, 1995, BIO-TECHNOL, V13, P1185, DOI 10.1038/nbt1195-1185; SHEWRY PR, 1995, BIOL REV, V70, P375, DOI 10.1111/j.1469-185X.1995.tb01195.x; SPENCER TM, 1990, THEOR APPL GENET, V79, P625, DOI 10.1007/BF00226875; SPENCER TM, 1992, PLANT MOL BIOL, V18, P201, DOI 10.1007/BF00034949; Srivastava V, 1996, THEOR APPL GENET, V92, P1031, DOI 10.1007/BF00224045; TAYLOR MG, 1993, PLANT CELL REP, V12, P491, DOI 10.1007/BF00236093; VASIL IK, 1994, PLANT MOL BIOL, V25, P925, DOI 10.1007/BF00014667; VASIL V, 1993, BIO-TECHNOL, V11, P1553, DOI 10.1038/nbt1293-1553; Wrigley CW, 1996, NATURE, V381, P738, DOI 10.1038/381738a0	24	161	196	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1155	1159		10.1038/nbt0996-1155	http://dx.doi.org/10.1038/nbt0996-1155			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631070				2022-12-25	WOS:A1996VF84300041
J	Schneider, A; Martin-Villalba, A; Weih, F; Vogel, J; Wirth, T; Schwaninger, M				Schneider, A; Martin-Villalba, A; Weih, F; Vogel, J; Wirth, T; Schwaninger, M			NF-kappa B is activated and promotes cell death in focal cerebral ischemia	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR; ARTERY OCCLUSION; SODIUM-SALICYLATE; INDUCED APOPTOSIS; OXIDATIVE STRESS; GLOBAL-ISCHEMIA; PRIMARY NEURONS; RAT; NEUROPROTECTION; PROTEIN	The transcription factor NF-kappa B is a regulator of cell death or survival. To investigate the role of NF-kappa B in neuronal cell death, we studied its activation in a rodent model of stroke. In the ischemic hemisphere, NF-kappa B was activated, as determined by increased expression of an NF-kappa B-driven reporter transgene, nuclear translocation of NF-kappa B in neurons and enhanced DNA binding of NF-kappa B subunits RelA and p50. In p50 knockout mice, ischemic damage was significantly reduced. This indicates a cell death-promoting role of NF-kappa B in focal ischemia. NF-kappa B may provide a new pharmacological target in neurologic disease.	Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; BASF LYNX Biosci AG, Dept Neurosci, D-69120 Heidelberg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Dept Physiol, D-69120 Heidelberg, Germany; Inst Radiobiol & Cell Res, D-97078 Wurzburg, Germany	Ruprecht Karls University Heidelberg; BASF; Helmholtz Association; Karlsruhe Institute of Technology	Schwaninger, M (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Wirth, Thomas/X-7172-2019	Martin-Villalba, Ana/0000-0002-9405-8910				Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Clark WM, 1997, NEUROL RES, V19, P641; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; LI Y, 1995, AM J PATHOL, V146, P1045; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; MARTINVILLALBA A, IN PRESS J NEUROSCI; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Namura S, 1998, J NEUROSCI, V18, P3659; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Perovic S, 1996, EUR J PHARMACOL, V317, P157, DOI 10.1016/S0014-2999(96)00712-1; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Rong YQ, 1996, J NEUROCHEM, V67, P662; Sandercock P, 1997, LANCET, V349, P1569; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; SCHNEIDER A, 1995, P NATL ACAD SCI USA, V92, P4447, DOI 10.1073/pnas.92.10.4447; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; VOGEL J, IN PRESS STROKE; WEIH F, 1994, ONCOGENE, V9, P3289; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	46	569	619	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					554	559		10.1038/8432	http://dx.doi.org/10.1038/8432			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229233				2022-12-25	WOS:000081497400037
J	Summerford, C; Samulski, RJ				Summerford, C; Samulski, RJ			Viral receptors and vector purification: New approaches for generating clinical-grade reagents	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS		Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Samulski, RJ (corresponding author), Univ N Carolina, Gene Therapy Ctr, 7119 Thurston Bowles,CB 7352, Chapel Hill, NC 27599 USA.							CLARK KR, 1995, HUM GENE THER, V6, P1329, DOI 10.1089/hum.1995.6.10-1329; CLARK KR, IN PRESS HUM GENE TH; Friedmann T., 1999, DEV HUMAN GENE THERA, P1; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Wistuba A, 1997, J VIROL, V71, P1341, DOI 10.1128/JVI.71.2.1341-1352.1997; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; ZOLOTUKHIN S, IN PRESS GENE THER; 1998, WILL BIOPR FDN M VIR	11	47	55	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					587	588		10.1038/8470	http://dx.doi.org/10.1038/8470			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229239				2022-12-25	WOS:000081497400043
J	Edelmann, W; Cohen, PE; Kneitz, B; Winand, N; Lia, M; Heyer, J; Kolodner, R; Pollard, JW; Kucherlapati, R				Edelmann, W; Cohen, PE; Kneitz, B; Winand, N; Lia, M; Heyer, J; Kolodner, R; Pollard, JW; Kucherlapati, R			Mammalian MutS homologue 5 is required for chromosome pairing in meiosis	NATURE GENETICS			English	Article							DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; CROSSING-OVER; GENE; MUTATION; MICE; MSH2; RECOMBINATION; ASSOCIATION	MSH5 (MutS homologue 5) is a member of a family of proteins known to be involved in DNA mismatch repair(1,2). Germline mutations in MSH2, MLH1 and GTBP (also known as MSH6) cause hereditary non-polyposis colon cancer (HNPCC) or Lynch syndrome(3-8). Inactivation of Msh2, Mlh1, Gtmbp (also known as Msh6) or Pms2 in mice leads to hereditary predisposition to intestinal and other cancers(9-14). Early studies in yeast revealed a role for some of these proteins, including Msh5, in meiosis(15-17). Gene targeting studies in mice confirmed roles for Mlh1 and Pms2 in mammalian meiosis(12-14,18). To assess the role of Msh5 in mammals, we generated and characterized mice with a null mutation in Msh5 Msh5(-/-) mice are viable but sterile. Meiosis in these mice is affected due to the disruption of chromosome pairing in prophase I. We found that this meiotic failure leads to a diminution in testicular size and a complete loss of ovarian structures, Our results show that normal Msh5 function is essential for meiotic progression and, in females, gonadal maintenance.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Dana-Farber Cancer Institute	Edelmann, W (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kucherlapati, Raju/ABC-8807-2021		NCI NIH HHS [CA 76329, N01-CN-65031, CA 67944] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN065031] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA076329, R01CA067944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COUNCE SJ, 1973, CHROMOSOMA, V44, P231, DOI 10.1007/BF00329119; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MCDONOUGH PG, 1972, PEDIATR CLIN N AM, V19, P631; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moens PB, 1998, CURR TOP DEV BIOL, V37, P241; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Plug AW, 1998, J CELL SCI, V111, P413; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SINGH RP, 1966, ANAT REC, V155, P369, DOI 10.1002/ar.1091550309; Spyropoulos B, 1994, Methods Mol Biol, V33, P131; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	30	294	301	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					123	127		10.1038/5075	http://dx.doi.org/10.1038/5075			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916805				2022-12-25	WOS:000077960700023
J	Levi, M; Friederich, PW; Middleton, S; de Groot, PG; Wu, YP; Harris, R; Biemond, BJ; Heijnen, HFG; Levin, J; ten Cate, JW				Levi, M; Friederich, PW; Middleton, S; de Groot, PG; Wu, YP; Harris, R; Biemond, BJ; Heijnen, HFG; Levin, J; ten Cate, JW			Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits	NATURE MEDICINE			English	Article							VESSEL WALL; INHIBITION; PLASMA; CELLS; TIME	Severe thrombocytopenia frequently occurs in patients receiving chemotherapy and in patients with autoimmune disorders. Thrombocytopenia is associated with bleeding, which may be serious and life threatening(1-3). Current treatment strategies for thrombocytopenia may require transfusion of allogeneic platelets, which is associated with serious drawbacks'. These include the occurrence of anti-platelet antibodies, which may result in refractoriness to further platelet transfusions, and the potential risk of transfer of blood-borne diseases(5,6). Therefore, we have recently developed a platelet substitute product (Synthocytes), which is composed of human albumin microcapsules with fibrinogen immobilized on their surface. Here we show that the intravenous administration of these microcapsules not only corrects the prolonged bleeding time in rabbits rendered thrombocytopenic either by anti-platelet antibodies or by chemotherapy, but also reduces bleeding from surgical wounds inflicted in the abdominal skin and musculature. No potential systemic prothrombotic effect of the microcapsules was observed in a model of rabbit venous thrombosis. As for the mechanism of action, experiments with normal and thrombocytopenic human blood in an endothelial cell matrix-coated perfusion chamber demonstrated an interaction between the fibrinogen-coated albumin microcapsules and native platelets. It was shown that the fibrinogen-coated albumin microcapsules could facilitate platelet adhesion to endothelial cell matrix and correct the impaired formation of platelet aggregates in relatively platelet-poor blood. This study indicates that fibrinogen-coated albumin microcapsules can act to improve primary hemostasis under thrombocytopenic conditions and may eventually be a promising agent for prophylaxis and treatment of bleeding in patients with severe thrombocytopenia.	Univ Amsterdam, Acad Med Ctr, Ctr Hemostasis Thrombosis Atherosclerosis & Infla, NL-1105 AZ Amsterdam, Netherlands; Andaris, Nottingham NG11 6JS, England; Univ Utrecht, Dept Hematol, NL-3508 GA Utrecht, Netherlands; Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94121 USA; VA Med Ctr, San Francisco, CA 94121 USA	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; University of California System; University of California San Francisco	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Hemostasis Thrombosis Atherosclerosis & Infla, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020					BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; BLAJCHMAN MA, 1979, J CLIN INVEST, V63, P1026, DOI 10.1172/JCI109371; BLAJCHMAN MA, 1997, TRANSFUS MED REV, V11, P99; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; EVATT BL, 1979, BLOOD, V54, P377; KUTER DJ, 1995, BLOOD, V85, P2710; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; McFarland J, 1997, NEW ENGL J MED, V337, P1861; *NIH CONS C, 1987, TRANSFUS MED REV, V1, P195; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; RODGERS RPC, 1990, SEMIN THROMB HEMOST, V16, P1, DOI 10.1055/s-2007-1002658; ROY AJ, 1973, TRANSFUSION, V13, P283, DOI 10.1111/j.1537-2995.1973.tb05490.x; SAELMAN EUM, 1993, ARTERIOSCLER THROMB, V13, P1164, DOI 10.1161/01.ATV.13.8.1164; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; SLICHTER SJ, 1995, HEMATOLOGY BASIC PRI, P419; VANBREUGEL HHFI, 1992, BLOOD, V80, P953; YEN RCK, 1995, TRANSFUSION, V35, P415; ZWAGINGA JJ, 1990, ARTERIOSCLEROSIS, V10, P437, DOI 10.1161/01.ATV.10.3.437	18	100	107	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					107	111		10.1038/4795	http://dx.doi.org/10.1038/4795			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883848				2022-12-25	WOS:000077885000038
J	Summerford, C; Bartlett, JS; Samulski, RJ				Summerford, C; Bartlett, JS; Samulski, RJ			alpha V beta 5 integrin: a co-receptor for adeno-associated virus type 2 infection	NATURE MEDICINE			English	Article							GENE-THERAPY; ENTRY; CELLS; ADENOVIRUS-2	Understanding the primary steps of viral entry can have important implications for strategies to prevent infection of known viral pathogens as well as determining parameters for efficient gene delivery using viral vectors. Recently, a two-step process for viral infection involving attachment of virus to a primary receptor (coxsackievirus adenovirus receptor and heparan sulfate proteoglycan) and subsequent mediation of virus entry by a coreceptor (alpha V integrins and HVEM) has been determined for both adenovirus and HSV, respectively(1-4). Heparan sulfate proteoglycan serves as a primary attachment receptor for adenoassociated virus type 2 (AAV-2)(ref. 5). Here we determined that alpha V beta 5 integrin plays a part in efficient AAV infection. Experiments using the chelating agent EDTA to disrupt integrin function resulted in a corresponding decrease in AAV infection, consistent with the possibility that integrin mediates infection. Viral overlay experiments on purified plasma membrane proteins as well as immunoprecipitated integrin beta 5 subunit demonstrated that AAV directly associates with the beta 5 subunit of alpha V beta 5 integrin. Genetically defined cells expressing alpha V beta 5 integrin showed increased susceptibility to AAV infection, demonstrating a biological role of this integrin in AAV infection. Finally, viral binding and internalization studies indicate that alpha V beta 5 integrin is: not a primary attachment receptor for AAV-2, bur is instead involved in facilitating virus internalization. This study supports the idea that alpha V beta 5 integrin serves as a co;receptor for AAV-2 virions, and should have a substantial effect on the use of AAV vectors in human gene therapy.	Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis & Pulm Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Samulski, RJ (corresponding author), Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [NHLBI 539490] Funding Source: Medline; PHS HHS [533016] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARTH A, 1981, DIPEPTIDYL PEPTIDASE, V2, P2; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Croyle MA, 1998, HUM GENE THER, V9, P561, DOI 10.1089/hum.1998.9.4-561; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; FERRARI FK, 1996, J VIROL, V7, P3277; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Gavrilovskaya IN, 1998, P NATL ACAD SCI USA, V95, P7074, DOI 10.1073/pnas.95.12.7074; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Goldman M, 1996, GENE THER, V3, P811; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; Hashimoto Y, 1997, BIOCHEM BIOPH RES CO, V240, P88, DOI 10.1006/bbrc.1997.7534; HENNACHE B, 1977, BIOCHEM J, V166, P237, DOI 10.1042/bj1660237; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; SHEIH M, 1992, J CELL BIOL, V116, P1273; Snyder R, 1996, CURRENT PROTOCOLS HU; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; SVENSSON U, 1984, J VIROL, V51, P687, DOI 10.1128/JVI.51.3.687-694.1984; Takayama K, 1998, GENE THER, V5, P361, DOI 10.1038/sj.gt.3300608; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WICHAM TJ, 1993, CELL, V73, P309; WICHAM TJ, 1994, J CELL BIOL, V127, P257; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998	29	521	564	2	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					78	82		10.1038/4768	http://dx.doi.org/10.1038/4768			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883843				2022-12-25	WOS:000077885000033
J	King, CA; Spellerberg, MB; Zhu, DL; Rice, J; Sahota, SS; Thompsett, AR; Hamblin, TJ; Radl, J; Stevenson, FK				King, CA; Spellerberg, MB; Zhu, DL; Rice, J; Sahota, SS; Thompsett, AR; Hamblin, TJ; Radl, J; Stevenson, FK			DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma	NATURE MEDICINE			English	Article							B-CELL LYMPHOMA; IDIOTYPIC VACCINATION; TUMOR; IMMUNIZATION	Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.	Southampton Univ Hosp Trust, Tenovus Lab, Mol Immunol Grp, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Stevenson, FK (corresponding author), Southampton Univ Hosp Trust, Tenovus Lab, Mol Immunol Grp, Southampton SO16 6YD, Hants, England.			Stevenson, Freda/0000-0002-0933-5021				Anderson R, 1996, INFECT IMMUN, V64, P3168, DOI 10.1128/IAI.64.8.3168-3173.1996; Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; Conry RM, 1996, SEMIN ONCOL, V23, P135; DAVIS HL, 1995, MOL CELL BIOL HUMAN, P368; DYKE RJ, 1991, CELL IMMUNOL, V132, P70, DOI 10.1016/0008-8749(91)90007-X; EISEN HN, 1975, TRANSPLANT P, V7, P209; George A J, 1989, Int Rev Immunol, V4, P271, DOI 10.3109/08830188909044783; Hawkins RE, 1997, HUM GENE THER, V8, P1287, DOI 10.1089/hum.1997.8.10-1287; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; KUMAR A, 1992, J IMMUNOL, V148, P1499; MANNING LS, 1992, BRIT J CANCER, V66, P1088, DOI 10.1038/bjc.1992.415; Rammensee H G, 1993, Chem Immunol, V57, P113; SCHEUERMANN RH, 1995, J EXP MED, V182, P903, DOI 10.1084/jem.182.4.903; Spellerberg MB, 1997, J IMMUNOL, V159, P1885; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Vollmers H. Peter, 1996, Human Antibodies and Hybridomas, V7, P37; WILSON A, 1990, J IMMUNOL, V145, P3973; Zhu D, 1998, IMMUNOLOGY, V93, P162, DOI 10.1046/j.1365-2567.1998.00428.x	22	225	262	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1281	1286		10.1038/3266	http://dx.doi.org/10.1038/3266			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809552				2022-12-25	WOS:000076731000037
J	Pennacchio, LA; Bouley, DM; Higgins, KM; Scott, MP; Noebels, JL; Myers, RM				Pennacchio, LA; Bouley, DM; Higgins, KM; Scott, MP; Noebels, JL; Myers, RM			Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice	NATURE GENETICS			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; TEAR FLUID; CATHEPSIN-B; DISEASE; GENE; MUTATIONS; PROTEOLYSIS; PROTEINS; STORAGE; IDENTIFICATION	Loss-of-function mutations in the gene (CSTB) encoding human cystatin B, a widely expressed cysteine protease inhibitor, are responsible for a severe neurological disorder known as Unverricht-Lundborg disease (EPM1). The primary cellular events and mechanisms underlying the disease are unknown. We found that mice lacking cystatin B develop myoclonic seizures and ataxia, similar to symptoms seen in the human disease. The principal cytopathology appears to be a loss of cerebellar granule cells, which frequently display condensed nuclei, fragmented DNA and other cellular changes characteristic of apoptosis. This mouse model of EPM1 provides evidence that cystatin B, a non-caspase cysteine protease inhibitor, has a role in preventing cerebellar apoptosis.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Baylor College of Medicine; Baylor College of Medicine	Myers, RM (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	myers@shgc.stanford.edu		Pennacchio, Len/0000-0002-8748-3732; Noebels, Jeffrey/0000-0002-2887-0839	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029709] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24064] Funding Source: Medline; NINDS NIH HHS [NS29709] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARKA T, 1991, CURR EYE RES, V10, P25, DOI 10.3109/02713689109007608; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; BINDOFF LA, 1991, J NEUROL SCI, V102, P17, DOI 10.1016/0022-510X(91)90088-O; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CARPENTER S, 1974, NEUROLOGY, V24, P531, DOI 10.1212/WNL.24.6.531; CEJKOVA J, 1989, HISTOCHEMISTRY, V92, P441, DOI 10.1007/BF00492502; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; ELDRIDGE R, 1983, LANCET, V2, P838, DOI 10.1016/s0140-6736(83)90749-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALTIA M, 1969, ACTA NEUROL SCAND, V45, P63; HARRIMAN DGF, 1955, BRAIN, V78, P325, DOI 10.1093/brain/78.3.325; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P333; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P307; KOSKINIEMI M, 1990, PAEDIATRIC EPILEPSY, P137; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KYLLERMAN M, 1991, EPILEPSIA, V32, P900, DOI 10.1111/j.1528-1157.1991.tb05549.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalioti MD, 1997, AM J HUM GENET, V60, P342; Lane SC, 1996, J NEUROCHEM, V67, P677; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARKS N, 1986, ARCH BIOCHEM BIOPHYS, V249, P489, DOI 10.1016/0003-9861(86)90026-3; NORIO R, 1979, CLIN GENET, V15, P382; OBRIEN JS, 1978, CLIN GENET, V14, P55; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pennacchio LA, 1996, GENOME RES, V6, P1103, DOI 10.1101/gr.6.11.1103; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; SALONEN EM, 1987, ACTA OPHTHALMOL, V65, P3; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; SAX DS, 1968, NEUROLOGY, V18, P1093, DOI 10.1212/WNL.18.11.1093; SCHOFFNER JM, 1990, CELL, V61, P931; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; TERVO T, 1989, GRAEF ARCH CLIN EXP, V227, P42, DOI 10.1007/BF02169824; TSUNG PK, 1981, CURR EYE RES, V1, P351, DOI 10.3109/02713688108998361; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; ZEMAN W, 1963, Ann Histochim, V8, P255; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	50	231	237	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					251	258		10.1038/3059	http://dx.doi.org/10.1038/3059			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806543				2022-12-25	WOS:000076698100018
J	Clifton-Bligh, RJ; Wentworth, JM; Heinz, P; Crisp, MS; John, R; Lazarus, JH; Ludgate, M; Chatterjee, VK				Clifton-Bligh, RJ; Wentworth, JM; Heinz, P; Crisp, MS; John, R; Lazarus, JH; Ludgate, M; Chatterjee, VK			Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia	NATURE GENETICS			English	Article							ENHANCER-BINDING PROTEIN; CONGENITAL HYPOTHYROIDISM; IDENTIFICATION; PROMOTER; HORMONE; MOUSE; TRANSCRIPTION; HOMEODOMAIN; PITUITARY; RECEPTOR	Congenital hypothyroidism occurs in one of every three to four thousand newborns, owing to complete or partial failure of thyroid gland development(1). Although thyroid hypoplasia has recently been associated with mutations in the thyrotropin (TSH) receptor(2,3), the cause of thyroid agenesis is unknown. Proteins including thyroid transcription factors 1 (TTF-l; refs 4,5) and 2 (TTF-2; refs 6,7) and Pax8 (refs 8,9) are abundant in the developing mouse thyroid and are known to regulate genes expressed during its differentiation (for example, thyroid peroxidase and thyroglobulin genes). TTF-2 is a member of the forkhead/winged-helix domain transcription factor family, many of which are key regulators of embryogenesis(10). Here we report that the transcription factor FKHL15 (ref. 11) is the human homologue of mouse TTF-2 (encoded by the Titf2 gene) and that two siblings with thyroid agenesis, cleft palate and choanal atresia(12) are homozygous for a missense mutation (Ala65Val) within its forkhead domain. The mutant protein exhibits impaired DNA binding and loss of transcriptional function. Our observations represent the first description of a genetic cause for thyroid agenesis.	Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Neath Gen Hosp, Dept Paediat, Neath SA11 2LQ, Wales; Univ Wales Hosp, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Hosp, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cardiff University; Cardiff University; Cardiff University	Chatterjee, VK (corresponding author), Addenbrookes Hosp, Dept Med, Level 5, Cambridge CB2 2QQ, England.	kkc1@mole.bio.cam.ac.uk	Lazarus, John H/H-5108-2017	Lazarus, John H/0000-0001-8852-704X; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Ludgate, Marian/0000-0002-7436-0821; Wentworth, John/0000-0002-5197-3529; Clifton-Bligh, Roderick/0000-0002-1545-0368	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramowicz MJ, 1997, J CLIN INVEST, V99, P3018, DOI 10.1172/JCI119497; ADAMS M, 1994, J CLIN INVEST, V94, P506, DOI 10.1172/JCI117362; Ahlbom BE, 1997, HUM GENET, V99, P186, DOI 10.1007/s004390050335; AZABLANC P, 1993, MOL ENDOCRINOL, V7, P1297, DOI 10.1210/me.7.10.1297; BAMFORTH JS, 1989, J MED GENET, V26, P49, DOI 10.1136/jmg.26.1.49; Biebermann H, 1997, NEW ENGL J MED, V336, P1390, DOI 10.1056/NEJM199705083361914; Chadwick BP, 1997, GENOMICS, V41, P390, DOI 10.1006/geno.1997.4692; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFELICE M, 1998, NATURE GENET; Devriendt K, 1998, NEW ENGL J MED, V338, P1317, DOI 10.1056/NEJM199804303381817; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GRANT DB, 1992, ARCH DIS CHILD, V67, P87, DOI 10.1136/adc.67.1.87; GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lapi P, 1997, THYROID, V7, P383, DOI 10.1089/thy.1997.7.383; LAZARUS JH, 1988, LANCET, V2, P52; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Perna MG, 1997, THYROID, V7, P377, DOI 10.1089/thy.1997.7.377; PLACHOV D, 1990, DEVELOPMENT, V110, P643; Roberts HE, 1997, AM J MED GENET, V71, P29, DOI 10.1002/(SICI)1096-8628(19970711)71:1<29::AID-AJMG5>3.0.CO;2-L; SAMUELS HH, 1974, J CLIN INVEST, V54, P853, DOI 10.1172/JCI107825; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; WOOD WM, 1989, J BIOL CHEM, V264, P14840; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	29	284	301	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1998	19	4					399	401		10.1038/1294	http://dx.doi.org/10.1038/1294			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697705				2022-12-25	WOS:000075107600027
J	Pitschke, M; Prior, R; Haupt, M; Riesner, D				Pitschke, M; Prior, R; Haupt, M; Riesner, D			Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy	NATURE MEDICINE			English	Article							DISEASE; PEPTIDE; DEMENTIA	Alzheimer's disease is associated with the intraparenchymal growth of plaque-like amyloid deposits(1-3). Amyloid plaques are formed by the progressive deposition and transformation of soluble amyloid beta-protein monomers into insoluble and fibrillar aggregates that contain amyloid beta-protein in a beta-pleated sheet conformation. This process is described as 'seeded polymerization' of the monomers with slow-nucleation and fast-growth kinetics(4). Soluble amyloid beta-protein monomers are present in the cortical extracellular space and in the cerebrospinal fluid(5,6) whereas insoluble aggregates so far can be found only by the examination of brain tissue by biopsy or autopsy. Here we present a biophysical method that uses the principle of seeded polymerization in combination with fluorescence correlation spectroscopy, which allowed us to detect single amyloid beta-peptide aggregates in the cerebrospinal fluid samples from Alzheimer's patients. All of 15 Alzheimer's samples but none of the 19 age-matched control samples produced large peaks with fluorescence correlation spectroscopy indicating the rapid aggregation of the fluorescent labelled synthetic amyloid beta-protein probe onto the amyloid beta-protein 'seeds' present in the cerebrospinal fluid. Our method could enable easy in vivo detection of the cerebral amyloid beta-protein pathology of Alzheimer's disease and might be of potential value to facilitate its routine diagnosis.	Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Neurol Klin, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Psychiat Klin, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Biol Med Forsch Zentrum, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Pitschke, M (corresponding author), Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany.							BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; Brown AM, 1997, J NEUROCHEM, V69, P1204; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; DILLING H, 1994, WHO INT KLASSIFIKATI; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; PRSINER SB, 1997, SCIENCE, V278, P245; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x	19	279	297	2	53	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					832	834		10.1038/nm0798-832	http://dx.doi.org/10.1038/nm0798-832			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662376				2022-12-25	WOS:000074543900039
J	Schultheis, PJ; Clarke, LL; Meneton, P; Miller, ML; Soleimani, M; Gawenis, LR; Riddle, TM; Duffy, JJ; Doetschman, T; Wang, T; Giebisch, G; Aronson, PS; Lorenz, JN; Shull, GE				Schultheis, PJ; Clarke, LL; Meneton, P; Miller, ML; Soleimani, M; Gawenis, LR; Riddle, TM; Duffy, JJ; Doetschman, T; Wang, T; Giebisch, G; Aronson, PS; Lorenz, JN; Shull, GE			Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger	NATURE GENETICS			English	Article							BLOOD-PRESSURE; BRUSH-BORDER; HYPOKALEMIC ALKALOSIS; BARTTERS-SYNDROME; EXPRESSION; MUTATIONS; ISOFORM; COTRANSPORTER; TRANSPORT; MEMBRANE	NHE3 is one of five plasma membrane Na+/H+ exchangers(1-3) and is encoded by the mouse gene Slc9a3. It is expressed on apical membranes of renal proximal tubule(4,5) and intestinal epithelial cells(6,7) and is thought to play a major role in NaCl and HCO3- absorption(4-10). As the distribution of NHE3 overlaps with that of the NHE2 isoform in kidney(7,11) and intestine(7,12,13), the function and relative importance of NHE3 in vivo is unclear. To analyse its physiological functions, we generated mice lacking NHE3 function. Homozygous mutant (Slc9a3(-/-)) mice survive, but they have slight diarrhoea and blood analysis revealed that they are mildly acidotic. HCO3- and fluid absorption are sharply reduced in proximal convoluted tubules, blood pressure is reduced and there is a severe absorptive defect in the intestine. Thus, compensatory mechanisms must limit gross perturbations of electrolyte and acid-base balance. Plasma aldosterone is increased in NHE3-deficient mice, and expression of both renin and the AE1 (Slc4a1) Cl-/HCO3- exchanger mRNAs are induced in kidney. In the colon, epithelial Na+ channel activity is increased and colonic H+.K+-ATPase mRNA is massively induced. These data show that NHE3 is the major absorptive Na+/H+ exchanger in kidney and intestine, and that lack of the exchanger impairs acid-base balance and Na+-fluid volume homeostasis.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Physiol, Cincinnati, OH 45267 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Univ Missouri, Dept Vet Biomed Sci, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Yale University; Yale University; University of Missouri System; University of Missouri Columbia	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		Meneton, Pierre/T-1216-2019; Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDDK NIH HHS [DK48816, R29 DK048816, DK50594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594, R56DK048816, R29DK048816, R01DK048816] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Aronson PS, 1997, AM J PHYSIOL-RENAL, V273, pF179, DOI 10.1152/ajprenal.1997.273.2.F179; Azuma KK, 1996, AM J PHYSIOL-CELL PH, V270, pC585, DOI 10.1152/ajpcell.1996.270.2.C585; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Bookstein C, 1997, AM J PHYSIOL-CELL PH, V273, pC1496, DOI 10.1152/ajpcell.1997.273.5.C1496; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Clarke LL, 1996, AM J PHYSIOL-GASTR L, V270, pG259, DOI 10.1152/ajpgi.1996.270.2.G259; DASILVA JCT, 1991, AM J PHYSIOL, V260, pF204, DOI 10.1152/ajprenal.1991.260.2.F204; Dudeja PK, 1996, AM J PHYSIOL-GASTR L, V271, pG483, DOI 10.1152/ajpgi.1996.271.3.G483; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FELL JM, 1992, J PEDIATR GASTR NUTR, V15, P112, DOI 10.1097/00005176-199208000-00002; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; KAUNITZ JD, 1995, TXB GASTROENTEROLOGY, P326; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POWELL DW, 1995, TXB GASTROENTEROLOGY, P813; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; TSE CM, 1992, J BIOL CHEM, V267, P9340; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG T, 1990, J PHARMACOL EXP THER, V252, P689; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; YUN CHC, 1993, J BIOL CHEM, V268, P206	30	650	660	4	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					282	285		10.1038/969	http://dx.doi.org/10.1038/969			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662405				2022-12-25	WOS:000074565900028
J	Gray, KA; Pogrebinsky, OS; Mrachko, GT; Xi, L; Monticello, DJ; Squires, CH				Gray, KA; Pogrebinsky, OS; Mrachko, GT; Xi, L; Monticello, DJ; Squires, CH			Molecular mechanisms of biocatalytic desulfurization of fossil fuels	NATURE BIOTECHNOLOGY			English	Article						Rhodococcus; biodesulfurization; biocatalysis; dibenzothiophene; monooxygenase; desulfinase; NADH:FMN oxidoreductase; flavin	SP STRAIN IGTS8; RHODOCOCCUS-ERYTHROPOLIS D-1; MICROBIAL DESULFURIZATION; BIOLUMINESCENT BACTERIA; PRISTINAMYCIN-IIB; GENUS RHODOCOCCUS; DIBENZOTHIOPHENE; GENES; OXIDOREDUCTASE; SULFOXIDATION	The development of biocatalytic desulfurization of petroleum fractions may allow its use in place of conventional hydrodesulfurization (HDS). Dibenzothiophene (DBT) is representative of a broad range of sulfur heterocycles found in petroleum that are recalcitrant to desulfurization via HDS. Rhodococcus sp. strain IGTS8 has the ability to convert DBT to 2-hydroxybiphenyl (HBP) with the release of inorganic sulfur. The conversion of DBT to HBP is catalyzed by a multienzyme pathway consisting of two monooxygenases and a desulfinase. The final reaction catalyzed by the desulfinase appears to be the rate limiting step in the pathway. Each of the enzymes has been purified to homogeneity and their kinetic and physical properties studied. Neither monooxygenase has a tightly bound cofactor and each requires an NADH-FMN oxidoreductase for activity. An NADH-FMN oxidoreductase has been purified from Rhodococcos and is a protein of approximately 25,000 molecular weight with no apparent sequence homology to any other protein in the databases. We describe a unique sulfur acquisition system that Rhodococcus uses to obtain sulfur from very stable heterocyclic molecules.			Gray, KA (corresponding author), ENERGY BIOSYST CORP,4200 RES FOREST DR,THE WOODLANDS,TX 77381, USA.							Batie CJ, 2019, CHEM BIOCH FLAVOENZY, P543; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; DENOME SA, 1994, J BACTERIOL, V176, P6707, DOI 10.1128/JB.176.21.6707-6716.1994; DENOME SA, 1993, APPL ENVIRON MICROB, V59, P2837, DOI 10.1128/AEM.59.9.2837-2843.1993; DUGLEBY RG, 1995, METHOD ENZYMOL, V249, P61; FINNERTY WR, 1992, ANNU REV MICROBIOL, V46, P193, DOI 10.1146/annurev.mi.46.100192.001205; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GALLAGHER JR, 1993, FEMS MICROBIOL LETT, V107, P31, DOI 10.1111/j.1574-6968.1993.tb05999.x; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.micro.46.1.565; HASTINGS JW, 1985, ADV MICROB PHYSIOL, V26, P235, DOI 10.1016/S0065-2911(08)60398-7; HOLLAND HL, 1988, CHEM REV, V88, P473, DOI 10.1021/cr00085a002; KEMAL C, 1977, J AM CHEM SOC, V99, P7272, DOI 10.1021/ja00464a030; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; KILBANE JJ, 1992, BIOTECHNOL BIOENG, V40, P1107, DOI 10.1002/bit.260400915; LEE K, 1995, BIOCHEM BIOPH RES CO, V212, P9, DOI 10.1006/bbrc.1995.1928; LI MZ, 1996, IN PRESS J BACTERIOL; LIGHT DR, 1982, BIOCHEMISTRY-US, V21, P2490, DOI 10.1021/bi00539a031; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MASSEY V, 1994, J BIOL CHEM, V269, P22549; MEIGHEN EA, 1988, ANNU REV MICROBIOL, V42, P151, DOI 10.1146/annurev.mi.42.100188.001055; MILES EW, 1967, BIOCHEMISTRY-US, V6, P1734, DOI 10.1021/bi00858a023; MONTICELLO DJ, 1985, ANNU REV MICROBIOL, V39, P371, DOI 10.1146/annurev.mi.39.100185.002103; MONTICELLO DJ, 1993, ENVIRON PROG, V12, P1, DOI 10.1002/ep.670120103; MONTICELLO DJ, 1994, HYDROCARB PROCESS, V2, P39; NELSON WL, 1969, PETROLEUM REFINERY E; OHSHIRO T, 1995, BIOSCI BIOTECH BIOCH, V59, P1349, DOI 10.1271/bbb.59.1349; OHSHIRO T, 1994, FEMS MICROBIOL LETT, V118, P341, DOI 10.1016/0378-1097(94)90526-6; OLSON ES, 1994, PREPRINTS DIV FUEL C, V39, P738; OMORI T, 1992, APPL ENVIRON MICROB, V58, P911, DOI 10.1128/AEM.58.3.911-915.1992; PIDDINGTON CS, 1995, APPL ENVIRON MICROB, V61, P468, DOI 10.1128/AEM.61.2.468-475.1995; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; WARHURST AM, 1994, CRIT REV BIOTECHNOL, V14, P29, DOI 10.1080/0738855031874407; XU Y, 1995, 95 GEN M AM SOC MICR	34	275	309	1	64	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1996	14	13					1705	1709		10.1038/nbt1296-1705	http://dx.doi.org/10.1038/nbt1296-1705			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VX107	9634856				2022-12-25	WOS:A1996VX10700034
J	DelRosario, M; Stephans, JC; Zakel, J; Escobedo, J; Giese, K				DelRosario, M; Stephans, JC; Zakel, J; Escobedo, J; Giese, K			Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription	NATURE BIOTECHNOLOGY			English	Article						HIV-1; Tat protein; transcription-based drug screening	LONG TERMINAL REPEAT; GENE-EXPRESSION; TAT ANTAGONIST; HIV-1; REPLICATION; TYPE-1; PROTEIN; LOOP; TRANSACTIVATION; ELONGATION	We describe a transcription-based assay system to screen for antiviral drugs in vivo, The system consists of two transcription units, a cytomegalovirus promoter driving a reporter gene physically linked to an HIV-1 promoter oriented in the opposite direction. Based on the arrangement of the transcription units, enhanced HIV-1 promoter activity in the presence of the viral transactivating Tat protein downregulates reporter gene expression initiated from the CMV promoter, Inhibitors of HIV-1 transcription relieve the suppression and are identified by an increase in reporter gene expression. This positive selection system allows discrimination between drugs that nonspecifically block cellular functions by cytotoxicity and molecules that specifically repress HIV-1 promoter activity.	CHIRON CORP,CHIRON TECHNOL,EMERYVILLE,CA 94608	Novartis								CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GRAHAM GJ, 1990, P NATL ACAD SCI USA, V87, P5817, DOI 10.1073/pnas.87.15.5817; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; HSU MC, 1993, P NATL ACAD SCI USA, V90, P6395, DOI 10.1073/pnas.90.14.6395; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SARVER N, 1992, AIDS RES HUM RETROV, V8, P659, DOI 10.1089/aid.1992.8.659; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WANG JC, 1991, J BIOL CHEM, V266, P6659; WITVROUW M, 1992, ANTIMICROB AGENTS CH, V36, P2628, DOI 10.1128/AAC.36.12.2628; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	11	12	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1592	1596						5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634828				2022-12-25	WOS:A1996VP83300029
J	Knoppers, BM				Knoppers, BM			Status, sale and patenting of human genetic material: an international survey	NATURE GENETICS			English	Editorial Material							DNA; INNOVATION	Following a decade of debate, the European Directive on the Legal Protection of Biotechnological Inventions(1) was adopted by the European Parliament and the Council of the European Union on July 6, 1998. The Directive constitutes a legal and social policy landmark in biotechnology, taking an explicit position on the contentious issue of the patentability of higher life forms. It fails, however, to provide definitive statements on the legal status of human genetic material or the possibility of personal financial gain in relation to such material. An overview of the international, regional and national positions las found in laws and official policy statements) on the status, commodification and patentability of human genetic material indicates that, although the Directive represents a consolidation of opinions, many issues remain unresolved.	Univ Montreal, Fac Droit, Ctr Droit Rech Droit Publ, Genet & Soc Project, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Knoppers, BM (corresponding author), Univ Montreal, Fac Droit, Ctr Droit Rech Droit Publ, Genet & Soc Project, Montreal, PQ H3C 3J7, Canada.	knoppers@droit.umontreal.ca						*ADV COMM GEN TEST, 1997, CODE PRACT GUID HUM; Baslar K., 1998, CONCEPT COMMON HERIT; Black J, 1998, Mod Law Rev, V61, P621; *COMM HLTH COUNC N, 1989, HER SCI SOC; *COMM OFF SCI TECH, 1995, HUM GEN SCI ITS CONS; *COUNC EUR, 1990, INT DIG HLTH LEGISLA, V41, P461; *COUNC EUR, 1997, INT DIG HLTH LEG, V48, P99; COUNCIL OF EUROPE, 1992, INT DIGEST HLTH LEGI, V43, P284; *DAN COUNC ETH, 1994, PAT HUM GEN REP; Eisenberg RS, 1998, TRENDS GENET, V14, P379, DOI 10.1016/S0168-9525(98)01589-3; *ETH LEG SOC ISS C, 1996, GENOME DIG, V3, P2; *EUR COMM EUR GROU, 1998, ETH ASP HUM TISS BAN; *EUR COMM WORK GRO, 1993, B MED ETHICS, P19; *FIGO COMM STUD ET, 1997, INT DIG HLTH LEG, V48, P447; *GROUP ADV ETH ASP, 1997, INT DIG HLTH LEG, V48, P423; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; *HUGO, 1995, GENOME DIG, V2, P6; *HUGO, 1997, GENOME DIG, V4, P3; *HUM RIGHTS EQ OPP, 1996, 5 HUM RIGHTS EQ OPP; *JAP SOC HUM GEN, 1996, EUBIOS J ASIAN INT B, V6, P137; Juengst ET, 1998, AM J HUM GENET, V63, P673, DOI 10.1086/302032; Knoppers B., 1991, HUMAN DIGNITY GENETI; Knoppers BM, 1998, AM J HUM GENET, V62, P474; Knoppers BM, 1998, GENOMICS, V50, P385, DOI 10.1006/geno.1998.5287; KNOPPERS BM, IN PRESS COMMERCIALI; *LAT AM HUM GEN PR, 1997, INT DIG HLTH LEG, V48, P424; *LAW REF COMM CAN, 1992, 66 LAW REF COMM CAN; Marshall E, 1998, SCIENCE, V282, P654, DOI 10.1126/science.282.5389.654; Merz JF, 1997, MOL DIAGN, V2, P299, DOI 10.1016/S1084-8592(97)80041-0; *MIN SOC AFF, 1993, 25 MIN SOC AFF; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; PHILLIPS JA, 1995, AM J HUM GENET, V57, P1499; Pottage A, 1998, Mod Law Rev, V61, P740, DOI 10.1111/1468-2230.00177; Service RF, 1998, SCIENCE, V282, P397, DOI 10.1126/science.282.5388.397; STERCKX S, 1997, BIOTECHNOLOGY PATENT; *UNESCO INT BIOETH, 1997, UN DECL HUM GEN HUM; *WHO, 1996, CONTR HER DIS; World Health Organization, 1998, PROP INT GUID ETH IS; *WORLD MED ASS DEC, 1993, INT DIG HLTH LEG, V44, P150; 1993, INT DIG HLTH LEG, V44, P362; 1994, INT DIG HLTH LEG, V45, P473	41	32	32	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					23	26		10.1038/8735	http://dx.doi.org/10.1038/8735			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319857				2022-12-25	WOS:000080096300018
J	Plebanski, M; Lee, EAM; Hannan, CM; Flanagan, KL; Gilbert, SC; Gravenor, MB; Hill, AVS				Plebanski, M; Lee, EAM; Hannan, CM; Flanagan, KL; Gilbert, SC; Gravenor, MB; Hill, AVS			Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONISTS; CLASS-I; MALARIA; PROTEIN; COMPLEX; PROLIFERATION; RECOGNITION; PROTECTION; VACCINE	Variation in epitopes of infectious pathogens inhibits various effector functions of T lymphocytes through antagonism of the T-cell receptor. However, a more powerful strategy for immune evasion would be to prevent the induction of T-cell responses. We report here mutual 'interference' with the priming of human T-cell responses by a pair of naturally occurring variants of a malaria cytotoxic T-cell epitope. Interference with priming also occurs in vivo for a murine malaria T-cell epitope. Reshaping of the T-cell repertoire by such immune interference during naive T-cell induction may provide a general mechanism for observed patterns of immunodominance and persistence by many polymorphic pathogens.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Plebanski, M (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England.		Gilbert, Sarah C./H-2857-2019; HILL, Adrian V>S>/C-1306-2008; Plebanski, Magdalena/AAU-3144-2021	Gilbert, Sarah C./0000-0002-6823-9750; , Magdalena/0000-0001-6889-3667; Flanagan, Katie/0000-0002-1575-1953	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; Apostolopoulos V, 1996, VACCINE, V14, P930, DOI 10.1016/0264-410X(95)00258-3; BENJAMIN KV, 1996, J EXP MED, V183, P1311; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; Daniel C, 1998, J IMMUNOL, V160, P3244; DAVENPORT MP, 1995, IMMUNOL TODAY, V16, P432, DOI 10.1016/0167-5699(95)80020-4; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; GUPTA S, 1995, P ROY SOC B-BIOL SCI, V261, P271, DOI 10.1098/rspb.1995.0147; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOLLSBERG P, 1995, P NATL ACAD SCI USA, V92, P4036, DOI 10.1073/pnas.92.9.4036; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KANEKO T, 1997, EUR J IMMUNOL, V27, P1787; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KIENERMAN P, 1995, EUR J IMMUNOL, V25, P1927; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; LANCASTER JS, 1996, NATURE, V363, P156; MOSS PAH, 1993, EUR J IMMUNOL, V23, P1153, DOI 10.1002/eji.1830230526; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4345::AID-IMMU4345&gt;3.0.CO;2-P; Plebanski M, 1997, J IMMUNOL, V158, P2849; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; RUPPERT J, 1995, CHEM IMMUNOL, V60, P61; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0	43	84	87	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					565	571		10.1038/8444	http://dx.doi.org/10.1038/8444			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229235				2022-12-25	WOS:000081497400039
J	Goedert, M; Spillantini, MG; Crowther, RA; Chen, SG; Parchi, P; Tabaton, M; Lanska, DJ; Markesbery, WR; Wilhelmsen, KC; Dickson, DW; Petersen, RB; Gambetti, P				Goedert, M; Spillantini, MG; Crowther, RA; Chen, SG; Parchi, P; Tabaton, M; Lanska, DJ; Markesbery, WR; Wilhelmsen, KC; Dickson, DW; Petersen, RB; Gambetti, P			Tau gene mutation in familial progressive subcortical gliosis	NATURE MEDICINE			English	Article							MULTIPLE SYSTEM TAUOPATHY; PAIRED HELICAL FILAMENTS; FRONTOTEMPORAL DEMENTIA; PROTEIN-TAU; PRESENILE-DEMENTIA; CHROMOSOME-17; ISOFORMS; PARKINSONISM; DISEASE; FTDP-17	Familial forms of frontotemporal dementias are associated with mutations in the tau gene. A kindred affected by progressive subcortical gliosis (PSG), a rare form of presenile dementia, has genetic linkage to chromosome 17q21-22 (refs. 1-3). This kindred (PSG-1) is included in the 'frontotemporal dementias and Parkinsonism linked to chromosome 17' group along with kindreds affected by apparently different forms of atypical dementias(4). Some of these kindreds have mutations in the tau gene(5-10). We report here that PSC-1 has a tau mutation at position +16 of the intron after exon 10. The mutation destabilizes a predicted stem-loop structure and leads to an over-representation of the soluble four-repeat tau isoforms, which assemble into wide, twisted, ribbon-like filaments and ultimately result in abundant neuronal and glial tau pathology. The mutations associated with PSC and other atypical dementias can be subdivided into three groups according to their tau gene locations and effects on tau. The existence of tau mutations with distinct pathogenetic mechanisms may explain the phenotypic heterogeneity of atypical dementias that previously led to their classification into separate disease entities.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Neurol, Cambridge CB2 2PY, England; Case Western Reserve Univ, Div Neuropathol, Cleveland, OH 44106 USA; Univ Genoa, Inst Neurol, I-16132 Genoa, Italy; Vet Affairs Med Ctr, Great Lakes Hlth Care Syst, Tomah, WI 54660 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53792 USA; Univ Kentucky, Dept Neurol & Pathol, Lexington, KY 40536 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Gallo Ctr, San Francisco, CA 94110 USA	MRC Laboratory Molecular Biology; University of Cambridge; Case Western Reserve University; University of Genoa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Wisconsin System; University of Wisconsin Madison; University of Kentucky; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Goedert, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Chen, Shu G./AAK-7301-2021; Chen, Shu G./O-4750-2014; Chen, Shu/Z-2943-2019; Parchi, Piero/L-9833-2015; Petersen, Robert/B-5075-2011	Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; Parchi, Piero/0000-0002-9444-9524; Petersen, Robert/0000-0002-3154-0072; Dickson, Dennis W/0000-0001-7189-7917				ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1990, BIOCHIM BIOPHYS ACTA, V1096, P1, DOI 10.1016/0925-4439(90)90004-9; DICKSON DW, 1998, NEUROSCI INTELL UNIT, V3, P165; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Gambetti P, 1997, NEUROLOGY, V49, P309, DOI 10.1212/WNL.49.1.309-c; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; LANSKA DJ, 1994, NEUROLOGY, V44, P1633, DOI 10.1212/WNL.44.9.1633; NEUMANN MA, 1967, BRAIN, V90, P405, DOI 10.1093/brain/90.2.405; PETERSEN RB, 1995, NEUROLOGY, V45, P1062, DOI 10.1212/WNL.45.6.1062; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737	25	165	171	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					454	457		10.1038/7454	http://dx.doi.org/10.1038/7454			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202939				2022-12-25	WOS:000079574300039
J	Scott, SE; Wilkinson, MJ				Scott, SE; Wilkinson, MJ			Low probability of chloroplast movement from oilseed rape (Brassica napus) into wild Brassica rapa	NATURE BIOTECHNOLOGY			English	Article						transplastomic crops; genetic modification; risk assessment; Brassica napus; chloroplast transformation	TRANSGENIC PLANTS; INHERITANCE; CONTAINMENT; RESISTANCE; PANACEA; DNA	Pollen-mediated movement of transgenes from transplastomic oilseed rape (Brassica napus) into wild relatives will be avoided if chloroplasts are maternally transmitted. We assess the probability of chloroplast exchange between conventional oilseed rape and wild Brassica rapa to model the future behavior of transplastomic cultivars. Primers specific to cpDNA were used to demonstrate maternal inheritance of chloroplasts in 47 natural hybrids between cultivated B. napus and wild B. rapa. We conclude that there will be no or negligible pollen-mediated chloroplast dispersal from oilseed rape. Transgene introgression could still occur in mixed populations, however, if B. napus acted as the recurrent female parent. Rate of transfer would then depend on the abundance of mixed populations, their persistence as mixtures, and hybridization frequency within stands. A low incidence of sympatry (0.6-0.7%) between wild B. rapa and cultivated B. napus along the river Thames, UK, in 1997 and 1998, suggests mixed stands will form only rarely. Eighteen feral populations of B. napus also showed a strong tendency toward rapid decline in plant number, seed return, and ultimately, extinction within 3 years, Conversely, hybrid production is significant in mixed stands, and the absence of control practices means that oilseed rape will have slightly greater persistence. We infer that some introgression from transplastomic B. napus into B. rapa is inevitable in mixed populations even though such populations will occur infrequently and will tend to lose B. napus plants relatively quickly. Chloroplast exchange will be extremely rare and scattered.	Univ Reading, Sch Plant Sci, Dept Agr Bot, Reading RG6 6AS, Berks, England	University of Reading	Wilkinson, MJ (corresponding author), Univ Reading, Sch Plant Sci, Dept Agr Bot, POB 221, Reading RG6 6AS, Berks, England.	M.J.Wilkinson@reading.ac.uk		Wilkinson, Michael/0000-0002-9881-6993				CORRIVEAU JL, 1988, AM J BOT, V75, P1443, DOI 10.2307/2444695; CRAWLEY MJ, 1995, P R SOC LOND B, V259, P45; Cummins JE, 1998, NAT BIOTECHNOL, V16, P401, DOI 10.1038/nbt0598-401b; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Daniell H, 1998, NAT BIOTECHNOL, V16, P602, DOI 10.1038/nbt0798-602; ERICKSON L, 1990, MOL GEN GENET, V222, P135, DOI 10.1007/BF00283034; Gray AJ, 1998, NATURE, V392, P653, DOI 10.1038/33537; JURGENSEN RB, 1998, ACTA HORTIC, V407, P193; Robert S, 1998, NATURE, V395, P25, DOI 10.1038/25628; SCHEFFLER JA, 1994, TRANSGENIC RES, V3, P263, DOI 10.1007/BF01973586; Scott SE, 1998, NATURE, V393, P320, DOI 10.1038/30642; Stewart CN, 1998, NAT BIOTECHNOL, V16, P401, DOI 10.1038/nbt0598-401a; TABERLET P, 1991, PLANT MOL BIOL, V17, P1105, DOI 10.1007/BF00037152; Wilkinson MJ, 1995, PROC BRIGHTON CROP, P1035	14	92	116	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					390	392		10.1038/7952	http://dx.doi.org/10.1038/7952			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207890				2022-12-25	WOS:000079574400030
J	Behrens, A; Sibilia, M; Wagner, EF				Behrens, A; Sibilia, M; Wagner, EF			Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation	NATURE GENETICS			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MICE LACKING; KAINIC ACID; FOS; RECOMBINATION; EXPRESSION; LETHALITY; INDUCTION; ABSENCE	c-Jun is a major component of the heterodimeric transcription factor AP-1 and is essential for embryonic development, as fetuses lacking Jun die at mid-gestation(1,2) with impaired hepatogenesis(1) and primary Jun(-/-) fibroblasts have a severe proliferation defect and undergo premature senescence in vitro(2). c-Jun and AP-1 activities are regulated by E-Jun N-terminal phosphorylation (JNP) at serines 63 and 73 through Jun N-terminal kinases(3,4) (JNKs). INP is thought to be required for the anti-apoptotic function of c-Jun during hepatogenesis, as mice lacking the JNK kinase SEK1 exhibit river defects similar to those seen in Jun(-/-) fetuses(5). To investigate the physiological relevance of JNP, we replaced endogenous Jun by a mutant Jun allele with serines 63 and 73 mutated to alanines (Jun(tm1Wag-); hereafter referred to as JunAA). Here we show that primary JunAA fibroblasts have proliferation- and stress-induced apoptotic defects, accompanied by reduced AP-1 activity. JunAA mice are viable and fertile, smaller than controls and resistant to epileptic seizures and neuronal apoptosis induced by the excitatory amino acid kainate. Primary mutant neurons are also protected from apoptosis and exhibit unaltered JNK activity. Our results provide evidence that JNP is dispensable for mouse development, and identify c-Jun as the essential substrate of INK signalling during kainate-induced neuronal apoptosis.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196; Sibilia, Maria/0000-0001-6129-5613; Behrens, Axel/0000-0002-1557-1143				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Morrison RS, 1996, J NEUROSCI, V16, P1337; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xiang H, 1998, J NEUROSCI, V18, P1363; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	22	576	591	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					326	329		10.1038/6854	http://dx.doi.org/10.1038/6854			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080190				2022-12-25	WOS:000078977900031
J	Redfern, CH; Coward, P; Degtyarev, MY; Lee, EK; Kwa, AT; Hennighausen, L; Bujard, H; Fishman, GI; Conklin, BR				Redfern, CH; Coward, P; Degtyarev, MY; Lee, EK; Kwa, AT; Hennighausen, L; Bujard, H; Fishman, GI; Conklin, BR			Conditional expression and signaling of a specifically designed G(i)-coupled receptor in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						G protein signaling; engineered opioid receptor; synthetic ligand	PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; DILATED CARDIOMYOPATHY; MAMMALIAN-CELLS; GI-ALPHA; HEART; TRANSDUCTION; ACTIVATION; LIGANDS	To control G protein signaling in vivo, we have modified G protein-coupled receptors to respond exclusively to synthetic small molecule agonists and not to their natural agonist(s), These engineered receptors are designated RASSLs (receptor activated solely by a synthetic ligand), A prototype RASSL (Ro1) based on the G(j)-coupled kappa opioid receptor was expressed in transgenic mice under the control of the tetracycline transactivator (tet) system, Activation of Ro1 expressed in the heart decreased heart rate by up to 80%, an expected effect of increased G(j) signaling. Maximal heart rate changes occurred in less than 1 min, demonstrating the speed of this inducible signaling system. This Ro1-mediated slowing of heart rate was also subject to desensitization, which lasted more than 24 h. Both the initial effect on heart rate and the desensitization occurred, even though Ro1 is derived from a human opioid receptor not normally involved in heart rate control. In addition, the tet system was used to induce Ro1 expression in hepatocytes and salivary gland, where G(j) signaling is known to control physiologic events such as proliferation and secretion, These studies demonstrate that a RASSL can be inducibly expressed in several mouse tissues and used in vivo to activate G protein signaling in a controllable fashion.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; NIDDKD, NIH, Bethesda, MD 20982 USA; Univ Heidelberg, Zentrum Mol Biol, D-6900 Heidelberg, Germany; Mt Sinai Sch Med, New York, NY 10029 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Ruprecht Karls University Heidelberg; Icahn School of Medicine at Mount Sinai	Conklin, BR (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.		Conklin, Bruce/E-4738-2019	Hennighausen, Lothar/0000-0001-8319-9841; Conklin, Bruce/0000-0003-1463-6061; Fishman, Glenn/0000-0002-2366-8527	NATIONAL CANCER INSTITUTE [K08CA071779] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71779] Funding Source: Medline; NHLBI NIH HHS [HL60664-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appleyard SM, 1997, J NEUROCHEM, V69, P2405; BOHM M, 1994, J MOL CELL CARDIOL, V26, P133, DOI 10.1006/jmcc.1994.1017; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FU LX, 1992, CARDIOVASC RES, V26, P950, DOI 10.1093/cvr/26.10.950; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; HOLMER SR, 1991, CIRCULATION, V84, P1891, DOI 10.1161/01.CIR.84.5.1891; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LEFKOWITZ R L, 1990, P84; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Newton GE, 1996, J CLIN INVEST, V98, P2756, DOI 10.1172/JCI119101; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Schnabel P, 1996, CELL SIGNAL, V8, P413, DOI 10.1016/S0898-6568(96)00087-3; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	24	146	147	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					165	169		10.1038/6165	http://dx.doi.org/10.1038/6165			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052353				2022-12-25	WOS:000078508300025
J	Matsuura, T; Miyai, K; Trakulnaleamsai, S; Yomo, T; Shima, Y; Miki, S; Yamamoto, K; Urabe, I				Matsuura, T; Miyai, K; Trakulnaleamsai, S; Yomo, T; Shima, Y; Miki, S; Yamamoto, K; Urabe, I			Evolutionary molecular engineering by random elongation mutagenesis	NATURE BIOTECHNOLOGY			English	Article						directed evolution; random mutagenesis; catalase; sequence space; fitness landscape	BACILLUS-STEAROTHERMOPHILUS; DIRECTED EVOLUTION; ESCHERICHIA-COLI; CATALASE-I; PEROXIDASE; PROTEINS; SEQUENCE	We describe a new method of random mutagenesis that employs the addition of peptide tails with random sequences to the C-terminal of enzyme molecules. A mutant population of catalase I from Bacillus stearothermophilus prepared by this method has a diversity in thermostability and enzyme activity equal to that obtained after random point mutagenesis. When a triple mutant of catalase (1108T/D130N/I222T)-the thermostability of which is much lower than that of the wild type-was subjected to random elongation mutagenesis, we generated a mutant population containing only mutants with higher thermostability than the triple mutant. Some had an even higher stability than the wild-type enzyme, whose thermostability is considered to be optimized. These results indicate that peptide addition expands the protein sequence space resulting in a new fitness landscape. The enzyme can then move along the routes of the new landscape until it reaches a new optimum. The combination of random elongation mutagenesis with random point mutagenesis should be a useful approach to the in vitro evolution of proteins with new properties.	Osaka Univ, Grad Sch Engn, Dept Biotechnol, Osaka 5650871, Japan; PRESTO, JST, Form & Funct Project, Osaka 5650871, Japan; Nara Med Univ, Dept Chem, Nara 6340813, Japan	Osaka University; Japan Science & Technology Agency (JST); Nara Medical University	Urabe, I (corresponding author), Osaka Univ, Grad Sch Engn, Dept Biotechnol, 2-1 Yamadaoka, Osaka 5650871, Japan.		matsuura, tomoaki/O-7368-2018; Matsuura, Tomoaki/W-6086-2019	matsuura, tomoaki/0000-0003-1015-6781; Matsuura, Tomoaki/0000-0003-1015-6781				Aita T, 1996, J THEOR BIOL, V182, P469, DOI 10.1006/jtbi.1996.0189; Kobayashi C, 1997, J BIOL CHEM, V272, P23011, DOI 10.1074/jbc.272.37.23011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPRASERT S, 1990, APPL MICROBIOL BIOT, V32, P690, DOI 10.1007/BF00164741; Maniatis T., 1982, MOL CLONING LAB MANU; Matsuura T, 1998, PROTEIN ENG, V11, P789, DOI 10.1093/protein/11.9.789; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; TRAKULNALEAMSAI S, 1995, J FERMENT BIOENG, V79, P107, DOI 10.1016/0922-338X(95)94076-4; TRAKULNALEAMSAI S, 1992, J FERMENT BIOENG, V74, P234, DOI 10.1016/0922-338X(92)90117-D; TRIGGSRAINE BL, 1987, GENE, V52, P121, DOI 10.1016/0378-1119(87)90038-2; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Yomo T, 1997, J THEOR BIOL, V188, P301, DOI 10.1006/jtbi.1997.0474; You L, 1996, PROTEIN ENG, V9, P77, DOI 10.1093/protein/9.1.77; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504	14	69	72	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					58	61		10.1038/5232	http://dx.doi.org/10.1038/5232			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920270				2022-12-25	WOS:000077979500026
J	Nezu, JI; Tamai, I; Oku, A; Ohashi, R; Yabuuchi, H; Hashimoto, N; Nikaido, H; Sai, A; Koizumi, K; Shoji, Y; Takada, G; Matsuishi, T; Yoshino, M; Kato, H; Ohura, T; Tsujimoto, G; Hayakawa, J; Shimane, M; Tsuji, A				Nezu, JI; Tamai, I; Oku, A; Ohashi, R; Yabuuchi, H; Hashimoto, N; Nikaido, H; Sai, A; Koizumi, K; Shoji, Y; Takada, G; Matsuishi, T; Yoshino, M; Kato, H; Ohura, T; Tsujimoto, G; Hayakawa, J; Shimane, M; Tsuji, A			Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter	NATURE GENETICS			English	Article							CARDIOMYOPATHY; CHROMOSOME-11	Primary systemic carnitine deficiency (SCD; OMIM 212140) is an autosomal recessive disorder characterized by progressive cardiomyopathy, skeletal myopathy, hypoglycaemia and hyperammonaemia(1-3), SCD has also been linked to sudden infant death syndrome(4). Membrane-physiological studies have suggested a defect of the carnitine transport system in the plasma membrane in SCD patients(5) and in the mouse model, juvenile visceral steatosis (jvs; ref, 6), Although the responsible loci have been mapped in both human(7) and mouse(8), the underlying gene has not yet been identified. Recently, we cloned and analysed the function of a novel transporter protein termed OCTN2 (ref, 9). Our observation that OCTN2 has the ability to transport carnitine in a sodium-dependent manner prompted us to search for mutations in the gene encoding OCTN2. SLC22A5. initially we analysed the mouse gene and found a missense mutation in Slc22a5 in jvs mice. Biochemical analysis revealed that this mutation abrogates carnitine transport, Subsequent analysis of the human gene identified four mutations in three SCD pedigrees. Affected individuals in one family were homozygous for the deletion of a 113-bp region containing the start codon. In the second pedigree, the affected individual was shown to be a compound heterozygote for two mutations that cause a frameshift and a premature stop codon, respectively. In an affected individual belonging to a third family, we found a homozygous splice-site mutation also resulting in a premature stop codon, These mutations provide the first evidence that loss of OCTN2 function causes SCD.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Fac Med, Inst Expt Anim, Kanazawa, Ishikawa 9208640, Japan; Akita Univ, Sch Med, Dept Hyg, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Pediat, Akita 0108543, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Tohoku Univ, Sch Med, Dept Pediat, Sendai, Miyagi 9808575, Japan; Natl Childrens Med Res Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548509, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Chugai Res Inst Mol Med, Ibaraki, Osaka 3004101, Japan	Kanazawa University; Kanazawa University; Akita University; Akita University; Kurume University; Tohoku University; National Center for Child Health & Development - Japan; Japan Science & Technology Agency (JST)	Tsuji, A (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	tsuji@kenroku.ipc.kanazawa-u.ac.jp	TAMAI, Ikumi/D-8412-2015	Yoshino, Makoto/0000-0001-9048-1490				BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; CHAPOY PR, 1980, NEW ENGL J MED, V303, P1389, DOI 10.1056/NEJM198012113032403; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Hashimoto N, 1998, BIOCHEM PHARMACOL, V55, P1729, DOI 10.1016/S0006-2952(97)00670-9; HORIUCHI M, 1994, BBA-MOL BASIS DIS, V1226, P25, DOI 10.1016/0925-4439(94)90054-X; KARPATI G, 1975, NEUROLOGY, V25, P16, DOI 10.1212/WNL.25.1.16; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MATSUISHI T, 1985, NEUROPEDIATRICS, V16, P6, DOI 10.1055/s-2008-1052536; NIKAIDO H, 1995, MAMM GENOME, V6, P369, DOI 10.1007/BF00364804; Okita K, 1996, GENOMICS, V33, P289, DOI 10.1006/geno.1996.0194; Rinaldo P, 1997, J PEDIATR-US, V131, P304, DOI 10.1016/S0022-3476(97)70171-9; Roe CR, 1995, METABOLIC MOL BASES, P1508; Shoji Y, 1998, AM J HUM GENET, V63, P101, DOI 10.1086/301911; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TRIPP ME, 1981, NEW ENGL J MED, V305, P385, DOI 10.1056/NEJM198108133050707; WABER LJ, 1982, J PEDIATR-US, V101, P700, DOI 10.1016/S0022-3476(82)80294-1; Walter JH, 1996, ARCH DIS CHILD, V74, P475, DOI 10.1136/adc.74.6.475	21	411	432	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					91	94		10.1038/5030	http://dx.doi.org/10.1038/5030			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916797				2022-12-25	WOS:000077960700015
J	Sekine, K; Ohuchi, H; Fujiwara, M; Yamasaki, M; Yoshizawa, T; Sato, T; Yagishita, N; Matsui, D; Koga, Y; Itoh, N; Kato, S				Sekine, K; Ohuchi, H; Fujiwara, M; Yamasaki, M; Yoshizawa, T; Sato, T; Yagishita, N; Matsui, D; Koga, Y; Itoh, N; Kato, S			Fgf10 is essential for limb and lung formation	NATURE GENETICS			English	Article							CHICK LIMB; VERTEBRATE LIMB; GROWTH; MORPHOGENESIS; INVOLVEMENT; EXPRESSION; GENE; INITIATION; INDUCTION; OUTGROWTH	The interactions between fibroblast growth factors (FGF) and their receptors have important roles in mediating mesenchymal-epithelial cell interactions during embryogenesis(1,2). In particular, Fgf10 is predicted to function as a regulator of brain, lung and limb development an the basis of its spatiotemporal expression pattern in the developing embryo. To define the role of Fgf10, we generated Fgf10-deficient mice. Fgf10(-/-) mice died at birth due to the lack of lung development Trachea was formed, but subsequent pulmonary branching morphogenesis was disrupted. In addition, mutant mice had complete truncation of the fore- and hindlimbs. In Fgf10(-/-) embryos, limb bud formation was initiated but outgrowth of the limb buds did not occur; however, formation of the clavicles was not affected. Analysis of the expression of marker genes in the mutant limb buds indicated that the apical ectodermal ridge (AER) and the tone of polarizing activity (ZPA) did not form. Thus, we show here that Fgf10 serves as an essential regulator of lung and limb formation.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genet Biochem, Kyoto 6068501, Japan; Sumitomo Pharmaceut Res Ctr, Osaka 554, Japan; CREST, Japan Sci & Technol Corp, Saitama 332, Japan	University of Tokyo; Kyoto University; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	uskato@hongo.ecc.u-tokyo.ac.jp		Yamasaki, Masahiro/0000-0002-5296-4974; Sekine, Keisuke/0000-0001-5133-0876; Yoshizawa, Tatsuya/0000-0002-5728-1996				Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grieshammer U, 1996, DEVELOPMENT, V122, P3851; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Ohuchi H, 1998, DEVELOPMENT, V125, P51; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUBIN L, 1972, DEV BIOL, V28, P94, DOI 10.1016/0012-1606(72)90129-7; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Vogel A, 1996, DEVELOPMENT, V122, P1737; Xu XL, 1998, DEVELOPMENT, V125, P753; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	30	906	932	0	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					138	141		10.1038/5096	http://dx.doi.org/10.1038/5096			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916808				2022-12-25	WOS:000077960700026
J	Wang, JM; Wilhelmsson, H; Graff, C; Li, H; Oldfors, A; Rustin, P; Bruning, JC; Kahn, CR; Clayton, DA; Barsh, GS; Thoren, P; Larsson, NG				Wang, JM; Wilhelmsson, H; Graff, C; Li, H; Oldfors, A; Rustin, P; Bruning, JC; Kahn, CR; Clayton, DA; Barsh, GS; Thoren, P; Larsson, NG			Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression	NATURE GENETICS			English	Article							KEARNS-SAYRE SYNDROME; SKELETAL-MUSCLE; DEVELOPMENTAL REGULATION; MESSENGER-RNAS; IN-VIVO; DEFICIENCY; DELETIONS; DISEASE; MICE; TRANSCRIPTION	Mutations of mitochondrial DNA (mtDNA) cause several well-recognized human genetic syndromes with deficient oxidative phosphorytation(1-4) and may also have a role in ageing and acquired diseases of old age(5). We report here that hallmarks of mtDNA mutation disorders can be reproduced in the mouse using a conditional mutation strategy tl manipulate the expression of the gene encoding mitochondrial transcription factor A (Tfam, previously named mtTFA), which regulates transcription and replication of mtDNA (refs 6,7). Using a loxP-flanked Tfam allele (Tfam(loxP); ref. 8) in combination with a cre-recombinase transgene under control of the muscle creatinine kinase promoter(9,10), we have disrupted Tfam in heart and muscle. Mutant animals develop a mosaic cardiac-specific progressive respiratory chain deficiency, dilated cardiomyopathy, atrioventricular heart conduction blocks and die at 2-4 weeks of age. This animal model reproduces biochemical, morphological and physiological features of the dilated cardiomyopathy of Kearns-Sayre syndrome(1-4). Furthermore, our findings provide genetic evidence that the respiratory chain is critical for normal heart function.	Karolinska Hosp, Dept Mol Med, Ctr Mol Med L8 02, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden; Sahlgrenska Hosp, Dept Pathol, S-41345 Gothenburg, Sweden; Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, INSERM U393, F-75015 Paris, France; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat & Genet, Stanford, CA 94305 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Stanford University; Karolinska Institutet	Larsson, NG (corresponding author), Karolinska Hosp, Dept Mol Med, Ctr Mol Med L8 02, S-17176 Stockholm, Sweden.	nils-goran.larsson@cmm.ki.se	graff, caroline/A-2545-2009; Larsson, Nils-Göran/GVS-5578-2022; Kahn, Ronald/AAY-2435-2021	Larsson, Nils-Göran/0000-0001-5100-996X; Kahn, Ronald/0000-0002-7583-9228; Graff, Caroline/0000-0002-9949-2951; Oldfors, Anders/0000-0002-5758-7397	NIGMS NIH HHS [R37-GM33088-28] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXENBORG JE, 1993, COMPUT METH PROG BIO, V41, P55, DOI 10.1016/0169-2607(93)90065-S; BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Connor MK, 1996, ARCH BIOCHEM BIOPHYS, V333, P103, DOI 10.1006/abbi.1996.0369; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; GROVE D, 1969, CIRC RES, V25, P473, DOI 10.1161/01.RES.25.4.473; HAKULINEN T, 1987, APPL STAT-J ROY ST C, V36, P309; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Johansson C, 1997, ACTA PHYSIOL SCAND, V160, P133, DOI 10.1046/j.1365-201X.1997.00134.x; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LARSSON NG, 1992, AM J HUM GENET, V51, P1201; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MOORE GW, 1980, AM HEART J, V100, P610, DOI 10.1016/0002-8703(80)90224-0; MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359; MULLERHOCKER J, 1992, HUM PATHOL, V23, P1431, DOI 10.1016/0046-8177(92)90065-B; Munnich A, 1996, EUR J PEDIATR, V155, P262; OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Weber K, 1997, AM J HUM GENET, V60, P373; ZAK R, 1974, CIRC RES, V35, P17	30	300	312	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					133	137		10.1038/5089	http://dx.doi.org/10.1038/5089			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916807				2022-12-25	WOS:000077960700025
J	Herault, Y; Rassoulzadegan, M; Cuzin, F; Duboule, D				Herault, Y; Rassoulzadegan, M; Cuzin, F; Duboule, D			Engineering chromosomes in mice through targeted meiotic recombination (TAMERE)	NATURE GENETICS			English	Article							HOXD COMPLEX; GENES; REGIONS	Functional studies of large transcription units, clustered genes and chromosomal loci require the design of novel experimental toots to engineer genomic macro-rearrangements. Here, we present a strategy to produce deficiencies or duplications by crossing mice carrying loxP sites in homologous loci. This trans-allelic targeted meiotic recombination (TAMERE) protocol allows for the combination of various alleles within a particular locus as well as for generation of interchromosomal unequal exchanges. Novel genetic configurations can thus be produced without multiple targeting and selection steps in embryonic stem (ES) cells. A concomitant deletion/duplication event of the Hoxd12 locus shows the potential of this approach. The high frequency of such targeted exchanges in vivo makes TAMERE a powerful genetic tool applicable to research areas in which complex genomic modifications are required.	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland; Univ Nice, INSERM U470, F-06108 Nice, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Sci 3,Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	Denis.Duboule@zoo.unige.ch	Herault, Yann/B-5500-2012; Rassoulzadegan, Minoo/O-7939-2016	Herault, Yann/0000-0001-7049-6900; duboule, denis/0000-0001-9961-2960				Beckers J, 1998, DEV DYNAM, V213, P1; Davis AP, 1996, DEVELOPMENT, V122, P1175; Dupe V, 1997, DEVELOPMENT, V124, P399; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Herault Y, 1998, DEVELOPMENT, V125, P1669; Kondo T, 1996, DEVELOPMENT, V122, P2651; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; Sharpe J, 1998, EMBO J, V17, P1788, DOI 10.1093/emboj/17.6.1788; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; VIDAL F, IN PRESS MOL REPROD; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	18	132	140	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					381	384		10.1038/3861	http://dx.doi.org/10.1038/3861			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843213				2022-12-25	WOS:000077199600028
J	Hager, J; Dina, C; Francke, S; Dubois, S; Houari, M; Vatin, V; Vaillant, E; Lorentz, N; Basdevant, A; Clement, K; Guy-Grand, B; Froguel, P				Hager, J; Dina, C; Francke, S; Dubois, S; Houari, M; Vatin, V; Vaillant, E; Lorentz, N; Basdevant, A; Clement, K; Guy-Grand, B; Froguel, P			A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10	NATURE GENETICS			English	Article							LEPTIN RECEPTOR GENE; HUMAN OB GENE; QUANTITATIVE TRAIT; MARKERS FLANKING; EXTREME OBESITY; PIMA-INDIANS; LINKAGE; MUTATION; ABSENCE; WEIGHT	Obesity, a common multifactorial disorder, is a major risk factor for type 2 diabetes, hypertension and coronary heart disease(1) (CHD). According to the definition of the World Health Organization (WHO), approximately 6-10% of the population in Westernized countries are considered obese(2). Epidemiological studies have shown that 30-70% of the variation in body weight may be attributable to genetic factors. To date, two genome-wide scans using different obesity-related quantitative traits have provided candidate regions for obesity(3,4). We have undertaken a genome-wide scan in affected sibpairs to identify chromosomal regions linked to obesity in a collection of French families. Model-free multipoint linkage analyses revealed evidence for linkage to a region on chromosome 10p (MLS=4.85). Two further loci on chromosomes 5cen-q and 2p showed suggestive evidence for linkage of serum leptin levels in a genome-wide context. The peak on chromosome 2 coincided with the region containing the gene (POMC) encoding pro-opiome-lanocortin, a locus previously linked to leptin levels and fat mass in a Mexican-American population(3) and shown to be mutated in obese humans(5). Our results suggest that there is a major gene on chromosome 10p implicated in the development of human obesity, and the existence of two further loci influencing leptin levels.	Inst Biol, CNRS EP 10, F-59019 Lille, France; Hop Hotel Dieu, Dept Nutr, Paris, France; Univ Bonn, Inst Klin Biochem, D-5300 Bonn, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Bonn	Froguel, P (corresponding author), Inst Biol, CNRS EP 10, 1 Rue Prof Calmette, F-59019 Lille, France.	jorg.hager@xenope.pasteur.lille.fr; froguel@xenope.pasteur-lille.fr	Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017; Clément, karine/R-1120-2017	Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; 				Chagnon YC, 1998, OBES RES, V6, P76, DOI 10.1002/j.1550-8528.1998.tb00318.x; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; deOnis M, 1996, AM J CLIN NUTR, V64, P650, DOI 10.1093/ajcn/64.4.650; Francke S, 1997, HUM GENET, V100, P491, DOI 10.1007/s004390050540; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Meunier F, 1997, GENET EPIDEMIOL, V14, P1107, DOI 10.1002/(SICI)1098-2272(1997)14:6<1107::AID-GEPI91>3.0.CO;2-K; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; NAGGERT JK, 1995, NAT GENET, V10, P153; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Norman RA, 1996, DIABETES, V45, P1229, DOI 10.2337/diabetes.45.9.1229; Norman RA, 1998, AM J HUM GENET, V62, P659, DOI 10.1086/301758; NORMAN RA, 1995, J CLIN INVEST, V96, P158, DOI 10.1172/JCI118016; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; TIRET L, 1992, GENET EPIDEMIOL, V9, P389, DOI 10.1002/gepi.1370090603; TRAN LD, 1994, SAGE STAT ANAL GENET; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	305	321	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1998	20	3					304	308		10.1038/3123	http://dx.doi.org/10.1038/3123			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806554				2022-12-25	WOS:000076698100029
J	Marton, MJ; DeRisi, JL; Bennett, HA; Iyer, VR; Meyer, MR; Roberts, CJ; Stoughton, R; Burchard, J; Slade, D; Dai, HY; Bassett, DE; Hartwell, LH; Brown, PO; Friend, SH				Marton, MJ; DeRisi, JL; Bennett, HA; Iyer, VR; Meyer, MR; Roberts, CJ; Stoughton, R; Burchard, J; Slade, D; Dai, HY; Bassett, DE; Hartwell, LH; Brown, PO; Friend, SH			Drug target validation and identification of secondary drug target effects using DNA microarrays	NATURE MEDICINE			English	Article							GENE-EXPRESSION PATTERNS; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; YEAST; CALCINEURIN; HYBRIDIZATION; PHOSPHATASE; BINDING	We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs.	Rosetta Inpharmat, Kirkland, WA 98034 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Merck & Company; Howard Hughes Medical Institute; Stanford University; Fred Hutchinson Cancer Center	Friend, SH (corresponding author), Rosetta Inpharmat, 12040 115th Ave NE, Kirkland, WA 98034 USA.	sfriend@rosetta.org		Bassett, Douglas/0000-0002-1619-4618				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Brachmann CB, 1998, YEAST, V14, P115; BULMER MG, 1979, PRINCIPLES STAT, P224; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SIKORSKI RS, 1989, GENETICS, V122, P19; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437	35	511	577	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1293	1301		10.1038/3282	http://dx.doi.org/10.1038/3282			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809554				2022-12-25	WOS:000076731000039
J	Majumdar, A; Khorlin, A; Dyatkina, N; Lin, FLM; Powell, J; Liu, J; Feiz, ZZ; Khripine, Y; Watanabe, KA; George, J; Glazer, PM; Seidman, MM				Majumdar, A; Khorlin, A; Dyatkina, N; Lin, FLM; Powell, J; Liu, J; Feiz, ZZ; Khripine, Y; Watanabe, KA; George, J; Glazer, PM; Seidman, MM			Targeted gene knockout mediated by triple helix forming oligonucleotides	NATURE GENETICS			English	Article							DOUBLE-STRAND BREAKS; ILLEGITIMATE RECOMBINATION; MAMMALIAN CHROMOSOME; BASE-PAIRS; HPRT GENE; DNA; SEQUENCES; BINDING; RECOGNITION; MUTAGENESIS	Triple helix forming oligonucleotides (TFOs) recognize and bind sequences in duplex DNA and have received considerable attention because of their potential for targeting specific genomic sites(1-3). TFOs can deliver DNA reactive reagents to specific sequences in purified chromosomal DNA (ref. 4) and nuclei(5). However, chromosome targeting in viable cells has not been demonstrated, and in vitro experiments indicate that chromatin structure is incompatible with tripler formation(6-8) We have prepared modified TFOs, linked to the DNA-crosslinking reagent psoralen. directed at a site in the Hprt gene. We show that stable Hprt-deficient clones can be recovered following introduction of the TFOs into viable cells and photoactivation of the psoralen. Analysis of 282 clones indicated that 85% contained mutations in the tripler target region. We observed mainly deletions and some insertions. These data indicate that appropriately constructed TFOs can find chromosomal targets, and suggest that the chromatin structure in the target region is more dynamic than predicted by the in vitro experiments.	NIA, NIH, Baltimore, MD 21224 USA; Codon Pharmaceut, Gaithersburg, MD 20877 USA; Yale Univ, Dept Therapeut Radiol, New Haven, CT 06510 USA; Ribozyme Pharmaceut Inc, Boulder, CO USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Yale University	Seidman, MM (corresponding author), NIA, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560				Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Brown PM, 1996, BIOCHEM J, V319, P607, DOI 10.1042/bj3190607; CARIELLO NF, 1993, J MOL BIOL, V231, P41, DOI 10.1006/jmbi.1993.1255; CARIELLO NF, 1994, MUTAT RES, V312, P173, DOI 10.1016/0165-1161(94)90023-X; CHUBB JM, 1992, TRENDS BIOTECHNOL, V10, P132, DOI 10.1016/0167-7799(92)90195-2; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; Gilar M, 1997, NUCLEIC ACIDS RES, V25, P3615, DOI 10.1093/nar/25.18.3615; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; Korshun VA, 1997, NUCLEOS NUCLEOT NUCL, V16, P1461, DOI 10.1080/07328319708006206; KOSHLAP KM, 1993, J AM CHEM SOC, V115, P7908, DOI 10.1021/ja00070a059; Kukreti S, 1997, NUCLEIC ACIDS RES, V25, P4264, DOI 10.1093/nar/25.21.4264; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; LAQUERBE A, 1995, MUTAT RES LETT, V346, P173, DOI 10.1016/0165-7992(95)90050-0; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; Neidle S, 1997, ANTI-CANCER DRUG DES, V12, P433; ORSON FM, 1994, NUCLEIC ACIDS RES, V22, P479, DOI 10.1093/nar/22.3.479; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; POSVIC TJ, 1989, J AM CHEM SOC, V111, P3059; ROSSITER BJF, 1991, GENOMICS, V9, P247, DOI 10.1016/0888-7543(91)90249-E; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schneider TD, 1997, NUCLEIC ACIDS RES, V25, P4408, DOI 10.1093/nar/25.21.4408; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; THACKER J, 1992, NUCLEIC ACIDS RES, V20, P6183, DOI 10.1093/nar/20.23.6183; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WESTIN L, 1995, NUCLEIC ACIDS RES, V23, P2184, DOI 10.1093/nar/23.12.2184	30	154	175	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					212	214		10.1038/2530	http://dx.doi.org/10.1038/2530			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771719				2022-12-25	WOS:000076231300028
J	Komanduri, KV; Viswanathan, MN; Wieder, ED; Schmidt, DK; Bredt, BM; Jacobson, MA; McCune, JM				Komanduri, KV; Viswanathan, MN; Wieder, ED; Schmidt, DK; Bredt, BM; Jacobson, MA; McCune, JM			Restoration of cytomegalovirus-specific CD4(+) T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; CELL CLONES	Recent studies of subjects infected with human immunodeficiency virus (HIV-1) have produced conflicting results about the extent of reconstitution possible in the CD4(+) lymphocyte repertoire after highly active antiretroviral therapy(1-3) (HAART). The effect of HAART on the incidence of opportunistic infections will probably depend on reconstitution of antigen-specific CD4(+) lymphocyte responses to important pathogens, including cytomegalovirus (CMV), the leading cause of blindness in AIDS(4-6) Several studies have demonstrated an important role for CD4(+) lymphocytes in controlling CMV replication in vitro and in clinical studies(7-13). It is now possible to quantitate antigen-specific CD4+ lymphocyte responses by flow cytometry(14). Using this method, we studied CMV-specific CD4(+) lymphocyte responses in individuals infected with HIV-1 with and without a history of active CMV-associated end organ disease (EOD), and in those with quiescent CMV EOD after ganciclovir therapy and HAART. The presence of active CMV-associated EOD strongly correlated with loss of CMV-specific lymphocyte responses (P = 0.0004). In contrast, patients with no history of CMV-associated EOD and most patients with quiescent EOD after HAART demonstrated strong CMV-specific CD4(+) lymphocyte responses. These data indicate that the loss of CMV-specific CD4(+) lymphocyte responses in individuals infected with HIV-1 who have active CMV EOD may be restored after ganciclovir therapy and HAART, which provides evidence for functional immune reconstitution to an important pathogen.	Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Gen Clin Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	McCune, JM (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.		Komanduri, Krishna V./G-6012-2011	Komanduri, Krishna V./0000-0003-3715-5236	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040312] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI2763, R01 AI40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALP NJ, 1991, J VIROL, V65, P4812, DOI 10.1128/JVI.65.9.4812-4820.1991; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BALTIMORE D, 1995, CELL, V82, P175, DOI 10.1016/0092-8674(95)90303-8; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CUNNINGHAM ET, 1998, DUANES FUNDAMENTALS, V2, P1; Davignon JL, 1996, J VIROL, V70, P2162, DOI 10.1128/JVI.70.4.2162-2169.1996; Gerard L, 1997, CLIN INFECT DIS, V24, P836, DOI 10.1093/clinids/24.5.836; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HOLLAND GN, 1982, AM J OPHTHALMOL, V93, P393, DOI 10.1016/0002-9394(82)90127-1; IHARA T, 1994, LEUKEMIA RES, V18, P485, DOI 10.1016/0145-2126(94)90086-8; Jacobson MA, 1997, NEW ENGL J MED, V337, P105, DOI 10.1056/NEJM199707103370207; Krause H, 1997, BONE MARROW TRANSPL, V19, P1111, DOI 10.1038/sj.bmt.1700801; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; SABBAJ S, 1992, J CLIN IMMUNOL, V12, P216, DOI 10.1007/BF00918092; SCHRIER RD, 1995, J CLIN INVEST, V95, P1741, DOI 10.1172/JCI117851; SCHULZ H, 1993, J SLEEP RES, V2, P1, DOI 10.1111/j.1365-2869.1993.tb00051.x; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603	20	327	334	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					953	956		10.1038/nm0898-953	http://dx.doi.org/10.1038/nm0898-953			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701250				2022-12-25	WOS:000075107400041
J	Lewin, AS; Drenser, KA; Hauswirth, WW; Nishikawa, S; Yasumura, D; Flannery, JG; LaVail, MM				Lewin, AS; Drenser, KA; Hauswirth, WW; Nishikawa, S; Yasumura, D; Flannery, JG; LaVail, MM			Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa	NATURE MEDICINE			English	Article							INHERITED RETINAL DYSTROPHY; MICE; EXPRESSION; DEGENERATION; EFFICIENT; GENE	Ribozymes, catalytic RNA molecules that cleave a complementary mRNA sequence, have potential as therapeutics for dominantly inherited disease. Twelve percent of American patients with the blinding disease autosomal dominant retinitis pigmentosa (ADRP) carry a substitution of histidine for proline at codon 23 (P23H) in their rhodopsin gene(1), resulting in photoreceptor cell death from the synthesis of the abnormal gene product. Ribozymes can discriminate and catalyze the in vitro destruction of P23H mutant mRNAs from a transgenic rat model of ADRP (ref. 2). Here, we demonstrate that in vivo expression of either a hammerhead or hairpin ribozyme in this rat model considerably slows the rate of photoreceptor degeneration for at least three months. Catalytically inactive control ribozymes had less effect on the retinal degeneration. Intracellular production of ribozymes in photoreceptors was achieved by transduction with a recombinant adeno-associated virus (rAAV) incorporating a rod opsin promoter. Ribozyme-directed cleavage of mutant mRNAs, therefore, may be an effective therapy for ADRP and also may be applicable to other inherited diseases.	Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Gene Therapy Ctr, Gainesville, FL 32610 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, Beckman Vis Ctr, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Vis Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Neurosci, Berkeley, CA 94720 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Lewin, AS (corresponding author), Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.			Flannery, John/0000-0002-0720-8897; Lewin, Alfred/0000-0002-4192-9727				ALTSCHULER M, 1992, GENE, V122, P85, DOI 10.1016/0378-1119(92)90035-N; Bertrand E, 1997, RNA, V3, P75; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; Drenser KA, 1998, INVEST OPHTH VIS SCI, V39, P681; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Hormes R, 1997, NUCLEIC ACIDS RES, V25, P769, DOI 10.1093/nar/25.4.769; HUANG PC, 1993, P NATL ACAD SCI USA, V90, P8484, DOI 10.1073/pnas.90.18.8484; LAVAIL MM, 1975, EXP EYE RES, V21, P167, DOI 10.1016/0014-4835(75)90080-9; LHuillier PJ, 1996, P NATL ACAD SCI USA, V93, P6698, DOI 10.1073/pnas.93.13.6698; Lieber A, 1996, J VIROL, V70, P3153, DOI 10.1128/JVI.70.5.3153-3158.1996; MICHON JJ, 1991, INVEST OPHTH VIS SCI, V32, P280; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027; ROSENFELD PJ, 1995, MOL GENETICS OCULAR, V1, P99; Rossi JJ, 1997, CIBA F SYMP, V209, P195; Steinberg R. H., 1996, Investigative Ophthalmology and Visual Science, V37, pS698; WEN R, 1995, J NEUROSCI, V15, P7377; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	22	332	356	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					967	971		10.1038/nm0898-967	http://dx.doi.org/10.1038/nm0898-967			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701253				2022-12-25	WOS:000075107400044
J	Capson, TL; Coley, PD; Kursar, TA				Capson, TL; Coley, PD; Kursar, TA			A new paradigm for drug discovery in tropical rainforests	NATURE BIOTECHNOLOGY			English	Editorial Material							BRINE SHRIMP; PLANTS		SMITHSONIAN TROP RES INST, BALBOA, PANAMA	Smithsonian Institution; Smithsonian Tropical Research Institute	Capson, TL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							Balick M. J., 1996, MED RESOURCES TROPIC; CLARK AM, 1993, ACS SYM SER, V534, P228; Coley P.D., 1991, PLANT ANIMAL INTERAC, P25; COLEY PD, 1996, IN PRESS ANN REV ECO, V27; Coley Phyllis D., 1996, P305; GENTRY AH, 1993, ACS SYM SER, V534, P13; LEVIN DA, 1976, AM NAT, V110, P261, DOI 10.1086/283063; MCLAUGHLIN JL, 1993, ACS SYM SER, V534, P112; Reid W.V., 1996, MED RESOURCES TROPIC, P142; SOLIS PN, 1993, PLANTA MED, V59, P250, DOI 10.1055/s-2006-959661	10	8	8	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1200	+		10.1038/nbt1096-1200	http://dx.doi.org/10.1038/nbt1096-1200			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631071				2022-12-25	WOS:A1996VK61800002
J	Pitcher, CJ; Quittner, C; Peterson, DM; Connors, M; Koup, RA; Maino, VC; Picker, LJ				Pitcher, CJ; Quittner, C; Peterson, DM; Connors, M; Koup, RA; Maino, VC; Picker, LJ			HIV-1-specific CD4(+) T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; BONE-MARROW; RESPONSES; LYMPHOCYTES; RECONSTITUTION; ACTIVATION; MICE; TRANSPLANTATION; CYTOMEGALOVIRUS	The role of HIV-1-specific CD4(+) T-cell responses in controlling HIV-1 infection remains unclear. Previous work has suggested that such cells are eliminated in the early stages of infection in most subjects, and thus cannot substantially contribute to host defense against HIV-l. Here, using flow cytometric detection of antigen-induced intracellular cytokines, we show that significant frequencies of gag specific, T-helper-l CD4(+) memory T cells are detectable in most subjects with active/progressive HIV-1 infection (median frequency, 0.12% of memory subset; range, 0-0.66%). Median frequencies of these cells were considerably higher in nonprogressive HIV-1 disease (0.40%), but there was substantial overlap between the two groups (range of nonprogressors, 0.10-1.7%). Continuous HIV-1 suppression with anti-retroviral therapy was associated with a time-dependent reduction in median frequencies of gag-specific CD4(+) memory T cells: 0.08% in subjects treated for 4-24 weeks, and 0.03% in subjects treated for 47-112 weeks. Thus, functional HIV-1-specific CD4(+) T cells are commonly available for support of anti-HIV-l effector responses in active disease, but their decline with anti-retroviral therapy indicates that immunologic participation in long-term HIV-1 control will probably require effective vaccination strategies.	Univ Texas, SW Med Ctr, Dept Pathol, Div Hematopathol & Immunol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Gen Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75235 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Becton Dickinson Immunocytometry Syst, San Jose, CA 95131 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Becton Dickinson	Pitcher, CJ (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Div Hematopathol & Immunol, Dallas, TX 75235 USA.				NIAID NIH HHS [AI31545, AI35522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031545, ZIAAI000855, Z01AI000855, R01AI035522, R01AI031545, R37AI035522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030-199811000-00004; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CALLAHAN KM, 1990, J IMMUNOL, V144, P3341; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Clerici M, 1996, AIDS, V10, P603, DOI 10.1097/00002030-199606000-00005; Collins RH, 1997, EXP HEMATOL, V25, P147; Cottrez F, 1997, J CLIN INVEST, V99, P257, DOI 10.1172/JCI119154; Ferbas J, 1998, AIDS RES HUM RETROV, V14, pS153; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Harcourt GC, 1998, J EXP MED, V188, P1785, DOI 10.1084/jem.188.10.1785; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Johnson R P, 1998, AIDS, V12 Suppl A, pS113; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Moss RB, 1998, AIDS RES HUM RETROV, V14, pS167; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Romieu R, 1998, INT IMMUNOL, V10, P1273, DOI 10.1093/intimm/10.9.1273; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenberg ES, 1998, AIDS RES HUM RETROV, V14, pS143; SCHWARTZ D, 1994, AIDS RES HUM RETROV, V10, P1703, DOI 10.1089/aid.1994.10.1703; Steinman R M, 1998, AIDS, V12 Suppl A, pS97; Valentine FT, 1998, AIDS RES HUM RETROV, V14, pS161; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Waldrop SL, 1998, J IMMUNOL, V161, P5284; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	34	657	668	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					518	525		10.1038/8400	http://dx.doi.org/10.1038/8400			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229228				2022-12-25	WOS:000081497400032
J	Weissleder, R; Tung, CH; Mahmood, U; Bogdanov, A				Weissleder, R; Tung, CH; Mahmood, U; Bogdanov, A			In vivo imaging of tumors with protease-activated near-infrared fluorescent probes	NATURE BIOTECHNOLOGY			English	Article						optical imaging; tumor targeting; proteases	MATRIX METALLOPROTEINASE INHIBITORS; CATHEPSIN-B; SERINE PROTEASES; BREAST-CANCER; EXPRESSION; PROGRESSION; DELIVERY; MMP-9; DERIVATIVES; MEDICINE	We have developed a method to image tumor-associated lysosomal protease activity in a xenograft mouse model in vivo using autoquenched near-infrared fluorescence (NIRF) probes. NIRF probes were bound to a long circulating graft copolymer consisting of poly-L-lysine and methoxypolyethylene glycol succinate. Following intravenous injection, the NIRF probe carrier accumulated in solid tumors due to its long circulation time and leakage through tumor neovasculature. Intratumoral NIRF signal was generated by lysosomal proteases in tumor cells that cleave the macromolecule, thereby releasing previously quenched fluorochrome. In vivo imaging showed a 12-fold increase in NIRF signal, allowing the detection of tumors with submillimeter-sized diameters. This strategy can be used to detect such early stage tumors in vivo and to probe for specific enzyme activity.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Weissleder, R (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02114 USA.	weissleder@helix.mgh.harvard.edu	Bogdanov, Alexei A/K-4946-2017; Tung, Ching-Hsuan/AIE-6009-2022; Tung, Ching-Hsuan/AHC-5070-2022	Bogdanov, Alexei A/0000-0003-4806-5869; Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; Mahmood, Umar/0000-0001-7414-6123; /0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [R01CA074424] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74424-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfano RR, 1997, ANN NY ACAD SCI, V820, P248, DOI 10.1111/j.1749-6632.1997.tb46200.x; Alfano RR, 1998, ANN NY ACAD SCI, V838, P14, DOI 10.1111/j.1749-6632.1998.tb08184.x; Anderson RT, 1997, EPIDEMIOLOGY, V8, P42, DOI 10.1097/00001648-199701000-00007; BARRETT AJ, 1981, ACTA BIOL MED GER, V40, P1513; Baum RP, 1998, Q J NUCL MED, V42, P33; Benaron DA, 1997, SCIENCE, V276, P2002, DOI 10.1126/science.276.5321.2002; Benaron DA, 1997, PHILOS T ROY SOC B, V352, P755, DOI 10.1098/rstb.1997.0059; Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; BOGDANOV A, 1995, ADV DRUG DELIVER REV, V16, P335, DOI 10.1016/0169-409X(95)00034-5; Bogdanov AA, 1996, BIOCONJUGATE CHEM, V7, P144, DOI 10.1021/bc950089b; Buchsbaum DJ, 1997, CANCER, V80, P2371, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2371::AID-CNCR6>3.3.CO;2-A; Callahan RJ, 1998, AM J ROENTGENOL, V171, P137, DOI 10.2214/ajr.171.1.9648777; Denis LJ, 1997, INVEST NEW DRUG, V15, P175, DOI 10.1023/A:1005855905442; Dessureault S, 1997, BREAST CANCER RES TR, V45, P29, DOI 10.1023/A:1005878113826; DeVita VT, 1997, CANC PRINCIPLES PRAC; ELSHIRBINY AM, 1994, ADV CLIN CHEM, V31, P99, DOI 10.1016/S0065-2423(08)60334-0; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Giavazzi R, 1998, CLIN CANCER RES, V4, P985; Goodwin DA, 1997, CANCER-AM CANCER SOC, V80, P2675; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HASHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1805, DOI 10.1093/oxfordjournals.jbchem.a133155; Hebden JC, 1997, BRIT J RADIOL, V70, pS206, DOI 10.1259/bjr.1997.0026; Hebden JC, 1997, PHYS MED BIOL, V42, P825, DOI 10.1088/0031-9155/42/5/007; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HUDIG D, 1989, MOL IMMUNOL, V26, P793, DOI 10.1016/0161-5890(89)90040-0; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; KENNEDY AR, 1993, PREV MED, V22, P796, DOI 10.1006/pmed.1993.1073; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kopans D B, 1997, Surg Oncol Clin N Am, V6, P233; LETO G, 1992, ANTICANCER RES, V12, P235; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; Manoharan R, 1998, PHOTOCHEM PHOTOBIOL, V67, P15, DOI 10.1562/0031-8655(1998)067<0015:RSAFPM>2.3.CO;2; Marecos E, 1998, BIOCONJUGATE CHEM, V9, P184, DOI 10.1021/bc970146w; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MULDOON LL, 1995, AM J PATHOL, V147, P1840; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; POWERS JC, 1989, J CELL BIOCHEM, V39, P33, DOI 10.1002/jcb.240390105; QUINTART J, 1979, J CELL BIOL, V82, P644, DOI 10.1083/jcb.82.3.644; Rha SY, 1998, ONCOL REP, V5, P875; Roselli M, 1996, J CLIN ONCOL, V14, P2031, DOI 10.1200/JCO.1996.14.7.2031; Rusckowski M, 1997, J PEPT RES, V50, P393; SHAU H, 1985, IMMUNOLOGY, V55, P647; Stocchi L, 1998, DIS COLON RECTUM, V41, P232, DOI 10.1007/BF02238254; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Teates C D, 1993, Curr Probl Diagn Radiol, V22, P229; TSURUGI K, 1980, EUR J BIOCHEM, V109, P9, DOI 10.1111/j.1432-1033.1980.tb04761.x; Villringer A, 1997, ADV EXP MED BIOL, V413, P1; Weissleder R, 1998, EUR J CANCER, V34, P1448, DOI 10.1016/S0959-8049(98)00195-6; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Wu J, 1997, P NATL ACAD SCI USA, V94, P8783, DOI 10.1073/pnas.94.16.8783; YAVELOW J, 1983, CANCER RES, V43, P2454; Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006	55	1339	1462	16	522	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					375	378		10.1038/7933	http://dx.doi.org/10.1038/7933			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207887				2022-12-25	WOS:000079574400027
J	Craft, N; Shostak, Y; Carey, M; Sawyers, CL				Craft, N; Shostak, Y; Carey, M; Sawyers, CL			A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase	NATURE MEDICINE			English	Article							EPIDERMAL GROWTH-FACTOR; ESTROGEN-RECEPTOR; BREAST-CANCER; IN-VIVO; MEDIATED TRANSCRIPTION; UPSTREAM ENHANCER; PROTO-ONCOGENE; CELL-LINES; AMPLIFICATION; ACTIVATION	Prostate cancer progresses from a hormone-sensitive, androgen-dependent stage to a hormone-refractory, androgen-independent tumor. The androgen receptor pathway functions in these androgen-independent tumors despite anti-androgen therapy. In our LAPC-4 prostate cancer model, androgen-independent sublines expressed higher levels of the HER-2/neu receptor tyrosine kinase than their androgen-dependent counterparts. Forced overexpression of HER-2/neu in androgen-dependent prostate cancer cells allowed ligand-independent growth. HER-2/neu activated the androgen receptor pathway in the absence of ligand and synergized with low levels of androgen to 'superactivate' the pathway. By modulating the response to low doses of androgen, a tyrosine kinase receptor can restore androgen receptor function to prostate cancer cells, a finding directly related to the clinical progression of prostate cancer.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Dept Med, 108333 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.		Sawyers, Charles/G-5327-2016	Carey, Michael/0000-0003-3899-6280	NIGMS NIH HHS [GM08042] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADNANE J, 1989, ONCOGENE, V4, P1389; Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; KUHN EJ, 1993, J UROLOGY, V150, P1427, DOI 10.1016/S0022-5347(17)35799-3; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Nagabhushan M, 1996, CANCER RES, V56, P3042; Pang S, 1997, CANCER RES, V57, P495; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; ROMIJN JC, 1988, PROSTATE, V12, P99, DOI 10.1002/pros.2990120112; Ross JS, 1997, CANCER-AM CANCER SOC, V79, P2162, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TALPIN ME, 1995, NEW ENGL J MED, V332, P1393; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; ZEILLINGER R, 1989, ONCOGENE, V4, P109	45	794	836	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					280	285		10.1038/6495	http://dx.doi.org/10.1038/6495			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086382				2022-12-25	WOS:000078851600031
J	Anseth, KS; Shastri, VR; Langer, R				Anseth, KS; Shastri, VR; Langer, R			Photopolymerizable degradable polyanhydrides with osteocompatibility	NATURE BIOTECHNOLOGY			English	Article						degradable networks; bone substitutes; drug delivery	INTRAPERITONEAL BARRIER; PREVENTION; REFORMATION; COMPOSITES; BONE	We have developed a new family of photopolymerizable, methacrylated anhydride monomers and oligomers that combine high strength, controlled degradation, and photoprocessibility in a singular system. Networks with degradation times ranging from 1 week to nearly 1 year and that retain up to 90% of their tensile modulus at 40% mass loss are attainable. In vivo studies in rats have shown that these networks possess excellent osteocompatibility. These combined properties could offer many advantages in medical applications ranging from dentistry to orthopedics.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA	Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder	Langer, R (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.				NIAMS NIH HHS [AR4197] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anseth KS, 1995, ADV POLYM SCI, V122, P177; ANSETH KS, 1995, MACROMOLECULES, V28, P4040, DOI 10.1021/ma00115a045; CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603; DANIELS AU, 1990, J APPL BIOMATER, V1, P57, DOI 10.1002/jab.770010109; Hill J. W., 1932, J AM CHEM SOC, V54, P1569; HILLWEST JL, 1994, OBSTET GYNECOL, V83, P59; KOHN DH, 1992, MAT SCI TECHNOLOGY, V14, P29; MUGGLL S, 1998, IN PRESS J BIOMED MA; STEINLEITNER A, 1991, OBSTET GYNECOL, V77, P48; STEINLEITNER A, 1992, FERTIL STERIL, V57, P305; SVALDI DC, 1998, WILEY POLYM NETWORKS, V1, P161; TORMALA P, 1988, Patent No. 4743257	12	160	184	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					156	159		10.1038/6152	http://dx.doi.org/10.1038/6152			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052351				2022-12-25	WOS:000078508300023
J	Tao, WF; Zhang, S; Turenchalk, GS; Stewart, RA; St John, MAR; Chen, WL; Xu, T				Tao, WF; Zhang, S; Turenchalk, GS; Stewart, RA; St John, MAR; Chen, WL; Xu, T			Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity	NATURE GENETICS			English	Article							PROTEIN-KINASE; GENETIC MOSAICS; CYCLIN-A; ENCODES; CANCER; CELLS; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; TRANSITION	We have previously used mosaic flies to screen for tumour suppressors or negative regulators of cell proliferation(1). The cellular composition of these flies resembles that of cancer patients who are chimaeric individuals carrying a small number of mutated somatic cells. One of the genes we identified is the large tumour suppressor gene, lats (also known as wts), which encodes a putative serine/threonine kinase(1,2). Somatic cells mutant for lats undergo extensive proliferation and form large tumours in many tissues in mosaic adults. Homozygous mutants for various lats alleles display a range of developmental defects including embryonic lethality(1). Although many tumour suppressors have been identified in Drosophila melanogaster(3-7) it is not clear whether these fly genes are directly relevant to tumorigenesis in mammals. Here, we have isolated mammalian homologues of Drosophila lats. Human LATS1 suppresses tumour growth and rescues all developmental defects, including embryonic lethality in flies. In mammalian cells, LATS1 is phosphorylated in a cell-cycle-dependent manner and complexes with CDC2 in early mitosis. LATS1-associated CDC2 has no mitotic cyclin partner and no kinase activity for histone H1. Furthermore, lats mutant cells in Drosophila abnormally accumulate cyclin A. These biochemical observations indicate that LATS is a novel negative regulator of CDC2/cyclin A, a finding supported by genetic data in Drosophila demonstrating that lats specifically interacts with cdc2 and cyclin A.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Biol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Cell Biol, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, 295 Congress Ave, New Haven, CT 06536 USA.	Tian.Xu@yale.edu	Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NCI NIH HHS [R01CA69408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY I, 1994, SURG ONCOL, V3, P153, DOI 10.1016/0960-7404(94)90044-2; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Bryant P.J, 1978, GENETICS BIOL DROSOP; CLEGG NJ, 1993, GENOME, V36, P676, DOI 10.1139/g93-091; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, DNA CLONING PRACTICA, P170; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; MAHONEY PA, 1991, CELL, V67, P583; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; StJohn MAR, 1997, AM J HUM GENET, V61, P1006, DOI 10.1086/301619; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053; ZINZAR SN, 1971, TRANSPLANTATION, V11, P499, DOI 10.1097/00007890-197105000-00015	30	226	245	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					177	181		10.1038/5960	http://dx.doi.org/10.1038/5960			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988268				2022-12-25	WOS:000078399500018
J	Marsh, DJ; Hollopeter, G; Huszar, D; Laufer, R; Yagaloff, KA; Fisher, SL; Burn, P; Palmiter, RD				Marsh, DJ; Hollopeter, G; Huszar, D; Laufer, R; Yagaloff, KA; Fisher, SL; Burn, P; Palmiter, RD			Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides	NATURE GENETICS			English	Article							MOLECULAR-CLONING; LEPTIN DEFICIENCY; OBESITY; GENE; IDENTIFICATION; NEUROPEPTIDE; ANTAGONIST; PROTEIN	Mutations reducing the functional activity of leptin(1,2), the leptin receptor(3,4), alpha-melanocyte stimulating hormone(5) (alpha-MSH) and the melanocortin-4 receptor(6) (Mc4r) all lead to obesity in mammals. Moreover, mutant mice that ectopically express either agouti(7) (Aula mice) or agouti-related protein(8) (Agrp), antagonists of melanocortin signalling(8,9), become obese. These data suggest that alpha-MSH signalling transduced by Mc4r tonically inhibits feeding; however, it is not known to what extent this pathway mediates leptin signalling. We show here that Mc4r-deficient (Mc4r(-/-)) mice do not respond to the anorectic actions of MTII, an MSH-like agonist, suggesting that alpha-MSH inhibits feeding primarily by activating Mc4r. Obese Mc4(-/-) mice do not respond significantly to the inhibitory effects of leptin on feeding, whereas non-obese Mc4r(-/-) mice do. These data demonstrate that melanocortin signalling transduced by Mc4r is not an exclusive target of leptin action and that factors resulting from obesity contribute to leptin resistance. Leptin resistance of obese Mc4r(-/-) mice does not prevent their response to the anorectic actions of ciliary neurotrophic factor (CNTF), corticotropin releasing factor (CRF), or urocortin; or the orexigenic actions of neuropeptide Y (NPY) or peptide YY (PYY), indicating that these neuromodulators act independently or downstream of Mdr signalling.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Millennium Pharmaceut, Cambridge, MA 02139 USA; Ist Ric Biol Mol P Angeletti, IRBM, I-00040 Rome, Italy; Hoffmann La Roche, Dept Metab Dis, Nutley, NJ 07110 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Merck & Company; Roche Holding	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	palmiter@u.washington.edu	Laufer, Ralph/H-9336-2013					Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Costa A, 1997, NEUROREPORT, V8, P1131, DOI 10.1097/00001756-199703240-00014; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HOLLOPETER G, IN PRESS REGUL PEPT; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	437	458	1	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					119	122		10.1038/5070	http://dx.doi.org/10.1038/5070			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916804				2022-12-25	WOS:000077960700022
J	Schierle, GS; Hansson, O; Leist, M; Nicotera, P; Widner, H; Brundin, P				Schierle, GS; Hansson, O; Leist, M; Nicotera, P; Widner, H; Brundin, P			Caspase inhibition reduces apoptosis and increases survival of nigral transplants	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; IN-VIVO; GRAFTS; GROWTH	Transplantation of embryonic nigral tissue ameliorates functional deficiencies in Parkinson disease(1,2). The main practical constraints of neural grafting are the shortage of human donor tissue and the poor survival of dopaminergic neurons grafted into patients, which is estimated at 5-10% (refs. 3,4). The required amount of human tissue could be considerably reduced if the neuronal survival was augmented. Studies in rats indicate that most implanted embryonic neurons die within 1 week of transplantation(5,6), and that most of this cell death is apoptotic(6). Modified peptides, such as acetyl-tyrosinyl-valyl-alanyl-aspartyl-chloro-methylketone (Ac-YVAD-cmk), that specifically inhibit proteases of the caspase family(7) effectively block apoptosis in a plethora of experimental paradigms, such as growth factor withdrawal(8), excitotoxicity(9), axotomy(10), cerebral ischemia(11) and brain trauma(12). Here we examined the effects of caspase inhibition by Ac-YVAD-cmk on cell death immediately after donor tissue preparation and on long-term graft survival. Treatment of the embryonic nigral cell suspension with AcYVAD-cmk mitigated DNA fragmentation and reduced apoptosis in transplants. It also increased survival of dopaminergic neurons grafted to hemiparkinsonian rats, and thereby substantially improved functional recovery.	Univ Lund, Wallenberg Neurosci Ctr, Sect Neuronal Survival, S-22362 Lund, Sweden; Univ Konstanz, Fac Biol, Chair Mol Toxicol, D-78457 Constance, Germany	Lund University; University of Konstanz	Schierle, GS (corresponding author), Univ Lund, Wallenberg Neurosci Ctr, Sect Neuronal Survival, Solvegatan 17, S-22362 Lund, Sweden.	Gabriele.Schierle@mphy.lu.se	Hansson, Oskar/A-7134-2013; Leist, Marcel/D-2133-2010	Hansson, Oskar/0000-0001-8467-7286; Leist, Marcel/0000-0002-3778-8693				Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; deBilbao F, 1996, NEUROREPORT, V7, P3051, DOI 10.1097/00001756-199611250-00051; Duan WM, 1998, EUR J NEUROSCI, V10, P2595, DOI 10.1046/j.1460-9568.1998.t01-1-00279.x; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Karlsson J, 1998, BRAIN RES, V805, P155, DOI 10.1016/S0006-8993(98)00702-1; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; MAHALIK TJ, 1994, EXP NEUROL, V129, P27, DOI 10.1006/exnr.1994.1144; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Rosenblad C, 1996, NEUROSCIENCE, V75, P979; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whiteside G, 1998, BRAIN RES PROTOC, V2, P160, DOI 10.1016/S1385-299X(97)00032-9; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zawada WM, 1998, BRAIN RES, V786, P96, DOI 10.1016/S0006-8993(97)01408-X	24	237	255	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					97	100		10.1038/4785	http://dx.doi.org/10.1038/4785			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883846				2022-12-25	WOS:000077885000036
J	Laken, SJ; Jackson, PE; Kinzler, KW; Vogelstein, B; Strickland, PT; Groopman, JD; Friesen, MD				Laken, SJ; Jackson, PE; Kinzler, KW; Vogelstein, B; Strickland, PT; Groopman, JD; Friesen, MD			Genotyping by mass spectrometric analysis of short DNA fragments	NATURE BIOTECHNOLOGY			English	Article						genomics; single nucleotide polymorphisms; type IIS restriction endonuclease	FAMILIAL ADENOMATOUS POLYPOSIS; POLYMERASE CHAIN-REACTION; GENE-MUTATIONS; BASE EXTENSION; PCR PRODUCTS; POLYMORPHISMS; DIAGNOSIS; APC; CANCER	A method has been developed to produce small DNA fragments from PCR products for analysis of defined DNA variations by mass spectrometry. The genomic region to be analyzed is PCR-amplified with primers containing a sequence for the type IIS restriction endonuclease Bpml. Bpml digestion of the resultant PCR products yields fragments as small as seven bases, which are then analyzed by electrospray ionization mass spectrometry. The approach was validated using seven different variants within the APC tumor suppressor gene, in which a perfect correlation was obtained with DNA sequencing. Both the sense and antisense strands were analyzed independently, and several variants can be analyzed simultaneously. These results provide the basis for a generally applicable and highly accurate method that directly queries the mass of variant DNA sequences.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Baltimore, MD 21218 USA; Int Agcy Res Canc, F-69372 Lyon, France; Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; World Health Organization; International Agency for Research on Cancer (IARC); Howard Hughes Medical Institute	Vogelstein, B (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		/X-4205-2019; Friesen, Marlin D/D-7328-2012	/0000-0003-4690-2133; 	NCI NIH HHS [P30 CA06973] Funding Source: Medline; NIEHS NIH HHS [P30 ES03819, P01 ES06052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, P01ES006052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Apffel A, 1997, ANAL CHEM, V69, P1320, DOI 10.1021/ac960916h; Braun A, 1997, CLIN CHEM, V43, P1151; Braun A, 1997, GENOMICS, V46, P18, DOI 10.1006/geno.1997.5011; CHANG LY, 1995, RAPID COMMUN MASS SP, V9, P772, DOI 10.1002/rcm.1290090910; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Crain PF, 1998, CURR OPIN BIOTECH, V9, P25, DOI 10.1016/S0958-1669(98)80080-3; De Stefano V, 1998, BLOOD, V91, P3562, DOI 10.1182/blood.V91.10.3562.3562_3562_3565; Fei ZD, 1998, NUCLEIC ACIDS RES, V26, P2827, DOI 10.1093/nar/26.11.2827; Griffin TJ, 1997, NAT BIOTECHNOL, V15, P1368, DOI 10.1038/nbt1297-1368; Haff LA, 1997, NUCLEIC ACIDS RES, V25, P3749, DOI 10.1093/nar/25.18.3749; Higgins GS, 1997, BIOTECHNIQUES, V23, P710, DOI 10.2144/97234st05; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LIU YH, 1995, RAPID COMMUN MASS SP, V9, P735, DOI 10.1002/rcm.1290090905; Martinez M, 1998, ARCH NEUROL-CHICAGO, V55, P810, DOI 10.1001/archneur.55.6.810; Miketova P, 1997, MOL BIOTECHNOL, V8, P249, DOI 10.1007/BF02760778; Muddiman DC, 1996, ANAL CHEM, V68, P3705, DOI 10.1021/ac960689j; Naito Y, 1997, J AM SOC MASS SPECTR, V8, P737, DOI 10.1016/S1044-0305(97)00083-4; Nollau P, 1997, CLIN CHEM, V43, P1114; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Riggins GJ, 1997, CANCER RES, V57, P2578; Ross PL, 1997, ANAL CHEM, V69, P3966, DOI 10.1021/ac970312t; Ross PL, 1997, ANAL CHEM, V69, P4197, DOI 10.1021/ac9703966; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tsuneyoshi T, 1997, RAPID COMMUN MASS SP, V11, P719, DOI 10.1002/(SICI)1097-0231(19970422)11:7<719::AID-RCM862>3.0.CO;2-J; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; Wada Y, 1998, J MASS SPECTROM, V33, P187, DOI 10.1002/(SICI)1096-9888(199802)33:2<187::AID-JMS625>3.0.CO;2-A	27	95	136	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1352	1356		10.1038/4333	http://dx.doi.org/10.1038/4333			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853618				2022-12-25	WOS:000077232600029
J	Stabila, PF; Wong, SC; Kaplan, FA; Tao, W				Stabila, PF; Wong, SC; Kaplan, FA; Tao, W			Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors	NATURE BIOTECHNOLOGY			English	Article						applied immunology; antibody design; opsonization; phagocytosis	HUMAN TRANSFERRIN RECEPTOR; COMPLEMENT ACTIVATION; HINGE REGION; MURINE MACROPHAGES; BINDING; SIGNAL; IMMUNOGLOBULINS; ENHANCEMENT; ANTIBODIES; AFFINITY	Antibody-dependent eel-mediated cytotoxicity plays an important role in the macrophage-mediated destruction of target cells. While the selectivity is based on antibody specificity, the lytic attack is triggered by Fc receptor-mediated respiratory burst. To mimic IgG opsonization, a chimeric antibody-like molecule, containing human IgG1 Fc, was expressed on the surface of mammalian cells. The transmembrane domain of the human transferrin receptor was fused in-frame to the N-terminus of the second and third domains of human IgG1 heavy-chain constant region. This fusion molecule was designed to take advantage of the type II membrane anchor property of the transferrin receptor to express the Fc portion of the molecule in a reverse orientation, such that the Fc portion projected away from the cell surface. This is in contrast to the conventional cell surface IgG, which is anchored by a C-terminal type I transmembrane domain. The cell surface expressed reverse Fc no longer activated complement, but retained Fc receptor-binding capability and activated superoxide production by macrophages. This activity was completely blocked by an Fc gamma R I-specific monoclonal antibody.	Cyto Therapeut Inc, Dept Immunol, Lincoln, RI 02865 USA; Cyto Therapeut Inc, Dept Cell & Mol Biol, Lincoln, RI 02865 USA		Tao, W (corresponding author), Cyto Therapeut Inc, Dept Immunol, Lincoln, RI 02865 USA.	WTAO@CYTO.COM						Adams D O, 1979, Adv Exp Med Biol, V121B, P195; ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; BURGER R, 1988, J IMMUNOL, V141, P553; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; DURDEN DL, 1994, EXP CELL RES, V211, P150, DOI 10.1006/excr.1994.1071; Hugl T.E., 1980, LABORATORY RES METHO, P443; HULETT MD, 1994, ADV IMMUNOL, V57, P69; Humphrey J H, 1969, Adv Immunol, V11, P75, DOI 10.1016/S0065-2776(08)60478-2; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JOHNSON WJ, 1986, J IMMUNOL, V136, P4704; JOHNSON WJ, 1985, MECHANISMS CELL MEDI, V2, P75; JOHNSTON PA, 1985, J IMMUNOL, V135, P513; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; LOWRIE DB, 1988, BRIT MED BULL, V44, P624, DOI 10.1093/oxfordjournals.bmb.a072272; MARGULIES DH, 1994, CURRENT PROTOCOLS IM, V1; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MOLLNES TE, 1988, CLIN EXP IMMUNOL, V73, P484; NATHAN CF, 1983, MACROPHAGE MEDIATED, P199; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; SCHNEIDER C, 1985, J CELL SCI, P139; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V15, P5175, DOI 10.1021/bi00668a035; SOMERS SD, 1986, J IMMUNOL, V136, P2323; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; TAO W, 1995, J LEUKOCYTE BIOL, V58, P203, DOI 10.1002/jlb.58.2.203; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	28	14	19	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1357	1360		10.1038/4339	http://dx.doi.org/10.1038/4339			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853619				2022-12-25	WOS:000077232600030
J	Morris, L; Martin, DJ; Quinn, TC; Chaisson, RE				Morris, L; Martin, DJ; Quinn, TC; Chaisson, RE			The importance of doing HIV research in developing countries	NATURE MEDICINE			English	Editorial Material							VIRAL LOAD; VIRUS LOAD; INFECTION; TRANSMISSION; HYDROXYUREA; DIDANOSINE; DISEASES; THERAPY; AFRICA; IMPACT		Natl Inst Virol, AIDS Virus Res Unit, Johannesburg, South Africa; NIAID, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Morris, L (corresponding author), Natl Inst Virol, AIDS Virus Res Unit, Johannesburg, South Africa.		Morris, Lynn/V-3941-2018	Morris, Lynn/0000-0003-3961-7828				Abdool Karim Q, 1997, AIDS, V11 Suppl B, pS143; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Bush CE, 1996, J ACQ IMMUN DEF SYND, V13, P23, DOI 10.1097/00042560-199609000-00004; CONNOR EM, 1994, NEW ENGL J MED, V331, P1171; Coutsoudis A, 1997, J ACQ IMMUN DEF SYND, V15, P86; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; GOLLETTI D, 1996, J IMMUNOL, V157, P1271; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hofmeyr GJ, 1997, BRIT MED J, V315, P199, DOI 10.1136/bmj.315.7102.199; Hogg RS, 1997, LANCET, V350, P1406, DOI 10.1016/S0140-6736(05)65188-4; Lori F, 1997, JAMA-J AM MED ASSOC, V277, P1437, DOI 10.1001/jama.277.18.1437; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Montaner JSG, 1997, J INFECT DIS, V175, P801, DOI 10.1086/513974; MORRIS L, 1998, 5 C RETR OPP INF CHI; Newell ML, 1997, AIDS, V11, pS165; RUTSCHMANN OT, 1998, 5 C RETR OPP INF CHI; SULKOWSKI M, IN PRESS J INFECT DI; VANPRAAG E, 1997, IAS NEWSLETTER, V8, P6; VUTHIPONGSE P, 1998, MMWR-MORBID MORTAL W, V47, P151	20	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1228	1229		10.1038/3206	http://dx.doi.org/10.1038/3206			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809535				2022-12-25	WOS:000076731000020
J	Polyak, K; Li, YB; Zhu, H; Lengauer, C; Willson, JKV; Markowitz, SD; Trush, MA; Kinzler, KW; Vogelstein, B				Polyak, K; Li, YB; Zhu, H; Lengauer, C; Willson, JKV; Markowitz, SD; Trush, MA; Kinzler, KW; Vogelstein, B			Somatic mutations of the mitochondrial genome in human colorectal tumours	NATURE GENETICS			English	Article							DNA; DISEASE; INSTABILITY; CANCER; CELLS; SEGREGATION; SELECTION; NUCLEAR; TUMORS	Alterations of oxidative phosphorylation in tumour cells were originally believed to have a causative role in cancerous growth(1). More recently, mitochondria have again received attention with regards to neoplasia, largely because of their role in apoptosis and other aspects of tumour biology(2-8). The mitochondrial genome is particularly susceptible to mutations because of the high level of reactive oxygen species (ROS) generation in this organelle, coupled with a low level of DNA repair(9-12). However, no detailed analysis of mitochondrial DNA in human tumours has yet been reported. In this study, we analysed the complete mtDNA genome of ten human colorectal cancer cell lines by sequencing and found mutations in seven (70%). The majority of mutations were transitions at purines, consistent with an ROS-related derivation. The mutations were somatic, and those evaluated occurred in the primary tumour from which the cell line was derived. Most of the mutations were homoplasmic, indicating that the mutant genome was dominant at the intracellular and intercellular levels. We showed that mitochondria can rapidly become homogeneous in colorectal cancer cells using cell fusions. These findings provide the first examples of homoplasmic mutations in the mtDNA of tumour cells and have potential implications for the abnormal metabolic and apoptotic processes in cancer.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Div Toxicol Sci, Baltimore, MD 21231 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Case Western Reserve University; Case Western Reserve University	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Howard Hughes Med Inst, Baltimore, MD 21231 USA.	vogelbe@welchlink.welch.jhu.edu			NCI NIH HHS [CA 43460, CA 57345, CA 67409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043460, R01CA067409, R37CA043460, R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMOUR JAL, 1994, HUM MOL GENET, V3, P599, DOI 10.1093/hmg/3.4.599; ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2; AUGENLICHT LH, 1992, J CELL BIOCHEM, P151; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; HEERDT BG, 1994, CANCER RES, V54, P3912; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI Y, 1997, OXYGEN RADICALS DIS, P237; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666; PARSONS R, 1995, CANCER RES, V55, P5548; Rudin CM, 1997, ANNU REV MED, V48, P267; SHAY JW, 1990, ANTICANCER RES, V10, P279; TALLINI G, 1994, CYTOGENET CELL GENET, V66, P253, DOI 10.1159/000133706; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace Douglas C., 1998, Biofactors, V7, P187; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112; YAMAMOTO H, 1992, BIOCHEM BIOPH RES CO, V182, P913, DOI 10.1016/0006-291X(92)91819-C	32	686	732	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1998	20	3					291	293		10.1038/3108	http://dx.doi.org/10.1038/3108			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806551				2022-12-25	WOS:000076698100026
J	Allen, KM; Gleeson, JG; Bagrodia, S; Partington, MW; MacMillan, JC; Cerione, RA; Mulley, JC; Walsh, CA				Allen, KM; Gleeson, JG; Bagrodia, S; Partington, MW; MacMillan, JC; Cerione, RA; Mulley, JC; Walsh, CA			PAK3 mutation in nonsyndromic X-linked mental retardation	NATURE GENETICS			English	Article							P21-ACTIVATED KINASE PAK1; ACTIVATED PROTEIN-KINASE; ADAPTER PROTEIN; FOCAL COMPLEXES; GTPASES; FAMILY; RHO; IDENTIFICATION; LOCALIZATION; CDC42	Nonsyndromic X-linked mental retardation (MRX) syndromes are clinically homogeneous but genetically heterogeneous disorders, whose genetic bases are largely unknown. Affected individuals in a multiplex pedigree with MRX (MRX30), previously mapped to Xq22, show a point mutation in the PAK3 (p21-activated kinase) gene, which encodes a serine-threonine kinase. PAK proteins are crucial effecters linking Rho GTPases to cytoskeletal reorganization and to nuclear signalling. The mutation produces premature termination, disrupting kinase function. MRI analysis showed no gross defects in brain development. Immunofluorescence analysis showed that PAK3 protein is highly expressed in postmitotic neurons of the developing and postnatal cerebral cortex and hippocampus. Signal transduction through Rho GTPases and PAK3 may be critical for human cognitive function.	Harvard Univ, Sch Med, Div Neurogenet, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol Biomed Sci, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Med Ctr, Boston, MA 02115 USA; Cornell Univ, Dept Mol Med, Ithaca, NY USA; Univ Newcastle, Newcastle, NSW 2308, Australia; Royal Brisbane Hosp, Queensland Clin Genet Serv, Brisbane, Qld 4029, Australia; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, Adelaide, SA, Australia	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Cornell University; University of Newcastle; Royal Brisbane & Women's Hospital; Womens & Childrens Hospital Australia	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Div Neurogenet, Beth Israel Deaconess Med Ctr, HIM 846,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cwalsh@bidmc.harvard.edu	MacMillan, John C/C-9591-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001701, R01NS035129] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10691] Funding Source: Medline; NINDS NIH HHS [5K12NS01701, R01 NS 35129] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN K, IN PRESS GENOMICS; Antonarakis SE, 1998, NAT GENET, V19, P106, DOI 10.1038/450; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Donnelly AJ, 1996, AM J MED GENET, V64, P113, DOI 10.1002/(SICI)1096-8628(19960712)64:1<113::AID-AJMG19>3.0.CO;2-Q; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Gedeon AK, 1996, AM J MED GENET, V64, P158, DOI 10.1002/(SICI)1096-8628(19960712)64:1<158::AID-AJMG26>3.3.CO;2-V; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Gregg RG, 1996, HUM MOL GENET, V5, P411, DOI 10.1093/hmg/5.3.411; Gu XX, 1996, J MED GENET, V33, P52, DOI 10.1136/jmg.33.1.52; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Illarioshkin SN, 1996, ANN NEUROL, V40, P75, DOI 10.1002/ana.410400113; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LUO L, 1925, CURR OPIN NEUROBIOL, V7, P8197; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ogilvie D J, 1996, Methods Mol Biol, V54, P131; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Ryan SG, 1997, NAT GENET, V17, P92, DOI 10.1038/ng0997-92; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	36	372	386	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1998	20	1					25	30		10.1038/1675	http://dx.doi.org/10.1038/1675			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731525				2022-12-25	WOS:000075671400013
J	Piccinni, MP; Beloni, L; Livi, C; Maggi, E; Scarselli, G; Romagnani, S				Piccinni, MP; Beloni, L; Livi, C; Maggi, E; Scarselli, G; Romagnani, S			Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions	NATURE MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; HUMAN ENDOMETRIUM; BLASTOCYST IMPLANTATION; TH2-TYPE CYTOKINES; IL-10 PRODUCTION; FETAL ALLOGRAFT; MESSENGER-RNA; FACTOR LIF; IFN-GAMMA; EXPRESSION	Leukemia inhibitory factor is essential for embryo implantation, and a shift from type 1 T-helper to type 2 T-helper response at the fetal-maternal interface may contribute to successful pregnancy. We show that LIF production is associated with type 2 T-helper cells, is upregulated by IL-4 and progesterone and is downregulated by IL-12 IFN-gamma and IFN-alpha. We also show a decreased production of LIF, IL-4 and IL-10 by decidual T cells of women with unexplained recurrent abortions in comparison with that of women with normal gestation. The defective production of LIF and/or type 2 T-helper cytokines may contribute to the development of unexplained recurrent abortions.	Univ Florence, Inst Internal Med Immonoallergol, I-50134 Florence, Italy; Univ Florence, Inst Obstet & Gynecol, I-50134 Florence, Italy	University of Florence; University of Florence	Romagnani, S (corresponding author), Univ Florence, Inst Internal Med Immonoallergol, 85 Viale Morgagni, I-50134 Florence, Italy.	s.romagnani@mednuc2.dfc.unifi.it	Maggi, Enrico/AAA-8045-2019	Maggi, Enrico/0000-0002-1824-3583				ARICI A, 1995, J CLIN ENDOCR METAB, V80, P1908, DOI 10.1210/jc.80.6.1908; BERKOWITZ RS, 1988, AM J OBSTET GYNECOL, V158, P199, DOI 10.1016/0002-9378(88)90810-1; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; CHAOUAT G, 1990, J REPROD FERTIL, V89, P447; CHAOUAT G, 1995, J IMMUNOL, V154, P4261; CHAOUAT G, 1990, EOS-RIV IMMUNOL, V10, P45; CHARNOCKJONES DS, 1994, J REPROD FERTIL, V101, P421; CROY BA, 1991, J REPROD IMMUNOL, V19, P149; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; DELAGE G, 1995, HUM REPROD, V10, P2483; Deneys V, 1997, TRANSPLANT P, V29, P2467, DOI 10.1016/S0041-1345(97)00451-X; HILL JA, 1995, JAMA-J AM MED ASSOC, V273, P1933, DOI 10.1001/jama.273.24.1933; HILL JA, 1991, BIOL REPROD, V44, P69; JOKHI PP, 1994, J IMMUNOL, V153, P4427; KING A, 1995, CYTOKINE, V7, P364, DOI 10.1006/cyto.1995.0046; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; Krishnan L, 1996, J IMMUNOL, V156, P644; Krishnan L, 1996, J IMMUNOL, V156, P653; Laird SM, 1997, HUM REPROD, V12, P569; Lavranos TC, 1995, J REPROD FERTIL, V105, P331, DOI 10.1530/jrf.0.1050331; LIN H, 1993, J IMMUNOL, V151, P4562; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; NICKERSON P, 1994, CURR OPIN IMMUNOL, V6, P757, DOI 10.1016/0952-7915(94)90081-7; Piccinni MP, 1996, IMMUNOL RES, V15, P141, DOI 10.1007/BF02918503; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUTHANTHIRAN M, 1995, J CLIN IMMUNOL, V15, P161, DOI 10.1007/BF01541085; SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3; Vogiagis D, 1996, J ENDOCRINOL, V148, P95, DOI 10.1677/joe.0.1480095; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WHITMIRE D, 1992, PHYS WORLD, V5, P21, DOI 10.1088/2058-7058/5/2/25	33	530	551	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1020	1024		10.1038/2006	http://dx.doi.org/10.1038/2006			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734394				2022-12-25	WOS:000075804100034
J	Rust, S; Walter, M; Funke, H; von Eckardstein, A; Cullen, P; Kroes, HY; Hordijk, R; Geisel, J; Kastelein, J; Molhuizen, HOF; Schreiner, M; Mischke, A; Hashmann, HW; Assmann, G				Rust, S; Walter, M; Funke, H; von Eckardstein, A; Cullen, P; Kroes, HY; Hordijk, R; Geisel, J; Kastelein, J; Molhuizen, HOF; Schreiner, M; Mischke, A; Hashmann, HW; Assmann, G			Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy	NATURE GENETICS			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CARDIOVASCULAR-DISEASE; CELLULAR CHOLESTEROL; GENETIC DISSECTION; COMPLEX TRAITS; LECITHIN; FIBROBLASTS; DEFICIENCY; EFFLUX	A low level of high density lipoprotein (HDL) cholesterol is a strong predictor of ischaemic heart disease (IHD) and myocardial infarction(1-3). One cause of low HDL-cholesterol is Tangier disease (TD), an autosomal codominant inherited condition first described in 1961 in two siblings on Tangier Island in the United States of America(4). Apart from low HDL-cholesterol levels and an increased incidence of atherosclerosis(5), TD is characterized by reduced total cholesterol, raised triglycerides, peripheral neuropathy and accumulation of cholesteryl esters in macrophages, which causes enlargement of the liver, spleen and tonsils(4,6). In contrast to two other monogenic HDL deficiencies in which defects in the plasma proteins apoA-I and LCAT interfere primarily with the formation of HDL (refs 7-10), TD shows a defect in cell signalling and the mobilization of cellular lipids(11-14). The genetic defect in TD is unknown, and identification of the Tangier gene will contribute to the understanding of this intracellular pathway and of HDL metabolism and its link with IHD. We report here the localization of the genetic defect in TD to chromosome 9q31, using a genome-wide graphical linkage exclusion strategy in one pedigree, complemented by classical rod score calculations at this region in a total of three pedigrees (combined lod 10.05 at D9S1784). We also provide evidence that TD may be due to a loss-of-function defect.	Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Munster, Inst Clin Chem, D-48149 Munster, Germany; Univ Munster, Lab Med, D-48149 Munster, Germany; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Saarlandes Kliniken, Klin Chem Zent Labor, D-66421 Homburg, Germany; Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Klin Schwabenland, D-88316 Isny Neutrauchburg, Germany	University of Munster; University of Munster; University of Munster; University of Groningen; Universitatsklinikum des Saarlandes; University of Amsterdam; Academic Medical Center Amsterdam	Rust, S (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Domagkstr 3, D-48149 Munster, Germany.	Rusts@uni-muenster.de	Mischke, Andre/D-3614-2011; Kastelein, John/AAF-7950-2020					ASSMANN G, 1977, J CLIN INVEST, V60, P1025, DOI 10.1172/JCI108853; ASSMANN G, 1986, PROCAM TRIAL; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FREDRICKSON D, 1961, ANN INTERN MED, V55, P1016, DOI 10.7326/0003-4819-55-6-1016; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; FUNKE H, 1991, P NATL ACAD SCI USA, V88, P4855, DOI 10.1073/pnas.88.11.4855; FUNKE H, 1993, J CLIN INVEST, V91, P677, DOI 10.1172/JCI116248; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; KARATHANASIS SK, 1987, P NATL ACAD SCI USA, V84, P7198, DOI 10.1073/pnas.84.20.7198; KROES HY, 1994, J MED GENET, V31, P156, DOI 10.1136/jmg.31.2.156; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; NIKALI K, 1995, AM J HUM GENET, V56, P1088; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; RISCH N, 1991, AM J HUM GENET, V48, P1058; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742	25	57	64	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					96	98		10.1038/1770	http://dx.doi.org/10.1038/1770			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731541				2022-12-25	WOS:000075671400029
J	Hirotsune, S; Fleck, MW; Gambello, MJ; Bix, GJ; Chen, A; Clark, GD; Ledbetter, DH; McBain, CJ; Wynshaw-Boris, A				Hirotsune, S; Fleck, MW; Gambello, MJ; Bix, GJ; Chen, A; Clark, GD; Ledbetter, DH; McBain, CJ; Wynshaw-Boris, A			Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality	NATURE GENETICS			English	Article							PLATELET-ACTIVATING-FACTOR; DIEKER LISSENCEPHALY GENE; CYCLIN-DEPENDENT KINASE-5; CORTICAL DEVELOPMENT; ASPERGILLUS-NIDULANS; CELL-MIGRATION; REELER MICE; BRAIN; PROTEIN; SUBUNIT	Heterozygous mutation or deletion of the beta subunit of platelet-activating factor acetylhydrolase (PAFAH1B1, also known as LIS1) in humans is associated with type I lissencephaly, a severe developmental brain disorder thought to result from abnormal neuronal migration. To further understand the function of PAFAH1B1, we produced three different mutant alleles in mouse Pafah1b1. Homozygous null mice die early in embryogenesis soon after implantation. Mice with one inactive allele display cortical, hippocampal and olfactory bulb disorganization resulting from delayed neuronal migration by a cell-autonomous neuronal pathway.. Mice with further reduction of Pafah1b1 activity display more severe brain disorganization as well as cerebellar defects. Our results demonstrate an essential, dosage-sensitive neuronal-specific role for Pafah1b1 in neuronal migration throughout the brain, and an essential role in early embryonic development. The phenotypes observed are distinct from those of other mouse mutants with neuronal migration defects, suggesting that Pafah1b1 participates in a novel pathway for neuronal migration.	NICHHD, Genet Dis Res Branch, Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Cellular & Mol Neurophysiol, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Baylor Coll Med, Cain Fdn Res Labs, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Cain Fdn Res Labs, Div Neurosci, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Chicago; Baylor College of Medicine; Baylor College of Medicine	Wynshaw-Boris, A (corresponding author), NICHHD, Genet Dis Res Branch, Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA.				NINDS NIH HHS [NS37146] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037146] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; ASOU H, 1992, NEUROSCI LETT, V144, P221, DOI 10.1016/0304-3940(92)90754-U; Barkovich AJ, 1996, NEUROPEDIATRICS, V27, P59, DOI 10.1055/s-2007-973750; Bix GJ, 1998, J NEUROSCI, V18, P307; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CAVINESS VS, 1982, DEV BRAIN RES, V4, P293, DOI 10.1016/0165-3806(82)90141-9; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Clark GD, 1995, NEUROREPORT, V6, P2569, DOI 10.1097/00001756-199512150-00029; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; DOVER R, 1994, HISTOCHEMISTRY, V102, P383, DOI 10.1007/BF00268909; Garrett W.M., 1998, BIOCHEMICA, V1, P17; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1997, GENOME RES, V7, P625, DOI 10.1101/gr.7.6.625; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157; Luna L.G., 1992, HISTOPATHOLOGICAL ME; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; NAGATA I, 1994, INT J DEV NEUROSCI, V12, P387, DOI 10.1016/0736-5748(94)90022-1; ORourke NA, 1996, NEURON, V16, P1061, DOI 10.1016/S0896-6273(00)80130-0; OSHIMA T, 1996, P NATL ACAD SCI USA, V93, P11173; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; REINER O, 1995, J NEUROSCI, V15, P3730; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RELD CB, 1996, PROGR BRAIN RES, P17; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WILLINS DA, 1995, GENETICS, V141, P1287; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297	43	473	481	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					333	339		10.1038/1221	http://dx.doi.org/10.1038/1221			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697693				2022-12-25	WOS:000075107600015
J	Woitach, JT; Zhang, MH; Niu, CH; Thorgeirsson, SS				Woitach, JT; Zhang, MH; Niu, CH; Thorgeirsson, SS			A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability	NATURE GENETICS			English	Article							LIVER EPITHELIAL-CELLS; GENE-PRODUCT; RB GENE; GROWTH FACTOR-BETA-1; TUMOR SUPPRESSOR; CARCINOMA-CELLS; IDENTIFICATION; EXPRESSION	The retinoblastoma (RB) gene is one of the most extensively studied tumour-suppressor genes(1). Deletion or inactivation of both RE alleles is an essential, rate-limiting step in the formation of retinoblastoma and osteosarcoma that arise in families that carry mutant RE (ref. 2). RE inactivation is also found in other human tumours(3-8). Whereas loss of RE function is associated with the loss of cellular proliferative control, introduction of a wild-type RE can suppress cell growth and tumorigenicity(5,9-12). Thus, identification of factors that interfere with and/or control the function of the RE protein is critical for understanding both cell-cycle control and oncogenesis. Here we describe a new gene, Bog (for B5T over-expressed gene), which was identified and shown to be overexpressed in several transformed rat liver epithelial (RLE) cell lines resistant to the growth-inhibitory effect of TGF-beta 1, as well as in primary human liver tumours. The Bog protein shares homology with other retinoblastoma-binding proteins and contains the Rb-binding motif LXCXE. Using the yeast two-hybrid system and co-immunoprecipitation. we demonstrated that Bog binds to Rb. In vivo, Bog/Rb complexes do not contain E2F-1, and Bog can displace E2F-1 from E2F-1/Rb complexes in vitro. Overexpression of Bog in normal RFE cells conferred resistance to the growth-inhibitory effect of TGF-beta 1. Furthermore, normal RLE cells are rapidly transformed when Bog is continuously overexpressed and form hepatoblastoma-like tumours when transplanted into nude mice. These data suggest that Bog may be important in the transformation process, in part due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta 1 through interaction with Rb and the subsequent displacement of E2F-1.	NCI, Expt Carcinogenesis Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, Div Basic Sci, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov						Altiok A, 1991, GROWTH FACTORS, V4, P117, DOI 10.3109/08977199109000263; Barrack ER, 1997, PROSTATE, V31, P61; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; CHENG J, 1990, BLOOD, V75, P730; GARFIELD S, 1988, MOL CARCINOGEN, V1, P189, DOI 10.1002/mc.2940010307; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUGGETT AC, 1991, CANCER RES, V51, P5929; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; Padgett Richard W., 1997, Cytokine and Growth Factor Reviews, V8, P1, DOI 10.1016/S1359-6101(96)00050-0; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VENTER DJ, 1991, ONCOGENE, V6, P445; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471; ZERFASS K, 1995, J GEN VIROL, V76, P1815, DOI 10.1099/0022-1317-76-7-1815	26	50	54	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1998	19	4					371	374		10.1038/1258	http://dx.doi.org/10.1038/1258			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697699				2022-12-25	WOS:000075107600021
J	Yan, H; Chen, CY; Kobayashi, R; Newport, J				Yan, H; Chen, CY; Kobayashi, R; Newport, J			Replication focus-forming activity 1 and the Werner syndrome gene product	NATURE GENETICS			English	Article							DNA-SYNTHESIS; CENTERS; PROTEIN; ORIGINS; YEAST	The initiation of DNA replication involves a minimum of four factors: a specific DNA sequence (origin), an initiator protein which binds to the origin, a helicase that unwinds the origin and a protein that binds single-stranded DNA that stabilizes the unwound origin(1). In eukaryotic cells, the origin recognition complex(2) (ORC) is the initiator protein and replication protein A (RPA; ref. 3) is the single-stranded DNA-binding protein. However, the helicase has not been identified and the nature of origins remains elusive, except in the case of Saccharomyces cerevisiae. A unique feature of eukaryotic DNA replication is that it occurs at a few-hundred discrete foci(4). It has thus been proposed that a real origin must contain a specific DNA sequence and must be attached to replication foci. Using Xenopus laevis egg extracts, we have identified and purified a 170-kD protein, focus-forming activity 1 (FFA-1), which is required for the formation of replication foci(5). Here we report that FFA-1 has DNA-helicase activity. Moreover, it is a homologue of the human Werner syndrome gene product WRN, a protein associated with premature ageing in humans(6).	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Fox Chase Cancer Center; Cold Spring Harbor Laboratory; University of California System; University of California San Diego	Yan, H (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave,W450, Philadelphia, PA 19111 USA.	hong_yan@fccc.edu						ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUKIWARA Y, 1985, WERNERS SYNDROME HUM, P459; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GOBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713; Imamura O, 1997, GENOMICS, V41, P298, DOI 10.1006/geno.1997.4661; Kornberg A., 1992, DNA REPLICATION; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YAN H, 1995, SCIENCE, V269, P1883, DOI 10.1126/science.7569932; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	25	122	125	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					375	378		10.1038/1263	http://dx.doi.org/10.1038/1263			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697700				2022-12-25	WOS:000075107600022
J	Okawa, A; Nakamura, I; Goto, S; Moriya, H; Nakamura, Y; Ikegawa, S				Okawa, A; Nakamura, I; Goto, S; Moriya, H; Nakamura, Y; Ikegawa, S			Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine	NATURE GENETICS			English	Article							NUCLEOSIDE-TRIPHOSPHATE PYROPHOSPHATASE; MEMBRANE GLYCOPROTEIN PC-1; INORGANIC PYROPHOSPHATE; EPIPHYSEAL CARTILAGE; PARATHYROID-HORMONE; ANTIGEN PC-1; PYROPHOSPHOHYDROLASE; GENERATION; CELLS; BONE	Ossification of the posterior longitudinal ligament of the spine (OPLL) is a common form of human myelopathy caused by a compression of the spinal cord by ectopic ossification of spinal ligaments(1,2). To elucidate the genetic basis for OPLL, we have been studying the ttw (tiptoe walking; previously designated twy) mouse, a naturally occurring mutant which exhibits ossification of the spinal ligaments very similar to human OPLL (refs 3,4). Using a positional candidate-gene approach, we determined the ttw phenotype is caused by a nonsense mutation (glycine 568 to stop) in the Npps gene which encodes nucleotide pyrophosphatase. This enzyme regulates soft-tissue calcification and bone mineralization by producing inorganic pyrophosphate, a major inhibitor of calcification(5-8). The accelerated bone formation characteristic of ttw mice is likely to result from dysfunction of NPPS caused by predicted truncation of the gene product, resulting in the loss of more than one-third of the native protein. Our results may lead to novel insights into the mechanism of ectopic ossification and the aetiology of human OPLL.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 108, Japan; Chiba Univ, Sch Med, Dept Orthopaed Surg, Chyuo Ku, Chiba 260, Japan; Shinshu Univ, Sch Med, Dept Orthopaed Surg, Matsumoto, Nagano 390, Japan	University of Tokyo; Chiba University; Shinshu University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	yusuke@ims.u-tokyo.ac.jp						ALBINNI U, 1982, CHIR ORG MOVIMENTO, V70, P15; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; CASWELL AM, 1987, BIOCHIM BIOPHYS ACTA, V924, P276, DOI 10.1016/0304-4165(87)90023-7; CASWELL AM, 1988, BIOCHIM BIOPHYS ACTA, V966, P310, DOI 10.1016/0304-4165(88)90080-3; DIETRICH W, 1992, GENETICS, V131, P423; FIROOZNIA H, 1982, NEW YORK STATE J MED, V82, P1193; FLEISCH H, 1981, METAB BONE DIS RELAT, V3, P279, DOI 10.1016/0221-8747(81)90044-8; GOTO S, 1997, OSSIFICATION POSTERI, P29; HARAHAP AR, 1988, J IMMUNOL, V141, P2317; Hosoda Y, 1981, Ryumachi, V21 Suppl, P157; HSU HHT, 1983, J BIOL CHEM, V258, P3463; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; OHTSUKA K, 1987, ARCH ORTHOP TRAUM SU, V106, P89, DOI 10.1007/BF00435420; Okawa A, 1998, MAMM GENOME, V9, P155, DOI 10.1007/s003359900707; ONO K, 1977, Spine, V2, P126, DOI 10.1097/00007632-197706000-00005; OYAJOBI BO, 1994, J BONE MINER RES, V9, P1259; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; SAKOU T, 1991, SPINE, V16, P1249, DOI 10.1097/00007632-199111000-00001; SIEGEL SA, 1983, J BIOL CHEM, V258, P8601; TERAKADO A, 1995, CALCIFIED TISSUE INT, V56, P135, DOI 10.1007/BF00296345; TERAYAMA K, 1989, SPINE, V14, P1184, DOI 10.1097/00007632-198911000-00009; TERKELTAUB R, 1994, ARTHRITIS RHEUM, V37, P934, DOI 10.1002/art.1780370624; TSUYAMA N, 1984, CLIN ORTHOP RELAT R, P71; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; YAMAZAKI M, 1991, CALCIFIED TISSUE INT, V48, P182, DOI 10.1007/BF02570553	26	314	329	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1998	19	3					271	273		10.1038/956	http://dx.doi.org/10.1038/956			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662402				2022-12-25	WOS:000074565900025
J	Palukaitis, P; Roossinck, MJ				Palukaitis, P; Roossinck, MJ			Spontaneous change of a benign satellite RNA of cucumber mosaic virus to a pathogenic variant	NATURE BIOTECHNOLOGY			English	Article						biocontrol; B5 satellite RNA; chlorosis; spontaneous mutation and selection	TRANSGENIC PLANTS; COAT PROTEIN; MEDIATED PROTECTION; EPIDEMIC CONDITIONS; TOMATO NECROSIS; HELPER VIRUS; CMV STRAINS; RESISTANCE; TOBACCO; SEQUENCES	Plant satellite RNAs generally reduce the level of helper virus accumulation and attenuate the disease symptoms induced by the helper virus that they depend upon for replication and packaging. As such, satellite RNAs could be used as biocontrol agents to reduce the level of disease in field crops, either by the application of a viral vaccine to healthy plants, car by the transgenic expression of satellite RNA in transformed plants. one such virus/satellite RNA system already under use in field tests is cucumber mosaic virus (CMV) and its satellite RNAs. However, in this system, some satellite RNAs also intensify viral disease in particular host plants. We passaged a satellite RNA of CMV with its helper virus to determine whether a satellite RNA that attenuates CMV-induced disease on tobacco plants could mutate to a pathogenic form, which might then be selected. In several experiments involving strains of CMV from each of the two subgroups, the satellite rapidly mutated to a pathogenic form, which was selected. This demonstrates an inherent risk associated with the use of attenuating satellite RNAs as a form of biocontrol of CMV.	SAMUEL ROBERTS NOBLE FDN INC, DIV PLANT BIOL, ARDMORE, OK 73402 USA; CORNELL UNIV, DEPT PLANT PATHOL, ITHACA, NY 14853 USA	Noble Research Institute; Cornell University								ARANDA MA, 1993, J VIROL, V67, P5896, DOI 10.1128/JVI.67.10.5896-5901.1993; Baker PF, 1960, ANN APPL BIOL, V48, P384, DOI 10.1111/j.1744-7348.1960.tb03534.x; BEACHTY R, 1993, SEMINARS VIROLOGY, V4, P1; BECK DL, 1994, P NATL ACAD SCI USA, V91, P10310, DOI 10.1073/pnas.91.22.10310; CARR JP, 1993, SEMIN VIROL, V4, P339, DOI 10.1006/smvy.1993.1032; COOPER B, 1995, VIROLOGY, V206, P307, DOI 10.1016/S0042-6822(95)80046-8; DEVIC M, 1990, J GEN VIROL, V71, P1443, DOI 10.1099/0022-1317-71-7-1443; GALLITELLI D, 1991, PLANT DIS, V75, P93, DOI 10.1094/PD-75-0093; GERLACH WL, 1987, NATURE, V328, P802, DOI 10.1038/328802a0; GONSALVES D, 1982, PHYTOPATHOLOGY, V72, P1533, DOI 10.1094/Phyto-72-1533; HABILI N, 1974, VIROLOGY, V57, P392, DOI 10.1016/0042-6822(74)90179-2; HACKLAND AF, 1994, ARCH VIROL, V139, P1, DOI 10.1007/BF01309451; HARRISON BD, 1987, NATURE, V328, P799, DOI 10.1038/328799a0; JACQUEMOND M, 1982, AGRONOMIE, V2, P533, DOI 10.1051/agro:19820605; JACQUEMOND M, 1981, AGRONOMIE, V1, P927, DOI 10.1051/agro:19811015; Jacquemond M, 1988, Mol Plant Microbe Interact, V1, P311, DOI 10.1094/MPMI-1-311; JACQUEMOND M, 1988, BIOCHEM BIOPH RES CO, V151, P388, DOI 10.1016/0006-291X(88)90605-5; JAEGLE M, 1990, J GEN VIROL, V71, P1905, DOI 10.1099/0022-1317-71-9-1905; JORDA C, 1992, PLANT DIS, V76, P363, DOI 10.1094/PD-76-0363; KAPER JM, 1986, J GEN VIROL, V67, P2241, DOI 10.1099/0022-1317-67-10-2241; KAPER JM, 1977, SCIENCE, V196, P429, DOI 10.1126/science.196.4288.429; KOSAKA Y, 1989, Annals of the Phytopathological Society of Japan, V55, P229, DOI 10.3186/jjphytopath.55.229; KURATH G, 1989, VIROLOGY, V173, P231, DOI 10.1016/0042-6822(89)90239-0; KURATH G, 1989, Molecular Plant-Microbe Interactions, V2, P91, DOI 10.1094/MPMI-2-091; LOMONOSSOFF GP, 1995, ANNU REV PHYTOPATHOL, V33, P323, DOI 10.1146/annurev.py.33.090195.001543; LOT H, 1972, Annales de Phytopathologie, V4, P25; MASUTA C, 1989, PLANT CELL, V1, P1165, DOI 10.1105/tpc.1.12.1165; Masuta Chikara, 1994, Annals of the Phytopathological Society of Japan, V60, P228, DOI 10.3186/jjphytopath.60.228; MCGARVEY PB, 1994, J AM SOC HORTIC SCI, V119, P642, DOI 10.21273/JASHS.119.3.642; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P563; MONTASSER MS, 1991, PLANT DIS, V75, P86, DOI 10.1094/PD-75-0086; OWEN J, 1988, VIROLOGY, V166, P495, DOI 10.1016/0042-6822(88)90520-X; Palukaitis P., 1991, Risk assessment in genetic engineering., P140; PALUKAITIS P, 1995, VIROLOGY, V206, P765, DOI 10.1016/S0042-6822(95)80006-9; PALUKAITIS P, 1992, ADV VIRUS RES, V41, P281, DOI 10.1016/B978-0-12-394314-9.00013-0; PALUKAITIS P, 1984, VIROLOGY, V132, P426, DOI 10.1016/0042-6822(84)90047-3; PALUKAITIS P, 1994, METH MOL G, V4, P237; PENA L, 1994, PLANT SCI, V100, P71, DOI 10.1016/0168-9452(94)90135-X; PO T, 1987, ANN APPL BIOL, V111, P143, DOI 10.1111/j.1744-7348.1987.tb01441.x; RIZZO TM, 1990, MOL GEN GENET, V222, P249, DOI 10.1007/BF00633825; ROOSSINCK MJ, 1995, J MOL EVOL, V40, P25, DOI 10.1007/BF00166593; ROOSSINCK MJ, 1992, MICROBIOL REV, V56, P265, DOI 10.1128/MMBR.56.2.265-279.1992; ROOSSINCK MJ, 1990, MOL PLANT MICROBE IN, V3, P188, DOI 10.1094/MPMI-3-188; SAITO Y, 1992, THEOR APPL GENET, V83, P679, DOI 10.1007/BF00226684; SAYAMA H, 1993, PHYTOPATHOLOGY, V83, P405, DOI 10.1094/Phyto-83-405; SLEAT DE, 1990, VIROLOGY, V176, P292, DOI 10.1016/0042-6822(90)90256-Q; SLEAT DE, 1990, P NATL ACAD SCI USA, V87, P2946, DOI 10.1073/pnas.87.8.2946; SLEAT DE, 1992, PLANT J, V2, P43, DOI 10.1046/j.1365-313X.1992.t01-49-00999.x; TAKANAMI Y, 1981, VIROLOGY, V109, P120, DOI 10.1016/0042-6822(81)90476-1; TEPFER M, 1993, BIO-TECHNOL, V11, P1125, DOI 10.1038/nbt1093-1125; TIEN P, 1991, ADV VIRUS RES, V39, P321; YIE Y, 1993, SEMIN VIROL, V4, P363, DOI 10.1006/smvy.1993.1035; YIE Y, 1995, TRANSGENIC RES, V4, P256, DOI 10.1007/BF01969119; YIE Y, 1992, MOL PLANT MICROBE IN, V5, P460, DOI 10.1094/MPMI-5-460; YOSHIDA K, 1985, Annals of the Phytopathological Society of Japan, V51, P238, DOI 10.3186/jjphytopath.51.238; ZHANG L, 1994, MOL PLANT MICROBE IN, V7, P208, DOI 10.1094/MPMI-7-0208	56	36	38	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1264	1268		10.1038/nbt1096-1264	http://dx.doi.org/10.1038/nbt1096-1264			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631090				2022-12-25	WOS:A1996VK61800024
J	Jost, B; Vilotte, JL; Duluc, I; Rodeau, JL; Freund, JN				Jost, B; Vilotte, JL; Duluc, I; Rodeau, JL; Freund, JN			Production of low-lactose milk by ectopic expression of intestinal lactase in the mouse mammary gland	NATURE BIOTECHNOLOGY			English	Article						lactose maldigestion; transgenic mice; fat globules	ALPHA-LACTALBUMIN; PHLORIZIN HYDROLASE; TRANSGENIC MICE; EPITHELIAL-CELLS; PROTEIN-C; MEMBRANE; INTOLERANCE; RAT; MATURATION; TISSUE	We have investigated, in mice, an in vivo method for producing low-lactose milk, based on the creation of transgenic animals carrying a hybrid gene in which the intestinal lactase-phlorizin hydrolase cDNA was placed under the control of the mammary-specific alpha-lactalbumin promoter. Transgenic females expressed lactase protein and activity during lactation at the apical side of mammary alveolar cells. Active lactase was also secreted into milk, anchored in the outer membrane of fat globules. Lactase synthesis in the mammary gland caused a significant decrease in milk lactose (50-85%) without obvious changes in fat and protein concentrations. Sucklings nourished with low-lactose milk developed normally. Hence, these data validate the use of transgenic animals expressing lactase in the mammary gland to produce low-lactose milk in vivo, and they demonstrate that the secretion of an intestinal digestive enzyme into milk can selectively modify its composition.	INSERM U381, Strasbourg, France; Inst Natl Rech Agron, CIJ, Jouy En Josas, France; CNRS, UPR 9009, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM U381, Strasbourg, France.	jean-noel.freund@inserm.u-strasbg.fr	DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016; Vilotte, Jean-Luc/AAF-4688-2019; Duluc, Isabelle/O-1972-2017	DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385				BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAND JC, 1991, AM J CLIN NUTR, V54, P148, DOI 10.1093/ajcn/54.1.148; BULLER HA, 1987, J BIOL CHEM, V262, P17206; Cooper B T, 1986, Dig Dis, V4, P72, DOI 10.1159/000171139; DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; DROHAN WN, 1994, TRANSGENIC RES, V3, P355, DOI 10.1007/BF01976767; DULUC I, 1994, J CELL BIOL, V126, P211, DOI 10.1083/jcb.126.1.211; DULUC I, 1993, J CELL BIOL, V123, P1577, DOI 10.1083/jcb.123.6.1577; DULUC I, 1991, GENE, V103, P275, DOI 10.1016/0378-1119(91)90286-K; FAERMAN A, 1995, J HISTOCHEM CYTOCHEM, V43, P461, DOI 10.1177/43.5.7730585; HANSEN SA, 1975, J CHROMATOGR, V105, P388, DOI 10.1016/S0021-9673(01)82270-6; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Jost B, 1997, BIOCHEM J, V327, P95, DOI 10.1042/bj3270095; KOLDOVSKY O, 1969, ANAL BIOCHEM, V27, P409, DOI 10.1016/0003-2697(69)90054-2; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LUCAS A, 1978, BRIT MED J, V1, P1018, DOI 10.1136/bmj.1.6119.1018; MEPHAM TB, 1987, PHYSL LACTATION, P30; Mercier J. C., 1986, Exploiting new technologies in animal breeding. Genetic developments., P122; MOLENAAR AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P611, DOI 10.1177/40.5.1374090; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; *NAT DAIR COUNC, 1985, DAIRY COUNCIL DIG, V56, P25; NEELE AM, 1995, GASTROENTEROLOGY, V109, P1234, DOI 10.1016/0016-5085(95)90583-9; NSIEMVO E, 1986, GEN PHYSIOL BIOPHYS, V5, P53; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; RODEAU JL, 1987, DEV BIOL, V120, P481, DOI 10.1016/0012-1606(87)90251-X; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SAHI T, 1994, SCAND J GASTROENTERO, V29, P7, DOI 10.3109/00365529409091740; SASAKI M, 1978, P NATL ACAD SCI USA, V75, P5020, DOI 10.1073/pnas.75.10.5020; SAVILAHTI E, 1983, ARCH DIS CHILD, V58, P246, DOI 10.1136/adc.58.4.246; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; STINNAKRE MG, 1994, P NATL ACAD SCI USA, V91, P6544, DOI 10.1073/pnas.91.14.6544; Suarez FL, 1995, ALIMENT PHARM THER, V9, P589, DOI 10.1111/j.1365-2036.1995.tb00427.x; TAMM A, 1994, SCAND J GASTROENTERO, V29, P55, DOI 10.3109/00365529409091744; VILLAKO K, 1994, SCAND J GASTROENTERO, V29, P36, DOI 10.3109/00365529409091743; VILOTTE JL, 1989, EUR J BIOCHEM, V186, P43, DOI 10.1111/j.1432-1033.1989.tb15175.x; VILOTTE JL, 1992, GENE, V119, P287, DOI 10.1016/0378-1119(92)90285-W; VILOTTE JL, 1996, ANIMAL GENET, V27, pA99	41	49	56	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					160	164		10.1038/6158	http://dx.doi.org/10.1038/6158			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052352				2022-12-25	WOS:000078508300024
J	Jiang, XR; Jimenez, G; Chang, E; Frolkis, M; Kusler, B; Sage, M; Beeche, M; Bodnar, AG; Wahl, GM; Tlsty, TD; Chiu, CP				Jiang, XR; Jimenez, G; Chang, E; Frolkis, M; Kusler, B; Sage, M; Beeche, M; Bodnar, AG; Wahl, GM; Tlsty, TD; Chiu, CP			Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype	NATURE GENETICS			English	Article							WILD-TYPE P53; NORMAL HUMAN FIBROBLASTS; NUDE-MICE; GENE AMPLIFICATION; CYCLE CONTROL; HUMAN BREAST; TUMORIGENICITY; MATRIGEL; INVITRO; PROTEIN	Expression of the human telomerase catalytic component, hTERT, in normal human somatic cells can reconstitute telomerase activity and extend their replicative lifespan(1,2). We report here that at twice the normal number of population doublings, telomerase-expressing human skin fibroblasts (BJ-hTERT) and retinal pigment epithelial cells (RPE-hTERT) retain normal growth control in response to serum deprivation, high cell density, G1 or GZ phase blockers and spindle inhibitors. In addition, we observed no cell growth in soft agar and detected no tumour formation in vivo. Thus, we find that telomerase expression in normal cells does not appear to induce changes associated with a malignant phenotype.	Geron Corp, Menlo Park, CA 94025 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Geron Corporation; Salk Institute; University of California System; University of California San Francisco	Chiu, CP (corresponding author), Geron Corp, Menlo Park, CA 94025 USA.	cchiu@geron.com			NCI NIH HHS [CA 61449, CA 42765, CA 51912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042765, R01CA061449, R01CA051912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BENN PA, 1976, AM J HUM GENET, V28, P465; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; JOHNSON TE, 1992, J CELL PHYSIOL, V150, P17, DOI 10.1002/jcp.1041500104; Khan SH, 1998, CANCER RES, V58, P396; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; SAKSELA E, 1963, P NATL ACAD SCI USA, V50, P390, DOI 10.1073/pnas.50.2.390; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wright WE, 1996, DEV GENET, V18, P173; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	23	531	565	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					111	114		10.1038/5056	http://dx.doi.org/10.1038/5056			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916802	Green Published			2022-12-25	WOS:000077960700020
J	Matsumura, Y; Uchida, S; Kondo, Y; Miyazaki, H; Ko, SBH; Hayama, A; Morimoto, T; Liu, W; Arisawa, M; Sasaki, S; Marumo, F				Matsumura, Y; Uchida, S; Kondo, Y; Miyazaki, H; Ko, SBH; Hayama, A; Morimoto, T; Liu, W; Arisawa, M; Sasaki, S; Marumo, F			Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel	NATURE GENETICS			English	Article							THIN ASCENDING LIMB; HUMAN KIDNEY; TRANSPORT; CLONING; HENLE; LOCALIZATION; MEDULLA; LOOP; GENE; RAT	CLC-K1 is a kidney-specific chloride channel that mediates transepithelial chloride transport in the thin ascending limb of Henle's loop (tAL) in the inner medulla(1,2). Transport of NaCl in the tAL is thought to be a component of urinary concentration in a passive model of the countercurrent multiplication system(3-5), but there has been no direct evidence that CLC-K1 is involved in urine concentration. To analyse the physiological function of CLC-K1 in vivo, we generated mice lacking CLC-K1 by targeted gene disruption. Clcnk1(-/-) mice were physically normal appearance, but produced approximately five times more urine than Clcnk1(-/-) and Clcnk(+/+) mice. After 24 hours of water deprivation, Clcnk1(-/-) mice were severely dehydrated and lethargic, with a decrease of approximately 27% in body weight. Intraperitoneal injection of the V2 agonist 1-deamino-8-D-arginine vasopressin (dDAVP) induced a threefold increase in urine osmolarity in Clcnk1(+/-) and Clcnk1(+/+) mice, whereas only a minimal increase was seen in Clcnk1(-/-) mice, indicating nephrogenic diabetes insipidus, After in vitro perfusion of the tAL, the lumen-to-bath chloride gradient did not produce a diffusion potential in Clcnk1(-/-) mice in contrast to Clcnk1(+/+) and Clcnk1(+/-) mice. These results establish that CLC-K1 has a role in urine concentration, and that the countercurrent system in the inner medulla is involved in the generation and maintenance of hypertonic medullary interstitium.	Tokyo Med & Dent Univ, Dept Internal Med 2, Tokyo, Japan; Tohoku Univ, Dept Pediat, Sch Med, Sendai, Miyagi 980, Japan	Tokyo Medical & Dental University (TMDU); Tohoku University	Uchida, S (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 2, Tokyo, Japan.		Uchida, Shinichi/D-1111-2013; Ko, Shigeru/H-3450-2012	Ko, Shigeru/0000-0003-1913-6357				DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; IMAI M, 1987, KIDNEY INT, V31, P565, DOI 10.1038/ki.1987.37; IMAI M, 1976, J CLIN INVEST, V58, P1054, DOI 10.1172/JCI108556; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOKKO JP, 1972, KIDNEY INT, V2, P214, DOI 10.1038/ki.1972.97; KONDO Y, 1987, AM J PHYSIOL, V253, pF1206; KONDO Y, 1987, AM J PHYSIOL, V253, pF1216; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; TAKEUCHI Y, 1995, KIDNEY INT, V48, P1497, DOI 10.1038/ki.1995.439; UCHIDA S, 1995, J CLIN INVEST, V95, P104, DOI 10.1172/JCI117626; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; YOSHITOMI K, 1988, J CLIN INVEST, V82, P866, DOI 10.1172/JCI113691	14	196	199	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					95	98		10.1038/5036	http://dx.doi.org/10.1038/5036			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916798				2022-12-25	WOS:000077960700016
J	Snel, B; Bork, P; Huynen, MA				Snel, B; Bork, P; Huynen, MA			Genome phylogeny based on gene content	NATURE GENETICS			English	Article							SEQUENCE; ARCHAEON	Species phylogenies derived from comparisons of single genes are rarely consistent with each other, due to horizontal gene transfer(1), unrecognized paralogy and highly variable rates of evolution(2). The advent of completely sequenced genomes allows the construction of a phylogeny that is less sensitive to such inconsistencies and more representative of whole-genomes than are single-gene trees. Here, we present a distance-based phytogeny(3) constructed on the basis of gene content, rather than on sequence identity, of 13 completely sequenced genomes of unicellular species. The similarity between two species is defined as the number of genes that they have in common divided by their total number of genes, Tn this type of phylogenetic analysis, evolutionary distance can be interpreted in terms of evolutionary events such as the acquisition and loss of genes, whereas the underlying properties (the gene content) can be interpreted in terms of function. As such, it takes a position intermediate to phylogenies based on single genes and phylogenies based on phenotypic characteristics. Although our comprehensive genome phylogeny is independent of phylogenies based on the level of sequence identity of individual genes, it correlates with the standard reference of prokarytic phylogeny based on sequence similarity of 16s rRNA (ref, 4). Thus, shared gene content between genomes is quantitatively determined by phylogeny, rather than by phenotype, and horizontal gene transfer has only a limited role in determining the gene content of genomes.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Utrecht, Bioinformat Grp, NL-3584 CH Utrecht, Netherlands	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Utrecht University	Bork, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bork@embl-heidelberg.de	Huynen, Martijn A/A-1530-2014; Snel, Berend/B-8886-2011; Bork, Peer/F-1813-2013; Huijnen, M.A./H-8051-2014	Huynen, Martijn A/0000-0001-6189-5491; Snel, Berend/0000-0002-5804-8547; Bork, Peer/0000-0002-2627-833X; 				Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Doolittle WF, 1998, CURR BIOL, V8, pR209, DOI 10.1016/S0960-9822(98)70127-7; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Huynen M, 1998, FEBS LETT, V426, P1, DOI 10.1016/S0014-5793(98)00276-2; Huynen MA, 1998, P NATL ACAD SCI USA, V95, P5849, DOI 10.1073/pnas.95.11.5849; Kaneko T, 1996, DNA Res, V3, P109; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KLENK HP, 1994, J MOL EVOL, V38, P420, DOI 10.1007/BF00163158; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WU CFJ, 1986, ANN STAT, V14, P1261, DOI 10.1214/aos/1176350142	30	494	517	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					108	110		10.1038/5052	http://dx.doi.org/10.1038/5052			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916801				2022-12-25	WOS:000077960700019
J	Desbarats, J; Duke, RC; Newell, MK				Desbarats, J; Duke, RC; Newell, MK			Newly discovered role for Fas ligand in the cell-cycle arrest of CD4(+) T cells	NATURE MEDICINE			English	Article							CONFER IMMUNE PRIVILEGE; CD95 LIGAND; GLD MICE; IN-VIVO; EXPRESSION; STIMULATION; REJECTION; CTLA-4; SUPERANTIGEN; ACTIVATION	Fas Ligand (FasL) can induce apoptosis of Fas-bearing cells. It is expressed on the cell surface of many tumor cells, immune-privileged tissues and activated lymphocytes. We report here that Fast can itself transduce signals, leading to cell-cycle arrest and cell death in CD4(+) T cells. In vitro, Fast engagement inhibited CD4(+) T-cell proliferation, cell-cycle progression, and IL-2 secretion. In vivo, FasL engagement prevented superantigen-mediated CD4(+), but not CD8(+), T-cell expansion. These findings demonstrate that FasL engagement regulates cell-cycle progression, and show that FasL engagement in vivo has a potent anti-inflammatory effect specific for CD4(+) T cells.	Univ Vermont, Coll Med, Dept Med, Div Immunobiol, Burlington, VT 05405 USA; Univ Colorado, Ctr Canc, Shreve Lab Tumor Immunol, Dept Med, Denver, CO 80262 USA; Univ Colorado, Ctr Canc, Shreve Lab Tumor Immunol, Dept Immunol, Denver, CO 80262 USA	University of Vermont; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Newell, MK (corresponding author), Univ Vermont, Coll Med, Dept Med, Div Immunobiol, Burlington, VT 05405 USA.	mnewell@zoo.uvm.edu		Desbarats, Julie/0000-0002-2495-7152	NIAID NIH HHS [AI40607, AI40394, R01AI33470] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040607, R44AI040394, R43AI040394, R01AI033470] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Arai H, 1997, NAT MED, V3, P843, DOI 10.1038/nm0897-843; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRUNNER T, 1995, NATURE, V373, P342; CHANDLER C, 1993, ARCH SURG-CHICAGO, V128, P279; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHU JL, 1995, J EXP MED, V181, P393, DOI 10.1084/jem.181.1.393; CORRY DB, 1994, J IMMUNOL, V153, P4142; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dou QP, 1997, J CELL BIOCHEM, V64, P586; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; Hahne M, 1996, EUR J IMMUNOL, V26, P721, DOI 10.1002/eji.1830260332; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Hutchings P, 1993, Autoimmunity, V15 Suppl, P21, DOI 10.3109/08916939309008856; Itoh N, 1997, J EXP MED, V186, P613, DOI 10.1084/jem.186.4.613; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JU ST, 1995, NATURE, V373, P345; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lau HT, 1997, NAT MED, V3, P727, DOI 10.1038/nm0797-727; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PRUDHOMME GJ, 1993, CLIN IMMUNOL IMMUNOP, V66, P185, DOI 10.1006/clin.1993.1024; Renno T, 1996, J EXP MED, V183, P431, DOI 10.1084/jem.183.2.431; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Seino K, 1997, TRANSPL P, V29, P1092, DOI 10.1016/S0041-1345(96)00421-6; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	41	86	90	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1377	1382		10.1038/3965	http://dx.doi.org/10.1038/3965			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846574				2022-12-25	WOS:000077336900032
J	Whitney, M; Rockenstein, E; Cantin, G; Knapp, T; Zlokarnik, G; Sanders, P; Durick, K; Craig, FF; Negulescu, PA				Whitney, M; Rockenstein, E; Cantin, G; Knapp, T; Zlokarnik, G; Sanders, P; Durick, K; Craig, FF; Negulescu, PA			A genome-wide functional assay of signal transduction in living mammalian cells	NATURE BIOTECHNOLOGY			English	Article						gene trap; beta-lactamase; flow cytometry; T-cell	EMBRYONIC STEM-CELLS; LYMPHOCYTE-T ACTIVATION; GENE TRAP SCREEN; INSERTIONAL MUTATIONS; TRANSCRIPTION FACTOR; REGULATED GENES; TUMOR PROMOTER; EXPRESSION; LACZ; MICE	We describe a genome-wide functional assay for rapid isolation of cell clones and genetic elements responsive to specific stimuli. A promoterless p-lactamase reporter gene was transfected into a human T-cell line to generate a living library of reporter-tagged clones. When loaded with a cell-permeable fluorogenic substrate, the cell library simultaneously reports the expression of a large number of endogenous genes. Flow cytometry was used to recover individual clones whose reporter-tagged genes were either induced or repressed following T-ceIl activation. Responsive clones were expanded and analyzed pharmacologically to identify patterns of regulation associated with specific genes. Although demonstrated using T cells, the genomic assay could be applied to map downstream transcriptional consequences for any propagating cell line in response to any stimulus of interest.	Aurora Biosci Corp, San Diego, CA 92121 USA		Negulescu, PA (corresponding author), Aurora Biosci Corp, 11010 Torreyana Rd, San Diego, CA 92121 USA.							AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Forrester LM, 1996, P NATL ACAD SCI USA, V93, P1677, DOI 10.1073/pnas.93.4.1677; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gogos JA, 1997, J VIROL, V71, P1644, DOI 10.1128/JVI.71.2.1644-1650.1997; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; KORCHAK HM, 1994, J BIOL CHEM, V269, P30281; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nagasawa M, 1997, J IMMUNOL, V158, P5146; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PATWARDHAN S, 1991, ONCOGENE, V6, P917; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; ROSENSTREICH DL, 1979, J IMMUNOL, V123, P1749; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WURST W, 1995, GENETICS, V139, P889; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	28	57	68	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1329	1333		10.1038/4302	http://dx.doi.org/10.1038/4302			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853613				2022-12-25	WOS:000077232600024
J	Li, YH; Behringer, RR				Li, YH; Behringer, RR			Esx1 is an X-chromosome-imprinted regulator of placental development and fetal growth	NATURE GENETICS			English	Article							MOUSE; CELLS; TISSUES	In marsupials and mice, the paternally derived X chromosome is preferentially inactivated in the placental tissues of female embryos(1-4). We show here that the X-linked homeobox gene Esx1 (refs 5,6), whose expression is restricted to extraembryonic tissues, is a chromosomally imprinted regulator of placental morphogenesis and trophoblast differentiation. Heterozygous female mice that inherited a mutant Esx1 allele from their father developed normally. Heterozygous females that inherited the Esx1 mutation from their mother, however, were born 20% smaller than normal and are identical in phenotype to hemizygous mutant males and homozygous mutant females. Although Esx1 mutant embryos were initially comparable in size with controls at 13.5 days post coitum (dpc), their placentas were significantly larger. Defects in the morphogenesis of the labyrinthine layer were observed as early as 11.5 dpc. Subsequently, vascularization abnormalities developed at the maternal-fetal interface, causing fetal growth retardation. These results identify Esx1 as the first essential X-chromosome-imprinted regulator of placental development that influences fetal growth, and may aid our understanding human placental insufficiency syndromes.	Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Behringer, RR (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	bhr@molgen.mda.uth.tmc.edu			NICHD NIH HHS [HD30284] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Branford WW, 1997, MECH DEVELOP, V65, P87, DOI 10.1016/S0925-4773(97)00058-0; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAVIES J, 1968, ACTA ANAT, V69, P542; Harbers K, 1996, P NATL ACAD SCI USA, V93, P12412, DOI 10.1073/pnas.93.22.12412; HARPER MI, 1982, J EMBRYOL EXP MORPH, V67, P127; HERNANDE.D, 1974, CELL TISSUE RES, V148, P381; JOLLIE WP, 1964, J ULTRA MOL STRUCT R, V10, P27, DOI 10.1016/S0022-5320(64)90018-8; Kaufman M.H., 1992, ATLAS MOUSE DEV; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; LOKE YW, 1995, HUMAN IMPLANTATION; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MULLER HK, 1994, CELL IMMUNOL, V157, P263, DOI 10.1006/cimm.1994.1221; TAGAKI N, 1975, NATURE, V256, P640; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANDEBERG JL, 1987, ISOZYMES CURRENT TOP, V15; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9	20	185	187	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1998	20	3					309	311		10.1038/3129	http://dx.doi.org/10.1038/3129			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806555				2022-12-25	WOS:000076698100030
J	Buchholz, CJ; Peng, KW; Morling, FJ; Zhang, J; Cosset, FL; Russell, SJ				Buchholz, CJ; Peng, KW; Morling, FJ; Zhang, J; Cosset, FL; Russell, SJ			In vivo selection of protease cleavage sites from retrovirus display libraries	NATURE BIOTECHNOLOGY			English	Article						protein engineering; combinatorial chemistry; randomized sequence	PHAGE DISPLAY; PRECURSOR PROTEINS; SURFACE DISPLAY; TECHNOLOGY; VECTORS	Phage display libraries are widely used for selection and optimization of polypeptide ligands or protease substrates. Because they are expressed and amplified in bacterial hosts, phage are not ideal for displaying eukaryotic polypeptides or for probing mammalian cells. As retroviruses do not suffer from these limitations we constructed plasmids encoding replication-competent murine leukemia viruses displaying a virally encoded epidermal growth factor (EGF) domain at the N-terminus of the envelope glycoprotein. The EGF-displaying viruses replicated freely on EGF receptor-poor cells without deleting the displayed EGF domain but did not propagate on EGF receptor-rich cells because they were sequestered by the EGF receptors. A retrovirus display library was then generated by diversifying the seven-residue linker between the envelope glycoprotein and the displayed EGF domain. Selective pressure for loss of EGF receptor-binding activity was applied to the library by serial passage on EGF receptor-rich HT1080 cells. The selected viruses propagated on these cells with wild-type efficiencies, a phenotype that was conferred by intracellular cleavage of their displayed linker sequences. The selected linker sequences invariably presented arginine-rich motifs matching the consensus cleavage signal for furin-like proteases. Retrovirus display libraries can be used for the selection of polypeptides interacting with components of living mammalian cells.	Cambridge Ctr Prot Engn, MRC Ctr, Cambridge CB2 2QH, England; Paul Ehrlich Inst, Abt Med Biotechnol, D-63225 Langen, Germany; Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France; Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA	MRC Laboratory Molecular Biology; University of Cambridge; Paul Ehrlich Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Mayo Clinic	Buchholz, CJ (corresponding author), Cambridge Ctr Prot Engn, MRC Ctr, Hills Rd, Cambridge CB2 2QH, England.	bucch@pei.de; sjr@mayo.edu	Cosset, François-Loïc/M-5862-2019	Cosset, François-Loïc/0000-0001-8842-3726; Buchholz, Christian/0000-0002-9837-7345				BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; Coombs GS, 1996, J BIOL CHEM, V271, P4461; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; Cosset FL, 1996, GENE THER, V3, P946; LITTLE M, 1993, TRENDS BIOTECHNOL, V11, P3, DOI 10.1016/0167-7799(93)90067-J; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nilson BHK, 1996, GENE THER, V3, P280; ONEIL KT, 1995, CURR OPIN STRUC BIOL, V5, P443, DOI 10.1016/0959-440X(95)80027-1; Peng KW, 1997, HUM GENE THER, V8, P729, DOI 10.1089/hum.1997.8.6-729; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; Stahl S, 1997, TRENDS BIOTECHNOL, V15, P185, DOI 10.1016/S0167-7799(97)01034-2; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	18	67	74	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					951	954		10.1038/nbt1098-951	http://dx.doi.org/10.1038/nbt1098-951			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788352				2022-12-25	WOS:000076323300031
J	Finette, BA; O'Neill, JP; Vacek, PM; Albertini, RJ				Finette, BA; O'Neill, JP; Vacek, PM; Albertini, RJ			Gene mutations with characteristic deletions in cord blood T lymphocytes associated with passive maternal exposure to tobacco smoke	NATURE MEDICINE			English	Article							CHILDRENS CANCER GROUP; CHILDHOOD-CANCER; V(D)J RECOMBINATION; PHOSPHORIBOSYLTRANSFERASE GENE; MUTANT FREQUENCIES; CIGARETTE-SMOKING; LUNG-TUMORS; LEUKEMIA; PREGNANCY; HPRT	We have investigated the molecular effects of passive maternal cigarette exposure in a newborn population and consider the possible implications of the observed genetic changes in the development of neoplastic diseases in children. We present a distribution analysis of somatic mutational events in a reporter gene, HPRT, in cord blood T lymphocytes from newborns after transplacental exposure to cigarette smoke. Analysis of 30 HPRT mutant isolates from 12 newborn infants born to mothers with no evidence of environmental exposure to cigarette smoke and 37 HPRT mutant isolates from 12 infants born to mothers exposed to passive cigarette smoke showed a significant difference in the HPRT mutational spectrum in those exposed in utero to cigarette smoke. The most notable change was an increase in 'illegitimate' genomic deletions mediated by V(D)J recombinase, a recombination event associated with hematopoietic malignancies in early childhood. Recent epidemiological studies of maternal and paternal cigarette smoke exposure and childhood cancers may need to be re-interpreted, given these results.	Univ Vermont, Dept Pediat, Burlington, VT 05405 USA; Univ Vermont, Genet Toxicol Lab, Burlington, VT 05405 USA; Univ Vermont, Dept Med, Burlington, VT 05405 USA; Univ Vermont, Dept Med Biostat, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont	Finette, BA (corresponding author), Univ Vermont, Dept Pediat, Burlington, VT 05405 USA.	finette@salus.med.uvm.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD001010, R01HD033648, R29HD035309] Funding Source: NIH RePORTER; NICHD NIH HHS [1R29HD35309-01A1, 1K11HD01010, 1RO1HDKA33648-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTINI RJ, 1990, PROG CLIN BIOL RES, V340, P15; ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BOTTO F, 1994, BIOCHEM BIOPH RES CO, V205, P1086, DOI 10.1006/bbrc.1994.2777; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BUCKLEY JD, 1989, CANCER RES, V49, P4030; Byrd RS, 1995, PEDIATR ANN, V24, P640, DOI 10.3928/0090-4481-19951201-07; Chen CL, 1996, BLOOD, V88, P2210, DOI 10.1182/blood.V88.6.2210.bloodjournal8862210; CHHABRA SK, 1995, CANCER RES, V55, P6017; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; Finette BA, 1997, MUTAT RES-FUND MOL M, V377, P115, DOI 10.1016/S0027-5107(97)00069-9; FINETTE BA, 1994, MUTAT RES, V308, P223, DOI 10.1016/0027-5107(94)90157-0; Finette BA, 1996, CANCER RES, V56, P1405; FUSCOE JC, 1991, CANCER RES, V51, P6001; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GREAVES MF, 1988, LEUKEMIA, V2, P120; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; INFANTERIVARD C, 1995, LANCET, V346, P177, DOI 10.1016/S0140-6736(95)91233-9; Issa JPJ, 1996, CANCER RES, V56, P3655; Klebanoff MA, 1996, AM J EPIDEMIOL, V144, P1028, DOI 10.1093/oxfordjournals.aje.a008874; Kyrtopoulos SA, 1997, CANCER DETECT PREV, V21, P391; LIPKOWITZ S, 1992, P NATL ACAD SCI USA, V89, P5301, DOI 10.1073/pnas.89.12.5301; MARTIN TR, 1986, AM J EPIDEMIOL, V124, P633, DOI 10.1093/oxfordjournals.aje.a114436; MCGREGOR WG, 1994, CANCER RES, V54, P4207; MORRIS JA, 1991, J CLIN PATHOL, V45, P378; OLDS DL, 1994, PEDIATRICS, V93, P221; ONEILL JP, IN PRESS ENV MOL MUT; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; Pluth JM, 1996, CANCER RES, V56, P2393; SCHMIDT CA, 1994, LEUKEMIA, V8, P102; Shu XO, 1996, JNCI-J NATL CANCER I, V88, P24, DOI 10.1093/jnci/88.1.24; Sorahan T, 1997, BRIT J CANCER, V76, P1525, DOI 10.1038/bjc.1997.589; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; STREISSGUTH AP, 1994, EFFECTS PRENATAL EXP, P148; TATES AD, 1991, MUTAT RES, V250, P483, DOI 10.1016/0027-5107(91)90205-3; VanVunakis H, 1987, ENV CARCINOGENS METH, P317; VREILING H, 1992, CARCINOGENESIS, V13, P1625; Walker VE, 1996, CANCER RES, V56, P4654; YEAZEL MW, 1995, CANCER-AM CANCER SOC, V75, P1718, DOI 10.1002/1097-0142(19950401)75:7<1718::AID-CNCR2820750725>3.0.CO;2-G	45	94	96	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1144	1151		10.1038/2640	http://dx.doi.org/10.1038/2640			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771747				2022-12-25	WOS:000076230100033
J	Hoyle, R				Hoyle, R			Therapeutics - Genentech is poised for an anti-cancer breakthrough	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	3	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					887	887		10.1038/nbt1098-887	http://dx.doi.org/10.1038/nbt1098-887			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788325	Bronze			2022-12-25	WOS:000076323300004
J	Sieber, V; Pluckthun, A; Schmid, FX				Sieber, V; Pluckthun, A; Schmid, FX			Selecting proteins with improved stability by a phage-based method	NATURE BIOTECHNOLOGY			English	Article						directed evolution; phage display; protein stabilization; proteolysis	INTACT DISULFIDE BONDS; IN-VIVO SELECTION; CONFORMATIONAL STABILITY; ESCHERICHIA-COLI; ADSORPTION PROTEIN; FILAMENTOUS PHAGE; RIBONUCLEASE-T1; ANTIBODY; EVOLUTION; FD	We describe a method for the stabilization of proteins that links the protease resistance of stabilized variants of a protein with the infectivity of a filamentous phage. A repertoire of variants of the protein to be stabilized is inserted between two domains (N2 and CT) of the gene-3-protein of the fd phage. The infectivity of fd phage is lost when the three domains are disconnected by the proteolytic cleavage of unstable protein inserts. Rounds of in vitro proteolysis, infection, and propagation can thus be performed to enrich those phage containing the most stable variants of the protein insert. This strategy discriminates between variants of a model protein (ribonuclease T1) differing in conformational stability and selects from a large repertoire variants that are only marginally more stable than others. Because fd phage are exceptionally stable and the proteolysis in the selection step takes place in vitro a wide range of solvent conditions can be used, tailored for the protein to be stabilized.	Univ Bayreuth, Biochem Lab, D-95440 Bayreuth, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Bayreuth; University of Zurich	Schmid, FX (corresponding author), Univ Bayreuth, Biochem Lab, POB 101251, D-95440 Bayreuth, Germany.	franz-xaver.schmid@uni-bayreuth.de	Plückthun, Andreas/C-2746-2009; Sieber, Volker/D-2006-2013	Plückthun, Andreas/0000-0003-4191-5306; Sieber, Volker/0000-0001-5458-9330				Bothmann H, 1998, NAT BIOTECHNOL, V16, P376, DOI 10.1038/nbt0498-376; Crameri A, 1996, NAT MED, V2, P100, DOI 10.1038/nm0196-100; CRISSMAN JW, 1984, VIROLOGY, V132, P445, DOI 10.1016/0042-6822(84)90049-7; DENG SJ, 1994, J BIOL CHEM, V269, P9533; Dunn IS, 1996, CURR OPIN BIOTECH, V7, P547, DOI 10.1016/S0958-1669(96)80060-7; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; Frech C, 1996, BIOCHEMISTRY-US, V35, P11386, DOI 10.1021/bi9608525; GEIGER T, 1987, J BIOL CHEM, V262, P785; Greener A, 1997, MOL BIOTECHNOL, V7, P189, DOI 10.1007/BF02761755; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; IKEHARA M, 1986, P NATL ACAD SCI USA, V83, P4695, DOI 10.1073/pnas.83.13.4695; JACKSON JR, 1995, J IMMUNOL, V154, P3310; Jung S, 1997, PROTEIN ENG, V10, P959, DOI 10.1093/protein/10.8.959; Kast P, 1997, CURR OPIN STRUC BIOL, V7, P470, DOI 10.1016/S0959-440X(97)80109-1; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P6475, DOI 10.1021/bi00479a020; KOLMAR H, 1995, J MOL BIOL, V251, P471, DOI 10.1006/jmbi.1995.0448; Krebber C, 1997, J MOL BIOL, V268, P607, DOI 10.1006/jmbi.1997.0981; KREMSER A, 1994, BIOCHEMISTRY-US, V33, P13954, DOI 10.1021/bi00250a051; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; MATSUMURA M, 1985, J BIOL CHEM, V260, P5298; MAYR LM, 1993, PROTEIN EXPRES PURIF, V4, P52, DOI 10.1006/prep.1993.1008; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; OOBATAKE M, 1979, J BIOCHEM, V86, P55; PACE CN, 1988, J BIOL CHEM, V263, P11820; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; QUAAS R, 1988, NUCLEOS NUCLEOT, V7, P619, DOI 10.1080/07328318808056297; Rubingh DN, 1997, CURR OPIN BIOTECH, V8, P417, DOI 10.1016/S0958-1669(97)80062-6; SALIVAR WO, 1964, VIROLOGY, V24, P359, DOI 10.1016/0042-6822(64)90173-4; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sauer RT, 1996, FOLD DES, V1, pR27, DOI 10.1016/S1359-0278(96)00015-6; Schindler T, 1996, BIOCHEMISTRY-US, V35, P16833, DOI 10.1021/bi962090j; SCHWIND P, 1992, EUR J BIOCHEM, V210, P431, DOI 10.1111/j.1432-1033.1992.tb17438.x; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; Skinner MM, 1996, P NATL ACAD SCI USA, V93, P10753, DOI 10.1073/pnas.93.20.10753; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Spada S, 1997, NAT MED, V3, P694, DOI 10.1038/nm0697-694; SPADA S, 1998, IN PRESS J MOL BIOL; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STENGELE I, 1990, J MOL BIOL, V212, P143, DOI 10.1016/0022-2836(90)90311-9; WALTER S, 1995, J MOL BIOL, V252, P133, DOI 10.1006/jmbi.1995.0480; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258; Zhou HXX, 1996, NAT STRUCT BIOL, V3, P446, DOI 10.1038/nsb0596-446	45	159	172	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					955	960		10.1038/nbt1098-955	http://dx.doi.org/10.1038/nbt1098-955			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788353				2022-12-25	WOS:000076323300032
J	Zhou, HY; Kuang, J; Zhong, L; Kuo, WL; Gray, JW; Sahin, A; Brinkley, BR; Sen, S				Zhou, HY; Kuang, J; Zhong, L; Kuo, WL; Gray, JW; Sahin, A; Brinkley, BR; Sen, S			Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation	NATURE GENETICS			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; POLO-LIKE KINASE; PROTEIN-KINASE; BREAST-CANCER; CHROMOSOME SEGREGATION; DNA-SEQUENCES; EXPRESSION; AURORA; YEAST; LOCALIZATION	The centrosomes are thought to maintain genomic stability through the establishment of bipolar spindles during cell division, ensuring equal segregation of replicated chromosomes to two daughter cells. Deregulated duplication and distribution of centrosomes have been implicated in chromosome segregation abnormalities, leading to aneuploidy seen in many cancer cell types. Here, we report that STK15 (also known as BTAK and aurora2), encoding a centrosome-associated kinase, is amplified and overexpressed in multiple human tumour cell types, and is involved in the induction of centrosome duplication-distribution abnormalities and aneuploidy in mammalian cells. STK15 amplification has been previously detected in breast tumour cell lines(1) and in colon tumours(2); here, we report its amplification in approximately 12% of primary breast tumours, as well as in breast, ovarian, colon, prostate, neuroblastoma and cervical cancer cell lines. Additionally, high expression of STK15 mRNA was detected in tumour cell lines without evidence of gene amplification. Ectopic expression of STK15 in mouse NIH 3T3 cells led to the appearance of abnormal centrosome number (amplification) and transformation in vitro. Finally, overexpression of STK15 in near diploid human breast epithelial cells revealed similar centrosome abnormality, as well as induction of aneuploidy. These findings suggest that STK15 is a critical kinase-encoding gene, whose overexpression leads to centrosome amplification, chromosomal instability and transformation in mammalian cells.	Univ Texas, MD Anderson Cancer Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Div Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of California System; University of California San Francisco	Sen, S (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ssen@mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [R37CA041424, R01CA061979, P01CA064255, R01CA041424] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41424, CA 61979, CA 64255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Bockmuhl U, 1996, LARYNGO RHINO OTOL, V75, P408, DOI 10.1055/s-2007-997605; Boveri T, 1914, ORIGIN MALIGNANT TUM; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; ISOLA JJ, 1995, AM J PATHOL, V147, P905; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Larramendy ML, 1997, AM J PATHOL, V150, P685; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SolinasToldo S, 1996, CANCER RES, V56, P3803; SOULE HD, 1990, CANCER RES, V50, P6075; TAAGEPERA S, 1995, EXP CELL RES, V221, P249, DOI 10.1006/excr.1995.1373; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	34	1107	1179	0	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1998	20	2					189	193		10.1038/2496	http://dx.doi.org/10.1038/2496			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771714				2022-12-25	WOS:000076231300023
J	Layne, SP; Beugelsdijk, TJ				Layne, SP; Beugelsdijk, TJ			Laboratory firepower for infectious disease research	NATURE BIOTECHNOLOGY			English	Article								Batch science machines could one day perform the work of hundreds of humans, enhancing public health surveillance, increasing experimental reproducibility, and liberating researchers from the bench so that they can focus on "big" conceptual problems.	Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Layne, SP (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, POB 951772, Los Angeles, CA 90095 USA.	spl@lvik.ph.ucla.edu; beugelsdijk@lanl.gov						Anderson WF, 1998, NATURE, V392, P25; *ASTM, 1998, E4952 ASTM SUBC; Belshe RB, 1998, LANCET, V351, P460, DOI 10.1016/S0140-6736(98)22007-1; Beugelsdijk T. J., 1989, Laboratory Robotics and Automation, V1, P11; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Gore A, 1996, ASM NEWS, V62, P448; HELLMAN CA, 1998, NAT MED VACCINE S, V4, P532; HERRLING PL, 1988, NATURE S, V392, P32; LAYNE SP, 1988, NATURE, V333, P511, DOI 10.1038/333511a0; Lederberg J, 1997, JAMA-J AM MED ASSOC, V278, P435; *NAT RES COUNC, 1998, IMPR CIV MED RESP CH; NAT'L RESEARCH COUNCIL, 1997, INT PROP RIGHTS RES; National Research Council, 1993, NAT COLL APPL INF TE; Tauxe RV, 1997, EMERG INFECT DIS, V3, P425, DOI 10.3201/eid0304.970403; *WHO, 1993, WEEKLY EPIDEMIOL REC, V68, P33; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	16	12	12	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					825	829		10.1038/nbt0998-825	http://dx.doi.org/10.1038/nbt0998-825			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743113				2022-12-25	WOS:000075671700026
J	Moriya, K; Fujie, H; Shintani, Y; Yotsuyanagi, H; Tsutsumi, T; Ishibashi, K; Matsuura, Y; Kimura, S; Miyamura, T; Koike, K				Moriya, K; Fujie, H; Shintani, Y; Yotsuyanagi, H; Tsutsumi, T; Ishibashi, K; Matsuura, Y; Kimura, S; Miyamura, T; Koike, K			The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice	NATURE MEDICINE			English	Article							RISK FACTOR; EXPRESSION; INFECTION; FEATURES; SUPPRESSION; CIRRHOSIS	Hepatitis C virus (HCV) is the main cause of chronic hepatitis worldwide. Chronic hepatitis ultimately results in the development of hepatocellular carcinoma(1,2) (HCC). However, the mechanism of hepatocarcinogenesis in chronic HCV infection is still unclear. The ability of the core protein of HCV to modulate gene transcription, cell proliferation and cell death(3-8) may be involved in the pathogenesis of HCC. Here, we report the development of HCC in two independent lines of mice transgenic for the HCV core gene, which develop hepatic steatosis early in life as a histological feature characteristic of chronic hepatitis C (ref. 9). After the age of 16 months, mice of both lines developed hepatic tumors that first appeared as adenomas containing fat droplets in the cytoplasm. Then HCC, a more poorly-differentiate neoplasia, developed from within the adenomas, presenting in a 'nodule-in-nodule' manner without cytoplasmic fat droplets; this closely resembled the histopathological characteristics of the early stage of HCC in patients with chronic hepatitis C (refs. 10,11). These results indicate that the HCV core protein has a chief role in the development of HCC, and that these transgenic mice provide good animal models for determining the molecular events in hepatocarcinogenesis with HCV infection.	Univ Tokyo, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138655, Japan; Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	University of Tokyo; Daiichi Sankyo Company Limited; National Institute of Infectious Diseases (NIID)	Koike, K (corresponding author), Univ Tokyo, Dept Internal Med 1, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							BACH N, 1992, HEPATOLOGY, V15, P572, DOI 10.1002/hep.1840150403; CAPORASO N, 1991, J HEPATOL, V12, P367, DOI 10.1016/0168-8278(91)90841-X; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; HINO O, 1994, INTERVIROLOGY, V37, P133, DOI 10.1159/000150368; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; KIM DW, 1994, JPN J MED SCI BIOL, V47, P211, DOI 10.7883/yoken1952.47.211; Koike K, 1997, P NATL ACAD SCI USA, V94, P233, DOI 10.1073/pnas.94.1.233; Matsuda J, 1998, JPN J CANCER RES, V89, P150, DOI 10.1111/j.1349-7006.1998.tb00543.x; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1997, JPN J MED SCI BIOL, V50, P169, DOI 10.7883/yoken1952.50.169; NAKAMURA K, 1992, EXP ANIM TOKYO, V41, P279, DOI 10.1538/expanim1978.41.3_279; NAKASHIMA O, 1995, HEPATOLOGY, V22, P101, DOI 10.1002/hep.1840220116; Paradis V, 1997, J CLIN PATHOL, V50, P401, DOI 10.1136/jcp.50.5.401; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SUGIHARA S, 1992, CANCER, V70, P1488, DOI 10.1002/1097-0142(19920915)70:6<1488::AID-CNCR2820700607>3.0.CO;2-J	23	990	1042	0	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1065	1067		10.1038/2053	http://dx.doi.org/10.1038/2053			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734402				2022-12-25	WOS:000075804100042
J	Sarraf, P; Mueller, E; Jones, D; King, FJ; DeAngelo, DJ; Partridge, JB; Holden, SA; Chen, LB; Singer, S; Fletcher, C; Spiegelman, BM				Sarraf, P; Mueller, E; Jones, D; King, FJ; DeAngelo, DJ; Partridge, JB; Holden, SA; Chen, LB; Singer, S; Fletcher, C; Spiegelman, BM			Differentiation and reversal of malignant changes in colon cancer through PPAR gamma	NATURE MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED RECEPTOR-GAMMA; LAMININ-BINDING PROTEIN; GENE-EXPRESSION; MESSENGER-RNAS; X-RECEPTOR; CELLS; ALPHA; MICE; ADIPOGENESIS	PPAR gamma is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPAR gamma is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPAR gamma ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPAR gamma.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Shionogi BioRes Corp, Lexington, MA 02421 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Shionogi & Company Limited	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Jones, Daniel/I-7399-2015	Singer, Samuel/0000-0001-9713-8230	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK-31405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; CHANTRET I, 1988, CANCER RES, V48, P1936; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawai K, 1997, ARZNEIMITTEL-FORSCH, V47, P356; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KONDOH N, 1992, CANCER RES, V52, P791; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MAFUNE K, 1990, CANCER RES, V50, P3888; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Menck HR, 1997, CA-CANCER J CLIN, V47, P161, DOI 10.3322/canjclin.47.3.161; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; THOMAS P, 1993, METASTATIC POTENTIAL, P1; TOMLINSON IPM, 1995, P NATL ACAD SCI USA, V92, P11130, DOI 10.1073/pnas.92.24.11130; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	887	911	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1046	1052		10.1038/2030	http://dx.doi.org/10.1038/2030			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734398				2022-12-25	WOS:000075804100038
J	Milik, M; Sauer, D; Brunmark, AP; Yuan, LL; Vitiello, A; Jackson, MR; Peterson, PA; Skolnick, J; Glass, CA				Milik, M; Sauer, D; Brunmark, AP; Yuan, LL; Vitiello, A; Jackson, MR; Peterson, PA; Skolnick, J; Glass, CA			Application of an artificial neural network to predict specific class I MHC binding peptide sequences	NATURE BIOTECHNOLOGY			English	Article						bioinformatics; applied immunology	H-2-DEFICIENT LYMPHOMA VARIANTS; DROSOPHILA-MELANOGASTER CELLS; MOLECULES; COMPLEX; PURIFICATION; MOTIFS; IDENTIFICATION; HLA-A2.1; RESIDUES; CLEAVAGE	Computational methods were used to predict the sequences of peptides that bind to the MHC class I molecule, K-b. The rules for predicting binding sequences, which are limited, are based on preferences for certain amino acids in certain positions of the peptide. It is apparent though, that binding can be influenced by the amino acids in all of the positions of the peptide. An artificial neural network (ANN) has the ability to simultaneously analyze the influence of all of the amino acids of the peptide and thus may improve binding predictions. ANNs were compared to statistically analyzed peptides for their abilities to predict the sequences of K-b binding peptides. ANN systems were trained on a library of binding and nonbinding peptide sequences from a phage display library. Statistical and ANN methods identified strong binding peptides with preferred amino acids. ANNs detected more subtle binding preferences, enabling them to predict medium binding peptides. The ability to predict class I MHC molecule binding peptides is useful for immunolological therapies involving cytotoxic-T cells.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Glass, CA (corresponding author), RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA.	cglass@prius.jnj.com		Milik, Mariusz/0000-0002-1787-9889				ADAMS HP, 1995, J IMMUNOL METHODS, V185, P181, DOI 10.1016/0022-1759(95)00111-M; BRUSIC V, 1994, COMPLEX SYSTEMS MECH, P253; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; Gulukota K, 1997, J MOL BIOL, V267, P1258, DOI 10.1006/jmbi.1997.0937; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KIDERA A, 1985, J PROTEIN CHEM, V4, P23, DOI 10.1007/BF01025492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LOHMANN R, 1994, PROTEIN SCI, V3, P1597, DOI 10.1002/pro.5560030924; Masters T., 1993, PRACTICAL NEURAL NET; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MILIK M, 1995, P 4 ANN C EV PROGR; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rumelhart D. E., 1996, PARALLEL DISTRIBUTED; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SCHNEIDER G, 1995, BIOPHYS J, V68, P434, DOI 10.1016/S0006-3495(95)80205-5; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; SMITH GP, 1988, VIROLOGY, V167, P156, DOI 10.1016/0042-6822(88)90065-7; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZELL A, 1997, STUTTGART NEURAL NET	35	57	65	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					753	756		10.1038/nbt0898-753	http://dx.doi.org/10.1038/nbt0898-753			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702774				2022-12-25	WOS:000075183400033
J	Nathanson, N				Nathanson, N			Harnessing research to control AIDS	NATURE MEDICINE			English	Editorial Material									NIH, Off AIDS Res, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Nathanson, N (corresponding author), NIH, Off AIDS Res, US Dept HHS, Bldg 31 4C02,9000 Rockville Pike, Bethesda, MD 20892 USA.								0	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					879	881		10.1038/nm0898-879	http://dx.doi.org/10.1038/nm0898-879			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701229	Bronze			2022-12-25	WOS:000075107400019
J	Kumamaru, T; Suenaga, H; Mitsuoka, M; Watanabe, T; Furukawa, K				Kumamaru, T; Suenaga, H; Mitsuoka, M; Watanabe, T; Furukawa, K			Enhanced degradation of polychlorinated biphenyls by directed evolution of biphenyl dioxygenase	NATURE BIOTECHNOLOGY			English	Article						molecular evolution; bioremediation	PSEUDOMONAS-PSEUDOALCALIGENES KF707; SP STRAIN LB400; ESCHERICHIA-COLI; DEGRADING BACTERIA; ENCODING BIPHENYL; IN-VITRO; CLONING; INDIGO; GENES; BIODEGRADATION	Biphenyl dioxygenases (BP Dox) from different organisms, which are involved in the initial oxygenation and subsequent degradation of polychlorinated biphenyls (PCB), are similar in structure but have different functions. The large subunit of Up Dox, encoded by the bphA1 gene, is crucial for substrate selectivity. Using the process of DNA shuffling, we randomly recombined the bphA1 genes of Pseudomonas pseudoalcaligenes KF707 and Burkholderia cepacia LB400 and selected for genes that expressed proteins with altered function. Upon expression in Escherichia coli, some of these evolved genes exhibited enhanced degradation capacity, not only for PCB and related biphenyl compounds, but for single aromatic hydrocarbons such as benzene and toluene, which are poor substrates for the original BP Dox.	Kyushu Univ, Dept Agr Chem, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Dept Agr Chem, Fukuoka 8128581, Japan.	kfurukaw@agr.kyushu-u.ac.jp	KENSUKE, FURUKAWA/R-3105-2019					ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; BOPP LH, 1986, J IND MICROBIOL, V1, P23, DOI 10.1007/BF01569413; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHUNG SY, 1994, BIOSCI BIOTECH BIOCH, V58, P2111, DOI 10.1271/bbb.58.2111; EATON RW, 1995, J BACTERIOL, V177, P6983, DOI 10.1128/jb.177.23.6983-6988.1995; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; FURUKAWA K, 1982, BIODEGRADATION DETOX, P33; Furukawa Kensuke, 1994, Biodegradation, V5, P289, DOI 10.1007/BF00696466; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; HART S, 1992, J GEN MICROBIOL, V138, P211, DOI 10.1099/00221287-138-1-211; HIROSE J, 1994, GENE, V138, P27; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; Kimura N, 1996, BIOSCI BIOTECH BIOCH, V60, P220, DOI 10.1271/bbb.60.220; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; LOIDA PJ, 1993, PROTEIN ENG, V6, P207, DOI 10.1093/protein/6.2.207; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MONDELLO F, 1997, APPL ENVIRON MICROB, V63, P3039; MURDOCK D, 1993, BIO-TECHNOL, V11, P381, DOI 10.1038/nbt0393-381; OConnor KE, 1997, APPL ENVIRON MICROB, V63, P4287, DOI 10.1128/AEM.63.11.4287-4291.1997; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Suyama A, 1996, J BACTERIOL, V178, P4039, DOI 10.1128/jb.178.14.4039-4046.1996; TAIRA K, 1992, J BIOL CHEM, V267, P4844; Unterman Ronald, 1996, V6, P209, DOI 10.1017/CBO9780511608414.009; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	35	175	215	2	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					663	666		10.1038/nbt0798-663	http://dx.doi.org/10.1038/nbt0798-663			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661201				2022-12-25	WOS:000074521800031
J	Walker, RE; Carter, CS; Muul, L; Natarajan, V; Herpin, BR; Leitman, SF; Klein, HG; Mullen, CA; Metcalf, JA; Baseler, M; Falloon, J; Davey, RT; Kovacs, JA; Polis, MA; Masur, H; Blaese, RM; Lane, HC				Walker, RE; Carter, CS; Muul, L; Natarajan, V; Herpin, BR; Leitman, SF; Klein, HG; Mullen, CA; Metcalf, JA; Baseler, M; Falloon, J; Davey, RT; Kovacs, JA; Polis, MA; Masur, H; Blaese, RM; Lane, HC			Peripheral expansion of pre-existing mature T cells is an important means of CD4(+) T-cell regeneration HIV-infected adults	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD LYMPHOCYTES; GENE-THERAPY; BONE-MARROW; IN-VIVO; TRIAL	The CD4(+) T-cell pool in HIV-infected patients is in a constant state of flux as CD4(+) T cells are infected and destroyed by HIV and new cells take their place. To study T-cell survival, we adoptively transferred peripheral blood lymphocytes transduced with the neomycin phosphotransferase gene between syngeneic twin pairs discordant for HIV infection. A stable fraction of marked CD4(+) T cells persisted in the circulation for four to eighteen weeks after transfer in all patients. After this time there was a precipitous decline in marked cells in three of the patients. At approximately six months, marked cells were in lymphoid tissues in proportions comparable to those found in peripheral blood. In two patients, the proportion of total signal for the transgene (found by PCR analysis) in the CD4/CD45RA(+) T-cell population relative to the CD4/CD45RO(+) population increased in the weeks after cell infusion. These findings indicate that genetically-marked CD4(+) T cells persist in vivo for weeks to months and that the CD4+ T-cell pool in adults is maintained mostly by the division of mature T cells rather than by differentiation of prethymic stem cells. Thus, after elements of the T-cell repertoire are lost through HIV infection, they may be difficult to replace.	NIAID, Immunoregulat Lab, Clin & Mol Retrovirol Sect, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Dept Transfus Med, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA; Frederick Canc Res & Dev Ctr, SAIC, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Lane, HC (corresponding author), NIAID, Immunoregulat Lab, Clin & Mol Retrovirol Sect, NIH, Bldg 10 Room 11S231, Bethesda, MD 20892 USA.	clane@nih.gov	Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Polis, Michael/0000-0002-9151-2268				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DEWAR RL, APPL BRANCHED DNA SI; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LEDERMAN M, 1997, 4 C RETR OPP INF WAS; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	22	101	103	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					852	856		10.1038/nm0798-852	http://dx.doi.org/10.1038/nm0798-852			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662381				2022-12-25	WOS:000074543900044
J	Finzi, D; Blankson, J; Siliciano, JD; Margolick, JB; Chadwick, K; Pierson, T; Smith, K; Lisziewicz, J; Lori, F; Flexner, C; Quinn, TC; Chaisson, RE; Rosenberg, E; Walker, B; Gange, S; Gallant, J; Siliciano, RF				Finzi, D; Blankson, J; Siliciano, JD; Margolick, JB; Chadwick, K; Pierson, T; Smith, K; Lisziewicz, J; Lori, F; Flexner, C; Quinn, TC; Chaisson, RE; Rosenberg, E; Walker, B; Gange, S; Gallant, J; Siliciano, RF			Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PERIPHERAL-BLOOD; LYMPH-NODES; IN-VIVO; LYMPHOCYTES; EXPRESSION; RESERVOIR; PLASMA; INDIVIDUALS	Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting CD4(+) T cells. We measured the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable. The mean half-life of the latent reservoir was very long (43.9 months). If the latent reservoir consists of only 1 x 10(5) cells, eradication could take as long as 60 years. Thus, latent infection of resting CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective anti-retroviral therapy.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA; Georgetown Univ, Washington, DC 20007 USA; RIGHT, Washington, DC 20007 USA; NIAID, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Cornell University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Johns Hopkins University	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010; Gange, Stephen/AGY-5004-2022	Gange, Stephen/0000-0001-7842-512X; Lisziewicz, Julianna/0000-0002-3349-4495	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000361, R01AI043222, ZIAAI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43222] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTLETT JG, 1998, MED MANAGEMENT HIV I; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CHUN TW, 1999, 6 C RETR OPP INF CHI; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOLKS T, 1986, J IMMUNOL, V136, P4049; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1998, J VIROL, V72, P2422; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; Harris M, 1997, J INFECT DIS, V176, P1388, DOI 10.1086/517328; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	40	1636	1680	0	73	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					512	517		10.1038/8394	http://dx.doi.org/10.1038/8394			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229227				2022-12-25	WOS:000081497400031
J	Kimata, JT; Kuller, L; Anderson, DB; Dailey, P; Overbaugh, J				Kimata, JT; Kuller, L; Anderson, DB; Dailey, P; Overbaugh, J			Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression	NATURE MEDICINE			English	Article							PLASMA VIRAL LOAD; HIV-1 INFECTION; ACQUIRED IMMUNODEFICIENCY; BIOLOGICAL PROPERTIES; REPLICATIVE CAPACITY; MACROPHAGE TROPISM; RHESUS-MONKEYS; MNE VARIANT; MACAQUES; TYPE-1	Genetic variants of human and simian immunodeficiency virus (HIV and SIV) that evolve during the course of infection and progression to AIDS are phenotypically and antigenically distinct from their progenitor viruses present at early stages of infection. However, it has been unclear how these late variants, which are typically T-cell tropic, cytopathic and resistant to neutralizing antibodies, influence the development of clinical AIDS. To address this, we infected macaques with cloned SIVs representing prototype variants from early-, intermediate- and late-stage infection having biological characteristics typical of viruses found at similar stages of HIV infection in humans. These studies demonstrate that sequential, phenotypic and antigenic variants represent viruses that have become increasingly fit for replication in the host, and our data support the hypothesis that emerging variants have increased pathogenicity and drive disease progression in SIV and HIV infection.	Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA; Chiron Diagnost, Chiron Ref Testing Lab, Emeryville, CA 94608 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Novartis; University of Washington; University of Washington Seattle	Overbaugh, J (corresponding author), Fred Hutchinson Canc Res Ctr, Program Mol Med, 1100 Fairview AveN,C3-168, Seattle, WA 98109 USA.			Kimata, Jason/0000-0002-0504-0090	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009337, R01AI034251] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [R01 AI34251, F32 AI09337, F32 AI009337, R01 AI034251] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1986, LANCET, V2, P660; BANAPOUR B, 1991, VIROLOGY, V183, P12, DOI 10.1016/0042-6822(91)90113-P; Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Connor RI, 1998, J VIROL, V72, P7501, DOI 10.1128/JVI.72.9.7501-7509.1998; Dailey P. J., 1995, Journal of Medical Primatology, V24, P209; DESROSIERS RC, 1991, AM J PATHOL, V139, P29; Edmonson P, 1998, J VIROL, V72, P405, DOI 10.1128/JVI.72.1.405-414.1998; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; FENYO EM, 1988, J VIROL, V62, P4414; FIORE JR, 1994, VIROLOGY, V204, P297, DOI 10.1006/viro.1994.1534; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; Glushakova S, 1998, NAT MED, V4, P346, DOI 10.1038/nm0398-346; Harris M, 1997, J INFECT DIS, V176, P1388, DOI 10.1086/517328; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; Kimata JT, 1997, J VIROL, V71, P7629, DOI 10.1128/JVI.71.10.7629-7639.1997; Kimata JT, 1998, J VIROL, V72, P245, DOI 10.1128/JVI.72.1.245-256.1998; KIMATA JT, IN PRESS J VIROL; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MORTON WR, 1989, J MED PRIMATOL, V18, P237; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OVERBAUGH J, 1992, J VIROL, V66, P5937, DOI 10.1128/JVI.66.10.5937-5948.1992; OVERBAUGH J, 1991, J VIROL, V65, P7025, DOI 10.1128/JVI.65.12.7025-7031.1991; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Rudensey LM, 1998, J VIROL, V72, P209, DOI 10.1128/JVI.72.1.209-217.1998; RUDENSEY LM, 1995, VIROLOGY, V207, P528, DOI 10.1006/viro.1995.1113; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; ZACK JA, 1994, AIDS S1, V8, pS43	45	154	155	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					535	541		10.1038/8414	http://dx.doi.org/10.1038/8414			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229230				2022-12-25	WOS:000081497400034
J	Jouanguy, E; Lamhamedi-Cherradi, S; Lammas, D; Dorman, SE; Fondaneche, MC; Dupuis, S; Doffinger, R; Altare, F; Girdlestone, J; Emile, JF; Ducoulombier, H; Edgar, D; Clarke, J; Oxelius, VA; Brai, M; Novelli, V; Heyne, K; Fischer, A; Holland, SM; Kumararatne, DS; Schreiber, RD; Casanova, JL				Jouanguy, E; Lamhamedi-Cherradi, S; Lammas, D; Dorman, SE; Fondaneche, MC; Dupuis, S; Doffinger, R; Altare, F; Girdlestone, J; Emile, JF; Ducoulombier, H; Edgar, D; Clarke, J; Oxelius, VA; Brai, M; Novelli, V; Heyne, K; Fischer, A; Holland, SM; Kumararatne, DS; Schreiber, RD; Casanova, JL			A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection	NATURE GENETICS			English	Article							INTERFERON-GAMMA-RECEPTOR; CALMETTE-GUERIN INFECTION; GENE; IDENTIFICATION; RESISTANCE; SEQUENCE; BCG; DEFICIENCY; CHILDREN; BINDING	The immunogenetic basis of severe infections caused by bacille Calmette-Guerin vaccine and environmental mycobacteria in humans remains largely unknown. We describe 18 patients from several generations of 12 unrelated families who were heterozygous for 1 to 5 overlapping IFNCR1 frameshift small deletions and a wild-type IFNGR1 allele. There were 12 independent mutation events at a single mutation site, defining a small deletion hotspot. Neighbouring sequence analysis favours a small deletion model of slipped mispairing events during replication. The mutant alleles encode cell-surface IFN gamma receptors that lack the intra-cytoplasmic domain, which, through a combination of impaired recycling, abrogated signalling and normal binding to IFN gamma exert a dominant-negative effect. We thus report a hotspot for human IFNGR1 small deletions that confer dominant susceptibility to infections caused by poorly virulent mycobacteria.	Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England; NIH, Host Def Lab, Bethesda, MD 20892 USA; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Hop Paul Brousse, Serv Anat Pathol, F-94804 Villejuif, France; Hop St Antoine, Serv Pediat, F-59019 Lille, France; Royal Victoria Hosp, Reg Immunol Serv, Belfast BT12 6BN, Antrim, North Ireland; Childrens Hosp, Resp & Cyst Fibrosis Unit, Birmingham B4 6NH, W Midlands, England; Univ Lund, Dept Pediat, S-22185 Lund, Sweden; Ist Patol Gen, I-90134 Palermo, Italy; Great Ormond St Hosp Children, Infect Dis Unit, London WC1N 3JH, England; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Birmingham Heartlands Hosp, Reg Dept Immunol, Birmingham, W Midlands, England; Washington Univ, Dept Pathol, St Louis, MO 63110 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Birmingham; National Institutes of Health (NIH) - USA; University of Birmingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Sorbonne Universite; Lund University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Heart of England NHS Foundation Trust; University of Birmingham; Washington University (WUSTL)	Casanova, JL (corresponding author), Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France.	casanova@ceylan.necker.fr	Schreiber, Robert/Q-7550-2019; Boisson-Dupuis, Stéphanie/I-2040-2017; Schreiber, Robert D/A-1276-2013; altare, frederic/K-8664-2015; Casanova, Jean-Laurent/I-3418-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Jouanguy, Emmanuelle/H-7901-2017	Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Schreiber, Robert D/0000-0001-6311-0432; altare, frederic/0000-0002-5077-4616; Jouanguy, Emmanuelle/0000-0002-7358-9157; Girdlestone, John/0000-0001-7422-9674; Edgar, John David Moore/0000-0003-2969-4475; Casanova, Jean-Laurent/0000-0002-7782-4169; Schreiber, Robert/0000-0003-1590-2341	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, Z01AI000647] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL L, 1988, AM J HUM GENET, V42, P256; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Altare F, 1998, CURR OPIN IMMUNOL, V10, P413, DOI 10.1016/S0952-7915(98)80114-3; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BENNETT RL, 1995, AM J HUM GENET, V56, P745, DOI 10.1007/BF01408073; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 1996, PEDIATRICS, V98, P774; CELADA A, 1985, J CLIN INVEST, V76, P2196, DOI 10.1172/JCI112228; Cooper DN, 1998, GENETIC BASIS HUMAN, P65; Coughlin CM, 1998, IMMUNITY, V9, P25, DOI 10.1016/S1074-7613(00)80585-3; de Jong R, 1998, SCIENCE, V280, P1435; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; Emile JF, 1997, J PATHOL, V181, P25, DOI 10.1002/(SICI)1096-9896(199701)181:1<25::AID-PATH747>3.0.CO;2-Z; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; Frucht DM, 1996, J IMMUNOL, V157, P411; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRUNDY CB, 1991, BLOOD, V78, P1027; HEYNE K, 1976, EUR J PEDIATR, V121, P179, DOI 10.1007/BF00445481; Holland SM, 1998, J INFECT DIS, V178, P1095, DOI 10.1086/515670; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1997, J INTERF CYTOK RES, V17, P583, DOI 10.1089/jir.1997.17.583; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; KRAWCZAK M, 1991, HUM GENET, V86, P425; KRAWCZAK M, 1993, HUMAN GENE MUTATIONS, P163; LAMBAMEDI S, 1998, INT J MOL MED, V1, P415; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Mckusick V.A., 1994, MENDELIAN INHERITANC; Merlin G, 1997, IMMUNOGENETICS, V45, P413, DOI 10.1007/s002510050223; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; RASZKA WV, 1994, CLIN PEDIATR, V33, P611, DOI 10.1177/000992289403301007; ROESLER J, IN PRESS EXP HAEMATO; Schonell M E, 1968, Tubercle, V49, P12, DOI 10.1016/S0041-3879(68)80003-0; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; Winfield JB, 1997, CLIN EXP IMMUNOL, V109, P1, DOI 10.1046/j.1365-2249.1997.00439.x	50	368	383	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					370	378		10.1038/7701	http://dx.doi.org/10.1038/7701			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192386				2022-12-25	WOS:000079439700017
J	Borsani, G; Bassi, MT; Sperandeo, MP; De Grandi, A; Buoninconti, A; Riboni, M; Manzoni, M; Incerti, B; Pepe, A; Andria, G; Ballabio, A; Sebastio, G				Borsani, G; Bassi, MT; Sperandeo, MP; De Grandi, A; Buoninconti, A; Riboni, M; Manzoni, M; Incerti, B; Pepe, A; Andria, G; Ballabio, A; Sebastio, G			SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance	NATURE GENETICS			English	Article							GENE; DATABASE	Lysinuric protein intolerance (LPI, MIM 222700) is an autosomal recessive multisystem disorder found mainly in Finland and Italy. On a normal diet, LPI patients present poor feeding, vomiting, diarrhoea, episodes of hyperammoniaemic coma and failure to thrive. Hepatosplenomegaly, osteoporosis and a life-threatening pulmonary involvement (alveolar proteinosis) are also seen(1). LIP is caused by defective cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in kidney and intestine(1). Metabolic derangement is characterized by increased renal excretion of CAA, reduced CAA absorption from intestine and orotic aciduria. The gene causing LPI was assigned using linkage analysis to chromosome 14q11.2 near the T-cell receptor alpha/delta chains locus, and a critical region has been defined(2). We have identified two new transcripts (SLC7A8 and SLC7A7) homologous to amino acid transporters, highly expressed in kidney and mapping in the LPI critical region. Mutational analysis of both transcripts revealed that SLC7A7 (for solute carrier family 7, member 7) is mutated in LPI. In five Italian patients, we found either an insertion or deletion in the coding sequence, which provides evidence of a causative role of SLC7A7 in LPI. Furthermore, we detected a splice acceptor change resulting in a frameshift and premature translation termination in four unrelated Finnish patients. The mutation may represent the founder LPI allele in Finland(2).	TIGEM, I-20132 Milan, Italy; Univ Naples, Dept Pediat, I-80131 Naples, Italy; Univ Vita & Salute, I-20132 Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Naples Federico II; Vita-Salute San Raffaele University	Borsani, G (corresponding author), TIGEM, San Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		andria, generoso/V-7172-2019; Borsani, Giuseppe/B-1709-2010; BALLABIO, Andrea/AAL-2672-2020; Melis, Daniela/AAD-3623-2019; Bassi, Maria Teresa T/A-3517-2014	Borsani, Giuseppe/0000-0003-0110-1148; BALLABIO, Andrea/0000-0003-1381-4604; Melis, Daniela/0000-0002-9458-3926; Bassi, Maria Teresa T/0000-0002-8236-1197	Telethon [TGM06S01, E.0652, TGM97000] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banfi S, 1998, TRENDS GENET, V14, P80, DOI 10.1016/S0168-9525(97)01354-1; Beckmann JS, 1996, AM J HUM GENET, V59, P1400; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Lauteala T, 1998, EUR J HUM GENET, V6, P612, DOI 10.1038/sj.ejhg.5200236; Lauteala T, 1997, AM J HUM GENET, V60, P1479, DOI 10.1086/515457; Lauteala T, 1997, HUM GENET, V100, P80, DOI 10.1007/s004390050469; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PARENTI G, 1995, J PEDIATR-US, V126, P246, DOI 10.1016/S0022-3476(95)70552-X; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Sambrook J., 2002, MOL CLONING LAB MANU; Simell O, 1995, METAB MOL BASES INHE, V1, P3603; Sperandeo MP, 1998, GENOMICS, V49, P230, DOI 10.1006/geno.1998.5252; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Wolf DA, 1996, CANCER RES, V56, P5012	21	176	183	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					297	301		10.1038/6815	http://dx.doi.org/10.1038/6815			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080183				2022-12-25	WOS:000078977900024
J	Burkart, V; Wang, ZQ; Radons, J; Heller, B; Herceg, Z; Stingl, L; Wagner, EF; Kolb, H				Burkart, V; Wang, ZQ; Radons, J; Heller, B; Herceg, Z; Stingl, L; Wagner, EF; Kolb, H			Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin	NATURE MEDICINE			English	Article							NITRIC-OXIDE GENERATION; SYNGENEIC ISLET CELLS; DNA-DAMAGE; NOD MICE; TOXICITY; NICOTINAMIDE; APOPTOSIS; ACTIVATION; SYNTHETASE; ALLOXAN	Human type 1 diabetes results from the selective destruction of insulin-producing pancreatic beta cells during islet inflammation. Cytokines and reactive radicals released during this process con tribute to beta-cell death. Here we show that mice with a disrupted gene coding for poly (ADP-ribose) polymerase (PARP(-/-) mice) are completely resistant to the development of diabetes induced by the beta-cell toxin streptozocin. The mice remained normoglycemic and maintained normal levels of total pancreatic insulin content and normal islet ultrastructure. Cultivated PARP(-/-) islet cells resisted streptozocin-induced lysis and maintained intracellular NAD(+) levels. Our results identify NAD(+) depletion caused by PARP activation as the dominant metabolic event in islet-cell destruction, and provide information for the development of strategies to prevent the progression or manifestation of the disease in individuals at risk of developing type 1 diabetes.	Univ Dusseldorf, Diabet Res Inst, D-40225 Dusseldorf, Germany; Int Agcy Res Canc, F-69008 Lyon, France; Res Inst Mol Pathol, A-1030 Vienna, Austria	Heinrich Heine University Dusseldorf; World Health Organization; International Agency for Research on Cancer (IARC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Burkart, V (corresponding author), Univ Dusseldorf, Diabet Res Inst, Hennekamp 65, D-40225 Dusseldorf, Germany.			Wagner, Erwin F/0000-0001-7872-0196				APPELS B, 1989, J IMMUNOL, V142, P3803; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BURKART V, 1992, INT J IMMUNOPHARMACO, V14, P1037, DOI 10.1016/0192-0561(92)90148-E; Cardinal JW, 1998, ENDOCRINOLOGY, V139, P2885, DOI 10.1210/en.139.6.2885; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; DELANEY CA, 1993, FEBS LETT, V333, P291, DOI 10.1016/0014-5793(93)80673-I; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Eguchi Y, 1997, CANCER RES, V57, P1835; EIZIRIK DL, 1988, ENDOCRINOLOGY, V123, P1001, DOI 10.1210/endo-123-2-1001; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FEHSEL K, 1993, DIABETES, V42, P496, DOI 10.2337/diabetes.42.3.496; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KOLB H, 1987, DIABETES METAB REV, V3, P751, DOI 10.1002/dmr.5610030308; KOLB H, 1990, Journal of Autoimmunity, V3, P117; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P179, DOI 10.1515/bchm3.1995.376.3.179; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; LAZARUS SS, 1973, DIABETES, V22, P499, DOI 10.2337/diab.22.7.499; LEDOUX SP, 1988, DIABETES, V37, P1015, DOI 10.2337/diabetes.37.8.1015; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; RASSCHAERT J, 1992, ENDOCRINOLOGY, V130, P3522, DOI 10.1210/en.130.6.3522; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; SESTILI P, 1990, J CANCER RES CLIN, V116, P615, DOI 10.1007/BF01637083; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simone E, 1996, HORM METAB RES, V28, P332, DOI 10.1055/s-2007-979808; Steiner L, 1997, DIABETOLOGIA, V40, P150, DOI 10.1007/s001250050656; SUAREZPINZON WL, 1994, ENDOCRINOLOGY, V134, P1006, DOI 10.1210/en.134.3.1006; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; TURK J, 1993, BIOCHEM BIOPH RES CO, V197, P1458, DOI 10.1006/bbrc.1993.2641; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAMADA K, 1982, DIABETES, V31, P749, DOI 10.2337/diabetes.31.9.749; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	38	305	337	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					314	319		10.1038/6535	http://dx.doi.org/10.1038/6535			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086388				2022-12-25	WOS:000078851600037
J	Crompton, T				Crompton, T			Feeding the world, harmoniously	NATURE BIOTECHNOLOGY			English	Editorial Material									UN, Int Dev Org, Int Ctr Genet Engn & Biotechnol, Liaison Off, Vienna, Austria		Crompton, T (corresponding author), UN, Int Dev Org, Int Ctr Genet Engn & Biotechnol, Liaison Off, Vienna, Austria.							CROMPTN T, 1998, J BIOLAW BUS, V2, P60; VONSCHOMBERG R, 1998, 90220EEC STOA	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					208	208		10.1038/6908	http://dx.doi.org/10.1038/6908			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096270	Bronze			2022-12-25	WOS:000078977500003
J	Schnitzler, N; Haase, G; Podbielski, A; Lutticken, R; Schweizer, KG				Schnitzler, N; Haase, G; Podbielski, A; Lutticken, R; Schweizer, KG			A co-stimulatory signal through ICAM-beta(2) integrin-binding potentiates neutrophil phagocytosis	NATURE MEDICINE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MAC-1 CD11B/CD18; ACTIVATION; STREPTOCOCCI; RECOGNITION; ANTIBODIES; LIGAND; SITE	The beta(2) integrin LFA-1 (lymphocyte function associated antigen; CD11a/CD18) is the common ligand for the intercellular adhesion molecules(1-4) (ICAMs). Integrins support cell function by providing co-stimulatory second signals that are a precondition for full cell activation first described for ICAM-1-binding to LFA-1 in lymphocytes(3,4). Integrins can also serve to activate functions associated with distinct subunits of other integrins(5). In addition to LFA-1, neutrophils express the beta(2) integrin Mac-1 (CD11b/CD18; CR3) that apparently contains multiple sites that bind invading microbes directly or through surface-fixed C3 (ref. 6), resulting in activation of the phagocyte function(7-11). Expression of the LFA-1 counter-receptor ICAM-1 on endothelial cells occurs only at the site of inflammation(12,13). Therefore, in neutrophils, ICAM-1 ligand binding could, as with lymphocytes, also play a part as a costimulatory signal to induce full phagocytotic function. We show that in neutrophils, the LFA-1 ligand interaction is the stimulatory signal to express full phagocytotic activation. This is best demonstrated by the rapid association of Streptococcus pyogenes with neutrophils, followed by ingestion, strong oxidative-burst induction and enhanced killing of these bacteria, which are well-known for their resistance to human neutrophil defense. These findings may contribute to the development of therapeutic strategies targeting the modulation of ICAM-1-leukocyte interaction.	Univ Hosp, Rhein Westfal TH Aachen, Natl Ref Ctr Streptococci, D-52057 Aachen, Germany; Univ Hosp Ulm, Dept Med Microbiol, D-89081 Ulm, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Med Immunol, D-52057 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Med Microbiol, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Ulm University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Haase, G (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Inst Med Microbiol, D-52057 Aachen, Germany.	haase@alpha.imib.rwth-aachen.de	Haase, Gerhard/C-6492-2009; Lütticken, Rudolf/B-2620-2009	Haase, Gerhard/0000-0001-7771-3189; Lütticken, Rudolf/0000-0002-7061-4759				BALTIMORE RS, 1977, J IMMUNOL, V118, P673; Berton G, 1996, INT J CLIN LAB RES, V26, P160, DOI 10.1007/BF02592978; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Kuhnemund O, 1998, APMIS, V106, P288; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MAYER CL, 1990, INFECT IMMUN, V58, P3765, DOI 10.1128/IAI.58.11.3765-3769.1990; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; Podbielski A, 1996, MOL MICROBIOL, V19, P429, DOI 10.1046/j.1365-2958.1996.377910.x; ROSS GD, 1985, J IMMUNOL, V134, P3307; ROZDZINSKI E, 1995, J CLIN INVEST, V95, P1078, DOI 10.1172/JCI117754; SALVADORI LG, 1995, J INFECT DIS, V171, P593, DOI 10.1093/infdis/171.3.593; SCHLOSSMANN SF, 1995, LEUCOCYTE TYPING, V5, P1548; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P231, DOI 10.1016/0928-8244(93)90017-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TUOMANEN EI, 1992, P 6 NOV NORD FDN S L, P297; VAN SG, 1990, J IMMUNOL, V144, P4579; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VERHOEF J, 1977, J IMMUNOL METHODS, V14, P303, DOI 10.1016/0022-1759(77)90141-7	25	56	59	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					231	235		10.1038/5597	http://dx.doi.org/10.1038/5597			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930874				2022-12-25	WOS:000078274400035
J	Moalem, G; Leibowitz-Amit, R; Yoles, E; Mor, F; Cohen, IR; Schwartz, M				Moalem, G; Leibowitz-Amit, R; Yoles, E; Mor, F; Cohen, IR; Schwartz, M			Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy	NATURE MEDICINE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS PATIENTS; RAT OPTIC-NERVE; LYMPHOCYTE-T; GROWTH-FACTOR; BRAIN INJURY; IMMUNE PRIVILEGE; WHITE MATTER; SPINAL-CORD	Autoimmunity to antigens of the central nervous system is usually considered detrimental. T cells specific to a central nervous system self antigen, such as myelin basic protein, can indeed induce experimental autoimmune encephalomyelitis, but such T cells may nevertheless appear in the blood of healthy individuals. We show here that autoimmune T cells specific to myelin basic protein can protect injured central nervous system neurons from secondary degeneration. After a partial crush injury of the optic nerve, rats injected with activated anti-myelin basic protein T cells retained approximately 300% more retinal ganglion cells with functionally intact axons than did rats injected with activated T cells specific for other antigens. Electrophysiological analysis confirmed this finding and suggested that the neuroprotection could result from a transient reduction in energy requirements owing to a transient reduction in nerve activity. These findings indicate that T-cell autoimmunity in the central nervous system, under certain circumstances, can exert a beneficial effect by protecting injured neurons from the spread of damage.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnschwar@weizmann.weizmann.c.il	Moalem-Taylor, Gila/C-3116-2008; Cohen, Irun R/B-3542-2009; Mor, Felix/K-1093-2012	Moalem-Taylor, Gila/0000-0003-3828-9527; 				Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1991, ANNU REV IMMUNOL, V9, P567, DOI 10.1146/annurev.iy.09.040191.003031; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GILLIS S, 1978, J IMMUNOL, V120, P2027; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HIRSHFELD H, 1970, FEBS LETT, V7, P317, DOI 10.1016/0014-5793(70)80193-4; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; LIU DX, 1994, J NEUROCHEM, V62, P37; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MARTIN R, 1990, J IMMUNOL, V145, P540; Martin R, 1997, J NEURAL TRANSM-SUPP, P53; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MEESON AP, 1994, EXP NEUROL, V129, P299, DOI 10.1006/exnr.1994.1172; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; MOR F, 1993, J CLIN INVEST, V92, P2199, DOI 10.1172/JCI116822; MOR F, 1992, J CLIN INVEST, V90, P2447, DOI 10.1172/JCI116136; MOR F, 1995, J IMMUNOL, V155, P3693; NAPARSTEK Y, 1983, EUR J IMMUNOL, V13, P418, DOI 10.1002/eji.1830130513; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; RANSOM BR, 1990, STROKE, V21, P52; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SPIEGLER OL, 1996, FASEB J, V10, P1296; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; YAROM Y, 1983, NATURE, V303, P246, DOI 10.1038/303246a0; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	53	707	729	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1999	5	1					49	55		10.1038/4734	http://dx.doi.org/10.1038/4734			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883839				2022-12-25	WOS:000077885000029
J	Vocero-Akbani, AM; Vander Heyden, N; Lissy, NA; Ratner, L; Dowdy, SF				Vocero-Akbani, AM; Vander Heyden, N; Lissy, NA; Ratner, L; Dowdy, SF			Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VARIANTS; IDENTIFICATION; INHIBITORS; INFECTIVITY; RESISTANCE; APOPTOSIS; DEATH	At present, treatment of HIV infection uses small inhibitory molecules that target HIV protease; however, the emergence of resistant HIV strains is increasingly problematic. To circumvent this, we report here a new 'Trojan horse' strategy to kill HIV-infected cells by exploiting HIV protease. We engineered a transducing, modified, apoptosis-promoting caspase-3 protein, TAT-Casp3, that substitutes HIV proteolytic cleavage sites for endogenous ones and efficiently transduces about 100% of cells, but remains inactive in uninfected cells. In HIV-infected cells, TAT-Casp3 becomes processed into an active form by HIV protease, resulting in apoptosis of the infected cell. This strategy could also be applied to other pathogens encoding specific proteases, such as hepatitis C virus, cytomegalovirus and malaria.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.	dowdy@pathology.wustl.edu		Ratner, Lee/0000-0003-2744-7294				Barrie KA, 1996, VIROLOGY, V219, P407, DOI 10.1006/viro.1996.0266; COATES PJ, 1994, J HISTOTECHNOL, V17, P261, DOI 10.1179/his.1994.17.3.261; Coffin J, 1997, RETROVIRUSES; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Gatlin J, 1998, VIROLOGY, V244, P87, DOI 10.1006/viro.1998.9083; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LILLEHOJ EP, 1988, J VIROL, V62, P3053, DOI 10.1128/JVI.62.8.3053-3058.1988; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; LOU X, 1998, CELL, V94, P481; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICE CM, 1996, FIELDS VIROLOGY, P931; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; VOCEROAKBANI A, IN PRESS METHODS ENZ; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	32	207	249	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					29	33		10.1038/4710	http://dx.doi.org/10.1038/4710			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883836				2022-12-25	WOS:000077885000026
J	Deeb, SS; Fajas, L; Nemoto, M; Pihlajamaki, J; Mykkanen, L; Kuusisto, J; Laakso, M; Fujimoto, W; Auwerx, J				Deeb, SS; Fajas, L; Nemoto, M; Pihlajamaki, J; Mykkanen, L; Kuusisto, J; Laakso, M; Fujimoto, W; Auwerx, J			A Pro12Ala substitution in PPAR gamma 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity	NATURE GENETICS			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; GLUCOSE-TOLERANCE; GENE-EXPRESSION; RESISTANCE; OBESITY; TRANSCRIPTION; ADIPOGENESIS; PROMOTER	The peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a transcription factor that has a pivotal role in adipocyte differentiation and expression of adipocyte-specific genes(1-3) The PPAR gamma 1 and gamma 2 isoforms result from alternative splicing(4) and have ligand-dependent and -independent activation domains. PPAR gamma 2 has an additional 28 amino acids at its amino terminus that renders its ligand-independent activation domain 5-10-fold more effective than that of PPAR gamma 1. Insulin stimulates the ligand-independent activation of PPAR gamma 1 and gamma 2 (ref. 5), however, obesity and nutritional factors only influence the expression of PPAR gamma 2 in human adipocytes(6). Here, we report that a relatively common Pro12Ala substitution in PPAR gamma 2 is associated with lower body mass index (BMI; P=0.027; 0.015) and improved insulin sensitivity among middle-aged and elderly Finns. A significant odds ratio (4.35, P=0.028) for the association of the Pro/Pro genotype with type 2 diabetes was observed among Japanese Americans. The PPAR gamma 2 Ala allele showed decreased binding affinity to the cognate promoter element and reduced ability to transactivate responsive promoters. These findings suggest that the PPAR gamma 2 Pro12Ala variant may contribute to the observed variability in BMI and insulin sensitivity in the general population.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Inst Pasteur, Dept Atherosclerose, U325 INSERM, F-59019 Lille, France; Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Kuopio University Hospital; University of Eastern Finland	Deeb, SS (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.		Coll, Lluis Fajas/C-8567-2014	Auwerx, Johan/0000-0002-5065-5393; Fajas, Lluis/0000-0002-1283-9503; Pihlajamaki, Jussi/0000-0002-6241-6859	NHLBI NIH HHS [HL30086] Funding Source: Medline; NIDDK NIH HHS [DK3117, DK 17047] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auwerx J, 1996, J MOL MED, V74, P347, DOI 10.1007/BF00210629; Beamer BA, 1997, BIOCHEM BIOPH RES CO, V233, P756, DOI 10.1006/bbrc.1997.6540; BOUCHARD C, 1995, INT J OBES REL METAB, V19, P510; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chagnon YC, 1998, OBES RES, V6, P76, DOI 10.1002/j.1550-8528.1998.tb00318.x; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; FUJIMOTO WY, 1989, DIABETES METAB REV, V5, P607, DOI 10.1002/dmr.5610050706; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KAHN CR, 1995, NATURE, V373, P384; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Meirhaeghe A, 1998, HUM MOL GENET, V7, P435, DOI 10.1093/hmg/7.3.435; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; MYKKANEN L, 1994, METABOLISM, V43, P523, DOI 10.1016/0026-0495(94)90088-4; NEVIN DN, 1994, ARTERIOSCLER THROMB, V14, P869, DOI 10.1161/01.ATV.14.6.869; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Norman RA, 1997, AM J HUM GENET, V60, P166; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230	30	1093	1160	1	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					284	287		10.1038/3099	http://dx.doi.org/10.1038/3099			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806549				2022-12-25	WOS:000076698100024
J	Koshland, DE				Koshland, DE			Conformational changes: How small is big enough?	NATURE MEDICINE			English	Editorial Material							SALMONELLA-TYPHIMURIUM; ASPARTATE RECEPTOR; DOMAIN; COOPERATIVITY; LIGAND		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Koshland, DE (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P107; BERG H, 1986, P NATL ACAD SCI USA, V83, P8989; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; CHEN X, 1997, BIOCHEM, V39, P11858; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; KOSHLAND DE, 1987, COLD SPRING HARB SYM, V52, P1; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KOSHLAND DE, 1963, SCIENCE, V142, P1533, DOI 10.1126/science.142.3599.1533; KOSHLAND DE, 1963, COLD SPRING HARB SYM, V28, P473, DOI 10.1101/SQB.1963.028.01.063; KOSHLAND DE, 1976, FED PROC, V35, P2104; Koshland Jr D.E, 1980, BACTERIAL CHEMOTAXIS; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; STEITZ TA, 1967, J BIOL CHEM, V242, P4662; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; THOMA JA, 1960, J AM CHEM SOC, V82, P3329, DOI 10.1021/ja01498a025; WYCKOFF HW, 1967, J BIOL CHEM, V242, P3749; YANKEELOV JA, 1965, J BIOL CHEM, V240, P1593	25	84	85	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1112	1114		10.1038/2605	http://dx.doi.org/10.1038/2605			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771734				2022-12-25	WOS:000076230100020
J	Nonogaki, K; Strack, AM; Dallman, MF; Tecott, LH				Nonogaki, K; Strack, AM; Dallman, MF; Tecott, LH			Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FACTOR-ALPHA; OBESE GENE; WEIGHT; EXPRESSION; LOCALIZATION; PROTEIN; BRAIN	Brain serotonin and leptin signaling contribute substantially to the regulation of feeding and energy expenditure. Here we show that young adult mice with a targeted mutation of the serotonin 5-HT2C receptor gene consume more food despite normal responses to exogenous leptin administration. Chronic hyperphagia leads to a 'middle-aged'-onset obesity associated with a partial leptin resistance of late onset. In addition, older mice develop insulin resistance and impaired glucose tolerance. Mutant mice also responded more to high-fat feeding, leading to hyperglycemia without hyperlipidemia. These findings demonstrate a dissociation of serotonin and leptin signaling in the regulation of feeding and indicate that a perturbation of brain serotonin systems can predispose to type 2 diabetes.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tecott, LH (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.							Abel E. Dale, 1996, P530; Blundell JE, 1995, OBES RES, V3, pS471, DOI 10.1002/j.1550-8528.1995.tb00214.x; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CRAPO PA, 1994, JOSLINS DIABETES MEL, P415; Curzon G, 1997, TRENDS PHARMACOL SCI, V18, P21, DOI 10.1016/S0165-6147(96)01003-6; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hotamisligil Gokhan S., 1996, P554; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Milatovich Athena, 1992, Human Molecular Genetics, V1, P681, DOI 10.1093/hmg/1.9.681; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Simansky KJ, 1996, BEHAV BRAIN RES, V73, P37, DOI 10.1016/0166-4328(96)00066-6; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; WRIGHT DE, 1995, J COMP NEUROL, V351, P357, DOI 10.1002/cne.903510304; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666	28	359	378	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1152	1156		10.1038/2647	http://dx.doi.org/10.1038/2647			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771748				2022-12-25	WOS:000076230100034
J	Agris, CH				Agris, CH			Patenting DNA sequences	NATURE BIOTECHNOLOGY			English	Editorial Material									Baker & Botts LLP, Houston, TX 77002 USA		Agris, CH (corresponding author), Baker & Botts LLP, Houston, TX 77002 USA.							Agris CH, 1996, NAT BIOTECHNOL, V14, P1309, DOI 10.1038/nbt1096-1309; Chahine KG, 1998, NAT BIOTECHNOL, V16, P683, DOI 10.1038/nbt0798-683; FABER RC, 1997, LENDIS MECH PATENT C	3	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					877	877		10.1038/nbt0998-877	http://dx.doi.org/10.1038/nbt0998-877			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743124				2022-12-25	WOS:000075671700037
J	Guo, Q; Fu, WM; Xie, J; Luo, H; Sells, SF; Geddes, JW; Bondada, V; Rangnekar, VM; Mattson, MP				Guo, Q; Fu, WM; Xie, J; Luo, H; Sells, SF; Geddes, JW; Bondada, V; Rangnekar, VM; Mattson, MP			Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; APOPTOSIS	Prostate apoptosis response-4 (Par-4) is a protein containing both a leucine zipper and a death domain that was isolated by differential screening for genes upregulated in prostate cancer cells undergoing apoptosis(1,2). Par-4 is expressed in the nervous system(3), where its function is unknown. In Alzheimer disease (AD), neurons may die by apoptosis, and amyloid beta-protein (A beta) may play a role in this(4-11). We report here that Par-4 expression is increased in vulnerable neurons in AD brain and is induced in cultured neurons undergoing apoptosis. Blockade of Par-4 expression or function prevented neuronal apoptosis induced by Ab and trophic factor withdrawl. Par-4 expression was enhanced, and mitochondrial dysfunction and apoptosis exacerbated, in cells expressing presenilin-1 mutations associated with early-onset inherited AD.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.		Mattson, Mark P/F-6038-2012					Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Keller JN, 1998, J NEUROSCI, V18, P4439; Keller JN, 1998, J NEUROSCI, V18, P687; Kruman I, 1997, J NEUROSCI, V17, P5089; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Mark RJ, 1996, MOL NEUROBIOL, V12, P211, DOI 10.1007/BF02755589; Mattson MP, 1997, NEUROREPORT, V8, P3817, DOI 10.1097/00001756-199712010-00031; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MATTSON MP, 1997, ADV CELL AGING GERON, V2, P299; Moretti A., 1997, ADV CELL AGING GERON, V2, P129; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031	27	236	257	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					957	962		10.1038/nm0898-957	http://dx.doi.org/10.1038/nm0898-957			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701251				2022-12-25	WOS:000075107400042
J	Kohl, S; Marx, T; Giddings, I; Jagle, H; Jacobson, SG; Apfelstedt-Sylla, E; Zrenner, E; Sharpe, LT; Wissinger, B				Kohl, S; Marx, T; Giddings, I; Jagle, H; Jacobson, SG; Apfelstedt-Sylla, E; Zrenner, E; Sharpe, LT; Wissinger, B			Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel	NATURE GENETICS			English	Article							FUNCTIONAL EXPRESSION; CHROMOSOMAL LOCALIZATION; RETINITIS-PIGMENTOSA; ROD; CLONING	Total colourblindness (OMIM 216900), also referred to as rod monochromacy (RM) or complete achromatopsia, is a rare, autosomal recessive inherited and congenital disorder characterized by photophobia, reduced visual acuity, nystagmus and the complete inability to discriminate between colours(1). Electroretinographic recordings show that in RM, rod photoreceptor function is normal, whereas cone photoreceptor responses are absent. The locus for RM has been mapped to chromosome 2q11 (ref. 2), however the gene underlying RM has not yet been identified. Recently a suitable candidate gene, CNGA3, encoding the alpha-subunit of the cone photoreceptor cCMP-gated cation channel, a key component of the phototransduction pathway, has been cloned and assigned to human chromosome 2q11 (refs 3,4). We report the identification of missense mutations in CNGA3 in five families with RM. Homozygous mutations are present in two families, whereas the remaining families show compound heterozygous mutations. In all cases, the segregation pattern of the mutations is consistent with the autosomal recessive inheritance of the disease and all mutations affect amino acids that are highly conserved among cyclic nucleotide gated channels (CNC) in various species. This is the first report of a colour vision disorder caused by defects other than mutations in the cone pigment genes, and implies at least in this instance a common genetic basis for phototransduction in the three different cone photoreceptors of the human retina.	Univ Tubingen, Augenklin, Genet Mol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Augenklin, Psychophys Lab, Forschungsstelle Expt Ohpthalmol, D-72076 Tubingen, Germany; Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany; Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Pennsylvania; Pennsylvania Medicine	Wissinger, B (corresponding author), Univ Tubingen, Augenklin, Genet Mol Lab, Schleichstr 12-16, D-72076 Tubingen, Germany.		Jägle, Herbert/GPP-2945-2022	Kohl, Susanne/0000-0002-6438-6331; Jacobson, Samuel/0000-0003-2122-169X; Giddings, Ian/0000-0003-1078-5780	NEI NIH HHS [EY-05627] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arbour NC, 1997, HUM MOL GENET, V6, P689, DOI 10.1093/hmg/6.5.689; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BROWN RL, 1995, BIOCHEMISTRY-US, V34, P8365, DOI 10.1021/bi00026a018; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; PITTLER SJ, 1992, J BIOL CHEM, V267, P6257; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; SHARPE LT, 1990, NIGHT VISION BASIC C; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wissinger B, 1997, EUR J NEUROSCI, V9, P2512, DOI 10.1111/j.1460-9568.1997.tb01680.x; WISSINGER B, IN PRESS GENOMICS; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	17	250	259	1	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					257	259		10.1038/935	http://dx.doi.org/10.1038/935			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662398				2022-12-25	WOS:000074565900021
J	Tacke, E; Salamini, F; Rohde, W				Tacke, E; Salamini, F; Rohde, W			Genetic engineering of potato for broad-spectrum protection against virus infection	NATURE BIOTECHNOLOGY			English	Article						cell-to-cell movement; phloem transport; plasmodesma; Solanum tuberosum	TOBACCO MOSAIC-VIRUS; COAT PROTEIN GENE; TRANSGENIC PLANTS; MOVEMENT PROTEIN; LEAFROLL VIRUS; RESISTANCE; EXPRESSION; INITIATION; VECTORS; RNA	Transgenic potato plants expressing mutant alleles of PLRV ORF4, the gene for the movement protein pr17 of this luteovirus, were generated for broad-range protection against virus infection. When tested for protection against infection by PLRV, all transgenic lines showed a significant reduction of virus antigen. Potato lines accumulating N- or C-terminally extended PLRV pr17 mutant proteins were resistant to infection by the unrelated potato viruses PW and PVX. Transgenic lines that did not express protein despite high transcript levels failed to exhibit virus resistance.	MAX PLANCK INST ZUCHTUNGSFORSCH,D-50829 COLOGNE,GERMANY	Max Planck Society								BARKER H, 1993, PLANT CELL REP, V13, P54, DOI 10.1007/BF00232316; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; Chay CA, 1996, VIROLOGY, V219, P57, DOI 10.1006/viro.1996.0222; COOPER B, 1995, VIROLOGY, V206, P307, DOI 10.1016/S0042-6822(95)80046-8; KAWCHUK LM, 1991, MOL PLANT MICROBE IN, V4, P247, DOI 10.1094/MPMI-4-247; LAPIDOT M, 1993, PLANT J, V4, P959, DOI 10.1046/j.1365-313X.1993.04060959.x; LOMONOSSOFF GP, 1995, ANNU REV PHYTOPATHOL, V33, P323, DOI 10.1146/annurev.py.33.090195.001543; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MALYSHENKO SI, 1993, J GEN VIROL, V74, P1149, DOI 10.1099/0022-1317-74-6-1149; MILLER WA, 1995, CRIT REV PLANT SCI, V14, P179, DOI 10.1080/713608119; QERCI M, 1995, PHYTOPATHOLOGY, V85, P1003; Ross H., 1986, POTATO BREEDING PROB, V13, P82; Schmitz J, 1996, NUCLEIC ACIDS RES, V24, P257, DOI 10.1093/nar/24.2.257; SCHMITZ J, 1995, THESIS U COLOGNE GER; Strittmatter G, 1996, MOL PLANT MICROBE IN, V9, P68, DOI 10.1094/MPMI-9-0068; TACKE E, 1991, J GEN VIROL, V72, P2035, DOI 10.1099/0022-1317-72-8-2035; TACKE E, 1993, VIROLOGY, V197, P274, DOI 10.1006/viro.1993.1588; TACKE E, 1990, J GEN VIROL, V71, P2265, DOI 10.1099/0022-1317-71-10-2265; Tacke E, 1995, PLANT J, V8, P907, DOI 10.1046/j.1365-313X.1995.8060907.x; TACKE E, 1995, BIOTECHNOLOGY PLANT, P353; Tacke E, 1996, P EAPR VIR SECT M, P15; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; VANDERWILK F, 1991, PLANT MOL BIOL, V17, P431, DOI 10.1007/BF00040637	24	41	43	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1597	1601		10.1038/nbt1196-1597	http://dx.doi.org/10.1038/nbt1196-1597			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634829				2022-12-25	WOS:A1996VP83300030
J	Rieder, MJ; Taylor, SL; Clark, AG; Nickerson, DA				Rieder, MJ; Taylor, SL; Clark, AG; Nickerson, DA			Sequence variation in the human angiotensin converting enzyme	NATURE GENETICS			English	Article							HUMAN LIPOPROTEIN-LIPASE; CARDIOVASCULAR-DISEASE; DNA-SEQUENCES; GENE; POLYMORPHISM; POPULATIONS; INFERENCE; GENOTYPE; AFRICAN; NUMBER	Angiotensin converting enzyme (encoded by the gene DCP1, also known as ACE) catalyses the conversion of angiotensin I to the physiologically active peptide angiotensin II, which controls fluid-electrolyte balance and systemic blood pressure. Because of its key function in the renin-angiotensin system, many association studies have been performed with DCP1. Nearly all studies have associated the presence (insertion, I) or absence (deletion, D) of a 287-bp Alu repeat element in intron 16 with the levels of circulating enzyme or cardiovascular pathophysiologies(1-3). Many epidemiological studies suggest that the DCP1*D allele confers increased susceptibility to cardiovascular disease; however, other reports have found no such association or even a beneficial effect (refs 4-7), We present here the complete genomic sequence of DCP1 from 11 individuals, representing the longest contiguous scan (24 kb) for sequence variation in human DNA, We identified 78 varying sites in 22 chromosomes that resolved into 13 distinct haplotypes. Of the variant sites, 17 were in absolute linkage disequilibrium with the commonly typed Alu insertion/deletion polymorphism, producing two distinct and distantly related clades. We also identified a major subdivision in the Alu deletion clade that enables further analysis of the traits associated with this gene. The diversity uncovered in DCP1 is comparable to that described for other regions in the human genomes-(8-11), The highly correlated structure in DCP1 raises important issues for the determination of functional DNA variants within genes and genetic studies in humans based on marker association.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Penn State Univ, Dept Biol, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Rieder, MJ (corresponding author), Univ Washington, Dept Mol Biotechnol, Box 357730, Seattle, WA 98195 USA.		Rieder, Michael J/L-2397-2013	Clark, Andrew/0000-0001-7159-8511	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058240, R01HL058238] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001436] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01436] Funding Source: Medline; NHLBI NIH HHS [HL58238, HL58240] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; EVANS AE, 1994, Q J MED, V87, P211; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; GRIFFITHS RC, 1994, STAT SCI, V9, P307, DOI 10.1214/ss/1177010378; Harding RM, 1997, AM J HUM GENET, V60, P772; Hey J, 1997, MOL BIOL EVOL, V14, P166, DOI 10.1093/oxfordjournals.molbev.a025749; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUDSON RR, 1985, GENETICS, V111, P147; Keavney B, 1998, HUM MOL GENET, V7, P1745, DOI 10.1093/hmg/7.11.1745; Long AD, 1998, GENETICS, V149, P999; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Nachman MW, 1998, GENETICS, V150, P1133; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; O'Donnell CJ, 1998, CIRCULATION, V97, P1766, DOI 10.1161/01.CIR.97.18.1766; O'Malley JP, 1998, CIRCULATION, V97, P1780, DOI 10.1161/01.CIR.97.18.1780; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Schunkert H, 1997, J MOL MED-JMM, V75, P867, DOI 10.1007/s001090050178; SCRIVER CR, 1996, VARIATION HUMAN GENO, P73; SING CF, 1992, EUR J EPIDEMIOL, V8, P3, DOI 10.1007/BF00145343; SOUBRIER F, 1994, EUR HEART J, V15, P24, DOI 10.1093/eurheartj/15.suppl_D.24; TAJIMA F, 1989, GENETICS, V123, P585; TAJIMA F, 1983, GENETICS, V105, P437; Tavare S, 1997, GENETICS, V145, P505; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	30	377	391	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					59	62		10.1038/8760	http://dx.doi.org/10.1038/8760			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319862				2022-12-25	WOS:000080096300023
J	Brune, W; Menard, C; Hobom, U; Odenbreit, S; Messerle, M; Koszinowski, UH				Brune, W; Menard, C; Hobom, U; Odenbreit, S; Messerle, M; Koszinowski, UH			Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis	NATURE BIOTECHNOLOGY			English	Article						BAC; transposon mutagenesis; cytomegalovirus; functional genomics	SIMPLEX VIRUS TYPE-1; MURINE CYTOMEGALOVIRUS; SHUTTLE MUTAGENESIS; MINI-TRANSPOSON; REPLICATION; SEQUENCE; GENOME; DNA; DELETION; CLONING	Herpesviruses are important pathogens in animals and humans. The large DNA genomes of several herpesviruses have been sequenced, but the function of the majority of putative genes is elusive. Determining which genes are essential for their replication is important for identifying potential chemotherapy targets, designing herpesvirus vectors, and generating attenuated vaccines. For this purpose, we recently reported that herpesvirus genomes can be maintained as infectious bacterial artificial chromosomes (BAC) in Escherichia coli. Here we describe a one-step procedure for random-insertion mutagenesis of a herpesvirus BAC using a Tn1721-based transposon system. Transposon insertion sites were determined by direct sequencing, and infectious virus was recovered by transfecting cultured cells with the mutant genomes. Lethal mutations were rescued by cotransfecting cells containing noninfectious genomes with the corresponding wild-type subgenomic fragments. We also constructed revertant genomes by allelic exchange in bacteria. These methods, which are generally applicable to any cloned herpesvirus genome, will facilitate analysis of gene function for this virus family.	Univ Munich, Max Von Pettenkofer Inst, Dept Virol, D-80336 Munich, Germany; Univ Munich, Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany	University of Munich; University of Munich	Koszinowski, UH (corresponding author), Univ Munich, Max Von Pettenkofer Inst, Dept Virol, Pettenkoferstr 9A, D-80336 Munich, Germany.	koszinowski@m3401.mpk.med.uni-muenchen.de	Brune, Wolfram/H-5058-2019	Brune, Wolfram/0000-0002-6078-5255; Messerle, Martin/0000-0002-1227-3933				BERG CM, 1989, MOBILE DNA, P879; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1447, DOI 10.1111/j.1365-2958.1991.tb00791.x; CHANG YE, 1993, J VIROL, V67, P6348, DOI 10.1128/JVI.67.11.6348-6356.1993; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; EBELING A, 1983, J VIROL, V47, P421, DOI 10.1128/JVI.47.3.421-433.1983; GLORIOSO JC, 1995, ANNU REV MICROBIOL, V49, P675, DOI 10.1146/annurev.mi.49.100195.003331; HAAS R, 1993, GENE, V130, P23, DOI 10.1016/0378-1119(93)90342-Z; Hengel H, 1998, TRENDS MICROBIOL, V6, P190, DOI 10.1016/S0966-842X(98)01255-4; JENKINS FJ, 1986, J VIROL, V59, P494, DOI 10.1128/JVI.59.2.494-499.1986; JENKINS FJ, 1985, P NATL ACAD SCI USA, V82, P4773, DOI 10.1073/pnas.82.14.4773; Kahrs AF, 1995, GENE, V167, P53, DOI 10.1016/0378-1119(95)00671-0; Martinez R, 1996, J VIROL, V70, P2075, DOI 10.1128/JVI.70.4.2075-2085.1996; Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759; Mocarski E, 1996, FIELDS VIROLOGY, P2447; Mocarski ES, 1996, INTERVIROLOGY, V39, P320, DOI 10.1159/000150503; Posfai G, 1997, J BACTERIOL, V179, P4426, DOI 10.1128/jb.179.13.4426-4428.1997; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; Roizman B, 1996, FIELDS VIROLOGY, P2231; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Simon MI, 1997, NAT BIOTECHNOL, V15, P839, DOI 10.1038/nbt0997-839; SPAETE RR, 1994, J GEN VIROL, V75, P3287, DOI 10.1099/0022-1317-75-12-3287; Stavropoulos TA, 1998, J VIROL, V72, P7137, DOI 10.1128/JVI.72.9.7137-7143.1998; WEBER PC, 1987, SCIENCE, V236, P576, DOI 10.1126/science.3033824	24	90	95	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					360	364		10.1038/7914	http://dx.doi.org/10.1038/7914			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207884				2022-12-25	WOS:000079574400024
J	Cherry, JR; Lamsa, MH; Schneider, P; Vind, J; Svendsen, A; Jones, A; Pedersen, AH				Cherry, JR; Lamsa, MH; Schneider, P; Vind, J; Svendsen, A; Jones, A; Pedersen, AH			Directed evolution of a fungal peroxidase	NATURE BIOTECHNOLOGY			English	Article						peroxidase; directed evolution; thermostability; DNA shuffling; protein engineering	COPRINUS-CINEREUS PEROXIDASE; SACCHAROMYCES-CEREVISIAE; PROTEIN; ACID; THERMOSTABILITY; RECOMBINATION; GENES	The Coprinus cinereus (CIP) heme peroxidase was subjected to multiple rounds of directed evolution in an effort to produce a mutant suitable for use as a dye-transfer inhibitor in laundry detergent. The wild-type peroxidase is rapidly inactivated under laundry conditions due to the high pH (10.5), high temperature (50 degrees C), and high peroxide concentration (5-10 mM). Peroxidase mutants were initially generated using two parallel approaches: site-directed mutagenesis based on structure-function considerations, and error-prone PCR to create random mutations. Mutants were expressed in Saccharomyces cerevisiae and screened for improved stability by measuring residual activity after incubation under conditions mimicking those in a washing machine. Manually combining mutations from the site-directed and random approaches led to a mutant with 110 times the thermal stability and 2.8 times the oxidative stability of wild-type CiP. In the final two rounds, mutants were randomly recombined by using the efficient yeast homologous recombination system to shuffle point mutations among a large number of parents, This in vivo shuffling led to the most dramatic improvements in oxidative stability, yielding a mutant with 174 times the thermal stability and 100 times the oxidative stability of wild-type CiP.	Novo Nordisk Biotech Inc, Davis, CA 95616 USA; Novo Nordisk AS, Enzyme Design, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Cherry, JR (corresponding author), Novo Nordisk Biotech Inc, 1445 Drew Ave, Davis, CA 95616 USA.	cherry@nnbt.com						Abelskov AK, 1997, BIOCHEMISTRY-US, V36, P9453, DOI 10.1021/bi970387r; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Leung DW, 1989, TECHNIQUE, V1, P11; LopezCamacho C, 1996, BIOCHEM J, V314, P833, DOI 10.1042/bj3140833; MANIVASAKAM P, 1993, NUCLEIC ACIDS RES, V21, P4414, DOI 10.1093/nar/21.18.4414; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Nedwin GE, 1997, ENVIR SCI R, V54, P13; PETERSEN JFW, 1993, J MOL BIOL, V232, P989, DOI 10.1006/jmbi.1993.1445; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POULOS TL, 1980, J BIOL CHEM, V255, P8199; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	19	248	278	2	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					379	384		10.1038/7939	http://dx.doi.org/10.1038/7939			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207888				2022-12-25	WOS:000079574400028
J	Maitra, A; Wistuba, II; Virmani, AK; Sakaguchi, M; Park, IW; Stucky, A; Milchgrub, S; Gibbons, D; Minna, JD; Gazdar, AF				Maitra, A; Wistuba, II; Virmani, AK; Sakaguchi, M; Park, IW; Stucky, A; Milchgrub, S; Gibbons, D; Minna, JD; Gazdar, AF			Enrichment of epithelial cells for molecular studies	NATURE MEDICINE			English	Article							LASER-CAPTURE MICRODISSECTION; BREAST-CANCER; PANCREATIC ADENOCARCINOMA; CARCINOMA; TUMOR; TISSUE; LINES; ALLELOTYPE; XENOGRAFTS; PCR		Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	gazdar@simmons.swmed.edu			NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAR JK, 1994, TUMORI, V80, P290, DOI 10.1177/030089169408000410; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Eaton MC, 1997, BIOTECHNIQUES, V22, P100, DOI 10.2144/97221st01; FOSTER HM, 1990, J SURG ONCOL, V45, P4; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gazdar AF, 1996, J CELL BIOCHEM, P1; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Going JJ, 1996, J PATHOL, V179, P121; HAHN SA, 1995, CANCER RES, V55, P4670; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; MCQUEEN HA, 1991, BRIT J CANCER, V63, P94, DOI 10.1038/bjc.1991.19; Racila E, 1998, P NATL ACAD SCI USA, V95, P4589, DOI 10.1073/pnas.95.8.4589; Reyes G, 1996, CANCER RES, V56, P5713; Sakaguchi M, 1999, BRIT J CANCER, V79, P416, DOI 10.1038/sj.bjc.6690065; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIBATA D, 1992, AM J PATHOL, V141, P539; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; Thiagalingam S, 1996, CANCER RES, V56, P2936; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	23	54	57	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					459	463		10.1038/7458	http://dx.doi.org/10.1038/7458			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202940				2022-12-25	WOS:000079574300040
J	Perez, GI; Robles, R; Knudson, CM; Flaws, JA; Korsmeyer, SJ; Tilly, JL				Perez, GI; Robles, R; Knudson, CM; Flaws, JA; Korsmeyer, SJ; Tilly, JL			Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency	NATURE GENETICS			English	Article							EXPRESSION; APOPTOSIS; BCL-2; MICE	Female mammals are endowed with a finite number of oocytes at birth, each enclosed by a single layer of somatic (granulosa) cells in a primordial follicle(1,2). The fate of most follicles is atretic degeneration(1,3), a process that culminates in near exhaustion of the oocyte reserve at approximately the fifth decade of life in women, leading to menopause(4,5). Apoptosis has a fundamental role in follicular atresia(6,7), and recent studies have shown that Bax, which is expressed in both granulosa cells(8,9) and oocytes(10), may be central to ovarian cell death(6-12). Here we show that young adult female Bax(-/-) mice possess threefold more primordial follicles in their ovarian reserve than their wild-type sisters, and this surfeit of follicles is maintained in advanced chronological age, such that 20-22-month-old female Bax(-/-) mice possess hundreds of follicles at ail developmental stages and exhibit ovarian steroid-driven uterine hypertrophy. These observations contrast with the ovarian and uterine atrophy seen in aged wild-type female mice. Aged female Bax(-/-) mice fail to become pregnant when housed with young adult males; however, metaphase II oocytes can be retrieved from, and corpora lutea form in, ovaries of aged Bax(-/-) females following superovulation with exogenous gonadotropins, and some oocytes are competent for in vitro fertilization and early embryogenesis. Therefore, ovarian lifespan can be extended by selectively disrupting Bax function, but other aspects of normal reproductive performance remain defective in aged Bax(-/-) female mice.	Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore	Tilly, JL (corresponding author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.		Perez, Gloria I/GMX-1286-2022	Knudson, Charles Michael/0000-0003-3964-5466	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49712] Funding Source: Medline; NIA NIH HHS [R01-AG12279] Funding Source: Medline; NICHD NIH HHS [R01-HD34226] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; GOSDEN RG, 1983, BIOL REPROD, V28, P255, DOI 10.1095/biolreprod28.2.255; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; HAMMOND CB, 1996, OBSTET GYNECOL, V87, P25; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kugu K, 1998, CELL DEATH DIFFER, V5, P67, DOI 10.1038/sj.cdd.4400316; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly J. L., 1996, CONTEMP OBSTET GYNEC, V41, P59; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TILLY JL, 1998, CELLS DIE COMPREHENS, P431; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	15	295	320	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					200	203		10.1038/5985	http://dx.doi.org/10.1038/5985			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988273				2022-12-25	WOS:000078399500023
J	Umana, P; Jean-Mairet, J; Moudry, R; Amstutz, H; Bailey, JE				Umana, P; Jean-Mairet, J; Moudry, R; Amstutz, H; Bailey, JE			Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity	NATURE BIOTECHNOLOGY			English	Article						glycosylation; effector function; antitumor antibody; tetracycline	TIME-OF-FLIGHT; MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; IN-VIVO; OLIGOSACCHARIDES; CELLS; GLYCOSYLATION; NEUROBLASTOMA; EXPRESSION; MODULATE	The glycosylation pattern of chCE7, an antineuroblastoma chimeric IgG1, was engineered in Chinese hamster ovary cells with tetracycline-regulated expression of beta(1,4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisected oligosaccharides that have been implicated in antibody-dependent cellular cytotoxicity (ADCC). Measurement of the ADCC activity of chCE7 produced at different tetracycline levels showed an optimal range of GnTIII expression for maximal chCE7 in vitro ADCC activity, and this activity correlated with the level of constant region-associated, bisected complex oligosaccharides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The new optimized variants of chCE7 exhibit substantial ADCC activity and, hence, may be useful for treatment of neuroblastoma. The strategy presented here should be applicable to optimize the ADCC activity of other therapeutic IgGs.	ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland; Swiss Red Cross, Blood Transfus Serv, Cent Lab, ZLB, CH-3000 Bern 22, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bailey, JE (corresponding author), ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland.							AMSTUTZ H, 1993, INT J CANCER, V53, P147, DOI 10.1002/ijc.2910530127; BERGWERFF AA, 1995, GLYCOCONJUGATE J, V12, P318, DOI 10.1007/BF00731335; BIBILA TA, 1995, BIOTECHNOL PROGR, V11, P1, DOI 10.1021/bp00031a001; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; Deo YM, 1997, IMMUNOL TODAY, V18, P127, DOI 10.1016/S0167-5699(97)01007-4; Dillman RO, 1997, CANCER BIOTHER RADIO, V12, P223, DOI 10.1089/cbr.1997.12.223; DURR U, 1993, EUR J NUCL MED, V20, P858; Field M, 1996, ANAL BIOCHEM, V239, P92, DOI 10.1006/abio.1996.0295; Frost JD, 1997, CANCER, V80, P317, DOI 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; KNSTER B, 1997, ANAL BIOCHEM, V250, P82; KOLBER MA, 1988, J IMMUNOL METHODS, V108, P255, DOI 10.1016/0022-1759(88)90427-9; Lifely MR, 1995, GLYCOBIOLOGY, V5, P813, DOI 10.1093/glycob/5.8.813; Lund J, 1996, J IMMUNOL, V157, P4963; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; REFF ME, 1994, BLOOD, V83, P435; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; STANLEY P, 1984, J BIOL CHEM, V261, P13370; Surfus JE, 1996, J IMMUNOTHER, V19, P184, DOI 10.1097/00002371-199605000-00003; TRILL JJ, 1995, CURR OPIN BIOTECH, V6, P553, DOI 10.1016/0958-1669(95)80092-1; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; YU IP, 1994, ARCH BIOCHEM BIOPHYS, V308, P387	26	573	1043	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					176	180		10.1038/6179	http://dx.doi.org/10.1038/6179			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052355				2022-12-25	WOS:000078508300027
J	Ito, Y; Sugimura, N; Kwon, OH; Imanishi, Y				Ito, Y; Sugimura, N; Kwon, OH; Imanishi, Y			Enzyme modification by polymers with solubilities that change in response to photoirradiation in organic media	NATURE BIOTECHNOLOGY			English	Article						photoresponsive polymer; solubility control; enzyme conjugate; organic solvents	SOLVENTS; PROTEINS; CHYMOTRYPSIN; SELECTIVITY	We have synthesized a hybrid subtilisin the solubility of which can be regulated by photoirradiation through coupling with a photoresponsive copolymer that carries spiropyran groups in its side chains. The copolymer was synthesized by polymerization of methacrylate, methacrylic acid, and spiropyran-carrying methacrylate. It was then covalently bonded to the amino groups of subtilisin Carlsberg via its carboxyl groups using a carbodiimide coupling agent. The hybrid subtilisin was perfectly soluble in toluene and efficiently catalyzed transesterification. After ultraviolet irradiation, the hybrid subtilisin precipitated and was easily and quantitatively recovered by centrifugation. Recovered hybrid subtilisin, resolubilized by visible light irradiation, retained its original transesterification activity even after several cycles of precipitation and solubilization.	NAIST, Grad Sch Mat Sci, Ikoma 6300101, Japan; PRESTO, JST, Kyoto 6190237, Japan; Kyoto Univ, Grad Sch Engn, Dept Chem Mat, Kyoto 6068501, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Kyoto University	Ito, Y (corresponding author), NAIST, Grad Sch Mat Sci, Ikoma 6300101, Japan.	yito@ms.aist-nara.ac.jp	Ito, Yoshihiro/F-4370-2012; Ito, Yoshihiro/T-1095-2019	Ito, Yoshihiro/0000-0002-1154-253X				Blanch HW, 1995, BIOCH ENG; BRACO L, 1990, P NATL ACAD SCI USA, V87, P274, DOI 10.1073/pnas.87.1.274; CHARLES M, 1974, BIOTECHNOL BIOENG, V16, P1553, DOI 10.1002/bit.260161113; CHEN G, 1994, BIOCONJUG CHEM, V4, P509; CHUNG DJ, 1994, J APPL POLYM SCI, V51, P2027, DOI 10.1002/app.1994.070511207; DABULIS K, 1992, BIOTECHNOL BIOENG, V39, P176, DOI 10.1002/bit.260390209; GROSS RA, 1998, ENZYMES POLYM SYNTHE; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HOSINO K, 1989, AGR BIOL CHEM TOKYO, V53, P1961; HOSINO K, 1994, J FERMENT BIOENG, V77, P407; INADA Y, 1995, TRENDS BIOTECHNOL, V13, P86, DOI 10.1016/S0167-7799(00)88912-X; IRIE M, 1985, MACROMOLECULES, V18, P2418, DOI 10.1021/ma00154a014; ITO Y, 1993, BIOCONJUGATE CHEM, V4, P358, DOI 10.1021/bc00023a009; ITO Y, 1994, BIOTECHNOL PROGR, V10, P398, DOI 10.1021/bp00028a009; ITO Y, 1996, POLYM MAT ENCY, P2157; KHMELNITSKY YL, 1994, J AM CHEM SOC, V116, P2647, DOI 10.1021/ja00085a066; Koskinen A., 1996, ENZYMATIC REACTIONS, DOI [10.1007/978-94-011-0611-5_11, DOI 10.1007/978-94-011-0611-5_11]; MATSUKATA M, 1994, J BIOCHEM-TOKYO, V116, P682, DOI 10.1093/oxfordjournals.jbchem.a124580; PARADKAR VM, 1994, BIOTECHNOL BIOENG, V43, P529, DOI 10.1002/bit.260430614; Park YS, 1998, MACROMOLECULES, V31, P2606, DOI 10.1021/ma9605199; Rich JO, 1997, J AM CHEM SOC, V119, P3245, DOI 10.1021/ja9637715; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; STAHL M, 1991, J AM CHEM SOC, V113, P9366; Wang P, 1997, NAT BIOTECHNOL, V15, P789, DOI 10.1038/nbt0897-789; Wangikar PP, 1997, J AM CHEM SOC, V119, P70, DOI 10.1021/ja962620z; WONG CH, 1994, ENZYMES SYNTHETIC OR; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014; YANG Z, 1993, J AM CHEM SOC, V115, P12251, DOI 10.1021/ja00079a003; ZAKS A, 1985, P NATL ACAD SCI USA, V82, P3192, DOI 10.1073/pnas.82.10.3192; ZAKS A, 1988, J BIOL CHEM, V263, P8017	31	54	56	2	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					73	75		10.1038/5250	http://dx.doi.org/10.1038/5250			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920273				2022-12-25	WOS:000077979500029
J	Redmond, TM; Yu, S; Lee, E; Bok, D; Hamasaki, D; Chen, N; Goletz, P; Ma, JX; Crouch, RK; Pfeifer, K				Redmond, TM; Yu, S; Lee, E; Bok, D; Hamasaki, D; Chen, N; Goletz, P; Ma, JX; Crouch, RK; Pfeifer, K			Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle	NATURE GENETICS			English	Article							PIGMENT-EPITHELIUM; BINDING-PROTEIN; GENE-TRANSFER; VITAMIN-A; MICROSOMAL PROTEIN; MOUSE RETINA; CELLS; MICE; ISOMERASE; RHODOPSIN	Mutation of RPE65 can cause severe blindness from birth or early childhood, and RPE65 protein is associated with retinal pigment epithelium (RPE) vitamin A metabolism. Here. we show that Rpe65-deficient mice exhibit changes in retinal physiology and biochemistry. Outer segment discs of rod photoreceptors in Rpe65(-/-) mice are disorganized compared with those of Rpe65(+/+) and Rpe65(+/-) mice. Rod function, as measured by electroretinography, is abolished in Rpe65(-/-) mice, although cone function remains. Rpe65(-/-) mice lack rhodopsin, but not opsin apoprotein. Furthermore, all-trans-retinyl esters over-accumulate in the RPE of Rpe65(-/-) mice, whereas 11-cis-retinyl esters are absent. Disruption of the RPE-based metabolism of all-trans-retinyl esters to 11-cis-retinal thus appears to underlie the Rpe65(-/-) phenotype, although cone pigment regeneration may be dependent on a separate pathway.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL 33101 USA; Med Univ S Carolina, Storm Eye Inst, Charleston, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Bascom Palmer Eye Institute; University of Miami; Medical University of South Carolina	Redmond, TM (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	redmond@helix.nih.gov			NATIONAL EYE INSTITUTE [R01EY000444, P30EY000331, R37EY000444, R01EY012231] Funding Source: NIH RePORTER; NEI NIH HHS [EY12231, EY00444, EY00331] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535; BERNSTEIN PS, 1987, J BIOL CHEM, V262, P16848; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BRIDGES CDB, 1989, VISION RES, V29, P1711, DOI 10.1016/0042-6989(89)90153-3; CARTERDAWSON L, 1986, DEV BIOL, V116, P431, DOI 10.1016/0012-1606(86)90144-2; CHEN J, 1994, P NATL ACAD SCI USA, V91, P2611, DOI 10.1073/pnas.91.7.2611; CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186; DAS SR, 1992, BIOCHEM J, V285, P907, DOI 10.1042/bj2850907; GOLDSTEIN EB, 1967, VISION RES, V7, P837, DOI 10.1016/0042-6989(67)90004-1; GOLDSTIEN EB, 1973, VISION RES, V83, P527; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; HELLER J, 1976, AM J OPHTHALMOL, V81, P93, DOI 10.1016/0002-9394(76)90198-7; HOOD DC, 1973, VISION RES, V13, P1943, DOI 10.1016/0042-6989(73)90065-5; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LANDERS GM, 1988, J CHROMATOGR, V438, P383, DOI 10.1016/S0021-9673(00)90269-3; Liou GI, 1998, J NEUROSCI, V18, P4511; MA JX, IN PRESS BIOCH BIOPH; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PEACHEY NS, 1993, NEUROSCI LETT, V162, P9, DOI 10.1016/0304-3940(93)90547-X; ROBISON WG, 1977, INVEST OPHTH VIS SCI, V16, P1110; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; Saari John C., 1994, P351; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; SMELAND S, 1995, BIOCHEM J, V305, P419, DOI 10.1042/bj3050419; Sullivan DM, 1996, INVEST OPHTH VIS SCI, V37, P766; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WIGGERT B, 1977, BIOCHIM BIOPHYS ACTA, V498, P366, DOI 10.1016/0304-4165(77)90275-6; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Wright AF, 1997, NAT GENET, V17, P132, DOI 10.1038/ng1097-132; YOUNG RW, 1970, INVEST OPHTH VISUAL, V9, P524	48	746	768	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					344	351		10.1038/3813	http://dx.doi.org/10.1038/3813			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843205				2022-12-25	WOS:000077199600020
J	Hoyle, R				Hoyle, R			Forensics - The FBI's national DNA database	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	18	19	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					987	987		10.1038/3402	http://dx.doi.org/10.1038/3402			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831012	Bronze			2022-12-25	WOS:000076870100004
J	Shimodaira, H; Filosi, N; Shibata, H; Suzuki, T; Radice, P; Kanamaru, R; Friend, SH; Kolodner, RD; Ishioka, C				Shimodaira, H; Filosi, N; Shibata, H; Suzuki, T; Radice, P; Kanamaru, R; Friend, SH; Kolodner, RD; Ishioka, C			Functional analysis of human MLH1 mutations in Saccharomyces cevevisiae	NATURE GENETICS			English	Article							DNA MISMATCH REPAIR; COLON-CANCER; CEREVISIAE; YEAST; GENETICS; HOMOLOG; GENES; HNPCC	Hereditary non-polyposis colorectal cancer (HNPCC; OMIM 120435-6) is a cancer-susceptibility syndrome(1) linked to inherited defects in human mismatch repair (MMR) genes(2). Germline missense human MLH1 (hMLH1) mutations are frequently detected in HNPCC (ref. 3), making functional characterization of mutations in hMLH1 critical to the development of genetic testing for HNPCC. Here, we describe a new method for detecting mutations in hMLHI using a dominant mutator effect of hMLH1 cDNA expressed in Saccharomyces cerevisiae. The majority of hMLH1 missense mutations identified in HNPCC patients abolish the dominant mutator effect. Furthermore, PCR amplification of hMLHI cDNA from mRNA from a HNPCC patient, followed by in vivo recombination into a gap expression vector, allowed detection of a heterozygous loss-of-function missense mutation in hMLH1 using this method. This functional assay offers a simple method for detecting and evaluating pathogenic mutations in hMLH1.	Tohoku Univ, Dept Clin Oncol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA; Ist Nazl Tumori, Div Expt Oncol, I-20133 Milan, Italy; Fred Hutchinson Canc Res Ctr, Seattle Project, Seattle, WA 98109 USA	Tohoku University; Harvard University; Dana-Farber Cancer Institute; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fred Hutchinson Cancer Center	Ishioka, C (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.		; Radice, Paolo/O-3119-2013	Ishioka, Chikashi/0000-0002-3023-1227; Radice, Paolo/0000-0001-6298-4111	NIGMS NIH HHS [GM44704] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; HENDERSON ST, 1993, GENETICS, V134, P57; Ishioka C, 1997, P NATL ACAD SCI USA, V94, P2449, DOI 10.1073/pnas.94.6.2449; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; Lynch HT, 1996, INT J CANCER, V69, P38, DOI 10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135; REENAN RAG, 1992, GENETICS, V132, P975; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7	20	117	121	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					384	389		10.1038/1277	http://dx.doi.org/10.1038/1277			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697702				2022-12-25	WOS:000075107600024
J	Horwitz, MS; Bradley, LM; Harbertson, J; Krahl, T; Lee, J; Sarvetnick, N				Horwitz, MS; Bradley, LM; Harbertson, J; Krahl, T; Lee, J; Sarvetnick, N			Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; T-CELL; IMMUNE-RESPONSE; MICE; PROLIFERATION; PATHOGENESIS; MELLITUS; SUSCEPTIBILITY; INFECTIONS; REPERTOIRE	Viral induction of autoimmunity is thought to occur by either bystander T-cell activation or molecular mimicry. Coxsackie B4 virus is strongly associated with the development of insulin-dependent diabetes mellitus in humans and shares sequence similarity with the islet autoantigen glutamic acid decarboxylase. We infected different strains of mice with Coxsackie B4 virus to discriminate between the two possible induction mechanisms, and found that mice with susceptible MHC alleles had no viral acceleration of diabetes, but mice with a T cell receptor transgene specific for a different islet autoantigen rapidly developed diabetes. These results show that diabetes induced by Coxsackie virus infection is a direct result of local infection leading to inflammation, tissue damage, and the release of sequestered islet antigen resulting in the re-stimulation of resting autoreactive T cells, further indicating that the islet antigen sensitization is an indirect consequence of the viral infection.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	noras@scripps.edu						Andreoletti L, 1997, J MED VIROL, V52, P121, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;121::AID-JMV1&gt;3.0.CO;2-5; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; Balasa B, 1997, J IMMUNOL, V159, P4620; Brabb T, 1997, J IMMUNOL, V159, P497; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Ehl S, 1997, J EXP MED, V185, P1241, DOI 10.1084/jem.185.7.1241; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; HARTIG PC, 1983, J MED VIROL, V11, P23, DOI 10.1002/jmv.1890110104; HYOTY H, 1995, DIABETES, V44, P652, DOI 10.2337/diabetes.44.6.652; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; Mueller R, 1997, IMMUNITY, V7, P411, DOI 10.1016/S1074-7613(00)80362-3; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NAHILL SR, 1993, J EXP MED, V177, P317, DOI 10.1084/jem.177.2.317; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PrevostBlondel A, 1997, VIROLOGY, V233, P93, DOI 10.1006/viro.1997.8604; SEE DM, 1995, J INFECT DIS, V171, P1131, DOI 10.1093/infdis/171.5.1131; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; TRIPP RA, 1995, J IMMUNOL, V154, P6013; UTZ U, 1993, NATURE, V364, P243, DOI 10.1038/364243a0; Wahlstrom J, 1997, EUR RESPIR J, V10, P772; WEBB SR, 1976, J EXP MED, V143, P1239, DOI 10.1084/jem.143.5.1239; YOON JW, 1978, J EXP MED, V148, P1068, DOI 10.1084/jem.148.4.1068; Yoon JW, 1990, CURR TOP MICROBIOL I, V164, P95; Zarozinski CC, 1997, J EXP MED, V185, P1629, DOI 10.1084/jem.185.9.1629	35	483	494	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					781	785		10.1038/nm0798-781	http://dx.doi.org/10.1038/nm0798-781			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662368				2022-12-25	WOS:000074543900031
J	Hirvonen, J; Kalia, YN; Guy, RH				Hirvonen, J; Kalia, YN; Guy, RH			Transdermal delivery of peptides by iontophoresis	NATURE BIOTECHNOLOGY			English	Article						iontophoresis; electroosmosis; skin; peptide delivery; transdermal administration	CONVECTIVE SOLVENT FLOW; IN-VITRO; SKIN; NAFARELIN; GLUCOSE; INVITRO; SYSTEM	Transdermal administration by iontophoresis (enhanced transport via the skin using the driving force of an applied electric field) has been successfully demonstrated but no formal relationship between peptide sequence/structure and efficiency of delivery has been established. There are notable examples, such as the lipophilic leutinizing hormone releasing hormone (LHRH) analogs, Nafarelin and Leuprolide, that exhibit down-regulation of their own transport across the skin under the influence of an iontophoretic current. The hypothesis that this phenomenon is due to neutralization of the skin's net negative charge by these cationic peptides was examined with LHRH oligopeptides. The impact of these compounds on the electroosmotic flow of solvent into the skin, which is induced by iontophoresis and which contributes significantly to the electrotransport of large, positively charged ions, was examined and quantified. Close juxtaposition of cationic and lipophilic residues profoundly inhibited electroosmosis and, presumably, peptide flux. The results indicate that the lipophilicity of the oligopeptides facilitates van der Waals interactions with hydrophobic patches along the transport route, thereby permitting the positively charged oligopeptide to interact with carboxylate side chains that give the skin its net negative charge at neutral pH. The lipophilic, cationic oligopeptide, therefore, becomes anchored in the transport path, neutralizing the original charge of the membrane, and completely altering the permselective properties of the skin.	CTR INTERUNIV RECH ENSEIGNEMENT PHARMAPEPTIDES, F-74166 ARCHAMPS, FRANCE; UNIV CALIF SAN FRANCISCO, DEPT BIOPHARMACEUT SCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV KUOPIO, DEPT PHARMACEUT TECHNOL, FIN-70211 KUOPIO, FINLAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Eastern Finland			Kalia, Yogeshvar/Q-6785-2018; Guy, Richard H/H-3471-2012; Kalia, Yogeshvar/M-4745-2019	Kalia, Yogeshvar/0000-0001-9049-5489; Kalia, Yogeshvar/0000-0001-9049-5489; Guy, Richard/0000-0003-3227-9862; Hirvonen, Jouni Tapio/0000-0002-5029-1657	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027839] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-27839] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMSDEN BG, 1995, AICHE J, V41, P1972, DOI 10.1002/aic.690410814; BURNETTE RR, 1988, J PHARM SCI, V77, P132, DOI 10.1002/jps.2600770208; BURNETTE RR, 1989, DRUGS PHARM SCI, V35, P247; CULLANDER C, 1991, J INVEST DERMATOL, V97, P55, DOI 10.1111/1523-1747.ep12478060; DELGADOCHARRO MB, 1995, INT J PHARM, V117, P165, DOI 10.1016/0378-5173(94)00323-W; DELGADOCHARRO MB, 1995, J CONTROL RELEASE, V35, P35, DOI 10.1016/0168-3659(95)00015-Z; DELGADOCHARRO MB, 1994, PHARMACEUT RES, V11, P929, DOI 10.1023/A:1018910715229; DELGADOCHARRO MB, 1996, IN PRESS ELECT CONTR; DOWNING DT, 1992, J LIPID RES, V33, P301; GLIKFELD P, 1988, PHARMACEUT RES, V5, P443, DOI 10.1023/A:1015944619348; GREEN PG, 1991, PHARMACEUT RES, V8, P1113, DOI 10.1023/A:1015894016235; GUY RH, 1995, NAT MED, V1, P1132, DOI 10.1038/nm1195-1132; HINSBERG WHMC, 1995, PHARMACEUT RES, V12, P1506, DOI 10.1023/A:1016243706415; HOOGSTRAATE AJ, 1994, J CONTROL RELEASE, V31, P41, DOI 10.1016/0168-3659(94)90249-6; KIM A, 1993, PHARMACEUT RES, V10, P1315, DOI 10.1023/A:1018969713547; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAU DTW, 1994, PHARMACEUT RES, V11, P1742, DOI 10.1023/A:1018963300092; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; PIKAL MJ, 1992, ADV DRUG DELIVER REV, V9, P201, DOI 10.1016/0169-409X(92)90024-K; Rao G, 1995, PHARM RES-DORDR, V12, P1869, DOI 10.1023/A:1016271301814; RAO G, 1993, PHARMACEUT RES, V10, P1751, DOI 10.1023/A:1018926215306; SCLAFANI J, 1993, PHARMACEUT RES, V10, P1521, DOI 10.1023/A:1018943929902; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; TAMADA JA, 1995, NAT MED, V1, P1198, DOI 10.1038/nm1195-1198; TURNER N, 1994, P INT S CONTROL REL, V21, P393; YOSHIDA NH, 1992, ADV DRUG DELIVER REV, V9, P239, DOI 10.1016/0169-409X(92)90025-L	26	48	55	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1996	14	13					1710	1713		10.1038/nbt1296-1710	http://dx.doi.org/10.1038/nbt1296-1710			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VX107	9634857				2022-12-25	WOS:A1996VX10700035
J	Rohlmann, A; Gotthardt, M; Willnow, TE; Hammer, RE; Herz, J				Rohlmann, A; Gotthardt, M; Willnow, TE; Hammer, RE; Herz, J			Sustained somatic gene inactivation by viral transfer of Cre recombinase	NATURE BIOTECHNOLOGY			English	Article						homologous recombination; LRP; protease; adenovirus	RECEPTOR-RELATED PROTEIN; SITE-SPECIFIC RECOMBINATION; ALPHA-2-MACROGLOBULIN RECEPTOR; TRANSGENIC MICE; EXPRESSION; LRP	Transgenic and knockout mice have proven invaluable tools for analyzing physiologically relevant functions of numerous genes. In some cases, however, pleiotropic effects that result from a variable requirement for a particular gene in different tissues, cell types, or stages of embryonic development may complicate the analysis due to a complex phenotype or embryonic lethality, The loxP/Cre-mediated recombination system, which allows tissue-specific gene targeting in the mouse, can be used to overcome these problems, A limitation of current methods is that a mouse carrying a loxP-tagged gene must be crossed with a transgenic mouse expressing the Cre recombinase in an appropriate tissue to obtain the desired gene rearrangement. We have used recombinant adenovirus carrying the Cre recombinase to induce virtually quantitative somatic cell gene disruption in the liver. The targeted gene was the multifunctional low-density lipoprotein receptor-related protein (LRP), a cell surface receptor for alpha(2)-macroglobulin and other ligands, Transient expression of Cre following adenoviral infection produced the predicted gene rearrangement, functionally inactivating LRP in the liver. Rearrangement occurred within 6 days after infection and remained stable for at least 28 days, the results demonstrate the suitability of adenoviral Cre gene transfer to induce long-term, quantitative, and temporally controlled gene disruption in the mouse.	UNIV TEXAS, SW MED CTR, DEPT MOL GENET, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Rohlmann, Astrid/0000-0003-0869-6893; Willnow, Thomas/0000-0001-9515-7921; Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERG N, 1980, COLD SPRING HARB SYM, V45, P297, DOI 10.1101/SQB.1981.045.01.042; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	25	107	112	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1562	1565		10.1038/nbt1196-1562	http://dx.doi.org/10.1038/nbt1196-1562			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634821				2022-12-25	WOS:A1996VP83300022
J	Xu, XL; Wagner, KU; Larson, D; Weaver, Z; Li, CL; Ried, T; Hennighausen, L; Wynshaw-Boris, A; Deng, CX				Xu, XL; Wagner, KU; Larson, D; Weaver, Z; Li, CL; Ried, T; Hennighausen, L; Wynshaw-Boris, A; Deng, CX			Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation	NATURE GENETICS			English	Article							SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; MOUSE; P53; EXPRESSION; MICE; RAD51; DIFFERENTIATION; LOCALIZATION; HOMOLOG	Cre-mediated excision of exon 11 of the breast-tumour suppressor gene Brca1 in mouse mammary epithelial cells causes increased apoptosis and abnormal ductal development Mammary tumour formation occurs after long latency and is associated with genetic instability characterized by aneuploidy, chromosomal rearrangements or alteration of Trp53 (encoding p53) transcription. To directly test the role of p53 in Brca1-associated tumorigenesis, we introduced a Trp53-null allele into mice with mammary epithelium-specific inactivation of Brca1. The loss of p53 accelerated the formation of mammary tumours in these females. Our results demonstrate that disruption of Brca1 causes genetic instability and triggers further alterations, including the inactivation of p53, that lead to tumour formation.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, Div Clin Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Wagner, Kay-Uwe/B-6044-2009	Hennighausen, Lothar/0000-0001-8319-9841; Wagner, Kay-Uwe/0000-0002-5081-0226; Weaver Ohler, Zoe/0000-0002-6287-2504	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000, ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cui JQ, 1998, ONCOL REP, V5, P585; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hill ADK, 1997, BRIT J SURG, V84, P1334; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Robinson GW, 1997, DEVELOPMENT, V124, P2701; ROTTER V, 1984, MOL CELL BIOL, V4, P383, DOI 10.1128/MCB.4.2.383; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	579	597	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					37	43		10.1038/8743	http://dx.doi.org/10.1038/8743			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319859				2022-12-25	WOS:000080096300020
J	Kadkol, SS; Brody, JR; Pevsner, J; Bai, JN; Pasternack, GR				Kadkol, SS; Brody, JR; Pevsner, J; Bai, JN; Pasternack, GR			Modulation of oncogenic potential by alternative gene use in human prostate cancer	NATURE MEDICINE			English	Article							PROTEIN; IDENTIFICATION; CARCINOMA; PHAPI; CELLS; PP32	Only a small percentage of primary prostate cancers have genetic changes. In contrast, nearly 90% of clinically significant human prostate cancers seems to express high levels of the nuclear phosphoprotein pp32 by in situ hybridization. Because pp32 inhibits oncogene-mediated transformation, we investigated its paradoxical expression in cancer by comparing the sequence and function of pp32 species from paired benign prostate tissue and adjacent prostatic carcinoma from three patients. Here we demonstrate that pp32 is expressed in benign prostatic tissue, but pp32r1 and pp32r2, closely-related genes located on different chromosomes, are expressed in prostate cancer. Although pp32 is a tumor suppressor, pp32r1 and pp32r2 are tumorigenic. Alternative use of the pp32, pp32r1 and pp32r2 genes may modulate the oncogenic potential of human prostate cancer.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Dept Neurol, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, 720 Rutland Ave, Baltimore, MD 21205 USA.	gpastern@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA054404] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 54404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; FINK TM, 1995, GENOMICS, V29, P309, DOI 10.1006/geno.1995.1257; FLEMING WH, 1986, CANCER RES, V46, P1535; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; MALEK SN, 1990, J BIOL CHEM, V265, P13400; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Ulitzur N, 1997, J BIOL CHEM, V272, P30577, DOI 10.1074/jbc.272.48.30577; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; WALENSKY LD, 1993, CANCER RES, V53, P4720	17	46	52	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					275	279		10.1038/6488	http://dx.doi.org/10.1038/6488			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086381				2022-12-25	WOS:000078851600030
J	Ueki, T; Kaneda, Y; Tsutsui, H; Nakanishi, K; Sawa, Y; Morishita, R; Matsumoto, K; Nakamura, T; Takahashi, H; Okamoto, E; Fujimoto, J				Ueki, T; Kaneda, Y; Tsutsui, H; Nakanishi, K; Sawa, Y; Morishita, R; Matsumoto, K; Nakamura, T; Takahashi, H; Okamoto, E; Fujimoto, J			Hepatocyte growth factor gene therapy of liver cirrhosis in rats	NATURE MEDICINE			English	Article							SCATTER FACTOR; CELL-DEATH; MOLECULAR-CLONING; FACTOR-BETA; EXPRESSION; FIBROSIS; PROTEIN; IDENTIFICATION; PURIFICATION; MECHANISM	Liver cirrhosis is the irreversible end result of fibrous scarring and hepatocellular regeneration, characterized by diffuse disorganization of the normal hepatic structure of regenerative nodules and fibrotic tissue(1). It is associated with prominent morbidity and mortality, and is induced by many factors, including chronic hepatitis virus infections, alcohol drinking and drug abuse. Hepatocyte growth factor (HGF), originally identified and cloned as a potent mitogen for hepatocytes(2-5), shows mitogenic, motogenic and morphogenic activities for a wide variety of cells(6-9). Moreover, HGF plays an essential part in the development and regeneration of the liver(6.7.10), and shows anti-apoptotic activity in hepatocytes(11). In a rat model of lethal liver cirrhosis produced by dimethylnitrosamine administrations, repeated transfections of the human HGF gene into skeletal muscles induced a high plasma level of human as well as enodogenous rat HGF, and tyrosine phosphorylation of the c-Met/HGF receptor. Transduction with the HGF gene also suppressed the increase of transforming growth factor-beta 1 (TGF-beta 1), which plays an essential part in the progression of liver cirrhosis, inhibited fibrogenesis and hepatocyte apoptosis, and produced the complete resolution of fibrosis in the cirrhotic liver, thereby improving the survival rate of rats with this severe illness. Thus, HGF gene therapy may be potentially useful for the treatment of patients with liver cirrhosis, which is otherwise fatal and untreatable by conventional therapy.	Hyogo Coll Med, Dept Surg 1, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Sch Med, Inst Cellular & Mol Biol, Suita, Osaka 5650871, Japan; Hyogo Coll Med, Dept Immunol & Med Zool, Nishinomiya, Hyogo, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Suita, Osaka 565, Japan; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Hyogo College of Medicine; Osaka University; Hyogo College of Medicine; Osaka University; Osaka University; Osaka University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Fujimoto, J (corresponding author), Hyogo Coll Med, Dept Surg 1, 1-1 Mukogawacho, Nishinomiya, Hyogo 6638501, Japan.		; MATSUMOTO, Kunio/D-8441-2015	Tsutsui, Hiroko/0000-0001-7928-4875; MATSUMOTO, Kunio/0000-0002-6532-4482				Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CONN HO, 1993, DIS LIVER, V2, P875; COOMBS DW, 1994, ACTA ANAESTH SCAND, V38, P388, DOI 10.1111/j.1399-6576.1994.tb03913.x; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; Hayashi S, 1996, BIOCHEM BIOPH RES CO, V220, P539, DOI 10.1006/bbrc.1996.0440; Hirano T, 1998, GENE THER, V5, P459, DOI 10.1038/sj.gt.3300617; JEZEQUEL AM, 1989, J HEPATOL, V8, P42, DOI 10.1016/0168-8278(89)90160-8; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PRITCHARD DJ, 1989, J PATHOL, V158, P253, DOI 10.1002/path.1711580314; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TANAKA Y, 1991, J PATHOL, V164, P273, DOI 10.1002/path.1711640314; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	30	515	562	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					226	230		10.1038/5593	http://dx.doi.org/10.1038/5593			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930873				2022-12-25	WOS:000078274400034
J	Cameron, EE; Bachman, KE; Myohanen, S; Herman, JG; Baylin, SB				Cameron, EE; Bachman, KE; Myohanen, S; Herman, JG; Baylin, SB			Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; DNA METHYLATION; CHROMATIN STRUCTURE; TOPOLOGY INVIVO; CPG ISLANDS; CELL-LINES; TRANSCRIPTION; ACETYLATION; PROMOTER	Densely methylated DNA associates with transcriptionally repressive chromatin characterized by the presence of underacetylated histones(1,2). Recently, these two epigenetic processes have been dynamically linked. The methyl-CpG-binding protein MeCP2 appears to reside in a complex with histone deacetylase activity(3,4). MeCP2 can mediate formation of transcriptionally repressive chromatin on methylated promoter templates in vitro, and this process can be reversed by trichostatin A (TSA), a specific inhibitor of histone deacetylase(3-5). Little is known, however, about the relative roles of methylation and histone deacetylase activity in the stable inhibition of transcription on densely methylated endogenous promoters, such as those for silenced alleles of imprinted genes(6), genes on the female inactive X chromosome(7) and tumour-suppressor genes inactivated in cancer cells(8,9). We show here that the hypermethylated genes MLH1, TIMP3 (TIMP3), CDKN2B (INK4B, p15) and CDKN2A (INK4, p16) cannot be transcriptionally reactivated with TSA alone in tumour cells in which we have shown that TSA alone can upregulate the expression of non-methylated genes. Following minimal demethylation and slight gene reactivation in the presence of low dose 5-aza-2'deoxycytidine (5Aza-dC), however, TSA treatment results in robust re-expression of each gene. TSA does not contribute to demethylation of the genes, and none of the treatments alter the chromatin structure associated with the hypermethylated promoters. Thus, although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Grad Program Cellular & Mol Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 424 N Bond St, Baltimore, MD 21231 USA.	sbaylin@welchlink.welch.jhu.edu						ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Drabik CE, 1997, J MOL BIOL, V267, P794, DOI 10.1006/jmbi.1997.0917; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kane MF, 1997, CANCER RES, V57, P808; KASLOW DC, 1987, P NATL ACAD SCI USA, V84, P6210, DOI 10.1073/pnas.84.17.6210; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; Riggs AD, 1998, CIBA F SYMP, V214, P214; RIGGS AD, 1998, NOVART FDN SYMP, V214, P225; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WICK M, 1995, BIOCHEM J, V311, P549, DOI 10.1042/bj3110549; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	30	1580	1640	1	95	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					103	107		10.1038/5047	http://dx.doi.org/10.1038/5047			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916800				2022-12-25	WOS:000077960700018
J	Legendre, D; Soumillion, P; Fastrez, J				Legendre, D; Soumillion, P; Fastrez, J			Engineering a regulatable enzyme for homogeneous immunoassays	NATURE BIOTECHNOLOGY			English	Article						biosensor; beta-lactamase; combinatorial libraries; peptide insertion; phage display; regulation	TEM-1 BETA-LACTAMASE; ALKALINE-PHOSPHATASE; CATALYTIC ACTIVITY; INVITRO EVALUATION; PEPTIDE LIBRARIES; DISPLAY LIBRARY; PHAGE DISPLAY; MUTAGENESIS; SELECTION; PROTEIN	We have engineered the phage displayed TEM-1 beta-lactamase to generate enzymes that can be used in homogeneous immunoassays because their activity can be modulated by binding to monoclonal antibodies (Mabs) raised against an unrelated protein. Random peptide libraries were genetically inserted into three loops to create hybrid enzymes with binding sites for Mabs. Insertion points were chosen to be close enough to the active site that complex formation could affect the activity. The antibiotic resistance provided by the beta-lactamase activity was used to select the clones encoding active enzymes. Biopanning of the active libraries on immobilized Mabs against the prostate specific antigen (PSA) or on streptavidin yielded enzymes with binding sites for these proteins. Their activity could be regulated by Mab or streptavidin binding. The dissociation constants of the complexes are in the 10(-9) to 10(-6) M range. In a competitive assay, PSA could be detected at a minimal concentration of 10(-9) M. The Mabs recognize mimotopes as no sequence similarity was found between inserts in regulated clones and fragments of the PSA sequence. The method can be developed to generate signaling molecules to be used for the detection of analytes in solution without identification of the epitope.	Univ Catholique Louvain, Lab Biochim Phys & Biopolymeres, B-1348 Louvain, Belgium	Universite Catholique Louvain	Fastrez, J (corresponding author), Univ Catholique Louvain, Lab Biochim Phys & Biopolymeres, Pl L Pasteur 1-1B, B-1348 Louvain, Belgium.	fastrez@bioc.ucl.ac.be						BRENNAN C, 1994, PROTEIN ENG, V7, P509, DOI 10.1093/protein/7.4.509; BRENNAN CA, 1995, P NATL ACAD SCI USA, V92, P5783, DOI 10.1073/pnas.92.13.5783; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Fastrez J, 1997, MOL BIOTECHNOL, V7, P37, DOI 10.1007/BF02821543; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FREIMUTH PI, 1990, J BIOL CHEM, V265, P896; Hallet B, 1997, NUCLEIC ACIDS RES, V25, P1866, DOI 10.1093/nar/25.9.1866; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES RN, 1982, J CLIN MICROBIOL, V15, P677, DOI 10.1128/JCM.15.4.677-683.1982; JONES RN, 1982, J CLIN MICROBIOL, V15, P954, DOI 10.1128/JCM.15.5.954-958.1982; KROOK M, 1995, J CHROMATOGR A, V711, P119, DOI 10.1016/0021-9673(95)00270-W; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; Nilsson O, 1997, BRIT J CANCER, V75, P789, DOI 10.1038/bjc.1997.142; OLSEN DB, 1993, METHOD ENZYMOL, V217, P189; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; Piironen T, 1998, PROTEIN SCI, V7, P259; RUBENSTEIN KE, 1972, BIOCHEM BIOPH RES CO, V47, P846, DOI 10.1016/0006-291X(72)90570-0; SINGH P, 1980, ANAL BIOCHEM, V104, P51, DOI 10.1016/0003-2697(80)90275-4; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; SMITH GP, 1993, METHOD ENZYMOL, V217, P229; SOUMILLION P, 1994, J MOL BIOL, V237, P415, DOI 10.1006/jmbi.1994.1244; Vanhove M, 1997, BIOCHEM J, V321, P413, DOI 10.1042/bj3210413; VIJAYAKUMAR S, 1995, J AM CHEM SOC, V117, P1722, DOI 10.1021/ja00111a008; WALEY SG, 1974, BIOCHEM J, V139, P789, DOI 10.1042/bj1390789; ZEBALA J, 1991, GENE, V100, P51, DOI 10.1016/0378-1119(91)90349-G	30	68	71	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					67	72		10.1038/5243	http://dx.doi.org/10.1038/5243			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920272				2022-12-25	WOS:000077979500028
J	Klein, C; Paul, JI; Sauve, K; Schmidt, MM; Arcangeli, L; Ransom, J; Trueheart, J; Manfredi, JP; Broach, JR; Murphy, AJ				Klein, C; Paul, JI; Sauve, K; Schmidt, MM; Arcangeli, L; Ransom, J; Trueheart, J; Manfredi, JP; Broach, JR; Murphy, AJ			Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast	NATURE BIOTECHNOLOGY			English	Article						G protein-coupled receptor; orphan receptor; signal transduction; pharmacology	PROTEIN-COUPLED RECEPTOR; FORMYL PEPTIDE RECEPTOR; LIPOXIN A(4); EXPRESSION; CLONING; CDNA; ANTAGONISTS; MEMBERS; FAMILY	We describe a procedure for isolating agonists for mammalian G protein-coupled receptors of unknown function, Human formyl peptide receptor like-1 (FPRL-1) receptor, originally identified as an orphan G protein-coupled receptor related to the formyl peptide receptor (FPR1), was expressed in Saccharomyces cells designed to couple receptor activation to histidine prototrophy. Selection for histidine prototrophs among transformants obtained with a plasmid-based library encoding random peptides identified six different agonists, each of whose production yielded autocrine stimulation of the receptor expressed in yeast. A synthetic version of each peptide promoted activation of FPRL-1 expressed in human embryonic kidney (HEK293) cells, and five of the peptides exhibited significant selectivity for activation of FPRL-1 relative to FPR1, One selective peptide was tested and found to mobilize calcium in isolated human neutrophils. This demonstrates that stimulation of FPRL-1 results in neutrophil activation and suggests that the receptor functions as a component of the inflammatory response, This autocrine selection protocol may be a generally applicable method for providing pharmacological tools to evaluate the physiological roles of the growing number of mammalian orphan G protein-coupled receptors.	Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Klein, C (corresponding author), Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA.			Murphy, Andrew/0000-0003-4152-4081; Broach, James/0000-0003-1197-0312				BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; CHEN J, 1995, J BIOL CHEM, V270, P23398, DOI 10.1074/jbc.270.40.23398; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DURSTIN M, 1994, BIOCHEM BIOPH RES CO, V201, P174, DOI 10.1006/bbrc.1994.1685; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Kaiser C., 1994, METHODS YEAST GENETI; KLOPOTOW.T, 1965, ARCH BIOCHEM BIOPHYS, V112, P562, DOI 10.1016/0003-9861(65)90096-2; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Manfredi JP, 1996, MOL CELL BIOL, V16, P4700; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Romano M, 1996, J IMMUNOL, V157, P2149; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STRUHL K, 1977, P NATL ACAD SCI USA, V74, P5255, DOI 10.1073/pnas.74.12.5255; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y	21	124	135	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1334	1337		10.1038/4310	http://dx.doi.org/10.1038/4310			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853614				2022-12-25	WOS:000077232600025
J	de Groot, MJA; Bundock, P; Hooykaas, PJJ; Beijersbergen, AGM				de Groot, MJA; Bundock, P; Hooykaas, PJJ; Beijersbergen, AGM			Agrobacterium tumefaciens-mediated transformation of filamentous fungi	NATURE BIOTECHNOLOGY			English	Article						gene transfer; Ti plasmid; protoplast; conidia	HYGROMYCIN-B RESISTANCE; HIGH-EFFICIENCY TRANSFORMATION; T-DNA; SACCHAROMYCES-CEREVISIAE; VIRULENCE SYSTEM; ASPERGILLUS; ELECTROPORATION; INTEGRATION; PROSPECTS	Agrobacterium tumefaciens transfers part of its Ti plasmid, the T-DNA, to plant cells during tumorigenesis, It is routinely used for the genetic modification of a wide range of plant species. We report that A. tumefaciens can also transfer its T-DNA efficiently to the filamentous fungus Aspergillus awamori, demonstrating DNA transfer between a prokaryote and a filamentous fungus. We transformed both protoplasts and conidia with frequencies that were improved up to 600-fold as compared with conventional techniques for transformation of A. awamori protoplasts, The majority of the A. awamori transformants contained a single T-DNA copy randomly integrated at a chromosomal locus, The T-DNA integrated into the A. awamori genome in a manner similar to that described for plants, We also transformed a variety of other filamentous fungi, including Aspergillus niger, Fusarium venenatum, Trichoderma reesei, Colletotrichum gloeosporioides, Neurospora crassa, and the mushroom Agaricus bisporus, demonstrating that transformation using A. tumefaciens is generally applicable to filamentous fungi.	Unilever Res Labs Vlaardingen, NL-3133 AT Vlaardingen, Netherlands; Leiden State Univ, Clusius Lab, Inst Mol Plant Sci, NL-2333 AL Leiden, Netherlands	Unilever; Leiden University; Leiden University - Excl LUMC	de Groot, MJA (corresponding author), Unilever Res Labs Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen, Netherlands.		Hooykaas, Paul JJ/S-4256-2017	Hooykaas, Paul JJ/0000-0002-9736-6927				BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; Bennett J. W., 1991, MORE GENE MANIPULATI, P441; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bundock P, 1996, P NATL ACAD SCI USA, V93, P15272, DOI 10.1073/pnas.93.26.15272; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; CHAKRABORTY BN, 1991, CAN J MICROBIOL, V37, P858, DOI 10.1139/m91-147; DEBLOCK M, 1993, EUPHYTICA, V71, P1, DOI 10.1007/BF00023461; DENDULKRAS A, 1995, METHODS MOL BIOL, V55; Dunn-Coleman N, 1998, NAT BIOTECHNOL, V16, P5, DOI 10.1038/nbt0198-5; FINKELSTEIN DB, 1992, BIOTECHNOLOGY FILAME, P113; Gouka RJ, 1997, APPL MICROBIOL BIOT, V47, P1, DOI 10.1007/s002530050880; Hamilton CM, 1996, P NATL ACAD SCI USA, V93, P9975, DOI 10.1073/pnas.93.18.9975; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HOOYKAAS PJJ, 1994, ANNU REV PHYTOPATHOL, V32, P157, DOI 10.1146/annurev.py.32.090194.001105; Ishida Y, 1996, NAT BIOTECHNOL, V14, P745, DOI 10.1038/nbt0696-745; KADO CI, 1991, CRIT REV PLANT SCI, V10, P1, DOI 10.1080/07352680490273310; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; OFFRINGA R, 1992, THESIS LEIDEN U LEID; PUNT PJ, 1992, METHOD ENZYMOL, V216, P447; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; ROYER JC, 1995, BIO-TECHNOL, V13, P1479, DOI 10.1038/nbt1295-1479; STEPHENSON S, 1994, AUSTR SOC BIOCH MOL, V26, P1; Tinland B, 1996, TRENDS PLANT SCI, V1, P178, DOI 10.1016/1360-1385(96)10020-0; vandeRhee MD, 1996, MOL GEN GENET, V250, P252, DOI 10.1007/BF02174382; WALDEN R, 1991, PLANT J, V1, P281, DOI 10.1046/j.1365-313X.1991.t01-6-00999.x; WARD M, 1989, EXP MYCOL, V13, P289, DOI 10.1016/0147-5975(89)90050-9; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	28	631	753	9	202	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					839	842		10.1038/nbt0998-839	http://dx.doi.org/10.1038/nbt0998-839			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743116				2022-12-25	WOS:000075671700029
J	Ehl, S; Aichele, P; Ramseier, H; Barchet, W; Hombach, J; Pircher, H; Hengartner, H; Zinkernagel, RM				Ehl, S; Aichele, P; Ramseier, H; Barchet, W; Hombach, J; Pircher, H; Hengartner, H; Zinkernagel, RM			Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection	NATURE MEDICINE			English	Article							BONE-MARROW; IN-VIVO; AUTOIMMUNE ENCEPHALOMYELITIS; TRANSPLANTATION TOLERANCE; VIRUS-INFECTION; TRANSGENIC MICE; INDUCTION; CHIMERISM; ACTIVATION; RECIPIENTS	We studied antigen-specific T-cell tolerization therapy using skin transplantation across a defined minor histocompatibility antigen difference. Specific tolerization protocols using short-lived peptide or long-lived spleen cells presenting the peptide as antigen prevented graft rejection without immunosuppression when started before or as long as 10 days after transplantation. Peptide-induced T-cell tolerance was transient, and antigen presentation by the graft was not sufficient to maintain tolerance. In contrast, transfer of antigen-expressing lymphoid cells induced long-lasting tolerance correlating with donor cell chimerism. These findings show that antigen-specific tolerization can induce graft acceptance even when begun after transplantation and that long-term graft survival depends on persistence of the tolerizing antigen.	Univ Zurich, Dept Pathol, Inst Expt Immunol, CH-8091 Zurich, Switzerland	University of Zurich	Ehl, S (corresponding author), Univ Zurich, Dept Pathol, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	stephanehl@aol.com; aichele@mpiib-berlin.mpg.de	Ehl, Stephan/AAM-6006-2020	Barchet, Winfried/0000-0002-6745-6606; Ehl, Stephan/0000-0002-9265-2721				Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Antoniou A, 1996, EUR J IMMUNOL, V26, P1094, DOI 10.1002/eji.1830260521; Bachmann MF, 1997, P NATL ACAD SCI USA, V94, P640, DOI 10.1073/pnas.94.2.640; BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; Ehl S, 1997, EUR J IMMUNOL, V27, P3404, DOI 10.1002/eji.1830271240; Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GarciaMorales R, 1997, J CLIN INVEST, V99, P1118, DOI 10.1172/JCI119240; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; ILSTAD ST, 1984, NATURE, V307, P168; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kundig TM, 1996, P NATL ACAD SCI USA, V93, P9716, DOI 10.1073/pnas.93.18.9716; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LUBAROFF DM, 1973, J IMMUNOL, V111, P65; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MADSEN JC, 1988, NATURE, V332, P161, DOI 10.1038/332161a0; MAEDA T, 1993, J IMMUNOL, V150, P753; MAMALAKI C, 1993, INT IMMUNOL, V5, P1285, DOI 10.1093/intimm/5.10.1285; MILLER RG, 1976, J IMMUNOL, V117, P1913; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MORECKI S, 1987, J EXP MED, V165, P1468, DOI 10.1084/jem.165.6.1468; MOSHKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHASHI PS, 1993, J IMMUNOL, V150, P5185; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P120, DOI 10.1002/eji.1830040211; RAMMENSEE HG, 1984, J IMMUNOL, V133, P2390; Rao AS, 1997, TRANSPL P, V29, P1184, DOI 10.1016/S0041-1345(96)00536-2; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; ROMBALL CG, 1993, J EXP MED, V178, P1637, DOI 10.1084/jem.178.5.1637; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; Wood K, 1996, IMMUNOL TODAY, V17, P584, DOI 10.1016/S0167-5699(96)10069-4; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	45	50	51	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1015	1019		10.1038/2001	http://dx.doi.org/10.1038/2001			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734393				2022-12-25	WOS:000075804100033
J	Park', L; Raman, KG; Lee, KJ; Lu, Y; Ferran, LJ; Chow, WS; Stern, D; Schmidt, AM				Park', L; Raman, KG; Lee, KJ; Lu, Y; Ferran, LJ; Chow, WS; Stern, D; Schmidt, AM			Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts	NATURE MEDICINE			English	Article							GLYCOSYLATION END-PRODUCTS; APOE-DEFICIENT MICE; OXIDANT STRESS; CARDIOVASCULAR-DISEASE; LIPOPROTEIN OXIDATION; VASCULAR-DISEASE; BINDING-PROTEINS; APOLIPOPROTEIN-E; CELL-SURFACE; VESSEL WALL	Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, 630 W 168th St, New York, NY 10032 USA.		YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56881] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DAHLQUIST G, 1982, DIABETES CARE, V5, P399, DOI 10.2337/diacare.5.4.399; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; GOWN AM, 1986, AM J PATHOL, V125, P191; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Jarrett RJ, 1996, DIABETIC MED, V13, pS15; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MOREL DW, 1989, J LIPID RES, V30, P1827; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; YAN SD, 1994, J BIOL CHEM, V269, P9889; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	36	950	986	1	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1025	1031		10.1038/2012	http://dx.doi.org/10.1038/2012			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734395				2022-12-25	WOS:000075804100035
J	Persidis, A				Persidis, A			Complement inhibitors	NATURE BIOTECHNOLOGY			English	Editorial Material							SYSTEM; REPERFUSION; ACTIVATION; DISEASE; INJURY; C3A; PIG		Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd,Suite 202, Charlottesville, VA 22901 USA.	apersidis@argonex.com						BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; Bordet J., 1896, ANN I PASTEUR PARIS, V10, P193; Cole LB, 1997, ACTA CRYSTALLOGR D, V53, P143, DOI 10.1107/S0907444996012991; GALLINARO R, 1992, SURG GYNECOL OBSTET, V174, P435; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Horstick G, 1997, CIRCULATION, V95, P701, DOI 10.1161/01.CIR.95.3.701; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; KILGORE KS, 1994, CARDIOVASC RES, V28, P437, DOI 10.1093/cvr/28.4.437; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1; LENNON VA, 1978, J EXP MED, V147, P973, DOI 10.1084/jem.147.4.973; Makrides SC, 1998, PHARMACOL REV, V50, P59; Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311; PENSKY J, 1961, J BIOL CHEM, V236, P1674; PICARD MD, 1996, GLYCOBIOLOGY, V6, P766; REGAL JF, 1993, J PHARMACOL EXP THER, V267, P979; ROBBINS RA, 1987, AM REV RESPIR DIS, V135, P651; Sahu A, 1996, J IMMUNOL, V157, P884; Shen Y, 1997, BRAIN RES PROTOC, V1, P186, DOI 10.1016/S1385-299X(96)00026-8; VASTHARE US, 1993, FASEB J, V7, pA424; WANG MW, 1992, HISTOCHEM J, V24, P102, DOI 10.1007/BF01082446; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; WEISMAN HF, 1990, T ASSOC AM PHYSICIAN, V103, P64; [No title captured]	24	7	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					882	883		10.1038/nbt0998-882	http://dx.doi.org/10.1038/nbt0998-882			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743126				2022-12-25	WOS:000075671700040
J	Vicart, P; Caron, A; Guicheney, P; Li, ZL; Prevost, MC; Faure, A; Chateau, D; Chapon, F; Tome, F; Dupret, JM; Paulin, D; Fardeau, M				Vicart, P; Caron, A; Guicheney, P; Li, ZL; Prevost, MC; Faure, A; Chateau, D; Chapon, F; Tome, F; Dupret, JM; Paulin, D; Fardeau, M			A missense mutation in the alpha B-crystallin chaperone gene causes a desmin-related myopathy	NATURE GENETICS			English	Article							INTERMEDIATE FILAMENTS; ACCUMULATION; PROTEINS; SEQUENCE; TISSUES; STORAGE; ACTIN; LENS	Desmin-related myopathies (DRM) are inherited neuromuscular disorders characterized by adult onset and delayed accumulation of aggregates of desmin, a protein belonging to the type III intermediate filament Family, in the sarcoplasma of skeletal and cardiac muscles(1,2). In this paper, we have mapped the locus for DRM in a large French pedigree to a 26-cM interval in chromosome 11q21-23. This region contains the alpha B-crystallin gene (CRYAB), a candidate gene encoding a 20-kD protein that is abundant in lens and is also present in a number of non-ocular tissues, including cardiac and skeletal muscle(3,4). alpha B-crystallin is a member of the small heat shock protein (shsp) family and possesses molecular chaperone activity(5). We identified an R120G missense mutation in CRYAB that co-segregates with the disease phenotype in this family. Muscle cell lines transfected with the mutant CRYAB cDNA showed intracellular aggregates that contain both desmin and alpha B-crystallin as observed in muscle fibers from DRM patients. These results are the first to identify a defect in a molecular chaperone as a cause for an inherited human muscle disorder.	Inst Pasteur, F-75015 Paris, France; Univ Paris 07, UFR Biochim, F-75005 Paris, France; Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U153, F-75013 Paris, France; Genethon, F-91002 Evry, France; CHU Cote Nacre, Neuropathol Lab, F-14033 Caen, France; Hop Robert Debre, INSERM, U458, F-75019 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Vicart, P (corresponding author), Inst Pasteur, 25 Rue Dr Roux, F-75015 Paris, France.	pvicart@pasteur.fr	Li, Zhenlin/E-3937-2016; Guicheney, Pascale/D-1034-2017	Guicheney, Pascale/0000-0002-7663-2050; LI, Zhenlin/0000-0002-3706-4505				Baeta AM, 1996, ACTA NEUROPATHOL, V92, P499, DOI 10.1007/s004010050552; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BERTINI E, 1991, ACTA NEUROPATHOL, V81, P632, DOI 10.1007/BF00296373; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Djabali K, 1997, J CELL SCI, V110, P2759; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARDEAU M, 1978, REV NEUROL, V134, P411; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Goebel HH, 1996, NEUROMUSCULAR DISORD, V6, P383, DOI 10.1016/0960-8966(96)85105-4; Graw J, 1997, BIOL CHEM, V378, P1331; Gyapay Gabor, 1996, Methods (Orlando), V9, P91, DOI 10.1006/meth.1996.0012; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HOROWITZ SH, 1994, MUSCLE NERVE, V17, P151, DOI 10.1002/mus.880170204; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JEANPIERRE C, 1993, MAMM GENOME, V4, P104, DOI 10.1007/BF00290434; Kato S, 1997, AM J PATHOL, V151, P611; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; Liao JH, 1998, BIOCHEM BIOPH RES CO, V244, P131, DOI 10.1006/bbrc.1998.8226; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Lobrinus JA, 1998, NEUROMUSCULAR DISORD, V8, P77, DOI 10.1016/S0960-8966(98)00005-4; Martin JL, 1997, CIRCULATION, V96, P4343; Neufer PD, 1998, AM J PHYSIOL-CELL PH, V274, pC341, DOI 10.1152/ajpcell.1998.274.2.C341; RAPPAPORT L, 1988, FEBS LETT, V231, P421, DOI 10.1016/0014-5793(88)80863-9; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Vicart P, 1996, HUM GENET, V98, P422, DOI 10.1007/s004390050233; Vignal Alain, 1993, V1, P211	30	878	907	1	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					92	95		10.1038/1765	http://dx.doi.org/10.1038/1765			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731540				2022-12-25	WOS:000075671400028
J	Bowen, WR; Hall, NJ; Pan, LC; Sharif, AO; Williams, PM				Bowen, WR; Hall, NJ; Pan, LC; Sharif, AO; Williams, PM			The relevance of particle size and zeta-potential in protein processing	NATURE BIOTECHNOLOGY			English	Editorial Material							COLLOIDAL DISPERSIONS; ULTRAFILTRATION		Univ Coll Swansea, Dept Chem & Biol Proc Engn, Ctr Complex Fluids Proc, Swansea SA2 8PP, W Glam, Wales	Swansea University	Bowen, WR (corresponding author), Univ Coll Swansea, Dept Chem & Biol Proc Engn, Ctr Complex Fluids Proc, Swansea SA2 8PP, W Glam, Wales.	r.bowen@swansea.ac.uk						Bowen WR, 1996, CHEM ENG SCI, V51, P4321, DOI 10.1016/0009-2509(96)83770-5; BOWEN WR, 1995, CHEM ENG SCI, V50, P1707, DOI 10.1016/0009-2509(95)00026-2; Bowen WR, 1996, J COLLOID INTERF SCI, V184, P241, DOI 10.1006/jcis.1996.0617; BOWEN WR, 1995, BIOTECHNOL BIOENG, V46, P28, DOI 10.1002/bit.260460105; BOWEN WR, IN PRESS COLLOIDS A; BOWEN WR, 1993, RECOVERY PROCESSES B, P559; Rowan WR, 1996, BIOTECHNOL BIOENG, V50, P125, DOI 10.1002/(SICI)1097-0290(19960420)50:2<125::AID-BIT2>3.0.CO;2-O	7	22	24	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					785	787		10.1038/nbt0898-785	http://dx.doi.org/10.1038/nbt0898-785			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702781				2022-12-25	WOS:000075183400040
J	Claydon, MA; Davey, SN; EdwardsJones, V; Gordon, DB				Claydon, MA; Davey, SN; EdwardsJones, V; Gordon, DB			The rapid identification of intact microorganisms using mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						microorganisms; mass spectrometry; MALDI-TOF		Antibiotic-resistant strains of bacteria continue to emerge, increasing the need for their fast and accurate identification. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS), has become a prominent technique in biological mass spectrometry, We report the application of MALDI-TOF-MS for the identification of intact Gram-negative and Gram-positive microorganisms taken directly from culture, Analysis of bacteria from a single colony is possible, allowing the screening of mixed cultures. Sample preparation is simple and the analysis automated, providing spectra within minutes. the spectra obtained allow identification of microorganisms from different genera, different species, and from different strains of the same species. The procedure provides a unique mass spectral fingerprint of the microorganism, produced from desorbed components of the cell wall, Consistent data were obtained from subcultures grown for 3-day and Ei-day periods, from the same cultures 1 day later and from fresh subcultures 2 months later.			Claydon, MA (corresponding author), MANCHESTER METROPOLITAN UNIV,DEPT BIOL SCI,CHESTER ST,MANCHESTER M1 5GD,LANCS,ENGLAND.							BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; COTTER RJ, 1992, ANAL CHEM, V64, pA1027, DOI 10.1021/ac00045a002; Dobson G., 1985, CHEM METHODS BACTERI, P237; Ewing W.H., 1986, EDWARDS EWINGS IDENT; Fenselau C., 1994, ACS S SERIES, V541; GALLAGHER RT, 1996, BIOMEDICAL APPL SPEC, V25, P329; HAGEN SR, 1995, J CHROMATOGR A, V693, P167; HELLER DN, 1987, BIOCHEM BIOPH RES CO, V142, P194, DOI 10.1016/0006-291X(87)90470-0; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Holland RD, 1996, RAPID COMMUN MASS SP, V10, P1227, DOI 10.1002/(SICI)1097-0231(19960731)10:10<1227::AID-RCM659>3.0.CO;2-6; Krishnamurthy T, 1996, RAPID COMMUN MASS SP, V10, P883, DOI 10.1002/(SICI)1097-0231(19960610)10:8<883::AID-RCM594>3.3.CO;2-M; Liang XL, 1996, RAPID COMMUN MASS SP, V10, P1219, DOI 10.1002/(SICI)1097-0231(19960731)10:10<1219::AID-RCM660>3.0.CO;2-R; Matsuo T., 1994, BIOL MASS SPECTROMET; MORSE A, 1995, MED MICROBIOLOGY, P35; ZUBAY G, 1993, IBOCHEMISTRY, P138	16	450	487	3	120	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1584	1586		10.1038/nbt1196-1584	http://dx.doi.org/10.1038/nbt1196-1584			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634826				2022-12-25	WOS:A1996VP83300027
J	Chan, EF; Gat, U; McNiff, JM; Fuchs, E				Chan, EF; Gat, U; McNiff, JM; Fuchs, E			A common human skin tumour is caused by activating mutations in beta-catenin	NATURE GENETICS			English	Article							ADENOMATOUS POLYPOSIS; GARDNER SYNDROME; PROTEIN; PHOSPHORYLATION; APC; UBIQUITINATION; CANCER; SIGNAL	WNT signalling orchestrates a number of developmental programs(1-3), In response to this stimulus, cytoplasmic beta-catenin (encoded by CTNNB1) is stabilized, enabling downstream transcriptional activation by members of the LEF/TCF family(4,5). One of the target genes for beta-catenin/TCF encodes c-MYC, explaining why constitutive activation of the WNT pathway can lead to cancer, particularly in the colon(6). Most colon cancers arise from mutations in the gene encoding adenomatous polyposis coli (APC), a protein required for ubiquitin-mediated degradation of beta-catenin(7), but a small percentage of colon and some other cancers harbour beta-catenin-stabilizing mutations (refs 8-17). Recently, we discovered that transgenic mice expressing an activated beta-catenin are predisposed to developing skin tumours resembling pilomatricoma(18). Given that the skin of these adult mice also exhibits signs of de novo hair-follicle morphogenesis, we wondered whether human pilomatricomas might originate from hair matrix cells and whether they might possess beta-catenin-stabilizing mutations. Here, we explore the cell origin and aetiology of this common human skin tumour. We found nuclear LEF-1 in the dividing tumour cells, providing biochemical evidence that pilomatricomas are derived from hair matrix cells. At least 75% of these tumours possess mutations affecting the amino-terminal segment, normally involved in phosphorylation-dependent, ubiquitin-mediated degradation of the protein. This percentage of CTNNB1 mutations is greater than in all other human tumours examined thus far, and directly implicates beta-catenin/LEF misregulation as the major cause of hair matrix cell tumorigenesis in humans.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Howard Hughes Medical Institute; University of Chicago; Yale University	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.		高, 雨莉/HGU-8187-2022; Fuchs, Elaine/G-1565-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER; NIAMS NIH HHS [NIH-RO1-AR31737] Funding Source: Medline; NIDCR NIH HHS [NCI-P50DE/CA-11921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Foulkes WD, 1995, QJM-MON J ASSOC PHYS, V88, P853; Fukuchi T, 1998, CANCER RES, V58, P3526; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller O, 1998, GENE CHROMOSOME CANC, V22, P37; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Palacios J, 1998, CANCER RES, V58, P1344; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Pujol RM, 1995, PEDIATR DERMATOL, V12, P331, DOI 10.1111/j.1525-1470.1995.tb00195.x; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Voeller HJ, 1998, CANCER RES, V58, P2520; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHOU P, 1995, GENE DEV, V9, P570; Zurawel RH, 1998, CANCER RES, V58, P896	30	486	515	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					410	413		10.1038/7747	http://dx.doi.org/10.1038/7747			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192393				2022-12-25	WOS:000079439700024
J	Persidis, A				Persidis, A			Antisense therapeutics	NATURE BIOTECHNOLOGY			English	Editorial Material							MESSENGER-RNA; PNA		Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.	apersidis@argonex.corn						Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Desai RP, 1999, APPL ENVIRON MICROB, V65, P936; Ecker DJ, 1998, NAT BIOTECHNOL, V16, P332, DOI 10.1038/nbt0498-332; Flechsler I, 1998, ADV EXP MED BIOL, V451, P469; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; Im SA, 1999, CANCER RES, V59, P895; Li YX, 1999, VIROLOGY, V255, P138, DOI 10.1006/viro.1998.9571; Monteith DK, 1998, TOXICOL SCI, V46, P365, DOI 10.1093/toxsci/46.2.365; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nielsen PE, 1999, CURR OPIN BIOTECH, V10, P71, DOI 10.1016/S0958-1669(99)80013-5; ORKIN SH, 1977, J BIOL CHEM, V252, P5606; ROSENBERG UB, 1985, NATURE, V313, P703, DOI 10.1038/313703a0; WORTZMAN MS, 1980, BIOCHIM BIOPHYS ACTA, V609, P84, DOI 10.1016/0005-2787(80)90203-8	14	29	32	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					403	404		10.1038/7973	http://dx.doi.org/10.1038/7973			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207893				2022-12-25	WOS:000079574400036
J	Sykes, KF; Johnston, SA				Sykes, KF; Johnston, SA			Linear expression elements: a rapid, in vivo, method to screen for gene functions	NATURE BIOTECHNOLOGY			English	Article						functional genomics; genetic vaccines; gene delivery; gene screening	IMMUNIZATION; DNA; CLONING	The increasing accumulation of genomic sequence information has accentuated the need for new methods to efficiently assess gene function and to prepare reagents to study these functions. Toward solving this general problem in functional genomics, we report a method by which any PCR-amplified open-reading frame (ORF) can be noncovalently linked to a eukaryotic promoter and terminator, and directly injected into animals to produce local gene expression. We also demonstrate that ORFs can be delivered into mice to produce antibodies specific for the encoded foreign protein by simply attaching mammalian promoter and terminator sequences. This technology makes it possible to screen large numbers of genes rapidly for their functions in vivo or to produce immune responses without the necessity of cloning, bacterial propagation, or protein purification.	Univ Texas, SW Med Ctr, Dept Internal Med, Ctr Biomed Invent, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnston, SA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Ctr Biomed Invent, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARRY MA, 1994, BIOTECHNIQUES, V16, P616; BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BUTTRICK PM, 1992, CIRC RES, V70, P193, DOI 10.1161/01.RES.70.1.193; FISHER R, 1985, J BIOL CHEM, V260, P1223; Harlow E., 1988, ANTIBODIES LAB MANUA; LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; Nisson P E, 1991, PCR Methods Appl, V1, P120; SANFORD J C, 1991, Technique (Philadelphia), V3, P3; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; WOLFF JA, 1990, SCIENCE, V246, P1464; XIE TD, 1993, BIOPHYS J, V65, P1684, DOI 10.1016/S0006-3495(93)81208-6	15	45	58	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					355	359		10.1038/7908	http://dx.doi.org/10.1038/7908			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207883				2022-12-25	WOS:000079574400023
J	Kaplan, HJ; Leibole, MA; Tezel, T; Ferguson, TA				Kaplan, HJ; Leibole, MA; Tezel, T; Ferguson, TA			Fas ligand (CD95 ligand) controls angiogenesis beneath the retina	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; BASEMENT-MEMBRANE; FACTOR EXPRESSION; IMMUNE PRIVILEGE; APOPTOSIS; DEATH; CELLS; INVOLVEMENT	A principal cause of blindness is subretinal neovascularization associated with age-related macular degeneration. Excised neovascular membranes from patients with age-related macular degeneration demonstrated a pattern of Fas(+) new vessels in the center of the vascular complex, surrounded by FasL(+) retinal pigment epithelial cells. In a murine model, Fas (CD95)-deficient (lpr) and Fast-defective (gld) mice had a significantly increased incidence of neovascularization compared with normal mice. Furthermore, in gld mice there is massive subretinal neovascularization with uncontrolled growth of vessels. We found that cultured choroidal endothelial cells were induced to undergo apoptosis by retinal pigment epithelial cells through a Fas-FasL interaction. In addition, antibody against Fas prevented vascular tube formation of choroidal endothelial cells derived from the eye in a three-dimensional in vitro assay. Thus, Fast expressed on retinal pigment epithelial cells may control the growth and development of new subretinal vessels that can damage vision.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Ferguson, TA (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.	ferguson@am.seer.wustl.edu			NEI NIH HHS [EY06765, EY08972] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008972] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Chan CC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1559, DOI 10.1001/archopht.1997.01100160729010; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DeLisser HM, 1997, AM J PATHOL, V151, P671; Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x; FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hammes HP, 1996, NAT MED, V2, P820; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590; KINSELLA JL, 1992, EXP CELL RES, V199, P56, DOI 10.1016/0014-4827(92)90461-G; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Luna J, 1996, LAB INVEST, V75, P563; Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741; MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SATA M, 1998, NAT MED, V4, P1; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; SUDA T, 1995, J IMMUNOL, V154, P3806; Suhara T, 1998, J IMMUNOL, V160, P4042; Thilenius ARB, 1997, EUR J IMMUNOL, V27, P1108, DOI 10.1002/eji.1830270510; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641	43	138	156	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					292	297		10.1038/6509	http://dx.doi.org/10.1038/6509			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086384				2022-12-25	WOS:000078851600033
J	Nishimura, M; Yu, G; Levesque, G; Zhang, DM; Ruel, L; Chen, F; Milman, P; Holmes, E; Liang, Y; Kawarai, T; Jo, E; Supala, A; Rogaeva, E; Xu, DM; Janus, C; Levesque, L; Bi, Q; Duthie, M; Rozmahel, R; Mattila, K; Lannfelt, L; Westaway, D; Mount, HTJ; Woodgett, J; Fraser, PE; St George-Hyslop, P				Nishimura, M; Yu, G; Levesque, G; Zhang, DM; Ruel, L; Chen, F; Milman, P; Holmes, E; Liang, Y; Kawarai, T; Jo, E; Supala, A; Rogaeva, E; Xu, DM; Janus, C; Levesque, L; Bi, Q; Duthie, M; Rozmahel, R; Mattila, K; Lannfelt, L; Westaway, D; Mount, HTJ; Woodgett, J; Fraser, PE; St George-Hyslop, P			Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex	NATURE MEDICINE			English	Article							SYNTHASE KINASE-3 ACTIVITY; MISSENSE MUTATIONS; TRANSFECTED CELLS; IN-VIVO; LITHIUM; GENE; CHROMOSOME-1; APOPTOSIS; MECHANISM; XENOPUS	The presenilin proteins are components of high-molecular-weight protein complexes in the endoplasmic reticulum and Golgi apparatus that also contain beta-catenin. We report here that presenilin mutations associated with familial Alzheimer disease (but not the non-pathogenic Glu318Gly polymorphism) alter the intracellular trafficking of beta-catenin after activation of the Wnt/beta-catenin signal transduction pathway. As with their effect on beta APP processing, the effect of PS1 mutations on trafficking of beta-catenin arises from a dominant 'gain of aberrant function' activity. These results indicate that mistrafficking of selected presenilin ligands is a candidate mechanism for the genesis of Alzheimer disease associated with presenilin mutations, and that dysfunction in the presenilin-beta-catenin protein complexes is central to this process.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Expt Therapeut, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Karolinska Inst, Huddinge Hosp, Novum, KFC,Dept Clin Neurosci & Family Med, S-14186 Huddinge, Sweden	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Karolinska Institutet	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Mount, Howard/B-4097-2013; Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Jo, Euijung/0000-0003-1131-2723	Canadian Institutes of Health Research [37920] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; ANANTH UEA, 1998, NEUROLOGY, V50, P111; Aplin AE, 1997, NEUROREPORT, V8, P639, DOI 10.1097/00001756-199702100-00012; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bird TD, 1996, ANN NEUROL, V40, P932, DOI 10.1002/ana.410400619; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Han YQ, 1997, J BIOL CHEM, V272, P9825; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Imahori K, 1997, J BIOCHEM, V121, P179; Irving NG, 1997, NEUROSCI LETT, V222, P71, DOI 10.1016/S0304-3940(97)13343-2; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Mattila KM, 1998, ANN NEUROL, V44, P965, DOI 10.1002/ana.410440617; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tan YZ, 1998, BBA-MOL BASIS DIS, V1407, P69, DOI 10.1016/S0925-4439(98)00031-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	42	198	207	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1999	5	2					164	169		10.1038/5526	http://dx.doi.org/10.1038/5526			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930863				2022-12-25	WOS:000078274400024
J	Watanabe, H; Yamada, Y				Watanabe, H; Yamada, Y			Mice lacking link protein develop dwarfism and craniofacial abnormalities	NATURE GENETICS			English	Article							HORMONE-RELATED PEPTIDE; PARATHYROID-HORMONE; CHONDROCYTE DIFFERENTIATION; SKELETAL DEVELOPMENT; ENDOCHONDRAL BONE; INDIAN HEDGEHOG; CORE PROTEIN; GENE; CARTILAGE; AGGRECAN	Link protein (LP), an extracellular matrix protein in cartilage, stabilizes aggregates of aggrecan and hyaluronan, giving cartilage its tensile strength and elasticity(1-3). Cartilage provides the template for endochondral ossification and is crucial for determining the length and width of the skeleton. During endochondral bone formation, hypertrophic chondrocytes die and the cartilage is replaced with bone matrix. Here, we have generated targeted mutations in mice in the gene encoding LP (Crtl1). Homozygotes showed defects in cartilage development and delayed bone formation with short limbs and craniofacial anomalies. Most Crtl1(tm1Nid/tm1Nid) mice died shortly after birth due to respiratory failure, but some survived and developed progressive dwarfism and lordosis of the cervical spine. They showed small epiphysis, slightly flared metaphysis of long bones and flattened vertebrae, characteristic of spondyloepiphyseal dysplasias. The cartilage contained significantly reduced aggrecan depositions in the hypertrophic zone, and decreased numbers of prehypertrophic and hypertrophic chondrocytes. Reduced Indian hedgehog (Ihh) expression was observed in prehypertrophic chondrocytes, and apoptosis was inhibited in hypertrophic chondrocytes. These results indicate that LP is important for the formation of proteoglycan aggregates and normal organization of hypertrophic chondrocytes, and suggest that cartilage matrix has a role in chondrocyte differentiation and maturation.	Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, Y (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.	yamada@yoda.nidr.nih.gov						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; DOEGE K, 1987, J BIOL CHEM, V262, P17757; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; Hascall V.C., 1991, CELL BIOL EXTRACELLU, P149; HECHT JT, 1991, NUCLEIC ACIDS RES, V19, P6666, DOI 10.1093/nar/19.23.6666; KONG RYC, 1993, EUR J BIOCHEM, V213, P99, DOI 10.1111/j.1432-1033.1993.tb17739.x; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Li YF, 1997, MATRIX BIOL, V16, P49, DOI 10.1016/S0945-053X(97)90071-8; McAlister W.H., 1995, DIAGNOSIS BONE JOINT, VThird ed., P4163; MUNDLOS S, 1991, MATRIX, V11, P339, DOI 10.1016/S0934-8832(11)80205-2; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; Peters PWJ, 1977, METHODS PRENATAL TOX, P153; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wallis GA, 1996, CURR BIOL, V6, P1577, DOI 10.1016/S0960-9822(02)70776-8; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154	29	144	147	2	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					225	229		10.1038/6016	http://dx.doi.org/10.1038/6016			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988279				2022-12-25	WOS:000078399500029
J	Lee, JK; Zaidi, SHE; Liu, P; Dawood, F; Cheah, AYL; Wen, WH; Saiki, Y; Rabinovitch, M				Lee, JK; Zaidi, SHE; Liu, P; Dawood, F; Cheah, AYL; Wen, WH; Saiki, Y; Rabinovitch, M			A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis	NATURE MEDICINE			English	Article							TRIFLUOROMETHYL KETONE INHIBITORS; ENCEPHALOMYOCARDITIS VIRUS; COXSACKIEVIRUS-B3 MYOCARDITIS; DILATED CARDIOMYOPATHY; VIRAL MYOCARDITIS; B3-INDUCED MYOCARDITIS; PROTEOLYTIC ACTIVITY; NEUTROPHIL ELASTASE; LEUKOCYTE ELASTASE; HUMAN-MONOCYTES	In viral myocarditis, inflammation and destruction of cardiac: myocytes leads to fibrosis, causing progressive impairment in cardiac function. Here we show the etiologic importance of serine elastase activity in the pathophysiology of acute viral myocarditis and the therapeutic efficacy of an elastase inhibitor. In DBA/2 mice inoculated with the encephalomyocarditis virus, a more than 150% increase in myocardial serine elastase activity is observed. This is suppressed by a selective serine elastase inhibitor, ZD0892, which is biologically effective after oral administration. Mice treated with this compound had little evidence of microvascular constriction and obstruction associated with myocarditis-induced ischemia reperfusion injury, much less inflammation and necrosis, only mild fibrosis and myocardial collagen deposition, and normal ventricular function, compared with the infected nontreated group.	Univ Toronto, Hosp Sick Children, Dept Pediat, Res Inst,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Res Inst,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Med, Res Inst,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto Hosp, Dept Med, Div Cardiol,Ctr Cardiovasc Res, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rabinovitch, M (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Res Inst,Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; CONSTANZONORDIN MR, 1985, J AM COLL CARDIOL, V6, P1078; Cowan B, 1996, J CLIN INVEST, V97, P2452, DOI 10.1172/JCI118692; Crinnion J N, 1994, Cardiovasc Surg, V2, P749; DINERMAN JL, 1990, J AM COLL CARDIOL, V15, P1559, DOI 10.1016/0735-1097(90)92826-N; DONG R, 1992, J CLIN INVEST, V90, P2022, DOI 10.1172/JCI116082; Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; FALLON JT, 1987, CONT ISSUES CARDIOVA, V18, P155; FRIZELLE S, 1992, AM J PATHOL, V141, P203; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; Hauck M, 1995, BIOCHEM MOL BIOL INT, V37, P45; Hirasawa K, 1996, J GEN VIROL, V77, P737, DOI 10.1099/0022-1317-77-4-737; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; KEELEY FW, 1984, EXP EYE RES, V39, P533, DOI 10.1016/0014-4835(84)90053-8; KISHIMOTO C, 1990, CIRC RES, V67, P589, DOI 10.1161/01.RES.67.3.589; KISHIMOTO C, 1990, CIRCULATION, V82, P982, DOI 10.1161/01.CIR.82.3.982; KISHIMOTO C, 1989, CIRC RES, V65, P934, DOI 10.1161/01.RES.65.4.934; LANE JR, 1992, J EXP MED, V175, P1123, DOI 10.1084/jem.175.4.1123; LIEBERMAN EB, 1991, J AM COLL CARDIOL, V18, P1617, DOI 10.1016/0735-1097(91)90493-S; LIU P, 1993, CARDIOVASC PATHOL, V2, P247, DOI 10.1016/1054-8807(93)90031-V; MATSUMORI A, 1982, CIRCULATION, V66, P355, DOI 10.1161/01.CIR.66.2.355; MOLLA A, 1993, J VIROL, V67, P4688, DOI 10.1128/JVI.67.8.4688-4695.1993; MYERS ML, 1985, CIRCULATION, V72, P915, DOI 10.1161/01.CIR.72.4.915; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; NICOLINI FA, 1991, AM HEART J, V122, P1245, DOI 10.1016/0002-8703(91)90562-V; OHO S, 1994, AM J PATHOL, V145, P202; REZKALLA S, 1990, CIRCULATION, V81, P1039, DOI 10.1161/01.CIR.81.3.1039; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SEKO Y, 1991, CIRCULATION, V84, P788, DOI 10.1161/01.CIR.84.2.788; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SILVER MA, 1989, AM HEART J, V118, P173, DOI 10.1016/0002-8703(89)90089-6; TAKADA H, 1995, CIRCULATION, V92, P1604, DOI 10.1161/01.CIR.92.6.1604; TESH RB, 1978, AM J TROP MED HYG, V27, P144, DOI 10.4269/ajtmh.1978.27.144; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Tiefenbacher CP, 1997, PFLUG ARCH EUR J PHY, V433, P563, DOI 10.1007/s004240050315; TOMINAGA M, 1991, CIRCULATION, V83, P2021, DOI 10.1161/01.CIR.83.6.2021; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; Veale CA, 1997, J MED CHEM, V40, P3173, DOI 10.1021/jm970250z; YAMADA T, 1994, CIRCULATION, V89, P846, DOI 10.1161/01.CIR.89.2.846; YAMADA T, 1992, JPN CIRC J, V56, P1138, DOI 10.1253/jcj.56.1138; ZIMMERMAN BJ, 1990, AM J PHYSIOL, V259, pH390, DOI 10.1152/ajpheart.1990.259.2.H390	44	56	58	4	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1383	1391		10.1038/3973	http://dx.doi.org/10.1038/3973			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846575				2022-12-25	WOS:000077336900033
J	Brown, MP; Topham, DJ; Sangster, MY; Zhao, JF; Flynn, KJ; Surman, SL; Woodland, DL; Doherty, PC; Farr, AG; Pattengale, PK; Brenner, MK				Brown, MP; Topham, DJ; Sangster, MY; Zhao, JF; Flynn, KJ; Surman, SL; Woodland, DL; Doherty, PC; Farr, AG; Pattengale, PK; Brenner, MK			Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; T-CELLS; TRANSGENIC MICE; ANTIGEN RECEPTOR; VIRUS-INFECTION; SELECTION; EXPRESSION; ACTIVATION; LYMPHOCYTES; THYMOCYTES	Inherited deficiency of the CD40 ligand (X-linked hyper-IgM syndrome) is characterized by failure of immunoglobulin isotype switching and severe defects of cell-mediated immunity. To test the potential for gene transfer therapy to correct this disorder, we transduced murine bone marrow or thymic cells with a retroviral vector containing the cDNA for the murine CD40 ligand (CD40L) and injected them into CD40L(-/-) mice.; Even low-level, constitutive expression of the transgene stimulated humoral and cellular immune functions in these mice. With extended follow-up, however, 12 of 19 treated mice developed T-lymphoproliferative disorders, ranging from polyclonal increases of lymphoblasts to overt monoclonal T-lymphoblastic lymphomas that involved multiple organs. Our findings show that constitutive (rather than tightly regulated), low-level expression of CD40L can produce abnormal proliferative responses in developing T lymphocytes, apparently through aberrant interaction between CD40L(+) and TCR alpha beta(+)CD40(+) thymocytes. Current methods of gene therapy may prove inappropriate for disorders involving highly regulated genes in essential positions in proliferative cascades.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; St Jude Childrens Res Hosp, Cell & Gene Therapy Program, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA	Baylor College of Medicine; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Children's Hospital Los Angeles	Brenner, MK (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 6621 Fannin St,MC3-3320, Houston, TX 77030 USA.		Brenner, Malcolm/Y-2509-2019; Doherty, Peter Charles/C-4185-2013; Brown, Michael/C-2081-2014	Doherty, Peter Charles/0000-0002-5028-3489; Brown, Michael/0000-0002-5796-1932; Sangster, Mark/0000-0002-1599-5894	NATIONAL CANCER INSTITUTE [R01CA078792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029579, R21AI037597, R01AI037597, R01AI029579] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78792] Funding Source: Medline; NIAID NIH HHS [AI-29579, AI-37597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN W, 1990, J IMMUNOL, V144, P3980; Anderson WF, 1998, NATURE, V392, P25; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Clegg CH, 1997, INT IMMUNOL, V9, P1111, DOI 10.1093/intimm/9.8.1111; COLE RA, 1975, LANCET, V1, P767; DANIELS CA, 1980, AM J PATHOL, V100, P663; Dunn RJ, 1997, J HISTOCHEM CYTOCHEM, V45, P129, DOI 10.1177/002215549704500116; EINERHAND MPW, 1993, BLOOD, V81, P254; EZINE S, 1993, INT IMMUNOL, V5, P89, DOI 10.1093/intimm/5.1.89; FANSLOW WC, 1994, J IMMUNOL, V152, P4262; FARINA SF, 1995, BLOOD, V86, P4124, DOI 10.1182/blood.V86.11.4124.bloodjournal86114124; FILIPOVICH AH, 1997, NONHODGKINS LYMPHOMA, P459; Flynn K, 1996, IMMUNOL CELL BIOL, V74, P413, DOI 10.1038/icb.1996.71; FOY TM, 1995, J EXP MED, V182, P1377, DOI 10.1084/jem.182.5.1377; FULEIHAN RL, 1997, IMMUNOLOGIST, V5, P133; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Grewal IS, 1997, IMMUNOL RES, V16, P59, DOI 10.1007/BF02786323; Grossmann ME, 1997, HUM GENE THER, V8, P1935, DOI 10.1089/hum.1997.8.16-1935; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; Harlow E., 1988, ANTIBODIES LAB MANUA, P99; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; HOAG WG, 1963, ANN NY ACAD SCI, V108, P805, DOI 10.1111/j.1749-6632.1963.tb13421.x; HOLLENBAUGH D, 1994, IMMUNOL REV, V138, P23, DOI 10.1111/j.1600-065X.1994.tb00845.x; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Kohn DB, 1996, BONE MARROW TRANSPL, V18, pS55; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; MILLER G, 1990, VIROLOGY, P563; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; PeguetNavarro J, 1997, J IMMUNOL, V158, P144; Qazilbash M H, 1995, J Hematother, V4, P91, DOI 10.1089/scd.1.1995.4.91; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; SANGSTER M, 1995, VIROLOGY, V212, P13, DOI 10.1006/viro.1995.1448; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Strzadala L, 1997, INT IMMUNOL, V9, P127, DOI 10.1093/intimm/9.1.127; Tokoro Y, 1996, EUR J IMMUNOL, V26, P1012, DOI 10.1002/eji.1830260509; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862; Zhou T, 1997, J CLIN IMMUNOL, V17, P74, DOI 10.1023/A:1027392613714; ZHOU T, 1993, J IMMUNOL, V150, P3651	52	102	105	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1253	1260		10.1038/3233	http://dx.doi.org/10.1038/3233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809548				2022-12-25	WOS:000076731000033
J	Hislop, AD; Good, MF; Mateo, L; Gardner, J; Gatei, MH; Daniel, RCW; Meyers, BV; Lavin, MF; Suhrbier, A				Hislop, AD; Good, MF; Mateo, L; Gardner, J; Gatei, MH; Daniel, RCW; Meyers, BV; Lavin, MF; Suhrbier, A			Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge	NATURE MEDICINE			English	Article							VIRUS; CELLS; INFECTION; MACAQUES; CD8(+); SHEEP	The development of prophylactic vaccines against retroviral diseases has been impeded by the lack of obvious immune correlates for protection(1,2). Cytotoxic T-lymphocyte (CTL)(3,4), CD4-lymphocyte(5), chemokine(6) and/or antibody responses(7) have all been associated with protection against HIV and AIDS; however, effective and safe vaccination strategies remain elusive(1,8). Here we show that vaccination with a minimal ovine CTL peptide epitope identified within gp51 of the retrovirus bovine leukemia virus (BLV), consistently induced peptide-specific CTLs. Only sheep whose CTLs were also capable of recognizing retrovirus-infected cells were fully protected when challenged with BLV. This retrovirus displays limited sequence variation(9); thus, in the relative absence of confounding CTL escape variants(10), virus-specific CTLs targeting a single epitope were able to prevent the establishment of a latent retroviral infection.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Univ Queensland, Sch Vet Sci & Anim Prod, St Lucia, Qld 4067, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Suhrbier, A (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Suhrbier, Andreas/0000-0001-8986-9025				ANDREW M, 1995, VET IMMUNOL IMMUNOP, V47, P311, DOI 10.1016/0165-2427(94)05410-T; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; BURTON DR, 1998, NAT MED, V54, P495; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COULSTON J, 1990, J GEN VIROL, V71, P1737, DOI 10.1099/0022-1317-71-8-1737; Dalgleish AG, 1998, CURR OPIN INFECT DIS, V11, P195, DOI 10.1097/00001432-199804000-00019; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; Garzino-Demo A, 1998, J CLIN IMMUNOL, V18, P243, DOI 10.1023/A:1027329721892; GATEI MH, 1993, J VIROL, V67, P1803, DOI 10.1128/JVI.67.4.1803-1810.1993; Kent SJ, 1996, J VIROL, V70, P4941, DOI 10.1128/JVI.70.8.4941-4947.1996; Kettmann R., 1994, The retroviridae: Volume 3, P39; MAMMERICKX M, 1988, LEUKEMIA, V2, P103; McClure SJ, 1995, IMMUNOL CELL BIOL, V73, P552, DOI 10.1038/icb.1995.87; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; SCALZO AA, 1995, J VIROL, V69, P1306, DOI 10.1128/JVI.69.2.1306-1309.1995; Thomson SA, 1998, J IMMUNOL, V160, P1717; YASUTOMI Y, 1995, J VIROL, V69, P2279, DOI 10.1128/JVI.69.4.2279-2284.1995	20	39	40	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1193	1196		10.1038/2690	http://dx.doi.org/10.1038/2690			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771756				2022-12-25	WOS:000076230100042
J	Savukoski, M; Klockars, T; Holmberg, V; Santavuori, P; Lander, ES; Peltonen, L				Savukoski, M; Klockars, T; Holmberg, V; Santavuori, P; Lander, ES; Peltonen, L			CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis	NATURE GENETICS			English	Article							JANSKY-BIELSCHOWSKY DISEASE; THIOESTERASE; ASSIGNMENT	The neuronal ceroid lipofuscinoses (NCLs) represent a group of common recessive inherited neurodegenerative disorders of childhood, with an incidence of 1:12,500 live births(1). They are characterized by accumulation of autofluorescent lipopigments in various tissues. Several forms of NCLs have been identified, based on age at onset, progression of disease, neurophysiological and histopathological findings and separate genetic loci(2-9) All types of NCL cause progressive visual and mental decline, motor disturbance, epilepsy and behavioral changes, and lead to premature death. One of the subtypes, Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCL; MIM256731) affects children at 4-7 years of age(10,11). The first symptom is motor clumsiness, followed by progressive visual failure, mental and motor deterioration and later by myoclonia and seizures. We have previously reported linkage for vLINCL on chromosome 13 (ref. 5) and constructed a long-range physical map over the region(12). Here, we report the positional cloning of a novel gene, CLN5, underlying this severe neurological disorder. The gene encodes a putative transmembrane protein which shows no homology to previously reported proteins. Sequence analysis of DNA samples from patients with three different haplotypes revealed three mutations; one deletion, one nonsense and one missense mutation, suggesting that mutations in this gene are responsible for vLINCL.	Univ Helsinki, Dept Med Genet, Helsinki 00300, Finland; Natl Publ Hlth Inst, Dept Human Mol Genet, Helsinki 00300, Finland; Univ Helsinki, Hosp Children & Adolescents, Dept Neurol, Helsinki 00300, Finland; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki; Massachusetts Institute of Technology (MIT); Whitehead Institute	Peltonen, L (corresponding author), Univ Helsinki, Dept Med Genet, Mannerheimintie 166, Helsinki 00300, Finland.	Leena.Peltonen@ktl.fi						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; JARVELA I, 1991, GENOMICS, V9, P170, DOI 10.1016/0888-7543(91)90235-7; Jarvela I, 1998, HUM MOL GENET, V7, P85, DOI 10.1093/hmg/7.1.85; Klockars T, 1996, GENOMICS, V35, P71, DOI 10.1006/geno.1996.0324; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Maniatis T., 1982, MOL CLONING LAB MANU; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; REESE MG, 1996, P PAC S BIOC; Rider J A, 1988, Am J Med Genet Suppl, V5, P21; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; SANTAVUORI P, 1982, NEUROPEDIATRICS, V13, P135, DOI 10.1055/s-2008-1059612; SANTAVUORI P, 1993, J INHERIT METAB DIS, V16, P230, DOI 10.1007/BF00710251; SAVUKOSKI M, 1994, AM J HUM GENET, V55, P695; SHARP J, HUM MOL GENET, V6, P591; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; Varilo T, 1996, AM J HUM GENET, V58, P506; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; [No title captured]	24	211	214	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					286	288		10.1038/975	http://dx.doi.org/10.1038/975			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662406				2022-12-25	WOS:000074565900029
J	Tang, BW; Bottinger, EP; Jakowlew, SB; Bagnall, KM; Mariano, J; Anver, MR; Letterio, JJ; Wakefield, LM				Tang, BW; Bottinger, EP; Jakowlew, SB; Bagnall, KM; Mariano, J; Anver, MR; Letterio, JJ; Wakefield, LM			Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency	NATURE MEDICINE			English	Article							FACTOR-BETA; DISEASE PROGRESSION; TRANSGENIC MICE; SKIN TUMORS; IN-VIVO; GENE; GROWTH-FACTOR-BETA-1; TGF-BETA-1; INHIBITION; EXPRESSION	Components of the transforming growth factor-beta (TGF-beta) signal pathway function as classic tumor suppressors, but the role of the TGF-beta s themselves is less clear. Here we show that mice heterozygous for deletion of the TGF-beta 1 gene express only 10-30% of wild-type TGF-beta 1 protein levels. Although grossly normal, these mice have a subtly altered proliferative phenotype, with increased cell turnover in the liver and lung. Treatment of these mice with chemical carcinogens resulted in enhanced tumorigenesis when compared with wild-type littermates. However, tumors in the heterozygous mice did not lose the remaining wild-type TGF-beta 1 allele, indicating that the TCF-beta 1 ligand is a new form of tumor suppressor that shows true haploid insufficiency in its ability to protect against tumorigenesis.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Natl Canc Inst, Cell & Canc Biol Dept, Rockville, MD 20850 USA; Sci Applicat Int Corp, Frederick Canc Res & Dev Ctr, Pathol Histotechnol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Wakefield, LM (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, 41 Lib Dr MSC 5055, Bethesda, MD 20892 USA.	wakefiel@dce41.nci.nih.gov	Wakefield, Lalage M/M-1963-2017	Wakefield, Lalage M/0000-0003-4124-5250				BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Bottinger EP, 1997, CANCER RES, V57, P5564; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Cambien F, 1996, HYPERTENSION, V28, P881, DOI 10.1161/01.HYP.28.5.881; CARR BI, 1986, CANCER RES, V46, P2330; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROCKER TT, 1970, CANCER RES, V30, P357; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DANIELPOUR D, 1995, J IMMUNOL METHODS, V180, P265, DOI 10.1016/0022-1759(94)00322-N; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DIWAN BA, 1984, CANCER LETT, V23, P223, DOI 10.1016/0304-3835(84)90157-5; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fajardo LF, 1996, LAB INVEST, V74, P600; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FIRTH CH, 1984, PATHOLOGY TUMORS LAB, V2, P223; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glick AB, 1996, CANCER RES, V56, P3645; GORSCH SM, 1992, CANCER RES, V52, P6949; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HUANG F, 1995, CELL GROWTH DIFFER, V6, P1635; Iavarone A, 1997, NATURE, V387, P417; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jakowlew SB, 1998, MOL CARCINOGEN, V22, P46, DOI 10.1002/(SICI)1098-2744(199805)22:1<46::AID-MC6>3.0.CO;2-J; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756-3282(96)00363-8; MARKOWITZ S, 1995, SCIENCE, V268, P336; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RAVITZMJ, 1997, ADV CANC RES, V71, P65; Rehm S, 1994, IARC Sci Publ, P325; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Tashiro H, 1997, CORONARY ARTERY DIS, V8, P143, DOI 10.1097/00019501-199703000-00004; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187	45	272	284	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					802	807		10.1038/nm0798-802	http://dx.doi.org/10.1038/nm0798-802			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662371				2022-12-25	WOS:000074543900034
J	Rane, SG; Dubus, P; Mettus, RV; Galbreath, EJ; Boden, G; Reddy, EP; Barbacid, M				Rane, SG; Dubus, P; Mettus, RV; Galbreath, EJ; Boden, G; Reddy, EP; Barbacid, M			Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia	NATURE GENETICS			English	Article							DEPENDENT KINASE INHIBITORS; PANCREATIC B-CELL; MICE LACKING; LEYDIG-CELLS; CYCLIN D1; GROWTH; GENE; PROLIFERATION; DISRUPTION; RAT	To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, we have targeted the mouse Cdk4 locus by homologous recombination to generate two strains of mice, one that lacks Cdk4 expression and one that expresses a Cdk4 molecule with an activating mutation. Embryonic fibroblasts proliferate normally in the absence of Cdk4 but have a delayed S phase on re-entry into the cell cycle. Moreover, mice devoid of Cdk4 are viable, but small in size and infertile. These mice also develop insulin-deficient diabetes due to a reduction in beta-islet pancreatic cells. In contrast, mice expressing a mutant Cdk4 that cannot bind the cell-cycle inhibitor p16(INK4a) display pancreatic hyperplasia due to abnormal proliferation of beta-islet cells. These results establish Cdk4 as an essential regulator of specific cell types.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Bordeaux 2, Lab Histol Embryol, F-33076 Bordeaux, France; Eli Lilly & Co, Indianapolis, IN 46285 USA; Temple Univ, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Gen Clin Res Ctr, Philadelphia, PA 19140 USA; Ctr Nacl Invest Oncol Carlos III, Madrid 28220, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; UDICE-French Research Universities; Universite de Bordeaux; Eli Lilly; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011	Dubus, Pierre/0000-0003-1803-4711; Galbreath, Elizabeth/0000-0003-0162-8329	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010221] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIAAA NIH HHS [R01-AA-10221] Funding Source: Medline; NIA NIH HHS [R01-AG-07988] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Ashcroft FM, 1992, INSULIN MOL BIOL PAT; Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Balvers M, 1998, ENDOCRINOLOGY, V139, P2960, DOI 10.1210/en.139.6.2960; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CAMERON DF, 1985, ANAT REC, V213, P53, DOI 10.1002/ar.1092130108; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DELLA NG, 1995, CELL TISSUE RES, V279, P411, DOI 10.1007/s004410050298; Dunlop M, 1996, BIOCHEM BIOPH RES CO, V218, P132, DOI 10.1006/bbrc.1996.0023; Duvillie B, 1997, P NATL ACAD SCI USA, V94, P5137, DOI 10.1073/pnas.94.10.5137; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GRANA X, 1995, ONCOGENE, V11, P211; HELLERSTROM C, 1984, DIABETOLOGIA, V26, P393; HELLERSTROM C, 1991, DIABETES, V40, P89, DOI 10.2337/diab.40.2.S89; HIRAMA T, 1995, BLOOD, V86, P841; HOPPENER JWM, 1994, J CELL BIOCHEM, V55, P39, DOI 10.1002/jcb.240550006; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lejeune H, 1998, J MOL ENDOCRINOL, V20, P1, DOI 10.1677/jme.0.0200001; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MARTINEZ AR, 1995, INT J FERTIL MENOP S, V40, P139; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MURRAY FT, 1983, METABOLISM, V32, P141, DOI 10.1016/S0026-0495(83)80028-6; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAYNE AH, 1995, BIOL REPROD, V52, P217, DOI 10.1095/biolreprod52.2.217; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SWENNE I, 1983, DIABETES, V32, P14, DOI 10.2337/diabetes.32.1.14; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UNGER R H, 1985, P1018; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	42	586	602	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					44	52		10.1038/8751	http://dx.doi.org/10.1038/8751			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319860				2022-12-25	WOS:000080096300021
J	Lee, JT; Davidow, LS; Warshawsky, D				Lee, JT; Davidow, LS; Warshawsky, D			Tsix, a gene antisense to Xist at the X-inactivation centre	NATURE GENETICS			English	Article							CHROMOSOME INACTIVATION; RNA; DNA; DIFFERENTIATION; STABILIZATION; INTERPHASE; EXPRESSION; NUCLEUS; INVITRO; REGION	In mammals, dosage compensation is achieved by X inactivation(1) and is regulated in cis by the X-inactivation centre(2) (Xic) and Xist (refs 3-5). The Xic controls X-chromosome counting, choice of X to inactivate and initiation of silencing. Xic action culminates in a change in Xist RNA property from a scarce, unstable RNA (refs 6,7) to highly expressed Xist RNA that coats the future inactive X (ref. 8). Deleting a 65-kb region downstream of Xist results in constitutive Xist expression and X inactivation, implying the presence of a cis-regulatory element(9). In this region, we now report the discovery of a gene antisense to Xist. Tsix is a 40-kb RNA originating 15 kb downstream of Xist and transcribed across the Xist locus. Tsix sequence is conserved at the human XIC. Tsix RNA has no conserved ORFs, is seen exclusively in the nucleus and is localized at Xic. Before the onset of X inactivation, Tsix is expressed from both X chromosomes. At the onset of X inactivation, Tsix expression becomes monoallelic, is associated with the future active X and persists until Xist is turned off. Tsix is not found on the inactive X once cells enter the X-inactivation pathway. Tsix has features suggesting a role in regulating the early steps of X inactivation, but not the silencing step.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02115 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE JA, IN PRESS P NATL ACAD; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	26	627	664	1	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					400	404		10.1038/7734	http://dx.doi.org/10.1038/7734			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192391				2022-12-25	WOS:000079439700022
J	Braun, JS; Novak, R; Herzog, KH; Bodner, SM; Cleveland, JL; Tuomanen, EI				Braun, JS; Novak, R; Herzog, KH; Bodner, SM; Cleveland, JL; Tuomanen, EI			Neuroprotection by a caspase inhibitor in acute bacterial meningitis	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; TISSUE-DAMAGE; APOPTOSIS; PROTEASE; PATHOPHYSIOLOGY; PATHOGENESIS; INFLAMMATION; GENERATION; ISCHEMIA	Half of the survivors of bacterial meningitis experience motor deficits, seizures, hearing loss or cognitive impairment, despite adequate bacterial killing by antibiotics. We demonstrate that the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (z-VAD-fmk) prevented hippocampal neuronal cell death and white blood cell influx into the cerebrospinal fluid compartment in experimental pneumococcal meningitis. Hippocampal neuronal death was due to apoptosis derived from the inflammatory response in the cerebrospinal fluid. Apoptosis was induced in vitro in human neurons by inflamed cerebrospinal fluid and was blocked by z-VAD-fmk. As apoptosis drives neuronal loss in pneumococcal meningitis, caspase inhibitors might provide a new therapeutic option directed specifically at reducing brain damage.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Tuomanen, EI (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	elaine.tuomanen@stjude.org	Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA076379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027913] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76379, P30 CA21765] Funding Source: Medline; NIAID NIH HHS [AI 27913] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BRAUN JS, 1998, ADV PEDIAT INFECT DI, V14, P49; CHEN YJ, 1994, MICROB PATHOGENESIS, V17, P203, DOI 10.1006/mpat.1994.1066; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dodel RC, 1998, NEUROSCIENCE, V86, P701, DOI 10.1016/S0306-4522(98)00154-7; Eichhold TH, 1997, J PHARMACEUT BIOMED, V16, P459, DOI 10.1016/S0731-7085(97)00102-7; Evers P, 1998, METHODS, V15, P133, DOI 10.1006/meth.1998.0616; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; Leib SL, 1996, J INFECT DIS, V173, P166, DOI 10.1093/infdis/173.1.166; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Pitrak DL, 1996, J CLIN INVEST, V98, P2714, DOI 10.1172/JCI119096; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; RONNETT GV, 1994, NEUROSCIENCE, V63, P1081, DOI 10.1016/0306-4522(94)90574-6; Roos Karen L., 1997, P335; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; TAUBER MG, 1992, J INFECT DIS, V166, P1045, DOI 10.1093/infdis/166.5.1045; TAUBER MG, 1994, METHOD ENZYMOL, V235, P93; TAUBER MG, 1997, DEFENSE BRAIN, P125; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557; Zysk G, 1996, J NEUROPATH EXP NEUR, V55, P722, DOI 10.1097/00005072-199606000-00006	31	217	228	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					298	302		10.1038/6514	http://dx.doi.org/10.1038/6514			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086385				2022-12-25	WOS:000078851600034
J	Agris, CH				Agris, CH			Patents - Intellectual property protection for plants	NATURE BIOTECHNOLOGY			English	Editorial Material																		EVANS DA, 1983, SCIENCE, V221, P949, DOI 10.1126/science.221.4614.949; Moffat AS, 1998, SCIENCE, V282, P2176, DOI 10.1126/science.282.5397.2176; *OJ EPO, 1984, T4983 OJ EPO, P112; *OJ EPO, 1990, T32087 OJ EPO, P71; *OJ EPO, 1995, T35693 OJ EPO, P545; 5840851; 5066830; 10289; 5844118	9	4	4	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					197	198		10.1038/6205	http://dx.doi.org/10.1038/6205			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052359				2022-12-25	WOS:000078508300031
J	Fang, GW; Weiser, B; Visosky, A; Moran, T; Burger, H				Fang, GW; Weiser, B; Visosky, A; Moran, T; Burger, H			PCR-mediated recombination: A general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA	NATURE MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; THERMOSTABLE DNA-POLYMERASE; OVERLAP EXTENSION; FIDELITY; AMPLIFICATION		New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; Albany Med Coll, Albany, NY 12208 USA	State University of New York (SUNY) System; Wadsworth Center; Albany Medical College	Burger, H (corresponding author), New York State Dept Hlth, Wadsworth Ctr, POB 22002,120 New Scotland Ave, Albany, NY 12201 USA.				NIAID NIH HHS [R01AI33334, U01AI35004] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033334, U01AI035004] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Eckert K A, 1991, PCR Methods Appl, V1, P17; Fang GW, 1996, J ACQ IMMUN DEF SYND, V12, P352, DOI 10.1097/00042560-199608010-00004; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; GU HM, 1991, BIOCHEM BIOPH RES CO, V177, P202, DOI 10.1016/0006-291X(91)91968-I; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KLUG J, 1991, NUCLEIC ACIDS RES, V19, P2793, DOI 10.1093/nar/19.10.2793; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MYERS G, 1996, HUMAN RETROVIRUSES A; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALMINEN MO, 1995, VIROLOGY, V213, P80, DOI 10.1006/viro.1995.1548; SANDHU GS, 1992, BIOTECHNIQUES, V12, P14; YOLOV AA, 1990, NUCLEIC ACIDS RES, V18, P3483	20	45	53	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					239	242		10.1038/5607	http://dx.doi.org/10.1038/5607			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930876				2022-12-25	WOS:000078274400037
J	Jensen, S; Gassama, MP; Heidmann, T				Jensen, S; Gassama, MP; Heidmann, T			Taming of transposable elements by homology-dependent gene silencing	NATURE GENETICS			English	Article							R-HYBRID DYSGENESIS; DROSOPHILA-MELANOGASTER; TRANSGENIC PLANTS; I-FACTOR; RNA; COSUPPRESSION; SUPPRESSION; REPEATS	Transposable elements can invade virgin genomes within a few generations, after which the elements are 'tamed' and retain only limited transpositional activity. Introduction of the I element, a transposon similar to mammalian LINE elements, into Drosophila melanogaster genomes devoid of such elements initially results in high-frequency transposition of the incoming transposon, high mutation rate, chromosomal nondisjunction and female sterility, a syndrome referred to as hybrid dysgenesis' (for review, see refs 2-4); a related syndrome has also been described in mammals(5). High-frequency transposition is transient, as the number of I elements reaches a finite value and transposition ceases after approximately ten generations(6,7). It has been proposed that the I elements encode a factor that negatively regulates their own transcription, but evidence for such a mechanism is lacking(8). Using the hybrid dysgenesis syndrome in Drosophila(1-4) as a model, we show here that transpositional activity of the I element can be repressed by prior introduction of transgenes expressing a small internal region of the I element. This autoregulation presents features characteristic of homology-dependent gene silencing, a process known as cosuppression(9-15) Repression does not require any translatable sequence, its severity correlates with transgene copy number and it develops in a generation-dependent manner via germline transmission of a silencing effector in females only. These results demonstrate that transposable elements are prone to and can be tamed by homology-dependent gene silencing, a process that may have emerged during the course of evolution as a specific defense mechanism against these elements.	Inst Gustave Roussy, CNRS, UMR 1537, Unite Retrovir Endogen & Elem Retroid Eucaryot, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 1537, Unite Retrovir Endogen & Elem Retroid Eucaryot, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	heidemann@igr.fr		Jensen, Silke/0000-0002-1858-8792				ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bingham PM, 1997, CELL, V90, P385, DOI 10.1016/S0092-8674(00)80496-1; BREGLIANO JC, 1980, SCIENCE, V207, P606, DOI 10.1126/science.6766221; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; Dawson A, 1997, EMBO J, V16, P4448, DOI 10.1093/emboj/16.14.4448; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FINNEGAN DJ, 1989, DROSOPHILA MELANOGAS, P503; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; JENSEN S, 1995, MOL GEN GENET, V248, P381, DOI 10.1007/BF02191637; JENSEN S, 1994, NUCLEIC ACIDS RES, V22, P1484, DOI 10.1093/nar/22.8.1484; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Meyer P, 1996, ANNU REV PLANT PHYS, V47, P23, DOI 10.1146/annurev.arplant.47.1.23; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PELISSON A, 1987, MOL GEN GENET, V207, P306, DOI 10.1007/BF00331594; Picard G, 1971, DIS, V46, P54; PRITCHARD MA, 1988, MOL GEN GENET, V214, P533, DOI 10.1007/BF00330491; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; VAUCHERET H, 1995, MOL GEN GENET, V248, P311, DOI 10.1007/BF02191598; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8	30	173	188	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					209	212		10.1038/5997	http://dx.doi.org/10.1038/5997			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988275				2022-12-25	WOS:000078399500025
J	Alexeev, V; Yoon, K				Alexeev, V; Yoon, K			Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide	NATURE BIOTECHNOLOGY			English	Article						gene repair; recombination; gene targeting; clonal analysis; chimeroplasty	SICKLE-CELL-ANEMIA; CHIMERIC RNA/DNA OLIGONUCLEOTIDE; TYROSINASE GENE; MOUSE TYROSINASE; MICE; MUTATION	Experimental strategies have been developed to correct point mutations using chimeric oligonucleotides composed of RNA and DNA. We used these RNA-DNA oligonucleotides to correct a point mutation in mouse tyrosinase, a key enzyme for melanin synthesis and pigmentation. Melanocytes derived from albino mice contain a homozygous point mutation (T (G) under bar T-->T (C) under bar T) in the tyrosinase gene, resulting in an amino acid change from Cys-->Ser. Correction of this point mutation results in the restoration of tyrosinase activity and melanin synthesis, thus changing the pigmentation of the cells. Upon transfection of the RNA-DNA oligonucleotide to albino melanocytes, we detected black-pigmented cells and isolated multiple single clones. All black-pigmented clones exhibited a correction of the point mutation in a single allele of the tyrosinase gene. A full-length tyrosinase was detected by an antityrosinase antibody, and the enzymatic activity was restored in all converted black-pigmented clones. Only degraded fragments were detected in albino cells due to proteolytic cleavage of mutant tyrosinase. The phenotype and genotype of converted black-pigmented clones was stable. These results demonstrate a permanent and stable gene correction by the RNA-DNA oligonucleotide at the level of genomic sequence, protein, and phenotypic change by clonal analysis.	Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Yoon, K (corresponding author), Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.	Yoon1@jeflin.tju.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044350] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR44350] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BOISSY RE, 1991, J INVEST DERMATOL, V97, P395, DOI 10.1111/1523-1747.ep12480976; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; HALABAN R, 1993, J INVEST DERMATOL, V100, pS176, DOI 10.1111/1523-1747.ep12465140; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; HUSZAR D, 1991, DEVELOPMENT, V113, P653; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KOTANI H, 1994, MOL CELL BIOL, V14, P1949, DOI 10.1128/MCB.14.3.1949; Kotani H, 1996, MOL GEN GENET, V250, P626; KOTANI H, 1994, MOL CELL BIOL, V14, P6097, DOI 10.1128/MCB.14.9.6097; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Santana E, 1998, J INVEST DERMATOL, V111, P1172, DOI 10.1046/j.1523-1747.1998.00403.x; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; Stasiak A, 1997, SCIENCE, V277, P460; Strauss M, 1998, NAT MED, V4, P274, DOI 10.1038/nm0398-274; TANAKA S, 1990, DEVELOPMENT, V108, P223; Thomas KR, 1997, SCIENCE, V275, P1404; Woolf TM, 1998, NAT BIOTECHNOL, V16, P341, DOI 10.1038/nbt0498-341; Xiang YF, 1997, J MOL MED-JMM, V75, P829, DOI 10.1007/s001090050172; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071	26	137	153	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1343	1346		10.1038/4322	http://dx.doi.org/10.1038/4322			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853616				2022-12-25	WOS:000077232600027
J	Yu, RN; Ito, M; Saunders, TL; Camper, SA; Jameson, JL				Yu, RN; Ito, M; Saunders, TL; Camper, SA; Jameson, JL			Role of Ahch in gonadal development and gametogenesis	NATURE GENETICS			English	Article							ADRENAL HYPOPLASIA CONGENITA; HYPOGONADOTROPIC HYPOGONADISM; ENDOCRINE DEVELOPMENT; DAX-1; RECEPTOR; MICE; EXPRESSION; MUTATIONS; DOMAIN; CELLS	Ahch (also known as Dax1) encodes a transcription factor that has been implicated in sex determination and gonadal differentiation(1-3). Mutations in human AHC cause X-linked, adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism(4,5) (HH). Duplication of the Xp21 dosage-sensitive sex reversal (DSS) region, which contains the Ahch locus(1), and transgenic overexpression of Ahch (ref. 6) cause male-to-female sex reversal. Using Cre-mediated disruption of Ahch, we have generated a mouse model of AHC-HH that allows the function of Ahch to be examined in both males and females. Although Ahch has been postulated to function as an ovarian determination gene(2,6), the loss of Ahch function in females does not affect ovarian development or fertility. Ahch is instead essential for the maintenance of spermatogenesis. Lack of Ahch causes progressive degeneration of the testicular germinal epithelium independent of abnormalities in gonadotropin and testosterone production and results in male sterility. Ahch is thus not an ovarian determining gene, but rather has a critical role in spermatogenesis.	Northwestern Univ, Sch Med, Div Endocrinol Metab & Internal Med, Chicago, IL 60611 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	Northwestern University; University of Michigan System; University of Michigan	Jameson, JL (corresponding author), Northwestern Univ, Sch Med, Div Endocrinol Metab & Internal Med, 303 E Super St, Chicago, IL 60611 USA.	ljameson@nwu.edu		Saunders, Thom/0000-0003-2015-101X; Jameson, James/0000-0001-9538-4059; Camper, Sally/0000-0001-8556-3379	NICHD NIH HHS [U54-HD-29164, P30-HD-28048, P01-HD-21921] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028048, U54HD029164] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; DUNN TB, 1970, JNCI-J NATL CANCER I, V44, P1323; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; ROSSANT J, 1995, NAT MED, V1, P592, DOI 10.1038/nm0695-592; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Swain A, 1997, ACTA PAEDIATR, V86, P46; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wurst W., 1993, Gene targeting: a practical approach., P33; Yu RN, 1998, TRENDS ENDOCRIN MET, V9, P169, DOI 10.1016/S1043-2760(98)00048-4; Yu RN, 1998, MOL ENDOCRINOL, V12, P1010, DOI 10.1210/me.12.7.1010; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	23	350	363	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					353	357		10.1038/3822	http://dx.doi.org/10.1038/3822			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843206				2022-12-25	WOS:000077199600021
J	Conway, KA; Harper, JD; Lansbury, PT				Conway, KA; Harper, JD; Lansbury, PT			Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; LEWY BODIES; PROTEIN; SCRAPIE	Two mutations in the gene encoding alpha-synuclein have been linked to early-onset Parkinson's disease(1-3) (PD). alpha-Synuclein is a component of Lewy bodies, the fibrous cytoplasmic inclusions characteristic of nigral dopaminergic neurons in the PD brain(4). This connection between genetics and pathology suggests that the alpha-synuclein mutations may promote PD pathogenesis by accelerating Lewy body formation. To test this, we studied alpha-synuclein folding and aggregation in vitro, in the absence of other Lewy body-associated molecules. We demonstrate here that both mutant forms of alpha-synuclein (A53T and A30P) are, like wild-type alpha-synuclein(5) (WT), disordered in dilute solution. However, at higher concentrations, Lewy body-like fibrils and discrete spherical assemblies are formed; most rapidly by A53T. Thus, mutation-induced acceleration of alpha-synuclein fibril formation may contribute to the early onset of familial PD.	Harvard Univ, Sch Med, Harvard Inst Med, Brigham & Womens Hosp,Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Lansbury, PT (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Brigham & Womens Hosp,Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.		Harper, James D/B-8701-2011	Harper, James/0000-0001-7895-8268				Baba M, 1998, AM J PATHOL, V152, P879; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; FORNO LS, 1993, NEURODEGENERATION, V2, P19; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	22	1208	1238	4	102	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1318	1320		10.1038/3311	http://dx.doi.org/10.1038/3311			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809558	Bronze			2022-12-25	WOS:000076731000043
J	Aihara, H; Miyazaki, J				Aihara, H; Miyazaki, J			Gene transfer into muscle by electroporation in vivo	NATURE BIOTECHNOLOGY			English	Article						drug delivery; gene therapy; DNA vaccine; cytokines	MOUSE SKELETAL-MUSCLE; PLASMID DNA; INTRAMUSCULAR INJECTION; EXPRESSION; INVIVO; INTERLEUKIN-5; VECTOR; CELLS; MICE	Among the nonviral techniques for gene transfer in vivo, the direct injection of plasmid DNA into muscle is simple, inexpensive, and safe, Applications of this method have been limited by the relatively low expression levels of the transferred gene. We investigated the applicability of in vivo electroporation for gene transfer into muscle, using plasmid DNA expressing interleukin-5 (IL-5) as the vector. The tibialis anterior muscles of mice were injected with the plasmid DNA, and then a pair of electrode needles were inserted into the DNA injection site to deliver electric pulses. Five days later, the serum IL-5 levels were assayed. Mice that did not receive electroporation had serum levels of 0.2 ng/ml. Electroporation enhanced the levels to over 20 ng/ml. Histochemical analysis of muscles injected with a lacZ expression plasmid showed that in vivo electroporation increased both the number of muscle fibers taking up plasmid DNA and the copy number of plasmids introduced into the cells. These results demonstrate that gene transfer into muscle by electroporation in vivo is more efficient than simple intramuscular DNA injection.	Osaka Univ, Sch Med, Dept Physiol Chem & Nutr, Osaka 5650871, Japan; Tohoku Univ, Sch Med, Dept Internal Med 3, Sendai, Miyagi 9800872, Japan	Osaka University; Tohoku University	Miyazaki, J (corresponding author), Osaka Univ, Sch Med, Dept Physiol Chem & Nutr, Osaka 5650871, Japan.		Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				Davis HL, 1995, ANN NY ACAD SCI, V772, P21, DOI 10.1111/j.1749-6632.1995.tb44728.x; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DAVIS HL, 1993, HUM GENE THER, V4, P733, DOI 10.1089/hum.1993.4.6-733; Heller R, 1996, FEBS LETT, V389, P225, DOI 10.1016/0014-5793(96)00590-X; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; MIYAZAKI J, 1989, GENE, V79, P269; Muramatsu T, 1997, BIOCHEM BIOPH RES CO, V230, P376, DOI 10.1006/bbrc.1996.5882; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Rols MP, 1998, NAT BIOTECHNOL, V16, P168, DOI 10.1038/nbt0298-168; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHOFIELD JP, 1995, BRIT MED BULL, V51, P56, DOI 10.1093/oxfordjournals.bmb.a072953; TAKATSU K, 1992, CURR OPIN IMMUNOL, V4, P299, DOI 10.1016/0952-7915(92)90080-X; TITOMIROV AV, 1991, BIOCHIM BIOPHYS ACTA, V1088, P131, DOI 10.1016/0167-4781(91)90162-F; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WELLS DJ, 1993, FEBS LETT, V332, P179, DOI 10.1016/0014-5793(93)80508-R; WELLS DJ, 1992, FEBS LETT, V306, P203, DOI 10.1016/0014-5793(92)81000-C; WOLF H, 1994, BIOPHYS J, V66, P524, DOI 10.1016/S0006-3495(94)80805-7; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	24	783	852	6	70	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					867	870		10.1038/nbt0998-867	http://dx.doi.org/10.1038/nbt0998-867			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743122				2022-12-25	WOS:000075671700035
J	Bashir, R; Britton, S; Strachan, T; Keers, S; Vafiadaki, E; Lako, M; Richard, I; Marchand, S; Bourg, N; Argov, Z; Sadeh, M; Mahjneh, I; Marconi, G; Passos-Bueno, MR; Moreira, ED; Zatz, M; Beckmann, JS; Bushby, K				Bashir, R; Britton, S; Strachan, T; Keers, S; Vafiadaki, E; Lako, M; Richard, I; Marchand, S; Bourg, N; Argov, Z; Sadeh, M; Mahjneh, I; Marconi, G; Passos-Bueno, MR; Moreira, ED; Zatz, M; Beckmann, JS; Bushby, K			A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B	NATURE GENETICS			English	Article							PRIMARY ADHALINOPATHY; GAMMA-SARCOGLYCAN; MIYOSHI MYOPATHY; BETA-SARCOGLYCAN; VESICLE FUSION; CHROMOSOME 2P; LOCUS; MUTATIONS; CONSTRUCTION; LIBRARIES	The limb-girdle muscular dystrophies are a genetically heterogeneous group of inherited progressive muscle disorders that affect mainly the proximal musculature, with evidence for at least three autosomal dominant and eight autosomal recessive loci. The latter mostly involve mutations in genes encoding components of the dystrophin-associated complex; another form is caused by mutations in the gene for the muscle-specific protease calpain 3. Using a positional cloning approach, we have identified the gene for a form of limb-girdle muscular dystrophy that we previously mapped to chromosome 2p13 (LGMD2B). This gene shows no homology to any known mammalian gene, but its predicted product is related to the C. elegans spermatogenesis factor fer-l. We have identified two homozygous frameshift mutations in this gene, resulting in muscular dystrophy of either proximal or distal onset in nine families. The proposed name 'dysferlin' combines the role of the gene in producing muscular dystrophy with its C. elegans homology.	Univ Newcastle Upon Tyne, Dept Human Genet, Mol Genet Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Genethon CNRS, URA 1922, F-91000 Evry, France; Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; Wolfson Hosp, Dept Neurol, Holon, Israel; Univ Florence, Dept Neurol & psychiat Sci, I-50121 Florence, Italy; Univ Sao Paulo, Dept Biol, BR-05508 Sao Paulo, Brazil	Newcastle University - UK; Centre National de la Recherche Scientifique (CNRS); Hebrew University of Jerusalem; University of Florence; Universidade de Sao Paulo	Bushby, K (corresponding author), Univ Newcastle Upon Tyne, Dept Human Genet, Mol Genet Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	kate.bushby@ncl.ac.uk	Moreira, Eloisa/K-9155-2014; Vafiadaki, Elizabeth/K-1171-2019; Zatz, Mayana/M-5338-2015; Beckmann, Jacques S/A-9772-2008; Richard, isabelle/J-8298-2013; Passos-Bueno, Maria Rita/I-6796-2016; Lako, Majlinda/B-6297-2013	Zatz, Mayana/0000-0003-3970-8025; Beckmann, Jacques S/0000-0002-9741-1900; Passos-Bueno, Maria Rita/0000-0002-9248-3008; lako, majlinda/0000-0003-1327-8573; Vafiadaki, Elizabeth/0000-0001-9931-7099	Telethon [1020] Funding Source: Medline	Telethon(Fondazione Telethon)		Achanzar WE, 1997, J CELL SCI, V110, P1073; ALLAMAND V, 1995, HUM MOL GENET, V4, P459, DOI 10.1093/hmg/4.3.459; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; Bashir R, 1996, GENOMICS, V33, P46, DOI 10.1006/geno.1996.0157; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BEJAOUI K, 1995, NEUROLOGY, V45, P768, DOI 10.1212/WNL.45.4.768; Bejaoui K, 1998, NEUROGENETICS, V1, P189, DOI 10.1007/s100480050028; Bernot A, 1997, NAT GENET, V17, P25; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BUSHBY KMD, 1997, DIAGNOSTIC CRITERIA, P17; Dincer P, 1997, ANN NEUROL, V42, P222, DOI 10.1002/ana.410420214; Eymard B, 1997, NEUROLOGY, V48, P1227, DOI 10.1212/WNL.48.5.1227; Fanin M, 1997, J MED GENET, V34, P973, DOI 10.1136/jmg.34.12.973; Fardeau M, 1996, BRAIN, V119, P295, DOI 10.1093/brain/119.1.295; FEINBERG AP, 1983, ANAL BIOCHEM, V32, P6; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gingrich JC, 1996, GENOMICS, V32, P65, DOI 10.1006/geno.1996.0077; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Illarioshkin SN, 1996, BRAIN, V119, P1895, DOI 10.1093/brain/119.6.1895; Illarioshkin SN, 1997, GENOMICS, V42, P345, DOI 10.1006/geno.1997.4725; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Liu J, 1998, GENOMICS, V49, P23, DOI 10.1006/geno.1998.5204; LUNT PW, 1991, J MED GENET, V28, P655, DOI 10.1136/jmg.28.10.655; Mahjneh I, 1996, NEUROMUSCULAR DISORD, V6, P483, DOI 10.1016/S0960-8966(96)00390-2; MAHJNEH I, 1992, NEUROMUSCULAR DISORD, V2, P277, DOI 10.1016/0960-8966(92)90060-J; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; PASSOSBUENO MR, 1995, GENOMICS, V27, P192, DOI 10.1006/geno.1995.1024; PassosBueno MR, 1996, J MED GENET, V33, P97, DOI 10.1136/jmg.33.2.97; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; Piccolo F, 1996, HUM MOL GENET, V5, P2019, DOI 10.1093/hmg/5.12.2019; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SENTER L, 1995, BIOCHEM BIOPH RES CO, V206, P57, DOI 10.1006/bbrc.1995.1009; SHERMAN F, 1986, LABORATORY COURSE MA, P117; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SORLMACHI H, 1995, J BIOL CHEM, V270, P31155; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weiler T, 1996, AM J HUM GENET, V59, P872; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	48	498	517	0	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					37	42		10.1038/1689	http://dx.doi.org/10.1038/1689			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731527				2022-12-25	WOS:000075671400015
J	SanMiguel, P; Gaut, BS; Tikhonov, A; Nakajima, Y; Bennetzen, JL				SanMiguel, P; Gaut, BS; Tikhonov, A; Nakajima, Y; Bennetzen, JL			The paleontology of intergene retrotransposons of maize	NATURE GENETICS			English	Article							NUCLEOTIDE-SEQUENCE; HIGHER-PLANTS; DNA; GENE; GENOME; METHYLATION; EVOLUTION; REGIONS; RETROELEMENTS; RECOMBINATION	Retrotransposons, transposable elements related to animal retroviruses, are found in all eukaryotes investigated and make up the majority of many plant genomes(1-5). Their ubiquity points to their importance, especially in their contribution to the large-scale structure of complex genomes. The nature and frequency of retro-element appearance, activation and amplification are poorly understood in all higher eukaryotes. Here we employ a novel approach to determine the insertion dates for 17 of 23 retrotransposons found near the maize adh1 gene, and two others from unlinked sites in the maize genome, by comparison of long terminal repeat (LTR) divergences with the sequence divergence between adh1 in maize and sorghum. All retrotransposons examined have inserted within the last six million years, most in the last three million years. The structure of the adh? region appears to be standard relative to the other gene-containing regions of the maize genome, thus suggesting that retrotransposon insertions have increased the size of the maize genome from approximately 1200 Mb to 2400 Mb in the last three million years. Furthermore, the results indicate an increased mutation rate in retrotransposons compared with genes.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Genet Program, W Lafayette, IN 47907 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Irvine	Bennetzen, JL (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	maize@bilbo.bio.purdue.edu	Tikhonov, Alexander/I-1453-2012; SanMiguel, Phillip J/I-2196-2015	Tikhonov, Alexander/0000-0003-3808-9701; SanMiguel, Phillip J/0000-0002-3742-9527				Avramova Z, 1996, PLANT J, V10, P1163, DOI 10.1046/j.1365-313X.1996.10061163.x; Bennetzen JL, 1996, TRENDS MICROBIOL, V4, P347, DOI 10.1016/0966-842X(96)10042-1; BENNETZEN JL, 1994, GENOME, V37, P565, DOI 10.1139/g94-081; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dooner HK, 1997, PLANT CELL, V9, P1633, DOI 10.1105/tpc.9.9.1633; FLAVELL AJ, 1992, NUCLEIC ACIDS RES, V20, P3639, DOI 10.1093/nar/20.14.3639; FLAVELL RB, 1974, BIOCHEM GENET, V12, P257, DOI 10.1007/BF00485947; Gaut BS, 1997, P NATL ACAD SCI USA, V94, P6809, DOI 10.1073/pnas.94.13.6809; GAUT BS, 1993, P NATL ACAD SCI USA, V90, P5095, DOI 10.1073/pnas.90.11.5095; Gaut BS, 1996, P NATL ACAD SCI USA, V93, P10274, DOI 10.1073/pnas.93.19.10274; GAUT BS, 1994, MOL BIOL EVOL, V11, P620; GRANDBASTIEN MA, 1992, TRENDS GENET, V8, P103, DOI 10.1016/0168-9525(92)90198-D; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; HU WM, 1995, MOL GEN GENET, V248, P471, DOI 10.1007/BF02191647; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; JIN YK, 1989, P NATL ACAD SCI USA, V86, P6235, DOI 10.1073/pnas.86.16.6235; JOHNS MA, 1983, GENETICS, V105, P733; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LEWIN B, 1997, GENES, V6, P603; NEI M, 1986, MOL BIOL EVOL, V3, P418; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; Sokal RR, 1995, BIOMETRY; Turcich MP, 1996, SEX PLANT REPROD, V9, P65, DOI 10.1007/BF02153053; VOYTAS DF, 1992, P NATL ACAD SCI USA, V89, P7124, DOI 10.1073/pnas.89.15.7124; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yoder JA, 1996, BIOL CHEM, V377, P605	30	721	761	0	75	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1998	20	1					43	45		10.1038/1695	http://dx.doi.org/10.1038/1695			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731528				2022-12-25	WOS:000075671400016
J	Thomsen, L; Robinson, TL; Lee, JCF; Farraway, LA; Hughes, MJG; Andrews, DW; Huizinga, JD				Thomsen, L; Robinson, TL; Lee, JCF; Farraway, LA; Hughes, MJG; Andrews, DW; Huizinga, JD			Interstitial cells of Cajal generate a rhythmic pacemaker current	NATURE MEDICINE			English	Article							COLON SMOOTH-MUSCLE; ACTION-POTENTIALS; CANINE COLON; SMALL-INTESTINE; PROTOONCOGENE; FREQUENCY	Networks of interstitial cells of Cajal embedded in the musculature of the gastrointestinal tract are involved in the generation of electrical pacemaker activity for gastrointestinal motility(1,2). This pacemaker activity manifests itself as rhythmic slow waves in membrane potential, and controls the frequency and propagation characteristics of gut contractile activity(3-6). Mice that lack a functional Kit receptor fail to develop the network of interstitial cells of Cajal associated with Auerbach's plexus in the moose small intestine(7,8) and do not generate slow wave activity(9,10). These cells could provide an essential component of slow wave activity (for example, a biochemical trigger that would be transferred to smooth muscle cells), or provide an actual pacemaker current that could initiate slow waves. Here we provide direct evidence that a single cell, identified as an interstitial cell of Cajal by light microscopy, electron microscopy and expression of Kit mRNA, generates spontaneous contractions and a rhythmic inward current that is insensitive to L-type calcium channel blockers. Identification of the pacemaker of gut motility will aid in the elucidation of the pathophysiology of intestinal motor disorders, and provide a target cell for pharmacological treatment.	McMaster Univ, Dept Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Intestinal Dis Res Program, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Huizinga, JD (corresponding author), McMaster Univ, Dept Biomed Sci, Hamilton, ON L8N 3Z5, Canada.	huizinga@mcmaster.ca		Andrews, David/0000-0002-9266-7157				Der-Silaphet T, 1998, GASTROENTEROLOGY, V114, P724, DOI 10.1016/S0016-5085(98)70586-4; Faussone Pellegrini M S, 1977, Arch Ital Anat Embriol, V82, P157; GOKKEL E, 1992, ONCOGENE, V7, P1423; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P15, DOI 10.1113/jphysiol.1991.sp018779; Huizinga JD, 1997, TRENDS PHARMACOL SCI, V18, P393, DOI 10.1016/S0165-6147(97)90668-4; Huizinga JD, 1998, J PHYSIOL-LONDON, V506, P843, DOI 10.1111/j.1469-7793.1998.843bv.x; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P31, DOI 10.1113/jphysiol.1991.sp018780; Kluppel M, 1998, DEV DYNAM, V211, P60; Komuro T, 1996, J AUTONOM NERV SYST, V61, P169, DOI 10.1016/S0165-1838(96)00078-1; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; Lecoin L, 1996, DEVELOPMENT, V122, P725; LEE HK, 1993, J PHYSIOL-LONDON, V460, P135, DOI 10.1113/jphysiol.1993.sp019463; LIU LWC, 1995, J PHARMACOL EXP THER, V275, P1058; Malysz J, 1995, CAN J PHYSIOL PHARM, V73, P1502, DOI 10.1139/y95-208; Malysz J, 1996, AM J PHYSIOL-GASTR L, V271, pG387, DOI 10.1152/ajpgi.1996.271.3.G387; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; THUNEBERG L, 1989, HDB PHYSL GASTROINTE, V1, P349; Tokutomi N, 1995, PFLUG ARCH EUR J PHY, V431, P169, DOI 10.1007/BF00410188; TOMITA T, 1981, SMOOTH MUSCLE ASSESS, P127; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; WARD SM, 1992, J PHYSIOL-LONDON, V455, P321, DOI 10.1113/jphysiol.1992.sp019304; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343	25	348	373	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					848	851		10.1038/nm0798-848	http://dx.doi.org/10.1038/nm0798-848			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662380				2022-12-25	WOS:000074543900043
J	Corti, O; Sabate, O; Horellou, P; Colin, P; Dumas, S; Buchet, D; Buc-Caron, MH; Mallet, J				Corti, O; Sabate, O; Horellou, P; Colin, P; Dumas, S; Buchet, D; Buc-Caron, MH; Mallet, J			A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors	NATURE BIOTECHNOLOGY			English	Article						doxycycline; adenovirus; human neural progenitors; tyrosine hydroxylase	CENTRAL-NERVOUS-SYSTEM; LONG-TERM EXPRESSION; PRODUCE L-DOPA; PARKINSONS-DISEASE; GENE-TRANSFER; MAMMALIAN-CELLS; SKIN FIBROBLASTS; TRANSGENIC MICE; MOUSE-BRAIN; RAT MODEL	Ex vivo gene transfer is emerging as a promising therapeutic approach to human neurodegenerative diseases. By combining efficient methodologies for cell amplification and gene delivery, large numbers of cells can be generated with the capacity to synthesize therapeutic molecules. These cells can then be transplanted into the degenerating central nervous system (CNS). Applying this approach to human diseases will require the development of suitable cellular vehicles, as well as safe gene delivery systems capable of tightly controlled transgene expression. For such brain repair technologies, human neural progenitors may be extremely valuable, because of their human CNS origin and developmental potential. We have used these cells to develop a system for the regulated expression of a gene of therapeutic potential. We report the construction of a single adenovirus encoding human tyrosine hydroxylase 1 (hTH-1) under the negative control of the tetracycline-based gene regulatory system. Human neural progenitors infected with this vector produced large amounts of hTH-1. Most importantly, doxycycline allowed a reversible switch of transgene transcription both in vitro and in vivo. This system may be applied to the development of therapies for human neurodegenerative diseases.	Hop La Pitie Salpetriere, CNRS, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Mallet, J (corresponding author), Hop La Pitie Salpetriere, CNRS, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, F-75013 Paris, France.		Corti, Olga/I-4981-2016; Horellou, Philippe/B-4290-2019; Corti, Olga/AAC-3160-2019	Corti, Olga/0000-0003-2093-7389; Horellou, Philippe/0000-0003-2467-8177; 				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BRUNDIN P, 1988, EXP BRAIN RES, V70, P192; BUC CM, 1995, NEUROBIOL DIS, V2, P37; Corti O, 1996, NEUROREPORT, V7, P1655, DOI 10.1097/00001756-199607080-00026; DUMAS S, 1992, J CHEM NEUROANAT, V5, P11, DOI 10.1016/0891-0618(92)90030-T; Fisher LJ, 1997, NEUROBIOL DIS, V4, P1, DOI 10.1006/nbdi.1997.0137; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; Freese A., 1997, Society for Neuroscience Abstracts, V23, P540; GENY C, 1994, J NEUROSCI, V14, P7553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; Horellou P, 1997, EXP NEUROL, V144, P131, DOI 10.1006/exnr.1996.6399; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kojima H, 1997, BIOCHEM BIOPH RES CO, V238, P569, DOI 10.1006/bbrc.1997.7183; Laniece P, 1996, J NEUROCHEM, V66, P1819; LIM B, 1989, P NATL ACAD SCI USA, V86, P8892, DOI 10.1073/pnas.86.22.8892; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; MARSDEN CD, 1976, LANCET, V1, P292, DOI 10.1016/S0140-6736(76)91416-1; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; Miller N, 1997, HUM GENE THER, V8, P803, DOI 10.1089/hum.1997.8.7-803; Mohammadi SA, 1997, GENE THER, V4, P993, DOI 10.1038/sj.gt.3300491; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; OBESO JA, 1994, EUR J NEUROSCI, V6, P889, DOI 10.1111/j.1460-9568.1994.tb00584.x; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; Pedersen EB, 1997, NEUROSCIENCE, V78, P685, DOI 10.1016/S0306-4522(96)00620-3; Raymon HK, 1997, EXP NEUROL, V144, P82, DOI 10.1006/exnr.1996.6392; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Uchida K, 1989, Hum Cell, V2, P150; UNGERSTEDT U, 1970, Brain Research, V24, P485, DOI 10.1016/0006-8993(70)90187-3; Whittemore S R, 1997, Adv Neurol, V72, P113; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011; Yu JS, 1996, CANCER RES, V56, P5423	45	82	87	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					349	354		10.1038/7901	http://dx.doi.org/10.1038/7901			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207882				2022-12-25	WOS:000079574400022
J	Fernandez, NC; Lozier, A; Flament, C; Ricciardi-Castagnoli, P; Bellet, D; Suter, M; Perricaudet, M; Tursz, T; Maraskovsky, E; Zitvogel, L				Fernandez, NC; Lozier, A; Flament, C; Ricciardi-Castagnoli, P; Bellet, D; Suter, M; Perricaudet, M; Tursz, T; Maraskovsky, E; Zitvogel, L			Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; FLT3 LIGAND; T-CELLS; MURINE TUMORS; IN-VIVO; INTERLEUKIN-12; MICE; ACTIVATION; THERAPY; COSTIMULATION	Cytotoxic T lymphocytes and natural killer cells are essential effecters of anti-tumor immune responses in vivo. Dendritic cells (DC) 'prime' tumor antigen-specific cytotoxic T lymphocytes; thus, we investigated whether DC might also trigger the innate, NK cell-mediated anti-tumor immunity. In mice with MHC class I-negative tumors, adoptively transferred- or Flt3 ligand-expanded DC promoted NK cell-dependent anti-tumor effects. In vitro studies demonstrated a cell-to-cell contact between DC and resting NK cells that resulted in a substantial increase in both NK cell cytolytic activity and IFN-gamma production. Thus, DC are involved in the interaction between innate and adaptive immune responses.	Inst Gustave Roussy, Dept Biol Clin, Unite Immunol, Villejuif, France; Inst Gustave Roussy, CNRS, UMR1582, Villejuif, France; Univ Milan, Dept Biotechnol & Biosci, Milan, Italy; Univ Zurich, Inst Virol, Zurich, Switzerland; Immunex Res & Dev Corp, Dept Immunobiol, Seattle, WA 98101 USA; Repatriat Med Ctr, Heidelberg, Vic, Australia; Ludwig Oncol Unit, Austin, Australia	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Milan; University of Milano-Bicocca; University of Zurich	Zitvogel, L (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Immunol, Villejuif, France.	zitvogel@igr.fr	Castagnoli, Paola/E-8288-2010	ZITVOGEL, laurence/0000-0003-1596-0998				ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANDYOPADHYAY S, 1986, J EXP MED, V164, P180, DOI 10.1084/jem.164.1.180; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Chambers BJ, 1996, IMMUNITY, V5, P311, DOI 10.1016/S1074-7613(00)80257-5; CHANG ZL, 1990, CELL IMMUNOL, V125, P183, DOI 10.1016/0008-8749(90)90073-Z; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Chen KY, 1997, CANCER RES, V57, P3511; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; GISMONDI A, 1991, J IMMUNOL, V146, P384; GRABBE S, 1991, J IMMUNOL, V146, P3656; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Johnson LL, 1997, J EXP MED, V186, P1799, DOI 10.1084/jem.186.11.1799; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Lang S, 1998, EUR J IMMUNOL, V28, P780, DOI 10.1002/(SICI)1521-4141(199803)28:03<780::AID-IMMU780>3.3.CO;2-#; Lanier LL, 1998, CELL, V92, P705, DOI 10.1016/S0092-8674(00)81398-7; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Lynch DH, 1997, NAT MED, V3, P625, DOI 10.1038/nm0697-625; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; MOALLI PA, 1987, AM J PATHOL, V128, P426; MONTEL AH, 1995, CELL IMMUNOL, V160, P104, DOI 10.1016/0008-8749(95)80015-B; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; SalazarMather TP, 1996, J IMMUNOL, V157, P3054; Shaw SG, 1998, J IMMUNOL, V161, P2817; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; TALMADGE JE, 1980, NATURE, V284, P622, DOI 10.1038/284622a0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	40	853	892	4	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					405	411		10.1038/7403	http://dx.doi.org/10.1038/7403			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202929				2022-12-25	WOS:000079574300029
J	Georgakopoulos, D; Christe, ME; Giewat, M; Seidman, CM; Seidman, JG; Kass, DA				Georgakopoulos, D; Christe, ME; Giewat, M; Seidman, CM; Seidman, JG; Kass, DA			The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation	NATURE MEDICINE			English	Article							RECEPTOR	Familial hypertrophic cardiomyopathy (FHC) is a genetic disorder resulting from mutations in genes encoding sarcomeric proteins(1,2). This typically induces hyperdynamic ejection(3), impaired relaxation, delayed early filling(4), myocyte disarray and fibrosis, and increased chamber end-systolic stiffness(5,6). To better understand the disease pathogenesis, early (primary) abnormalities must be distinguished from evolving responses to the genetic defect. We did in vivo analysis using a mouse model of FHC with an Arg403Gln alpha-cardiac myosin heavy chain missense mutation(7) and used newly developed methods for assessing in situ pressure-volume relations(8). Hearts of young mutant mice (6 weeks old), which show no chamber morphologic or gross histologic abnormalities, had altered contraction kinetics, with considerably delayed pressure relaxation and chamber filling, yet accelerated systolic pressure rise. Older mutant mice (20 weeks old), which develop fiber disarray and fibrosis, had diastolic and systolic kinetic changes similar to if not slightly less than those of younger mice. However, the hearts of older mutant mice also showed hyperdynamic contraction, with increased end-systolic chamber stiffness, outflow tract pressure gradients and a lower cardiac index due to reduced chamber filling; all 'hallmarks' of human disease. These data provide new insights into the temporal evolution of FHC. Such data may help direct new therapeutic strategies to diminish disease progression.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21287 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Div Cardiol, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Kass, DA (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Cardiol, 600 N Wolfe St, Baltimore, MD 21287 USA.	dkass@eureka.wbme.jhu.edu						BONOW RO, 1983, CIRCULATION, V68, P1062, DOI 10.1161/01.CIR.68.5.1062; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; Gotshall KR, 1997, P NATL ACAD SCI USA, V94, P4710, DOI 10.1073/pnas.94.9.4710; Grupp IL, 1998, AM J PHYSIOL-HEART C, V275, pH1338, DOI 10.1152/ajpheart.1998.275.4.H1338; KAPUKU GK, 1993, AM HEART J, V125, P1710, DOI 10.1016/0002-8703(93)90763-Y; LORENZ JN, 1997, AM J PHYSIOL-HEART C, V273, pH2826; Maughan DW, 1998, CIRCULATION, V98, P625; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Oberst L, 1998, J CLIN INVEST, V102, P1498, DOI 10.1172/JCI4088; Pak PH, 1998, CIRCULATION, V98, P242, DOI 10.1161/01.CIR.98.3.242; Pak PH, 1996, CIRCULATION, V94, P52, DOI 10.1161/01.CIR.94.1.52; Palatini P, 1998, AM J HYPERTENS, V11, P147, DOI 10.1016/S0895-7061(97)00412-3; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Seidman CE, 1995, MOL CARDIOVASCULAR M, P193; Shen YT, 1996, J PHARMACOL EXP THER, V278, P1435; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; SUGA H, 1974, CIRC RES, V35, P117, DOI 10.1161/01.RES.35.1.117; Sutton MS, 1998, NEW ENGL J MED, V338, P1303, DOI 10.1056/NEJM199804303381810; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WELCH WJ, 1995, AM J PHYSIOL-RENAL, V268, pF175, DOI 10.1152/ajprenal.1995.268.1.F175; Wen C, 1996, J CARDIOVASC PHARM, V27, P482, DOI 10.1097/00005344-199604000-00005; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	25	110	112	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					327	330		10.1038/6549	http://dx.doi.org/10.1038/6549			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086390				2022-12-25	WOS:000078851600039
J	Perl, AK; Dahl, U; Wilgenbus, P; Cremer, H; Semb, H; Christofori, G				Perl, AK; Dahl, U; Wilgenbus, P; Cremer, H; Semb, H; Christofori, G			Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells	NATURE MEDICINE			English	Article							N-CAM; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; POLYSIALIC ACID; NERVOUS-SYSTEM; GROWTH-FACTOR; NCAM; ISLETS; TUMORIGENESIS; AGGREGATION	As in the development of many human cancers, in a transgenic mouse model of beta-cell carcinogenesis (Rip1Tag2), expression of neural cell adhesion molecule (NCAM) changes from the 120-kDa isoform in normal tissue to the 140/180-kDa isoforms in tumors. NCAM-deficient Rip1Tag2 mice, generated by crossing Rip1Tag2 mice with NCAM knockout mice, develop metastases, a tumor stage that is not seen in normal Rip1Tag2 mice. In contrast, overexpression of NCAM 120 in NCAM-deficient Rip1Tag2 mice prevents tumor metastasis. The results indicate that the loss of NCAM-mediated cell adhesion is one rate-limiting step in the actual metastatic dissemination of beta tumor cells.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; Univ Marseille, CNRS,INSERM, IBDM LGPD, Marseille, France	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Umea University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Christofori, G (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Perl, Anne-Karina T/M-7174-2013	Perl, Anne-Karina T/0000-0002-8445-4565; Semb, Henrik/0000-0002-6747-787X; Cremer, Harold/0000-0002-8673-5176				Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CIRULLI V, 1994, J CELL SCI, V107, P1429; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CROSSIN KL, 1985, P NATL ACAD SCI USA, V82, P6942, DOI 10.1073/pnas.82.20.6942; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; Dahl U, 1996, DEVELOPMENT, V122, P2895; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; Fogar P, 1997, ANTICANCER RES, V17, P1227; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Goridis C, 1992, Semin Cell Biol, V3, P189; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hogan B, 1994, MANIPULATING MOUSE E; HUTTON JC, 1993, MOL ENDOCRINOL, V7, P1151, DOI 10.1210/me.7.9.1151; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; Kaiser U, 1996, LEUKEMIA LYMPHOMA, V20, P389, DOI 10.3109/10428199609052420; LACKIE PM, 1994, DIFFERENTIATION, V57, P119, DOI 10.1046/j.1432-0436.1994.5720119.x; LANGLEY OK, 1989, J HISTOCHEM CYTOCHEM, V37, P781, DOI 10.1177/37.6.2723399; LIPINSKI M, 1987, INT J CANCER, V40, P81, DOI 10.1002/ijc.2910400115; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; MOOLENAAR CEC, 1992, INT J CANCER, V51, P238, DOI 10.1002/ijc.2910510212; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2	38	114	115	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					286	291		10.1038/6502	http://dx.doi.org/10.1038/6502			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086383				2022-12-25	WOS:000078851600032
J	Vandecasteele, G; Eschenhagen, T; Scholz, H; Stein, B; Verde, I; Fischmeister, R				Vandecasteele, G; Eschenhagen, T; Scholz, H; Stein, B; Verde, I; Fischmeister, R			Muscarinic and beta-adrenergic regulation of heart rate, force of contraction and calcium current is preserved in mice lacking endothelial nitric oxide synthase	NATURE MEDICINE			English	Article							CARDIAC MYOCYTES; MYOCARDIUM; HYPERTENSION; GENE	Nitric oxide (NO) is an ubiquitous signaling molecule produced from L-arginine by NO synthase (NOS). In the Vasculature, NO mediates parasympathetic endothelium-dependent vasodilation. NO may also mediate the parasympathetic control of myocardial function(1). This is supported by the observations that NOS3, the endothelial constitutive NOS, is expressed in normal cardiac myocytes from rodents(2) and human(3), and NOS and/or guanylyl cyclase inhibitors antagonize the effect of muscarinic agonists on heart rate(4,5), atrio-ventricular conduction(6), contractility(2,4,7) and L-type calcium current(1,2,5,6). Here we examine the autonomic regulation of the heart in genetically engineered mice deficient in NOS3 (NOS3-KO)(ref. 8). We show that the chronotropic and inotropic responses to both beta-adrenergic and muscarinic agonists were unaltered in isolated cardiac tissue preparations from NOS3-KO mice, although these mice have a defective parasympathetic regulation of Vascular tone(8,9). Similarly, beta-adrenergic stimulation and muscarinic inhibition of the calcium current did not differ in cardiac myocytes from NOS3-KO mice and those from wild-type mice. RT-PCR did not demonstrate upregulation of other NOS isoforms. Similarly, G(i)/G(o) proteins and muscarinic receptor density were unaltered. These data refute the idea that NOS3 is obligatory for the normal autonomic control of cardiac muscle function(10).	Univ Paris Sud, Lab Cardiol Cellulaire & Mol, Fac Pharm, INSERM,U446, F-92296 Chatenay Malabry, France; Univ Hamburg, Krankenhaus Eppendorf, Inst Pharmakol, D-20246 Hamburg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Hamburg	Fischmeister, R (corresponding author), Univ Paris Sud, Lab Cardiol Cellulaire & Mol, Fac Pharm, INSERM,U446, F-92296 Chatenay Malabry, France.	Fisch@vjf.inserm.fr	Verde, Ignacio/M-3991-2013; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Verde, Ignacio/0000-0003-3492-5725; Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171				BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; Gallo MP, 1998, J PHYSIOL-LONDON, V506, P639, DOI 10.1111/j.1469-7793.1998.639bv.x; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Han XQ, 1998, P NATL ACAD SCI USA, V95, P6510, DOI 10.1073/pnas.95.11.6510; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Hare JM, 1998, J CLIN INVEST, V101, P1424, DOI 10.1172/JCI1012; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUI J, 1995, CARDIOVASC RES, V30, P372, DOI 10.1016/0008-6363(95)00055-0; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KILTER H, 1995, N-S ARCH PHARMACOL, V352, P308, DOI 10.1007/BF00168562; Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582; Mery PF, 1997, LIFE SCI, V60, P1113, DOI 10.1016/S0024-3205(97)00055-6; Mery PF, 1996, AM J PHYSIOL-HEART C, V270, pH1178, DOI 10.1152/ajpheart.1996.270.4.H1178; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Vandecasteele G, 1998, J PHYSIOL-LONDON, V506, P653, DOI 10.1111/j.1469-7793.1998.653bv.x; Wei CM, 1996, MAYO CLIN PROC, V71, P346, DOI 10.4065/71.4.346; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250	20	144	147	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					331	334		10.1038/6553	http://dx.doi.org/10.1038/6553			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086391	Green Submitted			2022-12-25	WOS:000078851600040
J	Cox, NJ; Frigge, M; Nicolae, DL; Concannon, P; Hanis, CL; Bell, GI; Kong, A				Cox, NJ; Frigge, M; Nicolae, DL; Concannon, P; Hanis, CL; Bell, GI; Kong, A			Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; COMPLEX TRAITS; EARLY-ONSET; GENE; MUTATIONS; MELLITUS; GLUCOKINASE; MODELS; MICE	Complex disorders such as diabetes, cardiovascular disease, asthma, hypertension and psychiatric illnesses account for a large and disproportionate share of health care costs, but remain poorly characterized with respect to aetiology. The transmission of such disorders is complex, reflecting the actions and interactions of multiple genetic and environmental factors. Genetic analyses that allow for the simultaneous consideration of susceptibility from multiple regions may improve the ability to map genes for complex disorders(1,2), but such analyses are currently computationally intensive and narrowly focused. We describe here an approach to assessing the evidence for statistical interactions between unlinked regions that allows multipoint allele-sharing analysis to take the evidence for linkage at one region into account in assessing the evidence for linkage over the rest of the genome. Using this method, we show that the interaction of genes on chromosomes 2 (NIDDM1) and 15 (near CYP19) makes a contribution to susceptibility to type 2 diabetes in Mexican Americans from Starr County, Texas.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; DeCODE Genet, IS-110 Reykjavik, Iceland; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77030 USA	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health Science Center Houston	Cox, NJ (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.			Concannon, Patrick/0000-0002-5801-1859; Nicolae, Dan/0000-0002-0918-4630	NIDDK NIH HHS [DK-47481, DK-20595] Funding Source: Medline; NIGMS NIH HHS [GM-46800] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047481, P60DK020595, P30DK020595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046800] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell GI, 1997, DIABETES REV, V5, P277; BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Buhler J, 1997, HUM HERED, V47, P211, DOI 10.1159/000154415; CORDELL HJ, 1995, AM J HUM GENET, V57, P920; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Iwasaki N, 1997, DIABETES, V46, P1504, DOI 10.2337/diabetes.46.9.1504; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MACLEAN CJ, 1993, AM J HUM GENET, V53, P353; Mahtani MM, 1996, NAT GENET, V14, P90, DOI 10.1038/ng0996-90; RISCH N, 1990, AM J HUM GENET, V46, P229; SCHORK NJ, 1993, AM J HUM GENET, V53, P1127; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	21	322	336	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					213	215		10.1038/6002	http://dx.doi.org/10.1038/6002			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988276				2022-12-25	WOS:000078399500026
J	Flanagan, WM; Wagner, RW; Grant, D; Lin, KY; Matteucci, MD				Flanagan, WM; Wagner, RW; Grant, D; Lin, KY; Matteucci, MD			Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide	NATURE BIOTECHNOLOGY			English	Article						antisense oligonucleotides; bioavailability; cell permeation; C-5 propyne	IN-VIVO; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; NUCLEAR DELIVERY; GENE INHIBITION; OLIGODEOXYNUCLEOTIDES; CELLS; PHARMACOKINETICS; ANALOGS; RNA; BINDING	One of the major barriers to the development of antisense therapeutics has been their poor bioavailability. Numerous oligonucleotide modifications have been synthesized and evaluated for enhanced cellular permeation with limited success. Phenoxazine, a tricyclic 2' deoxycytidine analog, was designed to improve stacking interactions between heterocycles of oligonucleotide/RNA hybrids and to enhance cellular uptake. However, the bioactivity and eel lu lar permeation properties of phenoxazine-modified oligonucleotides were unknown. Incorporation of four phenoxazine bases into a previously optimized C-5 propyne pyrimidine modified 7-mer phosphorothioate oligonucleotide targeting SV40 large T antigen enhanced in vitro binding affinity for its RNA target and redirected RNAse H-mediated cleavage as compared with the I-mer C-5 propynyl phosphorothioate oligonucleotide (S-ON). The phenoxazine/C-5 propynyl U 7-mer S-ON showed dose-dependent, sequence-specific, and target-selective antisense activity following microinjection into cells. Incubation of the phenoxazine/C-5 propynyl U S-ON with a variety of tissue culture cells, in the absence of any cationic lipid, revealed unaided cellular penetration, nuclear accumulation, and subsequent antisense activity. The unique permeation properties and gene-specific antisense activity of the 7-mer phenoxazine/C-5 propynyl U S-ON paves the way for developing potent, cost-effective, self-permeable antisense therapeutics.	Gilead Sci Inc, Foster City, CA 94404 USA	Gilead Sciences	Flanagan, WM (corresponding author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.	michael_flanagan@gilead.com; mark_matteucci@gilead.com						AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; Bijsterbosch MK, 1997, NUCLEIC ACIDS RES, V25, P3290, DOI 10.1093/nar/25.16.3290; Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923; DeLong RK, 1997, ANTISENSE NUCLEIC A, V7, P71, DOI 10.1089/oli.1.1997.7.71; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; Flanagan WM, 1998, CANCER METAST REV, V17, P169, DOI 10.1023/A:1006098218335; Flanagan WM, 1996, NAT BIOTECHNOL, V14, P1139, DOI 10.1038/nbt0996-1139; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; Geary RS, 1997, ANTI-CANCER DRUG DES, V12, P383; Giachetti Cristina, 1996, Journal of Investigative Dermatology, V107, P256, DOI 10.1111/1523-1747.ep12329755; Gutierrez AJ, 1997, BIOCHEMISTRY-US, V36, P743, DOI 10.1021/bi9620971; HUGHES JA, 1994, J PHARM SCI, V83, P597, DOI 10.1002/jps.2600830431; JONES RJ, 1993, J ORG CHEM, V58, P2983, DOI 10.1021/jo00063a014; KANG YS, 1995, DRUG METAB DISPOS, V23, P55; KRIEG AM, 1993, P NATL ACAD SCI USA, V90, P1048, DOI 10.1073/pnas.90.3.1048; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; LIN KY, 1995, J AM CHEM SOC, V117, P3873, DOI 10.1021/ja00118a026; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LU XM, 1994, J NUCL MED, V35, P269; Marcusson EG, 1998, NUCLEIC ACIDS RES, V26, P2016, DOI 10.1093/nar/26.8.2016; Matteucci M, 1997, CIBA F SYMP, V209, P5; MCKAY R, 1994, P NATL ACAD SCI USA, V91, P1762; MILLER PS, 1979, BIOCHEMISTRY-US, V18, P5134, DOI 10.1021/bi00590a017; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; NESTLE FO, 1994, J INVEST DERMATOL, V103, P569, DOI 10.1111/1523-1747.ep12396876; NIELSEN PE, 1994, BIOCONJUGATE CHEM, V5, P3, DOI 10.1021/bc00025a001; Partridge M, 1996, ANTISENSE NUCLEIC A, V6, P169, DOI 10.1089/oli.1.1996.6.169; Pichon C, 1997, ANTISENSE NUCLEIC A, V7, P335, DOI 10.1089/oli.1.1997.7.335; Plenat F, 1996, MOL MED TODAY, V2, P250, DOI 10.1016/1357-4310(96)88806-X; SPILLER DG, 1995, ANTISENSE RES DEV, V5, P13, DOI 10.1089/ard.1995.5.13; SRINIVASAN SK, 1995, J CLIN LAB ANAL, V9, P129, DOI 10.1002/jcla.1860090210; Stein CA, 1997, ANTISENSE NUCLEIC A, V7, P207, DOI 10.1089/oli.1.1997.7.207; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; STEPKOWSKI SM, 1994, J IMMUNOL, V153, P5336; VASSEUR JJ, 1992, J AM CHEM SOC, V114, P4006, DOI 10.1021/ja00036a076; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195	45	47	66	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					48	52		10.1038/5220	http://dx.doi.org/10.1038/5220			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920268				2022-12-25	WOS:000077979500024
J	Howell, WM; Jobs, M; Gyllensten, U; Brookes, AJ				Howell, WM; Jobs, M; Gyllensten, U; Brookes, AJ			Dynamic allele-specific hybridization - A new method for scoring single nucleotide polymorphisms.	NATURE BIOTECHNOLOGY			English	Editorial Material							AMPLIFICATION; PROBES		Univ Uppsala, Biomed Ctr, Dept Genet & Pathol, S-75123 Uppsala, Sweden	Uppsala University	Howell, WM (corresponding author), Univ Uppsala, Biomed Ctr, Dept Genet & Pathol, Box 589, S-75123 Uppsala, Sweden.							Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOWLEY PM, 1979, J BIOL CHEM, V254, P4876; STONEKING M, 1991, AM J HUM GENET, V48, P370; Syvanen A C, 1998, Methods Mol Biol, V98, P291; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; WU DY, 1989, GENOMICS, V4, P560, DOI 10.1016/0888-7543(89)90280-2	6	221	285	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					87	88		10.1038/5270	http://dx.doi.org/10.1038/5270			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920276				2022-12-25	WOS:000077979500033
J	Matveeva, O; Felden, B; Tsodikov, A; Johnston, J; Monia, BP; Atkins, JF; Gesteland, RF; Freier, SM				Matveeva, O; Felden, B; Tsodikov, A; Johnston, J; Monia, BP; Atkins, JF; Gesteland, RF; Freier, SM			Prediction of antisense oligonucleotide efficacy by in vitro methods	NATURE BIOTECHNOLOGY			English	Editorial Material							MESSENGER-RNA; OLIGODEOXYNUCLEOTIDE; HYBRIDIZATION; INHIBITION; EXPRESSION; KINASE		Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Huntsman Canc Ctr, Salt Lake City, UT 84108 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Isis Pharmaceuticals Inc	Matveeva, O (corresponding author), Univ Utah, Dept Human Genet, 6160 Eccles Genet Bldg, Salt Lake City, UT 84112 USA.	olgam@howard.genetics.utah.edu	Matveeva, Olga/AAH-3851-2020; felden, brice/L-4825-2015	Atkins, John/0000-0001-7933-0165	NIGMS NIH HHS [GM48152] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKH KR, RNA, V3, P429; DEAN NM, 1994, J BIOL CHEM, V269, P16416; Draper NR, 1982, APPL REGRESSION ANAL; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ho SP, 1998, NAT BIOTECHNOL, V16, P59, DOI 10.1038/nbt0198-59; Lima WF, 1997, J BIOL CHEM, V272, P626; Matveeva O, 1997, NUCLEIC ACIDS RES, V25, P5010, DOI 10.1093/nar/25.24.5010; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; Miraglia L, 1996, INT J IMMUNOPHARMACO, V18, P227, DOI 10.1016/0192-0561(96)84502-4; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Sheskin D.J., 1997, HDB PARAMETRIC NONPA; Southern EM, 1997, CIBA F SYMP, V209, P38; Stull RA, 1996, ANTISENSE NUCLEIC A, V6, P221, DOI 10.1089/oli.1.1996.6.221; Szoka FC, 1997, NAT BIOTECHNOL, V15, P509, DOI 10.1038/nbt0697-509; VICKERS TA, 1992, NUCLEIC ACIDS RES, V20, P3945, DOI 10.1093/nar/20.15.3945	15	40	75	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1374	1375		10.1038/4362	http://dx.doi.org/10.1038/4362			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853623				2022-12-25	WOS:000077232600034
J	Lefebvre, L; Viville, S; Barton, SC; Ishino, F; Keverne, EB; Surani, MA				Lefebvre, L; Viville, S; Barton, SC; Ishino, F; Keverne, EB; Surani, MA			Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene Mest	NATURE GENETICS			English	Article							SILVER-RUSSELL-SYNDROME; EMBRYONIC STEM-CELLS; UNIPARENTAL DISOMY; DIAGNOSTIC-CRITERIA; ANGELMAN-SYNDROME; HUMAN PEG1/MEST; MICE LACKING; CHROMOSOME-7; MOUSE; EXPRESSION	Mest (also known as Peg1), an imprinted gene expressed only from the paternal allele during development, was disrupted by gene targeting in embryonic stem (ES) cells. The targeted mutation is imprinted and reversibly silenced by passage through the female germ line. Paternal transmission activates the targeted allele and causes embryonic growth retardation associated with reduced postnatal survival rates in mutant progeny. More significantly. Mest-deficient females show abnormal maternal behaviour and impaired placentophagia, a distinctive mammalian behaviour. Our results provide evidence for the involvement of an imprinted gene in the control of adult behaviour.	Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Physiol Lab, Cambridge CB2 3EG, England; Tokyo Inst Technol, Ctr Gene Res, Midori Ku, Yokohama, Kanagawa 226, Japan; Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England	University of Cambridge; Tokyo Institute of Technology; University of Cambridge	Surani, MA (corresponding author), Wellcome CRC Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.	as10021@mole.bio.cam.ac.uk	Lefebvre, Louis/O-9309-2016	Lefebvre, Louis/0000-0001-5664-9480; Viville, Stephane/0000-0002-5088-3003	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ainscough J. F. X., 1996, Epigenetic mechanisms of gene regulation., P173; ALLEN ND, 1995, P NATL ACAD SCI USA, V92, P10782, DOI 10.1073/pnas.92.23.10782; BEECHEY CV, 1989, MOUSE NEWS LETT, V84, P82; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; Cattanach BM, 1997, MAMM GENOME, V8, P472, DOI 10.1007/s003359900479; CATTANACH BM, 1990, DEVELOPMENT, P63; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DICKINSON C, 1988, PHYSIOL BEHAV, V43, P313, DOI 10.1016/0031-9384(88)90193-X; Eggermann T, 1997, HUM GENET, V100, P415, DOI 10.1007/s004390050526; FRANZ JR, 1986, PHYSIOL BEHAV, V38, P629, DOI 10.1016/0031-9384(86)90256-8; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FUNDELE RH, 1994, DEV GENET, V15, P515, DOI 10.1002/dvg.1020150610; HAIG D, 1991, CELL, V64, P1045; HOGLUND P, 1994, AM J HUM GENET, V55, P747; HOLM VA, 1993, PEDIATRICS, V91, P398; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kikyo N, 1997, DEV BIOL, V190, P66, DOI 10.1006/dbio.1997.8681; Kobayashi S, 1997, HUM MOL GENET, V6, P781, DOI 10.1093/hmg/6.5.781; KOTZOT D, 1995, HUM MOL GENET, V4, P583, DOI 10.1093/hmg/4.4.583; KRISTAL MB, 1991, NEUROSCI BIOBEHAV R, V15, P425, DOI 10.1016/S0149-7634(05)80035-1; LANGLOIS S, 1995, J MED GENET, V32, P871, DOI 10.1136/jmg.32.11.871; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEDBETTER DH, 1995, HUM MOL GENET, V4, P1757, DOI 10.1093/hmg/4.suppl_1.1757; Lefebvre L, 1997, HUM MOL GENET, V6, P1907, DOI 10.1093/hmg/6.11.1907; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nishita Y, 1996, GENOMICS, V36, P539, DOI 10.1006/geno.1996.0502; NUMAN M, 1994, ACTA PAEDIATR, V83, P19, DOI 10.1111/j.1651-2227.1994.tb13261.x; PATTON MA, 1988, J MED GENET, V25, P557, DOI 10.1136/jmg.25.8.557; Preece MA, 1997, J MED GENET, V34, P6, DOI 10.1136/jmg.34.1.6; Riesewijk AM, 1997, GENOMICS, V42, P236, DOI 10.1006/geno.1997.4731; SADO T, 1993, DEV GROWTH DIFFER, V35, P551; SPENCE JE, 1988, AM J HUM GENET, V42, P217; SPOTILA LD, 1992, AM J HUM GENET, V51, P1396; Tada M, 1997, EMBO J, V16, P6510, DOI 10.1093/emboj/16.21.6510; Thomas SA, 1997, CELL, V91, P583, DOI 10.1016/S0092-8674(00)80446-8; VOSS R, 1989, AM J HUM GENET, V45, P373; WILLIAMS CA, 1995, AM J MED GENET, V56, P237, DOI 10.1002/ajmg.1320560224	42	439	449	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1998	20	2					163	169		10.1038/2464	http://dx.doi.org/10.1038/2464			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771709				2022-12-25	WOS:000076231300018
J	Kakinuma, Y; Hama, H; Sugiyama, F; Yagami, K; Goto, K; Murakami, K; Fukamizu, A				Kakinuma, Y; Hama, H; Sugiyama, F; Yagami, K; Goto, K; Murakami, K; Fukamizu, A			Impaired blood-brain barrier function in angiotensinogen-deficient mice	NATURE MEDICINE			English	Article							IV BINDING-SITES; ASTROCYTE RESPONSES; RECEPTOR SUBTYPE; MESSENGER-RNA; EXPRESSION; INJURY; GFAP; CULTURES	Astrocytes in the central nervous system have physiologically important roles in the response to brain injury(1,2). Brain damage results in disruption of the blood-brain barrier (BBB), producing detachment of astrocyte endfeet from endothelial cells(3). The resultant leakage of serum proteins from loosened tight junctions between endothelial cells produces brain edema. At the same time, reactive astrocytes migrate to the injured area, where they proliferate and produce extracellular matrix(4-6), thereby reconstituting the BBB. As astrocytes are known to express angiotensinogen(7,8), which is the precursor of angiotensins (Al to AIV), we have investigated a possible functional contribution of angiotensinogen or one of its metabolites to BBB reconstitution. The astrocytes of angiotensinogen knockout mice had very attenuated expression of glial fibrially acidic protein and decreased laminin production in response to cold injury, and ultimately incomplete reconstitution of impaired BBB function. Although these abnormalities were rescued by administration of All or AIV, the restoration of BBB function was not inhibited by All type 1 and 2 receptor antagonists. These findings provide evidence that astrocytes with angiotensins are required for functional maintenance of the BBB.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Pharmacol, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Lab Anim Res Ctr, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Natl Inst Adv Interdisciplinary Res, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan.	akif@sakura.cc.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Kakinuma, Yoshihiko/0000-0001-5470-9128				CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; deOliveira AM, 1995, BRAIN RES, V705, P177, DOI 10.1016/0006-8993(95)01158-7; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; GOLDSTEIN GW, 1986, SCI AM, V255, P70; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LEPRINCE G, 1991, GLIA, V4, P322, DOI 10.1002/glia.440040310; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LUDWIN SK, 1985, LAB INVEST, V52, P20; MILLERWING AV, 1993, J PHARMACOL EXP THER, V266, P1718; MILSTED A, 1990, P NATL ACAD SCI USA, V87, P5720, DOI 10.1073/pnas.87.15.5720; Moeller I, 1996, BRAIN RES, V712, P307, DOI 10.1016/0006-8993(95)01482-9; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; REIER PJ, 1986, CELL BIOL PATHOLOGY, P263; ROBERTS KA, 1995, BRAIN RES, V682, P13, DOI 10.1016/0006-8993(95)00289-3; SHIBOUTA Y, 1993, J PHARMACOL EXP THER, V266, P114; STORNETTA RL, 1988, SCIENCE, V242, P1444, DOI 10.1126/science.3201232; Sugiyama F, 1997, LAB ANIM SCI, V47, P545; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; WARNICK RE, 1995, J NEUROSCI METH, V58, P167, DOI 10.1016/0165-0270(94)00172-D; WRIGHT JW, 1995, FRONT NEUROENDOCRIN, V16, P23, DOI 10.1006/frne.1995.1002; Wright JW, 1996, PEPTIDES, V17, P1365, DOI 10.1016/S0196-9781(96)00226-4	25	119	123	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1078	1080		10.1038/2070	http://dx.doi.org/10.1038/2070			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734405	Green Submitted			2022-12-25	WOS:000075804100045
J	Neubauer, G; King, A; Rappsilber, J; Calvio, C; Watson, M; Ajuh, P; Sleeman, J; Lamond, A; Mann, M				Neubauer, G; King, A; Rappsilber, J; Calvio, C; Watson, M; Ajuh, P; Sleeman, J; Lamond, A; Mann, M			Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex	NATURE GENETICS			English	Article							POLYACRYLAMIDE GELS; IDENTIFICATION; GENOME; NANOELECTROSPRAY; HELICASE; U4/U6; BOX; U1	Many important cell mechanisms are carried our and regulated by multi-protein complexes, for example, transcription and RNA processing machinery, receptor complexes end cytoskeletal structures. Most of these complexes remain only partially characterized due to the difficulty of conventional protein analysis methods. The rapid expansion of DNA sequence databases now provides whole or partial gene sequences of model organisms, and recent advances in protein microcharacterization via mass spectrometry allow the possibility of linking these DNA sequences to the proteins in functional complexes(1). This approach has been demonstrated in organisms whose genomes have been sequenced(2), such as budding yeast. Here we report the first characterization of an entire mammalian multi-protein complex using these methods. The machinery that removes introns from mRNA percursors-the spliceosome-is a large multi-protein complex(3,4). Approximately half of the components excised from a two-dimensional gel separation of the spliceosome were found in protein sequence databases. Using nanoelectrospray mass spectrometry, the remainder were identified and cloned using public expressed sequence tag (EST) databases. Existing EST databases are thus already sufficiently complete to allow rapid characterization of large mammalian protein complexes via mass spectrometry.	European Mol Biol Lab, Prot & Peptide Grp, D-69115 Heidelberg, Germany; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	European Molecular Biology Laboratory (EMBL); University of Dundee	Mann, M (corresponding author), Odense Univ, Dept Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.	mann@cebi.ou.dk	Rappsilber, Juri/ABF-3328-2020; Rappsilber, Juri/B-7265-2015; Cinzia, Calvio/E-1353-2011; Mann, Matthias/A-3454-2013	Rappsilber, Juri/0000-0001-5999-1310; Cinzia, Calvio/0000-0003-1631-0452; Mann, Matthias/0000-0003-1292-4799; Watson, Mark/0000-0002-3557-101X; Sleeman, Judith/0000-0003-0345-6508; Lamond, Angus/0000-0001-6204-6045	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEGGS JD, 1995, PREMRNA PROCESSING, P79; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; CALVIO C, 1995, RNA, V1, P724; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lamond AI, 1997, TRENDS CELL BIOL, V7, P139, DOI 10.1016/S0962-8924(97)01031-3; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; Lauber J, 1997, RNA, V3, P926; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Molnar GM, 1997, P NATL ACAD SCI USA, V94, P7831, DOI 10.1073/pnas.94.15.7831; Moore M., 1993, RNA WORLD, P303; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SUKEGAWA J, 1995, J BIOL CHEM, V270, P15702, DOI 10.1074/jbc.270.26.15702; WILL CL, 1995, NUCL ACIDS MOL BIOL, P342; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	27	412	446	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1998	20	1					46	50		10.1038/1700	http://dx.doi.org/10.1038/1700			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731529				2022-12-25	WOS:000075671400017
J	Hodgson, O				Hodgson, O			Shrinking DNA diagnostics to fill the markets of the future	NATURE BIOTECHNOLOGY			English	Article								To reach the mass markets, diagnostic tests based on DNA will have to become much simpler, cheaper, and more reliable.											0	27	29	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					725	727		10.1038/nbt0898-725	http://dx.doi.org/10.1038/nbt0898-725			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702768				2022-12-25	WOS:000075183400026
J	Kern, F; Surel, IP; Brock, C; Freistedt, B; Radtke, H; Scheffold, A; Blasczyk, R; Reinke, P; Schneider-Mergener, J; Radbruch, A; Walden, P; Volk, HD				Kern, F; Surel, IP; Brock, C; Freistedt, B; Radtke, H; Scheffold, A; Blasczyk, R; Reinke, P; Schneider-Mergener, J; Radbruch, A; Walden, P; Volk, HD			T-cell epitope mapping by flow cytometry	NATURE MEDICINE			English	Article							RARE CELLS; FREQUENCY; CYTOMEGALOVIRUS; PROTEIN; CTL		Humboldt Univ, Fak Med, Inst Med Immunol, D-10098 Berlin, Germany; Humboldt Univ, Fak Med, Dermatol Klin, D-10098 Berlin, Germany; Humboldt Univ, Fak Med, Inst Transfus Med & Immunhamatol, D-10098 Berlin, Germany; Deutsch Rheuma Forsch Zentrum, D-10115 Berlin, Germany; Humboldt Univ, Fak Med, Med Klin, Schwerpunkt Hamatol & Onkol, D-13353 Berlin, Germany; Humboldt Univ, Fak Med, Med Klin, Schwerpunkt Nephrol & Intens Med, D-13353 Berlin, Germany	Humboldt University of Berlin; Humboldt University of Berlin; Humboldt University of Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ); Humboldt University of Berlin; Humboldt University of Berlin	Kern, F (corresponding author), Humboldt Univ, Fak Med, Inst Med Immunol, Campus Mitte, D-10098 Berlin, Germany.	kern@rz.charite.hu-berlin.de	volk, hans-dieter/AAV-8053-2021; Kern, Florian/AAE-6784-2022; Scheffold, Alexander/S-2090-2016	volk, hans-dieter/0000-0002-7743-6668; Kern, Florian/0000-0002-0368-8408; Scheffold, Alexander/0000-0002-0626-343X; Radbruch, Andreas/0000-0001-5753-0000; Blasczyk, Rainer/0000-0003-3875-3190; Reinke, Petra/0000-0003-0771-4375				Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; BORYSIEWICZ LK, 1988, J EXP MED, V168, P919, DOI 10.1084/jem.168.3.919; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; Diamond DJ, 1997, BLOOD, V90, P1751, DOI 10.1182/blood.V90.5.1751; GROSS HJ, 1993, CYTOMETRY, V14, P519, DOI 10.1002/cyto.990140511; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; PARKER KC, 1994, J IMMUNOL, V152, P163; RADBRUCH A, 1995, CURR OPIN IMMUNOL, V7, P270, DOI 10.1016/0952-7915(95)80014-X; Rammensee HG, 1997, MOL B INT U, P1; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996	14	240	253	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1998	4	8					975	978		10.1038/nm0898-975	http://dx.doi.org/10.1038/nm0898-975			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701254				2022-12-25	WOS:000075107400046
J	Kononen, J; Bubendorf, L; Kallioniemi, A; Barlund, M; Schraml, P; Leighton, S; Torhorst, J; Mihatsch, MJ; Sauter, G; Kallioniemi, OP				Kononen, J; Bubendorf, L; Kallioniemi, A; Barlund, M; Schraml, P; Leighton, S; Torhorst, J; Mihatsch, MJ; Sauter, G; Kallioniemi, OP			Tissue microarrays for high-throughput molecular profiling of tumor specimens	NATURE MEDICINE			English	Article							HUMAN BREAST-CANCER; AMPLIFICATION; HYBRIDIZATION; EXPRESSION; CARCINOMAS; ONCOGENE; BLOCK	Many genes and signalling pathways controlling cell proliferation, death and differentiation, as well as genomic integrity, are involved in cancer development. New techniques, such as serial analysis of gene expression and cDNA microarrays, have enabled measurement of the expression of thousands of genes in a single experiment, revealing many new, potentially important cancer genes(1,2). These genome screening tools can comprehensively survey one tumor at a time; however, analysis of hundreds of specimens from patients in different stages of disease is needed to establish the diagnostic, prognostic and therapeutic importance of each of the emerging cancer gene candidates. Here we have developed an array-based high-throughput technique that facilitates gene expression and copy number surveys of very large numbers of tumors. As many as 1000 cylindrical tissue biopsies from individual tumors can be distributed in a single tumor tissue microarray, Sections of the microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array, and consecutive sections allow the rapid analysis of hundreds of molecular markers in the same set of specimens. Our detection of six gene amplifications as well as p53 and estrogen receptor expression in breast cancer demonstrates the power of this technique for defining new subgroups of tumors.	Natl Human Genome Res Inst, Canc Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33521 Tampere, Finland; Tampere Univ Hosp, FIN-33521 Tampere, Finland; Beecher Instruments, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel; Tampere University; Tampere University; Tampere University Hospital	Kallioniemi, OP (corresponding author), Natl Human Genome Res Inst, Canc Genet Lab, NIH, 49 Convent Dr MSC 4470,Room 4A24, Bethesda, MD 20892 USA.		Bubendorf, Lukas/G-5299-2015; Kallioniemi, Olli P/H-5111-2011; Bubendorfl, Lukas/H-5880-2011	Bubendorf, Lukas/0000-0001-5970-1803; Kallioniemi, Olli P/0000-0002-3231-0332; Kallioniemi, Anne/0000-0003-3552-8158; Kononen, Juha/0000-0002-0157-2137; Barlund, Maarit/0000-0002-1469-5654				ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107; Barbareschi M, 1997, INT J CANCER, V74, P171, DOI 10.1002/(SICI)1097-0215(19970422)74:2<171::AID-IJC5>3.0.CO;2-W; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; BATTIFORA H, 1990, LAB INVEST, V63, P722; BATTIFORA H, 1986, LAB INVEST, V55, P244; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; Courjal F, 1997, CANCER RES, V57, P4360; DeRisi J, 1996, NAT GENET, V14, P457; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Molino A, 1997, BREAST CANCER RES TR, V45, P241, DOI 10.1023/A:1005769925670; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; NobenTrauth K, 1996, GENOMICS, V35, P610, DOI 10.1006/geno.1996.0408; Pauletti G, 1996, ONCOGENE, V13, P63; Persons DL, 1997, MODERN PATHOL, V10, P720; PRESS MF, 1994, CANCER RES, V54, P2771; Ried T, 1998, AM J PATHOL, V152, P325; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TANNER MM, 1994, CANCER RES, V54, P4257; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	20	3288	3675	4	233	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					844	847		10.1038/nm0798-844	http://dx.doi.org/10.1038/nm0798-844			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662379				2022-12-25	WOS:000074543900042
J	Merchant, AM; Zhu, ZP; Yuan, JQ; Goddard, A; Adams, CW; Presta, LG; Carter, P				Merchant, AM; Zhu, ZP; Yuan, JQ; Goddard, A; Adams, CW; Presta, LG; Carter, P			An efficient route to human bispecific IgG	NATURE BIOTECHNOLOGY			English	Article						applied immunology; antibody engineering; phage display	PHAGE DISPLAY LIBRARY; MONOCLONAL-ANTIBODY; HYBRID HYBRIDOMAS; PROTEIN; MUTAGENESIS; IMMUNOADHESIN; HUMANIZATION; SEQUENCES; DOMAINS; THERAPY	Production of bispecific IgG (BsIgG) by coexpressing two different antibodies is inefficient due to unwanted pairings of the component heavy and light chains. To overcome this problem, heavy chains were remodeled for heterodimerization using engineered disulfide bonds in combination with previously identified "knobs-into-holes" mutations. One of the variants, S354C:T366W/Y349'C:T366'S:L368'A:Y407'V, gave near quantitative (similar to 95%) heterodimerization, Light chain mispairing was circumvented by using an identical light chain for each arm of the BsIgG, Antibodies with identical light chains that bind to different antigens were identified from an scFv phage library with a very restricted light chain repertoire for the majority (50/55) of antigen pairs tested, A BsIgG capable of simultaneously binding to the human receptors HER3 and cMpI was prepared by coexpressing the common light chain and corresponding remodeled heavy chains followed by protein A chromatography. The engineered heavy chains retain their ability to support antibody-dependent cell-mediated cytotoxicity as demonstrated with an anti-HER2 antibody.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Biol Mol, San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Carter, P (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	pjc@gene.com						Atwell S, 1997, J MOL BIOL, V270, P26, DOI 10.1006/jmbi.1997.1116; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CARON PC, 1994, BLOOD, V83, P1760; Carter P, 1995, J Hematother, V4, P463, DOI 10.1089/scd.1.1995.4.463; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAMOW SM, 1994, J IMMUNOL, V153, P4268; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DIETSCH MT, 1993, J IMMUNOL METHODS, V162, P123, DOI 10.1016/0022-1759(93)90414-3; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FIGINI M, 1994, J MOL BIOL, V239, P68, DOI 10.1006/jmbi.1994.1351; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HALE G, 1988, LANCET, V2, P1394; Holliger Philipp, 1993, Current Opinion in Biotechnology, V4, P446, DOI 10.1016/0958-1669(93)90010-T; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; KABAT EA, 1991, SEQUENCES PROTEINS I, V1, P688; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MILLER S, 1990, J MOL BIOL, V216, P965, DOI 10.1016/S0022-2836(99)80014-X; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; RODRIGUES ML, 1995, CANCER RES, V55, P63; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SHARKEY RM, 1995, CANCER RES, V55, pS5935; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; SURESH MR, 1986, METHOD ENZYMOL, V121, P210; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VILLAFRANCA JE, 1983, SCIENCE, V222, P782, DOI 10.1126/science.6356360; Vincenti F, 1997, TRANSPLANTATION, V63, P33, DOI 10.1097/00007890-199701150-00007; WELLS JA, 1986, J BIOL CHEM, V261, P6564; Xie MH, 1997, NAT BIOTECHNOL, V15, P768, DOI 10.1038/nbt0897-768; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	41	302	617	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1998	16	7					677	681		10.1038/nbt0798-677	http://dx.doi.org/10.1038/nbt0798-677			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZX494	9661204				2022-12-25	WOS:000074521800034
J	Strom, TM; Nyakatura, G; Apfelstedt-Sylla, E; Hellebrand, H; Lorenz, B; Weber, BHF; Wutz, K; Gutwillinger, N; Ruther, K; Drescher, B; Sauer, C; Zrenner, E; Meitinger, T; Rosenthal, A; Meindl, A				Strom, TM; Nyakatura, G; Apfelstedt-Sylla, E; Hellebrand, H; Lorenz, B; Weber, BHF; Wutz, K; Gutwillinger, N; Ruther, K; Drescher, B; Sauer, C; Zrenner, E; Meitinger, T; Rosenthal, A; Meindl, A			An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness	NATURE GENETICS			English	Article							BETA-SUBUNIT; REGION; RP3	The locus for the incomplete form of X-linked congenital stationary night blindness (CSNB2) maps to a 1.1-Mb region in Xp11.23 between markers DXS722 and DXS255. We identified a retina-specific calcium channel alpha(1)-subunit gene (CACNA1F) in this region, consisting of 48 exons encoding 1966 amino acids and showing high homology to L-type calcium channel alpha(1)-subunits. Mutation analysis in 13 families with CSNB2 revealed nine different mutations in 10 families, including three nonsense and one frameshift mutation. These data indicate that aberrations in a voltage-gated calcium channel. presumably causing a decrease in neurotransmitter release from photoreceptor presynaptic terminals, are a frequent cause of CSNB2.	Univ Munich, Abt Med Genet, D-80336 Munchen, Germany; Univ Tubingen, Augenklin, D-72076 Tubingen, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; Univ Regensburg, Augenklin, D-93042 Regensburg, Germany; Inst Humangenet, D-97074 Wurzburg, Germany	University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg	Meindl, A (corresponding author), Univ Munich, Abt Med Genet, Goethestr 29, D-80336 Munchen, Germany.	alfons@pedgen.med.uni-muenchen.de	Meitinger, Thomas/O-1318-2015	Meitinger, Thomas/0000-0002-8838-8403; Weber, Bernhard H.F./0000-0002-8808-7723				BECHHANSEN NT, 1993, AM J HUM GENET, V52, P71; BERGEN AAB, 1995, HUM MOL GENET, V4, P931, DOI 10.1093/hmg/4.5.931; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Boycott KM, 1998, AM J HUM GENET, V62, P865, DOI 10.1086/301781; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Craxton M, 1993, Methods Mol Biol, V23, P149; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; HOGAN K, 1994, GENOMICS, V24, P608, DOI 10.1006/geno.1994.1677; HOOD DC, 1990, VISION RES, V30, P51, DOI 10.1016/0042-6989(90)90127-7; LEIMEISTER C, IN PRESS MECH DEV; Lorenz B, 1996, KLIN MONATSBL AUGENH, V208, P48, DOI 10.1055/s-2008-1035167; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MIYAKE Y, 1987, INVEST OPHTH VIS SCI, V28, P1816; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Ruether K, 1993, Ger J Ophthalmol, V2, P429; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Schmitz Y, 1997, NEUROSCIENCE, V78, P1209, DOI 10.1016/S0306-4522(96)00678-1; SCHUBERT G, 1952, OPHTHALMOLOGICA, V123, P396, DOI 10.1159/000301211; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Witkovsky P, 1997, J NEUROSCI, V17, P7297	26	368	377	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1998	19	3					260	263		10.1038/940	http://dx.doi.org/10.1038/940			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662399				2022-12-25	WOS:000074565900022
J	Ferguson, JA; Boles, TC; Adams, CP; Walt, DR				Ferguson, JA; Boles, TC; Adams, CP; Walt, DR			A fiber-optic DNA biosensor microarray for the analysis of gene expression	NATURE BIOTECHNOLOGY			English	Article						array sensors; oligonucleotides; fiber optics; fluorescence	STORAGE PHOSPHOR SCREEN; REAL-TIME DETECTION; OLIGONUCLEOTIDE ARRAYS; GLASS SUPPORTS; HYBRIDIZATION; IMMOBILIZATION; POLYMORPHISMS; MOLECULES; CHEMISTRY; ASSAYS	A fiber-optic biosensor array is described for the simultaneous analysis of multiple DNA sequences. A bundle of optical fibers was assembled with each fiber carrying a different oligonucleotide probe immobilized on its distal end. Hybridization of fluorescently labeled complementary oligonucleotides to the array was monitored by observing the increase in fluorescence that accompanied binding. The approach enables fast (<10 min) and sensitive (10 nM) detection of multiple DNA sequences simultaneously, with the potential for quantitative hybridization analysis.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155; MOSAIC TECHNOL,BOSTON,MA 02115	Tufts University					NIGMS NIH HHS [GM 48142] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATTIE KL, 1995, MOL PATHOLOGY, V41, P700; BRONK KS, 1995, ANAL CHEM, V67, P2750, DOI 10.1021/ac00113a005; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; EGGER D, 1995, J CLIN MICROBIOL, V33, P1442, DOI 10.1128/JCM.33.6.1442-1447.1995; EGGERS M, 1994, BIOTECHNIQUES, V17, P516; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; GRAHAM CR, 1992, BIOSENS BIOELECTRON, V7, P487, DOI 10.1016/0956-5663(92)80005-V; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; HASHIMOTO K, 1994, ANAL CHIM ACTA, V286, P219, DOI 10.1016/0003-2670(94)80163-0; ITO T, 1995, J NEUROSCI METH, V59, P265, DOI 10.1016/0165-0270(94)00212-Y; Khrapko K R, 1991, DNA Seq, V1, P375, DOI 10.3109/10425179109020793; Kolakowski B, 1996, ANAL CHEM, V68, P1197, DOI 10.1021/ac950878m; KREINER T, 1996, AM LAB, P3; KULP TJ, 1987, ANAL CHEM, V59, P2849, DOI 10.1021/ac00151a006; KUMKE MU, 1995, ANAL CHEM, V67, P3945, DOI 10.1021/ac00117a020; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; MATSON RS, 1995, ANAL BIOCHEM, V224, P110, DOI 10.1006/abio.1995.1014; MENGER FM, 1995, J ORG CHEM, V60, P6666, DOI 10.1021/jo00126a008; MILLAN KM, 1994, ANAL CHEM, V66, P2943, DOI 10.1021/ac00090a023; MUNKHOLM C, 1986, ANAL CHEM, V58, P1427, DOI 10.1021/ac00298a602; NGUYEN Q, 1995, ANAL BIOCHEM, V226, P59, DOI 10.1006/abio.1995.1191; NIKIFOROV TT, 1994, NUCLEIC ACIDS RES, V22, P4167, DOI 10.1093/nar/22.20.4167; PANDEY PC, 1994, ANAL CHEM, V66, P1236, DOI 10.1021/ac00080a007; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PIUNNO PAE, 1994, ANAL CHIM ACTA, V288, P205, DOI 10.1016/0003-2670(93)E0611-A; RASMUSSEN SR, 1991, ANAL BIOCHEM, V198, P138, DOI 10.1016/0003-2697(91)90518-X; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Southern EM, 1996, TRENDS GENET, V12, P110, DOI 10.1016/0168-9525(96)81422-3; STIMPSON DI, 1995, P NATL ACAD SCI USA, V92, P6379, DOI 10.1073/pnas.92.14.6379; STRACHAN NJC, 1995, LETT APPL MICROBIOL, V21, P5, DOI 10.1111/j.1472-765X.1995.tb00993.x; SUH JH, 1991, J AM CHEM SOC, V113, P4198, DOI 10.1021/ja00011a022; TOMBLINE G, 1996, BIOCHEM, V93, P2724; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; VANNESS J, 1991, NUCLEIC ACIDS RES, V19, P3345; WALT DR, 1994, TRAC-TREND ANAL CHEM, V13, P425, DOI 10.1016/0165-9936(94)85023-2; WATTS HJ, 1995, ANAL CHEM, V67, P4283, DOI 10.1021/ac00119a013; YAMAGUCHI S, 1993, ANAL CHEM, V65, P1925, DOI 10.1021/ac00062a019; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; Zammatteo N, 1996, ANAL BIOCHEM, V236, P85, DOI 10.1006/abio.1996.0135	40	188	318	0	66	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1996	14	13					1681	1684		10.1038/nbt1296-1681	http://dx.doi.org/10.1038/nbt1296-1681			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VX107	9634851				2022-12-25	WOS:A1996VX10700029
J	Deretic, V; PaganRamos, E; Zhang, YQ; Dhandayuthapani, S; Via, LE				Deretic, V; PaganRamos, E; Zhang, YQ; Dhandayuthapani, S; Via, LE			The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid	NATURE BIOTECHNOLOGY			English	Review						tuberculosis; INH sensitivity; oxidative stress	ALKYL HYDROPEROXIDE REDUCTASE; CATALASE-PEROXIDASE GENE; SALMONELLA-TYPHIMURIUM; ISONIAZID RESISTANCE; OXIDATIVE-STRESS; ESCHERICHIA-COLI; MOLECULAR MECHANISMS; KATG; FAMILY; OXYR	Mycobacterium tuberculosis is a natural mutant in oxyR, a close homolog of the central regulator of peroxide stress response in enteric bacteria, Inactivation of oxyR is specific for M. tuberculosis and other members of the M. tuberculosis complex, This phenomenon appears as a paradox due to the ability of this organism to parasitize host macrophages, in which the ingested organisms are likely to be exposed to reactive oxygen intermediates, However, the surprising finding that M. tuberculosis has multiple deletions, nonsense and frameshift mutations in oxyR may help explain the exceptionally high sensitivity of M. tuberculosis to the potent antituberculosis agent isoniazid. One of the genes affected by oxyR lesions, ahpC (encoding an alkylhydroperoxide reductase) may determine the intrinsic sensitivity of mycobacteria to isoniazid.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Deretic, V (corresponding author), UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, 5641 MED SCI BLDG 2, ANN ARBOR, MI 48109 USA.		Via, Laura/AAD-3917-2021; Zhang, Yiqiang/AAA-3143-2019	Via, Laura/0000-0001-6074-9521; Deretic, Vojo/0000-0002-3624-5208	NIAID NIH HHS [AI35217] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035217] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BEKIERKUNST A, 1966, SCIENCE, V152, P525, DOI 10.1126/science.152.3721.525; BERGH S, 1994, MOL MICROBIOL, V12, P534; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; COLSTON MJ, 1994, MOL MICROBIOL, V12, P359, DOI 10.1111/j.1365-2958.1994.tb01025.x; Dannenberg Arthur M. Jr., 1994, P459; DERETIC V, 1995, MOL MICROBIOL, V17, P889, DOI 10.1111/j.1365-2958.1995.mmi_17050889.x; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; DHANDAYUTHAPANI S, J BACTERIOL, V178, P12; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; GAYATHRIDEVI B, 1975, BIOCHEM J, V149, P187; HERMAN DJ, 1980, ANTIMICROB AGENTS CH, V17, P170; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1992, RES MICROBIOL, V143, P721, DOI 10.1016/0923-2508(92)90067-X; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; KASAROV LB, 1972, J BACTERIOL, V110, P600; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; KRUGERTHIEMER E, 1958, AM REV TUBERC PULM, V77, P364; Le Lirzin M, 1971, Rev Tuberc Pneumol (Paris), V35, P350; LONG ER, 1958, CHEM CHEMOTHERAPY TU, P362; MIDDLEBROOK G, 1953, SCIENCE, V118, P297, DOI 10.1126/science.118.3063.297; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V69, P471; Milano A, 1996, MOL MICROBIOL, V19, P113, DOI 10.1046/j.1365-2958.1996.352876.x; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; PRETORIUS GS, 1995, ANTIMICROB AGENTS CH, V39, P2276, DOI 10.1128/AAC.39.10.2276; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; ROSNER JL, 1993, ANTIMICROB AGENTS CH, V37, P2251, DOI 10.1128/AAC.37.10.2251; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; ROUSE DA, 1995, INFECT IMMUN, V63, P1427, DOI 10.1128/IAI.63.4.1427-1433.1995; RUSSELL DG, 1995, TRENDS CELL BIOL, V5, P125, DOI 10.1016/S0962-8924(00)88963-1; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SEYDEL JK, 1976, J MED CHEM, V19, P483, DOI 10.1021/jm00226a007; SHEMAN DR, 1996, SCIENCE, V272, P1641; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P408, DOI 10.1128/AAC.27.3.408; SREEVANTSAN S, UNPUB ANAL OXYRAHPC; STORZ G, 1987, P NATL ACAD SCI USA, V84, P8917, DOI 10.1073/pnas.84.24.8917; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; WINDER F, 1960, AM REV RESPIR DIS, V81, P68, DOI 10.1164/arrd.1960.81.1P1.68; Winder F, 1982, BIOL MYCOBACTERIA, V1, P354; YAMAGUCHI R, 1992, INFECT IMMUN, V60, P1210, DOI 10.1128/IAI.60.3.1210-1216.1992; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; YOUNG DB, 1993, J BACTERIOL, V175, P1, DOI 10.1128/JB.175.1.1-6.1993; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; ZHANG Y, IN PRESS P NATL ACAD; Zhang Ying, 1993, Trends in Microbiology, V1, P109, DOI 10.1016/0966-842X(93)90117-A; ZINNER K, 1977, ARCH BIOCHEM BIOPHYS, V180, P452, DOI 10.1016/0003-9861(77)90059-5	59	47	49	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1996	14	11					1557	1561		10.1038/nbt1196-1557	http://dx.doi.org/10.1038/nbt1196-1557			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VP833	9634820				2022-12-25	WOS:A1996VP83300021
J	Jansen, G; Thijssen, KL; Werner, P; van der Horst, M; Hazendonk, E; Plasterk, RHA				Jansen, G; Thijssen, KL; Werner, P; van der Horst, M; Hazendonk, E; Plasterk, RHA			The complete family of genes encoding G proteins of Caenorhabditis elegans	NATURE GENETICS			English	Article							C-ELEGANS; CHEMOSENSORY RECEPTORS; SENSORY NEURONS; CHEMOTAXIS; EXPRESSION; MUTATIONS; MUTANTS; SYSTEM; G(O)	Caenorhabditis elegans is the first animal whose genomic sequence has been determined(1). One of the new possibilities in post-sequence genetics is the analysis of complete gene families at once. We studied the family of heterotrimeric G proteins(2). C, elegans has 20 G alpha, 2 G beta and 2 G gamma genes. There is 1 homologue of each of the 4 mammalian classes of G alpha genes, G(i)/G(o)alpha, G(s)alpha, G(q)alpha and G(12)alpha, and there are 16 new alpha genes. Although the conserved G alpha subunits are expressed in many neurons and muscle cells(3-7), GFP fusions indicate that 14 new G alpha genes are expressed almost exclusively in a small subset of the chemosensory neurons of C, elegans(8,9). We generated loss-of-function alleles using target-selected gene inactivation(10,11). None of the amphid-expressed genes are essential for viability, and only four show any detectable phenotype (chemotaxis defects), suggesting extensive functional redundancy. On the basis of functional analysis, the 20 genes encoding G alpha proteins can be divided into two groups: those that encode subunits affecting muscle activity (homologues of G(i)/G(o)alpha G(s)alpha and G(q); refs 3-6), and those (14 new genes) that encode proteins most likely involved in perception.	Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Plasterk, RHA (corresponding author), Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	rplas@nki.nl	Jansen, Gert/HCI-8852-2022	Jansen, Gert/0000-0002-7524-171X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; CULOTTI JG, 1978, GENETICS, V90, P243; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Korswagen HC, 1997, GENE DEV, V11, P1493, DOI 10.1101/gad.11.12.1493; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Park JH, 1997, GENE, V194, P183, DOI 10.1016/S0378-1119(97)00122-4; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zwaal RR, 1997, GENETICS, V145, P715; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	30	230	277	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1999	21	4					414	419		10.1038/7753	http://dx.doi.org/10.1038/7753			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192394				2022-12-25	WOS:000079439700025
J	Jaye, M; Lynch, KJ; Krawiec, T; Marchadier, D; Maugeais, C; Doan, K; South, V; Amin, D; Perrone, M; Rader, DJ				Jaye, M; Lynch, KJ; Krawiec, T; Marchadier, D; Maugeais, C; Doan, K; South, V; Amin, D; Perrone, M; Rader, DJ			A novel endothelial-derived lipase that modulates HDL metabolism	NATURE GENETICS			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEPATIC TRIGLYCERIDE LIPASE; CHOLESTEROL LEVELS; PANCREATIC LIPASE; TRANSGENIC MICE; DEFICIENT MICE; GENE-TRANSFER; PLASMA HDL; ATHEROSCLEROSIS; OVEREXPRESSION	High-density lipoprotein (HDL) cholesterol levels are inversely associated with risk of atherosclerotic cardiovascular disease(1). At least 50% of the variation in HDL cholesterol levels is genetically determined(2,3), but the genes responsible for variation in HDL levels have not been fully elucidated. Lipoprotein lipase (LPL) and hepatic lipase (HL), two members of the triacylglyerol (TC) lipase family, both influence HDL metabolism(2,4-6) and the HL (LIPC) locus has been associated with variation in HDL cholesterol levels in humans(7,8). We describe here the cloning and in vivo functional analysis of a new member of the TG lipase family. In contrast to other family members, this new lipase is synthesized by endothelial cells in vitro and thus has been termed endothelial lipase (encoded by the LIPG gene). EL is expressed in vivo in organs including liver, lung, kidney and placenta, but not in skeletal muscle. In contrast to LPL and HL, EL has a lid of only 19 residues. EL has substantial phospholipase activity, but less triglyceride lipase activity. Overexpression of EL in mice reduced plasma concentrations of HDL cholesterol and its major protein apolipoprotein A-I. The endothelial expression, enzymatic profile and in vivo effects of EL suggest that it may have a role in lipoprotein metabolism and vascular biology.	Univ Penn, Hlth Syst, Dept Med, Philadelphia, PA 19104 USA; Rhone Poulenc Rorer, Res & Dev, Dept Cardiovasc Biol, Collegeville, PA 19426 USA	University of Pennsylvania	Rader, DJ (corresponding author), Univ Penn, Hlth Syst, Dept Med, Philadelphia, PA 19104 USA.							Bensadoun A, 1996, CURR OPIN LIPIDOL, V7, P77, DOI 10.1097/00041433-199604000-00005; BLADES B, 1993, ARTERIOSCLER THROMB, V13, P1227, DOI 10.1161/01.ATV.13.8.1227; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; COHEN JC, 1994, J CLIN INVEST, V94, P2377, DOI 10.1172/JCI117603; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Goldberg IJ, 1996, J LIPID RES, V37, P693; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Guerra R, 1997, P NATL ACAD SCI USA, V94, P4532, DOI 10.1073/pnas.94.9.4532; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HELLER DA, 1993, NEW ENGL J MED, V328, P1150, DOI 10.1056/NEJM199304223281603; Hokanson JE, 1997, INT J CLIN LAB RES, V27, P24, DOI 10.1007/BF02827239; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; MAHANEY MC, 1995, ARTERIOSCL THROM VAS, V15, P1730, DOI 10.1161/01.ATV.15.10.1730; Mahley RW, 1999, J LIPID RES, V40, P1; Mezdour H, 1997, J BIOL CHEM, V272, P13570, DOI 10.1074/jbc.272.21.13570; Murthy V, 1996, PHARMACOL THERAPEUT, V70, P101, DOI 10.1016/0163-7258(96)00005-8; PIMSTONE SN, 1995, ARTERIOSCL THROM VAS, V15, P1704, DOI 10.1161/01.ATV.15.10.1704; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; Tsukamoto K, 1997, J LIPID RES, V38, P1869; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	27	398	439	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					424	428		10.1038/7766	http://dx.doi.org/10.1038/7766			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192396				2022-12-25	WOS:000079439700027
J	Scott, DA; Wang, R; Kreman, TM; Sheffield, VC; Karniski, LP				Scott, DA; Wang, R; Kreman, TM; Sheffield, VC; Karniski, LP			The Pendred syndrome gene encodes a chloride-iodide transport protein	NATURE GENETICS			English	Article							SULFATE TRANSPORTER; EXCHANGE; CLONING; MUTATIONS; VESICLES; GOITER; MAPS	Pendred syndrome is the most common form of syndromic deafness and characterized by congenital sensorineural hearing loss and goitre(1-3). This disorder was mapped to chromosome 7 and the gene causing Pendred syndrome (PDS) was subsequently identified by positional cloning(4-6). PDS encodes a putative transmembrane protein designated pendrin. Pendrin is closely related to a family of sulfate transport proteins that includes the rat sulfate-anion transporter(7) (encoded by Sat-1; 29% amino acid sequence identity), the human diastrophic dysplasia sulfate transporter(8) (encoded by DTD; 32%) and the human sulfate transporter 'downregulated in adenoma'(9,10) (encoded by DRA; 45%), On the basis of this homology and the presence of a slightly modified sulfate-transporter signature sequence comprising its putative second transmembrane domain(6-9), pendrin has been proposed to function as a sulfate transporter. We were unable to detect evidence of sulfate transport following the expression of pendrin in Xenopus laevis oocytes by microinjection of PDS cRNA or in Sf9 cells following infection with PDS-recombinant baculovirus. The rates of transport for iodide and chloride were significantly increased following the expression of pendrin in both cell systems. Our results demonstrate that pendrin functions as a transporter of chloride and iodide, but not sulfate, and may provide insight into thyroid physiology and the pathophysiology of Pendred syndrome.	Dept Vet Affairs Med Ctr, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa	Karniski, LP (corresponding author), Dept Vet Affairs Med Ctr, Howard Hughes Med Inst, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Sheffield, Val/0000-0002-6282-0835	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK047881, R01DK047881] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00457] Funding Source: Medline; NIDDK NIH HHS [DK-47881] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOWICZ MJ, 1992, J CLIN INVEST, V90, P1200, DOI 10.1172/JCI115981; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BROWN CDA, 1989, AM J PHYSIOL, V257, pG661, DOI 10.1152/ajpgi.1989.257.4.G661; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Coyle B, 1996, NAT GENET, V12, P421, DOI 10.1038/ng0496-421; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; GORLIN JR, 1995, HEREDITARY HEARING L, P337; HAGEN GA, 1971, NEW ENGL J MED, V285, P1394, DOI 10.1056/NEJM197112162852502; HALLIGAN RD, 1991, AM J PHYSIOL, V260, pC347, DOI 10.1152/ajpcell.1991.260.2.C347; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; JOHNSEN T, 1986, ACTA OTO-LARYNGOL, V102, P239, DOI 10.3109/00016488609108673; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; Karniski LP, 1998, AM J PHYSIOL-RENAL, V275, pF79, DOI 10.1152/ajprenal.1998.275.1.F79; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Reardon W, 1997, QJM-MON J ASSOC PHYS, V90, P443, DOI 10.1093/qjmed/90.7.443; Reardon W, 1996, J MED GENET, V33, P1037, DOI 10.1136/jmg.33.12.1037; Sheffield VC, 1996, NAT GENET, V12, P424, DOI 10.1038/ng0496-424; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; TROTTER WR, 1960, BRIT MED BULL, V16, P92, DOI 10.1093/oxfordjournals.bmb.a069828	24	450	548	2	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					440	443		10.1038/7783	http://dx.doi.org/10.1038/7783			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192399				2022-12-25	WOS:000079439700030
J	Young, D; Lawlor, PA; Leone, P; Dragunow, M; During, MJ				Young, D; Lawlor, PA; Leone, P; Dragunow, M; During, MJ			Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective	NATURE MEDICINE			English	Article							NMDA RECEPTOR ACTIVATION; FIBROBLAST GROWTH-FACTOR; GENERATED GRANULE CELLS; RAT DENTATE GYRUS; NEUROTROPHIC FACTOR; ADULT-RAT; HIPPOCAMPAL-NEURONS; PROGENITOR CELLS; NEUROGENESIS; BRAIN	The mammalian brain has a high degree of plasticity, with dentate granule cell neurogenesis(1) and glial(2,3) proliferation stimulated by an enriched environment combining both complex inanimate and social stimulation. Moreover, rodents exposed to an enriched environment both before and after a cerebral insult show improved cognitive performance(1,4). One of the most robust associations of environmental enrichment is improved learning and memory in the Morris water maze, a spatial task that mainly involves the hippocampus(5). Furthermore, clinical evidence showing an association between higher educational attainment and reduced risk of Alzheimer(6) and Parkinson-related dementia(7) indicates that a stimulating environment has positive effects on cerebral health that may provide some resilience to cerebral insults. Here we show that in addition to its effects on neurogenesis, an enriched environment reduces spontaneous apoptotic cell death in the rat hippocampus by 45%. Moreover, these environmental conditions protect against kainate-induced seizures and excitotoxic injury. The enriched environment induces expression of glial-derived neurotrophic factor and brain-derived neurotrophic factor and increases phosphorylation of the transcription factor cyclic-AMP response element binding protein, indicating that the; influence of the environment on spontaneous apoptosis and cerebral resistance to insults may be mediated through transcription factor activation and induction of growth factor expression.	Univ Auckland, Sch Med, Dept Mol Med, Auckland 1, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurosurg, Philadelphia, PA 19107 USA	University of Auckland; Jefferson University	During, MJ (corresponding author), Univ Auckland, Sch Med, Dept Mol Med, Auckland 1, New Zealand.	Matthew.During@mail.tju.edu	During, Matthew/AAC-1388-2020	Young, Deborah/0000-0003-1085-2824				Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; CHENG B, 1995, J NEUROCHEM, V65, P2525; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CRESPO D, 1986, EXP BRAIN RES, V62, P541; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FIALA BA, 1978, EXP NEUROL, V59, P372, DOI 10.1016/0014-4886(78)90229-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LIU Z, 1993, BRAIN RES, V626, P335, DOI 10.1016/0006-8993(93)90598-H; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; MARTIN D, 1995, BRAIN RES, V683, P172, DOI 10.1016/0006-8993(95)00369-2; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/S0006-8993(96)00273-9; OLSSON T, 1995, NEUROSCI LETT, V189, P113, DOI 10.1016/0304-3940(95)11467-B; Parent JM, 1997, J NEUROSCI, V17, P3727; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Sah DWY, 1997, J NEUROBIOL, V32, P95, DOI 10.1002/(SICI)1097-4695(199701)32:1<95::AID-NEU9>3.0.CO;2-9; SEKI T, 1993, J NEUROSCI, V13, P2351, DOI 10.1523/JNEUROSCI.13-06-02351.1993; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Voyvodic JT, 1996, NEURON, V16, P693, DOI 10.1016/S0896-6273(00)80089-6; WALSH RN, 1969, J COMP NEUROL, V137, P361, DOI 10.1002/cne.901370309; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306	45	605	624	0	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					448	453		10.1038/7449	http://dx.doi.org/10.1038/7449			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202938				2022-12-25	WOS:000079574300038
J	Draptchinskaia, N; Gustavsson, P; Andersson, B; Pettersson, M; Willig, TN; Dianzani, I; Ball, S; Tchernia, G; Klar, J; Matsson, H; Tentler, D; Mohandas, N; Carlsson, B; Dahl, N				Draptchinskaia, N; Gustavsson, P; Andersson, B; Pettersson, M; Willig, TN; Dianzani, I; Ball, S; Tchernia, G; Klar, J; Matsson, H; Tentler, D; Mohandas, N; Carlsson, B; Dahl, N			The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia	NATURE GENETICS			English	Article							MESSENGER-RNAS; SEQUENCE-ANALYSIS; TURNER SYNDROME; DNA-SEQUENCE; ANEMIA; CHROMOSOME; EXPRESSION; GROWTH	Diamond-Blackfan anaemia (DBA) is a constitutional erythroblastopenia characterized by absent or decreased erythroid precursors. The disease, previously mapped to human chromosome 19q13, is frequently associated with a variety of malformation. To identify the gene involved in DBA, we cloned the chromosome 19q13 breakpoint in a patient with a reciprocal X; 19 chromosome translocation. The breakpoint occurred in the gene encoding ribosomal protein S19. Furthermore, we identified mutations in RPS19 in 10 of 40 unrelated DMA patients, including nonsense, frameshift, splice site and missense mutations, as well as two intragenic deletions. These mutations are associated with clinical features that suggest a function for RPS19 in erythropoiesis and embryogenesis.	Uppsala Univ, Dept Genet & Pathol, Clin Genet Unit, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Unit Med Genet, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Unit Pathol, S-75185 Uppsala, Sweden; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Hop Bicetre, AP HP, Dept Hematol, Le Kremlin Bicetre, France; Fac Med Paris Sud, Le Kremlin Bicetre, France; Univ Turin, Dept Pediat, I-10126 Turin, Italy; Univ London St Georges Hosp, Sch Med, Dept Haematol, London SW17 0RE, England	Uppsala University; Uppsala University; Uppsala University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Turin; St Georges University London	Dahl, N (corresponding author), Uppsala Univ, Dept Genet & Pathol, Clin Genet Unit, S-75185 Uppsala, Sweden.	niklas.dahl@klingen.uu.se	Klar, Joakim/H-2900-2019; Tentler, Dmitri/AAE-4519-2019; Matsson, Hans/A-5787-2019; Andersson, Bjorn/G-9832-2013	Klar, Joakim/0000-0003-4185-7409; Tentler, Dmitri/0000-0003-3976-1205; Matsson, Hans/0000-0001-6161-1559; Andersson, Bjorn/0000-0002-4624-0259	NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline; Telethon [E.0619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK026263, R37DK026263] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersson B, 1996, BIOTECHNIQUES, V20, P1022; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; BAGNARA GP, 1991, BLOOD, V78, P2203; Ball SE, 1996, BRIT J HAEMATOL, V94, P645, DOI 10.1046/j.1365-2141.1996.d01-1839.x; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMTON SE, 1994, GENETICS, V137, P1039; Diamond L K, 1976, Adv Pediatr, V22, P349; Dianzani I, 1996, BLOOD, V87, P2568, DOI 10.1182/blood.V87.6.2568.bloodjournal8762568; ETTER A, SCIENCE, V265, P954; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Gelbart WM, 1997, NUCLEIC ACIDS RES, V25, P63, DOI 10.1093/nar/25.1.63; Gustavsson P, 1997, NAT GENET, V16, P368, DOI 10.1038/ng0897-368; Gustavsson P, 1998, AM J HUM GENET, V63, P1388, DOI 10.1086/302100; Gustavsson P, 1997, J MED GENET, V34, P779, DOI 10.1136/jmg.34.9.779; HALPERIN DS, 1989, AM J PEDIAT HEMATOL, V11, P380; HART K, 1993, MECH DEVELOP, V43, P101, DOI 10.1016/0925-4773(93)90028-V; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HASHIMOTO S, 1994, IMMUNOGENETICS, V40, P287; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Janov AJ, 1996, MEDICINE, V75, P77, DOI 10.1097/00005792-199603000-00004; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; KONDOH N, 1992, CANCER RES, V52, P791; MCGUCKIN CP, 1995, BRIT J HAEMATOL, V89, P457, DOI 10.1111/j.1365-2141.1995.tb08349.x; Meyuhas Oded, 1996, V30, P363; MUGISHIMA H, 1995, BONE MARROW TRANSPL, V15, P55; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; PETTERSSON M, 1995, BLOOD, V86, P2747; Richards S., 1994, AUTOMATED DNA SEQUEN, P191; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; TSAI PH, 1989, BRIT J HAEMATOL, V73, P112, DOI 10.1111/j.1365-2141.1989.tb00229.x; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; Willig T N, 1998, Curr Opin Hematol, V5, P109; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; WOOL IG, 1996, RIBOSOMAL RNA GROUP, P153; Young N. S., 1994, APLASTIC ANEMIA ACQU	43	616	635	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					169	175		10.1038/5951	http://dx.doi.org/10.1038/5951			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988267				2022-12-25	WOS:000078399500017
J	Dyer, MR; Cohen, D; Herrling, PL				Dyer, MR; Cohen, D; Herrling, PL			Building a competitive functional genomics platform	NATURE BIOTECHNOLOGY			English	Article									Novartis Pharma, Basel, Switzerland; Novartis Pharma, E Hanover, NJ USA	Novartis; Novartis	Herrling, PL (corresponding author), Novartis Pharma, Basel, Switzerland.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE18	BE19		10.1038/4631	http://dx.doi.org/10.1038/4631			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052318				2022-12-25	WOS:000078529400009
J	Miller, HI				Miller, HI			The real curse of Frankenfood	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	6	6	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					113	113		10.1038/6075	http://dx.doi.org/10.1038/6075			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052332				2022-12-25	WOS:000078508300004
J	Schneider, S; Buchert, M; Georgiev, O; Catimel, B; Halford, M; Stacker, SA; Baechi, T; Moelling, K; Hovens, CM				Schneider, S; Buchert, M; Georgiev, O; Catimel, B; Halford, M; Stacker, SA; Baechi, T; Moelling, K; Hovens, CM			Mutagenesis and selection of PDZ domains that bind new protein targets	NATURE BIOTECHNOLOGY			English	Article						protein engineering; PDZ domains; in vivo screening; intracellular targeting	RECEPTOR; RECOGNITION; LIBRARIES; COMPLEXES; SEQUENCES; SYSTEM; SITES	PDZ domains are a recently characterized protein-recognition module. In most cases, PDZ domains bind to the C-terminal end of target proteins and are thought thereby to link these target proteins into functional signaling networks. We report the isolation of artificial PDZ domains selected via a mutagenesis screen in vivo, each recognizing a different C-terminal peptide. We demonstrate that the PDZ domains isolated can bind selectively to their target peptides in vitro and in vivo. Two of the target peptides chosen are the C-terminal ends of two cellular transmembrane proteins with which no known PDZ domains have been reported to interact. By targeting these artificial PDZ domains to the nucleus, interacting target peptides were efficiently transported to the same subcellular localization. One of the isolated PDZ domains was tested and shown to be efficiently directed to the plasma membrane when cotransfected with the full-length transmembrane protein in mammalian cells. Thus, artificial PDZ domains can be engineered and used to target intracellular proteins to different subcellular compartments.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland; Univ Zurich, Elekt Mikroskop Zent Lab, CH-8028 Zurich, Switzerland; Univ Zurich, Inst Mol Biol 2, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich	Moelling, K (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30-32, CH-8028 Zurich, Switzerland.			Stacker, Steven/0000-0003-4096-9273; Buchert, Michael/0000-0003-2672-0148; Hovens, Christopher/0000-0002-0610-1289; CATIMEL, Bruno/0000-0002-4350-6875				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchert M, 1997, BIOTECHNIQUES, V23, P396, DOI 10.2144/97233bm10; CADWELL RC, 1992, PCR METH APPL, V26, P259; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Catimel B, 1997, J CHROMATOGR A, V776, P15, DOI 10.1016/S0021-9673(97)00087-3; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Jones TL, 1997, ONCOGENE, V14, P2159, DOI 10.1038/sj.onc.1201082; Kast P, 1997, CURR OPIN STRUC BIOL, V7, P470, DOI 10.1016/S0959-440X(97)80109-1; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUNES S, 1985, J MOL BIOL, V184, P375, DOI 10.1016/0022-2836(85)90288-8; KURIAN J, 1997, ANNU REV BIOPH BIOM, V16, P6141; LOFAS S, 1995, BIOSENS BIOELECTRON, V10, P813, DOI 10.1016/0956-5663(95)99220-F; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Miller J.H., 1972, EXPT MOL GENETICS; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nord K, 1997, NAT BIOTECHNOL, V15, P772, DOI 10.1038/nbt0897-772; Nygren PA, 1997, CURR OPIN STRUC BIOL, V7, P463, DOI 10.1016/S0959-440X(97)80108-X; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRASAD R, 1993, CANCER RES, V53, P5624; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schneider S, 1997, GENE, V197, P337, DOI 10.1016/S0378-1119(97)00280-1; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805	35	72	84	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					170	175		10.1038/6172	http://dx.doi.org/10.1038/6172			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052354				2022-12-25	WOS:000078508300026
J	Hellerstein, M; Hanley, MB; Cesar, D; Siler, S; Papageorgopoulos, C; Wieder, E; Schmidt, D; Hoh, R; Neese, R; Macallan, D; Deeks, S; McCune, JM				Hellerstein, M; Hanley, MB; Cesar, D; Siler, S; Papageorgopoulos, C; Wieder, E; Schmidt, D; Hoh, R; Neese, R; Macallan, D; Deeks, S; McCune, JM			Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans	NATURE MEDICINE			English	Article							HIV-1 INFECTION; RAPID TURNOVER; CELL TURNOVER; IN-VIVO; DISEASE; RATES	The dynamic basis for T-cell depletion in late-stage HIV-1 disease remains controversial. Using a new, non-radioactive, endogenous labeling technique(1), we report direct measurements of circulating T-cell kinetics in normal and in HIV-l-infected humans. In healthy, HIV-l-seronegative subjects, CD4(+) and CD8(+) T cells had half-lives of 87 days and 77 days, respectively, with absolute production rates of 10 CD4(+) T cells/mu l per day and 6 CD8(+) T cells/mu l per day. In untreated HIV-l-infected subjects (with a mean CD4 level of 342 cells/mu l), the half-life of each subpopulation was less than 1/3 as long as those of healthy, HIV-l-seronegative subjects but was not compensated by an increased absolute production rate of CD4(+) T cells. After viral replication was suppressed by highly active antiretroviral therapy for 12 weeks, the production rates of circulating CD4(+) and CD8(+) T cells were considerably elevated; the kinetic basis of increased CD4 levels was greater production, not a longer half-life, of circulating cells. These direct measurements indicate that CD4(+) T-cell lymphopenia is due to both a shortened survival time and a failure to increase the production of circulating CD4(+) T cells. Our results focus attention on T-cell production systems in the pathogenesis of HIV-1 disease and the response to antiretroviral therapy.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94110 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes	Hellerstein, M (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.			Macallan, Derek/0000-0002-3014-7148				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bell E B, 1997, Semin Immunol, V9, P347, DOI 10.1006/smim.1997.0092; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Fleury S, 1998, NAT MED, V4, P794, DOI 10.1038/nm0798-794; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Mackall C L, 1997, Semin Immunol, V9, P339, DOI 10.1006/smim.1997.0091; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; ROSENBERG A, 1981, BIOMATHEMATICS CELL, V8, P143; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; WAINHOBSON S, 1995, NATURE, V373, P102, DOI 10.1038/373102a0; WATERLOW JC, 1978, PROTEIN TURNOVER MAM, P216; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Wolthers KC, 1998, IMMUNOL TODAY, V19, P44, DOI 10.1016/S0167-5699(97)01188-2; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; YOUNG AJ, 1995, INT IMMUNOL, V7, P1607, DOI 10.1093/intimm/7.10.1607; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	27	440	466	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					83	89		10.1038/4772	http://dx.doi.org/10.1038/4772			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883844				2022-12-25	WOS:000077885000034
J	Sherman, A; Dawson, A; Mather, C; Gilhooley, H; Li, Y; Mitchell, R; Finnegan, D; Sang, H				Sherman, A; Dawson, A; Mather, C; Gilhooley, H; Li, Y; Mitchell, R; Finnegan, D; Sang, H			Transposition of the Drosophila element mariner into the chicken germ line	NATURE BIOTECHNOLOGY			English	Article						transgenic animals; transposable element	TRANSPOSABLE ELEMENT; IN-VITRO; EXPRESSION; EMBRYO; DNA	The ability of the Drosophila transposable element mariner to transpose in the chicken was tested using a plasmid carrying an active mariner element injected into chick zygotes. Surviving embryos and chicks were analyzed for presence of mariner. Analysis of embryos that survived for at least 12 days of development indicated that mariner had transposed at high frequency into the chicken genome, Germline transmission of mariner from one of three surviving birds confirmed transposition. Analysis of the first-generation (G(1)) chicks showed that they each contained between one and three copies of mariner. Six different transposition events were represented in the G(1) birds, and the transposition was catalyzed by expression of the mariner element's transposase gene, Transmission from G(1) to G(2) occurred at a 1:1 ratio, Mariner therefore has potential for development as a vector for transgenesis in avian species.	Roslin Inst, Div Dev & Reprod, Roslin EH25 9PS, Midlothian, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh	Sang, H (corresponding author), Roslin Inst, Div Dev & Reprod, Roslin EH25 9PS, Midlothian, Scotland.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRYAN G, 1990, GENETICS, V125, P103; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Dawson A, 1998, NAT BIOTECHNOL, V16, P20, DOI 10.1038/nbt0198-20; Fadool JM, 1998, P NATL ACAD SCI USA, V95, P5182, DOI 10.1073/pnas.95.9.5182; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GARZA D, 1991, GENETICS, V128, P303; GUIEROSFILHO FJ, 1997, SCIENCE, V276, P1716; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; LOHE AR, 1995, GENETICS, V140, P183; LOVE J, 1994, BIO-TECHNOL, V12, P60, DOI 10.1038/nbt0194-60; MEDHORA M, 1991, GENETICS, V128, P311; PERRY M, 1991, ROUX ARCH DEV BIOL, V200, P312, DOI 10.1007/BF00665526; PERRY MM, 1988, NATURE, V331, P70, DOI 10.1038/331070a0; Raz E, 1998, CURR BIOL, V8, P82, DOI 10.1016/S0960-9822(98)70038-7; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; SANG H, 1989, Molecular Reproduction and Development, V1, P98, DOI 10.1002/mrd.1080010204; VELTEROP JS, 1995, GENE, V153, P63, DOI 10.1016/0378-1119(94)00790-Y; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755	18	116	128	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1050	1053		10.1038/3497	http://dx.doi.org/10.1038/3497			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831034				2022-12-25	WOS:000076870100027
J	Strautnieks, SS; Bull, LN; Knisely, AS; Kocoshis, S; Dahl, N; Arnell, H; Sokal, E; Dahan, K; Childs, S; Ling, V; Tanner, MS; Kagalwalla, AF; Nemeth, A; Pawlowska, J; Baker, A; Mieli-Vergani, G; Freimer, NB; Gardiner, RM; Thompson, RJ				Strautnieks, SS; Bull, LN; Knisely, AS; Kocoshis, S; Dahl, N; Arnell, H; Sokal, E; Dahan, K; Childs, S; Ling, V; Tanner, MS; Kagalwalla, AF; Nemeth, A; Pawlowska, J; Baker, A; Mieli-Vergani, G; Freimer, NB; Gardiner, RM; Thompson, RJ			A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis	NATURE GENETICS			English	Article							BYLER-DISEASE; P-GLYCOPROTEIN; IDENTIFICATION; HETEROGENEITY; LOCUS; ACID; 18Q21-Q22; SECRETION; MUTATIONS; MEMBRANE	The progressive familiar intrahepatic cholestases (PFIC) are a group of inherited disorders with severe cholestatic liver disease from early infancy. A subgroup characterized by normal serum cholesterol and gamma-glutamyltranspeptidase (gamma GT) levels is genetically heterogeneous with loci on chromosomes 2q (PFIC2) and 18q. The phenotype of the PFIC2-linked group is consistent with defective bile acid transport at the hepatocyte canalicular membrane. The PFIC2 gene has now been identified by mutations in a positional candidate, BSEP, which encodes a liver-specific ATP-binding cassette (ABC) transporter, sister of p-glycoprotein (SPGP). The product of the orthologous rat gene has been shown to be an effective bile acid transporter in vitro. These data provide evidence that SPCP is the human bile salt export pump (BSEP).	UCL, Sch Med, Dept Paediat, London W1N 8AA, England; Univ Calif San Francisco, Dept Psychiat, Ctr Neurobiol & Psychiat, Neurogenet Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Texas, Med Branch, Div Surg Pathol, Galveston, TX 77550 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden; Univ Catholique Louvain, Dept Pediat, B-1348 Louvain, Belgium; Univ Catholique Louvain, Dept Med Genet, B-1348 Louvain, Belgium; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Sheffield Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England; Huddinge Univ Hosp, Dept Pediat, S-14186 Huddinge, Sweden; Childrens Mem Hlth Inst, Warsaw, Poland; Kings Coll London Hosp, Dept Child Hlth, London, England; Kings Coll London, Sch Med & Dent, London, England; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA	University of London; University College London; UCL Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Uppsala University; Universite Catholique Louvain; Universite Catholique Louvain; British Columbia Cancer Agency; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; Karolinska Institutet; Children's Memorial Health Institute; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Thompson, RJ (corresponding author), UCL, Sch Med, Dept Paediat, Mortimer St, London W1N 8AA, England.	richard.j.thompson@kcl.ac.uk	Thompson, Richard J/B-7954-2009; Mieli-Vergani, Giorgina/G-5616-2011; Childs, Sarah/AAG-5111-2021	Thompson, Richard J/0000-0001-5652-0150; Mieli-Vergani, Giorgina/0000-0002-8215-4489; Pawlowska, Joanna/0000-0003-1154-8824; Childs, Sarah/0000-0003-2261-580X; Sokal, Etienne/0000-0001-5597-4708; Nemeth, Antal/0000-0002-6229-5882	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050697] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK50697] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALONSO EM, 1994, J PEDIATR GASTR NUTR, V18, P128, DOI 10.1097/00005176-199402000-00002; Arnell H, 1997, HUM GENET, V100, P378, DOI 10.1007/s004390050519; BROWN RS, 1995, P NATL ACAD SCI USA, V92, P5421, DOI 10.1073/pnas.92.12.5421; Bull LN, 1997, HEPATOLOGY, V26, P155; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; CARLTON VEH, 1995, HUM MOL GENET, V4, P1049, DOI 10.1093/hmg/4.6.1049; CHEN CJ, 1990, J BIOL CHEM, V265, P506; Childs S, 1998, CANCER RES, V58, P4160; CHILDS S, 1995, CANCER RES, V55, P2029; CLAYTON RJ, 1969, AM J DIS CHILD, V117, P112, DOI 10.1001/archpedi.1969.02100030114014; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; JACQUEMIN E, 1994, EUR J PEDIATR, V153, P424; JAVITT NB, 1967, GASTROENTEROLOGY, V53, P171; MAGGIORE G, 1987, J PEDIATR-US, V111, P251, DOI 10.1016/S0022-3476(87)80079-3; Marinelli RA, 1997, HEPATOLOGY, V26, P1081, DOI 10.1002/hep.510260539; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; NIELSEN IM, 1986, ACTA PAEDIATR SCAND, V75, P1010, DOI 10.1111/j.1651-2227.1986.tb10332.x; Popper H, 1970, Hum Pathol, V1, P1, DOI 10.1016/S0046-8177(70)80002-8; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Strautnieks SS, 1996, J MED GENET, V33, P833, DOI 10.1136/jmg.33.10.833; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; Suchy FJ, 1997, FASEB J, V11, P199, DOI 10.1096/fasebj.11.4.9068608; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITINGTON PF, 1994, J PEDIATR GASTR NUTR, V18, P134, DOI 10.1097/00005176-199402000-00003	37	766	791	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					233	238		10.1038/3034	http://dx.doi.org/10.1038/3034			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806540				2022-12-25	WOS:000076698100015
J	Wang, ZG; Ruggero, D; Ronchetti, S; Zhong, S; Gaboli, M; Rivi, R; Pandolfi, PP				Wang, ZG; Ruggero, D; Ronchetti, S; Zhong, S; Gaboli, M; Rivi, R; Pandolfi, PP			Pml is essential for multiple apoptotic pathways	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; FAS-MEDIATED APOPTOSIS; NECROSIS-FACTOR-ALPHA; RING FINGER DOMAIN; RETINOIC ACID; RAR-ALPHA; INTERFERON-GAMMA; DNA-DAMAGE; ICE-LIKE; CELLS	The PML gene of acute promyelocytic leukaemia (APL) encodes a cell growth and tumour suppressor, however, the mechanisms by which PML suppresses tumorigenesis are poorly understood. We show here that Pml is required for Fas- and caspase-dependent DNA-damage-induced apoptosis. We also found that Pml is essential for induction of programmed cell death by Fas, tumour necrosis factor a (TNF), ceramide and type I and II interferons (IFNs). As a result, Pml(-/-) mice and cells are protected from the lethal effects of ionizing radiation and anti-fas antibody. Pml is required for caspase 1 and caspase 3 activation upon exposure to these stimuli. The PML-RAR alpha fusion protein of APL renders haemopoietic progenitor cells resistant to Fas-, TNF- and IFN-induced apoptosis with a lack of caspase 3 activation, thus acting as a Pml dominant-negative product. These results demonstrate that Pml is a mediator of multiple apoptotic signals, and implicate inhibition of apoptosis in the pathogenesis of APL.	Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Mem Sloan Kettering Canc Ctr,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Mem Sloan Kettering Canc Ctr,Mol Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Mem Sloan Kettering Canc Ctr,Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Ronchetti, Simona/L-2325-2013	Ronchetti, Simona/0000-0002-5639-4243	NCI NIH HHS [CA-08748, CA 71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA071692, P30CA008748, R01CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; HONG SH, 1997, P NATL ACAD SCI USA, V94, P9038; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAVAU C, 1995, ONCOGENE, V11, P871; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; SELLERI C, 1995, J CELL PHYSIOL, V165, P538, DOI 10.1002/jcp.1041650312; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Stadler M, 1995, ONCOGENE, V11, P2565; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Wang ZG, 1998, SCIENCE, V279, P1547; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	41	471	491	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					266	272		10.1038/3073	http://dx.doi.org/10.1038/3073			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806545				2022-12-25	WOS:000076698100020
J	Soares, MP; Lin, Y; Anrather, J; Csizmadia, E; Takigami, K; Sato, K; Grey, ST; Colvin, RB; Choi, AM; Poss, KD; Bach, FH				Soares, MP; Lin, Y; Anrather, J; Csizmadia, E; Takigami, K; Sato, K; Grey, ST; Colvin, RB; Choi, AM; Poss, KD; Bach, FH			Expression of heme oxygenase-1 can determine cardiac xenograft survival	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; REJECTION; STRESS; ACCOMMODATION; ANTIOXIDANT; RESISTANCE; APOPTOSIS; FERRITIN; PROTEIN	The rejection of concordant xenografts, such as mouse-to-rat cardiac xenografts, is very similar to the delayed rejection of porcine-to-primate discordant xenografts(1,2-6). In concordant models, this type of rejection is prevented by brief complement inhibition by cobra venom factor (CVF) and sustained T-cell immunosuppression by cyclosporin A (CyA) (refs. 7-10). Mouse hearts that survive indefinitely in rats treated with CVF plus CyA express the anti-inflammatory gene heme oxygenase-l (HO-1) in their endothelial cells and smooth muscle cells(9,11-14). The anti-inflammatory properties of HO-1 are thought to rely on the ability of this enzyme to degrade heme and generate bilirubin, free iron and carbon monoxide(15) Bilirubin is a potent anti-oxidant(13), free iron upregulates the transcription of the cytoprotective gene, ferritin(16), and carbon monoxide is thought to be essential in regulating vascular relaxation in a manner similar to nitric oxide(15). We show here that the expression of the HO-1 gene is functionally associated with xenograft survival, and that rapid expression of HO-1 in cardiac xenografts can be essential to ensure long-term xenograft survival.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Sect, New Haven, CT 06513 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital; Yale University; Massachusetts Institute of Technology (MIT)	Soares, MP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA.		Soares, Miguel P/G-4188-2011; Grey, Shane T/B-3020-2008	Grey, Shane T/0000-0003-2160-1625; Poss, Kenneth/0000-0002-6743-5709; Soares, Miguel/0000-0002-9314-4833				Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BALLA G, 1992, J BIOL CHEM, V267, P18148; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; HASAN R, 1992, TRANSPLANTATION, V54, P408, DOI 10.1097/00007890-199209000-00004; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kobayashi T, 1997, TRANSPLANTATION, V64, P1255, DOI 10.1097/00007890-199711150-00005; Koyamada N, 1998, TRANSPLANTATION, V65, P1210, DOI 10.1097/00007890-199805150-00012; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lin SS, 1998, J CLIN INVEST, V101, P1745, DOI 10.1172/JCI2134; Lin YA, 1998, NAT MED, V4, P173, DOI 10.1038/nm0298-173; LOZADA C, 1995, P NATL ACAD SCI USA, V92, P8378, DOI 10.1073/pnas.92.18.8378; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Miyatake T, 1998, J IMMUNOL, V160, P4114; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; PLATT JL, 1994, IMMUNOL REV, V141, P127, DOI 10.1111/j.1600-065X.1994.tb00875.x; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Slowik MR, 1997, LAB INVEST, V77, P257; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	30	543	589	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1073	1077		10.1038/2063	http://dx.doi.org/10.1038/2063			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734404				2022-12-25	WOS:000075804100044
J	Blacker, D; Wilcox, MA; Laird, NM; Rodes, L; Horvath, SM; Go, RCP; Perry, R; Watson, B; Bassett, SS; McInnis, MG; Albert, MS; Hyman, BT; Tanzi, RE				Blacker, D; Wilcox, MA; Laird, NM; Rodes, L; Horvath, SM; Go, RCP; Perry, R; Watson, B; Bassett, SS; McInnis, MG; Albert, MS; Hyman, BT; Tanzi, RE			Alpha-2 macroglobulin is genetically associated with Alzheimer disease	NATURE GENETICS			English	Article							RECEPTOR-RELATED PROTEIN; APOLIPOPROTEIN-E; DEGRADATION; ALPHA(2)-MACROGLOBULIN; BINDING; COMPLEX; ALLELE	Alpha-2-macroglobulin (alpha-M-2; encoded by the gene A2M) is a serum pan-protease inhibitor that has been implicated in Alzheimer disease (AD) based on its ability to mediate the clearance and degradation of A beta, the major component of beta-amyloid deposits. Analysis of a deletion in the A2M gene at the 5' splice site of 'exon II' of the bait region (exon 18) revealed that inheritance of the deletion (A2M-2) confers increased risk for AD (Mantel-Haenzel odds ratio=3.56, P=0.001). The sibship disequilibrium test (SDT) also revealed a significant association between A2M and AD (P=0.00009). These values were comparable to those obtained for the APOE-epsilon 4 allele in the same sample, but in contrast to APOE-epsilon 4. A2M-2 did not affect age of onset. The observed association of A2M with AD did not appear to account for the previously published linkage of AD to chromosome 12, which we were unable to confirm in this sample. A2M, LRP1 (encoding the alpha-M-2 receptor) and the genes for two other LRP ligands, APOE and APP (encoding the amyloid P-protein precursor), have now all been genetically linked to AD, suggesting that these proteins may participate in a common neuropathogenic pathway leading to AD.	Massachusetts Gen Hosp, Genet & Aging Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA; Univ Alabama, Dept Epidemiol, Birmingham, AL USA; Johns Hopkins Med Inst, Dept Psychiat, Baltimore, MD USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine	Tanzi, RE (corresponding author), Massachusetts Gen Hosp, Genet & Aging Unit, Boston, MA 02114 USA.		Tanzi, Rudolph/AAE-9622-2019; McInnis, Melvin G/F-6963-2012	Tanzi, Rudolph/0000-0002-7032-1454; McInnis, Melvin G/0000-0002-0375-6247	NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH051066, U01MH046281, K21MH001118] Funding Source: NIH RePORTER; NIMH NIH HHS [U01 MH46281, K21 MH01118, U01 MH51066] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; BLACKER D, 1994, ARCH NEUROL-CHICAGO, V51, P1198, DOI 10.1001/archneur.1994.00540240042014; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; Blacker D, 1998, ARCH NEUROL-CHICAGO, V55, P294, DOI 10.1001/archneur.55.3.294; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Du YS, 1997, J NEUROCHEM, V69, P299; Du YS, 1998, J NEUROCHEM, V70, P1182; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; HOLLENBACH E, IN PRESS NEUROLOGY; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRAUTER K, 1995, NATURE, V377, P321; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lambert JC, 1997, HUM MOL GENET, V6, P2151, DOI 10.1093/hmg/6.12.2151; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; LOPES MB, 1993, FEBS LETT, V338, P301; MATTHIJS G, 1991, NUCLEIC ACIDS RES, V19, P5102, DOI 10.1093/nar/19.18.5102; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meyer MR, 1998, NAT GENET, V19, P321, DOI 10.1038/1206; Narita M, 1997, J NEUROCHEM, V69, P1904; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; WU WS, 1998, IN PRESS JAMA; Zhang ZY, 1996, AMYLOID, V3, P156, DOI 10.3109/13506129609045515	33	543	562	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					357	360		10.1038/1243	http://dx.doi.org/10.1038/1243			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697696				2022-12-25	WOS:000075107600018
J	Hoyle, R				Hoyle, R			Browner slams GE's hudson PCB campaign	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					700	700		10.1038/nbt0898-700	http://dx.doi.org/10.1038/nbt0898-700			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702754	Bronze			2022-12-25	WOS:000075183400006
J	Osbourn, JK; Earnshaw, JC; Johnson, KS; Parmentier, M; Timmermans, V; McCafferty, J				Osbourn, JK; Earnshaw, JC; Johnson, KS; Parmentier, M; Timmermans, V; McCafferty, J			Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library	NATURE BIOTECHNOLOGY			English	Article						applied immunology; proximity selection; biotin tyramine	FUNCTIONAL EXPRESSION; HIV-1; RECEPTOR; AMPLIFICATION; FRAGMENTS; CELLS	The seven trans-membrane chemokine receptor CCR-5 is a coreceptor for macrophage tropic HIV-1 strains. CCR-5 responds to a number of chemokines, including macrophage inflammatory protein (MIP)-1 alpha. We describe the use of MIP-1 alpha in a biotin tyramine-mediated proximity selection to guide the selection of CCR-5-specific phage antibodies from a large phage display human library. Proximity based selections resulted in a population of antibodies recognizing CCR-5 on primary CD4(+) lymphocytes, none of which blocked MIP-1 alpha binding to cells. The selected population of phage antibodies were subsequently used as guide molecules for a second phase of selection that was carried out in the absence of MIP-1 alpha. This generated a panel of CCR-5-binding antibodies, of which around 20% inhibited MIP-1 alpha binding to CD4(+). The single chain Fvs (scFv) generated by this step-back selection procedure also inhibited MIP-1 alpha-mediated calcium signaling.	Cambridge Antibody Technol Ltd, Melbourn SG8 6JJ, Cambs, England; Free Univ Brussels, Serv Genet Med, IRIBHN, Bruxelles, Belgium; Mol Devices Corp, Sunnyvale, CA 94089 USA	AstraZeneca; Universite Libre de Bruxelles	Osbourn, JK (corresponding author), Cambridge Antibody Technol Ltd, Sci Pk, Melbourn SG8 6JJ, Cambs, England.			Parmentier, Marc/0000-0001-8081-4685				ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BOBROW MN, 1992, J IMMUNOL METHODS, V150, P145, DOI 10.1016/0022-1759(92)90073-3; CAI XH, 1995, P NATL ACAD SCI USA, V92, P6537, DOI 10.1073/pnas.92.14.6537; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; KRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Osbourn JK, 1998, IMMUNOTECHNOLOGY, V3, P293, DOI 10.1016/S1380-2933(97)10007-0; Parsons HL, 1996, PROTEIN ENG, V9, P1043, DOI 10.1093/protein/9.11.1043; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309	17	42	87	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					778	781		10.1038/nbt0898-778	http://dx.doi.org/10.1038/nbt0898-778			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702779				2022-12-25	WOS:000075183400038
J	Concannon, P; Gogolin-Ewens, KJ; Hinds, DA; Wapelhorst, B; Morrison, VA; Stirling, B; Mitra, M; Farmer, J; Williams, SR; Cox, NJ; Bell, GI; Risch, N; Spielman, RS				Concannon, P; Gogolin-Ewens, KJ; Hinds, DA; Wapelhorst, B; Morrison, VA; Stirling, B; Mitra, M; Farmer, J; Williams, SR; Cox, NJ; Bell, GI; Risch, N; Spielman, RS			A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; COMPLEX TRAITS; GENE REGION; 15Q26 IDDM3; LOCUS; ASSOCIATION; MARKERS; DISEASE; PAIRS; HLA	During the past decade, the genetics of type 1 (insulin-dependent) diabetes mellitus (IDDM) has been studied extensively and the disorder has become a paradigm for genetically complex diseases. Previous genome screens(1,2) and studies focused on candidate genes(3-9) have provided evidence for genetic linkage between polymorphic DNA markers and 15 putative IDDM susceptibility loci, designated IDDM1-IDDM15. We have carried out a second-generation screen of the genome for linkage and analysed the data by multipoint linkage methods. An initial panel of 212 affected sibpairs (ASPs) was genotyped for 438 markers spanning all autosomes, and an additional 467 ASPs were used for follow-up genotyping. Other than the well-established linkage with the HLA region at chromosome 6p21.3, there was only one region, located on chromosome Iq and not previously reported, where the log likelihood ratio (lod) was greater than 3. Lods between 1.0 and 1.8 were found in six other regions, three of which have been reported in other studies. Another reported region(10), on chromosome 6q and loosely linked to HLA, also had an elevated led. Little or no support was found for most reported IDDM loci (lods were less than 1), despite larger sample sizes in the present study.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Pennsylvania; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Stanford University; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	Spielman, RS (corresponding author), Univ Penn, Sch Med, Dept Genet, 415 Curie Blvd, Philadelphia, PA 19104 USA.			Concannon, Patrick/0000-0002-5801-1859; Hinds, David/0000-0002-4911-803X; Martin, Beth/0000-0002-9661-014X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046627, R01DK046635, R01DK046618] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK046635, DK 46635, DK46627, DK46618] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIN SC, 1990, AUTOIMMUNITY, V7, P83, DOI 10.3109/08916939008993380; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; COPEMAN JB, 1995, NAT GENET, V9, P80, DOI 10.1038/ng0195-80; COX NJ, 1988, AM J HUM GENET, V42, P167; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Davies JL, 1996, HUM MOL GENET, V5, P1071, DOI 10.1093/hmg/5.7.1071; Delepine M, 1997, AM J HUM GENET, V60, P174; FIELD LL, 1994, NAT GENET, V8, P189, DOI 10.1038/ng1094-189; Field LL, 1996, GENOMICS, V33, P1, DOI 10.1006/geno.1996.0153; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; Hauser ER, 1996, GENET EPIDEMIOL, V13, P117, DOI 10.1002/(SICI)1098-2272(1996)13:2<117::AID-GEPI1>3.0.CO;2-5; Holmans P, 1997, AM J HUM GENET, V60, P657; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LaPorte R., 1995, DIABETES AM, V2nd ed, P37; LERNMARK A, 1990, AM J HUM GENET, V47, P1028; LUO DF, 1995, AM J HUM GENET, V57, P911; Luo DF, 1996, HUM MOL GENET, V5, P693, DOI 10.1093/hmg/5.5.693; Morahan G, 1996, SCIENCE, V272, P1811, DOI 10.1126/science.272.5269.1811; NERUP J, 1974, LANCET, V2, P864; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Owerbach D, 1997, DIABETES, V46, P1069, DOI 10.2337/diabetes.46.6.1069; OWERBACH D, 1995, DIABETES, V44, P132, DOI 10.2337/diabetes.44.1.132; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1987, AM J HUM GENET, V40, P1; ROWE RE, 1995, NAT GENET, V10, P240, DOI 10.1038/ng0695-240; SCHWAB SG, 1995, NAT GENET, V11, P325, DOI 10.1038/ng1195-325; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; THOMSON G, 1980, ANN HUM GENET, V43, P383, DOI 10.1111/j.1469-1809.1980.tb01572.x; Zamani M, 1996, HUM GENET, V98, P491, DOI 10.1007/s004390050245	33	281	286	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					292	296		10.1038/985	http://dx.doi.org/10.1038/985			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662408				2022-12-25	WOS:000074565900031
J	Geula, C; Wu, CK; Saroff, D; Lorenzo, A; Yuan, ML; Yankner, BA				Geula, C; Wu, CK; Saroff, D; Lorenzo, A; Yuan, ML; Yankner, BA			Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity	NATURE MEDICINE			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; TRANSGENIC MICE; CEREBRAL-CORTEX; SENILE PLAQUES; PEPTIDE; INVITRO; TAU; PHOSPHORYLATION; AGGREGATION	The formation of fibrillar deposits of amyloid beta protein (A beta) in the brain is a pathological hallmark of Alzheimer's disease(1.2) (AD). A central question is whether A beta plays a direct role in the neurodegenerative process in AD (refs. 3,4). The involvement of A beta in the neurodegenerative process is suggested by the neurotoxicity of the fibrillar form of A beta in vitro(5-11). However, mice transgenic for the A beta precursor protein that develop amyloid deposits in the brain do not show the degree of neuronal loss or tau phosphorylation found in AD (refs. 12-16). Here we show that microinjection of plaque-equivalent concentrations of fibrillar, but not soluble, A beta in the aged rhesus monkey cerebral cortex results in profound neuronal loss, tau phosphorylation and microglial proliferation. Fibrillar A beta at plaque-equivalent concentrations is not toxic in the young adult rhesus brain. A beta toxicity in vivo is also highly species-specific; toxicity is greater in aged rhesus monkeys than in aged marmoset monkeys, and is not significant in aged rats. These results suggest that AB neurotoxicity in vivo is a pathological response of the aging brain, which is most pronounced in higher order primates. Thus, longevity may contribute to the unique susceptibility of humans to Alzheimer's disease by rendering the brain vulnerable to A beta neurotoxicity.	Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Sect Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Geula, C (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA.	cgeula@west.bidmc.harvard.edu			NIA NIH HHS [AG10282] Funding Source: Medline; NINDS NIH HHS [NS30352] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG010282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BONS N, 1991, NEUROBIOL AGING, V13, P99; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUSCIGLIO J, 1992, NEUROBIOL AGING, V13, P609, DOI 10.1016/0197-4580(92)90065-6; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; Frey P, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P447; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Giulian D, 1996, J NEUROSCI, V16, P6021; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Irizarry MC, 1997, J NEUROSCI, V17, P7053; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MANDELKOW EM, 1993, ANN NY ACAD SCI, V695, P209, DOI 10.1111/j.1749-6632.1993.tb23054.x; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PODLISNY MB, 1993, AM J PATHOL, V142, P17; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; STRUBLE RG, 1985, BRAIN RES, V361, P267, DOI 10.1016/0006-8993(85)91298-3; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; WALKER LC, 1990, ACTA NEUROPATHOL, V80, P381, DOI 10.1007/BF00307691; Weldon DT, 1998, J NEUROSCI, V18, P2161; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	36	472	496	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					827	831		10.1038/nm0798-827	http://dx.doi.org/10.1038/nm0798-827			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662375				2022-12-25	WOS:000074543900038
J	Baghdiguian, S; Martin, M; Richard, I; Pons, F; Astier, C; Bourg, N; Hay, RT; Chemaly, R; Halaby, G; Loiselet, J; Anderson, LVB; de Munain, AL; Fardeau, M; Mangeat, P; Beckmann, JS; Lefranc, G				Baghdiguian, S; Martin, M; Richard, I; Pons, F; Astier, C; Bourg, N; Hay, RT; Chemaly, R; Halaby, G; Loiselet, J; Anderson, LVB; de Munain, AL; Fardeau, M; Mangeat, P; Beckmann, JS; Lefranc, G			Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the I kappa B alpha/NF-kappa B pathway in limb-girdle muscular dystrophy type 2A	NATURE MEDICINE			English	Article							MUSCLE-SPECIFIC CALPAIN; NUCLEAR-LOCALIZATION; DNA-FRAGMENTATION; EXPRESSION; PROTEIN; ACTIVATION; BCL-2; DOMAIN; VITRO; GENE		Univ Montpellier 2, CNRS, UMR 5539, Lab Dynam Mol Interact Membranaires, F-34095 Montpellier 5, France; Univ Montpellier 2, Lab Motilite Cellulaire, EPHE, F-34095 Montpellier, France; CNRS, URA 1992, F-91002 Evry, France; Fac Pharm Montpellier, INSERM, U300, F-34060 Montpellier 1, France; Univ St Andrews, Sch Biol & Med Sci, St Andrews KY16 9AL, Fife, Scotland; St Josephs Univ, Hotel Dieu, Beyrouth, Lebanon; St Josephs Univ, Fac Med, Beyrouth, Lebanon; Univ Newcastle Upon Tyne, Sch Med, Dept Neurobiol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Hosp Ntra SRA, Dept Neurol, San Sebastian 20080, Spain; INSERM, CNRS, U153, UA614, F-75005 Paris, France; CNRS, UPR 1142, Inst Human Genet, Immunogenet Mol Lab, F-34095 Montpellier 5, France; Univ Montpellier 2, F-34095 Montpellier 5, France; Genethon, F-91002 Evry, France; URA CNRS 1992, F-91002 Evry, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of St Andrews; Saint Joseph University Beirut; Saint Joseph University Beirut; Newcastle University - UK; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)	Lefranc, G (corresponding author), Univ Montpellier 2, CNRS, UMR 5539, Lab Dynam Mol Interact Membranaires, Case 107,Pl Eugene Bataillon, F-34095 Montpellier 5, France.		DE MUNAIN, ADOLFO LOPEZ/AAB-1824-2020; Beckmann, Jacques S/A-9772-2008; Hay, Ronald T/F-9338-2011; Richard, isabelle/J-8298-2013	Beckmann, Jacques S/0000-0002-9741-1900; Hay, Ronald T/0000-0001-7113-9024; MARTIN, Marianne/0000-0001-8932-3129; Baghdiguian, Stephen/0000-0002-2992-9708; /0000-0002-9509-4032				Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; Anderson LVB, 1998, AM J PATHOL, V153, P1169, DOI 10.1016/S0002-9440(10)65661-1; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Beckmann J, 1998, NEUROMUSCULAR DISORD, P123; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; EDOM F, 1994, DEV BIOL, V164, P219, DOI 10.1006/dbio.1994.1193; Fardeau M, 1996, BRAIN, V119, P295, DOI 10.1093/brain/119.1.295; Fougerousse F, 1998, GENOMICS, V48, P145, DOI 10.1006/geno.1997.5160; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Marini J F, 1991, Neuromuscul Disord, V1, P397, DOI 10.1016/0960-8966(91)90003-B; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; PONS F, 1993, NEUROMUSCULAR DISORD, V3, P507, DOI 10.1016/0960-8966(93)90106-T; Richard I, 1997, AM J HUM GENET, V60, P1128; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sandri M, 1998, LAB INVEST, V78, P1005; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; Stehlik C, 1998, BIOCHEM BIOPH RES CO, V243, P827, DOI 10.1006/bbrc.1998.8185; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tews DS, 1997, NEUROPATH APPL NEURO, V23, P331, DOI 10.1046/j.1365-2990.1997.5998059.x; Tews DS, 1996, NEUROMUSCULAR DISORD, V6, P265, DOI 10.1016/0960-8966(96)00018-1; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHILIANG C, 1997, P NATL ACAD SCI USA, V94, P10057	39	234	245	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					503	511		10.1038/8385	http://dx.doi.org/10.1038/8385			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229226				2022-12-25	WOS:000081497400030
J	John, DCA; Watson, R; Kind, AJ; Scott, AR; Kadler, KE; Bulleid, NJ				John, DCA; Watson, R; Kind, AJ; Scott, AR; Kadler, KE; Bulleid, NJ			Expression of an engineered form of recombinant procollagen in mouse milk	NATURE BIOTECHNOLOGY			English	Article						recombinant procollagen; transgenic animals; protein engineering	HUMAN PROLYL 4-HYDROXYLASE; TRIPLE-HELIX; REQUIRES COEXPRESSION; III PROCOLLAGEN; TRANSGENIC MICE; COLLAGEN; PROTEIN; SUBUNIT; SYSTEM; ASSOCIATION	We have examined the suitability of the mouse mammary gland for expression of novel recombinant procollagens that can be used for biomedical applications. We generated transgenic mouse lines containing cDNA constructs encoding recombinant procollagen, along with the alpha and beta subunits of prolyl 4-hydroxylase, an enzyme that modifies the collagen into a form that is stable at body temperature, The lines expressed relatively high levels (50-200 mu g/ml) of recombinant procollagen in milk, As engineered, the recombinant procollagen was shortened and consisted of a pro alpha 2(I) chain capable of forming a triple-helical homotrimer not normally found in nature, Analysis of the product demonstrated that (1) the pro alpha chains formed disulphide-linked trimers, (2) the trimers contained a thermostable triple-helical domain, (3) the N-propeptides were aligned correctly, and (4) the expressed procollagen was not proteolytically processed to collagen in milk.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; PPL Therapeut Scotland Ltd, Roslin EH25 9PP, Midlothian, Scotland	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.	neil.bulleid@man.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Bulleid, Neil/0000-0002-9839-5279	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold WV, 1997, MATRIX BIOL, V16, P105, DOI 10.1016/S0945-053X(97)90039-1; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; Colman A, 1998, BIOCHEM SOC SYMP, P141; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Paleyanda RK, 1997, NAT BIOTECHNOL, V15, P971, DOI 10.1038/nbt1097-971; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Prunkard D, 1996, NAT BIOTECHNOL, V14, P867, DOI 10.1038/nbt0796-867; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Stromqvist M, 1997, TRANSGENIC RES, V6, P271, DOI 10.1023/A:1018406611380; TEERLINK T, 1989, CLIN CHIM ACTA, V183, P309, DOI 10.1016/0009-8981(89)90365-3; TOMAN D, 1996, 6 INT C MOL BIOL PAT; VanCott KE, 1996, J MOL RECOGNIT, V9, P407, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<407::AID-JMR277>3.0.CO;2-X; Vuorela A, 1997, EMBO J, V16, P6702, DOI 10.1093/emboj/16.22.6702; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yarus S, 1997, TRANSGENIC RES, V6, P51, DOI 10.1023/A:1018405116406	31	68	79	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					385	389		10.1038/7945	http://dx.doi.org/10.1038/7945			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207889				2022-12-25	WOS:000079574400029
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Retroposition of autosomal mRNA yielded testis-specific gene family on human Y chromosome	NATURE GENETICS			English	Article							DROSOPHILA-MIRANDA; X-CHROMOSOME; HUMAN GENOME; DAZ GENE; MAP; EVOLUTION; CANDIDATE; HOMOLOG; DNA	Most genes in the human NRY (non-recombining portion of the Y chromosome) can be assigned to one of two groups: X-homologous genes or testis-specific gene families with no obvious X-chromosomal homologues(1,2). The CDY genes have been localized to the human Y chromosome(1), and we report here that they are derivatives of a conventional single-copy gene, CDYL (CDY-like), located on human chromosome 13 and mouse chromosome 6. CDY genes retain CDYL exonic sequences but lack its introns. In mice, whose evolutionary linkeage diverged before the appearance of the Y-linked derivatives, the autosomal Cdyl gene produces two transcripts; one is expressed ubiquitously and the other is expressed in testes only. In humans, autosomal CDYL produces only the ubiquitous transcript; the testis-specific transcript is the province of the Y-borne CDY genes. Our data indicate that CDY genes arose during primate evolution by retroposition of a CDYL mRNA and amplification of the retroposed gene. Retroposition contributed to the gene content of the human Y chromosome, together with two other molecular evolutionary processes: persistence of a subset of genes shared wit the X chromosome(3,4) and transposition of genomic DNA harbouring intact transcription units(5).	MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Page, DC (corresponding author), MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.							Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; EICHER EM, 1989, GENETICS, V122, P181; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; GANGULY R, 1992, P NATL ACAD SCI USA, V89, P1340, DOI 10.1073/pnas.89.4.1340; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Ohno S., 1967, SEX CHROMOSOMES SEX; PILBEAM D, 1984, SCI AM, V250, P84, DOI 10.1038/scientificamerican0384-84; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; Shan ZH, 1996, HUM MOL GENET, V5, P2005, DOI 10.1093/hmg/5.12.2005; Steinemann M, 1997, GENETICS, V145, P261; STEINEMANN M, 1992, P NATL ACAD SCI USA, V89, P7591, DOI 10.1073/pnas.89.16.7591; Vogt P. H., 1997, Cytogenetics and Cell Genetics, V79, P1, DOI 10.1159/000134680; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATSON JM, 1991, P NATL ACAD SCI USA, V88, P11256, DOI 10.1073/pnas.88.24.11256; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013	25	167	176	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					429	433		10.1038/7771	http://dx.doi.org/10.1038/7771			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192397				2022-12-25	WOS:000079439700028
J	Tsujikawa, M; Kurahashi, H; Tanaka, T; Nishida, K; Shimomura, Y; Tano, Y; Nakamura, Y				Tsujikawa, M; Kurahashi, H; Tanaka, T; Nishida, K; Shimomura, Y; Tano, Y; Nakamura, Y			Identification of the gene responsible for gelatinous drop-like corneal dystrophy	NATURE GENETICS			English	Article							FAMILIAL AMYLOIDOSIS; MONOCLONAL-ANTIBODY; GELSOLIN GENE; SEQUENCE; SPECIFICITY; RS7-3G11; MUTATION; FINNISH; PIP2; DNA	Gelatinous drop-like corneal dystrophy (GDLD; OMIM 204870) is an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness(1-4), with an incidence of 1 in 300,000 in Japan(5). Our previous genetic linkage study localized the gene responsible to a 2.6-cM interval on chromosome 1p (ref. 6). Clinical manifestations, which appear in the first decade of life, include blurred vision, photophobia and foreign-body sensation. By the third decade, raised, yellowish-grey, gelatinous masses severely impair visual acuity, and lamellar keratoplasty is required for most patients'. Here we report DNA sequencing, cDNA cloning and mutational analyses of four deleterious mutations (Q118X, 632delA, Q207X and S170X) in M1S1 (formerly TROP2 and GA733-1), encoding a gastrointestinal tumour-associated antigen. The Q118X mutation was the most common alteration in the GDLD patients examined, accounting for 33 of 40 (82.5%) disease alleles in our panel of families. Protein expression anaysis revealed aggregation of the mutated, truncated protein in the perinuclear region, whereas the normal protein was distributed diffusely in the cytoplasm with a homogenous or fine granular pattern. Our successful identification of the gene that is defective in GDLD should facilitate genetic diagnosis and potentially treatment of the disease, and enhance general understanding of the mechanisms of amyloidosis.	Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med Genet,Div Clin Genet, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 565, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto 602, Japan	Osaka University; Osaka University; University of Tokyo; Kyoto Prefectural University of Medicine	Nakamura, Y (corresponding author), Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med Genet,Div Clin Genet, Suita, Osaka 565, Japan.		Tanaka, Toshihiro/J-9310-2014	Tanaka, Toshihiro/0000-0001-6201-9784; Nishida, Kohji/0000-0001-9069-3610				BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; DELACHAPELLE A, 1992, GENOMICS, V13, P898, DOI 10.1016/0888-7543(92)90182-R; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; HALTIA M, 1992, AM J MED GENET, V42, P357, DOI 10.1002/ajmg.1320420321; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MIOTTI S, 1987, INT J CANCER, V39, P297, DOI 10.1002/ijc.2910390306; MONDINO BJ, 1981, AM J OPHTHALMOL, V92, P732, DOI 10.1016/S0002-9394(14)74671-9; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; NAKAIZUMI Y, 1914, ACTA SOC OPHTHALMOL, V18, P949; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; SANTO RM, 1995, OPHTHALMOLOGY, V102, P557, DOI 10.1016/S0161-6420(95)30982-7; SMOLIN G, 1994, CORNEA, P499; STEIN R, 1993, INT J CANCER, V55, P938, DOI 10.1002/ijc.2910550611; Tsujikawa M, 1998, AM J HUM GENET, V63, P1073, DOI 10.1086/302071; WEBER FL, 1980, ARCH OPHTHALMOL-CHIC, V98, P144, DOI 10.1001/archopht.1980.01020030146017; YU FX, 1992, J BIOL CHEM, V267, P14616	20	126	137	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					420	423		10.1038/7759	http://dx.doi.org/10.1038/7759			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192395				2022-12-25	WOS:000079439700026
J	Wang, CY; Cusack, JC; Liu, R; Baldwin, AS				Wang, CY; Cusack, JC; Liu, R; Baldwin, AS			Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; TNF-ALPHA; IONIZING-RADIATION; CELL-DEATH; ANTICANCER DRUGS; NECROSIS-FACTOR; CANCER-THERAPY; GENE-TRANSFER; LUNG-CANCER; ACTIVATION	Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-oncogenic therapies such as chemotherapy and radiation effect their responses. Resistance to apoptosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these cancer therapies. The transcription factor NF-kappa B is activated by chemotherapy and by irradiation in some cancer cell lines. Furthermore, inhibition of NF-kappa B in vitro leads to enhanced apoptosis in response to a variety of different stimuli. We show here that inhibition of NF-kappa B through the adenoviral delivery of a modified form of I kappa B alpha, the inhibitor of NF-kappa B, sensitizes chemoresistant tumors to the apoptotic potential of TNF alpha and of the chemotherapeutic compound CPT-11, resulting in tumor regression. These results demonstrate that the activation of NF-kappa B in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish the inhibition of NF-kappa B as a new approach to adjuvant therapy in cancer treatment.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Dent, Dept Endodont, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cusack, JC (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Campus Box 7295, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA073756, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080, CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chmura SJ, 1997, CANCER RES, V57, P4340; Conner EM, 1997, J PHARMACOL EXP THER, V282, P1615; Cusack JC, 1996, CANCER GENE THER, V3, P245; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Eggermont AMM, 1996, J INFLAMM, V47, P104; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Held KD, 1997, APOPTOSIS, V2, P265, DOI 10.1023/A:1026485003280; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; KAWATO Y, 1991, CANCER RES, V51, P4187; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lowe SW, 1997, NAT MED, V3, P606, DOI 10.1038/nm0697-606; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Mauceri HJ, 1996, CANCER RES, V56, P4311; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MERLINO G, 1994, SEMIN CANCER BIOL, V5, P13; Oshita F, 1997, J CLIN ONCOL, V15, P304, DOI 10.1200/JCO.1997.15.1.304; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Slater AFG, 1995, BIOCHEM J, V312, P833, DOI 10.1042/bj3120833; Spriggs D. R., 1992, TUMOR NECROSIS FACTO, P383; TAKIMOTO CH, 1996, CANC CHEMOTHERAPY BI, P463; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weichselbaum Ralph R., 1997, Lancet (North American Edition), V349, P10	43	893	931	1	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					412	417		10.1038/7410	http://dx.doi.org/10.1038/7410			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202930	Green Submitted			2022-12-25	WOS:000079574300030
J	St John, MAR; Tao, WF; Fei, XL; Fukumoto, R; Carcangiu, ML; Brownstein, DG; Parlow, AF; McGrath, J; Xu, TA				St John, MAR; Tao, WF; Fei, XL; Fukumoto, R; Carcangiu, ML; Brownstein, DG; Parlow, AF; McGrath, J; Xu, TA			Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction	NATURE GENETICS			English	Article							CYCLINS; PROLIFERATION; HYPERPLASIA; ENCODES; LACKING; CANCER; KINASE; MOUSE; CELLS	The lats gene has been identified as a tumour suppressor in Drosophila melanogaster using mosaic screens(1). Mosaic flies carrying somatic cells that are mutant for lats develop large tumours in many organs(1,2). The human LATS1 homologue res cues embryonic lethality and inhibits tumour growth in lats mutant flies, demonstrating the functional conservation of this gene(3). Biochemical and genetic analyses have revealed that LATS1 functions as a negative regulator of CDC2 (ref. 3). These data suggest that mammalian LATS1 may have a role in tumorigenesis. To elucidate the function of mammalian LATS1, we have generated Lats1(-/-) mice. Lats1(-/-) animals exhibit a lack of mammary grand development, infertility and growth retardation. Accompanying these defects are hyperplastic changes in the pituitary and decreased serum hormone levels. The reproductive hormone defects of Lats1(-/-) mice are reminiscent of isolated LH-hypogonadotropic hypogonadism and corpus luteum insufficiency in humans. Furthermore, Lats1(-/-) mice develop soft-tissue sarcomas and ovarian stromal cell tumours and are highly sensitive to carcinogenic treatments. Our data demonstrate a role for Lats1 in mammalian tumorigenesis and specific endocrine dysfunction.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cell Biol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Comparat Med Sect, New Haven, CT 06536 USA; Univ Calif Los Angeles, Harbor Med Ctr, Natl Hormone & Pituitary Program, Torrance, CA 90509 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; Yale University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Xu, TA (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	Tian.Xu@yale.edu			NCI NIH HHS [R01CA69408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLEMENT PB, 1997, HISTOLOGY PATHOLOGIS, P934; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; WHEATER PR, 1987, FUNCTIONAL HISTOLOGY, P290; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; XU TA, 1995, DEVELOPMENT, V121, P1053	22	350	358	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					182	186		10.1038/5965	http://dx.doi.org/10.1038/5965			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988269				2022-12-25	WOS:000078399500019
J	Qing, K; Mah, C; Hansen, J; Zhou, SZ; Dwarki, V; Srivastava, A				Qing, K; Mah, C; Hansen, J; Zhou, SZ; Dwarki, V; Srivastava, A			Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; SURFACE HEPARAN-SULFATE; TRANSGENE EXPRESSION; HUMAN-CELLS; TRANSDUCTION; BINDING; INTEGRATION; SITE; AAV; DIFFERENTIATION	Adeno-associated virus 2 (AAV)-based vectors have gained attention as a potentially useful alternative to the more commonly used retroviral and adenoviral vectors for human gene therapy. Although AAV uses the ubiquitously expressed cell surface heparan sulfate proteoglycan (HSPG) as a receptor, the transduction efficiency of AAV vectors varies greatly in different cells and tissues in vitro and in vivo. We demonstrate here that cell surface expression of HSPG alone is insufficient for AAV infection, and that AAV also requires human fibroblast growth factor receptor 1 (FGFR1) as a co-receptor for successful viral entry into the host cell. We document that cells that do not express either HSPG or FGFR1 fail to bind AAV and, consequently, are resistant to infection by AAV. These non-permissive cells are successfully transduced by AAV vectors after stable transfections with cDNAs encoding the murine HSPG and the human FGFR1. Furthermore, AAV infection of permissive cells, known to express both FGFR1 and the epidermal growth factor receptor, is abrogated by treatment of cells with basic fibroblast growth factor, but not with epidermal growth factor. The identification of FGFR1 as a co-receptor for AAV should provide new insights not only into its role in the life cycle of AAV, but also in the optimal use of AAV vectors in human gene therapy.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Chiron Corp, Dept Virol, Emeryville, CA 94608 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Novartis	Srivastava, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058881, R01HL048342, P01HL053586] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-53586, HL-48342, HL-58881] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bartlett JS, 1998, NAT MED, V4, P635, DOI 10.1038/nm0598-635; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Berns KI, 1996, CURR TOP MICROBIOL, V218, P1; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Jackson T, 1996, J VIROL, V70, P5282, DOI 10.1128/JVI.70.8.5282-5287.1996; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kearns WG, 1996, GENE THER, V3, P748; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; Kube DM, 1997, NUCLEIC ACIDS RES, V25, P3375, DOI 10.1093/nar/25.16.3375; Laquerre S, 1998, J VIROL, V72, P6119, DOI 10.1128/JVI.72.7.6119-6130.1998; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Ledoux Dominique, 1992, Progress in Growth Factor Research, V4, P107, DOI 10.1016/0955-2235(92)90026-E; Mah C, 1998, J VIROL, V72, P9835, DOI 10.1128/JVI.72.12.9835-9843.1998; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Ponnazhagan S, 1997, GENE, V190, P203, DOI 10.1016/S0378-1119(96)00576-8; Ponnazhagan S, 1997, J VIROL, V71, P8262, DOI 10.1128/JVI.71.11.8262-8267.1997; Ponnazhagan S, 1996, J GEN VIROL, V77, P1111, DOI 10.1099/0022-1317-77-6-1111; Ponnazhagan S, 1997, HUM GENE THER, V8, P275, DOI 10.1089/hum.1997.8.3-275; Qing KY, 1997, P NATL ACAD SCI USA, V94, P10879, DOI 10.1073/pnas.94.20.10879; Qing KY, 1998, J VIROL, V72, P1593, DOI 10.1128/JVI.72.2.1593-1599.1998; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHEIH H, 1992, J CELL BIOL, V116, P1273; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Strawn LM, 1996, CANCER RES, V56, P3540; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Wang XS, 1998, J VIROL, V72, P5472, DOI 10.1128/JVI.72.7.5472-5480.1998	40	521	569	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					71	77		10.1038/4758	http://dx.doi.org/10.1038/4758			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883842				2022-12-25	WOS:000077885000032
J	Mascarenhas, D				Mascarenhas, D			Negotiating the maze of biotech "tool patents" - Circumventing existing patents may be a shortcut to getting your recombinant protein to market.	NATURE BIOTECHNOLOGY			English	Editorial Material									Celtrix Pharmaceut Inc, Santa Clara, CA 95054 USA		Mascarenhas, D (corresponding author), Celtrix Pharmaceut Inc, 3055 Patrick Henry Dr, Santa Clara, CA 95054 USA.							LAVALLIE ER, 1993, BIOTECHNOLOGY, V11, P189; Olson P, 1998, PROTEIN EXPRES PURIF, V14, P160, DOI 10.1006/prep.1998.0973; Zhang Y, 1998, PROTEIN EXPRES PURIF, V12, P159, DOI 10.1006/prep.1997.0834	3	2	2	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1371	1372		10.1038/4357	http://dx.doi.org/10.1038/4357			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853622				2022-12-25	WOS:000077232600033
J	Spirio, LN; Samowitz, W; Robertson, J; Robertson, M; Burt, RW; Leppert, M; White, R				Spirio, LN; Samowitz, W; Robertson, J; Robertson, M; Burt, RW; Leppert, M; White, R			Alleles of APC modulate the frequency and classes of mutations that read to colon polyps	NATURE GENETICS			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; GENE; IDENTIFICATION; CHROMOSOME-5Q21; TUMORS; REGION; LOCUS; FAP	Most inherited mutant alleles of the adenomatosis polyposis coli gene (APC) cause the appearance of large numbers of colon polyps(1-4), the familial polyposis syndrome. (These mutant alleles are designated APC(p) alleles.) A subset of APC mutations, the attenuated or APC(AP) alleles, predispose to only a few colon polyps(5). This leads to the hypothesis that if mutation of the inherited normal allele is rate limiting in polyp development, the increased number of polyps associated with the APC(p) allele indicates that the frequency of mutations that can lead to polyp formation is higher among APC(p) carriers than among APC(AP) carriers. We have previously suggested that the APC protein might modulate the frequency of mutations, such as loss of heterozygosity(6) (LOH), necessary for colon polyp formation(5). We thus reasoned that tumours from patients who carry an APC(AP) allele might show a reduced frequency of LOH compared with tumours from patients who carry an APC(p) allele. Loss of AAPC mutant alleles is designated as LOHAP. Screening of tumours from APC(AP) carriers revealed a reduction of LOH compared with that of an unselected group of polyposis patients(7). In fact, no loss of the inherited APC(N) allele was observed, although sequencing showed that the inherited APC(N) allele had frequently undergone point mutations and small deletions in the tumours. A low frequency loss of the inherited APC(AP) allele was seen. These findings support the suggestion that the APC(AP) allele has residual gene activity and that this activity modulates the spectrum and frequency of mutations that lead to adenoma formation.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	White, R (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	ray.white@hci.utah.edu						ADAMSON D, 1995, AM J HUM GENET, V57, P619; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SAMOWITZ WS, 1995, GASTROENTEROLOGY, V109, P1765, DOI 10.1016/0016-5085(95)90742-4; SAMOWITZ WS, 1995, CANCER RES, V55, P3732; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; Spirio LN, 1996, CANCER RES, V56, P955; VANDERLUIJT RB, 1995, HUM GENET, V96, P705, DOI 10.1007/BF00210303; VARESCO L, 1994, HUM GENET, V93, P281, DOI 10.1007/BF00212023; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	19	114	115	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					385	388		10.1038/3865	http://dx.doi.org/10.1038/3865			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843214				2022-12-25	WOS:000077199600029
J	Bartoli, F; Nuzzo, M; Urbanelli, L; Bellintani, F; Prezzi, C; Cortese, R; Monaci, P				Bartoli, F; Nuzzo, M; Urbanelli, L; Bellintani, F; Prezzi, C; Cortese, R; Monaci, P			DNA-based selection and screening of peptide ligands	NATURE BIOTECHNOLOGY			English	Article						phage display; HCV; diagnostics; PCR	HEPATITIS-C VIRUS; PHAGE DISPLAY; FUSION PROTEINS; LIBRARIES; SERA; HYBRIDIZATION; PURIFICATION; ANTIBODIES; EPITOPES; PCR	Phage display selection strategies rely on the physical link between the displayed heterologous protein ligand and the DNA encoding it. Thus, genes expressing a ligand with a specific binding affinity can be selected rapidly. To improve the specificity and sensitivity of this technology for potential use in identifying ligands to a specific antibody present in a complex mixture, we incorporated a DNA selection step along with the phage display technology. Ligands for hepatitis C virus (HCV) antibodies present in serum were identified by panning a phage-displayed random peptide library against pools of serum HCV antibodies. An additional DNA hybridization screening step using single-stranded DNA isolated from one of the pools increased the specificity and sensitivity, resulting in the selection of an HCV antibody ligand with diagnostic potential.	Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy; IRCCSS, Kenton, I-00173 Rome, Italy	Merck & Company	Monaci, P (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30-600, I-00040 Rome, Italy.	monaci@irbm.it	Urbanelli, Lorena/G-4936-2010	Urbanelli, Lorena/0000-0003-0621-8476				ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; Bartoli F, 1996, BIOTECHNIQUES, V20, P554; Birch DE, 1996, NATURE, V381, P445, DOI 10.1038/381445a0; DENTE L, 1994, GENE, V148, P7, DOI 10.1016/0378-1119(94)90227-5; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FOLGORI A, 1994, EMBO J, V13, P2236, DOI 10.1002/j.1460-2075.1994.tb06501.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; KHUDYAKOV YE, 1995, VIROLOGY, V206, P666, DOI 10.1016/S0042-6822(95)80086-7; LIVAK KJ, 1995, PCR METH APPL, V4, P357; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Mennuni C, 1997, J MOL BIOL, V268, P599, DOI 10.1006/jmbi.1997.0946; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Prezzi C, 1996, J IMMUNOL, V156, P4504; SAMBROO J, 1989, MOL CLONING LAB MANU; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA E, 1993, J MED VIROL, V39, P318, DOI 10.1002/jmv.1890390411; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303	21	22	28	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1068	1073		10.1038/3525	http://dx.doi.org/10.1038/3525			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831038				2022-12-25	WOS:000076870100031
J	Lauro, D; Kido, Y; Castle, AL; Zarnowski, MJ; Hayashi, H; Ebina, Y; Hayashi, H; Accili, D				Lauro, D; Kido, Y; Castle, AL; Zarnowski, MJ; Hayashi, H; Ebina, Y; Hayashi, H; Accili, D			Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue	NATURE GENETICS			English	Article							TRANSGENIC MICE; DIABETES-MELLITUS; BETA-CELL; RECEPTOR; RESISTANCE; NIDDM; GENE; EXPRESSION	Type 2 diabetes is a complex metabolic disorder characterized by peripheral insulin resistance and impaired beta cell function(1,2) Insulin resistance is inherited as a non-mendelian trait(3). In genetically predisposed individuals, resistance of skeletal muscle and adipose tissue to insulin action precedes the onset of clinical diabetes, and is thought to contribute to hyperglycaemia by leading to impaired beta cell function and increased hepatic glucose production(4,5). It is not clear whether beta cell and liver defects are also genetically determined(2). To test the hypothesis that insulin resistance in muscle and fat is sufficient to cause type 2 diabetes in the absence of intrinsic beta cell and liver abnormality, we generated transgenic mice that were insulin-resistant in skeletal muscle and adipose tissue. These mice developed all the prodromal features of type 2 diabetes hut, despite the compounded effect of peripheral insulin resistance and a mild impairment of beta cell function, failed to become diabetic. These findings indicate the need for a critical re-examination of the primary site(s) of insulin resistance in diabetes.	NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; Univ Tokushima, Inst Enzyme Res, Tokushima 770, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tokushima University	Accili, D (corresponding author), NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA.		Lauro, Davide/K-4683-2018	Hayashi, Hideki/0000-0003-4585-6542; Lauro, Davide/0000-0002-8597-4415				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bogardus Clifton, 1996, P459; BOSCHERO AC, 1995, AM J PHYSIOL-ENDOC M, V268, pE336, DOI 10.1152/ajpendo.1995.268.2.E336; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHANG PY, 1994, J BIOL CHEM, V269, P16034; Cinti S, 1998, DIABETOLOGIA, V41, P171, DOI 10.1007/s001250050886; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; Kahn CR, 1996, ANNU REV MED, V47, P509; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; NISHIYAMA T, 1994, GENE, V141, P187, DOI 10.1016/0378-1119(94)90569-X; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOLMAN EL, 1973, J BIOL CHEM, V248, P4552; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wang LH, 1997, BIOCHEM BIOPH RES CO, V240, P446, DOI 10.1006/bbrc.1997.7677; WEBER TM, 1988, INSULIN RECEPTOR; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	23	104	113	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1998	20	3					294	298		10.1038/3112	http://dx.doi.org/10.1038/3112			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806552				2022-12-25	WOS:000076698100027
J	Naito, T; Matsuura, A; Ishikawa, F				Naito, T; Matsuura, A; Ishikawa, F			Circular chromosome formation in a fission yeast mutant defective in two ATM homologues	NATURE GENETICS			English	Article							ATAXIA-TELANGIECTASIA GENE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CHECKPOINT GENE; TELOMERASE; GENOME; TEL1	Telomeres, found at chromosomal ends, are essential for stable maintenance of linear chromosomes in eukaryotes. The ATM family of genes, including budding yeast TEL1 (refs 1,2), fission yeast rad3(+) (ref. 3) and human ATM (ref. 4), have been reported to be involved in telomere length regulation(5-7), although the significance of the telomere phenotypes observed with the mutated genes remains elusive. We have cloned tel1(+), another fission yeast ATM homologue, and found that a tel1rad3 double mutant lost all telomeric DNA sequences. Thus, the ATM homologues are essential in telomere maintenance. The mutant grew poorly and formed irregular-shaped colonies, probably due to chromosome instability, however, during prolonged culture of the double mutant, cells forming normal round-shaped colonies arose at a relatively high frequency. All three chromosomes in these derivative cells were circular and lacked telomeric sequences. To our knowledge, this is the first report of eukaryotic cells whose chromosomes are all circular. Upon meiosis, these derivative cells produced few viable spores. Therefore, the exclusively circular genome lacking telomeric sequences is proficient for mitotic growth, but does not permit meiosis.	Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Ishikawa, F (corresponding author), Tokyo Inst Technol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Matsuura, Akira/J-3864-2017; Matsuura, Akira/AAO-1572-2021; Ishikawa, Fuyuki/AAU-4056-2021	Matsuura, Akira/0000-0002-2300-7227; Matsuura, Akira/0000-0002-2300-7227; Ishikawa, Fuyuki/0000-0002-5580-2305				Alfa C., 1993, EXPT FISSION YEAST; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; DINGWALL A, 1990, Methods (Orlando), V1, P160, DOI 10.1016/S1046-2023(05)80131-8; FAN JB, 1992, NUCLEIC ACIDS RES, V20, P5943, DOI 10.1093/nar/20.22.5943; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HABER JE, 1984, GENETICS, V106, P185; HIRAOKA N, 1984, PLANT CELL TISS ORG, V3, P349, DOI 10.1007/BF00043087; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; McClintock B, 1941, GENETICS, V26, P234; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MORTIMER R K, 1990, Methods (Orlando), V1, P169, DOI 10.1016/S1046-2023(05)80132-X; MURAKAMI S, 1995, MOL GEN GENET, V246, P671, DOI 10.1007/BF00290712; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; NIWA O, 1985, CURR GENET, V9, P463, DOI 10.1007/BF00434051; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUGAWARA NF, 1989, DNA SEQUENCES TELOME; THERMAN E, 1993, HUMAN CHROMOSOMES	28	202	205	2	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1998	20	2					203	206		10.1038/2517	http://dx.doi.org/10.1038/2517			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	125HL	9771717				2022-12-25	WOS:000076231300026
J	Grillot-Courvalin, C; Goussard, S; Huetz, F; Ojcius, DM; Courvalin, P				Grillot-Courvalin, C; Goussard, S; Huetz, F; Ojcius, DM; Courvalin, P			Functional gene transfer from intracellular bacteria to mammalian cells	NATURE BIOTECHNOLOGY			English	Article						DNA delivery; gene therapy; mucosal immunity	RESPIRATORY EPITHELIAL-CELLS; DNA-MEDIATED IMMUNIZATION; ESCHERICHIA-COLI K-12; LISTERIA-MONOCYTOGENES; SHIGELLA-FLEXNERI; DELIVERY VEHICLE; PLASMID TRANSFER; PROTEIN; INVASION	We provide evidence of direct transfer of functional DNA from bacteria to mammalian cells. An Escherichia coli K12 diaminopimelate auxotroph made invasive by cloning the invasin gene from Yersinia pseudotuberculosis transfers DNA after simple co-incubation, into a variety of mammalian cell lines. Transfer efficiency was enhanced in some cells by coexpression of the gene for listeriolysin from Listeria monocytogenes. Expression of the acquired genes occurs in both dividing and quiescent cells. The only requirement for bacteria to transfer genetic material into nonprofessional phagocytic cells and macrophages is the ability to invade the host cell.	Inst Pasteur, Unite Agents Antibacteriens, F-75724 Paris 15, France; Inst Pasteur, Unite Immunogenet, F-75724 Paris, France; Inst Pasteur, Unite Biol Interact Cellulaires, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Grillot-Courvalin, C (corresponding author), Inst Pasteur, Unite Agents Antibacteriens, F-75724 Paris 15, France.		Huetz, François/T-3386-2019	Huetz, Francois/0000-0001-8704-1881				BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; Burns JL, 1996, INFECT IMMUN, V64, P4054, DOI 10.1128/IAI.64.10.4054-4059.1996; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COSSART P, 1989, INFECT IMMUN, V57, P3629, DOI 10.1128/IAI.57.11.3629-3636.1989; Courvalin P, 1995, CR ACAD SCI III-VIE, V318, P1207; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Dietrich G, 1998, NAT BIOTECHNOL, V16, P181, DOI 10.1038/nbt0298-181; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HEITMANN D, 1993, BIOSYSTEMS, V29, P37, DOI 10.1016/0303-2647(93)90080-V; ISBERG RR, 1988, INFECT IMMUN, V56, P2133, DOI 10.1128/IAI.56.8.2133-2138.1988; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; Ojcius DM, 1998, J IMMUNOL, V160, P1297; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; SANSONETTI PJ, 1983, INFECT IMMUN, V39, P1392, DOI 10.1128/IAI.39.3.1392-1402.1983; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; Sizemore DR, 1997, VACCINE, V15, P804, DOI 10.1016/S0264-410X(96)00252-6; Sonnhammer ELL, 1997, CURR BIOL, V7, pR463; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; TRIEUCUOT P, 1987, FEMS MICROBIOL LETT, V48, P289, DOI 10.1111/j.1574-6968.1987.tb02558.x	28	180	208	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					862	866		10.1038/nbt0998-862	http://dx.doi.org/10.1038/nbt0998-862			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743121				2022-12-25	WOS:000075671700034
J	Schwahn, U; Lenzner, S; Dong, J; Feil, S; Hinzmann, B; van Duijnhoven, G; Kirschner, R; Hemberger, M; Bergen, AAB; Rosenberg, T; Pinckers, AJLG; Fundele, R; Rosenthal, A; Cremers, FPM; Ropers, HH; Berger, W				Schwahn, U; Lenzner, S; Dong, J; Feil, S; Hinzmann, B; van Duijnhoven, G; Kirschner, R; Hemberger, M; Bergen, AAB; Rosenberg, T; Pinckers, AJLG; Fundele, R; Rosenthal, A; Cremers, FPM; Ropers, HH; Berger, W			Positional cloning of the gene for X-linked retinitis pigmentosa 2	NATURE GENETICS			English	Article							L1 SEQUENCE; YAC CONTIG; INSERTION; IDENTIFICATION; ELEMENT; TUBULIN; CELL; DNA; PHOTORECEPTORS; POLYMORPHISM	X-linked retinitis pigmentosa (XLRP) results from mutations in at least two different loci, designated RP2 and RP3, located at Xp11.3 and Xp21.1, respectively. The RP3 gene was recently isolated by positional cloning, whereas the RP2 locus was mapped genetically to a 5-cM interval. We have screened this region for genomic rearrangements by the YAC representation hybridization (YRH) technique and detected a LINE1 (L1) insertion in one XLRP patient. The L1 retrotransposition occurred in an intron of a novel gene that consisted of five exons and encoded a polypeptide of 350 amino acids. Subsequently, nonsense, missense and frameshift mutations, as well as two small deletions, were identified in six additional patients. The predicted gene product shows homology with human cofactor C, a protein involved in the ultimate step of beta-tubulin folding. Our data provide evidence that mutations in this gene, designated RP2, are responsible for progressive retinal degeneration.	Max Planck Inst Mol Genet, Berlin, Dahlem, Germany; Gesell Genomforsch MBH, MetaGen, Berlin, Germany; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Netherlands Ophthalm Res Inst, Dept Ophthalmogenet, NL-1100 AC Amsterdam, Netherlands; Natl Eye Clin Visually Impaired, Hellerup, Denmark; Univ Nijmegen Hosp, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands	Max Planck Society; Radboud University Nijmegen; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Radboud University Nijmegen	Berger, W (corresponding author), Max Planck Inst Mol Genet, Berlin, Dahlem, Germany.		Bergen, Arthur/J-3637-2013; Cremers, Frans/A-5625-2014	Cremers, Frans/0000-0002-4954-5592; Hemberger, Myriam/0000-0003-3332-6958; Bergen, Arthur/0000-0002-6333-9576; Kirschner-Schwabe, Renate/0000-0001-6335-3274				Adam GIR, 1996, DEVELOPMENT, V122, P839; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BHATTACHARYA SS, 1984, NATURE, V309, P253, DOI 10.1038/309253a0; BOCCACCIO C, 1990, GENE, V88, P181, DOI 10.1016/0378-1119(90)90030-U; Buraczynska M, 1997, AM J HUM GENET, V61, P1287, DOI 10.1086/301646; COLEMAN MP, 1994, GENOMICS, V21, P337, DOI 10.1006/geno.1994.1274; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; ECONOMOUPACHNIS A, 1985, P NATL ACAD SCI USA, V9, P2857; Frantz SA, 1996, MAMM GENOME, V7, P865, DOI 10.1007/s003359900256; HAGEMANN T, 1994, GENOMICS, V21, P262, DOI 10.1006/geno.1994.1255; ISHIHARA A, 1997, BIOTECHNIQUES, V23, P120; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LEWIS GP, 1995, INVEST OPHTH VIS SCI, V36, P2404; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEINDL A, 1996, NAT GENET, V13, P36; MIKI Y, 1992, CANCER RES, V52, P643; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; MURESAN V, 1993, J CELL SCI, V104, P1229; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; OTT J, 1990, P NATL ACAD SCI USA, V87, P701, DOI 10.1073/pnas.87.2.701; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 1996, HUM MOL GENET, V5, P827, DOI 10.1093/hmg/5.6.827; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SALE WS, 1988, CELL MOTIL CYTOSKEL, V9, P243, DOI 10.1002/cm.970090306; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SKOWRONSKI J, 1986, COLD SPRING HARB SYM, V51, P457, DOI 10.1101/SQB.1986.051.01.055; Takahara T, 1996, HUM MOL GENET, V5, P989, DOI 10.1093/hmg/5.7.989; TEAGUE PW, 1994, AM J HUM GENET, V55, P105; Thiselton DL, 1996, GENOME RES, V6, P1093, DOI 10.1101/gr.6.11.1093; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; WATANABE M, 1991, J NEUROBIOL, V22, P85, DOI 10.1002/neu.480220109; WIRTH B, 1988, Genomics, V2, P263, DOI 10.1016/0888-7543(88)90011-0; WOODFORD BJ, 1989, CELL TISSUE RES, V256, P495	36	286	301	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1998	19	4					327	332		10.1038/1214	http://dx.doi.org/10.1038/1214			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	106AM	9697692				2022-12-25	WOS:000075107600014
J	Taylor, DA; Atkins, BZ; Hungspreugs, P; Jones, TR; Reedy, MC; Hutcheson, KA; Glower, DD; Kraus, WE				Taylor, DA; Atkins, BZ; Hungspreugs, P; Jones, TR; Reedy, MC; Hutcheson, KA; Glower, DD; Kraus, WE			Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation	NATURE MEDICINE			English	Article							LONG-TERM SURVIVAL; RABBITS	The adult heart lacks reserve cardiocytes and cannot regenerate. Therefore, a large acute myocardial infarction often develops into congestive heart failure. To attempt to prevent this progression, we transplanted skeletal myoblasts into cryoinfarcted myocardium of the same rabbits tautologous transfer), monitored cardiac function in vivo for two to six weeks and examined serial sections of the hearts by light and electron microscopy. Islands of different sizes comprising elongated, striated cells that retained characteristics of both skeletal and cardiac cells were found in the cryoinfarct. In rabbits in which myoblasts were incorporated, myocardial performance was improved. The ability to regenerate functioning muscle after autologous myoblast transplantation could have a important effect on patients after acute myocardial infarction.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Taylor, DA (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 3327, Durham, NC 27710 USA.			Kraus, William E/0000-0003-1930-9684	NHLBI NIH HHS [2R01HL5798-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISCHOFF R, 1975, ANAT REC, V182, P215, DOI 10.1002/ar.1091820207; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; DRAKEHOLLAND AJ, 1993, BASIC RES CARDIOL, V88, P250; GILL W, 1970, CRYOBIOLOGY, V6, P347, DOI 10.1016/S0011-2240(70)80089-X; GILL W, 1971, BRIT J SURG, V58, P870; GLANTZ SA, 1978, CIRC RES, V42, P171, DOI 10.1161/01.RES.42.2.171; GLOWER DD, 1985, CIRCULATION, V71, P994, DOI 10.1161/01.CIR.71.5.994; Guerette B, 1997, CELL TRANSPLANT, V6, P101, DOI 10.1016/S0963-6897(96)00230-8; Jarvis JC, 1997, BAKKEN RES, V11, P269; KLUNG MG, 1996, J CLIN INVEST, V98, P216; KOH GY, 1993, AM J PHYSIOL, V264, pH1727, DOI 10.1152/ajpheart.1993.264.5.H1727; MAGID NM, 1992, AM J PHYSIOL, V263, pH226, DOI 10.1152/ajpheart.1992.263.1.H226; Marelli D, 1992, Cell Transplant, V1, P383; Robinson SW, 1996, CELL TRANSPLANT, V5, P77, DOI 10.1016/0963-6897(95)02016-0; Silvestry SC, 1996, J MOL CELL CARDIOL, V28, P815, DOI 10.1006/jmcc.1996.0076; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; STOCKDALE FE, 1990, ADV EXP MED BIOL, V280, P7; Taylor DA, 1997, P ASSOC AM PHYSICIAN, V109, P245; WATT DJ, 1994, NATURE, V368, P406, DOI 10.1038/368406a0	19	852	969	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					929	933		10.1038/nm0898-929	http://dx.doi.org/10.1038/nm0898-929			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701245				2022-12-25	WOS:000075107400036
J	Mein, CA; Esposito, L; Dunn, MG; Johnson, GCL; Timms, AE; Goy, JV; Smith, AN; Sebag-Montefiore, L; Merriman, ME; Wilson, AJ; Pritchard, LE; Cucca, F; Barnett, AH; Bain, SC; Todd, JA				Mein, CA; Esposito, L; Dunn, MG; Johnson, GCL; Timms, AE; Goy, JV; Smith, AN; Sebag-Montefiore, L; Merriman, ME; Wilson, AJ; Pritchard, LE; Cucca, F; Barnett, AH; Bain, SC; Todd, JA			A search for type 1 diabetes susceptibility genes in families from the United Kingdom	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; MELLITUS IDDM; 15Q26 IDDM3; INSULIN; LOCUS; REGION	Genetic analysis of a mouse model of major histocompatability complex (MHC)-associated autoimmune type 1 (insulin-dependent) diabetes mellitus (IDDM) has shown that the disease is caused by a combination of a major effect at the MHC and at least ten other susceptibility loci elsewhere in the genome(1,2) A genome-wide scan of 93 affected sibpair families (ASP) from the UK (UK93) indicated a similar genetic basis for human type 1 diabetes, with the major genetic component at the MHC locus (IDDM1) explaining 34% of the familial clustering of the disease (lambda(s) = 2.5; refs 3,4). In the present report, we have analysed a further 263 multiplex families from the same population (UK263) to provide a total UK data set of 356 ASP families (UK356). Only four regions of the genome outside IDDM1/MHC, which was stilt the only major locus detected, were not excluded at lambda(s) = 3 and lod=-2, of which two showed evidence of linkage: chromosome 10p13-p11 (maximum lod score (MLS) = 4.7, P = 3 x 10(-6), lambda(s) = 1.56) and chromosome 16q22-16q24 (MLS = 3.4, P = 6.5 x 10(-5), lambda(s) = 1.6) These and other novel regions, including chromosome 14q12-q21 and chromosome 19p13-19q13, could potentially harbour disease loci but confirmation and fine mapping cannot be pursued effectively using conventional linkage analysis. instead, more powerful linkage disequilibrium-based(5-7) and haplotype mapping approaches(8) must be used; such data is already emerging for several type 1 diabetes loci detected initially by linkage(6,8-13).	Univ Oxford, Nuffield Dept Surg, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Birmingham Heartlands Hosp, Dept Med, Birmingham B9 5SS, W Midlands, England	University of Oxford; Wellcome Centre for Human Genetics; Heart of England NHS Foundation Trust; University of Birmingham	Todd, JA (corresponding author), Univ Oxford, Nuffield Dept Surg, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; Wilson, Amanda/0000-0001-5681-9611; Mein, Charles/0000-0003-0811-9658; CUCCA, Francesco/0000-0002-7414-1995	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; COPEMAN JB, 1995, NAT GENET, V9, P80, DOI 10.1038/ng0195-80; COX NJ, 1988, AM J HUM GENET, V42, P167; CUCCA F, IN PRESS DIABETES; CUCCA F, IN PRESS NATURE GENE; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Delepine M, 1997, AM J HUM GENET, V60, P174; Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143; FIELD LL, 1994, NAT GENET, V8, P189, DOI 10.1038/ng1094-189; Field LL, 1996, GENOMICS, V33, P1, DOI 10.1006/geno.1996.0153; Hauser ER, 1996, GENET EPIDEMIOL, V13, P117, DOI 10.1002/(SICI)1098-2272(1996)13:2<117::AID-GEPI1>3.0.CO;2-5; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; Kristiansen OP, 1998, DIABETES, V47, P281, DOI 10.2337/diab.47.2.281; Luo DF, 1996, HUM MOL GENET, V5, P693, DOI 10.1093/hmg/5.5.693; LYONS PA, INPRESS GENETICS AUT; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; Merriman TR, 1998, HUM MOL GENET, V7, P517, DOI 10.1093/hmg/7.3.517; Morahan G, 1996, SCIENCE, V272, P1811, DOI 10.1126/science.272.5269.1811; NAKAGAWA Y, IN PRESS AM J HUM GE; Podolin PL, 1998, MAMM GENOME, V9, P283, DOI 10.1007/s003359900749; PRITCHARD LE, 1997, THESIS U OXFORD; Reed P, 1997, HUM MOL GENET, V6, P1011, DOI 10.1093/hmg/6.7.1011; RISCH N, 1993, AM J HUM GENET, V53, P702; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; THOMSON G, 1988, AM J HUM GENET, V43, P799; VANDEWALLE CL, 1993, DIABETOLOGIA, V36, P1155, DOI 10.1007/BF00401060; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Zamani M, 1996, HUM GENET, V98, P491, DOI 10.1007/s004390050245	30	291	299	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1998	19	3					297	300		10.1038/991	http://dx.doi.org/10.1038/991			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662409				2022-12-25	WOS:000074565900032
J	Nickerson, DA; Taylor, SL; Weiss, KM; Clark, AG; Hutchinson, RG; Stengard, J; Salomaa, V; Vartiainen, E; Boerwinkle, E; Sing, CF				Nickerson, DA; Taylor, SL; Weiss, KM; Clark, AG; Hutchinson, RG; Stengard, J; Salomaa, V; Vartiainen, E; Boerwinkle, E; Sing, CF			DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene	NATURE GENETICS			English	Article							HUMAN GENOME; LPL GENE; POLYMORPHISMS; ATHEROSCLEROSIS; MUTATION; FAMILY	Lipoprotein lipase plays a central role in lipid metabolism and the gene that encodes this enzyme (LPL) is a candidate susceptibility gene for cardiovascular disease. Here we report the complete sequence of a fraction of the LPL gene for 71 individuals (142 chromosomes) from three populations that may have different histories affecting the organization of the sequence variation. Eighty-eight sites in this 9.7 kb vary among individuals from these three populations. Of these, 79 were single nucleotide substitutions and 9 sites involved insertion-deletion variations. The average nucleotide diversity across the region was 0.2% (or on average 1 variable site every 500 bp). At 34 of these sites, the variation was found in only one of the populations, reflecting the differing population and mutational histories. If LPL is a typical human gene, the pattern of sequence variation that exists in introns as well as exons, even for the small number of samples considered here, will present challenges for the identification of sites, or combinations of sites, that influence Variation in risk of disease in the population at large.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98125 USA; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Helsinki, Finland; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77225 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Mississippi; University of Mississippi Medical Center; Finland National Institute for Health & Welfare; University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Nickerson, DA (corresponding author), Univ Washington, Dept Mol Biotechnol, Box 357730, Seattle, WA 98125 USA.	debnick@u.washington.edu		Sing, Charles/0000-0001-5872-7956; Clark, Andrew/0000-0001-7159-8511	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058238, R01HL058239, R01HL058240] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58240, HL58238, HL58239] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CAVALLISFORZA LL, 1990, AM J HUM GENET, V46, P649; CLARK AG, UNPUB AM J HUM GENET; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; Crandall Keith A., 1996, P137; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; EDWARDS A, 1991, AM J HUM GENET, V49, P746; Eng C, 1997, NAT BIOTECHNOL, V15, P422, DOI 10.1038/nbt0597-422; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FISHER KL, 1987, NUCLEIC ACIDS RES, V15, P7657, DOI 10.1093/nar/15.18.7657; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Harding RM, 1997, AM J HUM GENET, V60, P772; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HEINZMANN C, 1987, NUCLEIC ACIDS RES, V15, P6763, DOI 10.1093/nar/15.16.6763; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KRYGLYAK L, 1997, NAT GENET, V17, P21; Kwok PY, 1996, GENOMICS, V31, P123, DOI 10.1006/geno.1996.0019; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LI WH, 1991, GENETICS, V129, P513; LI WH, 1997, MOL EVOLUTION, P178; Murthy V, 1996, PHARMACOL THERAPEUT, V70, P101, DOI 10.1016/0163-7258(96)00005-8; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; OLSON MV, 1995, SCIENCE, V270, P394, DOI 10.1126/science.270.5235.394; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Roberts RJ, 1997, NUCLEIC ACIDS RES, V25, P248, DOI 10.1093/nar/25.1.248; Rowen L, 1997, SCIENCE, V278, P605, DOI 10.1126/science.278.5338.605; SING CF, 1996, VARIATION HUMAN GENO, P211; TEMPLETON AR, 1996, VARIATION HUMAN GENO, P259; VOGEL F, 1977, J MOL EVOL, V9, P159, DOI 10.1007/BF01732746; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISS KM, 1997, GENETIC VARIATION HU; WIEBUSCH H, 1992, CIRCULATION, V86, P1; Zhang HF, 1996, BBA-LIPID LIPID MET, V1302, P159, DOI 10.1016/0005-2760(96)00059-8	41	404	429	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1998	19	3					233	240		10.1038/907	http://dx.doi.org/10.1038/907			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662394				2022-12-25	WOS:000074565900017
J	Hoyle, R				Hoyle, R			Taking the hex off transgenic plant exports	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	1	1	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1996	14	13					1628	1628		10.1038/nbt1296-1628	http://dx.doi.org/10.1038/nbt1296-1628			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VX107	9634830	Bronze			2022-12-25	WOS:A1996VX10700003
J	French, RR; Chan, HTC; Tutt, AL; Glennie, MJ				French, RR; Chan, HTC; Tutt, AL; Glennie, MJ			CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help	NATURE MEDICINE			English	Article							HUMAN B-CELLS; DENDRITIC CELLS; IN-VIVO; MEDIATED-IMMUNITY; LEISHMANIA-MAJOR; APOPTOTIC CELLS; TUMOR-ANTIGENS; LIGAND; LYMPHOCYTES; ACTIVATION	CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8(+) T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40(+) lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40(-) lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8(+) T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.	Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Glennie, MJ (corresponding author), Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England.	M.J.Glennie@soton.ac.uk		chan, claude/0000-0003-0530-9480				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Cardoso AA, 1997, BLOOD, V90, P549, DOI 10.1182/blood.V90.2.549.549_549_561; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; Dilloo D, 1997, BLOOD, V90, P1927, DOI 10.1182/blood.V90.5.1927; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GEORGE AJT, 1991, HYBRIDOMA, V10, P219, DOI 10.1089/hyb.1991.10.219; GEORGE AJT, 1987, J IMMUNOL, V138, P628; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Honeychurch J, 1997, CANCER IMMUNOL IMMUN, V45, P171, DOI 10.1007/s002620050425; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; Kato K, 1998, J CLIN INVEST, V101, P1133, DOI 10.1172/JCI1472; Khanna R, 1997, J IMMUNOL, V159, P5782; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; Pistoia V, 1997, IMMUNOL TODAY, V18, P343, DOI 10.1016/S0167-5699(97)01080-3; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Roskrow M, 1997, BLOOD, V90, P2601; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Schultze JL, 1997, BLOOD, V89, P3806, DOI 10.1182/blood.V89.10.3806.3806_3806_3816; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Stout RD, 1996, J IMMUNOL, V156, P8; Tutt AL, 1998, J IMMUNOL, V161, P3176; TUTT AL, 1995, J IMMUNOL, V155, P2960; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Wiley JA, 1997, J IMMUNOL, V158, P2932	41	344	383	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					548	553		10.1038/8426	http://dx.doi.org/10.1038/8426			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229232				2022-12-25	WOS:000081497400036
J	Torrents, D; Mykkanen, J; Pineda, M; Feliubadalo, L; Estevez, R; de Cid, R; Sanjurjo, P; Zorzano, A; Nunes, V; Huoponen, K; Reinikainen, A; Simell, O; Savontaus, ML; Aula, P; Palacin, M				Torrents, D; Mykkanen, J; Pineda, M; Feliubadalo, L; Estevez, R; de Cid, R; Sanjurjo, P; Zorzano, A; Nunes, V; Huoponen, K; Reinikainen, A; Simell, O; Savontaus, ML; Aula, P; Palacin, M			Identification of SLC7A7, encoding y(+)LAT-1, as the lysinuric protein intolerance gene	NATURE GENETICS			English	Article							HUMAN ERYTHROCYTES; TRANSPORT; CYSTINURIA; MEMBRANE	Lysinuric protein intolerance (LPI; OMIM 222700) is a rare, recessive disorder with a worldwide distribution, but with a high prevalence in the Finnish population(1); symptoms include failure to thrive, growth retardation, muscle hypotonia and hepatosplenomegaly. A defect in the plasma membrane transport of dibasic amino acids has been demonstrated at the basolateral membrane of epithelial cells in small intestine and in renal tubules(2-4) and in plasma membrane of cultured skin fibroblasts(5) from LPI patients. The gene causing LPI has been assigned by linkage analysis to 14q11-13. Here we report mutations in SLC7A7 cDNA (encoding y(+)L amino acid transporter-1, y(+)LAT-1), which expresses dibasic amino-acid transport activity and is located in the LPI region, in 31 Finnish LPI patients and 1 Spanish patient. The Finnish patients are homozygous for a founder missense mutation leading to a premature stop codon. The Spanish patient is a compound heterozygote with a missense mutation in one allele and a frameshift mutation in the other. The frameshift mutation generates a premature stop codon, eliminating the last one-third of the protein. The missense mutation abolishes y(+)LAT-1 amino-acid transport activity when co-expressed with the heavy chain of the cell-surface antigen 4F2 (4F2hc, also known as CD98) in Xenopus laevis oocytes. Our data establish that mutations in SLC7A7 cause LPI.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Turku Univ, Dept Med Genet, Turku 20520, Finland; Hosp Llobregat, Hosp Duran & Reynolds, IRO, Dept Mol Genet, Barcelona 08907, Spain; Univ Basque Country, Hosp Cruces, Dept Pediat, Baracaldo, Bizcaia, Spain; Univ Turku, Dept Biol, SF-20500 Turku, Finland; Turku Univ, Cent Hosp, Dept Pediat, Turku 20520, Finland; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki 00014, Finland	University of Barcelona; University of Turku; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; Hospital Universitario Cruces; University of Basque Country; University of Turku; University of Turku; University of Helsinki	Palacin, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	mpalacin@porthos.bio.ub.es	Nunes, Virginia/AAD-1014-2019; Feliubadalo, Lidia/G-4577-2016; Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Nunes, Virginia/D-4356-2014; Riu, Marta Pineda/I-1497-2015; de Cid, Rafael/I-4220-2015; Mykkänen, Juha/Q-1663-2015; Sanjurjo, Pablo/E-1647-2012; de cid, rafael/Q-2952-2016; Estevez, Raul/D-8610-2015; Torrents, David/G-5785-2015	Nunes, Virginia/0000-0002-5747-9310; Feliubadalo, Lidia/0000-0002-1736-0112; Nunes, Virginia/0000-0002-5747-9310; Riu, Marta Pineda/0000-0002-5403-5845; Mykkänen, Juha/0000-0001-9898-2660; de cid, rafael/0000-0003-3579-6777; Estevez, Raul/0000-0003-1579-650X; Palacin, Manuel/0000-0002-8670-293X; Torrents, David/0000-0002-6086-9037				ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CHEESEMAN CI, 1983, J PHYSIOL-LONDON, V338, P87, DOI 10.1113/jphysiol.1983.sp014662; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DESJEUX JF, 1980, J CLIN INVEST, V65, P1382, DOI 10.1172/JCI109802; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Deves R., 1998, PHYSIOL REV, V78, P478; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; GOTTESDIENER KM, 1988, MOL CELL BIOL, V8, P3809, DOI 10.1128/MCB.8.9.3809; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Lauteala T, 1998, EUR J HUM GENET, V6, P612, DOI 10.1038/sj.ejhg.5200236; Lauteala T, 1997, AM J HUM GENET, V60, P1479, DOI 10.1086/515457; Lauteala T, 1997, HUM GENET, V100, P80, DOI 10.1007/s004390050469; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peltonen L, 1995, BIOL CHEM H-S, V376, P697; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; RAJANTIE J, 1980, LANCET, V1, P1219; RAJANTIE J, 1981, J CLIN INVEST, V67, P1078, DOI 10.1172/JCI110120; SANJURJO P, 1995, AN ESP PEDIATR, V42, P219; Simell O, 1995, METAB MOL BASES INHE, V1, P3603; SMITH DW, 1987, P NATL ACAD SCI USA, V84, P7711, DOI 10.1073/pnas.84.21.7711; Sperandeo MP, 1998, GENOMICS, V49, P230, DOI 10.1006/geno.1998.5252; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437	27	214	221	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					293	296		10.1038/6809	http://dx.doi.org/10.1038/6809			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080182				2022-12-25	WOS:000078977900023
J	Guo, Q; Fu, WM; Sopher, BL; Miller, MW; Ware, CB; Martin, GM; Mattson, MP				Guo, Q; Fu, WM; Sopher, BL; Miller, MW; Ware, CB; Martin, GM; Mattson, MP			Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; CORTICAL-NEURONS; BETA-PEPTIDE; GLUTAMATE; CALCIUM; NEUROTOXICITY; HOMEOSTASIS; APOPTOSIS; MUTATION	Excitotoxicity, a form of neuronal injury in which excessive activation of glutamate receptors results in cellular calcium overload(1,2) has been implicated in the pathogenesis of Alzheimer disease(3,4) (AD), although direct evidence is lacking. Mutations in the presenilin-1 (PS1) gene on chromosome 14 are causally linked to many cases of early-onset inherited AD (refs. 5,6). We generated PS1 mutant mice (PS1M146VKI) that express the PS1 M146V targeted allele at normal physiological levels. Although PS1M146VKI mice have no overt mutant phenotype, they are hypersensitive to seizure-induced synaptic degeneration and necrotic neuronal death in the hippocampus. Cultured hippocampal neurons from PS1M146VKI mice have increased vulnerability to death induced by glutamate, which is correlated with perturbed calcium homeostasis, increased oxidative stress and mitochondrial dysfunction. Agents that suppress calcium influx or release and antioxidants protect neurons against the excitotoxic action of the PS1 mutation. These findings establish a direct link between a genetic defect that causes AD and excitotoxic neuronal degeneration, and indicate new avenues for therapeutic intervention in AD patients.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	University of Kentucky; University of Kentucky; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.	mmattson@aging.coa.uky.edu	Mattson, Mark P/F-6038-2012					Ancolio K, 1997, J NEUROCHEM, V69, P2494, DOI 10.1046/j.1471-4159.1997.69062494.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Keller JN, 1998, J NEUROSCI, V18, P4439; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OLNEY JW, 1978, NATURE, V271, P557, DOI 10.1038/271557a0; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; White RJ, 1996, J NEUROSCI, V16, P5688; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	30	390	410	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					101	106		10.1038/4789	http://dx.doi.org/10.1038/4789			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883847				2022-12-25	WOS:000077885000037
J	Robertson, MP; Ellington, AD				Robertson, MP; Ellington, AD			In vitro selection of an allosteric ribozyme that transduces analytes to amplicons	NATURE BIOTECHNOLOGY			English	Article						aptazyme; allostery; diagnostic	DEPENDENT PROTEIN-KINASE; HAMMERHEAD RIBOZYME; RNA; IDENTIFICATION; SEQUENCES; DOMAIN; REGION	We have selected an allosteric ribozyme ligase from a random sequence population that is activated up to 10,000-fold by oligonucleotide effecters. The ribozyme conforms to a classic two-state model for allostery in which the equilibrium between inactive and active conformers is dramatically altered by the presence of effector ligands. In the presence of the effector the allosteric ribozyme ligase generates templates that can subsequently be amplified using conventional amplification technologies, such as RT-PCR. Thus, the allosteric ribozyme can transduce (or convert) analytes into amplicons. We demonstrate two potential diagnostic applications of the selected allosteric ribozyme ligase:'counting' short oligonucleotide effecters by RT-PCR, and counting a non-nucleic acid effector, ATP, by ligation.	Univ Texas, Dept Chem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), Univ Texas, Dept Chem, Austin, TX 78712 USA.							Araki M, 1998, NUCLEIC ACIDS RES, V26, P3379, DOI 10.1093/nar/26.14.3379; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Breaker RR, 1997, CHEM REV, V97, P371, DOI 10.1021/cr960008k; Costa M, 1997, J MOL BIOL, V267, P520, DOI 10.1006/jmbi.1996.0882; Creighton T. E., 1993, PROTEINS STRUCTURES; CUENOUD B, 1995, NATURE, V375, P611, DOI 10.1038/375611a0; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; Hager AJ, 1997, CHEM BIOL, V4, P607, DOI 10.1016/S1074-5521(97)90246-5; HERSCHLAG D, 1994, BIOCHEMISTRY-US, V33, P5291, DOI 10.1021/bi00183a036; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; Pan T, 1997, CURR OPIN CHEM BIOL, V1, P17, DOI 10.1016/S1367-5931(97)80104-4; PORTA H, 1995, BIO-TECHNOL, V13, P161, DOI 10.1038/nbt0295-161; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; Tang J, 1998, NUCLEIC ACIDS RES, V26, P4214, DOI 10.1093/nar/26.18.4214; Tang J, 1997, RNA, V3, P914; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; Tanner MA, 1997, RNA, V3, P1037; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726	22	194	223	1	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1999	17	1					62	66		10.1038/5236	http://dx.doi.org/10.1038/5236			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	156AP	9920271				2022-12-25	WOS:000077979500027
J	Zhu, ZQ; Yao, JB; Johns, T; Fu, K; De Bie, I; MacMillan, C; Cuthbert, AP; Newbold, RF; Wang, JC; Chevrette, M; Brown, GK; Brown, RM; Shoubridge, EA				Zhu, ZQ; Yao, JB; Johns, T; Fu, K; De Bie, I; MacMillan, C; Cuthbert, AP; Newbold, RF; Wang, JC; Chevrette, M; Brown, GK; Brown, RM; Shoubridge, EA			SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; FUNCTIONAL COMPLEMENTATION; MONOCHROMOSOME TRANSFER; MITOCHONDRIAL DISEASES; BIDIRECTIONAL PROMOTER; MOLECULAR ANALYSIS; MICROCELL HYBRIDS; COMMON-CAUSE; GENE	Leigh Syndrome (LS) is a severe neurological disorder characterized by bilaterally symmetrical necrotic lesions in subcortical brain regions that is commonly associated with systemic cytochrome c oxidase (COX) deficiency. COX deficiency is an autosomal recessive trait and most patients belong to a single genetic complementation group. DNA sequence analysis of the genes encoding the structural subunits of the COX complex has failed to identify a pathogenic mutation. Using microcell-mediated chromosome transfer, we mapped the gene defect in this disorder to chromosome 9q34 by complementation of the respiratory chain deficiency in patient fibroblasts. Analysis of a candidate gene (SURF1) of unknown function revealed several mutations, all of which predict a truncated protein. These data suggest a role for SURF1 in the biogenesis of the COX complex and define a new class of gene defects causing human neurodegenerative disease.	Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; Brunel Univ, Dept Biol & Biochem, Uxbridge UB8 3PH, Middx, England; McGill Univ, Dept Surg, Montreal Gen Hosp, Res Inst,Urol Div, Montreal, PQ H3A 2T5, Canada; Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England	McGill University; McGill University; Brunel University; McGill University; University of Oxford	Shoubridge, EA (corresponding author), Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.		De Bie, Isabelle/M-1793-2019					Adams PL, 1997, ANN NEUROL, V41, P268, DOI 10.1002/ana.410410219; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brown GK, 1996, J INHERIT METAB DIS, V19, P553, DOI 10.1007/BF01799116; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; Brown RM, 1996, J INHERIT METAB DIS, V19, P752, DOI 10.1007/BF01799168; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; COMPTON T, 1993, J VIROL, V67, P3644, DOI 10.1128/JVI.67.6.3644-3648.1993; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Dahl H.-H. M., 1992, Human Mutation, V1, P97, DOI 10.1002/humu.1380010203; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; GIALLONGO A, 1989, MOL CELL BIOL, V9, P224, DOI 10.1128/MCB.9.1.224; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; GLERUM DM, 1988, FEBS LETT, V236, P100, DOI 10.1016/0014-5793(88)80293-X; HAYASAKA K, 1989, J INHERIT METAB DIS, V12, P247, DOI 10.1007/BF01799214; HEISER WC, 1994, ANAL BIOCHEM, V217, P185, DOI 10.1006/abio.1994.1108; HUXLEY C, 1990, MOL CELL BIOL, V10, P605, DOI 10.1128/MCB.10.2.605; INNIS MA, 1990, PCR PROTOCOLS, P54; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KALIMO H, 1979, ANN NEUROL, V6, P200, DOI 10.1002/ana.410060304; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; Lee N, 1998, BBA-MOL BASIS DIS, V1406, P1, DOI 10.1016/S0925-4439(98)00003-9; LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216; LENNARD A, 1994, DNA CELL BIOL, V13, P1117, DOI 10.1089/dna.1994.13.1117; LENNARD AC, 1991, MOL CELL BIOL, V11, P1281, DOI 10.1128/MCB.11.3.1281; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LOMBES A, 1991, NEUROLOGY, V41, P491, DOI 10.1212/WNL.41.4.491; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MERANTE F, 1993, AM J HUM GENET, V53, P481; MORAES CT, 1991, AM J HUM GENET, V48, P492; Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107; MULERO JJ, 1993, GENETICS, V133, P509; Munaro M, 1997, HUM MOL GENET, V6, P221, DOI 10.1093/hmg/6.2.221; Newbold Robert F., 1996, P53; Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311; ROBINSON BH, 1987, J PEDIATR-US, V110, P216, DOI 10.1016/S0022-3476(87)80157-9; Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; VANCOSTER R, 1991, J NEUROL SCI, V104, P97, DOI 10.1016/0022-510X(91)90222-S; VANERVEN PMM, 1987, CLIN NEUROL NEUROSUR, V89, P217, DOI 10.1016/S0303-8467(87)80020-3; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805	56	481	491	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					337	343		10.1038/3804	http://dx.doi.org/10.1038/3804			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843204				2022-12-25	WOS:000077199600019
J	Fink, L; Seeger, W; Ermert, L; Hanze, J; Stahl, U; Grimminger, F; Kummer, W; Bohle, RM				Fink, L; Seeger, W; Ermert, L; Hanze, J; Stahl, U; Grimminger, F; Kummer, W; Bohle, RM			Real-time quantitative RT-PCR after laser-assisted cell picking	NATURE MEDICINE			English	Article							SINGLE CELLS		Univ Giessen, Dept Pathol, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med, D-35390 Giessen, Germany; Univ Giessen, Dept Pediat, D-35390 Giessen, Germany; Univ Giessen, Inst Anat & Cell Biol, D-35390 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen	Fink, L (corresponding author), Univ Giessen, Dept Pathol, Langhansstr 10, D-35392 Giessen, Germany.			Grimminger, Friedrich/0000-0001-8725-6276; Kummer, Wolfgang/0000-0002-3946-0683; Hanze, Jorg/0000-0001-5424-7808; Seeger, Werner/0000-0003-1946-0894				Becker I, 1997, HISTOCHEM CELL BIOL, V108, P447, DOI 10.1007/s004180050185; BRADY G, 1993, METHOD ENZYMOL, V225, P611; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; ENSER JE, 1995, AM J PHYSIOL, V269, pC1140; ERMERT L, IN PRESS J PHARM EXP; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLLON SD, 1991, J CONSULT CLIN PSYCH, V59, P88, DOI 10.1037/0022-006X.59.1.88; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; Kueppers Ralf, 1993, EMBO (European Molecular Biology Organization) Journal, V12, P4955; Kummer W, 1998, NEUROREPORT, V9, P2209, DOI 10.1097/00001756-199807130-00011; LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761; LIVAK KJ, 1995, PCR METH APPL, V4, P357; OLIVER JC, 1993, LYMPHOKINE CYTOK RES, V12, P115; *PERK ELM CORP, 1997, US B PERK ELM CORP, V2; SEEGER W, 1994, METHOD ENZYMOL, V233, P549	16	517	530	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1329	1333		10.1038/3327	http://dx.doi.org/10.1038/3327			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809560				2022-12-25	WOS:000076731000045
J	Masternak, K; Barras, E; Zufferey, M; Conrad, B; Corthals, G; Aebersold, R; Sanchez, JC; Hochstrasser, DF; Mach, B; Reith, W				Masternak, K; Barras, E; Zufferey, M; Conrad, B; Corthals, G; Aebersold, R; Sanchez, JC; Hochstrasser, DF; Mach, B; Reith, W			A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients	NATURE GENETICS			English	Article							BARE LYMPHOCYTE SYNDROME; REGULATORY FACTOR; BINDING-PROTEIN; TRANSCRIPTION-FACTOR; X-BOX; COOPERATIVE BINDING; CDNA CLONING; NF-Y; COMPLEX; COMPLEMENTATION	Major histocompatibility class II (MHC-II) molecules are transmembrane proteins that have a central role in development and control of the immune system. They are encoded by a multigene family and their expression is tightly regulated. MHC-II deficiency (OMIM 209920) is an autosomal recessive immunodeficiency syndrome resulting from defects in trans-acting factors essential for transcription of MHC-II genes(1,2). There are four genetic complementation groups(3-5) (A, B, C and D), reflecting the existence of four MHC-II regulators(2). The factors defective in groups A (CIITA), C (RFX5) and D (RFXAP) have been identified(6-8). CIITA is a non-DNA-binding co-activator that controls the cell-type specificity and inducibility of MHC-II expression(6,9) RFX5 and RFXAP are two subunits of RFX, a multi-protein complex that binds the X box motif of MHC-II promoters(10,11). Mutations in the genes encoding RFX5 (RFX5) or RFXAP (RFXAP) abolish binding of RFX (refs 7,8,12), Similar to groups C and D, group B is characterized by a defect in RFX binding(2,10,11), and although it accounts for the majority of patients, the factor defective in group B has remained unknown. We report here the isolation of RFX by a novel single-step DNA-affinity purification approach and the identification of RFXANK, the gene encoding a third subunit of RFX. RFXANK restores MHC-II expression in cell lines from patients in group B and is mutated in these patients. RFXANK contains a protein-protein interaction region consisting of three ankyrin repeats. Its interaction with RFX5 and RFXAP is essential for binding of the RFX complex to MHC-II promoters.	Univ Geneva, Sch Med, Dept Genet & Microbiol, Louis Jeantet Lab Mol Genet, CH-1211 Geneva, Switzerland; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Hosp Geneva, Cent Lab Clin Chem, CH-1211 Geneva, Switzerland	University of Geneva; University of Washington; University of Washington Seattle; University of Geneva	Mach, B (corresponding author), Univ Geneva, Sch Med, Dept Genet & Microbiol, Louis Jeantet Lab Mol Genet, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	Bernard.Mach@medecine.unige.ch; Walter.Reith@medecine.unige.ch	Corthals, Garry/G-9417-2016	Corthals, Garry/0000-0001-9423-5596				Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GYGI SG, IN PRESS ELECTROPHOR; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P6269, DOI 10.1093/nar/19.22.6269; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; LISOWSKAGROSPIERRE B, 1994, HUM MOL GENET, V3, P953, DOI 10.1093/hmg/3.6.953; LouisPlence P, 1997, J IMMUNOL, V159, P3899; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Moreno CS, 1997, J IMMUNOL, V158, P5841; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1998, PRIMARY IMMUNODEFICI; Rosen FS, 1993, IMMUNODEFICIENCIES, P141; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SEIDL C, 1992, J IMMUNOL, V148, P1576; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; Villard J, 1997, NEW ENGL J MED, V337, P748, DOI 10.1056/NEJM199709113371104; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385	30	229	239	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1998	20	3					273	277		10.1038/3081	http://dx.doi.org/10.1038/3081			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	133QW	9806546				2022-12-25	WOS:000076698100021
J	Ermolaeva, O; Rastogi, M; Pruitt, KD; Schuler, GD; Bittner, ML; Chen, YD; Simon, R; Meltzer, P; Trent, JM; Boguski, MS				Ermolaeva, O; Rastogi, M; Pruitt, KD; Schuler, GD; Bittner, ML; Chen, YD; Simon, R; Meltzer, P; Trent, JM; Boguski, MS			Data management and analysis for gene expression arrays	NATURE GENETICS			English	Article							SERIAL ANALYSIS; HYBRIDIZATION; GENOME; MICROARRAY; PATTERNS; MAP	Microarray technology makes it possible to simultaneously study the expression of thousands of genes during a single experiment. We have developed an information system, ArrayDB, to manage and analyse large-scale expression data. The underlying relational database was designed to allow flexibility in the nature and structure of data input and also in the generation of standard or customized reports through a web-browser interface. ArrayDB provides varied options for data retrieval and analysis tools that should facilitate the interpretation of complex hybridization results. A sampling of ArrayDB storage, retrieval and analysis capabilities is available (www.nhgri.nih.gov/DIR/LCG/15K/HTML/), along with information on a set of approximately 15,000 genes used to fabricate several widely used microarrays. Information stored in ArrayDB is used to provide integrated gene expression reports by linking array target sequences with NCBl's Entrez retrieval system, UniGene and KEGG pathway views. The integration of externa I information resources is essential in interpreting intrinsic patterns and relationships in large-scale gene expression data.	NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NCI, Biometr Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Boguski, MS (corresponding author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.			Pruitt, Kim/0000-0001-7950-1374				Adams MD, 1996, BIOESSAYS, V18, P261, DOI 10.1002/bies.950180402; Berry M, 1997, DATA MINING TECHNIQU; BISHOP JO, 1974, CELL, V3, P341, DOI 10.1016/0092-8674(74)90048-8; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Chen Y., 1997, BIOMED OPTICS, V2, P364; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GALAU GA, 1974, CELL, V2, P9, DOI 10.1016/0092-8674(74)90003-8; Greenspun P, 1997, DATABASE BACKED WEB; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Kanehisa M, 1997, TRENDS GENET, V13, P375, DOI 10.1016/S0168-9525(97)01223-7; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; LEWIN B, 1974, GENE EXPRESSION, V1; LEWIN B, 1977, GENE EXPRESSION; Lewin B. M., 1974, GENE EXPRESSION, V2; Lewin B. M., 1970, MOL BASIS GENE EXPRE; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; NIRENBERG M, 1961, P NATL ACAD SCI USA, V47, P1588, DOI 10.1073/pnas.47.10.1588; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Taylor J. H., 1965, SELECTED PAPERS MOL; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	29	238	271	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					19	23		10.1038/1670	http://dx.doi.org/10.1038/1670			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731524				2022-12-25	WOS:000075671400012
J	Grossmann, M; Leitolf, H; Weintraub, BD; Szkudlinski, MW				Grossmann, M; Leitolf, H; Weintraub, BD; Szkudlinski, MW			A rational design strategy for protein hormone superagonists	NATURE BIOTECHNOLOGY			English	Article						protein engineering; human thyroid-stimulating hormone; modeling; evolution	HUMAN CHORIONIC-GONADOTROPIN; THYROID-STIMULATING HORMONE; SITE-DIRECTED MUTAGENESIS; HUMAN GROWTH-HORMONE; GLYCOPROTEIN HORMONES; HUMAN THYROTROPIN; TSH RECEPTOR; BIOACTIVITY; EXPRESSION; RESIDUES	By combining evolutionary considerations, sequence comparisons and homology modeling we have designed recombinant human thyroid-stimulating hormone (hTSH) analogs with increased receptor binding and activity. The introduction of seven basic residues into the peripheral loops of hTSH resulted in up to a 50,000-fold increase in receptor binding affinity and 1300-fold increase in intrinsic activity. Such analogs are not only of potential clinical interest but can be tools to explore molecular aspects of conventional as well as nonclassical actions of glycoprotein hormones. These design strategies should be applicable to the development of novel analogs of other related hormones and growth factors with a variety of therapeutic and basic science applications, particularly for proteins that have undergone evolutionary decrease in bioactivity.	Univ Maryland, Sch Med, Dept Med, Mol Endocrinol Lab, Baltimore, MD 21201 USA; UMBI, Inst Human Virol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Szkudlinski, MW (corresponding author), Univ Maryland, Sch Med, Dept Med, Mol Endocrinol Lab, Baltimore, MD 21201 USA.							Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; FERRARA N, 1997, ENDOCR REV, V18, P14; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; SZKUDLINSKI MW, 1997, CURR OPIN ENDOCRINOL, V4, P354, DOI DOI 10.1097/00060793-199710000-00007; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; Vassart G, 1996, ANN ENDOCRINOL-PARIS, V57, P50; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	24	27	31	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					871	875		10.1038/nbt0998-871	http://dx.doi.org/10.1038/nbt0998-871			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743123				2022-12-25	WOS:000075671700036
J	Fehr, T; Naim, HY; Bachmann, MF; Ochsenbein, AF; Spielhofer, P; Bucher, E; Hengartner, H; Billeter, MA; Zinkernagel, RM				Fehr, T; Naim, HY; Bachmann, MF; Ochsenbein, AF; Spielhofer, P; Bucher, E; Hengartner, H; Billeter, MA; Zinkernagel, RM			T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; LYMPHOCYTES-B; ACTIVATION; ANTIGEN; MICE; IMMUNOGENICITY; INACTIVATION; MODEL	B-cell activation depends on the intensity of B-cell receptor cross-linking. Studies of haptenated antigens' and vesicular stomatitis virus(2) (VSV) have demonstrated a correlation between antigen repetitiveness and the degree to which B-cell activation is independent of T cells. Here, we compare neutralizing antibody responses to inactivated VSV with those to two inactivated human pathogenic viruses: highly cytopathic poliovirus (PV) and poorly cytopathic measles virus (MV). The rigidly structured PV efficiently induced neutralizing IgM antibodies independent of T cells. In contrast, neutralizing antibodies to the pleomorphic MV were dependent on helper T cells. To test whether this resulted from the differences in virus structure or the capacity of MV to induce cell fusion and/or immunosuppression, we analyzed antibody responses to chimeric MV expressing VSV glycoprotein instead of MV fusion protein and hemagglutinin(3). IgM antibodies were independent of T cells; in addition, we found IgG responses dependent on T-cell help that were enduring and protective against lethal VSV infection. Because chimeric MV viruses look like MV ultrastructurally, we conclude that not only structural differences in the envelope but also the ability of MV to induce immunosuppression may limit its capacity to directly activate B cells. These findings are relevant for our understanding of E-cell activation by two prototypic human pathogenic viruses and for the design of new recombinant vaccines.	Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Zurich Honggerberg, Inst Mol Biol 1, CH-8093 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Zinkernagel, RM (corresponding author), Univ Zurich Hosp, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.			Ochsenbein, Adrian/0000-0003-1773-5436				BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Bachmann MF, 1995, EUR J IMMUNOL, V25, P3445, DOI 10.1002/eji.1830251236; Bachmann MF, 1996, IMMUNOL TODAY, V17, P553, DOI 10.1016/S0167-5699(96)10066-9; BACHMANN MF, 1994, MED MICROBIOL IMMUN, V183, P95, DOI 10.1007/BF00277160; BORCA MV, 1986, IMMUNOLOGY, V59, P261; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURNS WH, 1975, NATURE, V256, P654, DOI 10.1038/256654a0; CHARAN S, 1986, J IMMUNOL, V136, P3057; DINTZIS RZ, 1983, J IMMUNOL, V131, P2196; DRILLIEN R, 1988, P NATL ACAD SCI USA, V85, P1252, DOI 10.1073/pnas.85.4.1252; Fehr T, 1996, CELL IMMUNOL, V168, P184, DOI 10.1006/cimm.1996.0065; GOODMANSNITKOFF G, 1981, J EXP MED, V153, P1489, DOI 10.1084/jem.153.6.1489; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KIMURA S, 1987, J IMMUNOL, V138, P4387; MANGENEY M, 1989, CELL IMMUNOL, V122, P329, DOI 10.1016/0008-8749(89)90081-6; MCCHESNEY MB, 1987, J VIROL, V61, P3441, DOI 10.1128/JVI.61.11.3441-3447.1987; MCCHESNEY MB, 1986, J EXP MED, V163, P1331; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Ravanel K, 1997, J EXP MED, V186, P269, DOI 10.1084/jem.186.2.269; Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; SzomolanyiTsuda E, 1996, J EXP MED, V183, P403, DOI 10.1084/jem.183.2.403; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985	25	40	43	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					945	948		10.1038/nm0898-945	http://dx.doi.org/10.1038/nm0898-945			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701248	Bronze			2022-12-25	WOS:000075107400039
J	Palfi, S; Conde, F; Riche, D; Brouillet, E; Dautry, C; Mittoux, V; Chibois, A; Peschanski, M; Hantraye, P				Palfi, S; Conde, F; Riche, D; Brouillet, E; Dautry, C; Mittoux, V; Chibois, A; Peschanski, M; Hantraye, P			Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease	NATURE MEDICINE			English	Article							EXCITOTOXIC LESIONS; BRAIN; PERFORMANCE; IMPAIRMENT; MOVEMENTS; DARPP-32; RECOVERY	Substitutive therapy using fetal striatal grafts in animal models of Huntington disease (HD) have already demonstrated obvious beneficial effects on motor indices(1). Using a new phenotypic model of HD recently designed in primates(2,3), we demonstrate here complete and persistent recovery in a frontal-type cognitive task two to five months after intrastriatal allografting. The striatal allografts also reduce the occurence of dystonia, a major abnormal movement associated with HD. These results show the capacity of fetal neurons to provide a renewed substrate for both cognitive and motor systems in the lesioned adult brain. They also support the use of neural transplantation as a potential therapy for HD.	Serv Hosp Frederic Joliot, CNRS,URA 2210, CEA, DSV,DRM, F-91401 Orsay, France; Fac Med, INSERM, U421, F-94010 Creteil, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Hantraye, P (corresponding author), Serv Hosp Frederic Joliot, CNRS,URA 2210, CEA, DSV,DRM, 4 Pl Gen Leclerc, F-91401 Orsay, France.		Peschanski, Marc/N-5769-2017; Brouillet, Emmanuel/B-4784-2014	Brouillet, Emmanuel/0000-0001-6322-7403				BRANDT J, 1988, ANN NEUROL, V23, P555, DOI 10.1002/ana.410230605; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; BRUNDIN P, 1985, BRAIN RES, V331, P251, DOI 10.1016/0006-8993(85)91550-1; BURNS LH, 1995, NEUROSCIENCE, V64, P1007, DOI 10.1016/0306-4522(94)00431-4; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; CHEN KS, 1994, FUNCTIONAL NEURAL TR, P295; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; DUNNETT SB, 1994, FUNCTIONAL NEURAL TR, P217; HANTRAYE P, 1990, EXP NEUROL, V108, P91, DOI 10.1016/0014-4886(90)90014-J; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; HARPER PS, 1991, HUNTINGTONS DIS, V1; HEMMINGS HC, 1984, J NEUROSCI, V4, P99; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P557; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; Jentsch JD, 1997, SCIENCE, V277, P953, DOI 10.1126/science.277.5328.953; MAYER E, 1992, EUR J NEUROSCI, V4, P119, DOI 10.1111/j.1460-9568.1992.tb00858.x; Naimi S, 1996, EXP NEUROL, V137, P15, DOI 10.1006/exnr.1996.0002; PAKZABAN P, 1993, EXP BRAIN RES, V97, P13; Palfi SP, 1996, J NEUROSCI, V16, P3019; PESCHANSKI M, 1995, NEUROSCIENCE, V68, P273, DOI 10.1016/0306-4522(95)00162-C; SCHNEIDER JS, 1992, VULN BRAIN ENV, P293; Sinden J. D., 1994, FUNCTIONAL NEURAL TR, P253; STERNBERGER LA, 1985, IMMUNOCYTOCHEMISTRY; SZABO J, 1984, J COMP NEUROL, V222, P265, DOI 10.1002/cne.902220208	24	120	122	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					963	966		10.1038/nm0898-963	http://dx.doi.org/10.1038/nm0898-963			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701252				2022-12-25	WOS:000075107400043
J	Shusta, EV; Raines, RT; Pluckthun, A; Wittrup, KD				Shusta, EV; Raines, RT; Pluckthun, A; Wittrup, KD			Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments	NATURE BIOTECHNOLOGY			English	Article						expression system; yeast; BiP; PDI	PROTEIN DISULFIDE-ISOMERASE; EFFICIENT PRODUCTION; FUNCTIONAL ANTIBODY; ESCHERICHIA-COLI; BINDING-PROTEIN; HIGH-COPY; YEAST; OVEREXPRESSION; EXPRESSION; BIP	We have produced single-chain antibody fragments (scFv) in Saccharomyces cerevisiae at levels up to 20 mg/L in shake flask culture by a combination of expression level tuning and overexpression of folding assistants. Overexpression of the chaperone BiP or protein disulfide isomerase (PDI) increases secretion titers 2-8 fold for five scFvs. The increases occur for scFv expression levels ranging from low copy to ER-saturating overexpression. The disulfide isomerase activity of PDI, rather than its chaperone activity, is responsible for the secretion increases. A synergistic increase in scFv production occurs upon coover-expression of BiP and PDI.	Univ Illinois, Dept Chem Engn, Urbana, IL 61801 USA; Univ Wisconsin, Dept Biochem, Madison, WI USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Zurich	Wittrup, KD (corresponding author), Univ Illinois, Dept Chem Engn, Urbana, IL 61801 USA.	wittrup@uiuc.edu	Plückthun, Andreas/C-2746-2009; Raines, Ronald T./A-5009-2013	Plückthun, Andreas/0000-0003-4191-5306; Raines, Ronald T./0000-0001-7164-1719				CLEMENTS JM, 1991, GENE, V106, P267, DOI 10.1016/0378-1119(91)90209-T; DORAI H, 1994, BIO-TECHNOL, V12, P890, DOI 10.1038/nbt0994-890; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FABER KN, 1995, YEAST, V11, P1331, DOI 10.1002/yea.320111402; FitzGerald K, 1997, PROTEIN ENG, V10, P1221, DOI 10.1093/protein/10.10.1221; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harmsen MM, 1996, APPL MICROBIOL BIOT, V46, P365, DOI 10.1007/s002530050831; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; Hiatt A, 1993, Int Rev Immunol, V10, P139, DOI 10.3109/08830189309061691; HODGSON J, 1991, BIO-TECHNOL, V9, P421; HORWITZ AH, 1988, P NATL ACAD SCI USA, V85, P8678, DOI 10.1073/pnas.85.22.8678; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; KNAPPIK A, 1995, THESIS U ZURICH; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LILIE H, 1994, J BIOL CHEM, V269, P14290; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MYLIN LM, 1990, METHOD ENZYMOL, V185, P297; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NYYSSONEN E, 1993, BIO-TECHNOL, V11, P591, DOI 10.1038/nbt0593-591; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; Parekh RN, 1996, BIOTECHNOL PROGR, V12, P16, DOI 10.1021/bp9500627; Parekh RN, 1997, BIOTECHNOL PROGR, V13, P117, DOI 10.1021/bp970009d; RIDDER R, 1995, BIO-TECHNOL, V13, P255, DOI 10.1038/nbt0395-255; Robinson AS, 1996, J BIOL CHEM, V271, P10017, DOI 10.1074/jbc.271.17.10017; ROBINSON AS, 1995, BIOTECHNOL PROGR, V11, P171, DOI 10.1021/bp00032a009; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; Ryabova LA, 1997, NAT BIOTECHNOL, V15, P79, DOI 10.1038/nbt0197-79; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Von Mehren Margaret, 1996, Current Opinion in Oncology, V8, P493; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WOOD CR, 1985, NATURE, V314, P446, DOI 10.1038/314446a0; WU XC, 1993, BIO-TECHNOL, V11, P71, DOI 10.1038/nbt0193-71	42	197	262	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1998	16	8					773	777		10.1038/nbt0898-773	http://dx.doi.org/10.1038/nbt0898-773			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	107AJ	9702778				2022-12-25	WOS:000075183400037
J	Kusumi, K; Sun, ES; Kerrebrock, AW; Bronson, RT; Chi, DC; Bulotsky, MS; Spencer, JB; Birren, BW; Frankel, WN; Lander, ES				Kusumi, K; Sun, ES; Kerrebrock, AW; Bronson, RT; Chi, DC; Bulotsky, MS; Spencer, JB; Birren, BW; Frankel, WN; Lander, ES			The mouse pudgy mutation disrupts Delta homologue Dll3 and initiation of early somite boundaries	NATURE GENETICS			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; GENE FAMILY; EMBRYOGENESIS; TRANSCRIPTION; SEGMENTATION; EXPRESSION; GENOME	Pudgy (pu) homozygous mice exhibit clear patterning defects at the earliest stages of somitogenesis, resulting in adult mice with severe vertebral and rib deformities(1). By positional cloning and complementation, we have determined that the pu phenotype is caused by a mutation in the delta-like 3 gene (Dll3), which is homologous to the Notch-ligand Delta in Drosophila. Histological and molecular marker analyses show that the pu mutation disrupts the proper formation of morphological borders in early somite formation and of rostral-caudal compartment boundaries within somites. Viability analysis also indicates an important role in early development. The results point to a key role for a Notch-signalling pathway in the initiation of patterning of vertebrate paraxial mesoderm.	Natl Inst Med Res, MRC, London NW7 1AA, England; MIT, Dept Biol, Cambridge, MA 02139 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Jackson Lab, Bar Harbor, ME 04609 USA	MRC National Institute for Medical Research; Massachusetts Institute of Technology (MIT); Tufts University; Tufts University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Jackson Laboratory	Lander, ES (corresponding author), Natl Inst Med Res, MRC, Ridgeway, London NW7 1AA, England.		Kusumi, Kenro/J-2626-2012	Kusumi, Kenro/0000-0002-1458-4540; Spencer, Jessica/0000-0001-8156-514X				BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DIETRICH W, 1992, GENETICS, V131, P423; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; GRUNEBERG HANS, 1961, GENET RES, V2, P384, DOI 10.1017/S0016672300000860; Haldi ML, 1996, MAMM GENOME, V7, P767, DOI 10.1007/s003359900228; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Kaufman M.H., 1992, ATLAS MOUSE DEV; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; OKA C, 1995, DEVELOPMENT, V121, P3291; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Sambrook J., 2002, MOL CLONING LAB MANU; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WILKINSON DG, 1992, IN SITU HYBRIDIZATON; WILLIAMS R, 1995, MECH DEVELOP, V53, P357, DOI 10.1016/0925-4773(95)00451-3; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0	30	234	248	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1998	19	3					274	278		10.1038/961	http://dx.doi.org/10.1038/961			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZX892	9662403				2022-12-25	WOS:000074565900026
J	Astwood, JD; Leach, JN; Fuchs, RL				Astwood, JD; Leach, JN; Fuchs, RL			Stability of food allergens to digestion in vitro	NATURE BIOTECHNOLOGY			English	Article						allergens; food; safety; stability; digestion	MAJOR PEANUT ALLERGEN; ATOPIC-DERMATITIS; BETA-LACTOGLOBULIN; PROTEINS; IDENTIFICATION; MUSTARD; HYPERSENSITIVITY; ANTIBODIES; HYDROLYSIS; SERA	An integral part of the safety assessment of genetically modified plants is consideration of possible human health effects, especially food allergy. prospective testing for allergenicity of proteins obtained from sources with no prior history of causing allergy has been difficult because of the absence of valid methods and models. Food allergens may share physicochemical properties that distinguish them from nonallergens, properties that may be used as a tool to predict the inherent allergenicity of proteins newly introduced into the food supply by genetic engineering. One candidate property is stability to digestion. We have systematically evaluated the stability of food allergens that are active via the gastrointestinal tract in a simple model of gastric digestion, emphasizing the major allergens of plant-derived foods such as legumes (peanuts and soybean). Important food allergens were stable to digestion in the gastric model (simulated gastric fluid). For example, soybean beta-conglycinin was stable for 60 min. In contrast, nonallergenic food proteins, such as spinach ribulose bis-phosphate carboxylase/oxygenase, were digested in simulated gastric fluid within 15 sec. The data are consistent with the hypothesis that food allergens must exhibit sufficient gastric stability to reach the intestinal mucosa where absorption and sensitization (development of atopy) can occur. Thus, the stability to digestion is a significant and valid parameter that distinguishes food allergens from nonallergens.	MONSANTO CO,REGULATORY SCI,ST LOUIS,MO 63198	Monsanto								ASSELIN J, 1989, J FOOD SCI, V54, P1037, DOI 10.1111/j.1365-2621.1989.tb07938.x; Astwood JD, 1996, TRENDS FOOD SCI TECH, V7, P219, DOI 10.1016/0924-2244(96)10026-1; *BOARD TRUST, 1995, US PHARM, V23, P2053; BURKS AW, 1994, INT ARCH ALLERGY IMM, V105, P143; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CHAPENTIER BA, 1984, J AGR FOOD CHEM, V32, P908; CHRISTY KG, 1989, BIOTECHNIQUES, V7, P692; DELAPENA MAG, 1991, INT ARCH ALLER A IMM, V96, P263, DOI 10.1159/000235505; DESHPANDE SS, 1987, J FOOD SCI, V52, P1326, DOI 10.1111/j.1365-2621.1987.tb14074.x; FUCHS RL, 1993, BIO-TECHNOL, V11, P1543, DOI 10.1038/nbt1293-1543; FUCHS RL, 1995, APPL PRINCIPLES SUBS, P63; HADDAD ZH, 1979, ANN ALLERGY, V42, P368; Harlow E., 1988, ANTIBODIES LABORATOR, P1; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; Lavrik PB, 1995, ACS SYM SER, V605, P148; LIENER IE, 1976, J FOOD SCI, V41, P1076, DOI 10.1111/j.1365-2621.1976.tb14391.x; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; METCALFE DD, 1996, ALLERGENICITY FOODS; MONSALVE RI, 1993, BIOCHEM J, V293, P625, DOI 10.1042/bj2930625; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; OGAWA T, 1991, J NUTR SCI VITAMINOL, V37, P555, DOI 10.3177/jnsv.37.555; OGAWA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1030, DOI 10.1271/bbb.57.1030; Padgette Stephen R., 1996, P53; PANCONESI E, 1980, CONTACT DERMATITIS, V6, P294, DOI 10.1111/j.1600-0536.1980.tb04943.x; Reed AJ, 1996, J AGR FOOD CHEM, V44, P388, DOI 10.1021/jf9504071; Ryle A. P., 1984, METHOD ENZYMAT AN, P228; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHWARTZ HR, 1980, ANN ALLERGY, V45, P242; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; TAYLOR SL, 1986, J FOOD PROTECT, V49, P239, DOI 10.4315/0362-028X-49.3.239; TSUJI H, 1993, J NUTR SCI VITAMINOL, V39, P389, DOI 10.3177/jnsv.39.389; Vieths Stefan, 1996, P130; 1992, FED REGISTER, V57, P22984	36	702	770	7	291	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1269	1273		10.1038/nbt1096-1269	http://dx.doi.org/10.1038/nbt1096-1269			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631091				2022-12-25	WOS:A1996VK61800025
J	Chui, DH; Tanahashi, H; Ozawa, K; Ikeda, S; Checler, F; Ueda, O; Suzuki, H; Araki, W; Inoue, H; Shirotani, K; Takahashi, K; Gallyas, F; Tabira, T				Chui, DH; Tanahashi, H; Ozawa, K; Ikeda, S; Checler, F; Ueda, O; Suzuki, H; Araki, W; Inoue, H; Shirotani, K; Takahashi, K; Gallyas, F; Tabira, T			Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation	NATURE MEDICINE			English	Article							BETA-PROTEIN; MUTANT PRESENILIN-1; PRECURSOR PROTEIN; SENILE PLAQUES; IN-VIVO; DISEASE; APOPTOSIS; DEPOSITION; NEURONS; CELLS	Familial Alzheimer disease mutations of presenilin 1 (PS-1) enhance the generation of A beta 1-42, indicating that PS-1 is involved in amyloidogenesis. However, PS-l transgenic mice have failed to show amyloid plaques in their brains. Because PS-l mutations facilitate apoptotic neuronal death in vitro, we did careful quantitative studies in PS-1 transgenic mice and found that neurodegeneration was significantly accelerated in mice older than 13 months (aged mice) with familial Alzheimer disease mutant PS-1, without amyloid plaque formation. However, there were significantly more neurons containing intracellularly deposited A beta 42 in aged mutant transgenic mice. Our data indicate that the pathogenic role of the PS-1 mutation is upstream of the amyloid cascade.	NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka 4128531, Japan; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Pecs, Sch Med, Dept Neurosurg, Pecs, Hungary	National Center for Neurology & Psychiatry - Japan; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Pecs	Tabira, T (corresponding author), NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.		Checler, Frederic/C-1241-2009; Gallyas, Ferenc/C-5450-2009; Araki, Wataru/G-7913-2014	Checler, Frederic/0000-0003-2098-1750; Araki, Wataru/0000-0001-8467-6937; Inoue, Haruhisa/0000-0003-4736-9537				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; CHUI DH, 1994, AM J PATHOL, V145, P771; Chui DH, 1998, J NEUROSCI RES, V53, P99; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GALLYAS F, 1993, J NEUROSCI METH, V50, P159, DOI 10.1016/0165-0270(93)90004-B; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P504, DOI 10.1007/BF00310027; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Guo Q, 1997, J NEUROSCI, V17, P4212; Haass C, 1998, J NEURAL TRANSM-SUPP, P159; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Kamimura K, 1998, J NEUROL SCI, V160, P76, DOI 10.1016/S0022-510X(98)00219-6; KOIKE F, 1988, J NEUROL SCI, V85, P9, DOI 10.1016/0022-510X(88)90031-7; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Liu XZ, 1997, J NEUROSCI, V17, P5395; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	29	316	332	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					560	564		10.1038/8438	http://dx.doi.org/10.1038/8438			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229234				2022-12-25	WOS:000081497400038
J	Baize, S; Leroy, EM; Georges-Courbot, MC; Capron, M; Lansoud-Soukate, J; Debre, P; Fisher-Hoch, SP; McCormick, JB; McCormick, JB; Georges, AJ				Baize, S; Leroy, EM; Georges-Courbot, MC; Capron, M; Lansoud-Soukate, J; Debre, P; Fisher-Hoch, SP; McCormick, JB; McCormick, JB; Georges, AJ			Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients	NATURE MEDICINE			English	Article							FAS LIGAND; RHESUS-MONKEYS; T-CELLS; RELEASE	Ebola virus is very pathogenic in humans. It induces an acute hemorrhagic fever that leads to death in about 70% of patients'. We compared the immune responses of patients who died from Ebola virus disease with those who survived during two large outbreaks in 1996 in Gabon. In survivors, early and increasing levels of IgG, directed mainly against the nucleoprotein and the 40-kDa viral protein, were followed by clearance of circulating viral antigen and activation of cytotoxic T cells, which was indicated by the upregulation of Fast, perforin, CD28 and gamma interferon mRNA in peripheral blood mononuclear cells. In contrast, fatal infection was characterized by impaired humoral responses, with absent specific IgG and barely detectable IgM. Early activation of T cells, indicated by mRNA patterns in peripheral blood mononuclear cells and considerable release of gamma interferon in plasma, was followed in the days preceding death by the disappearance of T cell-related mRNA (including CD3 and CD8). DNA fragmentation in blood leukocytes and release of 41/7 nuclear matrix protein in plasma indicated that massive intravascular apoptosis proceeded relentlessly during the last 5 days of life. Thus, events very early in Ebola virus infection determine the control of viral replication and recovery or catastrophic illness and death.	Ctr Int Rech Med Franceville, Franceville, Gabon; Inst Pasteur, Ctr Immunol & Biol Parasitaire, INSERM, U167, F-59019 Lille, France; Hop La Pitie Salpetriere, Lab Cent Immunol Cellulaire & Tissulaire, CNRS, U625, Paris, France; Fdn Marcel Merieux, F-69002 Lyon, France; Pasteur Merieux Connaught, F-69260 Marcy Etoile, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Baize, S (corresponding author), Ctr Int Rech Med Franceville, BP 769, Franceville, Gabon.	sbaize@cirmf.sci.ga; eleroy@cirmf.sci.ga	LEROY, Eric M/I-4347-2016	LEROY, Eric M/0000-0003-0022-0890; McCormick, Joseph/0000-0002-5844-8102; Baize, Sylvain/0000-0002-3234-7477				BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; FELDMANN H, 1991, VIROLOGY, V182, P353, DOI 10.1016/0042-6822(91)90680-A; Feldmann H, 1996, J VIROL, V70, P2208, DOI 10.1128/JVI.70.4.2208-2214.1996; FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GeorgesCourbot MC, 1997, EMERG INFECT DIS, V3, P59, DOI 10.3201/eid0301.970107; Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140; Jeon SH, 1998, INT IMMUNOL, V10, P1519, DOI 10.1093/intimm/10.10.1519; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kiener PA, 1997, J IMMUNOL, V159, P1594; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MILLER T, 1993, BIOTECHNIQUES, V15, P1042; Peters CJ, 1999, CURR TOP MICROBIOL, V235, P85; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; *WHO, 1985, WORKSH VIR HAEM FEV; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; ZAKI SR, 1996, INT C EB VIR RES	24	426	443	0	52	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					423	426		10.1038/7422	http://dx.doi.org/10.1038/7422			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202932				2022-12-25	WOS:000079574300032
J	Niederreither, K; Subbarayan, V; Dolle, P; Chambon, P				Niederreither, K; Subbarayan, V; Dolle, P; Chambon, P			Embryonic retinoic acid synthesis is essential for early mouse post-implantation development	NATURE GENETICS			English	Article							HEART DEVELOPMENT; NERVOUS-SYSTEM; HENSEN NODE; EXPRESSION; DEHYDROGENASE; GENE; IDENTIFICATION; RECEPTORS; PATTERNS	A number of studies have suggested that the active derivative of vitamin A, retinoic acid (RA), may be important for early development of mammalian embryos(1,2). Severe vitamin A deprivation in rodents results in maternal infertility(3), precluding a thorough investigation of the role of RA during embryogenesis, Here we show that production of RA by the retinaldehyde dehydrogenase-2 (Raldh2) enzyme(4,5) is required for mouse embryo survival and early morphogenesis. Raldh2 is an HAD-dependent aldehyde dehydrogenase with high substrate specificity for retinaldehyde(4,5). Its pattern of expression during mouse development has suggested that it may be responsible for embryonic RA synthesis(4,6). We generated a targeted disruption of the mouse Raldh2 gene and found that Raldh2(-/-) embryos, which die at midgestation without undergoing axial rotation (body turning), exhibit shortening along the anterioposterior axis and do not form limb buds. Their heart consists of a single, medial, dilated cavity. Their frontonasal region is truncated and their otocysts are severely reduced. These defects result from a block in embryonic RA synthesis, as shown by the lack of activity of RA-responsive transgenes, the altered expression of an RA-target homeobox gene and the near full rescue of the mutant phenotype by maternal RA administration, Our data establish that RA synthesized by the post-implantation mammalian embryo is an essential developmental hormone whose lack leads to early embryo death.	ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090				Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Ang HL, 1997, DEV DYNAM, V208, P536; ANG SL, 1994, DEVELOPMENT, V120, P2979; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Blumberg B, 1997, SEMIN CELL DEV BIOL, V8, P417, DOI 10.1006/scdb.1997.0165; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CONLON RA, 1995, TRENDS GENET, V11, P314, DOI 10.1016/S0168-9525(00)89089-7; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Dierich A, 1997, METHODS IN DEVELOPMENTAL TOXICOLOGY AND BIOLOGY, P111; DUPE V, 1997, DEVELOPMENT, V124, P339; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; Maden M, 1998, DEVELOPMENT, V125, P4133; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Moss JB, 1998, DEV BIOL, V199, P55, DOI 10.1006/dbio.1998.8911; Neela J, 1997, NATL MED J INDIA, V10, P15; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; TWAL W, 1995, DEV BIOL, V168, P225, DOI 10.1006/dbio.1995.1075; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	29	821	848	1	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					444	448		10.1038/7788	http://dx.doi.org/10.1038/7788			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192400				2022-12-25	WOS:000079439700031
J	Yasunaga, S; Grati, M; Cohen-Salmon, M; El-Amraoui, A; Mustapha, M; Salem, N; El-Zir, E; Loiselet, J; Petit, C				Yasunaga, S; Grati, M; Cohen-Salmon, M; El-Amraoui, A; Mustapha, M; Salem, N; El-Zir, E; Loiselet, J; Petit, C			A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness	NATURE GENETICS			English	Article							MYOSIN-VIIA GENE; RECESSIVE DEAFNESS; C-2-DOMAIN PROTEINS; VESICLE FUSION; HAIR-CELLS; C-2 DOMAIN; SYNAPTOTAGMIN; RABPHILIN-3A; JERVELL; BINDING	Using a candidate gene approach, we identified a novel human gene, OTOF, underlying an autosomal recessive, nonsyndromic prelingual deafness, DFNB9. The same nonsense mutation was detected in four unrelated affected families of Lebanese origin. OTOF is the second member of a mammalian gene family related to Caenorhabditis elegans fer-1. It encodes a predicted cytosolic protein (of 1,230 aa) with three C2 domains and a single carboxy-terminal transmembrane domain. The sequence homologies and predicted structure of otoferlin, the protein encoded by OTOF, suggest its involvement in vesicle membrane fusion. In the inner ear, the expression of the orthologous mouse gene, mainly in the sensory hair cells, indicates that such a role could apply to synaptic vesicles.	Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; St Josephs Univ, Fac Med, Biochim Lab, Beyrouth, Lebanon; Hop Sacre Coeur, Clin Audiol, Baabda, Brazilia, Lebanon	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Saint Joseph University Beirut	Petit, C (corresponding author), Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.		Grati, M'hamed/C-9563-2011	EL-AMRAOUI, Aziz/0000-0003-2692-4984; Grati, M'hamed/0000-0002-4490-1682; Cohen-Salmon, Martine/0000-0002-5312-8476; Grati, Mhamed/0000-0001-5149-3245; Petit, Christine/0000-0002-9069-002X				Achanzar WE, 1997, J CELL SCI, V110, P1073; Avraham KB, 1998, NAT MED, V4, P1238, DOI 10.1038/3215; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Chaib H, 1996, HUM MOL GENET, V5, P155, DOI 10.1093/hmg/5.1.155; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Leal SM, 1998, EUR J HUM GENET, V6, P341, DOI 10.1038/sj.ejhg.5200201; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Richardson GP, 1997, J NEUROSCI, V17, P9506; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SAFIEDDINE S, IN PRESS EUR J NEURO; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; SCOTT DA, 1998, MOL BIOL HEARING DEA, P63; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Spicer SS, 1998, HEARING RES, V118, P1, DOI 10.1016/S0378-5955(98)00006-9; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Xiang MQ, 1998, DEVELOPMENT, V125, P3935; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	49	372	409	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					363	369		10.1038/7693	http://dx.doi.org/10.1038/7693			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192385				2022-12-25	WOS:000079439700016
J	Baba, TW; Liska, V; Khimani, AH; Ray, NB; Dailey, PJ; Penninck, D; Bronson, R; Greene, MF; McClure, HM; Martin, LN; Ruprecht, RM				Baba, TW; Liska, V; Khimani, AH; Ray, NB; Dailey, PJ; Penninck, D; Bronson, R; Greene, MF; McClure, HM; Martin, LN; Ruprecht, RM			Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques	NATURE MEDICINE			English	Article							CELL-FREE SIV; RHESUS-MONKEYS; NEF GENE; MUCOSAL INFECTION; IN-VIVO; VACCINE; LYMPHOCYTES; PROTECTION; CHALLENGE; CD4	A substantial risk in using live attenuated, multiply deleted viruses as vaccines against AIDS is their potential to induce AIDS. A mutant of the simian immunodeficiency virus (SIV) with large deletions in nef and vpr and in the negative regulatory element induced AIDS in six of eight infant macaques vaccinated orally or intravenously. Early signs of immune dysfunction were seen in the remaining two offspring. Prolonged follow-up of sixteen vaccinated adult macaques also showed resurgence of chronic viremia in four animals: two of these developed early signs of disease and one died of AIDS. We conclude that this multiply deleted SIV is pathogenic and that human AIDS vaccines built on similar prototypes may cause AIDS.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pediat, Div Newborn Med, Boston, MA 02111 USA; Chiron Corp, Emeryville, CA 94608 USA; Tufts Univ, Sch Vet Med, Dept Radiol, N Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA; Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Tufts University; Novartis; Tufts University; Tufts University; Harvard University; Massachusetts General Hospital; Emory University; Emory University	Ruprecht, RM (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [R01-AI32330, R01-AI35533, UO1-AI24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024345, R01AI032330, R01AI024345, R01AI035533] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; AMEDEE AM, 1995, J VIROL, V69, P7982, DOI 10.1128/JVI.69.12.7982-7990.1995; BABA TW, 1995, SCIENCE, V270, P1220; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BASKIN GB, 1991, VET PATHOL, V28, P506, DOI 10.1177/030098589102800607; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CLEMENTS JE, 1995, J VIROL, V69, P2737, DOI 10.1128/JVI.69.5.2737-2744.1995; Connor RI, 1998, J VIROL, V72, P7501, DOI 10.1128/JVI.72.9.7501-7509.1998; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DAVISONFAIRBURN B, 1990, J MED PRIMATOL, V19, P381; DESROSIERS RC, 1994, AIDS RES HUM RETROV, V10, P331, DOI 10.1089/aid.1994.10.331; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; FOX CH, 1993, CURRENT PROTOCOLS IM; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KINDT TJ, 1992, ADV IMMUNOL, V52, P425, DOI 10.1016/S0065-2776(08)60880-9; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; LETVIN NL, 1990, J ACQ IMMUN DEF SYND, V3, P1023; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; Liska V, 1997, AIDS RES HUM RETROV, V13, P1147, DOI 10.1089/aid.1997.13.1147; Liska V, 1997, AIDS RES HUM RETROV, V13, P433, DOI 10.1089/aid.1997.13.433; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Norley S, 1996, VIROLOGY, V219, P195, DOI 10.1006/viro.1996.0237; OCHS HD, 1991, J MED PRIMATOL, V20, P193; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; ROSENBERG YJ, 1994, AIDS RES HUM RETROV, V10, P863, DOI 10.1089/aid.1994.10.863; Ruprecht R M, 1996, AIDS, V10 Suppl A, pS33, DOI 10.1097/00002030-199601001-00005; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Tsai CC, 1997, AIDS RES HUM RETROV, V13, P707, DOI 10.1089/aid.1997.13.707; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277	42	321	331	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					194	203		10.1038/5557	http://dx.doi.org/10.1038/5557			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930868				2022-12-25	WOS:000078274400029
J	Deak, M; Horvath, GV; Davletova, S; Torok, K; Sass, L; Vass, I; Barna, B; Kiraly, Z; Dudits, D				Deak, M; Horvath, GV; Davletova, S; Torok, K; Sass, L; Vass, I; Barna, B; Kiraly, Z; Dudits, D			Plants ectopically expressing the iron-binding protein, ferritin, are tolerant to oxidative damage and pathogens	NATURE BIOTECHNOLOGY			English	Article						stress; reactive oxygen species; paraquat; necrosis; iron	PEA PISUM-SATIVUM; TRANSGENIC PLANTS; HYDROGEN-PEROXIDE; OXYGEN RADICALS; MAIZE FERRITIN; ABSCISIC-ACID; STRESS; DEFENSE; RESISTANCE; PARAQUAT	Transgenic tobacco plants that synthesize alfalfa ferritin in vegetative tissues-either in its processed form in chloroplasts or in the cytoplasmic nonprocessed form-retained photosynthetic function upon free radical toxicity generated by iron excess or paraquat treatment. Progeny of transgenic plants accumulating ferritin in their leaves exhibited tolerance to necrotic damage caused by viral (tobacco necrosis virus) and fungal (Alternaria alternata, Botrytis cinerea) infections. These transformants exhibited normal photosynthetic function and chlorophyll content under greenhouse conditions. We propose that by sequestering intracellular iron involved in generation of the very reactive hydroxyl radicals through a Fenton reaction, ferritin protects plant cells from oxidative damage induced by a wide range of stresses.	Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6726 Szeged, Hungary; Bay Zoltan Appl Res Fdn, Inst Biotechnol, H-6726 Szeged, Hungary; Hungarian Acad Sci, Inst Plant Protect, H-1525 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Centre for Agricultural Research	Dudits, D (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, Temesvari Krt 62, H-6726 Szeged, Hungary.	dudits@nucleua.szbk.u-szeged.hu	Davletova, Sholpan/K-5764-2015; Vass, Imre/AAS-6171-2021	Davletova, Sholpan/0000-0003-4759-3256; Vass, Imre/0000-0003-4987-7842				ALLEN RD, 1995, PLANT PHYSIOL, V107, P1049, DOI 10.1104/pp.107.4.1049; ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BABBS CF, 1989, PLANT PHYSIOL, V90, P1267, DOI 10.1104/pp.90.4.1267; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; BALLA G, 1992, J BIOL CHEM, V267, P18148; BARNA B, 1993, NATURWISSENSCHAFTEN, V80, P420, DOI 10.1007/BF01168338; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BOWLER C, 1991, EMBO J, V10, P1723, DOI 10.1002/j.1460-2075.1991.tb07696.x; Briat JF, 1997, TRENDS PLANT SCI, V2, P187, DOI 10.1016/S1360-1385(97)85225-9; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CLAES B, 1991, PLANT J, V1, P15, DOI 10.1111/j.1365-313X.1991.00015.x; EISTNER EF, 1982, ANNU REV PLANT PHYS, V33, P73; ELSTNER EF, 1994, OXYGEN ENV STRESS PL, P131; FOBISLOISY I, 1995, EUR J BIOCHEM, V231, P609, DOI 10.1111/j.1432-1033.1995.0609d.x; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; JOURNET EP, 1987, METHOD ENZYMOL, V148, P234; KAMPFENKEL K, 1995, PLANT PHYSIOL, V107, P725, DOI 10.1104/pp.107.3.725; KIRALY Z, 1993, OXYGEN FREE RADICALS AND SCAVENGERS IN THE NATURAL SCIENCES, P9; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; LOBREAUX S, 1991, BIOCHEM J, V274, P601, DOI 10.1042/bj2740601; LOBREAUX S, 1992, BIOCHEM J, V288, P931, DOI 10.1042/bj2880931; Low PS, 1996, PHYSIOL PLANTARUM, V96, P533, DOI 10.1111/j.1399-3054.1996.tb00469.x; MAES M, 1992, NUCLEIC ACIDS RES, V20, P4374, DOI 10.1093/nar/20.16.4374; MITRA A, 1994, PLANT PHYSIOL, V106, P977, DOI 10.1104/pp.106.3.977; Mullineaux PM, 1996, BIOCHEM SOC T, V24, P829, DOI 10.1042/bst0240829; NECHUSHTAI R, 1985, PLANT MOL BIOL, V4, P377, DOI 10.1007/BF02418259; OUF MF, 1993, CEREAL RES COMMUN, V21, P31; PENG M, 1992, PHYTOPATHOLOGY, V82, P696, DOI 10.1094/Phyto-82-696; PERL A, 1993, THEOR APPL GENET, V85, P568, DOI 10.1007/BF00220915; Prince A. H., 1989, FREE RADICAL RES COM, V8, P61; RENNENBERG H, 1994, BIOCHEM SOC T, V22, P936, DOI 10.1042/bst0220936; REPINE JE, 1981, J BIOL CHEM, V256, P7094; Sambrook J., 2002, MOL CLONING LAB MANU; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS CE, 1986, J BIOL CHEM, V261, P3064; VANWUYTSWINKEL O, 1995, BIOCHEM J, V305, P253, DOI 10.1042/bj3050253; Vass I, 1996, BIOCHEMISTRY-US, V35, P8964, DOI 10.1021/bi9530595; VILE GF, 1993, J BIOL CHEM, V268, P14678; ZER H, 1994, PHYSIOL PLANTARUM, V92, P437, DOI 10.1111/j.1399-3054.1994.tb08833.x	45	149	182	4	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					192	196		10.1038/6198	http://dx.doi.org/10.1038/6198			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052358				2022-12-25	WOS:000078508300030
J	Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA; Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF				Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA; Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF			Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27(Kip1) induces cell migration	NATURE MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PHOSPHORYLATION; INHIBITION; DELIVERY; DOMAINS; PRB		Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.							Anderson WF, 1998, NATURE, V392, P25; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	19	851	978	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1449	1452		10.1038/4042	http://dx.doi.org/10.1038/4042			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846587				2022-12-25	WOS:000077336900045
J	Vos, P; Simons, G; Jesse, T; Wijbrandi, J; Heinen, L; Hogers, R; Frijters, A; Groenendijk, J; Diergaarde, P; Reijans, M; Fierens-Onstenk, J; de Both, M; Peleman, J; Liharska, T; Hontelez, J; Zabeau, M				Vos, P; Simons, G; Jesse, T; Wijbrandi, J; Heinen, L; Hogers, R; Frijters, A; Groenendijk, J; Diergaarde, P; Reijans, M; Fierens-Onstenk, J; de Both, M; Peleman, J; Liharska, T; Hontelez, J; Zabeau, M			The tomato Mi-1 gene confers resistance to both root-knot nematodes and potato aphids	NATURE BIOTECHNOLOGY			English	Article						agricultural engineering; plant biology	DISEASE RESISTANCE; LYCOPERSICON-PERUVIANUM; PATHOGEN AVIRULENCE; ARABIDOPSIS; TRANSFORMATION; SPECIFICITY; VECTORS; LOCUS; AFLP	Mi-1, a Lycopersicon peruvianum gene conferring resistance to the agricultural pests, root-knot nematodes, and introgressed into tomato, has been cloned using a selective restriction fragment amplification based strategy. Complementation analysis of a susceptible tomato line with a 100 kb cosmid array yielded a single cosmid clone capable of conferring resistance both to the root-knot nematode Meloidogyne incognita and to an unrelated pathogen, the potato aphid Macrosiphum euphorbiae. This resistance was stable. The Mi-1 gene encodes a protein sharing structural features with the nucleotide-binding site leucine-rich repeat-containing type of plant resistance genes.	Keygene NV, NL-6700 AE Wageningen, Netherlands; Wageningen Univ Agr, Dept Biol Mol, NL-6709 DB Wageningen, Netherlands	Keygene N.V.; Wageningen University & Research	Vos, P (corresponding author), Keygene NV, Agro Business Pk,POB216, NL-6700 AE Wageningen, Netherlands.	keygene@euronet.nl						BAILEY D. M., 1941, PROC AMER SOC HORT SCI, V38, P573; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Blackman R.L., 1984, APHIDS WORLDS CROPS; Cai DG, 1997, SCIENCE, V275, P832, DOI 10.1126/science.275.5301.832; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEBLAERE R, 1987, METHOD ENZYMOL, V153, P277; DeWit PJGM, 1997, TRENDS PLANT SCI, V2, P452, DOI 10.1016/S1360-1385(97)01139-4; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; GILBERT J. C, 1956, PROC AMER SOC HORT SCI, V68, P437; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Hammond-Kosack KE, 1998, PLANT CELL, V10, P1251, DOI 10.1105/tpc.10.8.1251; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jones DA, 1997, ADV BOT RES, V24, P89; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KALOSHIAN I, 1995, P NATL ACAD SCI USA, V92, P622, DOI 10.1073/pnas.92.2.622; Kaloshian I, 1998, MOL GEN GENET, V257, P376, DOI 10.1007/s004380050660; KOORNNEEF M, 1987, TOMATO BIOTECHNOLOGY, P169; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; Mai W. F., 1985, An advanced treatise on Meloidogyne. Volume 1: Biology and control., P11; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Simons G, 1998, PLANT CELL, V10, P1055, DOI 10.1105/tpc.10.6.1055; Simons G, 1997, GENOMICS, V44, P61, DOI 10.1006/geno.1997.4844; VANDERVOORT JR, 1997, IN PRESS THEOR APPL, V95; Veremis JC, 1996, THEOR APPL GENET, V93, P950, DOI 10.1007/BF00224098; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; YAGHOOBI J, 1995, THEOR APPL GENET, V91, P457, DOI 10.1007/BF00222973	29	228	258	0	61	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1365	1369		10.1038/4350	http://dx.doi.org/10.1038/4350			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853621				2022-12-25	WOS:000077232600032
J	Dove, A				Dove, A			Pulling green biotechnology out of the red	NATURE BIOTECHNOLOGY			English	Article								Significant environmental advantages may be gained by applying biotechnologies further upstream in industrial processes.										Burken JG, 1996, J ENVIRON ENG-ASCE, V122, P958, DOI 10.1061/(ASCE)0733-9372(1996)122:11(958); Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925	2	2	2	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1022	1024		10.1038/3466	http://dx.doi.org/10.1038/3466			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831029				2022-12-25	WOS:000076870100022
J	Kemp, S; Wei, HM; Lu, JF; Braiterman, LT; McGuinness, MC; Moser, AB; Watkins, PA; Smith, KD				Kemp, S; Wei, HM; Lu, JF; Braiterman, LT; McGuinness, MC; Moser, AB; Watkins, PA; Smith, KD			Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy	NATURE MEDICINE			English	Article							PEROXISOMAL MEMBRANE-PROTEIN; FETAL HEMOGLOBIN PRODUCTION; ACID BETA-OXIDATION; SICKLE-CELL-ANEMIA; CHAIN FATTY-ACIDS; ABC-TRANSPORTER; SACCHAROMYCES-CEREVISIAE; SODIUM-BUTYRATE; ALD-GENE; EXPRESSION	As more functional redundancy in mammalian cells is discovered, enhanced expression of genes involved in alternative pathways may become an effective form of gene therapy. X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder with impaired very-long-chain fatty acid metabolism. The X-ALD gene encodes a peroxisomal membrane protein (ALDP) that is part of a small family of related peroxisomal membrane proteins. We show that 4-phenylbutyrate treatment of cells from both X-ALD patients and X-ALD knockout mice results in decreased levels of and increased beta-oxidation of very-long-chain fatty acids; increased expression of the peroxisomal protein ALDRP; and induction of peroxisome proliferation. We also demonstrate that ALDP and ALDRP are functionally related, by ALDRP cDNA complementation of X-ALD fibroblasts. Finally, we demonstrate the in vivo efficacy of dietary 4-phenylbutyrate treatment through its production of a substantial reduction of very-long-chain fatty acid levels in the brain and adrenal glands of X-ALD mice.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Smith, KD (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway,Room 400A, Baltimore, MD 21205 USA.		Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X; Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD24061, HD10981] Funding Source: Medline; NIDDK NIH HHS [DK51149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051149] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albet S, 1997, FEBS LETT, V405, P394, DOI 10.1016/S0014-5793(97)00122-1; AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V201, P1541, DOI 10.1006/bbrc.1994.1879; BOLES DJ, 1991, BIOCHEM MED METAB B, V45, P74, DOI 10.1016/0885-4505(91)90010-I; Braiterman LT, 1998, HUM MOL GENET, V7, P239, DOI 10.1093/hmg/7.2.239; CARSTEA ED, 1992, BIOCHEM BIOPH RES CO, V184, P1477, DOI 10.1016/S0006-291X(05)80049-X; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; Cooke J, 1997, TRENDS GENET, V13, P360, DOI 10.1016/S0168-9525(97)01233-X; DENG G, 1992, CANCER RES, V52, P3378; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1994, BLOOD, V84, P339; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Feigenbaum V, 1996, AM J HUM GENET, V58, P1135; Fouquet F, 1997, NEUROBIOL DIS, V3, P271, DOI 10.1006/nbdi.1997.0127; FREGEAU CJ, 1992, NUCLEIC ACIDS RES, V20, P3113, DOI 10.1093/nar/20.12.3113; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KEMP S, 1994, BIOCHEM BIOPH RES CO, V202, P647, DOI 10.1006/bbrc.1994.1979; Kemp S, 1996, J INHERIT METAB DIS, V19, P667, DOI 10.1007/BF01799844; KOK F, 1995, HUM MUTAT, V6, P104, DOI 10.1002/humu.1380060203; Krasemann EW, 1996, HUM GENET, V97, P194, DOI 10.1007/BF02265264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LIGTENBERG MJL, 1995, AM J HUM GENET, V56, P44; LIU L, 1995, CYTOKINE, V7, P449, DOI 10.1006/cyto.1995.0061; LOES DJ, 1994, AM J NEURORADIOL, V15, P1767; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Maestri NE, 1996, NEW ENGL J MED, V335, P855, DOI 10.1056/NEJM199609193351204; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Moser HW, 1997, BRAIN, V120, P1485, DOI 10.1093/brain/120.8.1485; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; MOSER HW, 1995, METABOLIC BASIS INHE, P4256; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; OHBA T, 1994, GENOMICS, V24, P370, DOI 10.1006/geno.1994.1630; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; Pineau T, 1996, BIOCHEM PHARMACOL, V52, P659, DOI 10.1016/0006-2952(96)00340-1; POULOS A, 1994, ANN NEUROL, V36, P741, DOI 10.1002/ana.410360509; POWERS JM, 1985, CLIN NEUROPATHOL, V4, P181; RAM Z, 1994, CANCER RES, V54, P2923; RASMUSSEN M, 1994, NEUROCHEM RES, V19, P1073, DOI 10.1007/BF00968719; Reddy J. K., 1996, ANN NY ACAD SCI, V804, P801; Roush W, 1997, SCIENCE, V276, P35, DOI 10.1126/science.276.5309.35; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; WATKINS PA, 1995, AM J HUM GENET, V57, P292; ZENGERHAIN J, 1992, NEW DEV FATTY ACID O, P339	57	189	200	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1261	1268		10.1038/3242	http://dx.doi.org/10.1038/3242			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809549				2022-12-25	WOS:000076731000034
J	Zhang, HG; Liu, D; Heike, Y; Yang, PA; Wang, Z; Wang, XY; Curiel, DT; Zhou, T; Mountz, JD				Zhang, HG; Liu, D; Heike, Y; Yang, PA; Wang, Z; Wang, XY; Curiel, DT; Zhou, T; Mountz, JD			Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells	NATURE BIOTECHNOLOGY			English	Article						gene therapy; apoptosis; immune response	MEDIATED GENE-TRANSFER; IMMUNE-RESPONSE; RECOMBINANT ADENOVIRUS; TRANSGENE EXPRESSION; IN-VIVO; APOPTOSIS; THERAPY; VECTORS; MICE	A major problem associated with adenovirus gene therapy is the T cell-mediated immune response, which is elicited by inoculation of the adenovirus vector and leads to rapid clearance of the virus and loss of transgene expression. In this study, the immune response to adenovirus was prevented by induction of specific T-cell tolerance by pretreatment with adenovirus-infected antigen-presenting cells (APC) that express Fas ligand, Compared with control-treated mice, the tolerized mice showed prolonged expression of lacZ upon administration of AdCMVlacZ 1 week after tolerance induction. In contrast to the control mice, the tolerized mice did not display proliferation of CD3+ T cells in the spleen in response to AdCMVlacZ, Tolerance induction also was indicated by the lower production of interferon-gamma and interleukin-2 by peripheral T cells isolated from AdCMVlacZ-challenged tolerized mice than by AdCMVlacZ-challenged control-treated mice. The T-cell tolerance was specific for the adenovirus as the T-cell responses to irrelative murine cytomegalovirus remained unimpaired. Our results indicate that adenovirus-specific T-cell tolerance can be induced by APCs that coexpress Fas ligand and adenovirus antigens. We propose that this new strategy can be used to induce tolerance to adenovirus vector gene therapy with resultant prolonged expression of the transgene.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Gene Therapy Program, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mountz, JD (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.	John.Mountz@CCC.UAB.EDU			NIAMS NIH HHS [R01-AR-42547, N01-AR-6-2224] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042547, N01AR062224] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Cheng JH, 1997, J IMMUNOL, V159, P674; Christ M, 1997, IMMUNOL LETT, V57, P19, DOI 10.1016/S0165-2478(97)00049-7; DEMATTEO RP, 1995, ANN SURG, V222, P229, DOI 10.1097/00000658-199509000-00002; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; Grim J, 1998, J MOL MED-JMM, V76, P451, DOI 10.1007/s001090050237; Juillard V, 1995, EUR J IMMUNOL, V25, P3467, DOI 10.1002/eji.1830251239; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LARSEN CP, 1995, TRANSPLANTATION, V60, P221, DOI 10.1097/00007890-199508000-00002; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Muruve DA, 1997, TRANSPLANTATION, V64, P542, DOI 10.1097/00007890-199708150-00031; Muruve DA, 1997, HUM GENE THER, V8, P955, DOI 10.1089/hum.1997.8.8-955; Piche A, 1998, CANCER RES, V58, P2134; Qin LH, 1997, HUM GENE THER, V8, P1365, DOI 10.1089/hum.1997.8.11-1365; Schowalter DB, 1997, GENE THER, V4, P853, DOI 10.1038/sj.gt.3300466; Sigalla J, 1997, HUM GENE THER, V8, P1625, DOI 10.1089/hum.1997.8.13-1625; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549; Zhang HG, 1998, HUM GENE THER, V9, P1875, DOI 10.1089/hum.1998.9.13-1875; Zhang HG, 1998, J VIROL, V72, P2483, DOI 10.1128/JVI.72.3.2483-2490.1998; ZHOU T, 1992, J EXP MED, V176, P1063, DOI 10.1084/jem.176.4.1063; Zsengeller ZK, 1997, HUM GENE THER, V8, P935, DOI 10.1089/hum.1997.8.8-935; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	35	72	76	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1998	16	11					1045	1049		10.1038/3488	http://dx.doi.org/10.1038/3488			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	136QF	9831033				2022-12-25	WOS:000076870100026
J	Martinerie, J; Adam, C; Le Van Quyen, M; Baulac, M; Clemenceau, S; Renault, B; Varela, FJ				Martinerie, J; Adam, C; Le Van Quyen, M; Baulac, M; Clemenceau, S; Renault, B; Varela, FJ			Epileptic seizures can be anticipated by non-linear analysis	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; RECONSTRUCTION; DYNAMICS; BRAIN	Epileptic seizures are a principal brain dysfunction with important public health implications, as they affect 0.8% of humans. Many of these patients (20%) are resistant to treatment with drugs'. The ability to anticipate the onset of seizures in such cases would permit clinical interventions. The view of chronic focal epilepsy now is that abnormally discharging neurons act as pacemakers to recruit and entrain other normal neurons by loss of inhibition and synchronization into a critical mass(2). Thus, preictal changes should be detectable during the stages of recruitment. Traditional signal analyses, such as the count of focal spike density(3), the frequency coherence(4) or spectral analyses are not reliable predictors. Non-linear indicators may undergo consistent changes around seizure onset(5-7). Our objective was to follow the transition into seizure by reconstructing intracranial recordings in implanted patients as trajectories in a phase space and then introduce non-linear indicators to characterize them(8,9). These indicators take into account the extended spatio-temporal nature of the epileptic recruitment processes(10) and the corresponding physiological events governed by short-term causalities in the time series. We demonstrate that in most cases (17 of 19), seizure onset could be anticipated well in advance (between 2-6 minutes beforehand), and that all subjects seemed to share a similar 'route' towards seizure.	Hop La Pitie Salpetriere, CNRS UPR 640, Lab Neurosci Cognit & Imagerie Cerebrale, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Unite Epileptol, F-75651 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Martinerie, J (corresponding author), Hop La Pitie Salpetriere, CNRS UPR 640, Lab Neurosci Cognit & Imagerie Cerebrale, 47 Blvd Hop, F-75651 Paris 13, France.							ABARBANEL HDI, 1995, ANAL OBSERVED CHAOTI, P17; Casdagli MC, 1997, ELECTROEN CLIN NEURO, V102, P98, DOI 10.1016/S0921-884X(96)95195-4; Casdagli MC, 1997, PHYSICA D, V108, P12, DOI 10.1016/S0167-2789(97)82003-9; DASILVA FHL, 1995, HDB BRAIN THEORY NEU, P367; DUCKROW RB, 1992, ELECTROEN CLIN NEURO, V82, P415, DOI 10.1016/0013-4694(92)90046-K; GOTMAN J, 1982, EPILEPSIA, V23, P432; Lachaux JP, 1997, HUM BRAIN MAPP, V5, P26, DOI 10.1002/(SICI)1097-0193(1997)5:1<26::AID-HBM4>3.0.CO;2-P; LANGE HH, 1983, ELECTROEN CLIN NEURO, V56, P543, DOI 10.1016/0013-4694(83)90022-6; LASEMIDIS LD, 1991, MEASURING CHAOS BRAI, P49; Lehnertz K, 1998, PHYS REV LETT, V80, P5019, DOI 10.1103/PhysRevLett.80.5019; Lerner DE, 1996, PHYSICA D, V97, P563, DOI 10.1016/0167-2789(96)00085-1; Manuca R, 1998, MATH BIOSCI, V147, P1, DOI 10.1016/S0025-5564(97)00055-2; McLachlan RS, 1997, J CLIN NEUROPHYSIOL, V14, P358, DOI 10.1097/00004691-199709000-00002; PRICHARD D, 1994, PHYS REV LETT, V73, P951, DOI 10.1103/PhysRevLett.73.951; ROSENSTEIN MT, 1994, PHYSICA D, V73, P82, DOI 10.1016/0167-2789(94)90226-7; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SCHIFF SJ, 1994, NATURE, V370, P615, DOI 10.1038/370615a0; VELASCO F, 1995, EPILEPSIA, V36, P63, DOI 10.1111/j.1528-1157.1995.tb01667.x; WEISER HG, 1989, REFLEX SEIZURES REFL, P49; WYLER AR, 1992, EPILEPSY WINDOW BRAI, P415	20	336	369	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1173	1176		10.1038/2667	http://dx.doi.org/10.1038/2667			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771751				2022-12-25	WOS:000076230100037
J	Mignon, A; Guidotti, JE; Mitchell, C; Fabre, M; Wernet, A; De La Coste, A; Soubrane, O; Gilgenkrantz, H; Kahn, A				Mignon, A; Guidotti, JE; Mitchell, C; Fabre, M; Wernet, A; De La Coste, A; Soubrane, O; Gilgenkrantz, H; Kahn, A			Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes	NATURE MEDICINE			English	Article							GENE-THERAPY; MICE; TRANSPLANTATION; REGENERATION; APOPTOSIS; VECTORS	Hepatocyte transplantation might represent a potential therapeutic alternative to liver transplantation in the future(1,2); however, transplanted cells have a limited capacity to repopulate the liver, as they do not proliferate under normal conditions. Recently, studies in urokinase (uPA) transgenic mice(3-5) and in fumarylacetoacetate hydrolase (FAH)-deficient mice(6) have shown that the liver can be repopulated by genetically engineered hepatocytes harboring a selective advantage over resident hepatocytes(7). We have reported that transgenic mice expressing human Bcl-2 in their hepatocytes are protected from Fas/CD95-mediated liver apoptosis(8). We now show that Bcl-2 transplanted hepatocytes selectively repopulate the liver of mice treated with nonlethal doses of the anti-fas antibody Jo2. FK 506 immunosuppressed mice were transplanted by splenic injection with Bcl-2 hepatocytes. The livers of female recipients were repopulated by male Bcl-2 transgenic hepatocytes, as much as 16%, after 8 to 12 administrations of Jo2. This only occurred after anti-fas treatment, confirming that resistance to Fas-induced apoptosis constituted the selective advantage of these transplanted hepatocytes. Thus, we have demonstrated a method for increasing genetic reconstitution of the liver through selective repopulation with modified transgenic hepatocytes, which will allow optimization of cell and gene therapy in the liver.	Univ Paris 05, INSERM U129 ICGM, F-75014 Paris, France; Hop Kremlin Bicetre, F-94275 Le Kremlin Bicetre, France; Hop Cochin, Serv Chirurg Digest, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Kahn, A (corresponding author), Univ Paris 05, INSERM U129 ICGM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	kahn@icgm.cochin.inserm.fr	Guidotti, Jacques-Emmanuel/M-9014-2018; Gilgenkrantz, Helene/G-5534-2017; Soubrane, Olivier/H-7799-2016; Soubrane, Olivier/ABB-4434-2021	gilgenkrantz, helene/0000-0001-6770-4561; guidotti, jacques-emmanuel/0000-0001-9285-8167				BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lake JR, 1998, NEW ENGL J MED, V338, P1463, DOI 10.1056/NEJM199805143382012; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Peeters MJTFDV, 1997, HEPATOLOGY, V25, P884, DOI 10.1002/hep.510250416; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; RHIM JA, 1995, P NATL ACAD SCI USA, V92, P4942, DOI 10.1073/pnas.92.11.4942; SAMBROOK J, 1989, MOL CLONING LAB MANA; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Wilson JM, 1996, NAT GENET, V12, P232, DOI 10.1038/ng0396-232; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	17	149	159	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1185	1188		10.1038/2681	http://dx.doi.org/10.1038/2681			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771754				2022-12-25	WOS:000076230100040
J	Young, K; Lin, S; Sun, L; Lee, E; Modi, M; Hellings, S; Husbands, M; Ozenberger, B; Franco, R				Young, K; Lin, S; Sun, L; Lee, E; Modi, M; Hellings, S; Husbands, M; Ozenberger, B; Franco, R			Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen	NATURE BIOTECHNOLOGY			English	Article						drug screen; protein-protein interaction; neurotransmitter	PROTEIN-COUPLED RECEPTORS; REVERSE 2-HYBRID SYSTEM; BETA-GAMMA-SUBUNITS; FUNCTIONAL EXPRESSION; CA2+ CHANNELS; SACCHAROMYCES-CEREVISIAE; ALPHA(1) SUBUNIT; NEURONS; DOMAIN; INHIBITION	The interaction of the N-type calcium channel beta 3 subunit with the alpha 1B subunit alters the activation/inactivation kinetics and the maximal conductance of the channel. The defined protein-protein interaction of the human alpha 1B and beta 3 subunits provides a target for small-molecule modulation of N-type channel activity. We describe a high throughput screen based on a counterselection yeast two-hybrid assay, which was used to identify small molecules that disrupt alpha 1B-beta 3 subunit interactions and Inhibit N-type calcium channel activity. These small molecules may be a new class of calcium channel antagonists with therapeutic potential.	Wyeth Ayerst Res, CNS Disorders, Princeton, NJ 08543 USA; Cyanamid Agr Res Ctr, Princeton, NJ 08543 USA; Wyeth Ayerst Res, CNS MCB, Princeton, NJ 08543 USA	Pfizer; Pfizer	Franco, R (corresponding author), Wyeth Ayerst Res, CNS Disorders, Princeton, NJ 08543 USA.	francor@war.wyeth.com						ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; Bai C, 1997, METHOD ENZYMOL, V283, P141; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY M, 1993, CURRENT PROTOCOLS MO; HARPER JW, 1993, CELL, V75, P805; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Huang J, 1997, P NATL ACAD SCI USA, V94, P13396, DOI 10.1073/pnas.94.25.13396; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; Leanna CA, 1996, NUCLEIC ACIDS RES, V24, P3341, DOI 10.1093/nar/24.17.3341; MANIATIS T, 1992, MOL CLONING; MINTZ IM, 1993, NEUROPHARMACOLOGY, V32, P1161, DOI 10.1016/0028-3908(93)90010-Z; NEWCOMB R, 1994, BRAIN RES, V638, P95, DOI 10.1016/0006-8993(94)90637-8; OZENBERGER BA, 1995, MOL ENDOCRINOL, V9, P1321, DOI 10.1210/me.9.10.1321; Page KM, 1998, J NEUROSCI, V18, P4815; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Rose MD., 1990, METHODS YEAST GENETI; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	41	89	101	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					946	950		10.1038/nbt1098-946	http://dx.doi.org/10.1038/nbt1098-946			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788351				2022-12-25	WOS:000076323300030
J	Nasu, Y; Timme, TL; Yang, G; Bangma, CH; Li, LK; Ren, CZ; Park, SH; DeLeon, M; Wang, JX; Thompson, TC				Nasu, Y; Timme, TL; Yang, G; Bangma, CH; Li, LK; Ren, CZ; Park, SH; DeLeon, M; Wang, JX; Thompson, TC			Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells	NATURE MEDICINE			English	Article							BCL-2; CHOLESTEROL	Although prostate cancer cells are often initially sensitive to androgen ablation, they eventually lose this response and continue to survive, grow and spread in the absence of androgenic steroids. The mechanism(s) that underlie resistance to androgen ablation therapy remain mostly unknown. We have demonstrated that elevated caveolin protein levels are associated with human prostate cancer progression in pathological specimens(1). Here we show that suppression of caveolin expression by a stably transfected antisense caveolin-1 cDNA vector converted androgen-insensitive metastatic mouse prostate cancer cells to an androgen-sensitive phenotype. Orthotopically grown tumors and low-density cell cultures derived from antisense caveolin clones had increased apoptosis in the absence of androgenic steroids, whereas similarly grown tumors and cells from vector (control) clones and parental cells were not sensitive to androgens. Studies using a representative antisense caveolin clone showed that selection for androgen resistance in vivo correlated with increased caveolin levels, and that adenovirus-mediated caveolin expression blocked androgen sensitivity. Our results identify a new candidate gene for hormone-resistant prostate cancer in man and indicate that androgen insensitivity can be an inherent property of metastatic prostate cancer.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Thompson, TC (corresponding author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.	timothyt@bcm.tmc.edu	de Leon, Mony/AAP-7890-2021		NCI NIH HHS [CA50588, CA68814] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050588, R01CA068814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Furuya Y, 1996, CLIN CANCER RES, V2, P389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; Hall S. J., 1997, CLIN EXP METASTAS, V15, P484; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huggins C, 1941, CANCER RES, V1, P293; Krajewska M, 1996, AM J PATHOL, V148, P1567; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; THOMPSON TC, 1995, ONCOGENE, V10, P869; Yang G, 1996, CANCER, V78, P1267, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1267::AID-CNCR15>3.0.CO;2-Z; Yang G, 1998, CLIN CANCER RES, V4, P1873	15	168	176	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1062	1064		10.1038/2048	http://dx.doi.org/10.1038/2048			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734401				2022-12-25	WOS:000075804100041
J	Simpson, AJG; Perez, JF				Simpson, AJG; Perez, JF			Latin America - ONSA, the Sao Paulo virtual genomics institute	NATURE BIOTECHNOLOGY			English	Editorial Material									Ludwig Inst Canc Res, Canc Genet Lab, Sao Paulo, Brazil; Univ Sao Paulo, BR-05508 Sao Paulo, Brazil; FAPESP, Sao Paulo, Brazil	Ludwig Institute for Cancer Research; Universidade de Sao Paulo; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	Simpson, AJG (corresponding author), Ludwig Inst Canc Res, Canc Genet Lab, Sao Paulo, Brazil.		Simpson, Amelia/HGB-1823-2022					CHANG CJ, 1993, P 12 C INT ORG CITR, P194; HARTUNG JS, 1994, PHYTOPATHOLOGY, V84, P591, DOI 10.1094/Phyto-84-591	2	26	28	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1998	16	9					795	796		10.1038/nbt0998-795	http://dx.doi.org/10.1038/nbt0998-795			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	115NN	9743092				2022-12-25	WOS:000075671700004
J	Tourtellotte, WG; Milbrandt, J				Tourtellotte, WG; Milbrandt, J			Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3	NATURE GENETICS			English	Article							PERIPHERAL NERVOUS-SYSTEM; TARGETED MUTATION; NEUROTROPHIN-3; AFFERENTS; LIMB; RAT; DIFFERENTIATION; DEPENDENCE; EXPRESSION; DEFICITS	Muscle spindles are skeletal muscle sensory organs that provide axial and limb position information (proprioception) to the central nervous system. Spindles consist of encapsulated muscle fibers (intrafusal fibers) that are innervated by specialized motor and sensory axons. Although the molecular mechanisms involved in spindle ontogeny are poorly understood, the innervation of a subset of developing myotubes (type I) by peripheral sensory afferents (group la) is a critical event for inducing intrafusal fiber differentiation and subsequent spindle formation(1-3) The Egr family of zinc-finger transcription factors, whose members include Egr1 (NGFI-A), Egr2 (Krox-20), Egr3 and Egr4 (NGFI-C), are thought to regulate critical genetic programs involved in cellular growth and differentiation (refs 4-8, and W.G.T. et al., manuscript submitted). Mice deficient in Egr3 were generated by gene targeting and had gait ataxia, increased frequency of perinatal mortality, scoliosis, resting tremors and ptosis. Although extrafusal skeletal muscle fibers appeared normal, Egr3-deficient animals lacked muscle spindles, a finding that is consistent with their profound gait ataxia. Egr3 was highly expressed in developing muscle spindles, but not in la afferent neurons or their terminals during developmental periods that coincided with the induction of spindle morphogenesis by sensory afferent axons. These results indicate that type I myotubes are dependent upon Egr3-mediated transcription for proper spindle development.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Neuropathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Lab Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.			Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [CA13730] Funding Source: Medline; NIMH NIH HHS [MH1426] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001426] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; COPRAY JCVM, 1994, DEV BRAIN RES, V81, P57, DOI 10.1016/0165-3806(94)90068-X; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; DUCHEN LW, 1977, J ANAT, V123, P763; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; KAWAMURA Y, 1977, J NEUROPATH EXP NEUR, V36, P853, DOI 10.1097/00005072-197709000-00009; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KUCERA J, 1995, J COMP NEUROL, V363, P307, DOI 10.1002/cne.903630211; KUCERA J, 1995, ANAT EMBRYOL, V192, P149; KUCERA J, 1992, ANAT EMBRYOL, V186, P301; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MITHANI S, 1987, PSYCHOPHARMACOLOGY, V93, P94, DOI 10.1007/BF02439593; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; O'Donovan KJ, 1998, J NEUROCHEM, V70, P1241; Ringstedt T, 1997, DEVELOPMENT, V124, P2603; SHAMI SK, 1993, PHLEBOLOGY, V8, P72, DOI 10.1177/026835559300800207; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Yamagata K, 1994, Learn Mem, V1, P140; ZELENA J, 1957, J EMBRYOL EXP MORPH, V5, P283	26	203	205	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1998	20	1					87	91		10.1038/1757	http://dx.doi.org/10.1038/1757			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	115NK	9731539				2022-12-25	WOS:000075671400027
J	Jarvis, DL; Finn, EE				Jarvis, DL; Finn, EE			Modifying the insect cell N-glycosylation pathway with immediate early baculovirus expression vectors	NATURE BIOTECHNOLOGY			English	Article						baculovirus expression vectors; insect cells; glycoproteins; glycosylation; expression systems; protein processing	NUCLEAR POLYHEDROSIS-VIRUS; ASPARAGINE-LINKED OLIGOSACCHARIDES; HAMSTER OVARY CELLS; TISSUE-PLASMINOGEN-ACTIVATOR; SPODOPTERA-FRUGIPERDA CELLS; MEMBRANE-GLYCOPROTEINS; MONOCLONAL-ANTIBODY; STRUCTURAL PROTEINS; LEPIDOPTERAN CELLS; GENE	The baculovirus-insect cell expression system is well-suited for recombinant glycoprotein production because baculovirus vectors can provide high levels of expression and insect cells can modify newly synthesized proteins in eucaryotic fashion. However, the N-glycosylation pathway of baculovirus-infected insect cells differs from the pathway found in higher eucaryotes, as indicated by the fact that glycoproteins produced in the baculovirus system typically lack complex biantennary N-linked oligosaccharide side chains containing penultimate galactose and terminal sialic acid residues. We recently developed a new type of baculovirus vector that cart express foreign genes immediately after infection under the control of the viral ie1 promoter. These immediate early baculovirus expression vectors can be used to modify the insect cell N-glycosylation pathway and produce a foreign glycoprotein with more extensively processed N-linked oligosaccharides, These vectors can also be used to study the influence of the late steps in N-linked oligosaccharide processing on glycoprotein function. Further development could lead to baculovirus-insect cell expression systems that can produce recombinant glycoproteins with complex biantennary N-linked oligosaccharides structurally identical to those produced by higher eucaryotes.	TEXAS A&M UNIV, CTR ADV INVERTEBRATE MOL SCI, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Jarvis, DL (corresponding author), TEXAS A&M UNIV, DEPT ENTOMOL, COLLEGE STN, TX 77843 USA.			Jarvis, Donald/0000-0002-8104-7155	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049734] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049734, GM49734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; BERGER EG, 1986, FEBS LETT, V203, P64, DOI 10.1016/0014-5793(86)81437-5; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLISSARD GW, 1992, J VIROL, V66, P6829, DOI 10.1128/JVI.66.11.6829-6835.1992; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P655, DOI 10.1016/0005-2736(81)90096-1; CHEN WY, 1991, J BIOL CHEM, V266, P4081; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; GRABENHORST E, 1993, EUR J BIOCHEM, V215, P189, DOI 10.1111/j.1432-1033.1993.tb18022.x; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOHMANN AW, 1983, VIROLOGY, V125, P432, DOI 10.1016/0042-6822(83)90214-3; HSIEH P, 1984, J BIOL CHEM, V259, P2375; Jarvis D L, 1995, Methods Mol Biol, V39, P187; JARVIS DL, 1990, BIO-TECHNOL, V8, P950, DOI 10.1038/nbt1090-950; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JARVIS DL, 1994, VIROLOGY, V205, P300, DOI 10.1006/viro.1994.1646; JARVIS DL, 1995, VIROLOGY, V212, P500, DOI 10.1006/viro.1995.1508; JARVIS DL, 1996, IN PRESS PROTEIN EXP; JARVIS DL, 1996, IN PRESS GLYCOBIOLOG; JARVIS DL, 1993, INSECT CELL CULTURE, P193; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KALSNER I, 1995, GLYCOCONJUGATE J, V12, P360, DOI 10.1007/BF00731339; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; KNEPPER TP, 1992, BIOCHEMISTRY-US, V31, P11651, DOI 10.1021/bi00161a053; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EU, 1989, J BIOL CHEM, V264, P13848; LICARI PJ, 1993, BIOTECHNOL PROGR, V9, P146, DOI 10.1021/bp00020a005; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MINCH SL, 1995, BIOTECHNOL PROGR, V11, P348, DOI 10.1021/bp00033a015; MURHAMMER DW, 1988, BIO-TECHNOL, V6, P1411, DOI 10.1038/nbt1288-1411; NAGAO E, 1987, INSECT BIOCHEM, V17, P531, DOI 10.1016/0020-1790(87)90051-5; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; REN JX, 1995, BIOCHEMISTRY-US, V34, P2489, DOI 10.1021/bi00008a012; RODEMS SM, 1993, J VIROL, V67, P5776, DOI 10.1128/JVI.67.10.5776-5785.1993; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; RYAN RO, 1985, ARCH BIOCHEM BIOPHYS, V243, P115, DOI 10.1016/0003-9861(85)90779-9; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SMITH GE, 1983, J VIROL, V46, P584, DOI 10.1128/JVI.46.2.584-593.1983; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Summers MD, 1987, TEXAS AGR EXPT STATI; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; VOLKMAN LE, 1985, VIROLOGY, V143, P185, DOI 10.1016/0042-6822(85)90107-2; VOLKMAN LE, 1984, VIROLOGY, V133, P354, DOI 10.1016/0042-6822(84)90401-X; VOLKMAN LE, 1986, CURR TOP MICROBIOL, V131, P103; Wagner R, 1996, GLYCOBIOLOGY, V6, P165, DOI 10.1093/glycob/6.2.165; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; WATHEN MW, 1991, BIOCHEMISTRY-US, V30, P2863, DOI 10.1021/bi00225a019; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019	57	106	128	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1288	1292		10.1038/nbt1096-1288	http://dx.doi.org/10.1038/nbt1096-1288			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631095				2022-12-25	WOS:A1996VK61800029
